Extended Version . This Link Downloads a File

Published by: IDIBAPS Rosselló, 149-153 08036 Barcelona

Editorial board IDIBAPS Scientiﬁc Coordination Office

Art direction & graphic design Marc Montalà www.marcmontala.com

Cover photo © Irene Portolés

ANNUAL SCIENTIFIC REPORT 2018

INDEX

08 Foreword IDIBAPS Director’s foreword About IDIBAPS Staff Research and innovation outputs Funding Institutional projects Scientiﬁc facilities Training Communication and public engagement News

56 Area 1 Biological aggression and response mechanisms

94 Area 2 Respiratory, cardiovascular and renal pathobiology and bioengineering

152 Area 3 Liver, digestive system and metabolism

218 Area 4 Clinical and experimental neuroscience

276 Area 5 Oncology and haematology

332 Transversal research groups

343 Team and group leaders index ANNUAL SCIENTIFIC REPORT 2018

FOREWORD IDIBAPS

It is a great privilege and satisfaction to present in this 2018 Annual Report the activities and outstanding achievements of all the people working at IDIBAPS. Our scientific contributions are improving the understanding of the diseases we study and are changing the way we practice medicine. Our commitment to society stimulates us to spread this knowledge and these values to citizens of all ages. From the institutional perspective, I would like to highlight the work to culminate our new strategic plan (2018-2022), which was discussed by a broad representation of the research and management communities. An analysis of the current situation of biomedical research and the social and scientific challenges that we all face have led us to define the strategic objectives and actions that will serve as a roadmap for addressing the complex situation in which we work. Major effort will be dedicated to consoli- dating and improving excellence in translational research, attracting and retaining talent, particularly with the crucial task of generational renewal and the need to promote the clinician scientist career. We need to reinforce innovation and technology translation to attain the highest impact in clinical practice and optimize the resources to achieve the desired objectives. Next year will be crucial for the institutional fusion of IDIBAPS and Fundació Clínic per a la Recerca Biomèdica (SUMA project), which should facilitate research in the Clínic Barcelona Campus. This year, the Board of Governors accepted the nomination of Prof José María Mato as new President of the Scientific Advisory Board (SAB), replacing Prof Jesús Ávila, who remains as member of the SAB. We welcome Prof Amparo Cano, Full Professor of the Autonomous University of Madrid and researcher at the Institute of Biomedical Research “Alberto Sols”, and Dr Pura Muñoz, ICREA researcher at Pompeu Fabra University, as new members of the SAB,replacing Dr Guadalupe García-Tsa, Roberto Grozman, Bartolome Celli and Miguel Ángel Pozo. We are extremely grateful to all of them for their contributions to the success of IDIBAPS. The SAB is instrumental in guaranteeing the high standards in the scientific goals of the Institute. This year, the Direction and Administration of IDIBAPS also made an extra effort to provide all the key performance Indicators (KPIs) required by the Instituto de Salud Carlos III Health Institute (ISCIII) to renew our accreditation as . In addition, we compiled all the documents requested by Fundación Científica de la Asociación Española Contra el Cáncer (FC-AECC) to obtain the new accreditation as a recognized center in Cancer Research. The major strength of IDIBAPS continues to be the intense and excellent scientific production of its researchers, who in 2018 have maintained the high level reached in previous years. Of more than 1,100 original articles published, almost 350 (31%) were in first-decile journals and 170 (16%) in top journals (impact factor over 10). Our researchers also published 314 reviews and editorial articles, which unders- cores the high level of international leadership of our researchers. These excellent contributions encom- pass a broad spectrum of activities, from novel discoveries that are changing treatment standards to basic studies that improve understanding of the diseases in question. It would be difficult to summarize the tremendous amount of contributions, but some examples worthy of mention include the seminal contributions in the treatment of hepatocellular carcinoma, nosocomial pneumonia, cardiac arrhythmias, and the use of stem cells for the treatment of chronic inflammatory bowel disease. They have also provided important novel information on the evolution of diseases such as autoimmune encephalitis and hepatitis C. From a more basic perspective, our scientists have developed animal models for understanding liver fibrosis and treatment of cirrhosis, and have elucidated the genome-wide epigenomic modifications that shape the development of chronic lymphocytic leukemia. I should also mention the 39 international clinical guidelines, in which our researchers have participated, setting the standards for diagnostic procedures and therapeutic management of a variety of diseases–clear proof of the institutional spirit and commitment to translate research into clinical practice. To sustain this production activity, IDIBAPS researchers have raised a significant amount of national and international funds, with more than 200 new projects from competitive and private sources. Indeed, IDIBAPS appears to be one of the national institutions with a better success rate in the ISCIII and H2020 programs. In 2018, two groups from IDIBAPS obtained a prestigious ERC Synergy grant in collaboration with two groups from CNAG-CRG to participate in the international project of the Human

9 Cell Atlas and study the chronic lymphocytic leukemia at a single cell level. Three groups obtained the highly competitive grants from the La Caixa Health program, two groups participate in major European consortiums funded by the FC-AECC, together with charities from the UK (CRUK) and Italy (AIRC) to study hepatocellular carcinoma and early manifestations of hematological disorders, and one group obtained a PO1 grant from the National Institutes of Health of the USA. A special extraordinary achievement that deserves our deepest gratitude is the commitment and generosity of more than 1,600 donors raising more than one million euros, which has made it possible to initiate the immunotherapy program with the innovative CAR-T cell strategies in the project that we have named the ARI-project, after the lovely person who inspired all of us in this endeavor and who we all miss. None of all this would have been possible without the commitment of our researchers. In 2018, we welcomed two new junior group leaders, Patricia Pérez-Galán as head of the group Microenviron- ment in lymphoma pathogenesis and therapy and Virginia Amador as head of the group Functional characterization of oncogenic mechanisms in lymphomagenesis. Our Junior Group Leader Iñaki Martín-Subero was also awarded an ICREA professor position. We should all be proud of the recognition of Dr Àlvar Agustí as the 2018 Clinical Biomedical Research awardee of the Lilly Foundation and of the inclusion of 13 of our researchers among the 1% most cited investigators according to Clarivate Analytics. IDIBAPS is firmly committed to promoting the education of the young scientific community. In 2018, 96 students defended their theses. We have organized 41 institutional seminars and a special mention goes to our Stepping-Stone training program, which seeks to provide young researchers at IDIBAPS with the non-scientific tools and skills that are key to the development of their careers. One of the major difficulties we have continued to face in 2018 is limited institutional funding for renewing and improving our support infrastructure. Nevertheless, IDIBAPS core facilities are making a tremendous effort to help our scientists reach their objectives. The activity of our five core facilities has increased significantly, providing almost 600 services. In 2018, the Biobank, the KTT and the Clinical Trials Unit, were recognized by the ISCIII as key participants in the respective national networks, Red Nacional de Biobancos, ITEMAS and SCREN. Of particular importance was the grant obtained from the Spanish Ministry of Science, Innovation and Universities to renew our informatics infrastructure. This support will allow us to meet the needs of our groups and expand the power of the many projects developed in our institution on the generation and analysis of biomedical big data. Science needs to reach and permeate our society. We have developed new initiatives to reinforce our commitment in this regard. In 2018, we organized 48 activities that reached 2,131 people of all ages, from 4 years old in the Science Summer Camps and programs for young students who want to follow a scientific career, to the most elderly attending the talks at the Urgell Civic Center. It is notable that some of these activities received competitive funding from Barcelona City Council. We also began construction of the new website, which will improve the visibility of our researchers and of the institution. This new website will be linked to the new website of Hospital Clínic de Barcelona and the Portal Clínic, to reinforce collaboration between the two institutions. We are well prepared to face the challenges that 2019 will bring us. Of particular importance is the continuing implementation of our Strategic Plan in a context of social change and economical constraint that, conditions that, we must acknowledge, are jeopardizing the high levels of scientific achievement not only of IDIBAPS but of the entire scientific community in our country. Our commitment as an institution and as individual researchers is unquestionably pushing science forward. Our greatest reward is to experience for ourselves how this work improves the life of our patients. IDIBAPS will continue to be an excellent benchmark center in this endeavor.

Elías Campo Director

10 About IDIBAPS

The Institut d’Investigacions Additionally, 3 transversal groups perform Biomèdiques August Pi i Sunyer research in Primary Care, Nursing, (IDIBAPS) is a biomedical research Pharmacology and Clinical Trials. institute of excellence. It combines clinical and basic research in order to accelerate Scientific breakthroughs are never the result the translation of the knowledge to the of chance. They are the fruit of long-term benefit of the patients. IDIBAPS is a commitments that involve not only CERCA (Research Centers of Catalonia) researchers, but also society as a whole. center and was first accredited as Instituto de Investigación Sanitaria (Instituto de IDIBAPS is a consortium that has made such Salud Carlos III) in 2009. a commitment, to encourage translational research, innovation and technological Founded in 1996, it is a public consortium progress in the field of biomedicine, through formed by the Generalitat de Catalunya, different programmes addressing diseases Hospital Clínic de Barcelona, School of with a high prevalence, morbidity and mortality Medicine and Health Sciences of the in our society. University of Barcelona and, as an associated partner, the CSIC’s Barcelona Biomedical The data presented in this Annual Scientific Research Institute. Report details the ever-growing scientific achievements made by IDIBAPS investigators The Fundació Clínic per a la Recerca and their capacity for attracting public and Biomèdica (FCRB) is a key institution to private funding. This enormous potential for understand the functioning of IDIBAPS as a capturing resources and their translation into whole. It is a research foundation that provides applied results for clinical practice constitute researchers with administrative and the best guarantee for securing the future of management support. The IDIBAPS research the Institute and its impact on society and community is composed of more than 1,500 industry. people, grouped into 107 groups organized across 5 different areas of knowledge.

AREA 1 Biological aggression and response mechanisms

AREA 2 Respiratory, cardiovascular and renal pathobiology and bioengineering

AREA 3 Liver, digestive system and metabolism

AREA 4 Clinical and experimental neuroscience

AREA 5 Oncology and haematology

11 FOREWORD IDIBAPS

Organisation chart

IDIBAPS requires a solid administrative infrastructure to support the state of the art research developed by its researchers.

IDIBAPS works together with the Fundació Clínic per a la Recerca Biomèdica (FCRB) to ensure efficiency and quality in the services offered to its research staff, in particular, in the areas of research project management and administration.

Elías Campo, MD PhD Marga Nadal, PhD Rosa Vilavella Director of IDIBAPS and of FCRB Director of Strategy General Manager

Gemma Pedrola Arantxa Fernández Laura Lopera Secretary Secretary Secretary [email protected] [email protected] [email protected] T. +34 93 312 94 11 T.+34 93 227 18 30 T. +34 93 227 18 42 CEK, mezzanine floor CEK, mezzanine floor CEK, mezzanine floor

Gemma Llaverías Marta Fernández Head of the Scientiﬁc Head of the Human Resources Office Coordination Office Sònia Meléndez Elisenda Vendrell Head of the Accounting and Finance Office Head of the KTT Office Ernest Costa Daniel Arbós Head of the TIC Office Head of the Communication Office Juan Suero Gemma Pascual Head of the Purchasing Head of the Institutional Actions Office and General Services Office

Sandra Piquer Guillem Masdeu Coordinator of IDIBAPS laboratories Head of the Legal Office

Aina Rodríguez RESEARCH MANAGEMENT OFFICE Head of IDIBAPS core facilities Sandra Pérez and Biobank coordinator Head of the Pre-Award Office for National Grants

Juan Abolaﬁa Head of the Pre-Award Office for International Grants

Judit Martínez Head of the Post-award Grants Office

12 Governance and structure

Governance is exercised through the following boards and committees:

THE BOARD OF GOVERNORS THE SCIENTIFIC ADVISORY BOARD Jesús San Miguel Hospital Clínico de Salamanca Conformed by representatives of the External leading scientists chosen by the different institutions of the consortium, Board of Governors, compose this board Francisco Sánchez-Madrid supervises IDIBAPS actions, budget and to advise IDIBAPS on the different Hospital La Princesa, Madrid results. Its mission is to take scientific scientific issues affecting its activities. Eugenio Santos decisions in consultation with the These leading scientists have in-depth Centro de Investigación del Cáncer (CIC), Scientific Advisory Board, and to evaluate knowledge of the Spanish, European Salamanca the implementation of the strategic plan. and/or American R+D+I systems as they hold positions in prestigious research Antonio Vidal-Puig CHAIRMAN institutions. School of Clinical Medicine, Joan Gómez Pallarés University of Cambridge, UK General Director, Direcció General de CHAIRMAN Recerca, Departament d’ Empresa i José María Mato Coneixement. Generalitat de Catalunya CIC bioGUNE, Bilbao

VICE-CHAIRMAN BOARD MEMBERS THE STEERING COMMITTEE Josep Maria Campistol Jesús Ávila General Manager, Hospital Clínic de Centro de Biología Molecular Which is responsible for the supervision Barcelona Severo Ochoa (CBM), Madrid of the progress achieved by the ﬁve IDIBAPS research areas, the recruitment BOARD MEMBERS Fernando Arenzana-Seisdedos of new scientists within the framework of Albert Barberà Institut Pasteur, Shangai, China different research programmes, and the General Director, Direcció General de evaluation of IDIBAPS training Recerca I Innovació en Salut, Departament Amparo Cano programmes. de Salut, Generalitat de Catalunya Instituto de Investigaciones Biomédicas "Alberto Sols", CSIC-UAM, Madrid CHAIRMAN Domènec Espriu Elías Campo Research Vice-Dean, Universitat de Barcelona Francisco Fernández Avilés Director Hospital Gregorio Marañón, Madrid Lluís Calvo MEMBERS Institutional Coordinator, Consejo Superior de Ramon Gomis Neus Agell Investigaciones Cientíﬁcas (CSIC) in Catalonia IDIBAPS, Barcelona Vice-Dean of School of Medicine and Health Sciences Francesc Cardellach José López Barneo Universitat de Barcelona Dean of the School of Medicine, Universitat de Instituto de Biomedicina de Sevilla (IBiS) Barcelona Cristina Fillat Carlos López Otín Group Leader Elías Campo Universidad de Oviedo Gene therapy and cancer Director, IDIBAPS Carlos Macaya Joan Carles García-Pagán Antoni Castells Hospital Clínico San Carlos, Madrid Research Deputy Director (HCB) Medical Director, Hospital Clínic de Barcelona Óscar Marín Josep Maria Llovet Roser Cortés King's College London, UK Group Leader Director, Instituto de Investigaciones Translational research in hepatic oncology Biomédicas de Barcelona (IIBB-CSIC) Federico Mayor Centro de Biología Molecular Anna Planas SECRETARY Severo Ochoa, Madrid Coordinator of the IDIBAPS Research Area 4 Lluís Rovira Director, CERCA Pura Muñoz Rosa Vilavella ICREA, Universitat Pompeu Fabra General Manager

Angel Pellicer SECRETARY NYU School of Medicine, New York, US Marga Nadal Strategy Director Ciril Rozman Hospital Clínic de Barcelona, Universitat de Barcelona

13 FOREWORD IDIBAPS

THE INTERNAL ADVISORY COMMITTEE GUEST MEMBERS The Clinical Research Ethics Committee Montserrat Batlle (Comitè d’Ètica d’Investigació amb IDIBAPS researchers representing all Works Committee President Medicaments - CEIm) of the HCB research areas advise the IDIBAPS director [email protected] to implement the strategic decisions taken Jaume Bosch by the Board of Governors. Researcher The Animal Experimentation Hepatic hemodynamics and portal hypertension Ethics Committee (Comitè d’Ètica CHAIRMAN d’Experimentació Animal - CEEA) Elías Campo Francesc Cardellach of the UB Director Dean of the School of Medicine Universitat de Barcelona Biosafety Committee (CBS) STEERING COMMITTEE REPRESENTATIVES [email protected] Josep Maria Llovet Fàtima Crispi Group Leader Researcher Core Facilities Committees Translational research in hepatic oncology Fetal and perinatal medicine [email protected]

Joan Carles García-Pagán Roser Cortés Mentoring Committee Research Deputy Director Director Hospital Clínic de Barcelona Instituto de Investigaciones Biomédicas de Training Committee Barcelona (IIBB-CSIC) [email protected] INSTITUTIONAL REPRESENTATIVES Joan Cid Josep M. Gatell Clinicians and Research Committee Physicians’ Representatives National Coordinator of the RETIC on AIDS Hospital Clínic de Barcelona Ombuds Committee Francesc Graus Anna Novials Guadalupe Mengod Cellex building representative Francesca Pons Deputy Director Marc Roda Instituto de Investigaciones Biomédicas Anna Novials Joan Serratosa de Barcelona (IIBB-CSIC) Group Leader [email protected] Pathogenesis and prevention of diabetes AREA REPRESENTATIVES Works council AREA 1 Carmen Peralta [email protected] Josep Maria Miró, Coordinator Group Leader [email protected] Maria Cinta Cid, Representative Liver transplantation and graft viability

AREA 2 Azucena Salas Ramón Farré, Coordinator Researcher Joan Albert Barberà, Representative Inﬂammatory bowel disease (IBD)

AREA 3 Antonio Sisó Jordi Bruix, Coordinator CAPSBE, Primary Care Francesc Balaguer, Representative Research Coordinator

AREA 4 Gisela Sugranyes Anna Planas, Coordinator Junior Group Leader Josep Dalmau, Representative Multimodal neuroimaging in high risk and early psychosis

AREA 5 Dolors Colomer, Coordinator SECRETARY Aleix Prat, Representative Marga Nadal Strategy Director

TRAINING COORDINATOR Neus Agell Vice-Dean of School of Medicine and Health Sciences Universitat de Barcelona

14 Research areas, teams and groups

AREA 1. AREA 3. BIOLOGICAL AGRESSION LIVER, DIGESTIVE SYSTEM AND METABOLISM AND RESPONSE MECHANISMS 3.1. Gynecological endocrinology and human reproduction 1.1. Inflammatory joint diseases (IJDs) 3.2. Fetal and perinatal medicine 1.2. Systemic autoimmune diseases 3.3. Viral, toxic and metabolic hepatopathies 1.2.1. Systemic vasculitis 3.4. Mechanisms of liver disease and complications of cirrhosis 1.3. Infectious diseases and AIDS 3.4.1. Inflammation and liver disease 1.3.1. AIDS and HIV Infection 3.4.2. Chronic liver diseases: molecular mechanisms and clinical 1.3.2. Endocarditis. Cardiovascular infections. Experimental Model consequences 1.3.3. Infections in solid-organ transplant recipients 3.4.3. Translational research in new therapeutic and diagnostic 1.3.4. Nosocomial infection study group strategies in liver diseases 1.4. Immune receptors of the innate and adaptive system 3.4.4. Liver plasticity and tissue repair 1.6. Immunogenetics of the autoinflammatory response 3.5. Hepatic oncology 1.7. Emergencies: processes and pathologies 3.5.1. Translational research in hepatic oncology 1.8. Molecular and cellular bases of inflammation 3.5.2. Hepatocelular signaling and cancer Structural and biological mass spectrometry 3.6. Hepatic hemodynamics and portal hypertension. 1.9. Ocular inflammation: clinical and experimental studies Hemorrhage from ruptured gastroesophageal varices 3.6.1. Angiogenesis in liver diseases 3.6.2. Regulation of liver microcirculation in cirrhosis and hepatic vascular diseases AREA 2. 3.6.3. Vascular biology of the liver RESPIRATORY, CARDIOVASCULAR AND RENAL 3.7. Inflammatory bowel disease PATHOBIOLOGY AND BIOENGINEERING 3.8. Cholestasis and bone pathology 3.8.1. Cholestasis 2.1. Atherosclerosis, coronary disease and heart failure 3.8.2. Bone metabolic disease 2.2. Arrhythmias, resynchronization and cardiac imaging 3.9. 2.2.1. Vascular cell biology Mitochondrial regulation of cell death and steatohepatitis 3.10. 2.2.2. Arrythmias and physical activity Liver transplantation and graft viability 2.2.3. Atrial fibrillation biopathology and therapy 3.10.1. Protective strategies against hepatic 2.2.4. Cardiac imaging ischemia-reperfusion injury 2.3. Nephro-urological diseases and kidney transplantation 3.11. Gastrointestinal and pancreatic oncology 2.3.1. Translational research in posttrasplant neoplasia 3.11.1. Genetic predisposition to gastrointenstinal cancer 3.11.2. Gene therapy and cancer 2.4. Cardiovascular, nutrition and aging unit 2.5. Respiratory biophysics and bioengineering 3.12. Inherited metabolic diseases 3.13. 2.6. Applied research in infectious respiratory diseases, critically Genomic programming of beta cells and diabetes ill patients and lung cancer 3.14. Diabetes: metabolic and molecular networks 2.6.1. Breathing disturbances in sleep 3.14.1. Neuronal control of metabolism (NEUCOME) 3.14.2 Pancreatic islets: biomarkers and function 2.7. Physiopathological mechanisms of respiratory illnesses 3.14.3. Endocrine disorders: crosstalk between molecular and 2.7.1. Translational research in pulmonary vascular diseases: metabolic determinants cell proliferation and apoptotic mechamism in pulmonary 3.14.4. Pathogenesis and treatment of autoimmunity arterial hypertension. 3.14.5. Translational research in diabetes, lipids and obesity 2.8. Clinical and experimental respiratory immunoallergy 3.15. Pathogenesis and prevention of diabetes 2.8.1. Sinofasal inflammatory and olfactory research group (INGENIO) 2.9. Inflammation and repair in respiratory illnesses 2.10. Genetic and urological tumors

15 FOREWORD IDIBAPS

AREA 4. AREA 5. CLINICAL AND EXPERIMENTAL NEUROSCIENCE ONCOLOGY AND HAEMATOLOGY

4.1. Neuropharmacology and experimental neuropathology 5.1. Oncological molecular pathology 4.1.1 . Systems neuropharmacology 5.1.1. Molecular pathology of lymphoid neoplasms 4.1.2 . Molecular neuropharmacology 5.1.2. Molecular pathology of solid tumors 4.1.3. Cellular neurobiology 5.1.3. Transcriptional regulation of gene expression 5.1.4. Biomedical epigenomics 4.1.4. Neurotoxicity and neurodegeneration mechanisms 5.1.5. Functional characterization of oncogenic mechanisms in lymphomagenesis 4.2. Brain ischemia: clinical and experimental studies 5.2. Diagnosis and therapy in oncology 4.3. Parkinson disease and other neurodegenerative movement 5.3. Molecular biology of reproduction and development disorders: clinical and experimental research 5.4. Genetics 5.5. 4.4. Neurophysiology and functional studies of the nervous system Melanoma: imaging, genetics and immunology 5.6. Hematopoietic progenitor cell transplantation 4.4.1. Neurophysiology 5.7. Hematological oncology 4.5. Muscle research and mitochondrial function 5.7.1. Myeloma and other monoclonal gammapathies 4.6. Pathophysiology and treatment of neurodegenerative disorders 5.7.2. Myeloid neoplasmas 5.7.3. Mechanisms of progression in monoclonal gammopathies 4.7. Biological bases of psychiatric disorders and nuclear psychiatry 5.7.4. Lymphoid neoplasms 4.7.1. Schizophrenia 5.8. Physiopathology and molecular bases in hematology 4.7.2. Child and adolescent psychiatry and psychology 5.8.1. Microenvironment in lymphoma pathogenesis and therapy 4.7.3. Addictions group 5.9. Hemotherapy - hemostasis 4.7.4. Multimodal neuroimaging in high risk and early psychosis 5.10. Molecular and translational oncology 4.7.5. Bipolar disorders 5.11. Cell proliferation and signaling 5.12. 4.8. Neuropsychology Cell compartments and signalling 5.12.1. Signal transduction and cell cycle 4.9. Systems neuroscience 5.12.2. Endocytosis and intracellular trafficking of proteins and cholesterol 4.9.1. Theoretical neurobiology of cortical circuits 5.12.3. Lipid trafficking and disease 4.9.2. Cortical circuit dynamics 5.13. Translational genomics and targeted therapeutics in solid tumors 4.10. Clinical and experimental neuroimmunology 4.10.1. Pathogenesis of autoimmune neuronal disorders 4.10.2. Advanced imaging in neuroimmunological diseases (IMAGINEM) 4.10.3. Pathogenesis and new treatments in multiple sclerosis TRANSVERSAL RESEARCH GROUPS 4.11. Neurobiology unit T.1. Primary healthcare transversal research group 4.12. Alzheimer’s disease and other cognitive disorders T.2. Research in nursing T.3. Clinical pharmacology

16 Staff

M TOTAL 37% 1,627 W 63%

1. PREDOCTORAL RESEARCHERS (R1) 8 26% 7 63% WOMEN 37% MAN

1 2. POSTDOCTORAL RESEARCHERS (R2) 6 19%

68% WOMEN 32% MAN

5 3. RESEARCHERS (R3A) 4 22% 2 51% WOMEN 49% MAN

3 4. JUNIOR GROUP LEADERS (R3B) 1%

40% WOMEN 60% MAN

1. PREDOCTORAL RESEARCHERS (R1) 5. GROUP LEADERS (R4) 2. POSTDOCTORAL RESEARCHERS (R2) 6% 3. RESEARCHERS (R3A) 4. JUNIOR GROUP LEADERS (R3B) 24% WOMEN 76% MAN 5. GROUP LEADERS (R4) 6. TECHNICAL SUPPORT 6. TECHNICAL SUPPORT 17% 7. CORE FACILITIES 8. MANAGEMENT STAFF 82% WOMEN 18% MAN

7. CORE FACILITIES 3%

85% WOMEN 15% MAN

8. MANAGEMENT STAFF 6%

66% WOMEN 34% MAN

17 FOREWORD IDIBAPS

Recruitment and retention of talent programs

INSTITUCIÓ CATALANA DE RECERCA IDIBAPS 80/20 PROGRAMME IDIBAPS 50/50 PROGRAMME I ESTUDIS AVANÇATS (ICREA) With the final mission to strengthen With the final mission to strengthen translational clinical research IDIBAPS translational clinical research, IDIBAPS launched this program in 2013. The 80/20 and Hospital Clinic of Barcelona started in researchers are consolidated clinical 2012 this pioneering program designed to investigators from Hospital Clinic and facilitate the combination of research and IDIBAPS with no reductions in the care clinical activity. The 50/50 researchers are load due to management positions within young medical staff specialists (MD) with a the Hospital organization and strategic strong research career (PhD) built up, at ICREA, the Catalan Institute for Research research projects to develop. The least in part, in the most prestigious foreign and Advanced Studies, is a foundation beneficiaries of this program release 30 research centers. These junior group supported by the Catalan Government that hours devoted to weekly care activities leaders are called to be the future clinical recruits top scientists for the Catalan R&D (80% of a full-time dedication) to dedicate research group leaders that this institution system. Currently IDIBAPS has six ICREA to research. It consists in a 3-year position will need. Research Professors: extendable for additional 2 years prior positive evaluation. Felicia Alexandra Hanzu Josep Dalmau Endocrine disorders: crosstalk between Pathogenesis of autoimmune neuronal Maria Cinta Cid molecular and metabolic determinants disorders Systemic vasculitis Ignacio Revuelta Josep M. Llovet Josep M. Miró Translational research in posttransplant Translational research in hepatic oncology Endocarditis. Cardiovascular infections. neoplasia Experimental model José Ignacio Martín-Subero Isabel Blanco Biomedical epigenomics Translational research in pulmonary vascular diseases: cell proliferation and apoptotic Albert Pol mechanisms in pulmonary arterial Lipid trafficking and disease hypertension

Antonio Postigo Gisela Sugranyes Transcriptional regulation of gene expression Multimodal neuroimaging in high risk and early psychosis María Victoria Sánchez-Vives Systems neuroscience Carlos Fernández de Larrea Mechanisms of progression in monoclonal gammopathies

Eduard Guasch Arrhythmias and physical activity

Sara Llufriu Advanced imaging in neuroimmunological diseases (ImaginEM)

18 PHD4MD PROGRAMME Elisa Pose PROJECT A systems biology approach to understanding the molecular pathogenesis of chronic liver disease progression. PRINCIPAL INVESTIGATORS Pere Ginés (IDIBAPS) and Patrick Aloy (IRB Barcelona) The health system requires an increasing number of physician-scientists with a deep Irene López understanding of research and medicine PROJECT to ensure that discoveries in fundamental Splicing factor mutations in hematological research can reach clinical practice. The malignancies. objective of the PhD4MD programme is to PRINCIPAL INVESTIGATORS provide medical doctors with advanced Dolors Colomer (IDIBAPS) and Juan Valcárcel hands-on training on the latest fields of (CRG) research and cutting-edge technologies. Ultimately, the medical professionals Alexandra Pérez enrolled in the program will obtain their PROJECT PhD title from one of the associated Multiple system atrophy: synuclein Universities. regulation and biomarkers discovery. Medical professionals who enroll in the PRINCIPAL INVESTIGATORS PhD4MD programme will carry out a M José Martí (IDIBAPS) and Gian Tartaglia project in translational research jointly (CRG) coordinated by a basic and a clinical research investigator, belonging to one of Francisco Aya the four participating institutions: the CRG PROJECT (Centre for Genomic Regulation), the IRB Targeting of BRAF mutant mRNA Barcelona, the IDIBAPS and the VHIR (Vall alternative splicing in melanoma. d'Hebron Research Institute). PRINCIPAL INVESTIGATORS The PhD4MD programme was launched Ana Arance (IDIBAPS) and Juan Valcárcel for the first time in 2015 and 2 new (CRG) positions were awarded in 2018. During this year, 7 awardees of the programme Fernanda Inés Hernández have been working at IDIBAPS. PROJECT Cellular senescense in fibrosing interstitial lung diseases Juan Miguel Cejalvo PRINCIPAL INVESTIGATORS PROJECT Jacobo Sellarés (IDIBAPS) and Manuel Uncovering the molecular and cellular Serrano (IRB) mechanisms of metastatic dormancy in luminal breast cancer. PRINCIPAL INVESTIGATORS Aleix Prat (IDIBAPS) and Roger Gomis (IRB Barcelona)

Csaba Fehér PROJECT Systems vaccinology to guide effective and safe hiv therapeutic vaccines. PRINCIPAL INVESTIGATORS Felipe García / Mireia Arnedo (IDIBAPS) and Patrick Aloy (IRB Barcelona)

19 FOREWORD IDIBAPS

Research Scientiﬁc and publications innovation outputs

Publication output and indicators.

OUTPUT TOTAL IF MEAN IF %Q1 %D1

Original articles 1.111 7.237 6,51 67% 31%

Reviews 253 1.534 6,06 49% 28%

Editorials 61 466 7,64 67% 44%

Clinical guidelines 39 261 6,69 54% 38%

Case reports 40 136 3,40 45% 10%

Letters 96 993 10,34 70% 51%

Consortium publications 41 616 15,02 88% 68%

TOTAL 1.641 11.242 6,85 64% 33%

FIGURE LEGEND Output % Q1 Total number of documents published in scholarly % of publications published in journals ranked in the first journals indexed in the ISI Web of Science. quartile (top 25%) of their category as ordered by the 2017 Journal Citation Reports. Total IF Accumulated impact factor of all the scientific % D1 publications. % of publications published in journals ranked in the first decile (top 10%) of their category as ordered by the 2017 Mean IF Journal Citation Reports. Mean impact factor of all the scientific publications.

20 Evolution of the total number of original articles (A) and the total number of original articles per area (B).

A) Number of original articles

1.127 1.111 1.092 1.025 1.004

2014 2015 2016 2017 2018

B) Number of original articles per area 336 319 298 296 289 292 282 280 284 280 262 249 249 259 248 229 227 225 194 188 179 180 165 169 156 2015 2015 2015 2015 2015 2014 2016 2017 2018 2014 2016 2017 2018 2014 2016 2017 2018 2014 2016 2017 2018 2014 2016 2017 2018

AREA 1 AREA 2 AREA 3 AREA 4 AREA 5

FIGURE LEGEND Only original articles were taken into consideration. Publications resulting from collaboration between teams from different areas have been counted once for each area, so the sum of the articles per area is higher than the total.

Evolution of the mean IF (A) and % Q1 (B).

A) Mean IF B) % Q1 6,5 6,1 69% 69% 69% 5,7 5,6 67% 5,5 66%

2014 2015 2016 2017 2018 2014 2015 2016 2017 2018

FIGURE LEGEND Only original articles were taken into consideration. %Q1: % of publications published in journals ranked in the ﬁrst quartile (top 25%) of their category as ordered by the 2017 Journal Citation Reports.

21 FOREWORD IDIBAPS

Original articles in the highest impact TABLE A factor journals (IF>10).

TOTAL JOURNAL IF ORIGINAL ARTICLES New England journal of medicine 79,26 6 Lancet 53,254 3 Number of original articles Jama-journal of the american medical association 47,661 3 in IF>10 journals. Nature 41,577 1 170 (see table A). Science 41,058 1 Lancet oncology 36,421 5 Nature medicine 32,621 1 The lancet neurology 27,144 4 The lancet infectious diseases 25,148 2 Originals with IDIBAPS European heart journal 23,425 4 54 main contribution. Cell stem cell 23,29 1 (see table B). The lancet. Respiratory medicine 21,466 1 Jama oncol 20,871 1 Gastroenterology 20,773 7 Cell metabolism 20,565 1 Nature cell biology 19,064 1 Circulation 18,881 6 European urology 17,581 1 Gut 17,016 6 Journal of the american college of cardiology 16,834 7 Science translational medicine 16,71 1 Jama psychiatry 16,642 5 American journal of respiratory and critical care medicine 15,239 5 Blood 15,132 5 Journal of hepatology 15,04 11 Intensive care medicine 15,008 2 Neuron 14,319 1 Annals of the rheumatic diseases 12,35 2 Hepatology 14,079 12 Annals of oncology 13,93 4 Acs nano 13,709 1 Diabetes care 13,397 2 American journal of psychiatry 13,396 1 J Allergy clin immunol pract 13,258 1 Journal of clinical investigation 13,251 3 Alzheimer's and dementia 12,764 5 Nature communications 12,353 5 Annals of the rheumatic diseases 12,35 1 European respiratory journal 12,244 8 Nano letters 12,08 1 Molecular psychiatry 11,64 1 Journal of pineal research 11,613 1 Nucleic acids research 11,561 1 Science advances 11,511 1 Jama neurology 11,46 1 Journal of the national cancer institute 11,238 1 Autophagy 11,1 1 Brain; A journal of neurology 10,848 2 The lancet haematology 10,698 2 European journal of heart failure 10,683 3 Annals of neurology 10,25 2 Jacc: cardiovascular imaging 10,247 1 American journal of gastroenterology 10,231 3 Clinical cancer research 10,199 6 Leukemia 10,023 7 TOTAL 170

22 TABLE B

TEAMS AUTHORS TITLE REFERENCE IF INVOLVED

Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Primary Prevention of Cardiovascular Disease Journal 79,26 1.03 / 2.04 / 4.08 Arós F, Gómez-Gracia E, Ruiz-Gutiérrez V, Fiol M, with a Mediterranean Diet Supplemented with New england journal Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pintó Extra-Virgin Olive Oil or Nuts. of medicine. X, Basora J, Muñoz MA, Sorlí JV, Martínez JA, Fitó M, Gea 378(25):e34 A, Hernán MA, Martínez-González MA, PREDIMED Study Investigators.

Rimassa L, Assenat E, Peck-Radosavljevic M, Pracht M, Tivantinib for second-line treatment of Lancet oncology. 36,421 3.05 Zagonel V, Mathurin P, Rota Caremoli E, Porta C, Daniele MET-high, advanced hepatocellular (18):30146-3 B, Bolondi L, Mazzaferro V, Harris W, Damjanov N, carcinoma (METIV-HCC): a ﬁnal analysis of Pastorelli D, Reig M, Knox J, Negri F, Trojan J, López a phase 3, randomised, placebo-controlled López C, Personeni N, Decaens T, Dupuy M, Sieghart W, study. Abbadessa G, Schwartz B, Lamar M, Goldberg T, Shuster D, Santoro A, Bruix J.

Beekman R, Chapaprieta V, Russiñol N, Vilarrasa-Blasi The reference epigenome and regulatory Nature medicine. 32,621 5.01 / 5.07 / 5.08 R, Verdaguer-Dot N, Martens JHA, Duran-Ferrer M, Kulis chromatin landscape of chronic lymphocytic 24(6):868-880 M, Serra F, Javierre BM, Wingett SW, Clot G, Queirós AC, leukemia. Castellano G, Blanc J, Gut M, Merkel A, Heath S, Vlasova A, Ullrich S, Palumbo E, Enjuanes A, Martín-García D, Beà S, Pinyol M, Aymerich M, Royo R, Puiggros M, Torrents D, Datta A, Lowy E, Kostadima M, Roller M, Clarke L, Flicek P, Agirre X, Prosper F, Baumann T, Delgado J, López-Guillermo A, Fraser P, Yaspo ML, Guigó R, Siebert R, Martí-Renom MA, Puente XS, López-Otín C, Gut I, Stunnenberg HG, Campo E, Martin-Subero JI.

Armangue T, Spatola M, Vlagea A, Mattozzi S, Frequency, symptoms, risk factors, and The lancet neurology. 27,144 1.06 / 4.10 Cárceles-Cordon M, Martinez-Heras E, Llufriu S, Muchart outcomes of autoimmune encephalitis after 17(9):760-772 J, Erro ME, Abraira L, Moris G, Monros-Giménez L, herpes simplex encephalitis: a prospective Corral-Corral Í, Montejo C, Toledo M, Bataller L, Secondi observational study and retrospective G, Ariño H, Martínez-Hernández E, Juan M, Marcos MA, analysis. Alsina L, Saiz A, Rosenfeld MR, Graus F, Dalmau J, Spanish Herpes Simplex Encephalitis Study Group.

Torres A., Zhong N., Pachl J., Timsit J., Kollef M., Chen Z., Ceftazidime-avibactam versus meropenem in The lancet infectious 25,148 2.06 Song J., Taylor D., Laud P., Stone G., Chow J. nosocomial pneumonia, including ventilator diseases. -associated pneumonia (REPROVE): A 18(3):285-295 randomised, double-blind, phase 3 non- inferiority trial.

Brignole, Michele; Pokushalov, Evgeny; Pentimalli, A randomized controlled trial of atrioventricu- European heart 23,425 2.02 Francesco; Palmisano, Pietro; Chieffo, Enrico; Occhetta, lar junction ablation and cardiac resynchroni- journal. Eraldo; Quartieri, Fabio; Calo, Leonardo; Ungar, Andrea; zation therapy in patients with permanent 39(45):3999-4008 Mont, Lluis; Menozzi, Carlo; Alboni, Paolo; Bertero, atrial ﬁbrillation and narrow QRS. Giovanni; Klersy, Catherine; Noventa, Franco; Brignole, M.; Oddone, D.; Donateo, O.; Maggi, R.; Croci, F.; Solano, A.; Pentimalli, F.; Palmisano, P.; Landolina, M.; Chieffo, E.; Taravelli, E.; Occhetta, E.; Quartieri, F.; Bottoni, N.; Iori, M.; Calo, L.; Sgueglia, M.; Pieragnoli; Giorni, A.; Nesti, M.; Giannini, I.; Ungar, A.; Padeletti, L.; Pokushalov, E.; Romanov, A.; Peregudov, I.; Vidorreda, S.; Nunez, R.; Mont, L.; APAF-CRT Investigators

Coll M., Perea L., Boon R., Leite S., Vallverdú J., Generation of Hepatic Stellate Cells from Cell stem cell. 23,29 3.04 Mannaerts I., Smout A., El Taghdouini A., Blaya D., Human Pluripotent Stem Cells Enables In Vitro 23(1):101-113.E7 Rodrigo-Torres D., Graupera I., Aguilar-Bravo B., Chesne Modeling of Liver Fibrosis. C., Najimi M., Sokal E., Lozano J., van Grunsven L., Verfaillie C., Sancho-Bru P.

Tripathi DM, Vilaseca M, Lafoz E, Garcia-Calderó H, Simvastatin Prevents Progression of Acute on Gastroenterology. 20,773 3.06 Viegas Haute G, Fernández-Iglesias A, Rodrigues de Chronic Liver Failure in Rats With Cirrhosis 155(5):1564-1577 Oliveira J, García-Pagán JC, Bosch J, Gracia-Sancho J. and Portal Hypertension.

Panés J, García-Olmo D, Van Assche G, Colombel JF, Long-term Efficacy and Safety of Stem Cell Gastroenterology. 20,773 3.07 Reinisch W, Baumgart DC, Dignass A, Nachury M, Therapy (Cx601) for Complex Perianal 154(5):1334-1342.E4 Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Fistulas in Patients With Crohn's Disease. Goldin E, Richard MP, Diez MC, Tagarro I, Leselbaum A, Danese S, ADMIRE CD Study Group Collaborators.

23 FOREWORD IDIBAPS

Bonacci M, Lens S, Mariño Z, Londoño MC, Long-Term Outcomes of Patients With Gastroenterology. 20,773 1.02 / 3.03 / 3.04 Rodriguez-Tajes S, Sánchez-Tapias JM, Ramos-Casals M, HCV-Associated Cryoglobulinemic 155(2):311-315.E6. Hernández-Rodríguez J, Forns X. Vasculitis After Virologic Cure.

Ortega-Paz L, Brugaletta S, Ariotti S, Akkerhuis KM, Adenosine and Ticagrelor Plasma Levels in Circulation. 18,881 2.01 Karagiannis A, Windecker S, Valgimigli M, HI-TECH Patients With and Without Ticagrelor-Rela- 138(6):646-648. investigators. ted Dyspnea.

Luna J, Boni J, Cuatrecasas M, Boﬁll-De Ros X, DYRK1A modulates c-MET in pancreatic Gut. 17,943 3.11 / 5.01 Núñez-Manchón E, Gironella M, Vaquero EC, Arbones ML, ductal adenocarcinoma to drive tumour 68(8):1465-1476 de la Luna S, Fillat C. growth.

Carballal S, Maisterra S, López-Serrano A, Gimeno- Real-life chromoendoscopy for neoplasia Gut. 17,016 3.07 / 3.11 / 5.01 García AZ, Vera MI, Marín-Garbriel JC, Díaz-Tasende J, detection and characterisation in long-stan- 67(1):70-78 Márquez L, Álvarez MA, Hernández L, De Castro L, Gordillo ding IBD. J, Puig I, Vega P, Bustamante-Balén M, Acevedo J, Peñas B, López-Cerón M, Ricart E, Cuatrecasas M, Jimeno M, Pellisé M, EndoCAR group of the Spanish Gastroentero- logical Association and Spanish Digestive Endoscopy Society.

Fernández J, Acevedo J, Wiest R, Gustot T, Amoros A, Bacterial and fungal infections in Gut. 17,016 3.04 Deulofeu C, Reverter E, Martínez J, Saliba F, Jalan R, Welzel acute-on-chronic liver failure: Prevalence, 67(10):1870-1880 T, Pavesi M, Hernández-Tejero M, Ginès P, Arroyo V, characteristics and impact on prognosis. European Foundation for the Study of Chronic Liver Failure.

Ekren PK, Ranzani OT, Ceccato A, Li Bassi G, Muñoz Evaluation of the 2016 Infectious Diseases American journal of 15,239 2.06 Conejero E, Ferrer M, Niederman MS, Torres A. Society of America/American Thoracic respiratory and critical Society Guideline Criteria for Risk of Multi- drug care medicine. Resistant Pathogens in Hospital- acquired and 197(6):826-830 Ventilator-associated Pneumonia Patients in the Intensive Care Unit.

Almagro P, De la Sierra A, Acosta E, Navarro A, Garcia ME, Spirometrically Conﬁrmed COPD Worsens American journal of 15,239 2.09 / 5.01 Valdivieso S, Castañeda T, Agustí A. Long-term Prognosis After Percutaneous respiratory and critical care medicine. Coronary Intervention. 197(6):824-826

Mendez, Raul; Menendez, Rosario; Cilloniz, Catia; Initial Inﬂammatory Proﬁle in Community-ac- American journal of 15,239 2.06 Amara-Elori, Isabel; Amaro, Rosanel; Gonzalez, Paula; quired Pneumonia Depends on Time since respiratory and critical Posadas, Tomas; Gimeno, Alexandra; Espana, Pedro P.; Onset of Symptoms. care medicine. Almirall, Jordi; Torres, Antoni. 198(3):370-378

Clot G, Jares P, Giné E, Navarro A, Royo C, Pinyol M, A gene signature that distinguishes Blood. 15,132 5.01 / 5.07 / 5.08 Martín-Garcia D, Demajo S, Espinet B, Salar A, Ferrer A, conventional and leukemic nonnodal mantle 132(4):413-422 Muntañola A, Aymerich M, Rauert-Wunderlich H, Jaffe ES, cell lymphoma helps predict outcome. Connors JM, Gascoyne RD, Delabie J, López-Guillermo A, Ott G, Wright GW, Staudt LM, Rosenwald A, Scott DW, Rimsza LM, Beà S, Campo E.

Crespo G., Trota N., Londoño M., Mauro E., Baliellas C., The efficacy of direct anti-HCV drugs Journal of hepatology. 15,04 3.03 / 3.10 Castells L., Castellote J., Tort J., Forns X., Navasa M. improves early post-liver transplant survival 69(1):11-17 and induces signiﬁcant changes in waiting list composition.

Agarwal K, Castells L, Müllhaupt B, Rosenberg WMC, McNabb B, Sofosbuvir/Velpatasvir for 12 Weeks in Journal of hepatology. 15,04 3.03 Arterburn S, Camus G, McNally J, Stamm LM, Brainard DM, Mani Genotype 1-4 HCV-Infected Liver Transplant 69(3):603-607 Subramanian G, Mariño Z, Dufour JF, Forns X. Recipients.

Londoño M., Souza L., Lozano J., Miquel R., Abraldes J., Molecular proﬁling of subclinical Journal of hepatology. 15,04 3.03 / 3.10 Llovet L., Quaglia A., Rimola A., Navasa M., inﬂammatory lesions in long-term surviving 69(3):626-634 Sánchez-Fueyo A. adult liver transplant recipients.

Finn R., Merle P., Granito A., Huang Y., Bodoky G., Pracht M., Outcomes of sequential treatment with sora- Journal of hepatology. 15,04 3.05 Yokosuka O., Rosmorduc O., Gerolami R., Caparello C., fenib followed by regorafenib for HCC: 69(2):353-358 Cabrera R., Chang C., Sun W., LeBerre M., Baumhauer A., Additio- nal analyses from the phase III Meinhardt G., Bruix J. RESORCE trial.

Solà E, Solé C, Simón-Talero M, Martín-Llahí M, Castellote J, Midodrine &albumin for preventing Journal of hepatology. 15,04 3.04 / 3.10 / 4.08 Garcia-Martínez R, Moreira R, Torrens M, Márquez F, complications in patients with cirrhosis 69(6):1250-1259 Fabrellas N, de Prada G, Huelin P, Lopez Benaiges E, Ventura awaiting Liver transplantation. M, Manríquez M, Nazar A, Ariza X, Suñé P, Graupera I, Pose E, Colmenero J, Pavesi M, Guevara M, Navasa M, Xiol X, Córdoba J, Vargas V, Ginès P.

24 Welte T, Dellinger RP, Ebelt H, Ferrer M, Opal SM, Singer Efficacy and safety of trimodulin, a novel Intensive care 15,008 2.06 M, Vincent JL, Werdan K, Martin-Loeches I, Almirall J, polyclonal antibody preparation, in patients medicine. Artigas A, Ignacio Ayestarán J, Nuding S, Ferrer R, Sirgo with severe community-acquired pneumo- 44(4):438-448 Rodríguez G, Shankar-Hari M, Álvarez-Lerma F, Riessen nia: a randomized, placebo-controlled, R, Sirvent JM, Kluge S, Zacharowski K, Bonastre Mora J, double-blind, multicenter, phase II trial Lapp H, Wöbker G, Achtzehn U, Brealey D, Kempa A, (CIGMA study). Sánchez García M, Brederlau J, Kochanek M, Reschreiter HP, Wise MP, Belohradsky BH, Bobenhausen I, Dälken B, Dubovy P, Langohr P, Mayer M, Schüttrumpf J, Wartenberg-Demand A, Wippermann U, Wolf D, Torres A.

Delia Blaya; Beatriz Aguilar-Bravo; Fengie Hao; Silvia Expression of microRNA-155 in inﬂammatory Hepatology. 14,079 3.04 / 3.09 Casacuberta-Serra; Mar Coll; Luis Perea; Julia Vallverdu; cells modulates liver injury. 68(2):691-706 Isabel Graupera; Elisa Pose; Barquinero Mañez, Jordi; Francisco Javier Cubero; Juan Caballería; Pere Ginès; Pau Sancho-Bru.

Alcaraz-Quiles J., Casulleras M., Oettl K., Titos E., Oxidized Albumin Triggers a Cytokine Storm Hepatology. 14,079 3.04 Flores-Costa R., Duran-Güell M., López-Vicario C., Pavesi in Leukocytes Through P38 Mitogen-Activa- 68(5):1937-1952 M., Stauber R., Arroyo V., Clària J. ted Protein Kinase: Role in Systemic Inﬂammation in Decompensated Cirrhosis.

Rimola J, Díaz-González Á, Darnell A, Varela M, Pons F, Complete response under sorafenib in Hepatology. 14,079 3.05 / 3.06 / 5.02 Hernandez-Guerra M, Delgado M, Castroagudin J, Matilla patients with hepatocellular carcinoma. 67(2):612-622 A, Sangro B, Rodriguez de Lope C, Sala M, Gonzalez C, Relationship with dermatologic adverse Huertas C, Minguez B, Ayuso C, Bruix J, Reig M. events.

Mauro E, Crespo G, Montironi C, Londoño MC, Portal pressure and liver stiffness measure- Hepatology. 14,079 3.03 / 3.05 / Hernández-Gea V, Ruiz P, Sastre L, Lombardo J, Mariño ments in the prediction of ﬁbrosis regression 67(5):1683-1694 3.06 / 3.10 Z, Díaz A, Colmenero J, Rimola A, Garcia-Pagán JC, after SVR in recurrent hepatitis C. Brunet M, Forns X, Navasa M .

Reau N, Kwo PY, Rhee S, Brown RS, Agarwal K, Angus P, Glecaprevir/Pibrentasvir Treatment in Liver Hepatology. 14,079 3.03 Gane E, Kao JH, Mantry PS, Mutimer D, Reddy KR, Tran or Kidney Transplant Patients With Hepatitis 68(4):1298-1307 TT, Hu YB, Gulati A, Krishnan P, Dumas EO, Porcalla A, C Virus Infection. Shulman NS, Liu W, Samanta S, Trinh R, Forns X.

Blasi A, Calvo A, Prado V, Reverter E, Reverter JC, Coagulation failure in patients with Hepatology. 14,079 3.04 / 3.10 / 5.09 Hernández-Tejero M, Aziz F, Amoros A, Cardenas A, Acute-on-Chronic Liver Failure (ACLF) and 68(6):2325-2337 Fernández J. decompensated cirrhosis: beyond INR.

Paré L, Pascual T, Seguí E, Teixidó C, Gonzalez-Cao M, Association between PD1 mRNA and Annals of oncology. 13,93 1.06 / 3.01 / 3.05 Galván P, Rodríguez A, González B, Cuatrecasas M, response to anti-PD1 monotherapy across 29(10):2121-2128 / 5.01 / 5.13 Pineda E, Torné A, Crespo G, Martin-Algarra S, Pérez-Ruiz multiple cancer-types. E, Reig Ò, Viladot M, Font C, Adamo B, Vidal M, Gaba L, Muñoz M, Victoria I, Ruiz G, Viñolas N, Mellado B, Maurel J, Garcia-Corbacho J, Molina-Vila MÁ, Juan M, Llovet JM, Reguart N, Arance A, Prat A.

Nuciforo P, Pascual T, Cortés J, Llombart-Cussac A, A predictive model of pathological response Annals of oncology. 13,93 1.03 / 5.13 Fasani R, Paré L, Oliveira M, Galvan P, Martínez N, based on tumor cellularity and tumor-inﬁltra- 29(1):170-177 Bermejo B, Vidal M, Pernas S, López R, Muñoz M, Garau I, ting lymphocytes (CelTIL) in HER2-positive Manso L, Alarcón J, Martínez E, Rodrik-Outmezguine V, breast cancer treated with chemo-free dual Brase JC, Villagrasa P, Prat A., Holgado E. HER2 blockade.

Singha S; Shao K; Ellestad KK; Yang Y; Santamaria P. Nanoparticles for Immune Stimulation Against Acs nano. 13,709 3.14 Infection, Cancer, and Autoimmunity. 12(11):10621-10635

Gimenez M., Tannen AJ, Reddy M, Moscardo V, Revisiting the Relationships Between Diabetes care. 13,397 3.14 Conget I, Oliver N. Measures of Glycemic Control and 41(2):326-332 Hypoglycemia in Continuous Glucose Monitoring Data Sets.

Mariño-Sanchez F, Valls-Mateus M, Haag O, Alobid I, Smell loss is associated with severe and J allergy clin immunol 13,258 2.08 Bousquet J, Mullol J. uncontrolled disease in children and pract. adolescents with persistent allergic rhinitis. 6(5):1752-1755.E3

Albero R, Enjuanes A, Demajo S, Castellano G, Pinyol M, Cyclin D1 overexpression induces global Journal of clinical 13,251 5.01 / 5.08 García N, Capdevila C, Clot G, Suárez-Cisneros H, transcriptional downregulation in lymphoid investigation. Shimada M, Karube K, López-Guerra M, Colomer D, Beà neosplasms. 128(9):4132-4147 S, Martin-Subero JI, Campo E, Jares P.

25 FOREWORD IDIBAPS

Liu Y., Siles L., Lu X., Dean K., Cuatrecasas M., Postigo A., Mitotic polarization of transcription factors Nature communica- 12,353 5.01 Dean D. during asymmetric division establishes fate tions. of forming cancer cells. 9(1):2424

Cilloniz C, Ferrer M, Liapikou A, Garcia-Vidal C, Acute Respiratory Distress Syndrome in European respiratory 12,244 1.03 / 2.06 Gabarrus A, Ceccato A, Puig de La Bellacasa J, Blasi F, Mechanically-Ventilated Patients with journal. Torres A. Community-Acquired Pneumonia. 51(3)

Alcázar-Navarrete B, Ruiz Rodríguez O, Conde Baena P, Persistently elevated exhaled nitric oxide European respiratory 12,244 2.09 Romero Palacios PJ, Agusti A. fraction is associated with increased risk of journal. exacerbation in COPD. 51(1)

Celli, Bartolome R.; Locantore, Nicholas; Tal-Singer, Ruth; Emphysema and extrapulmonary tissue loss European respiratory 12,244 2.09 Riley, John; Miller, Bruce; Vestbo, Jorgen; Yates, Julie C.; in COPD: a multi-organ loss of tissue journal. Silverman, Edwin K.; Owen, Caroline A.; Divo, Miguel; phenotype. 51(2) Pinto-Plata, Victor; Wouters, Emiel F. M.; Faner, Rosa; Agusti, Alvar;ECLIPSE Study Investigators.

Melgar-Lesmes P., Luquero A, Parra-Robert M, Mora A, Graphene-Dendrimer Nanostars for Nano letters. 12,08 3.04 Ribera J, Edelman ER, Jiménez W. Targeted Macrophage Overexpression of 18(9):5839-5845 Metalloproteinase 9 and Hepatic Fibrosis Precision Therapy.

Corpas R., Griñán-Ferré C., Palomera-Ávalos V., Porquet Melatonin induces mechanisms of brain Journal of pineal 11,613 4.01 / 5.09 D., García de Frutos P., Franciscato Cozzolino S., resilience against neurodegeneration. research. Rodríguez-Farré E., Pallàs M., Sanfeliu C., Cardoso B. 65(4):e12515

Ninfali C., Siles L., Darling D., Postigo A. Regulation of muscle atrophy-related genes Nucleic acids 11,561 5.01 by the opposing transcriptional activities of research. ZEB1/CtBP and FOXO3. 46(20):10697-10708

Andorra M., Nakamura K, Lampert EJ, Pulido-Valdeoli- Assessing Biological and Methodological Jama neurology. 11,46 4.10 vas I, Zubizarreta I, Llufriu S, Martinez-Heras E, Sola-Valls Aspects of Brain Volume Loss in Multiple 75(10):1246-1255 N, Sepulveda M, Tercero-Uribe A, Blanco Y, Saiz A, Sclerosis. Villoslada P, Martinez-Lapiscina EH.

Petit-Pedrol M., Sell J., Planagumà J., Mannara F., LGI1 antibodies alter Kv1.1 and AMPA Brain; a journal of 10,848 4.04 / 4.10 Radosevic M., Haselmann H., Ceanga M., Sabater L., receptors changing synaptic excitability, neurology. Spatola M., Soto D., Gasull X., Dalmau J., Geis C. plasticity and memory. 141(11):3144-3159

Miró Ò, Tost J, Gil V, Martín-Sánchez FJ, Llorens P, The BRONCH-AHF study: effects on European journal of 10,683 1.07 Herrero P, Mebazaa A, Harjola VP, Ríos J, Marco-Hernán- short-term outcome of nebulized bronchodi- heart failure. dez J, Collins SP, Peacock WF, Hollander JE, Lorca MT, lators in emergency department patients 20(4):822-826 Jacob J, ICA-SEMES Research Group. diagnosed with acute heart failure.

Acosta J, Fernández-Armenta J, Borràs R, Anguera I, Scar Characterization to Predict Life-Threa- Jacc: cardiovascular 10,247 2.01 / 2.02 Bisbal F, Martí-Almor J, Tolosana JM, Penela D, Andreu D, tening Arrhythmic Events and Sudden imaging. Soto-Iglesias D, Evertz R, Matiello M, Alonso C, Villuendas Cardiac Death in Patients With Cardiac 11(4):561-572 R, de Caralt TM, Perea RJ, Ortiz JT, Bosch X, Serra L, Resynchronization Therapy: The Planes X, Greiser A, Ekinci O, Lasalvia L, Mont L, GAUDI-CRT Study. Berruezo A.

Reig, Anna; Sese, Pilar; Pares, Albert. Effects of Bezaﬁbrate on Outcome and American journal of 10,231 3.08 Pruritus in Primary Biliary Cholangitis With gastroenterology. Suboptimal Ursodeoxycholic Acid 113(1):49-55 Response.

Ordás I, Domènech E, Mañosa M, García-Sánchez V, Post-operative morbidity and mortality of a American journal of 10,231 2.03 / 3.07 / 3.11 Iglesias-Flores E, Rodríguez-Moranta F, Márquez L, cohort of steroid refractory acute severe gastroenterology. Merino O, Fernández-Bañares F, Gomollón F, Vera M, ulcerative colitis: Nationwide multicenter 113(7):1009-1016 Gutiérrez A, LLaó J, Gisbert JP, Aguas M, Arias L, study of the GETECCU ENEIDA Registry. Rodríguez-Lago I, Muñoz C, Alcaide N, Calvet X, Rodríguez C, Montoro MA, García S, De Castro ML, Piqueras M, Pareja L, Ribes J, Panés J, Esteve M, ENEIDA registry of GETECCU.

Lim, Ho Yeong; Merle, Philippe; Weiss, Karl Heinz; Yau, Phase II Studies with Refametinib or Clinical cancer 10,199 3.05 Thomas; Ross, Paul; Mazzaferro, Vincenzo; Blanc, Refametinib plus Sorafenib in Patients with research. Jean-Frederic; Ma, Yuk Ting; Yen, Chia Jui; Kocsis, Judit; RAS-Mutated Hepatocellular Carcinoma. 24(19):4650-4661 Choo, Su Pin; Sukeepaisarnjaroen, Wattana; Gerolami, Rene; Dufour, Jean-Francois; Gane, Edward J.; Ryoo, Baek-Yeol; Peck-Radosavljevic, Markus; Thong Dao; Yeo, Winnie; Lamlertthon, Wisut; Thongsawat, Satawat; Teufel, Michael; Roth, Katrin; Reis, Diego; Childs, Barrett H.; Krissel, Heiko; Llovet, Josep M.

26 Hernández-Boluda J., Pereira A., Correa J., Alvarez-La- Performance of the myeloﬁbrosis secondary Leukemia. 10,023 5.07 rrán A., Ferrer-Marín F., Raya J., Martínez-López J., to PV and ET-prognostic model (MYSEC-PM) 32(2):553-555 Pérez-Encinas M., Estrada N., Velez P., Fox M., in a series of 262 patients from the Spanish García-Gutiérrez V., Payer A., Kerguelen A., Cuevas B., registry of myeloﬁbrosis. Durán M., Ramírez M., Gómez-Casares M., Mata-Váz- quez M., Mora E., Martínez-Valverde C., Gómez M., Cervantes F.

Nadeu F., Clot G, Delgado J, Martín-García D, Baumann Clinical impact of the subclonal architecture Leukemia. 10,023 5.01 / 5.07 / 5.08 T, Salaverria I, Beà S, Pinyol M, Jares P, Navarro A, and mutational complexity in chronic 32(3):645-653 Suárez-Cisneros H, Aymerich M, Rozman M, Villamor N, lymphocytic leukemia. Colomer D, González M, Alcoceba M, Terol MJ, Navarro B, Colado E, Payer ÁR, Puente XS, López-Otín C, López-Guillermo A, Enjuanes A, Campo E.

Karube K, Enjuanes A, Dlouhy I, Jares P, Martin-Garcia D, Integrating genomic alterations in diffuse Leukemia. 10,023 5.01 / 5.04 / 5.07 Nadeu F, Ordóñez GR, Rovira J, Clot G, Royo C, Navarro large B-cell lymphoma identiﬁes new 32(3):675-684 A, Gonzalez-Farre B, Vagheﬁ A, Castellano G, relevant pathways and potential therapeutic Rubio-Perez C, Tamborero D, Briones J, Salar A, Sancho targets. JM, Mercadal S, Gonzalez-Barca E, Escoda L, Miyoshi H, Ohshima K, Miyawaki K, Kato K, Akashi K, Mozos A, Colomo L, Alcoceba M, Valera A, Carrió A, Costa D, Lopez-Bigas N, Schmitz R, Staudt LM, Salaverria I, López-Guillermo A, Campo E.

De Larrea C., Isola I., Pereira A., Cibeira M., Magnano L., Evolving M-protein pattern in patients with Leukemia. 10,023 1.06 / 5.07 / Tovar N., Rodríguez-Lobato L., Calvo X., Aróstegui J., Díaz smoldering multiple myeloma: impact on 32(6):1427-1434 5.08 / 5.09 T., Lozano E., Rozman M., Yagüe J., Bladé J., Rosiñol L. early progression

FIGURE LEGEND Original articles with main author (ﬁrst, last or corresponding author) from IDIBAPS.

27 FOREWORD IDIBAPS

Translation of knowledge and innovation

CLINICAL GUIDELINES

As a general perspective of IDIBAPS’ impact in society, it is worth mentioning that every year our researchers participate in the Clinical guidelines elaboration of international clinical guides. published in 2018. These guidelines have a remarkable impact 39 in patients’ care and medical practice.

TEAMS AUTHORS TITLE REFERENCE IF Q/D1 INVOLVED

Masip J, Peacock WF, Price S, Cullen L, Martin-Sanchez Indications and practical approach to European heart journal. 23,425 Q1/D1 1.07 FJ, Seferovic P, Maisel AS, Miro O, Filippatos G, Vrints C, non-invasive ventilation in acute heart failure. 39(1):17-25 Christ M, Cowie M, Platz E, McMurray J, DiSomma S, Zeymer U, Bueno H, Gale CP, Lettino M, Tavares M, Ruschitzka F, Mebazaa A, Harjola VP, Mueller C, Acute Heart Failure Study Group of the Acute Cardiovascular Care Association and the Committee on Acute Heart Failure of the Heart Failure Association of the European Society of Cardiology.

Rutter MD, Beintaris I, Valori R, Chiu HM, Corley DA, World Endoscopy Organization Consensus Gastroenterology. 20,773 Q1/D1 5.01 Cuatrecasas M, Dekker E, Forsberg A, Gore-Booth J, Statements on Post-Colonoscopy and 155(3):909-925.E3 Haug U, Kaminski MF, Matsuda T, Meijer GA, Morris E, Post-Imaging Colorectal Cancer. Plumb AA, Rabeneck L, Robertson DJ, Schoen RE, Singh H, Tinmouth J, Young GP, Sanduleanu S.

Borgmann H, Cooperberg M, Murphy D, Loeb S, N'Dow J, Online Professionalism-2018 Update of European urology. 17,581 Q1/D1 2.10 Ribal MJ, Woo H, Rouprêt M, Winterbottom A, Wijburg C, European Association of Urology (@Uroweb) 74(5):644-650 Wirth M, Catto J, Kutikov A. Recommendations on the Appropriate Use of Social Media.

Angeli P., Bernardi M., Villanueva C., Francoz C., EASL Clinical Practice Guidelines for the Journal of hepatology. 15,040 Q1/D1 3.04 Mookerjee R., Trebicka J., Krag A., Laleman W., Gines P. management of patients with decompensated 69(2):406-460 cirrhosis.

Galle, PR.; Forner, A; Llovet, JM.; Mazzaferro, V; EASL Clinical Practice Guidelines: Manage- Journal of hepatology. 15,040 Q1/D1 3.05 Piscaglia, F; Raoul, JL; Schirmacher, P; Vilgrain, V. ment of hepatocellular carcinoma. 69(1):182-236

European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Manage- Journal of hepatology, 15,040 Q1/D1 4.07 ment of alcohol-related liver disease. supplement. 69(1):154-181

Aapro M; Beguin Y; Bokemeyer C; Dicato M; Gascon P; Management of anaemia and iron deﬁciency in Annals of oncology. 13,930 Q1/D1 5.10 Glaspy J; Hofmann A; Link H; Littlewood T; Ludwig H; patients with cancer: ESMO Clinical Practice 29(supplement_4):i- Österborg A; Pronzato P; Santini V; Schrijvers D; Stauder Guidelines. v96-iv110 R; Jordan K; Herrstedt J; ESMO Guidelines Committee.

Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro 4th ESO-ESMO International Consensus Annals of oncology. 13,930 Q1/D1 5.13 M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Guidelines for Advanced Breast Cancer (ABC 4). 29(8):1634-1657 Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortés J, Curigliano G, Diéras V, El Saghir NS, Eniu A, Fallowﬁeld L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP.

Vogel A, Cervantes A, Chau I, Daniele B, Llovet J, Meyer Hepatocellular carcinoma: ESMO Clinical Annals of oncology. 13,930 Q1/D1 3.05 T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher Practice Guidelines for diagnosis, treatment 29(4): iv238-iv255 P, Verslype C, Zech CJ, Arnold D, Martinelli E, ESMO and follow-up. Guidelines Committee.

Guidi J, Brakemeier EL, Bockting CLH, Cosci F, Cuijpers Methodological Recommendations for Trials Psychotherapy and 13,122 Q1/D1 4.07 P, Jarrett RB, Linden M, Marks I, Peretti CS, Rafanelli C, of Psychological Interventions. psychosomatics. Rief W, Schneider S, Schnyder U, Sensky T, Tomba E, 87(5):276-284 Vazquez C, Vieta E, Zipfel S, Wright JH, Fava GA.

28 Harjola V., Parissis J., Brunner-La Rocca H., Celutkiene J., Comprehensive in-hospital monitoring in European journal of 10,683 Q1/D1 1.07 Chioncel O., Collins S., De Backer D., Filippatos G., Gayat acute heart failure: Applications for clinical heart failure. E., Hill L., Lainscak M., Lassus J., Masip J., Mebazaa A., practice and future directions for research. A 20(7):1081-1099 Miró Ò., Mortara A., Mueller C., Mullens W., Nieminen M., statement from the Acute Heart Failure Rudiger A., Ruschitzka F., Seferovic P., Sionis A., Committee of the Heart Failure Association Vieillard-Baron A., Weinstein J., de Boer R., Crespo-Leiro (HFA) of the European Society of Cardiology M., Piepoli M., Riley J. (ESC).

Langlois MR; Chapman MJ; Cobbaert C; Mora S; Quantifying Atherogenic Lipoproteins: Clinical chemistry. 8,636 Q1/D1 2.04 Remaley AT; Ros E; Watts GF; Borén J; Baum H; Current and Future Challenges in the Era of 64(7):1006-1033 Bruckert E; Catapano A; Descamps OS; Von Eckardstein Personalized Medicine and Very Low A; Kamstrup PR; Kolovou G; Kronenberg F; Langsted A; Concentrations of LDL Cholesterol. A Pulkki K; Rifai N; Sypniewska G; Wiklund O; Nordestgaard Consensus Statement from EAS and EFLM. BRG; European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative.

Augé J, Vent J, Agache I, Airaksinen L, Campo Mozo P, Position Paper on the Standardization of Nasal Allergy. 73(8): 6,048 Q1 2.08 Chaker A, Cingi C, Durham S, Fokkens W, Gevaert P, Allergen Challenges. 1597-1608 Giotakis A, Hellings P, Herknerova M, Hox V, Klimek L, La Melia C, Mullol J, Muluk NB, Muraro A, Naito K, Pfaar O, Riechelmann H, Rondon C, Rudenko M, Samolinski B, Tasca I, Tomazic P, Vogt K, Wagenmann M, Yeryomenko G, Zhang L, Mösges R.

Coelho Neto M, Ludwin A, Borrell A, Benacerraf B, Counting ovarian antral follicles by ultrasound: Ultrasound in obstetrics 5,654 Q1/D1 3.02 Dewailly D, da Silva Costa F, Condous G, Alcazar J, a practical guide. and gynecology. Jokubkiene L, Guerriero S, Van den Bosch T, Martins W. 51(1):10-20

Kotecha D, Breithardt G, Camm AJ, Lip GYH, Schotten U, Integrating new approaches to atrial Europace. 5,231 Q1 2.02 Ahlsson A, Arnar D, Atar D, Auricchio A, Bax J, Benussi S, ﬁbrillation management: the 6th AFNET/E- 20(3):395-407 Blomstrom-Lundqvist C, Borggrefe M, Boriani G, Brandes HRA Consensus Conference. A, Calkins H, Casadei B, Castellá M, Chua W, Crijns H, Dobrev D, Fabritz L, Feuring M, Freedman B, Gerth A, Goette A, Guasch E, Haase D, Hatem S, Haeusler KG, Heidbuchel H, Hendriks J, Hunter C, Kääb S, Kespohl S, Landmesser U, Lane DA, Lewalter T, Mont L, Nabauer M, Nielsen JC, Oeff M, Oldgren J, Oto A, Pison L, Potpara T, Ravens U, Richard-Lordereau I, Rienstra M, Savelieva I, Schnabel R, Sinner MF, Sommer P, Themistoclakis S, Van Gelder IC, Vardas PE, Verma A, Wakili R, Weber E, Werring D, Willems S, Ziegler A, Hindricks G, Kirchhof P.

Calkins, Hugh; Hindricks, Gerhard; Cappato, Riccardo; 2017 HRS/EHRA/ECAS/APHRS/SOLAECE Europace. 20(1):e1-e160 5,231 Q1 2.02 Kim, Young-Hoon; Saad, Eduardo B.; Aguinaga, Luis; expert consensus statement on catheter and Akar, Joseph G.; Badhwar, Vinay; Brugada, Josep; surgical ablation of atrial ﬁbrillation. Camm, John; Chen, Peng-Sheng; Chen, Shih-Ann; Chung, Mina K.; Nielsen, Jens Cosedis; Curtis, Anne B.; Davies, D. Wyn; Day, John D.; d'Avila, Andre; de Groot, N. M. S. (Natasja); Di Biase, Luigi; Duytschaever, Mattias; Edgerton, James R.; Ellenbogen, Kenneth A.; Ellinor, Patrick T.; Ernst, Sabine; Fenelon, Guilherme; Gerstenfeld, Edward P.; Haines, David E.; Haissaguerre, Michel; Helm, Robert H.; Hylek, Elaine; Jackman, Warren M.; Jalife, Jose; Kalman, Jonathan M.; Kautzner, Josef; Kottkamp, Hans; Kuck, Karl Heinz; Kumagai, Koichiro; Lee, Richard; Lewalter, Thorsten; Lindsay, Bruce D.; Macle, Laurent; Mansour, Moussa; Marchlinski, Francis E.; Michaud, Gregory F.; Nakagawa, Hiroshi; Natale, Andrea; Nattel, Stanley; Okumura, Ken; Packer, Douglas; Pokushalov, Evgeny; Reynolds, Matthew R.; Sanders, Prashanthan; Scanavacca, Mauricio; Schilling, Richard; Tondo, Claudio; Tsao, Hsuan-Ming; Verma, Atul; Wilber, David J.; Yamane, Teiichi;EHRA; AHA; Soc Latinoamer Estimulacion; APHRS; ACC; ECAS; STS; CHRS; JHRS; Soc Brasileira Arritmias Cardiacas.

Patel, Maxine X.; Sethi, Faisil N.; Barnes, Thomas R. E.; Dix, Joint BAP NAPICU evidence-based Journal of 4,738 Q1/D1 4.07 Roland; Dratcu, Luiz; Fox, Bernard; Garriga, Marina; consensus guidelines for the clinical psychopharmacology. Haste, Julie C.; Kahl, Kai G.; Lingford-Hughes, Anne; management of acute disturbance: 32(6):601-640 McAllister-Williams, Hamish; O'Brien, Aileen; Parker, De-escalation and rapid tranquillisation. Caroline; Paterson, Brodie; Paton, Carol; Posporelis, Sotiris; Taylor, David M.; Vieta, Eduard; Voellm, Birgit; Wilson-Jones, Charlotte; Woods, Laura.

29 FOREWORD IDIBAPS

Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Canadian Network for Mood and Anxiety Bipolar disorders. 4,490 Q1 4.07 Frey BN, Sharma V, Goldstein BI, Rej S, Beaulieu S, Alda Treatments (CANMAT) and International 20(2):97-170 M, MacQueen G, Milev RV, Ravindran A, O'Donovan C, Society for Bipolar Disorders (ISBD) 2018 McIntosh D, Lam RW, Vazquez G, Kapczinski F, McIntyre guidelines for the management of patients RS, Kozicky J, Kanba S, Lafer B, Suppes T, Calabrese JR, with bipolar disorder. Vieta E, Malhi G, Post RM, Berk M .

Sanz M., Ceriello A., Buysschaert M., Chapple I., Demmer Scientiﬁc evidence on the links between Journal of clinical 4,046 Q1/D1 3.15 R., Graziani F., Herrera D., Jepsen S., Lione L., Madianos P., periodontal diseases and diabetes: Consensus periodontology. Mathur M., Montanya E., Shapira L., Tonetti M., Vegh D. report and guidelines of the joint workshop on 45(2):138-149 periodontal diseases and diabetes by the International Diabetes Federation and the European Federation of Periodontology.

Alquézar-Arbé A, Sanchís J, Guillén E, Bardají A, Miró Ò, Cardiac troponin measurement and Emergencias. 3,608 Q1 1.07 Ordóñez-Llanos J. interpretation in the diagnosis of acute 30(5):336-349 myocardial infarction in the emergency department: a consensus statement.

Geberhiwot T, Moro A, Dardis A, Ramaswami U, Sirrs S, Consensus clinical management guidelines Orphanet journal of 3,607 Q2 3.12 Marfa M, Vanier M, Walterfang M, Bolton S, Dawson C, for Niemann-Pick disease type C. rare diseases. 13(1):50 Héron B, Stampfer M, Imrie J, Hendriksz C, Gissen P, Crushell E, Coll MJ, Nadjar Y, Klünemann H, Mengel E, Hrebicek M, Jones S, Ory D, Bembi B, Patterson M.

Martin-Loeches I, Rodriguez AH, Torres A. New guidelines for hospital-acquired Current opinion in 3,120 Q2 2.06 pneumonia/ventilator-associated pneumonia: critical care. USA vs. Europe. 24(5):347-352

Ryom L, Boesecke C, Bracchi M, Ambrosioni J, Pozniak Highlights of the 2017 European AIDS Clinical Hiv medicine. 2,932 Q2 1.03 A, Arribas J, Behrens G, Mallon P, Puoti M, Rauch A, Miro Society (EACS) Guidelines for the treatment 19(5):309-315 JM, Kirk O, Marzolini C, Lundgren JD, Battegay M, EACS of adult HIV-positive persons version 9.0. Governing Board.

Barberà JA, Román A, Gómez-Sánchez MÁ, Blanco I, Guidelines on the Diagnosis and Treatment of Archivos de 2,633 Q2 2.07 Otero R, López-Reyes R, Otero I, Pérez-Peñate G, Sala E, Pulmonary Hypertension: Summary of bronconeumologia. Escribano P . Recommendations. 54(4):205-215

Pleguezuelos E., Gimeno-Santos E., Hernández C., Recommendations on non-Pharmacological Archivos de 2,633 Q2 2.07 Mata M., Palacios L., Piñera P., Molina J., Chiner E., Treatment in Chronic Obstructive Pulmonary bronconeumologia. Miravitlles M. Disease From the Spanish COPD Guidelines 54(11):568-575 (GesEPOC 2017).

Ceriello A., Gavin J., Boulton A., Blickstead R., McGill M., The Berlin Declaration: A call to action to Diabetes research 2,548 Q3 3.15 Raz I., Sadikot S., Wood D., Cos X., Khunti K., Kalra S., Das improve early actions related to type 2 and clinical practice. A., López C. diabetes. How can specialist care help? 139:392-399

Wise SK, Lin SY, Toskala E, Orlandi RR, Akdis CA, Alt JA, International Consensus Statement on Allergy Int forum allergy rh. 2,454 Q1 2.08 Azar A, Baroody FM, Bachert C, Canonica GW, Chacko T, and Rhinology: Allergic Rhinitis. 8(2):108-352 Cingi C, Ciprandi G, Corey J, Cox LS, Creticos PS, Custovic A, Damask C, DeConde A, DelGaudio JM, Ebert CS, Eloy JA, Flanagan CE, Fokkens WJ, Franzese C, Gosepath J, Halderman A, Hamilton RG, Hoffman HJ, Hohlfeld JM, Houser SM, Hwang PH, Incorvaia C, Jarvis D, Khalid AN, Kilpeläinen M, Kingdom TT, Krouse H, Larenas-Linnemann D, Laury AM, Lee SE, Levy JM, Luong AU, Marple BF, McCoul ED, McMains KC, Melén E, Mims JW, Moscato G, Mullol J, Nelson HS, Patadia M, Pawankar R, Pfaar O, Platt MP, Reisacher W, Rondón C, Rudmik L, Ryan M, Sastre J, Schlosser RJ, Settipane RA, Sharma HP, Sheikh A, Smith TL, Tantilipikorn P, Tversky JR, Veling MC, Wang Y, Westman M, Wickman M, Zacharek M.

Balañá C., Alonso M., Hernandez A., Perez-Segura P., SEOM clinical guidelines for anaplastic Clinical and 2,392 Q3 5.13 Pineda E., Ramos A., Sanchez A., Teixidor P., Verger E., gliomas (2017). translational Benavides M. oncology. 20(1):16-21

Berrocal A., Arance A., Castellon V., de la Cruz L., SEOM clinical guideline for the management Clinical and 2,392 Q3 5.13 Espinosa E., Cao M., Larriba J., Márquez-Rodas I., Soria A., of malignant melanoma (2017). translational Algarra S. oncology. 20(1):69-74

30 Cassinello J., Arranz J., Piulats J., Sánchez A., Pérez-Valderra- SEOM clinical guidelines for the treatment of Clinical and translational 2,392 Q3 5.13 ma B., Mellado B., Climent M., Olmos D., Carles J., Lázaro M. metastatic prostate cancer (2017). oncology. 20(1):57-68

Lopez Lopez, R.; Camps Herrero, C.; Khosravi-Shahi, P.; Oncologist's knowledge and implementation Clinical and translational 2,392 Q3 5.10 Guillem Porta, V.; Carrato Mena, A.; Garcia-Foncillas, J.; Cruz of guidelines for breakthrough cancer pain in oncology. 20(5):613-618 Hernandez, J. J.; Gascon Vilaplana, P.; Anton Torres, A.; Spain: CONOCE study. Diaz-Rubio, E.; Feyjoo Saus, M.; Aranda Aguilar, E.

Gutzmer R., Harrington K., Hoeller C., Lebbé C., Malvehy Practical clinical guide on the use of European journal of 1,944 Q2 5.05 J., Öhrling K., Downey G., Dummer R. talimogene laherparepvec monotherapy in dermatology. patients with unresectable melanoma in 28(6):736-749 Europe.

Garcia-Vidal C, Alastruey-Izquierdo A, Aguilar-Guisado Executive summary of clinical practice Enfermedades 1,707 Q3 1.03; 5.06 M, Carratalà J, Castro C, Fernández-Ruiz M, Aguado JM, guideline for the management of invasive infecciosas y Fernández JM, Fortún J, Garnacho-Montero J, Gavaldà J, diseases caused by Aspergillus: 2018 Update microbiologia clínica. Gudiol C, Guinea J, Gómez-López A, Muñoz P, Pemán J, by the GEMICOMED-SEIMC/REIPI. Rovira M, Ruiz-Camps I, Cuenca-Estrella M.

Rivero, Antonio; Polo, Rosa; Lopez Aldeguer, Jose; Lozano, Executive summary of the GESIDA/National Enfermedades 1,707 Q3 1.03 Fernando; Antela, Antonio; Ramon Arribas, Jose; Asensi, AIDS Plan Consensus Document on infecciosas y Victor; Berenguer, Juan; Ramon Blanco, Jose; Luis Antiretroviral Therapy in Adults Infected by microbiologia clínica. Casado, Jose; Clotet, Bonaventura; Crespo, Manuel; the Human Immunodeﬁciency Virus (Updated 36(7):435-445 Domingo, Pere; Duenas, Carlos; Maria Gatell, Jose; Luis January 2017). Gomez-Sirvent, Juan; Gonzalez-Garcia, Juan; Antonio Iribarren, Jose; Bernaldo de Quiros, Juan Carlos Lopez; Lopez Cortes, Luis Fernando; Emilio Losa, Juan; Mallolas, Josep; Marino, Ana; Martinez, Esteban; Miro, Jose M.; Moreno, Santiago; Palacios, Rosario; Pasquau, Juan; Antonio Pineda, Juan; Podzamczer, Daniel; Portilla, Joaquin; Poveda, Eva; Pulido, Federico; Rubio, Rafael; Santos, Jesus; Sanz Moreno, Jose; Sanz Sanz, Jesus; Jesus Tellez, Maria; de la Torre, Javier; Tuset, Montserrat; Perez Molina, Jose A.; AIDS Study Grp GESIDA Span.

Alonso-Cerezo M., Calero Ruiz M., Chantada-Abal V., de la Recommendations regarding the genetic and Urgencias en pediatría. 1,168 Q3 5.03 Fuente-Hernández L., García-Cobaleda I., García-Ochoa immunological study of reproductive 151(4):161.E1-161.E12 C., García-Sagredo J., Nuñez R., Oliva R., Orera-Clemente dysfunction. M., Pintado-Vera D., Sanchez-Ramon S.

Albéniz E, Pellisé M, Gimeno García AZ, Lucendo AJ, Clinical guidelines for endoscopic mucosal Gastroenterologia y 1,078 Q4 3.11 Alonso Aguirre PA, Herreros de Tejada A, Álvarez MA, resection of non-pedunculated colorectal hepatologia. Fraile M, Herráiz Bayod M, López Rosés L, Martínez Ares lesions. 41(3):175-190 D, Ono A, Parra Blanco A, Redondo E, Sánchez Yagüe A, Soto S, Díaz Tasende J, Montes Díaz M, Téllez MR, García O, Zuñiga Ripa A, Hernández Conde M, Alberca de Las Parras F, Gargallo C, Saperas E, Navas MM, Gordillo J, Ramos Zabala F, Echevarría JM, Bustamante M, González Haba M, González Huix F, González Suárez B, Vila Costas JJ, Guarner Argente C, Múgica F, Cobián J, Rodríguez Sánchez J, López Viedma B, Pin N, Marín Gabriel JC, Nogales Ó, de la Peña J, Navajas León FJ, León Brito H, Remedios D, Esteban JM, Barquero D, Martínez Cara JG, Martínez Alcalá F, Fernández Urién I, Valdivielso E, en nombre del Grupo Español de Resección Endoscópica de la Sociedad Española de Endoscopia Digestiva.

Aller R., Fernández-Rodríguez C., lo Iacono O., Bañares R., Consensus document. Management of Gastroenterologia y 1,078 Q4 3.05; 3.09 Abad J., Carrión J., García-Monzón C., Caballería J., non-alcoholic fatty liver disease (NAFLD). hepatologia. Berenguer M., Rodríguez-Perálvarez M., Miranda J., Clinical practice guideline. 41(5):328-349 Vilar-Gómez E., Crespo J., García-Cortés M., Reig M., Navarro J., Gallego R., Genescà J., Arias-Loste M., Pareja M., Albillos A., Muntané J., Jorquera F., Solà E., Hernández-Guerra M., Rojo M., Salmerón J., Caballería L., Diago M., Molina E., Bataller R., Romero-Gómez M.

Cubiella J., Marzo-Castillejo M., Mascort-Roca J., Clinical practice guideline. Diagnosis and Gastroenterologia y 1,078 Q4 3.11 Amador-Romero F., Bellas-Beceiro B., Clofent-Vilaplana J., prevention of colorectal cancer. 2018 Update. hepatologia. Carballal S., Ferrándiz-Santos J., Gimeno-García A., 41(9):585-596 Jover R., Mangas-Sanjuán C., Moreira L., Pellisè M., Quintero E., Rodríguez-Camacho E., Vega-Villaamil P.

Calleja, Jose L.; Macias, Juan; Forns, Xavier; Garcia, Guidelines on treatment of hepatitis C virus Gastroenterologia y 1,078 Q4 3.03 Federico; Berenguer, Marina; Garcia Deltoro, Miguel; Buti, infection. Spanish Association for the Study of hepatologia. Maria; Granados, Rafael; Carrion, Jose A.; Morano, Luis; the Liver (AEEH). 41(9):597-608 Fernandez, Inmaculada; Coste, Pablo; Pineda, Juan A.;

31 FOREWORD IDIBAPS

CLINICAL TRIALS Clinical trials PORTFOLIO OF SPIN-OFFS by research area (%) The IDIBAPS constitutes the ideal setting The activity of IDIBAPS researchers for completing a number of the crucial gave rise to 1 new company based on the steps in the development of new medical knowledge from IDIBAPS/HCB: products. Basic biomedical research and 18 Biomarkers Clinical Diagnosis and applied clinical research, together with Applications, SL, a project led by Dr. 31 9% specialized healthcare practice, are 15%15% Molina. aspects of IDIBAPS that may be very 32 useful for the development of drugs. 15%15% IDIBAPS researchers have founded 11 spin-offs since 2008, 10 of which are active companies 11% The adjacent graphics summarize the number that together employ more than 50 people. of active clinical trials in 2018. 11%24 11% In 2018, 209 new clinical trials were opened 8239% and overall, there were 503 active clinical trials. Spinoffs from IDIBAPS researchers 39% 11%22 Most of these clinical trials correspond to where IDIBAPS or FCRB participate 11% phase III (43%). as shareholders:

OWL METABOLOMICS (2008) http://www.owlmetabolomics.com/

2018 Dr. Joan Caballeria 89 OWL is a biotechnology company in the field AREA 1 of Metabolomics with pioneering diagnostics 64 AREA 2 products and unique R&D services for the AREA 3 40 scientific community. The OWLiver Test is AREA 4 the first in vitro test for determining steatosis AREA 5 13 3 and NASH. OTHERS PHASE I PHASE II PHASE III PHASE IV OTHERS TRANSPLANT BIOMEDICALS (2014) https://www.transplantbiomed.com/ Dr. Carmen Peralta Transplant Biomedicals is a European company based in Barcelona aimed to TOTAL become an international leader in the field of organ, tissue and cell preservation. The 209 company is at the end-stage of the development of VIVIAN®, a new generation disposable organ preservation device for kidney and available for hospital use. The device integrates the Hypothermic Ultrasound By scientific areas, most of the trials are Preservation Technology (HUPT), a performed in the area of hemato-oncology. revolutionary proprietary and patented technology that leads to superior preservation of organs during ex-vivo conditions.

VIRTUAL BODYWORKS (2015) https://virtualbodyworks.com/ PATENTS AND LICENSE AGREEMENTS Dr. Maria Victoria Sanchez-Vives The Institute currently manages 52 patent Virtual Bodyworks is changing the the future of families and 8 proprietary software, 38 social, medical and psychological rehabilitation. license agreements have been signed with They are developing several tools such as: i-Cortex several industry partners. (a tool that facilitates the neurological and physical rehabilitation of individuals who have experienced During 2018 10 new patent applications were a wide range of traumas ranging from chronic ﬁled: 4 priority patents, 3 PCTs, and 3 patents pain management to stroke) and VRespect.Me entered into National Phases in several countries. (a powerful virtual reality experience designed Besides, 2 new license agreements were signed to rehabilitate men with a history of domestic with national and international companies. violence, the only scientiﬁcally proven product of its kind in the market).

32 ESTIMTRACK (2016) Spinoffs from IDIBAPS researchers http://www.estimtrack.com/ where IDIBAPS or FCRB do not participate Dr. Jaume Balust as shareholders: Estimtrack provides an intelligent set of tools to schedule, track and orchestrate all involved TRANSMURAL BIOTECH (2009) The Agency for Business Competitiveness www.transmuralbiotech.com personnel in surgical procedures and (ACCIÓ) of the Government of Catalonia Dr. Eduard Gratacós operating rooms based on Machine Learning awarded IDIBAPS in 2016 with the TECNIO logo, (ML), which improves the efficiency of Transmural Biotech is developing innovative thus identifying the institute as a facilitator of operating room tracks in healthcare products and services in the perinatal ﬁeld by access to technology and a body helping organizations by 31% applying image analysis technologies that businesses to gain knowledge of the technology facilitate a better diagnosis in a non-invasive way generated in their scientiﬁc and technical BARCELONA LIVER BIOSERVICES (2017) and representing a saving for the health system. environment. http://liver.barcelona/

Dr. Jordi Gracia-Sancho BIONURE (2009) BLB is a contract research organization that www.bionure.com offers cutting-edge research services and Dr. Pablo Villoslada consultancy in the field of liver diseases. They Bionure is a clinical stage biotechnology provide tailored reliable solutions to different company. Based on more than 15-year of partners for successful strategic decision research in neuroprotection, the company making. The ExoLiver, a patented product, develops new first-in-class disease-modifier allows co-culture of healthy or diseased drugs able to slow down, stop or reverse the hepatic cells, unravels key biological data damaging process affecting neurons for the obtained in a human-like system, therefore treatment of degenerative, ischemic, toxic and representing the ultimate pre-clinical step in inflammatory diseases of the nervous system. any development pipeline.

AELIX THERAPEUTICS (2015) BIOMARKERS CLINICAL DIAGNOSIS AND APPLICATIONS (2018) www.aelixtherapeutics.com Dr. Rafael Molina Dr. Josep M. Gatell BLB is a contract researchThe aim of this AELIX Therapeutics is a clinical stage company is the development of tumour biotechnology company focused on the markers for clinical application through the development of a therapeutic HIV vaccine to creation of computer algorithms for the be used in cure/eradication strategies. The evaluation and detection of cancer. HIV Vaccine program is based on an innovative T cell vaccine immunogen design that directs the body’s immune defence to the most vulnerable parts of HIV.

FREEOX BIOTECH (2017) www.freeoxbiotech.com Dr. Ángel Chamorro Freeox Biotech is an innovative company born to discover and develop medicines addressed to reduce the effects of the oxidative stress in the organism, and especially those related to the neurological and cardiovascular system. The company is focused mainly in Stroke, a condition characterized by the interruption of blood ﬂow to the brain which is a leading cause of death and disability worldwide.

33 FOREWORD IDIBAPS

Funding

From a ﬁnancial and managerial 7 5 6 perspective, IDIBAPS and FCRB are 4 IDIBAPS EXECUTED FUNDS managed in a global and consolidated 1 COMPETITIVE PROJECTS 16,452,456 € manner. 3 2 GENERALITAT DE CATALUNYA 5,947,412 € The two institutions share the principal 3 PRIVATE PROJECTS 2,774,095 € investigators (PI) accredited by 4 CAPITAL GRANT 924,237 € 5 OTHER INCOME 858,192 € IDIBAPS, who have funds, projects and 6 CORE FACILITIES 732,333 € resources in both entities. Annually, the 7 FINANCIAL INCOME 237,706 € 2 1 research executed by IDIBAPS accredited PIs is almost 93% of the TOTAL 27,926,431 € executed research activity, with the remaining 7% executed by non-accredited PIs

9 In 2018, the two entities recorded 53,8 M€ FCRB EXECUTED FUNDS 7 8 consolidated of income and 53 M€ of 6 expenditure, of which 43.8 M€ were directly 1 CLINICAL TRIALS AND PRIVATE PROJECTS 13,494,764 € 5 2 COMPETITIVE PROJECTS 5,148,934 € related to the execution of research projects. 3 DONATIONS AND PATRONAGE 3,437,167 € Around 11% of this amount corresponds to the 4 4 TEACHING FUNDING 2,206,500 € contribution of the Generalitat de Catalunya 5 INTERCOMPANY SERVICES 1,770,985 € from the Departament d’Empresa i 1 6 RENTAL INCOME 1,316,941 € 3 7 CAPITAL GRANT 1,031,998 € Coneixement and the Departament de Salut 8 MANAGEMENT CLINICAL TRIAL 329,531 € 9 FINANCIAL INCOME 963 €

2 TOTAL 28,737,784 €

2 IDIBAPS EXTERNAL FUNDING PER SOURCE

1 NATIONAL 14,384,677€ 2 INTERNATIONAL 4,841,874€

TOTAL 19,226,552€ 1

6 1 EXTERNAL FUNDING BY RESEARCH AREA 5 2 1 BIOLOGICAL AGGRESSION AND... 1,958,527€ 2 RESPIRATORY, CARDIOVASCULAR AND... 2,050,477€ 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM 7,049,431€ 4 CLINICAL AND EXPERIMENTAL NEURO... 4,548,197€ 5 ONCOLOGY AND HAEMATOLOGY 2,292,115 € 4 6 OTHERS 1,327,805 €

TOTAL 19,226,552€ 3

34 New competitive projects

The granted external funding supports mainly research projects and human resources grants. Some of these resources also fund scientiﬁc equipments or facilities. IDIBAPS researchers are competitive in a wide range of opportunities launched at different levels (International, Spanish or Catalan). Regardless the funding’s origin, many of the granted activities are co-funded by the European Regional Development Fund (ERDF).

TOTAL 243 186 57

PROJECTS HUMAN RESOURCES GRANTS

PROJECTS (2 EC COORDINATED) 23 INTERNATIONAL 23 12 EC > 2 COORDINATED 3 NIH 8 OTHER INTERNATIONAL AGENCIES

PROJECTS 80 SPANISH 124 HUMAN RESOURCES GRANTS 44

PROJECTS 83 CATALAN 96 HUMAN RESOURCES GRANTS 13

35 FOREWORD IDIBAPS

The following table classiﬁes the 243 new competitive projects in 2018 per funding agency. Additionally, the funding institutions are grouped in two sections, public (84%) and private (16%):

COMPETITIVE PUBLIC FUNDING NUMBER OF PROJECTS TOTAL 204 Catalan institutions 92 Ajuntament de Barcelona 2 Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) 73 Generalitat de Catalunya 17 National institutions 97 Instituto de Salud Carlos III (ISCIII) 78 Ministerio de Ciencia, Innovación y Universidades (MICIU)* 14 Ministerio de Educación, Cultura y Deporte 5 International institutions 15 European Commission 12 National Institute of Health (NIH) 3

*Previously known as MINECO

COMPETITIVE PRIVATE FUNDING NUMBER OF PROJECTS

TOTAL 39 Catalan institutions 4 Fundació Academia de Ciències Mèdiques i de la Salut de Catalunya i Balears 2 Fundació La Marató de TV3 2 National institutions 27 Asociación Duchenne Parent Project España 1 Asociación Española de Gastroenterología (AEG) 1 Bankia S.A. 1 Fundación Alicia Koplowitz 1 Fundación Bancaria “La Caixa” 5 Fundación BBVA 1 Fundación Cientíﬁca Asociación Española Contra el Cáncer (AECC) 7 Fundación de Investigación Médica Mutua Madrileña 1 Fundación Española de Hematología y Hemoterapia (FEHH) 1 Fundación Quirón Salud 1 Fundación Sociedad Española de Endocrinología y Nutrición (SEEN) 1 Fundación Sociedad Española de Endoscopia Digestiva (SEED) 1 Fundación Sociedad Española de Oncología Médica (SEOM) 1 Fundación Telefónica 1 GILEAD Sciencies 2 Sociedad Española de Alergología e Inmunología Clínica (SEAIC) 1 International institutions 8 AMGEN 1 Breast Cancer Now 1 Cancer Research UK 2 European Crohn's and Colitis Organisation (ECCO) 1 Fundação BIAL 1 Gilead Sciences 1 The Guthy-Jackson Charitable Foundation 1

36 Active competitive projects

In 2018, there were 592 active competitive projects, 154 initiated during the year.

TOTAL 592 477 115

PROJECTS HUMAN RESOURCES GRANTS

PROJECTS 91 64 EC > 13 COORDINATED 5 NIH INTERNATIONAL 92 22 OTHER INTERNATIONAL AGENCIES

HUMAN RESOURCES GRANT 1 EC > 1 COORDINATED

PROJECTS 263 SPANISH 345 HUMAN RESOURCES GRANTS 82

PROJECTS 123 CATALAN 155 HUMAN RESOURCES GRANTS 32

37 FOREWORD IDIBAPS

Leadership in EU funded projects

IDIBAPS has a strong background both participating and leading competitive projects supported by the European Commission.

In 2018, the European projects led by IDIBAPS researchers are listed below. They are classiﬁed in two sections:

MONOCONTRACT COLLABORATIVE

EUROPEAN RESEARCH COUNCIL FUTURIZE LIVERSCREEN MITOSENSING A step ahead to tackle future trends in Screening for liver ﬁbrosis. A population-based Decoding mitochondrial nutrient-sensing addictions. study in European countries. programs in POMC neurons as key determinants of metabolic health. Dr. Silvia Matrai / Dr. Antoni Gual Dr. Pere Ginès 2018 – 2020 2018 – 2019 Dr. Marc Claret Call: CE_JUST-2017-AG-DRUG Call: EIT Health 2017 2017 – 2022 Official code: 806964 Official code: 18258 Call: CE_H2020-ERC-2016_Consolidator grant Official code: 725004 HIVACAR SloW-Dyn Evaluating a Combination of Immune-based Dinámica de las oscilaciones lentas: EUROPEAN RESEARCH COUNCIL Therapies to Achieve a Functional Cure of HIV experimentos, análisis, modelos e PRIORS Infection. intervenciones terapéuticas. Neural circuit dynamics underlying expectation and their impact on the variability of Dr. Felipe Garcia Dr. Maria Victoria Sanchez-Vives perceptual choices. 2017 – 2021 2015 – 2018 Call: H2020-SC1-2016-RTD Call: FlaG-ERA ministerio de Economía y Dr. Jaime de la Rocha Official code: 731626 Competividad (MINECO) 2015 – 2021 Official code: PCIN-2015-162-C02-01 Call: CE_ H2020-ERC-2015_Consolidator grant Official code: 683209 IMLINFO Red Transfronteriza de Immunoterapias Sys4MS Personalizadas para Linfomas no- Hodgkin. Cuidado personalizado de salud en la MARIE SŁODOWSKA CURIE ACTIONS Esclerosis Múltiple usando herramientas de BITRECS Dr. Patricia Pérez Galán medicina de sistemas. Biomedicine international training research 2018 – 2020 programme for excellent clinician-scientists. Call: CE_Interreg-16_POCTEFA Dr. Pablo Villoslada Official code: EFA281/16 2016 – 2019 Dr. Elías Campo Call: ERANET 2015 2017 – 2022 Official code: ID43 Call: CE_H2020-MSCA-COF-16 INTEGRATE Official code: 754550 Joint Action on integrating prevention, testing and linkage to care strategies acros HIV, viral TRANSCOLONCAN hepatitis, TB and STIs in Europe. Identifying Biomarkers Through Translational MARIE SŁODOWSKA CURIE ACTIONS Research for Prevention and Stratiﬁcation of NANOBreg Dr. Agata Raquel León Colorectal Cancer. A new therapeutic platform based on 2017 – 2020 nanotechnology to promote T- and B- Call: HP-JA-2016 Dr. Sergi Castellví regulatory networks. Official code: 761319 2018 – 2022 Call:CE_H2020-COST17 Dr. Javier Vega Official code: CA17118 Lab: Dr. Pere Santamaría LIVERHOPE 2016 – 2018 Simvastatin and rifaximin as new therapy for Call: CE_H2020-MSCA-IF-15 patients with decompensated cirrhosis. TWIST Official code: 704522 Capacity building in the application of EU drug Dr. Pere Ginès research – Training With STakeholders. 2017 – 2022 Call: H2020-SC1-2016-RTD Dr. Antoni Gual Official code: 731875 2017 – 2018 Call: CE_JUST-2016-AG-DRU Official code: 759685

38 Institutional projects

BITRECS SIMPACT HRS4R

Biomedicine international training Synergies in International Management Human Resources Strategy for research programme for excellent and Promotion Activities for a Common Researchers. clinician-scientists. Success Leadership Strategy in R&D&I . WEB WEB PARTICIPANTS www.clinicbarcelona.org/en/idibaps/ www.bitrecs.idibaps.org IDIBAPS (Coordinator) and Clinic research-career Foundation for Biomedical Research, FCRB.

SIMPACT is the 3-year collaborative project (2015-2018) between IDIBAPS and FCRB to increase the participation, success and leadership of both institutions in Europe and worldwide. It is supported by the Spanish BITRECS is a 60-month research and training Ministry of Economy and Competitiveness IDIBAPS is awarded with the logo “HR fellowship programme (2017 - 2022) having as (MINECO). Excellence in research” since 2015. Thus, it main aim to recruit 10 excellent and highly has acquired a commitment to implement the motivated postdoctoral clinician-scientists The specific objectives of the project are: European Charter for Researchers and the through two international peer-reviewed Code of Conduct for the Recruitment of opportunities. 1) Increase the visibility and recognition of the Researchers (Charter & Code) in their policies In 2018, this IDIBAPS programme with the Institute internationally. and practices. support of the European Commission, has 2) Improve the quality of the institutional opened and spread worldwide the two management support in European Projects. In 2018, IDIBAPS is has implemented its expected calls to attract talented scientists. 3) Create new synergies and long-term updated Action Plan (2017-2020) resulting Moreover, an agreement with “La Caixa” collaborations with actors of the private from the interim assessment performed in Foundation has been reached to provide with sector. 2017. Some actions under preparation to be additional funding to the programme. concluded at early 2019 are: 1) the integration In 2018, the last activities linked to the project of the HRS4R vision and strategy into the A 36-month contract will be offered to the has been performed such as: supporting IDIBAPS Strategic Plan (2018-2021); 2) the selected fellows. They will implement their specific trainings for researchers to improve updating of some institutional documents own research project fitted into one of the their competitiveness for the European such as “Research Career at IDIBAPS” and IDIBAPS research lines while performing one Research Council (ERC) grants; collaborating “Code of Good Practice in Scientific of the two available mobility schemes. in the dissemination of the BITRECS Research”; and, 3) the launching of the Attractive incentives, as well as, life-long programme and its calls to improve their recruitment policy at IDIBAPS according to training and networking opportunities will be impact, as well as organising training “in house” the Open, Transparent, Merit-based also provided to these experienced events for the research community. Recruitment (OTM-R). researchers in order to boost their research careers. As a result, they are expected to benefit from this unique opportunity with the final goal to become clinician-scientist leaders in the future.

Europa Redes y Gestores, reference EUC2014-C-51553

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 754550 and “La Caixa” Foundation

39 FOREWORD IDIBAPS

IDIBAPS

Science Party - “Looking for health”.

In 2018, IDIBAPS was granted for ﬁrst time by Institute of Culture (ICUB) from Ajuntament de Barcelona to organise an activity for promoting scientiﬁc culture to be run during the Week of Science that was composed by:

1) During the morning: Hands-on scientiﬁc workshops for high school students and their teachers to help them better know IDIBAPS and its science as well as to promote their future as scientists. 2) During the afternoon: Hands-on scientiﬁc activities for children and their families together with a show about science for everyone.

The bad weather allowed performing the morning activity according to the plan but the afternoon activity had to be postponed.

The Science Party resulted in 250 high-school students that got engaged performing those activities meanwhile learning new concepts and their applicability to healthcare from experienced researchers. Thus, it helped IDIBAPS to be better known and more accessible to the society as well as to promote the culture in science in the city of Barcelona.

Amb el suport de:

40 Spanish Biomedical Networks

ISCIII Networks

RESEARCH NETWORKS CIBERS RETICS

The Networked Biomedical Research Centres (Centros de Investigacion Biomédica en Red, CIBERs and also CIBERNED) and the Cooperative Research Topic Networks (Redes Temáticas de Investigación Coopera- Two IDIBAPS researchers are Scientific Thirteen IDIBAPS high-level researchers are tiva en Salud, RETICs) represent a cooperati- Directors in their corresponding CIBERs as also members of RETICs networks. According ve way of understanding biomedical research leaders of their corresponding fields of to their field of work they are distributed in the to achieve excellent results. research: following structures: In 2018, IDIBAPS has been related to most of the existing virtual research structures as it is Dr. Jordi Bruix, Scientific Director at CIBER INVICTUS described below: for Hepatic and digestive diseases (CIBEREHD). Cerebral Vascular Diseases 1 www.ciberehd.org OFTARED The main purpose of this CIBER is the promotion Eye Diseases: Prevention, early detection and protection of health through the promotion and treatment of prevalent, degenerative 2 of research of a basic nature and oriented to and chronic ocular pathology clinical and translational aspects in the area of REDINREN Hepatic and Digestive Diseases. Renal Research 1 REEM Dr. Eduard Vieta, Scientific Director at Multiple Sclerosis 3 CIBER for Mental health (CIBERSAM). RIER www.cibersam.es Research in Inflammation and Rheumatic Diseases 1 The mission of this network is to provide ARADyAL answers and solutions to treat mental illnesses Asthma, allergic and adverse reactions 1 and thus improve the quality of life of citizens. RTA Addictive Disorders 1 To sum up, thirty top IDIBAPS researchers are SAMID members of CIBER networks and CIBERNED Maternal and Child Health and Development 1 in those proportions: REDRIS Research in Aids 1 TERCELL CIBERDEM Cell Therapy network 1 Diabetes and assoc. metabolic disorders 3 CIBERER Rare diseases 6 CIBEROBN Obesity and nutrition 2 CIBERES Respiratory diseases 5 CIBERSAM Mental health 2 CIBERCV Cardiovascular 1 CIBERONC Oncology 2 CIBERNED Neurodegenerative diseases 1 CIBEREHD Hepatic and digestive diseases 8

41 FOREWORD IDIBAPS

Other Networks

ITEMAS NETWORK SPANISH CLINICAL RESEARCH NETWORK OF TUMOR BANKS OF https://www.itemas.org NETWORK, SCREN CATALONIA (XBTC)

The Medical Technology Innovation Platform IDIBAPS Principle Investigators are supported IDIBAPS Biobank has a tumour bank (ITEMAS) has as a partner IDIBAPS. This by the Fundació Clínic per la Recerca composed by nearly one million samples network is one of the Thematic Platforms for Biomèdica (FCRB) and also by the IDIBAPS representative of tumoral tissues belonged to Cooperative Research as a key component in its Core Facility of Medical Statistics while patients with cancer or other kind of diseases. multidimensional vision of innovation within its performing their clinical research and also their In 2006 as part of the Oncology Master Plan of area of interest. clinical trials. It is for this purpose that the Catalonia led by Dr. Pedro L. Fernández the ITEMAS aims to promote innovation in medical SCReN network has as members both FCRB Network of Tumor Banks of Catalonia (XBTC) technology as an essential tool in making the and IDIBAPS. was created. Spanish National Health System more This platform is responsible for grouping 31 This structure compile 11 sources of tumour sustainable. It also supports the development of Units of Clinical Research and Clinical trials. Its samples linked to the main hospitals of the culture of innovation necessary to facilitate objective is to achieve high quality standards in Catalonia. IDIBAPS Biobank is the coordinator integration of all the relevant agents in the field of all clinical research procedures, from the node of the XBTC network. medical technology. design to the final dissemination of the results. The core of the ITEMAS comprises the The participants of the SCReN network have innovation units of 29 large hospitals belonging different profiles such as researchers, to the Spanish National Health System, in cooperative groups, research centres addition to the Ministry of Health, Social Services between others. and Equality and the National Center for Cardiovascular Research (CNIC). The network is organized into internal programmes:

1) Regulation and monitoring 2) Pharmacovigilance 3) Methodology, biostatistics and data management 4) Coordination and training. It is noteworthy to mention that the IDIBAPS Core Facility of Medical Statistics, since 2014 until 2018, has been appointed to be the Spanish leader of SPANISH NETWORK the above-mentioned programme “Methodo- OF BIOBANKS PLATFORM logy, biostatistics and data management”.

IDIBAPS Biobank is part of the Spanish Network of Biobanks Platform. The main aim of this collaborative initiative is to provide an added value to the National Health System, favoring the development and quality of scientific production. Its members are biobanks of hospitals, autonomic networks, virtual biobancs, biobanks of the main research centers linked to healthcare institutions, between others. This network is grouped into five working programs being all led by one single scientific coordination:

1) Strategic collections 2) Networked services 3) Research, development and innovation 4) Ethics, law and society 5) Coordination and training

42 Scientiﬁc CEK, CELLEX, facilities Esther Koplowitz Biomedical Research Center Research Center

Inaugurated by the end of 2010 and with Since 2013, CELLEX center is a space space for more than 350 researchers, the with four floors located in the UB School CEK building receives international of Medicine. Thanks to the collaboration scientists and PhD students, fostering the between the public and private sectors exchange of experience and professional 2,290 m2 of laboratories, scientific and synergies. technological services and other spaces are available to the research developed at The building has a laboratory area of 4,860 m2 IDIBAPS and the University of Barcelona. on the ground. In the basement one underground floor offers a total area of The renovation and adaptation of these areas 2,485 m2, including space for scientific core is mainly the result of a donation from the facilities, a category 2 radioactive CELLEX Foundation. non-encapsulated sources type facility Part of the contribution of the IDIBAPS has (IRA-3029), and a BSL-3 laboratory GMO been funded with ERDF funds from the notified (A/ES/13/I-11). Generalitat de Catalunya and the rest comes The CEK building was made possible thanks from specific calls by the Instituto de Salud to the contribution of several public and private Carlos III.These IDIBAPS facilities home over institutions, the Generalitat de Catalunya, the 200 researchers. Ministerio de Economía y Competitividad, and the Instituto de Salud Carlos III, as well as from the support of other donors such as the Fundación Esther Koplowitz, Fundació Privada Cellex, Acció Sardà Farriol para la Investigación en Diabetes and Laboratorios Esteve.

43 FOREWORD IDIBAPS

Core facilities

Excellent biomedical research requires SERVICES the use of high-cost techniques and equipment. IDIBAPS has ﬁve core facilities NEW NEW TOTAL to provide all researchers with big INTERNAL USERS EXTERNAL USERS ATTENDED USERS infrastructures and high quality technical expertise: BIOBANK 35 27 197

Biobank of Hospital Clínic-IDIBAPS CYTOMETRY 8 4 165 Neurological tissue bank Tumour bank GENOMICS 26 12 78 Biologic ﬂuids bank MAGNETIC 24 8 54 RESONANCE Cytometry and cell sorting MEDICAL 15 10 219 Flow citometry STATISTICS Cell sorting

Functional Genomics NGS Transcriptomics RESEARCH

ACKNOWLEDGED Magnetic Resonance Imaging PUBLICATIONS PUBLICATIONS 3T 7T BIOBANK 21 29 Image lab CYTOMETRY - 2 Medical Statistics Statistics GENOMICS 6 5 Data management MAGNETIC Information technology 2 6 RESONANCE

MEDICAL 39 - On the other hand, IDIBAPS has an STATISTICS agreement with its consortium partners to optimise investments in infrastructures so duplicities are avoided and a wider spectrum of scientiﬁc services can be offered to the community. Universitat de Barcelona at the Clinic Campus, provides researchers with some complementary infrastructures such as microscopy, animal facility, library and proteomics.

PEOPLE Anna Bosch, PhD (until april 2018) Aina Rodríguez, PhD (since june 2018) Head of core facilities

Meritxell Rufet Administrative support

Soraya Pérez Administrative support

44 Biobank of Hospital Flow cytometry Clínic - IDIBAPS and cell sorting

FOR FURTHER INFORMATION Tumour bank and anatomical pathology FOR FURTHER INFORMATION www.clinicbiobanc.org collections [email protected] [email protected] It is a repository of tumoural and non-tumoural frozen tissue samples from around 12.000 PEOPLE NEUROLOGICAL TISSUE BANK cancer patients. Additionally, the Anatomical Crespo, Isabel, PhD [email protected] Pathology collection consists of paraffin- Head of core facility embedded tissue samples from tumors and TUMOUR BANK other diseases, which gathers more than two [email protected] million tissue blocks. All these samples are surplus to diagnostic requirements from the DESCRIPTION BLOOD AND FLUID BANK Department of Anatomical Pathology in the biobanc.fl[email protected] Hospital Clínic and are essential for current The Flow Cytometry core facility provides large-scale tissue research projects. Different high quality state-of-the-art multiparametric diagnosis consultants from Hospital Clinic help flow cytometry and cell sorting PEOPLE us in the histopathological evaluation of instrumentation as well as associated BIOBANK samples. expertise and services to all investigators at IDIBAPS and other outside customers. Skilled Joan Carles García Pagán, MD, PhD (HCB) Biological fluids bank staff provide help with experimental design, Scientific director This repository contains samples of, among sample acquisition, data analysis, sorting and others, metabolic, inflammatory bowel, help with interpreting the data and producing Anna Bosch, PhD (until april 2018) oncological, digestive, psychiatric and figures for publication. Aina Rodríguez, PhD (since june 2018) maternal and foetal diseases. It houses a large Head of core facility range of samples of scientific interest, primarily The facility has upgraded their BD FACS Aria DNA, serum and plasma, which are provided SORP cell sorter with the last version of the by doctors’ surgeries and laboratories where software BD FACSDiVa (v8.0.1) that includes blood and fluids are taken for lab tests and support for index sorting and sorting using DESCRIPTION blood and fluids donation. Terasaki plates.

The Biobank coordinates the collection, processing, storage and transfer of human biological samples to promote biomedical research of the highest standard. In compliance with the legal and ethical framework, the Biobank only provides samples to projects that have been approved by the ethical and scientific committees. With the aim of optimizing the human resources and equipment in the Biobank, this facility offers a wide range of services for the processing and analysis of the samples gathered by the research groups. All the procedures performed at the Biobank are carried out under ISO 9001:2015 certification. The Biobank’s catalogue of samples is formed by the samples collected by three large banks, all of which have extensive experience in research with human samples and which are available for scientific purposes for the consolidation of personalised medicine:

Neurological tissue bank A nervous tissue repository (brain and spinal cord) created from donations from deceased donors with or without neurological disorders. Brain tissue samples are sent to scientiﬁc researchers worldwide, in order to help to increase the understanding of the human brain and to develop therapies for neurological diseases.

45 FOREWORD IDIBAPS

Functional Magnetic Medical genomics resonance statistics imaging

FOR FURTHER INFORMATION FOR FURTHER INFORMATION FOR FURTHER INFORMATION [email protected] [email protected] [email protected]

PEOPLE PEOPLE PEOPLE Pedro Jares, PhD (HCB) Núria Bargalló MD, PhD (HCB) Ferran Torres, MD, PhD (HCB) Scientiﬁc director Head of core facility Head of core facility

Magda Pinyol, PhD Head of core facility DESCRIPTION DESCRIPTION

The MRI core facility is equipped with a 7 Tesla Medical Statistics is an IDIBAPS core facility DESCRIPTION Bruker magnet for small animal imaging and a that provides methodological and statistical PRISMA 3 Tesla magnet for humans support for IDIBAPS research projects and The Functional Genomics core facility (upgraded in 2017 thanks to own funds and those of allied institutions. provides access to different high throughput funds obtained from Ministerio de Economia y The main objective is to promote clinical genomic technologies to the researchers. Competitividad and FEDER). During 2018, all research excellence and facilitate resources The facility manages samples for genomic acquisition protocols were optimized and to achieve this. analysis including transcriptional profiling, low running in regular basis for all clinical studies. The platform’s tasks are conducted in density and large-scale genotyping, gene compliance with the International Conference copy number analysis and gene-panel The main objectives of this of Harmonisation guidelines, European and sequencing using different technological Core Facility are: local laws, as well as with the regulatory platforms such as real-time PCR, digital recommendations. Standard Operating quantification, microarrays and - To provide services related to medical Procedures (SOPs) are in place to fulfil those next-generation sequencing. imaging techniques for researchers from standards. In addition, the facility offers advice on IDIBAPS and other institutions, and to experimental design and application of industries connected with health. genomic techonologies - To perform first-rate basic and clinical research into medical imaging using structural and functional magnetic resonance imaging, magnetic resonance spectroscopy, molecular imaging, other types of medical imaging and image processing. - Training of the users and keeping the state of art in MRI techniques to enable researchers conducting experimental and clinical studies, thereby allowing them to explore the advantages of translational research. - To complement this infrastructure we count with the Laboratory of Image Analysis where the users have different workstations available to use with the most common softwares used in the MR Field installed.

46 Training Doctoral theses

Doctoral theses 107 defended in 2018.

Theses with 6 European mention.

THESIS AUTHOR TITLE THESIS DIRECTORS

Alvaro Eguileor Giné Deciphering the transcriptome and additional roles of Sox11 in mantle cell lymphoma. Amador V, Campo E

Endometriosis pathogenesis: The relationship between oxidative stress, ﬁbrosis and immunological Iñaki González Foruria dysfunction. Carmona F, Chapron C

Estudio de prevalencia de manifestaciones musculo-esqueleticos autoinmunes sistémicas y reumáticas en Rosana Maris Quintana Cervera R, Peláez I una comunidad originaria (qom) de la ciudad de Rosario, Santa Fe, Argentina.

Characterization of novel actionable molecular subgroups in Hepatocellular Carcinoma: Immune class and Iris Martínez Quetglas Llovet JM IGF2-driven tumors.

Ignasi Rodríguez Pintó Catastrophic antiphospholipid syndrome: treatment and prognosis. Espinosa G, Shoenfeld Y

Elena Vila Navarro MicroRNA biomarkers for early detection of pancreatic ductal adenocarcinoma and functional characteri- Gironella M zation of miR-93 in the pancreatic carcinogenesis. Técnicas de imagen y mapeo electroanatómico para la identicación y caracterización del sustrato de las Juan Acosta Martínez arritmias ventriculares. Implicaciones en la ablación con catéter y en la estratificación de riesgo de arritmias Berruezo A ventriculares malignas. Identificación y prevalencia de factores precipitantes de insuficiencia cardíaca aguda en los servicios de Alfons Aguirre Tejedo Miró Ò, Llorens P urgencias españoles y su relación con el pronóstico a corto y medio plazo.

Nadia Alberghina Nuevas aplicaciones de la ultrasonografía endoscópica (USE) en oncología digestiva. Ginés A,Fernandez G

Inﬂuencia de factores séricos y genéticos en la respuesta inﬂamatoria sistémica en pacientes cirróticos José Alcaraz Quiles Clària J descompensados.

Elena Alvarez Periel Dual role of Cdk5 on cognitive deﬁcits and striatal vulnerability in Huntington's disease. Ginés S

Hugo Jorge Alves Figuereido Improving islet-graft revascularization. Gomis R

María Amat Foraster Modulating NMDA receptors in the thalamo-cortical system. A novel approach to treat major depression. Artigas F (External supervisor)

Antonio Jesus Amor Predicción de eventos cardiovasculares: De las escalas de riesgo al uso de biomarcadores. Ortega E

Mecanismos moleculares del riesgo metabólico y cardiovascular en el Síndrome de Cushing antes y Gloria Beatriz Aranda después de la curación: Enfoque traslacional. Hanzu F, Halperin I

Ingrid Cecibel Arteaga Detección precoz de ﬁbrosis hepática en población adulta. Parés A, Caballeria LL

Patricia Bassas Freixas Caracterización de la expresión de ácido ribonucleico mensajero en distintos subtipos histológicos de Prat A carcinoma basocelular.

Helena Bassolas Molina Resposta T especíﬁca contra antígens de la microbiota comensal en la malaltia de Crohn i inhibició de Salas A RORyt com a estratègia terapèutica.

Àngela Bellmunt Fontanet Papel de los exosomas en la comunicación entre las células tumorales Closa D, Lorente J y los macrófagos en el carcinoma laríngeo.

Anna Blazquez Ventura Donation of gametes and Risk of Preeclampsia. Figueras F, Vassena R

Boosting intravenous administration of therapeutic viral vectors using Pau Brugada Vilà an oligopeptide-modiﬁed poly (b -amino ester)s-based coating technology. Fillat C

47 FOREWORD IDIBAPS

Guillem R. Caldentey Adrover Paper del sistema GAS6-TAM en el remodelat ventricular postinfart agut de miocardi. Ortiz JT, Bosch X

Factores pronósticos para la supervivencia y recidiva en los pacientes con carcinoma hepatocelular Mihai Calin Pavel sobrepasando los criterios de Milán sometidos a trasplante hepático de donante vivo. Garcia-Valdecasas JC

Xavier Calvo González Valoració pronòstica de les síndromes mielodisplàstiques i de la leucèmia mielomonocítica crònica. Nomdedeu B

Tratamiento del carcinoma in situ de la mama. Beneﬁcio de la administración de una dosis adicional en el lecho María José Cambra Serés de la tumorectomía a la radioterapia complementaria de toda la mama tras la cirugía conservadora. Estudio Biete A retrospectivo.

Javier Caradeux Bull Longitudinal assessment for the prediction of abnormal fetal growth. Figueras F

Sabela Carballal Ramil Caracterización clínica y endoscópica de formas de alto riesgo de cáncer colorrectal. Balaguer F, Pellisé M

Cristina Casajuana Kögel La unitat estandarditzada de cànnabis: un instrument per a la valoració del consum de cànnabis i dels seus riscs. Gual A

Laila Rosalie Cochon Coen Bayesian Statistical Modeling for Clinical Decision Making in Emergency Medicine. Nicolas JM

Andrea Comella Bolla Neuronal differentiation and maturation of human pluripotent stem cells for modeling Huntington’s disease. Canals JM

Isabel Conde Mir Compatibilitat clínica entre marcapassos cardíacs i aparells electrònics odontològics: Estudi in vivo. Mont L, Miranda J

Jordi Creus Muncunill Dual role of mTOR in Huntington's disease: contribution to striatal neuronal survival and dysfunction. Pérez E

Andrés Cruz Herranz Retinal imaging in preclinical models of neuroinﬂammatory disease. Martínez-Lapiscina EH, Villoslada P

David de la Rosa Carrillo Análisis del impacto clínico, pronóstico y económico de los pacientes con bronquiectasias y EPOC. Agusti C

Análisis de la anatomía y funcionalidad foveal en ojos de pacientes con agujero macular Bàrbara Delàs Alos Casaroli MaranoR, Nadal J idiopático antes y después de la cirugía.

Ana Esteve Solé Primary and secondary immunodeﬁciencies of the IL-12/IFN-y axis. Juan M, Alsina L

El vínculo materno-infantil: Evaluación y detección de los factores de riesgo prenatales en madres Borja Farré Sender Valdés M, Garcia-Esteve LL diagnosticadas de un trastorno mental.

Ana Fernandez Arcos Caracterización clínica, polisomnograﬁca y evolutiva del trastorno de conducta de sueño Rem Idiopático. Iranzo A

Ús d'organoides humans per a l'estudi de la barrera epitelial i la resposta a productes microbians en la Elena Ferrer Picón Salas A, Dotti I malaltia inﬂamatòria intestinal.

Identiﬁcació de mutacions en gens implicats en el metabolisme de l’àcid lipòic Xènia Ferrer Cortès Ribes A en l’acidúrica 3- metilglutacònica.

Marc Figueras Roca Caracterització dels Factors Clínics i Biològics associats Adán A a l'Edema Macular Diabètic en la Diabetis Mellitus Tipus II.

Marta Fontcuberta Pi-Sunyer Desenvolupament de noves estratègies per generar cèl·lules productores d'insulina. Gasa R, Gomis R

Interfacing the Cerebral Cortex: Two-dimensional recording techniques and electrical stimulation to Julia Franziska Weinert Sánchez-Vives MV explore and modulate spatio-temporal network dynamics in the cortex.

Mecanismos reguladores de la angiogénesis mediada por la vía del factor de crecimiento endotelial Javier Gallego Pinos Fernández M (VEGF) en hipertensión portal i cirrosis.

Anna Isabel Garcia Diaz Visuospatial and visuoperceptual impairment and its structural correlates as measures of cognitive decline Junqué C, Segura B in Parkinson's disease.

Ester Garcia Pras Mecanismes moleculars i cel·lulars de la neovascularització associada Fernández M a la hipertensió portal i la cirrosi hepàtica.

Alfonso Gerardo García Therapautic strategies based on neuroprotective mechanisms of neurotrophic Alberch J factors in Huntington's Disease models.

48 Laura García Otero Fetal cardiovascular remodelling in HIV pregnancies. Crispi F, López M

Juan Miguel Garrido Ocaña Evaluación de satisfacción de los pacientes que acuden a una Unidad de Trastornos Bipolares. Grande I, Trilla A

Insuﬁciencia renal en la cirrosis: Validación de los criterios akin y utilidad de la Ngal en el diagnóstico Cláudia Gonçalves Fagundes diferencial. Ginés P, Guevara M

Alexandre González Rodríguez Biomarcadors de resposta farmacològica en dones postmenopàusiques amb esquizofrènia. Bernardo M, Catalan R

Mariona Guitart-Mampel Mitochondrial implication in intrauterine growth restriction and cardiovascular remodeling. Cardellach F, Garrabou G

Hatice Gulcin Gumus Intrauterine therapy for fetal growth restriction. Crispi F, Ley D

Evaluación de la seguridad, tolerabilidad y adherencia a la proﬁlaxis post-exposición como Lorna Leal Alexander Garcia F estrategia para la prevención de la infección por el virus de la inmunodeﬁciencia humana.

María Eriong Lee Vergés. Novel therapeutic strategies for chronic lymphocytic leukemia. Colomer D

Hugo López Pelayo Beure o viure: el dilema davant la malatia mèdica relacionada amb el consum d'alcohol. Gual A

Technological insights into a histopathological and protein composition analysis of aortic aneurysms in Júlia López Guimet Egea G Marfan syndrome.

Lluna Mª López Ortiz Development of a formulation and stable pharmaceutical form for adenoviral vectors. Abian J, Avilés FX

María Constanza Lucero Pacientes infectados por VIH con buen control inmunovirológico: prevalencia de eventos no-SIDA Garcia F y marcadores de evolución. Estudio de factores clínico-biológicos relacionados con el microambiente, la transformación Laura Magnano Mayer López Guillermo A histológica y la respuesta al tratamiento en pacientes con linfoma folicular.

Ramon Marquès Mascarell Caracterización de una nueva ﬁtasa y su expresión en Pichia pastoris. Aligué RM

Caracterització genètica del Limfoma de Cèl·lules del Mantell i la Leucèmia Limfàtica Crònica David Martin García Beà S mitjançant microarrays i tècniques de seqüenciació: noves eines pel diagnòstic i pronòstic.

Inﬂuencia de las mutaciones genéticas en las características clínicas, biológicas y evolutivas de los Soﬁa Alejandra Martínez Trillos Villamor N pacientes con leucemia linfática crónica y linfoma linfocítico.

Anna Mensa Vilaró Implicació del mosaïcisme genètic en les immunodeﬁciències primàries. Aróstegui JI

Laia Miquel De Montagut Impacte del consum d'alcohol en l'ús de recursos i costos sanitaris. Gual A

Enrique Mir Fuertes Endothelial dysfunction ocurring in acute graft-versus-host disease. Diaz-Ricart MI, Palomo M Potential preventive and therapeutic agents.

Joan Ignasi Mir Coll Regulation of pancreatic beta cell mass and function: the role of glycogen metabolism Gomis R, Gasa R and other intrinsic factors.

Jezid Enrique Miranda Quintero Phenomapping of fetal growth restriction. Gratacós E, Crispi F

Ruth Montalbo Calafell Estudi del Carcinoma Urotelial. Identiﬁcació de biomarcadors amb valor diagnòstic i pronòstic. Mengual L, Izquierdo L

Dolor crónico generalizado y Fibromialgia: estudio de pruebas objetivas, comorbilidad, Enma Marianela Morales Espinoza Sisó A, Ramos M complejidad y gasto sanitario.

Detecció de la regressió post-biòpsia de la neoplàsia cervical intraepitelial. Meritxell Munmany Delgado Torné A, Del Pino M Valor de la colposcòpia immediata preconització.

Andrè Nogueira Nazar Valoración de la función ventricular izquierda en la cirrosis hepática: relación con la hemodinámica Ginés P sistémica y la disfunción renal.

Luis Perea Sanchez Las células estrelladas hepáticas en las enfermedades del hígado Sancho-Bru P y el desarrollo de nuevos modelos de ﬁbrosis.

49 FOREWORD IDIBAPS

María del Mar Petit Pedrol Antigens and mechanisms of immune-mediated encephalitis. Dalmau J

Núria Planell Picola Estudi transcripcional de la Colitis Ulcerosa. Caracterizació i cerca de biomarcadors. Salas A, Lozano JJ

Renal disease among patients with hiv infection: prevalence, risk factors, and evolution after renal Marina Pontello Cristelli Miró JM, Cofan F transplantation.

Miriam Potrony Mateu Characterization of genetic factors associated with melanoma susceptibility and prognosis. Puig S

Eﬁcacia del uso de la tecnología en el tratamiento de la diabetes tipo I en nuestro entorno. Carmen Quirós López Conget I, Giménez M De las Bombas de insulina al páncreas artiﬁcial.

Tri Rahmat Basuki Longitudinal Study of Fetal Growth in Low-Risk Population. Gratacós E, Figueras F

Evaluación de los síntomas psiquiátricos en pacientes con epilepsia refractaria intervenidos Sònia Ramos Perdigués Pintor L, Baillès E quirúrgicamente a través de un estudio prospectivo controlado durante 12 meses.

Preclinical evaluation of the antitumor activity of a new CXCR4 inhibitor: a novel therapeutic approach in Clara Recasens Zorzo Pérez P, Roué G diffuse large B-cell lymphoma.

Adriano Rodríguez Trujillo Utilidad de la determinación VPH, genotipado y tinción dual p16/Ki67 en la prevención Torné A, Del Pino M secundaria del cáncer de cuello de útero.

Luis Gerardo Rodríguez Lobato Factores pronóstico en pacientes con amiloidosis sistémica por cadenas ligeras. Fernández De Larrea C, Bladé J

Natalia Rodríguez Ferret Bases biológicas de la ﬁsiopatología y la farmacología del trastorno obsesivo-compulsivo de inicio Morer A, Gassó P en la infancia y la adolescencia. Inﬂuencia de la genética y la desregulación inmunológica.

Sally Sabra Maternal Heavy Metals and Toxins Exposure and their inﬂuences on Gratacós E, Gómez MD Fetal Growth Restriction Clinical Subtypes.

Anna Sala Puigdollers Estudio de repetibilidad y reproductuvidad del grosor retiniano y coroideo mediante tomografía de coherencia Adán A, Zarranz J óptica de dominio swept source y comparación con dominio espectral en el Edema Macular Diabético.

Bernardo Francisco Sánchez Biomarcadores de calidad visual percibida en pacientes con neuritis óptica aguda y esclerosis múltiple. Villoslada P, Adan A

Irene Sangrador Escrig Zeb1 en las células estrelladas del páncreas: implicación en la oncogénesis pancreática Vaquero EC dependiente de Kras.

Alfonso Santamaría Gadea Uso endoscópico del colgajo pericraneal para la reconstrucción nasal y de base de cráneo. Alobid I, Enseñat J

Sandra Santasusagna Canal Exosomes i microRNAS en biòpsia líquida com a biomarcadors pronòstics del càncer de colon. Monzó M, Navarro A

Historia natural de la infección crónica por el VHB en Portadores Inactivos y Pacientes en Zona Gris e Martin Sebastian Bonacci Impacto Virológico, Inmunológico y Clínico del Tratamiento con Antivirales de Acción Directa sobre la Forns X, Lens S Vasculitis Crioglobulinémica asociada al VHC.

Berta Serra Navarro Implicació de la senyalització dependent de Gsa en l'establiment de la massa cel·lular ß. Gomis R, Gasa R

Laura Sin Díaz Papel del p21 en la regulación de la vía de Wnt y su implicación en la neurogénesis. Bachs O

Marianna Spatola Neuronal antibody-mediated encephalitis: Clinical characterization and pathological mechanisms. Dalmau J

Monique Carolina Suarez New Therapeutic approaches for obstructive sleep apnea. Almendros I, Montserrat JM

Núria Suelves Caballol Evaluation of therapeutic targets for the treatment of behavioral alterations and Ginés S neuropathology in Huntington's disease.

Marta María Tasende Presedo Abordaje transanal en patología rectal. De Lacy A

Gemma Tell Martí Rol del gen de pigmentació MC1R en la susceptibilitat a malalties neurodegeneratives. Puig S, Puig JA

Ákos Tényi A Systems Medicine approach to multimorbidity -Towards personalised care Roca J, Cano I for patients with Chronic Obstructive Pulmonary Disease.

50 Interleukin-6(IL-6)IL-6 receptor and persistence of inﬂammation in Giant Cell Arteritis. Nekane Terrades Garcia Cid MC Effects of IL-6 receptor blockade with tocilizumab.

Análisis del valor pronóstico del perﬁl de expresión génica en la leucemia mieloblástica Montserrat Torrebadell Burriel Esteve J, Camós M aguda de riesgo citogenético intermedio según la opción terapéutica post-remisión.

Marcadores de inﬂamación en pacientes infectados por el virus de la inmunodeﬁciencia Berta Torres Murillo Garcia F humana en tratamiento antirretroviral.

Anna Tutusaus López Identiﬁcación de dianas terapéuticas en ﬁbrosis hepáticas y cáncer. Marí M, Morales A

Impacte de les alteracions anatòmiques intranasals sobre els símptomes, la resposta al Meritxell Valls Mateus Mullol J, Mariño F tractament mèdic i la qualitat de vida en nens i adolescents amb rinitis al·lèrgica persistent.

Evaluación de las alteraciones de la coagulación de los donantes a corazón parado, su relación Marina Vendrell Jordà Fondevila C, Garcia-Valdecasas JC con la viabilidad de los injertos hepáticos y posibles acciones terapéuticas.

Norma Verdolini Self and Hetero-Aggression: Clinical Implications in Bipolar Disorder and Mixed States Vieta E, Pacchiarotti I

51 FOREWORD IDIBAPS

Seminars Stepping-stone training programme

It is a training programme that seeks to provide predoctoral (R1) and postdoctoral (R2) researchers at IDIBAPS with non-scientiﬁc tools and skills which Institutional are key for the development of their careers. 41 Seminars

IDIBAPS SEMINAR 6 6

IN -HOUSE SEMINARS 6 Sessions in 2018 NEUROSCIENCES SEMINAR 6

CAMPUS CLINIC CANCER SEMINAR 7 188 CORE FACILITY SEMINAR 4

IIBB-CSIC/IDIBAPS SEMINAR Attendees in 2018 3

LIVER SEMINAR 9

52 Communication and public engagement

MEDIA RELATIONS PUBLIC ENGAGEMENT SOCIAL MEDIA

Press Activities Facebook 31 releases 48 organised 2112 page likes* (11 different categories of activities) Twitter 8290 followers* PUBLIC RELATIONS 2,131 Audience Reached Linkedin Events 2062 followes* 17 organised *at december 31 ACTIVITIES Primary school students

Summer Camp. 30 Assistants

ACTIVITIES ACTIVITIES Secondary school students General Public

“A la recerca de la salut” Escolab. at Centre Cívic Urgell 164 Participants 848 Assistants

Brain Awareness Week. La Marató de TV3. 240 Participants 70 Assistants

Barcelona Int. Youth Science Pint of Science. ChallengeVisits. 10 75 Assistants Participants

Bojos per la Medicina. European Researcher’s Night. 60 Participants 150 Assistants

IDIBAPS Science Party. Barcelona “Festa de la Ciència” 250 Participants 165 Assistants

53 FOREWORD IDIBAPS

News

FEBRUARY IDIBAPS and Hospital Clínic unveil a 1 new Resonance Magnetic Imaging 3T scanner. (Foto 1)

MARCH Alvar Agustí, awarded the Fundación Lilly Biomedical Research Prize 2018. (Foto 2)

JULY IDIBAPS researchers awarded with two "la Caixa" Foundation grants for biomedical research projects. (Foto 3)

OCTOBER Elias Campo, new member of the National Academy of Medicine of the United States.

IDIBAPS and CRG researchers awarded with an 8,3 M€ ERC Synergy grant to 2 unravel chronic lymphocytic leukemia. (Foto 4)

IDIBAPS participates in two international projects to advance in traslational cancer research .

NOVEMBER 250 students from 12 catalan institutes participate in the IDIBAPS’ Science Party. (Foto 5)

Thirteen researchers of the Hospital Clínic-IDIBAPS and the University of Barcelona appear in the list of the most inﬂuential scientists worldwide. (Foto 6)

54 4

55 ANNUAL SCIENTIFIC REPORT 2018

AREA 1

BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS 1

BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

1.1 Inﬂammatory joint diseases (IJDs) 58 Raimon Sanmartí

1.2 Systemic autoimmune diseases 60 Ricard Cervera

1.3 Infectious diseases and AIDS 66 Josep M. Miró

1.4 Immune receptors of the innate and adaptive system 76 Francisco Lozano

1.6 Immunogenetics of the autoinﬂammatory response 79 Jordi Yagüe

1.7 Emergencies: processes and pathologies 82 Oscar Miró

1.8 Molecular and cellular bases of inﬂammation. 88 Structural and biological mass spectrometry Daniel Closa

1.9 Ocular inﬂammation: clinical and experimental studies 90 Alfredo Adán

57 AREA 1 BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

Inﬂammatory joint 1.1 diseases (IJDs)

- Search of biomarkers of clinical reactivation and radiographic progression. LOCATION

HCB building 3. Immunopathology of synovitis in chronic arthritis - Utility in pathogenesis, differential diagnosis and prognosis of rheumatoid arthritis and psoriatic arthritis. Immuno pathological changes induced by KEYWORDS biological treatments. Mechanism of 1. Rheumatoid arthritis TEAM LEADER action of targeted therapies. Synovial 2. Psoriatic arthritis Raimon Sanmartí (HCB) response biomarkers. 3. Pathogenesis T. 93 227 54 00 (Ext.: 2236/2604) 4. Biomarkers 4. Pharmacogenomics of chronic [email protected] 5. Targeted therapies arthritis - Genetic biomarkers associated to biological therapy response in rheuma RESEARCHERS toid arthritis and psoriatic arthritis Juan de Dios Cañete (HCB)

Original publications POST-DOCTORAL RESEARCHERS from 2016 to 2018 Raul Antonio Castellanos (HCB) PUBLICATIONS Maria Raquel Celis (FCRB) YEAR I.F. TOTAL Q1 Q2 Andrea Cuervo (FCRB) Originals / I.F.: 43.766 María Victoria Hernández (HCB) 2016 58.21 14 8 5 Rosa M Morla Novell (FCRB) 1. Lauper K, Nordström DC, Pavelka K, 2017 85.96 16 7 5 Felipe Julio Ramirez (FCRB) Hernández MV, Kvien TK, Kristianslund EK, 2018 43.77 9 7 1 Virginia Ruiz-Esquide (FCRB) Santos MJ, Rotar Ž, Iannone F, Codreanu C, Lukina G, Gale SL, Sarsour K, Luder Y, Courvoisier DS, Gabay C. Comparative effectiveness of tocilizumab versus TNF STRATEGIC OBJECTIVES inhibitors as monotherapy or in TEAM INVOLVED IN combination with conventional synthetic RIER Promotion of research into the most disease-modifying antirheumatic drugs in prevalent chronic forms of immune mediated patients with rheumatoid arthritis after the inflammatory arthritis: rheumatoid arthritis use of at least one biologic disease- (RA) and spondyloarthritis, including psoriatic modifying antirheumatic drug: analyses arthritis. from the pan-European TOCERRA register collaboration. ANNALS OF THE RHEUMATIC DISEASES. 77(9):1276-1282. I.F.: 12.350 MAIN LINES OF RESEARCH 2. Balsa A, Sanmarti R, Rosas J, Martin V, 1. Prognostic factors in early arthritis Cabez A, Gómez S, Montoro M . Drug - Prognostic factors (clinical and immuno immunogenicity in patients with genetic) in patients with recent-onset inflammatory arthritis and secondary rheumatoid arthritis. failure to tumour necrosis factor inhibitor - Production of new synthetic citrullinated therapies: the REASON study. peptides for the design of immunoassa RHEUMATOLOGY. 57(4):688-693. I.F.: 5.245 ys with diagnostic and prognostic value in recent-onset rheumatoid arthritis and 3. Choy, Ernest; Caporali, Roberto; Xavier, palindromic rheumatism. Ricardo; Fautrel, Bruno; Sanmarti, Raimon; Bao, Min; Bernasconi, Corrado; 2. Clinical and sonographic Petho-Schramm, Attila. Subcutaneous characterization of clinical remission tocilizumab in rheumatoid arthritis: - Definition and clinical characterization of findings from the common-framework subclinical “active synovitis” phase 4 study programme TOZURA - Immunopathological and molecular conducted in 22 countries. characterization of subclinical “active RHEUMATOLOGY. 57(3):499-507. I.F.: 5.245 synovitis”.

58 INFLAMMATORY JOINT DISEASES (IJDS) 1.1

4. Diaz-Torne C, Ortiz MDA, Moya P, Review / I.F.: 12.925 Cañete JD. Biomarcadores sinoviales para Hernandez MV, Reina D, Castellvi I, De la clasificación diagnóstica de las artritis Agustin JJ, Fuente D, Corominas H, Sanmarti 1. Ramírez J, Nieto-González JC, Curbelo indiferenciadas. Estudio prospectivo R, Zamora C, Cantó E, Vidal S . The Rodríguez R, Castañeda S, Carmona L. basado en patrones vasculares, combination of IL-6 and its soluble Prevalence and risk factors for inmunohistoquímica y expresión génica. receptor is associated with the response osteoporosis and fractures in axial Sponsored by: Instituto de Salud Carlos III of rheumatoid arthritis patients to spondyloarthritis: A systematic review and (ISCIII). PI14/00785 tocilizumab. SEMINARS IN ARTHRITIS AND meta-analysis. SEMINARS IN ARTHRITIS Duration: 01/01/2015-30/06/2019 RHEUMATISM. 47(6):757-764. I.F.: 4.356 AND RHEUMATISM. 48(1):44-52. I.F.: 4.356 Cañete JD. Red Temática de Investigación 5. Inciarte-Mundo J, Ramirez J, Hernández 2. Sanmartí R, Ruiz-Esquide V, Bastida C, Soy Cooperativa en Salud - Inflamación y MV, Ruiz-Esquide V, Cuervo A, D . Tocilizumab in the treatment of adult enfermedades reumáticas. Cabrera-Villalba SR, Pascal M, Yagüe J, rheumatoid arthritis. IMMUNOTHERAPY. Sponsored by: Instituto de Salud Carlos III Cañete JD, Sanmarti R . Calprotectin 10(6):447-464. I.F.: 3.461 (ISCIII). RD16/0012/0010 strongly and independently predicts Duration: 01/01/2017 - 31/12/2021 relapse in rheumatoid arthritis and 3. Ramírez J, Cañete JD. Anakinra for the polyarticular psoriatic arthritis patients treatment of rheumatoid arthritis: a safety Cañete JD. Red de Investigación en treated with tumor necrosis factor evaluation. EXPERT OPINION ON DRUG Inflamación y Enfermedades Reumáticas inhibitors: a 1-year prospective cohort SAFETY. 17(7):727-732. I.F.: 3.156 (RIER). study. ARTHRITIS RESEARCH AND Sponsored by: Instituto de Salud Carlos III THERAPY. 20(1):275. I.F.: 4.269 4. Martín-López M., Carmona L., Balsa A., (ISCIII). RD12/0009/0016 Calvo-Alén J., Sanmartí R., Tornero J., Rosas Duration: 01/01/2013 – 31/12/2018 6. Bastida C, Ruiz-Esquide V, Pascal M, de J. Serum drug levels of biologic agents in Vries Schultink AHM, Yagüe J, Sanmartí R, the management of rheumatoid arthritis Cañete JD. REMRABIT: Clinical validation Huitema ADR, Soy D . Fixed dosing of and spondyloarthritis: a systematic review. of genetic markers to predict persistent intravenous tocilizumab in rheumatoid RHEUMATOLOGY INTERNATIONAL. remission in rheumatoid arthritis patients arthritis. Results from a population 38(6):975-983. I.F.: 1.952 treated with biological therapy. pharmacokinetic analysis. BRITISH Sponsored by: Fundación Profesor Novoa JOURNAL OF CLINICAL PHARMACOLOGY. Santos. FIS_PMP15 (PMP15/00032) 84(4):716-725. I.F.: 3.838 Letters / I.F.: 12.35 Duration: 01/01/2016-31/12/2019

7. Gomara, Maria J.; Rodriguez, Javier; Bleda, 1. Sanmarti R, Ramírez J, Castellanos-Moreira Maria J.; Salvador, Juan P.; Sanmarti, Raimon; R, Cabrera-Villalba SR, Ruiz-Esquide V, Haro, Isabel. Comparative study of the Salvador G. Ultrasound ﬁndings in diagnostic and prognostic value of palindromic rheumatism. ANNALS OF THE antibodies against chimeric citrullinated RHEUMATIC DISEASES. I.F.: 12.350 synthetic peptides and CCP3/CCP3.1 assays. CLINICAL CHEMISTRY AND LABORATORY MEDICINE. 56(2):285-293. Case Reports / I.F.: 4.356 I.F.: 3.556 1. Florez H, Morlà R, Castellanos-Moreira R, 8. Lopez-Rodriguez R., Perez-Pampin E., Sanmartí R. Sustained response to Marquez A., Blanco F., Joven B., Carreira P., rituximab in a TNFi-induced Ferrer M., Caliz R., Valor L., Narvaez J., Cañete ANCA-vasculitis developed in a patient J., Del Carmen Ordoñez M., Manrique-Arija S., with rheumatoid arthritis. SEMINARS IN Vasilopoulos Y., Balsa A., Pascual-Salcedo D., ARTHRITIS AND RHEUMATISM. Moreno-Ramos M., Alegre-Sancho J., 47(4):e15-e16. I.F.: 4.356 Navarro-Sarabia F., Moreira V., Garcia-Portales R., Raya E., Magro-Checa C., Martin J., Gomez-Reino J., Gonzalez A. Validation study of genetic biomarkers of GRANTS FOR RESEARCH IN PROGRESS response to TNF inhibitors in rheumatoid arthritis. PLOS ONE. 13(5):e0196793. Cañete JD. Biomarcadores sinoviales y I.F.: 2.766 séricos de mal pronóstico en Artritis Indeferenciadas de inicio. Un estudio 9. Queiro R., Cañete J. Impact of longitudinal, prospectivo, de 18 meses de cardiovascular risk factors on the seguimiento. achievement of therapeutic goals in psoriatic Sponsored by: Instituto de Salud Carlos III arthritis: is there any association? CLINICAL (ISCIII). PI17/00993 RHEUMATOLOGY. 37(3):661-666. I.F.: 2.141 Duration: 01/01/2018-31/12/2020

59 AREA 1 BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

Systemic 1.2 autoimmune diseases

Pamela Doti (HCB) Nerea Iniesta (HCB) LOCATION Alba Jerez (HCB) HCB building Carolina Sánchez (HCB) CELLEX building, ﬂoor 4B Roser Alba-Rovira (IDIBAPS) Javier Marco-Hernández (HCB) Michelle Villarreal-Compagny (HCB)

ADMINISTRATIVE STAFF Isabel Chaves (HCB) KEYWORDS TEAM LEADER 1. Systemic autoimmune diseases Ricard Cervera (HCB) COLLABORATORS 2. Systemic lupus erythematosus T. 93 227 57 74 Xavier Bosch (HCB) 3. Systemic vasculitis [email protected] Antoni Sisó (EAP Les Corts) 4. Antiphospholipid syndrome Ana García-Martínez (HCB) 5. Sjögren's syndrome Roberto Ríos-Garcés (FCRB) GROUP LEADER

Maria Cinta Cid (HCB) VISITING SCIENTISTS T. 93 227 57 74 Soﬁa Arteaga (Universidad de Bogotá, [email protected] Colòmbia) Fabiola Atzeni (Università di Messina, Itàlia) Pilar Brito-Zerón (Hospital CIMA, Barcelona, Original publications RESEARCHERS Spain) from 2016 to 2018 Ricardo P Casaroli-Marano (HCB) Antonio Chamorro (Hospital Clínico de Gerard Espinosa (HCB) YEAR I.F. TOTAL Q1 Q2 Salamanca, Spain) Laura Pelegrín (HCB) Sandra Consani (Hospital Maciel, 2016 150.05 28 15 10 Manuel Ramos-Casals (HCB) Montevideo, Uruguai) 2017 331.90 35 20 6 Georgina Espígol-Frigolé (HCB-IDIBAPS) Gloria de la Red (Hospital de l'Esperit Sant, José Hernández-Rodríguez (HCB) 2018 140.42 31 15 8 Santa Coloma de Gramenet, Spain) Manuel Ferreira (Hospital de Santa Maria, POST-DOCTORAL RESEARCHERS Lisboa, Portugal) Marc Corbera-Bellalta (IDIBAPS) Alejandra Flores-Chavez (Universidad de Ester Planas (IDIBAPS) Colima, Mèxic) Sergio Prieto-González (HCB) TEAM INVOLVED IN Mario García-carrasco (Benemérita AGAUR_SGR17: 819, 1413, 1592 Nekane Terrades-Garcia (IDIBAPS) Universidad de Puebla, Mèxic) Hoda Gheitasi (Hospital de Teheran, Iran) PRE-DOCTORAL RESEARCHERS Maria Kourilovich (Hospital Monte Sinaí, Emmanuel Coloma-Bazán (HCB) Cuenca, Ecuador)

AWARDS Sarcoidosis Clinic Award Institution: World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) Awardee/s: Dr. Manuel Ramos-Casals TEAM Ricard Cervera

60 SYSTEMIC AUTOIMMUNE DISEASES 1.2

Miguel Angel Plasín (Hospital de Mollet, 4. Autoinflammatory diseases: PUBLICATIONS Spain) - Epidemiological studies on the clinical Joan Plaza (Hospital de Viladecans, Spain) manifestations and long-term evolution of Originals / I.F.: 140.423 Isaac Pons (Hospital d'Igualada, Spain) these diseases. Rosanna Quintana (Hospital Provincial de 1. Bonacci M, Lens S, Mariño Z, Londoño MC, Rosario, Argentina) Rodriguez-Tajes S, Sánchez-Tapias JM, Ramos-Casals M, Hernández-Rodríguez J, RESEARCH GROUP Forns X . Long-Term Outcomes of Patients SYSTEMIC VASCULITIS With HCV-Associated Cryoglobulinemic STRATEGIC OBJECTIVES Vasculitis After Virologic Cure. GASTROENTEROLOGY. 155(2):311-315. The research team promotes clinical and I.F.: 20.773 translational research on systemic autoimmune diseases in a multidisciplinary 2. Mendel A, Bernatsky SB, Hanly JG, Urowitz manner, with the participation of members of MB, Clarke AE, Romero-Diaz J, Gordon C, Bae the Departments of Autoimmune Diseases, SC, Wallace DJ, Merrill JT, Buyon JP, Isenberg Ophthalmology, Nephrology, Immunology, GROUP LEADER DA, Rahman A, Ginzler EM, Petri M, Dooley Hemostasis, Obstetrics and Dermatology, Maria Cinta Cid (HCB) MA, Fortin PR, Gladman DD, Steinsson K, among others. These activities are carried out Ramsey-Goldman R, Khamashta MA, Aranow in collaboration with many international We are interested in investigating C, Mackay M, Alarcón GS, Manzi S, Nived O, working groups. mechanisms involved in vascular Jönsen A, Zoma AA, van Vollenhoven RF, inflammation and remodelling in systemic Ramos-Casals M, Ruiz-Irastorza G, Lim S, vasculitis with the ultimate goal of identifying Kalunian KC, Inanc M, Kamen DL, Peschken CA, biomarkers of disease activity and Jacobsen S, Askanase A, Sanchez- Guerrero J, MAIN LINES OF RESEARCH therapeutic targets. Bruce IN, Costedoat-Chalumeau N, Vinet É. Low We are also interested in delimitating clinical aspirin use and high prevalence of 1. Systemic lupus erythematosus, phenotypes and outcomes as well as in pre-eclampsia risk factors among pregnant antiphospholipid syndrome and therapeutic innovation with targeted women in a multinational SLE inception systemic sclerosis: therapies, participating in the design and cohort. ANNALS OF THE RHEUMATIC - Epidemiological studies on the clinical development of innovative international DISEASES. 78(7):1010-1012. I.F.: 12.350 manifestations and long-term evolution of clinical trials. these diseases. The group also participates in massive 3. Herrera C, Marcos M, Carbonell C, - Clinical trials in new biological therapies. genotyping and national and international Mirón-Canelo J, Espinosa G, Cervera R, registries of systemic vasculitis, as well as in Chamorro A. Association between allelic 2. Sjögren’s syndrome, autoimmune the development of international guidelines variants of the human glucocorticoid manifestations of hepatitis C virus and recommendations for the definitions, receptor gene and autoimmune diseases: infection and biological therapies: classification and management of systemic A systematic review and meta-analysis. - Study of IgG4 disease associated with vasculitis and related diseases. AUTOIMMUNITY REVIEWS. 17(5):449-456. Sjögren’s. I.F.: 8.745 - Validation of ESSDAI and ESSPRI activity scores, - Development of new international classification criteria for Sjögren’s.

3. Systemic vasculitis: - Investigation of the mechanisms involved in vascular inflammation and remodelling in systemic vasculitis. Identification of biomarkers and new therapeutic targets. - Development of ex-vivo culture models for studying factors implicated in the perpetuation of inflammation and in vascular remodelling.in giant-cell arteritis - Clinical trials investigating targeted therapies in the management of systemic vasculitis. - Clinical phenotypes and outcomes in systemic vasculitis - Immunogenetics of systemic vasculitis GROUP Maria Cinta Cid

61 AREA 1 BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

4. Costedoat-Chalumeau N, Houssiau F, Inception Cohort. RHEUMATOLOGY. Bruce I, Petri M, Ginzler E, Dooley M, Steinsson Izmirly P, Le Guern V, Navarra S, Jolly M, 57(4):677-687. I.F.: 5.245 K, Ramsey-Goldman R, Zoma A, Manzi S, Ruiz-Irastorza G, Baron G, Hachulla E, Nived O, Jonsen A, Khamashta M, Alarcón G, Agmon-Levin N, Shoenfeld Y, Dall'Ara F, 8. Rodríguez-Pintó I, Espinosa G, Erkan D, Chatham W, van Vollenhoven R, Aranow C, Buyon J, Deligny C, Cervera R, Lazaro E, Shoenfeld Y, Cervera R, CAPS Registry Mackay M, Ruiz-Irastorza G, Ramos-Casals Bezanahary H, Leroux G, Morel N, Viallard J, Project Group . The effect of triple therapy M, Lim S, Inanc M, Kalunian K, Jacobsen S, Pineau C, Galicier L, Van Vollenhoven R, on the mortality of catastrophic Peschken C, Kamen D, Hanly J, Li Q, Su L. Tincani A, Nguyen H, Gondran G, Zahr N, anti-phospholipid syndrome patients. Cerebrovascular Events in Systemic Pouchot J, Piette J, Petri M, Isenberg D. RHEUMATOLOGY. 57(7):1264-1270. I.F.: 5.245 Lupus Erythematosus: Results From an A Prospective International Study on International Inception Cohort Study. Adherence to Treatment in 305 Patients 9. Legault K, Schunemann H, Hillis C, Yeung C, ARTHRITIS CARE AND RESEARCH. With Flaring SLE: Assessment by Drug Akl E, Carrier M, Cervera R, Crowther M, 70(10):1478-1487. I.F.: 4.149 Levels and Self-Administered Dentali F, Erkan D, Espinosa G, Khamashta M, Questionnaires. CLINICAL Meerpohl J, Moffat K, O'Brien S, Pengo V, 13. Mesquida M, Molins B, Llorenç V, PHARMACOLOGY AND THERAPEUTICS. Rand J, Rodriguez Pinto I, Thom L, Iorio A. Hernández MV, Espinosa G, Sainz de la Maza 103(6):1074-1082. I.F.: 6.544 McMaster RARE-Bestpractices clinical M, Adán A. Twenty-four month follow-up of practice guideline on diagnosis and tocilizumab therapy for refractory 5. Fernandez-Robredo, Patricia; Recalde, management of the catastrophic uveitis-related macular edema. RETINA. Sergio; Hernandez, Maria; Zarranz-Ventura, antiphospholipid syndrome. JOURNAL OF 38(7):1361-1370. I.F.: 4.013 Javier; Molins, Blanca; Casaroli-Marano, THROMBOSIS AND HAEMOSTASIS. Ricardo P.; Adan, Alfredo; Saenz-de-Viteri, 16(8):1656-1664. I.F.: 4.899 14. Miró Ò, Yates C, Dines A, Wood D, Dargan Manuel; Garcia-Layana, Alfredo. Novel P, Galán I, Jerez A, Puiguriguer J, Waring W, Association of High c-Reactive Protein 10. Isenberg D, Sturgess J, Allen E, Aranow C, Moughty A, O’connor N, Heyerdahl F, Hovda Levels and A69S at Risk Alleles in Wet Askanase A, Sang-Cheol B, Bernatsky S, K, Vallersnes O, Paasma R, Põld K, Jürgens G, Age-Related Macular Degeneration Bruce I, Buyon J, Cervera R, Clarke A, Dooley Megarbane B, Anand J, Liakoni E, Liechti M, Women. FRONTIERS IN IMMUNOLOGY. M, Fortin P, Ginzler E, Gladman D, Hanly J, Eyer F, Zacharov S, Caganova B, Giraudon I, 9(1862):1862. I.F.: 5.511 Inanc M, Jacobsen S, Kamen D, Khamashta M, Galicia M. Emergencies related to Lim S, Manzi S, Nived O, Peschken C, Petri M, recreational drug abuse in Spain 6. Espígol-Frigolé G, Planas-Rigol E, Lozano E, Kalunian K, Rahman A, Ramsey-Goldman R, compared to emergencies attended in 3 Corbera-Bellalta M, Terrades-García N, Romero-Diaz J, Ruiz-Irastorza G, European areas. EMERGENCIAS. Prieto-González S, García-Martínez A, Sanchez-Guerrero J, Steinsson K, Sturfelt G, 30(6):384-394. I.F.: 3.608 Hernández-Rodríguez J, Grau J, Cid M. Urowitz M, van Vollenhoven R, Wallace D, Expression and function of IL12/23 related Zoma A, Merrill J, Gordon C. Study of Flare 15. De Castro-Miró M; Tonda R; Marfany G; cytokine subunits (p35, p40, and p19) in Assessment in Systemic Lupus Casaroli-Marano R; Gonzàlez-Duarte R. giant-cell arteritis lesions: Contribution of Erythematosus Based on Paper Patients. Novel mutation in the choroideremia gene p40 to Th1-and Th17-mediated ARTHRITIS CARE AND RESEARCH. and multi-mendelian phenotypes in inﬂammatory pathways. FRONTIERS IN 70(1):98-103. I.F.: 4.149 Spanish families. BRITISH JOURNAL OF IMMUNOLOGY. 9(809):809. I.F.: 5.511 OPHTHALMOLOGY. 102(10):1378-1386 11. Barber MRW, Hanly JG, Su L, Urowitz MB, I.F.: 3.384 7. Little, Jayne; Parker, Ben; Lunt, Mark; Hanly, St Pierre Y, Romero-Diaz J, Gordon C, Bae SC, John G.; Urowitz, Murray B.; Clarke, Ann E.; Bernatsky S, Wallace DJ, Isenberg DA, 16. Llorenç V, Benejam G, Mesquida M, Sainz Romero-Diaz, Juanita; Gordon, Caroline; Bae, Rahman A, Ginzler EM, Petri M, Bruce IN, de la Maza M, Molins B, Alba C, Pelegrin L, Sang-Cheol; Bernatsky, Sasha; Wallace, Fortin PR, Gladman DD, Sanchez-Guerrero J, Martínez JA, Adán A. Antituberculous Daniel J.; Merrill, Joan T.; Buyon, Jill; Isenberg, Ramsey-Goldman R, Khamashta MA, Aranow Treatment Itself Might Prevent Visual David A.; Rahman, Anisur; Ginzler, Ellen M.; C, Mackay M, Alarcón GS, Manzi S, Nived O, Impairment in Presumed Tuberculosis- Petri, Michelle; Dooley, Mary Anne; Fortin, Paul; Jönsen A, Zoma AA, van Vollenhoven RF, Related Uveitis. OCULAR IMMUNOLOGY Gladman, Dafna D.; Steinsson, Kristjan; Ramos-Casals M, Ruiz-Irastorza G, Lim SS, AND INFLAMMATION. 5:1-8. I.F.: 3.348 Ramsey-Goldman, Rosalind; Khamashta, Kalunian KC, Inanc M, Kamen DL, Peschken Munther A.; Aranow, Cynthia; Mackay, CA, Jacobsen S, Askanase A, Theriault C, 17. Fernández-Codina A; Pinilla B; Meggan; Alarcon, Graciela S.; Manzi, Susan; Farewell V, Clarke AE. Economic evaluation Pinal-Fernandez I; López C; Fraile-Rodriguez Nived, Ola; Jonsen, Andreas; Zoma, Asad A.; of lupus nephritis in the Systemic Lupus G; Fonseca-Aizpuru E; Carballo I; Brito-Zeron van Vollenhoven, Ronald F.; Ramos-Casals, International Collaborating Clinics P; Feijoo-Massó C; López-Dupla M; María C; Manuel; Ruiz-Irastorza, Guillermo; Lim, Sung inception cohort using a multistate model Martínez-Valle F. Spanish Registry of IgG4 Sam; Kalunian, Kenneth C.; Inanc, Murat; approach. ARTHRITIS CARE AND Related Disease (REERIGG4) investigators; Kamen, Diane L.; Peschken, Christine A.; RESEARCH. 70(9):1294-1302. I.F.: 4.149 Autoimmune Diseases Group (GEAS); Jacobsen, Soren; Askanase, Anca; Spanish Internal Medicine Society (SEMI). Sanchez-Guerrero, Jorge; Bruce, Ian N. 12. Hanly J, Li Q, Su L, Urowitz M, Gordon C, Treatment and outcomes in patients with Glucocorticoid use and factors associated Bae S, Romero-Diaz J, Sanchez-Guerrero J, IgG4-related disease using the IgG4 with variability in this use in the Systemic Bernatsky S, Clarke A, Wallace D, Isenberg D, responder index. JOINT BONE SPINE. Lupus International Collaborating Clinics Rahman A, Merrill J, Fortin P, Gladman D, 85(6):721-726. I.F.: 3.304

62 SYSTEMIC AUTOIMMUNE DISEASES 1.2

18. Flores-Chávez A, Kostov B, Solans R, 22. Gómez-Puerta J, Ortiz-Reyes B, Urrego T, Chamorro, A. J.; Colunga, D.; Corbella, X.; Fraile G, Maure B, Feijoo-Massó C, Rascón FJ, Vanegas-García A, Muñoz C, González L, Egurbide, M. V.; Espinosa, G.; Fonollosa, V.; Pérez-Alvarez R, Zamora-Pasadas M, Cervera R, Vásquez G. Urinary neutrophil Freire, M.; Garcia Hernandez, F. J.; Gonzalez García-Pérez A, Lopez-Dupla M, gelatinase-associated lipocalin and Leon, R.; Guillen del Castillo, A.; Iniesta, N.; Duarte-Millán MÁ, Ripoll M, Fonseca-Aizpuru monocyte chemoattractant protein 1 as Lorenzo, R.; Madronero, A. B.; Mari, B.; Marin, E, Guisado-Vasco P, Pinilla B, de-la-Red G, biomarkers for lupus nephritis in A.; Ortego-Centeno, N.; Perez Conesa, M.; Chamorro AJ, Morcillo C, Fanlo P, Soto- Colombian SLE patients. LUPUS. Pestana, M.; Pla, X.; Rios Blanco, J. J.; Cárdenas MJ, Retamozo S, Ramos- Casals M, 27(4):637-646. I.F.: 2.969 Rodriguez Carballeira, M.; Rubio Rivas, M.; Ruiz Brito-Zerón P, GEAS-SS SEMI Registry. Munoz, M.; Saez Comet, L.; Segovia, P.; Severe, life-threatening phenotype of 23. Plasín-Rodríguez M, Rodríguez-Pintó I, Simeon, C. P.; Soto, A.; Tari, E.; Todoli, J. A.; primary Sjögren's syndrome: clinical Patricio P, Monteagudo J, Cervera R, Reverter Tolosa, C.; Trapiella, L.; Vargas Hitos, J. A.; characterisation and outcomes in 1580 J, Espinosa G, Tàssies D. The H1 haplotype Verdejo, G.;RESCLE Investigators. First patients (GEAS-SS Registry). CLINICAL of the endothelial protein C receptor clinical symptom as a prognostic factor in AND EXPERIMENTAL RHEUMATOLOGY. 36 protects against arterial thrombosis in systemic sclerosis: results of a Suppl 112(3):121-129. I.F.: 3.201 patients with antiphospholipid syndrome. retrospective nationwide cohort study. THROMBOSIS RESEARCH. 169:128-134. CLINICAL RHEUMATOLOGY. 19. Rodríguez-Carballeira M, Solans R, I.F.: 2.779 37(4):999-1009. I.F.: 2.141 Larrañaga J, García-Hernández F, Rios-Fernández R, Nieto J, Solanich X, 24. Mendoza-Pinto, Claudia; Rojas-Villarraga, 27. Quintana R, Goñi M, Mathern N, Jorfen M, Martínez-Valle F, Fonseca E, Muñoz F, Fraile Adriana; Molano-Gonzalez, Nicolas; Conti S, Nieto R, Sanabria A, Prigione C, G, de Escalante B, Boldova R, Hurtado R, Jimenez-Herrera, Erick A.; de la Luz Leon- Silvestre A, García V, Pons-Estel G, Cervera R, Espinosa G. Venous thrombosis and relapses Vazquez, Maria; Montiel-Jarquin, Alvaro; García C, Peláez-Ballestas I, Alarcón G, in patients with Behcet's disease. Descriptive Garcia-Carrasco, Mario; Cervera, Ricard. Pons-Estel B. Rheumatoid arthritis in the analysis from Spanish network of Behcet's Bone mineral density and vertebral indigenous qom population of Rosario, disease (REGEB cohort). CLINICAL AND fractures in patients with systemic lupus Argentina: aggressive and disabling EXPERIMENTAL RHEUMATOLOGY. erythematosus: A systematic review and disease with inadequate adherence to 36(6):40-44. I.F.: 3.201 meta-regression. PLOS ONE. 13(6):e0196113. treatment in a community-based cohort I.F.: 2.766 study. CLINICAL RHEUMATOLOGY. 20. Brito-Zerón P, Acar-Denizli N, Ng WF, 37(9):2323-2330. I.F.: 2.141 Zeher M, Rasmussen A, Mandl T, Seror R, Li X, 25. González-Serna D, Carmona EG, Baldini C, Gottenberg JE, Danda D, Quartuccio Ortego-Centeno N, Simeón CP, Solans R, 28. Watad A, Quaresma M, Bragazzi N, L, Priori R, Hernandez-Molina G, Armagan B, Hernández-Rodríguez J, Tolosa C, Castañeda Cervera R, Tervaert J, Amital H, Shoenfeld Y. Kruize AA, Kwok SK, Kvarnström M, S, Narváez J, Martinez-Valle F,, Witte T, The autoimmune/inﬂammatory syndrome Praprotnik S, Sène D, Bartoloni E, Solans R, Neumann T, Holle J, Beretta L, Boiardi L, Emmi induced by adjuvants (ASIA)/Shoenfeld’s Rischmueller M, Suzuki Y, Isenberg DA, Valim G, Cimmino MA, Vaglio A, Herrick AL, Denton syndrome: descriptive analysis of 300 V, Wiland P, Nordmark G, Fraile G, Bootsma H, CP, Salvarani C, Cid MC, Morgan AW, patients from the international ASIA Nakamura T, Giacomelli R, Fonseca C, González-Gay MA, Martín J, syndrome registry. CLINICAL Devauchelle-Pensec V, Knopf A, Bombardieri Márquez A European GCA Consortium, RHEUMATOLOGY. 37(2):483-493. I.F.: 2.141 M, Trevisani VF, Hammenfors D, Pasoto SG, European Scleroderma Group. A TNFSF13B Retamozo S, Gheita TA, Atzeni F, Morel J, functional variant is not involved in 29. Brito-Zerón P, Acar-Denizli N, Sisó-Almirall Vollenveider C, Horvath IF, Sivils KL, Olsson P, systemic sclerosis and giant cell arteritis A, Bosch X, Hernández F, Vilanova S, Villalta M, De Vita S, Sánchez-Guerrero J, Kilic L, susceptibility. PLOS ONE. 13(12):e0209343. Kostov B, Paradela M, Sanchez M, Ramírez J, Wahren-Herlenius M, Mariette X, Ramos- I.F.: 2.766 Muxí A, Berruezo A, Galceran-Chaves C, Xaubet Casals M, Sjögren Big Data Consortium. How A, Agustí C, Sellarés J, Ramos-Casals M. The immunological proﬁle drives clinical 26. Rubio-Rivas, Manuel; Corbella, Xavier; Burden of Comorbidity and Complexity in phenotype of primary Sjögren's syndrome Pestana-Fernandez, Melany; Tolosa-Vilella, Sarcoidosis: Impact of Associated Chronic at diagnosis: analysis of 10,500 patients Carles; Guillen-del Castillo, Alfredo; Diseases. LUNG. 196(2):239-248. I.F.: 2.101 (Sjögren Big Data Project). CLINICAL AND Colunga-Arguelles, Dolores; Trapiella- EXPERIMENTAL RHEUMATOLOGY. Martinez, Luis; Iniesta-Arandia, Nerea; Jesus 30. Sanchez-Cano D; Ortego-Centeno N; 36(3):102-112. I.F.: 3.201 Castillo-Palma, Maria; Saez-Comet, Luis; Callejas J; Plá V; Ríos-Fernández R; Victoria Egurbide-Arberas, Maria; Tolosa-Vilella C; Espinosa-Garriga G; 21. González-Echavarri C, Capdevila O, Ortego-Centeno, Norberto; Freire, Mayka; Colunga-Argüelles D; Egurbide-Arberas M; Espinosa G, Suárez S, Marín-Ballvé A, Antonio Vargas-Hitos, Jose; Jose Rubio-Rivas M; Freire M; Ríos-Blanco J; González-León R, Rodríguez-Carballeira M, Rios-Blanco, Juan; Antonio Todoli-Parra, Jose; Trapiella-Martínez L; Rodríguez-Carballeira M; Fonseca-Aizpuru E, Pinilla B, Pallarés L, Rodriguez-Carballeira, Monica; Marin-Ballve, Marin-Ballvé A; Pla-Salas X; Simeón-Aznar C. Ruiz-Irastorza G. Infections in newly Adela; Segovia-Alonso, Pablo; Pla-Salas, Interstitial lung disease in systemic diagnosed Spanish patients with systemic Xavier; Belen Madronero-Vuelta, Ana; sclerosis: data from the spanish lupus erythematosus: data from the Ruiz-Munoz, Manuel; Fonollosa-Pla, Vicent; scleroderma study group. RELES cohort. LUPUS. 27(14):2253-2261. Pilar Simeon-Aznar, Carmen; Callejas Moraga, RHEUMATOLOGY INTERNATIONAL. I.F.: 2.969 E.; Calvo, E.; Carbonell, C.; Castillo, M. J.; 38(3):363-374. I.F.: 1.952

63 AREA 1 BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

31. Jaume Alijotas Reig, Enrique Esteve Hibiscus: hydroxychloroquine for the Alobid I. Nasoseptal Perforation: from Valverde, Raquel Ferrer Oliveras, Elisa Llurba secondary prevention of thrombotic and Etiology to Treatment. CURRENT ALLERGY Olivé, Amelia Ruffatti, Angela Tincani, Elmina obstetrical events in primary AND ASTHMA REPORTS. 18(1):5. I.F.: 3.449 Lefkou, Mª Tiziana Bertero, Gerard Espinosa antiphospholipid syndrome. Garriga, Sara de Carolis, Patrizia Rovere AUTOIMMUNITY REVIEWS. 17(12):1153-1168. 10. Samson, Maxime; Espigol-Frigole, Querini, Krista Lundelin, Elisa Picardo, Arsene I.F.: 8.745 Georgina; Terrades-Garcia, Nekane; Mekinian, EUROPEAN study group. Prieto-Gonzalez, Sergio; Corbera-Bellalta, Comparative study between obstetric 5. Escárcega RO, Lipinski MJ, Marc; Alba-Rovira, Roser; antiphospholipid syndrome and obstetric García-Carrasco M, Mendoza-Pinto C, Hernandez-Rodriguez, Jose; Audia, Sylvain; morbidity related with antiphospholipid Galvez-Romero JL, Cervera R . Inflammation Bonnotte, Bernard; Cid, Maria C. Biological antibodies. MEDICINA CLINICA. and atherosclerosis: Cardiovascular treatments in giant cell arteritis & 151(6):215-222. I.F.: 1.168 evaluation in patients with autoimmune Takayasu arteritis. EUROPEAN JOURNAL diseases. AUTOIMMUNITY REVIEWS. OF INTERNAL MEDICINE. 50:12-19. I.F.: 3.282 17(7):703-708. I.F.: 8.745 Review / I.F.: 97.302 11. Brito-Zerón P, Retamozo S, Ramos-Casals 6. Slart, Riemer H. J. A.; Glaudemans, Andor W. M. Phenotyping Sjögren's syndrome: 1. Roccatello, Dario; Saadoun, David; J. M.; Chareonthaitawee, Panithaya; Treglia, towards a personalised management of Ramos-Casals, Manuel; Tzioufas, Athanasios Giorgio; Besson, Florent L.; Bley, Thorsten A.; the disease. CLINICAL AND EXPERIMENTAL G.; Fervenza, Fernando C.; Cacoub, Patrice; Blockmans, Daniel; Boellaard, Ronald; Buceriu, RHEUMATOLOGY. 36(3):198-209. I.F.: 3.201 Zignego, Anna Linda; Ferri, Clodoveo. Jan; Carril, Jose Manuel; Chen, Wengen; Cid, Cryoglobulinaemia. NATURE REVIEWS Maria C.; Dagupta, Bhaskar; Dorbala, Sharmila; 12. Mendoza-Pinto C, García-Carrasco M, DISEASE PRIMERS. 4(1):11. I.F.: 16.071 Gheysens, Olivier; Hyafil, Fabien; Jain, Shaifali; Cervera R . Role of Infectious Diseases in Klink, Thorsten; van der Laken, Conny J.; the Antiphospholipid Syndrome (Including 2. Barturen G, Beretta L, Cervera R, Van Lomena, Francisco; Massollo, Michela; Its Catastrophic Variant). CURRENT Vollenhoven R, Alarcón-Riquelme ME. Prieto-Gonzalez, Sergio; Luqmani, Raashid; RHEUMATOLOGY REPORTS. 20(10):62. Moving towards a molecular taxonomy of Roivainen, Anne; Salvarani, Carlo; Saraste, I.F.: 3.079 autoimmune rheumatic diseases. NATURE Antti; Schirmer, Michael; Verberne, Hein J.; REVIEWS RHEUMATOLOGY. 14(2):75-93. Versari, Annibale; Voskuyl, Alexandre E.; 13. García-Carrasco M, Jiménez-Herrera E, I.F.: 15.661 Walter, Martin A.; Camellino, Dario; Brouwer, Gálvez-Romero J, Mendoza-Pinto C, Elisabeth; Cimmino, Marco A.; Abidov, Aiden; Méndez-Martínez S, Etchegaray-Morales I, 3. Retamozo, Soledad; Flores-Chavez, Agostini, Denis; Beanlands, Rob S.; Munguía-Realpozo P, Vázquez de Alejandra; Consuegra-Fernandez, Marta; Delgado-Bolton, Roberto C.; Einstein, Andrew Lara-Cisneros L, Santa Cruz F, Cervera R. The Lozano, Francisco; Ramos-Casals, Manuel; J.; Gimelli, Alessia; Miller, Edward J.; Sciagra, anti-thrombotic effects of vitamin D and Brito-Zeron, Pilar. Cytokines as therapeutic Roberto; Signore, Alberto;Writing Grp; their possible relationship with targets in primary Sjögren syndrome. Reviewer Grp. FDG-PET/CT(A) imaging in antiphospholipid syndrome. LUPUS. PHARMACOLOGY AND THERAPEUTICS. large vessel vasculitis and polymyalgia 27(14):2181-2189. I.F.: 2.969 184:81-97. I.F.: 10.376 rheumatica: joint procedural recommendation of the EANM, SNMMI, 14. Hernández-Rodríguez J, Ruiz-Ortiz E, 4. Belizna C, Pregnolato F, Abad S, and the PET Interest Group (PIG), and Yagüe J. Monogenic autoinflammatory Alijotas-Reig J, Amital H, Amoura Z, Andreoli L, endorsed by the ASNC. EUROPEAN diseases: General concepts and Andres E, Aouba A, Apras Bilgen S, Arnaud L, JOURNAL OF NUCLEAR MEDICINE AND presentation in adult patients. MEDICINA Bienvenu B, Bitsadze V, Blanco P, Blank M, MOLECULAR IMAGING. 45(7):1250-1269. CLINICA. 150(2):67-74. I.F.: 1.168 Borghi MO, Caligaro A, Candrea E, Canti V, I.F.: 7.704 Chiche L, Chretien JM, Cohen Tervaert JW, Damian L, Delross T, Dernis E, Devreese K, 7. Cervera, Ricard; Rodriguez-Pinto, Ignasi; Case Reports / I.F.: 4.943 Djokovic A, Esteve-Valverde E, Favaro M, Espinosa, Gerard. The diagnosis and clinical Fassot C, Ferrer-Oliveras R, Godon A, management of the catastrophic 1. López-Mato P, Zamora-Martínez C, Hamidou M, Hasan M, Henrion D, Imbert B, antiphospholipid syndrome: A Carbajal S, Estevez M, Rodriguez-Pinto I, Jeandel PY, Jeannin P, Jego P, Jourde-Chiche comprehensive review. JOURNAL OF Cervera R, Prieto-González S, Espinosa G. N, Khizroeva J, Lambotte O, Landron C, Latino AUTOIMMUNITY. 92:1-11. I.F.: 7.607 All that glitters is not lupus. LUPUS. JO, Lazaro E, de Leeuw K, Le Gallou T, Kiliç L, 27(6):1047-1048. I.F.: 2.969 Limper M, Loufrani L, Lubin R, Magy-Bertrand 8. Terrades-Garcia, Nekane; Cid, Maria C. N, Mahe G, Makatsariya A, Martin T, Muchardt Pathogenesis of giant-cell arteritis: How 2. Combalia A, Losno R, Prieto-González S, C, Nagy G, Omarjee L, Van Paasen P, Pernod targeted therapies are influencing our Mascaró J. Rituximab in refractory chronic G, Perrinet F, Pïres Rosa G, Pistorius MA, understanding of the mechanisms spontaneous urticaria: An encouraging Ruffatti A, Said F, Saulnier P, Sene D, Sentilhes involved. RHEUMATOLOGY. therapeutic approach. SKIN L, Shovman O, Sibilia J, Sinescu C, 57(suppl_2):ii51-ii62. I.F.: 5.245 PHARMACOLOGY AND PHYSIOLOGY. Stanisavljevic N, Stojanovich L, Tam LS, 31(4):184-187. I.F.: 1.974 Tincani A, Tollis F, Udry S, Ungeheuer MN, 9. Pereira C, Santamaría A, Langdon C, Versini M, Cervera R, Meroni PL . López-Chacón M, Hernández-Rodríguez J,

64 SYSTEMIC AUTOIMMUNE DISEASES 1.2

Consortium Publications / I.F.: 23.003 (ISCIII). PI14/00196 Ramos Casals M. HarmonicSS: Duration: 01/01/2015-30/06/2018 Harmonization and integrative analysis of 1. Ortiz-Fernández L, Carmona FD, regional, national and international López-Mejías R, González-Escribano MF, Cervera R. Molecular Reclassification to Cohorts on primary Sjögrens Syndrome Lyons PA, Morgan AW, Sawalha AH, Smith Find Clinically Useful Biomarkers for towards improved stratification, treatment KGC, González-Gay MA, Martín J, Spanish Systemic Autoimmune Diseases. and health policy. GCA Study Group, UK GCA Consortium, Sponsored by: European Comission. Sponsored by: European Comission. Turkish Takayasu Study Group, Vasculitis CE_IMI12_8th_1stg (115565) CE_H2020-SC1_16abr1s (731944) Clinical Research Consortium, IgAV Study Duration: 01/02/2014-31/01/2019 Duration: 01/01/2017-30/06/2020 Group, AAV Study group Spanish GCA Study Group, UK GCA Consortium, Turkish Cid MC. Dilatació d'aorta ascendent i Takayasu Study Group, Vasculitis Clinical aneurismes coronaris en pacients amb Research Consortium, IgAV Study Group, vasculitis sistèmiques (arteritis de cèlules DOCTORAL THESES AAV Study group. Cross-phenotype gegants i malaltia de Kawasaki). Rol de la analysis of Immunochip data identifies via HIF en remodelatge/inflamació Cervera R, Peláez I. Estudio de prevalencia KDM4C as a relevant locus for the vascular. de manifestaciones musculo-esqueleticos development of systemic vasculitis. Sponsored by: Fundació la Marató de TV3. autoinmunes sistémicas y reumáticas en ANNALS OF THE RHEUMATIC DISEASES. TV3_Cor_15 una comunidad originaria (qom) de la 77(4):589-595. I.F.: 12.350 Duration: 10/05/2016-09/05/2019 ciudad de Rosario, Santa Fe, Argentina. PhD student: Rosana Maris Quintana 2. Márquez A, Kerick M, Zhernakova A, Cid MC. Interacciones multi-celulares en la Gutierrez-Achury J, Chen WM, progresión de las enfermedades Espinosa G, Shoenfeld Y. Catastrophic Onengut-Gumuscu S, González-Álvaro I, inflamatorias crónicas y síndromes antiphospholipid syndrome: treatment and Rodriguez-Rodriguez L, Rios-Fernández R, linfoproliferativos: modelos 3D para prognosis. González-Gay MA,, Mayes MD, Raychaudhuri investigar inmunoterapias dirigidas. PhD student: Ignasi Rodríguez Pintó S, Rich SS, Wijmenga C, Martín J Coeliac Sponsored by: Ministerio de Economía y Disease Immunochip Consortium, Competitividad (MINECO). Casaroli MaranoR, Nadal J. Análisis de la Rheumatoid Arthritis Consortium International SAF2017-88275-R anatomía y funcionalidad foveal en ojos de for Immunochip (RACI), International Duration: 01/01/2018-31/12/2020 pacientes con agujero macular idiopático Scleroderma Group, Type 1 Diabetes antes y después de la cirugía. Genetics Consortium. Meta-analysis of Cid MC. Interacción bidireccional entre los PhD student: Bàrbara Delàs Alos Immunochip data of four autoimmune linfocitos y su microembiente en diseases reveals novel single-disease and enfermedades inflamatorias crónicas y Cid MC. Interleukin-6(IL-6)IL-6 receptor cross-phenotype associations. GENOME síndromes linfoproliferativos como fuente and persistence of inflammation in Giant MEDICINE. 10(1):97. I.F.: 8.898 de nuevas terapias. Cell Arteritis. Effects of IL-6 receptor Sponsored by: Ministerio de Economía y blockade with tocilizumab. 3. Martín-Sánchez FJ, Llopis García G, Competitividad (MINECO). PhD student: Nekane Terrades Garcia González-Colaço Harmand M, Fernandez SAF2014-57708-R Pérez C, González Del Castillo J, Llorens P, Duration: 01/01/2015-30/06/2018 Ramos M, Sisó A. Dolor crónico Herrero P, Jacob J, Gil V, generalizado y Fibromialgia: estudio de Domínguez-Rodriguez A, Rossello X, Miró O, EspÍgol G. Vasculitis de pequeño vaso pruebas objetivas, comorbilidad, en representación de los investigadores del rodeando a una arteria temporal complejidad y gasto sanitario. Registro OAK, Resto de investigadores del preservada: significado clínico y búsqueda PhD student: Enma Marianela Morales registro OAK. Identification of Senior At de biomarcadores de utilidad diagnóstica. Espinoza Risk scale predicts 30-day mortality Sponsored by: Instituto de Salud Carlos III among older patients with acute heart (ISCIII). PI15/00092 failure. MEDICINA INTENSIVA. :30218-3. Duration: 01/01/2016-30/04/2019 I.F.: 1.755 Ramos Casals M. Development of evidence-based and consensus-based eular recommendations on the therapeutic GRANTS FOR RESEARCH IN PROGRESS management of sjögren's syndrome. Sponsored by: European League Against Casaroli-Marano R. Potencial terapéutico Rheumatism. INT_EULAR_2014 (CLI074) de las células progenitoras pluripotentes Duration: 01/05/2015-30/09/2018 inducidas (IPSC) y las células progenitoras mesenquimales del estroma de la médula ósea (MSCs) nestina positivas para la regeneración de la superficie ocular. Sponsored by: Instituto de Salud Carlos III

65 AREA 1 BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

Infectious diseases 1.3 and AIDS

Mireia Arnedo (IDIBAPS) José Luis Blanco (HCB) LOCATION Felipe García (HCB) CELLEX building, ﬂoor 4A Montserrat Laguno (HCB) Agata Raquel León (HCB-IDIBAPS) Esteban Martinez (HCB) Montserrat Plana (IDIBAPS) WEB Josep M. Gatell (HCB) www.clinicbarcelona.org/ Ana Del Río (HCB) en/idibaps/research-areas Carolina García (HCB) TEAM LEADER Jose Antonio Martinez (FCRB) Josep M. Miró (HCB) T. 93 227 54 00 (Ext.: 2765) POST-DOCTORAL RESEARCHERS [email protected] Juan Carlos Enrique Ambrosioni (HCB) KEYWORDS Maria Alexandra Cañas (FCRB) 1. HIV Cristina García (FCRB) 2. AIDS Christian Manzardo (FCRB) GROUP LEADERS Eduardo Quintana (HCB) 3. Endocarditis Josep Mallolas (HCB) Elena Sandoval (HCB) Nosocomial infections 4. T. 93 227 54 00 (Ext.: 3312) Laura Linares (IDIBAPS) 5. Immune suppressed patients [email protected] Núria Climent (IDIBAPS) Alberto Crespo (FCRB) Josep M. Miró (HCB) Lorna Anabel Leal (IDIBAPS) T. 93 227 54 00 (Ext.: 2765) María Martínez (HCB) [email protected] Maria Sonsoles Sanchez (FCRB) Narcís Saubi (FCRB) Original publications Asunción Moreno (HCB) Berta Torres (FCRB) from 2016 to 2018 T. 93 227 54 00 (Ext.: 2657) Olívia Tort (IDIBAPS) [email protected] Laura Morata (HCB) YEAR I.F. TOTAL Q1 Q2

2016 308.79 64 45 9 Alex Soriano (HCB) PRE-DOCTORAL RESEARCHERS

2017 344.32 67 48 12 T. 93 227 54 00 (Ext.: 5708) Javier García-González (FCRB) [email protected] Delia Garcia-Pares (FCRB) 2018 362.18 68 44 12 Marta Hernández (FCRB) EMERITUS Juan Manuel Pericas (IDIBAPS) Josep Mensa (HCB) Adrián Tellez (FCRB) Maria Fernanda Solano (FCRB) RESEARCHERS Wein Chun (FCRB) TEAM INVOLVED IN Marta Bodro (HCB) Lorena De La Mora (HCB) RIS REIPI AGAUR_SGR17: 1432, 1067 TEAM Josep M. Miró

66 INFECTIOUS DISEASES AND AIDS 1.3

Yoshiki Eto (FCRB) MAIN LINES OF RESEARCH - Infections in solid organ transplant Csaba Fehér (IDIBAPS) recipients (Dr A. Moreno) Ana González (FCRB) 1. In the AIDS field: - Non-nosocomial and nosocomial Alexy Junior Inciarte (IDIBAPS) - Pharmacogenomics and health-care associated infections and Athina Kilpelainen (FCRB) pharmacokinetics community-acquired infections. Jhon Fredy Rojas (FCRB) - Immuno-pathogenesis of HIV infection Evaluation of new antibiotic and Celia Cardozo (HCB) and immune responses against HIV. antifungal drugs (Dr A. Soriano). Pedro Puerta (HCB) - Development of preventive and Olga Rodriguez (HCB) therapeutic vaccines. - Mechanisms of senescence in HIV TECHNICIANS infection. RESEARCH GROUP Manuel Enric Bargalló (IDIBAPS) - Microbiota in HIV-infected patients - AIDS AND HIV INFECTION Pilar Callau (FCRB) Primary HIV infection: eradication and Tuixent Escriba (IDIBAPS) functional cure strategies. Tania Gonzalez (FCRB) - Opportunistic diseases: tuberculosis, Carmen Hurtado (FCRB) human papillomavirus, anal cancer. M. José Maleno (FCRB) - HIV and non-AIDS related tumours. Laia Miralles (IDIBAPS) - Solid organ transplantation in Cristina Rovira (IDIBAPS) HIV-infected patients. Montserrat Sola (FCRB) - Epidemiological studies based on GROUP LEADER cohorts (PISCIS, ART-CC, COHERE, Josep Mallolas (HCB) ADMINISTRATIVE STAFF EuroSida). Irene Ruiz (IDIBAPS) - Antiretroviral treatment: Efficacy and This group studies the clinical, diagnostic, Raquel Aguiló (HCB) safety of new antiretroviral drugs. Studies therapeutic and preventive aspects of HIV Maria Carmen Mensa (IDIBAPS) of resistance. New antiretroviral infection and HIV-HCV coinfection.The strategies. scientific contribution of this line of research COLLABORATORS - Prevention strategies: PEP and PrE. is very competitive and is internationally Manel Almela (HCB) - Incidence and management of non-AIDS renowned. Carles Falces (HCB) defining events. Aging. STDs. This group of investigators focuses on David Fuster (HCB) - HCV and HBV coinfection. Efficacy and exploration of the potential for eradicating HIV Jaume Llopis (UB) safety of new direct-antiviral drugs (DAA) infection and on reconstruction of the immune José M Tolosana (HCB) against HCV. system, including the development of Bárbara Vidal (HCB) - New health-care strategies: telemedicine, preventive and therapeutic vaccines. Elisa de Lazzari (FCRB) shared health-care unit with primary care Dr. Mallolas is currently the Co-director of the Joan Joseph (FCRB) and OPAT programs. HIVACAT project on research therapeutic Marta Subirana (FCRB) and preventive vaccines against HIV infection. 2. In the general infections field: - Clinical and experimental endocarditis. Cohort studies (ICE, GAMES) (Dr J.M. Miró). STRATEGIC OBJECTIVES

1. In the AIDS ﬁeld: - HIV immune-pathogenesis and HIV vaccines. - New antiretrovirals, non-AIDS deﬁning diseases, aging and senescence, primary HIV infection. - HIV cure strategies - New direct-antiviral drugs (DAA) against HCV in HCV/HIV-coinfected patients

2. In the general infections ﬁeld: - Infective endocarditis, including experimental endocarditis in animal models. - Infection in solid-organ transplant recipients, including HIV-infected patients. - Nosocomial infections. Antimicrobial use. Orthopedic infections. GROUP Josep M. Miró

67 68 by theFIS. actively participatein multicenterpr Infectious Diseases ResearchNetwork(REIPI)and components aremembersoftheSpanish Digestive, RenalandCardiacDiseases). Its and withthedifferent specialized inMicrobiologyandImmunology, been carriedoutjointlywithresearchers infec an increaseintheprevalenceofbacterial We haveshownthatMBLandTLRcondition (kidney, liver,heartandrenal-pancreas). undergoing transplantationofsolidorgans bacteremia, especiallyMDR,inpatients clinical andevolutivecharacteristicsof In recentyears,thisgrouphasstudiedthe Asunción Moreno GROUP LEADER TRANSPLANT RECIPIENTS INFECTIONS INSOLID-ORGAN RESEARCH GROUP daptomycin, telavancin,ceftaroline,andothers. and imipenem),ornewantibioticssuchas new antibioticcombinations(phosphomycin aureus (GISA)haveevaluatedtheactivityof intermediate- resistantStaphylococcus endocarditis duetoMRSAandglyc Studies usingtheexperimentalmodelof aureus (MSSAandMRSA,respectively). sensitive and-resistantStaphylococcus endocarditis producedbymethicillin- (ICE) thathaverevealedanincreasein of local,nationalorinternationalcohorts endocarditis. Thisisdonebasedonstudies therapeutic aspectsofinfectious clinical, diagnostic,preventiveand This groupstudiestheepidemiological, Josep M.Miró GROUP LEADER INFECTIONS. EXPERIMENTALMODEL ENDOCARDITIS. CARDIOVASCULAR RESEARCH GROUP AREA 1 tion andCMVdisease.Thesestudies have

BIOLOGICAL AGGRESSION ANDRESPONSEMECHANISMS (HCB) (HCB) Transplant Units(Institutesof

ojects funded opeptide

GROUP Alex Soriano STUDY GROUP NOSOCOMIAL INFECTION RESEARCH GROUP Therapy vsUsual CareonClinical Investigators. Fowler VG,StaphylococcalBacteremia ME, SchrankJ,SimsM,WrayD,Zervos M, P, Miro JM,PericasRiska Hachem R,HortonJ,JenkinsTC,Levine D, Cook P,CoreyGR,CrowleyAL,Daly J,Gu Chaftari AM,ChowSC,ChuVH,Carugati M, DJ, CosgroveSE,AycockPS,Baddley JW, 1. Originals / PUBLICATIONS and infectionsrelatedtoorthopedicimplants. bacteremia, infectionsinIntensiveCareUnits, in thetreatmentandmanagementof scientific contributionisparticularlynotorious nosocomial (in-hospital)infections.The therapeutic andpreventiveaspectsof This groupstudiestheclinical,diagnostic, Alex Soriano GROUP LEADER HollandTL,RaadI,BoucherHW,Anderson I.F.:362.179 (HCB) Effect ofAlgorithm-Based Rubin Z,Rupp 71(24):2731-2740. I.F.:16.834 AMERICAN COLLEGEOFCARDIOLOGY. Mitral ValveProlapse. Patients WithBicuspidAorticValveor (GAMES). de laEndocarditisinfecciosaenEspaña Endocarditis-Grupo deApoyoalManejo Garcia-Pavia P,SpanishCollaborationon Reguera IglesiasJM,NavasE,DominguezF, Urkola X,LepeJA,RodriguezAlvarezR, JM, FalcesC,GonzalezRicoKortajarena Martínez SellésM,González-RamalloV,Miro 2. 320(12):1249-1258. I.F.:47.661 MEDICAL ASSOCIATION. JAMA- JOURNALOFTHEAMERICAN Bacteremia: ARandomizedClinicalTrial. Patients withStaphylococcal and SeriousAdverseEventsin Success C, GabarrusA,Ceccato A,PuigdeLa 4. MEDICINE. score matchingstudy. severe influenzapneumonia:apropensity treatment incriticallyillpatients with GETGAG StudyGroup. M, RestrepoMI,TorresA,Martín-Loeches I, M, CorreigE,Marín-CorralJ,Vallverdú-Vidal Garnacho-Montero J,SociasL,DelValleOrtíz Guardiola J,YébenesJC,SorianoA, J, Sole-ViolanDíazE,BodíM,TreflerS, 3. Zegri-Reiriz I,deAlarcónA,MuñozP, Moreno G,RodríguezA,ReyesLF,Gomez Cilloniz C,FerrerM, LiapikouA,Garcia-Vidal Infective Endocarditisin 44(9):1470-1482.I.F.:15.008 Corticosteroid

INTENSIVE CARE JOURNAL OFTHE JOURNAL INFECTIOUS DISEASES AND AIDS 1.3

Bellacasa J, Blasi F, Torres A . Acute Castelnuovo, Barbara; Chene, Genevieve; 14. Lombardo-Quezada J, Sanclemente G, Respiratory Distress Syndrome in Coelho, Lara; Collins, Intira Jeannie; Colmenero J, Español-Rego M, Arias MT, Ruiz Mechanically-Ventilated Patients with Costagliola, Dominique; Crabtree-Ramirez, P, Mauro E, Sastre L, Crespo G, Rimola A, Community-Acquired Pneumonia. Brenda; Dabis, Francois; Monforte, Antonella Moreno A, Lozano F, Navasa M. Mannose- EUROPEAN RESPIRATORY JOURNAL. 51(3). d'Arminio; Davies, Mary-Ann; De Wit, binding lectin deficient donors increase I.F.: 12.244 Stephane; Delpech, Valerie; De La Mata, the risk of bacterial infection and bacterial Nicole L.; Duda, Stephany; Freeman, Aimee; infection-related mortality after liver 5. Vergara, Andrea; Cilloniz, Catia; Luque, Gange, Stephen J.; Grabmeier transplantation. AMERICAN JOURNAL OF Nestor; Garcia-Vidal, Carolina; Tejero, Javier; -Pfistershammer, Katharina; Gunsenheimer- TRANSPLANTATION. 18(1):197-206. I.F.: 6.493 Perello, Rafael; Maria Lucena, Carmen; Torres, Bartmeyer, Barbara; Jiamsakul, Awachana; Antoni; Angeles Marcos, Maria. Detection of Kitahata, Mari M.; Law, Matthew; Manzardo, 15. Manzardo C, Londoño MC, Castells L, human cytomegalovirus in Christian; McGowan, Catherine; Meyer, Testillano M, Luis Montero J, Peñafiel J, bronchoalveolar lavage of intensive care Laurence; Moore, Richard; Mussini, Cristina; Subirana M, Moreno A, Aguilera V, Luisa unit patients. EUROPEAN RESPIRATORY Nakigoz, Gertrude; Nash, Denis; Ng, Oon Tek; González-Diéguez M, Calvo-Pulido J, Xiol X, JOURNAL. 51(2). I.F.: 12.244 Obel, Niels; Pantazis, Nikos; Poda, Armel; Salcedo M, Cuervas-Mons V, Manuel Sousa J, Raben, Dorthe; Reiss, Peter; Riggen, Larry; Suarez F, Serrano T, Ignacio Herrero J, 6. Ambrosioni J, Urra X, Hernández-Meneses Sabin, Caroline; Sinayobye, Jean d'Amour; Jiménez M, Fernandez JR, Giménez C, Del M, Almela M, Falces C, Tellez A, Quintana E, Sonnerborg, Anders; Stoeckle, Marcel; Thorne, Campo S, Esteban-Mur JI, Crespo G, de la Fuster D, Sandoval E, Vidal B, Tolosana JM, Claire; Torti, Carlo; Twizere, Christella; Wasmuth, Rosa G, Rimola A, Miro JM,and the FIPSE Moreno A, Chamorro A, Miró JM, Hospital Jan-Christian; Wittkop, Linda; Wools- LT-HIV investigators. Direct-acting antivirals Clínic Infective Endocarditis Study Group . Kaloustian, Kara; Yotebieng, Marcel; Kirk, Ole; are effective and safe in Mechanical thrombectomy for acute Egger, Matthias. Global Trends in CD4 Cell HCV/HIV-coinfected liver transplant ischemic stroke secondary to infective Count at the Start of Antiretroviral recipients who experience recurrence of endocarditis. CLINICAL INFECTIOUS Therapy: Collaborative Study of hepatitis C: A prospective nationwide DISEASES. 66(8):1286-1289. I.F.: 9.117 Treatment Programs. CLINICAL cohort study. AMERICAN JOURNAL OF INFECTIOUS DISEASES. 66(6):893-903. TRANSPLANTATION. 18(10):2513-2522. 7. M Wouthuyzen Bakker, MM Kheir, I Moya, I.F.: 9.117 I.F.: 6.493 AJ Rondon, M Kheir, L Lozano, J Parvizi, A Soriano. Failure after two-stage exchange 11. Kumar D, Ferreira VH, Blumberg E, Silveira 16. Gutierrez-Rivas, Monica; Angeles arthroplasty for treatment of F, Cordero E, Perez-Romero P, Aydillo T, Jimenez-Sousa, Maria; Rallon, Norma; Luis periprosthetic joint infection: the role of Danziger-Isakov L, Limaye AP, Carratala J, Jimenez, Jose; Restrepo, Clara; Leon, Agathe; antibiotics in the cement spacer. CLIN Munoz P, Montejo M, Lopez-Medrano F, Montero-Alonso, Marta; Gonzalez-Garcia, INFECT DIS. I.F.: 9.117 Farinas MC, Gavalda J, Moreno A, Levi M, Juan; Angeles Munoz-Fernandez, Maria; Fortun J, Torre-Cisneros J, Englund JA, Natori Miguel Benito, Jose; Resino, Salvador;ECRIS 8. Cillóniz C, Miguel-Escuder L, Pedro-Bonet Y, Husain S, Reid G, Sharma TS, Humar A. Integrated Spanish AIDS Res. High Plasma ML, Falcó V, Lopez Y, García-Vidal C, A Five-year Prospective Multi-center Levels of sTNF-R1 and CCL11 Are Related Gabarrús A, Moreno A, Torres A, Miró JM, Evaluation of Influenza Infection in to CD4+T-Cells Fall in Human Legionella-HIV Researchers . Transplant Recipients. CLINICAL Immunodeficiency Virus Elite Controllers Community-Acquired Legionella INFECTIOUS DISEASES. 67(9):1322-1329. With a Sustained Virologic Control. Pneumonia in HIV-Infected Adult Patients: I.F.: 9.117 FRONTIERS IN IMMUNOLOGY. 9(1399):1399. A Matched Case-Control Study. CLINICAL I.F.: 5.511 INFECTIOUS DISEASES. 67(6):958-961. 12. Benito JM, Ortiz MC, Leon A, Sarabia LA, I.F.: 9.117 Ligos JM, Montoya M, Garcia M, Ruiz-Mateos 17. Nicolás D, Ambrosioni J, de Lazzari E, E, Palacios R, Cabello A, Restrepo C, Suarez A, Manzardo C, Agüero F, Mosquera 9. Téllez A, Ambrosioni J, Llopis J, Pericàs JM, Rodriguez C, del Romero J, Leal M, Munoz- MM, Costa J, Ligero C, Marcos MÁ, Falces C, Almela M, Garcia de la Mària C, Fernandez MA, Alcami J, Garcia F, Gorgolas Sánchez-Palomino S, Fernández E, Plana M, Hernandez-Meneses M, Vidal B, Sandoval E, M, Rallon N. Class-modeling analysis Yerly S, Gatell JM, Miró JM, Hospital Clinic Quintana E, Fuster D, Tolosana JM, Marco F, reveals T-cell homeostasis disturbances Acute/Recent HIV Study Group. Moreno A, Miro JM, Hospital Clínic Infective involved in loss of immune control in elite Epidemiological changes of acute/recent Endocarditis Investigators . Epidemiology, controllers. BMC MEDICINE. 16(1):30. I.F.: 9.088 HIV-1 infection in Barcelona, Spain clinical features and outcome of infective (1997-2015): A prospective cohort study. endocarditis due to Abiotrophia spp. and 13. Climent N., García I., Marradi M., Chiodo F., CLINICAL MICROBIOLOGY AND INFECTION. Granulicatella spp.: Report of 76 cases Miralles L., Maleno M., Gatell J., García F., I.F.: 5.394 (2000-2015). CLINICAL INFECTIOUS Penadés S., Plana M. Loading dendritic cells DISEASES. 66(1):104-111. I.F.: 9.117 with gold nanoparticles (GNPs) bearing 18. López-Medrano F, Fernández-Ruiz M, HIV-peptides and mannosides enhance Silva JT, Carver PL, van Delden C, Merino E, 10. Anderegg, Nanina; Panayidou, Klea; Abo, HIV-specific T cell responses. Pérez-Saez MJ, Montero M, Coussement J, Yao; Alejos, Belen; Althoff, Keri N.; Anastos, NANOMEDICINE: NANOTECHNOLOGY, de Abreu Mazzolin M, Cervera C, Santos L, Kathryn; Antinori, Andrea; Balestre, Eric; BIOLOGY, AND MEDICINE. 14(2):339-351. Sabé N, Scemla A, Cordero E, Cruzado-Vega Becquet, Renaud; Castagna, Antonella; I.F.: 6.500 L, Martín-Moreno PL, Len Ó, Rudas E, Ponce

69 AREA 1 BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

de León A, Arriola M, Lauzurica R, David MD, 22. Leal L, Guardo A, Morón-López S, 28. Suárez-Lledó M, Martínez-Cibrián N, González-Rico C, Henríquez-Palop F, Fortún Salgado M, Mothe B, Heirman C, Pannus P, Gutiérrez-García G, Dimova-Svetoslavova V, J, Nucci M, Manuel O, Paño-Pardo JR, Montejo Vanham G, van den Ham H, Gruters R, Marcos MA, Martín-Antonio B, Martínez-Trillos M, Vena A, Sánchez-Sobrino B, Mazuecos A, Andeweg A, Van Meirvenne S, Pich J, Arnaiz J, A, Villamor N, Rosiñol L, Martínez C, Pascual J, Horcajada JP, Lecompte T, Moreno Gatell J, Brander C, Thielemans K, Fernández-Avilés F, García-Vidal C, A, Carratalà J, Blanes M, Hernández D, Martínez-Picado J, Plana M, García F. Phase I Urbano-Ispizua Á, Rovira M . Deleterious Hernández-Méndez EA, Fariñas MC, clinical trial of an intranodally administered Effect of Steroids on Cytomegalovirus Perelló-Carrascosa M, Muñoz P, Andrés A, mRNA-based therapeutic vaccine against Infection Rate after Allogeneic Stem Cell Aguado JM, Spanish Network for Research in HIV-1 infection. AIDS. 32(17):2533-2545. Transplantation Depends on Pretransplant Infectious Diseases (REIPI), Group for the I.F.: 4.914 Cytomegalovirus Serostatus of Donors and Study of Infection in Transplant Recipients Recipients. BIOLOGY OF BLOOD AND (GESITRA) of the Spanish Society of Clinical 23. Leyes P, Cofan M, González-Cordón A, De MARROW TRANSPLANTATION. Microbiology and Infectious Diseases Lazzari E, Trabal J, Domingo P, Negredo E, 24(10):2088-2093. I.F.: 4.484 (SEIMC), Study Group for Infections in Vidal F, Forga M, Gatell J, Ros E, Martínez E. Compromised Hosts (ESGICH) of the Increased cholesterol absorption rather 29. Pernas M, Tarancon-Diez L, European Society of Clinical Microbiology and than synthesis is involved in boosted Rodriguez-Gallego E, Gomez J, Prado JG, Infectious Diseases (ESCMID), Swiss protease inhibitor-Associated Casado C, Dominguez-Molina B, Olivares I, Transplant Cohort Study (STCS). hypercholesterolaemia. AIDS. Coiras M, Leon A, Rodriguez C, Benito JM, Multinational retrospective case-control 32(10):1309-1316. I.F.: 4.914 Rallon N, Plana M, Martínez-Madrid O, Dapena study of risk factors for the development of M, Iribarren JA, del Romero J, Garcia F, Alcami late invasive pulmonary aspergillosis 24. Rojas J, Blanco JL, Sanchez-Palomino S, J, Munoz-Fernandez MA, Vidal F, Leal M, following kidney transplantation. CLINICAL Marcos MA, Guardo AC, Gonzalez-Cordon A, Lopez-Galindez C, Ruiz-Mateos E; ECRIS MICROBIOLOGY AND INFECTION. Lonca M, Tricas A, Rodriguez A, Romero A, integrated in the Spanish AIDS Research 24(2):192-198. I.F.: 5.394 Miro JM, Mallolas J, Gatell JM, Plana M, Network. Factors Leading to the Loss of Martinez E . A maintenance Natural Elite Control of HIV-1 Infection. 19. Coll J; Videla S; Leon A; Ornelas A; Garcia three-day-per-week schedule with the JOURNAL OF VIROLOGY. 92(5):e01805-17. F; Fernandez E; Blanco JL; Carrillo A; Bravo I; single tablet regimen I.F.: 4.368 Meulbroek M; García-Cuyas F; González V; efavirenz/emtricitabine/tenofovir Casabona J; Leal L; Clotet B; Brander C; disoproxil fumarate is effective and 30. Ripa M, Morata L, Rodríguez-Núñez O, Check-Ear Project. Early Detection Of Hiv decreases sub-clinical toxicity: the Cardozo C, Puerta-Alcalde P, Infection And Of Asymptomatic Sexually A-TRI-WEEK pilot trial. AIDS. Hernández-Meneses M, Ambrosioni J, Linares Transmitted Infections Among Men Who 32(12):1633-1641. I.F.: 4.914 L, Bodro M, Valcárcel A, Casals C, Have Sex With Men. CLINICAL Guerrero-León MLA, Almela M, Garcia-Vidal MICROBIOLOGY AND INFECTION. 25. Hoy, Jennifer F.; Richardson, Robyn; C, Del Río A, Marco F, Mensa J, Martínez JA, 24(5):540-545. I.F.: 5.394 Ebeling, Peter R.; Rojas, Jhon; Pocock, Soriano A . Short-Term Peripheral Venous Nicholas; Kerr, Stephen J.; Martinez, Esteban; Catheter-Related Bloodstream Infections: 20. Blanco JL, Rojas J, Paredes R, Negredo E, Carr, Andrew; ZEST Study Investigators. Evidence for Increasing Prevalence of Mallolas J, Casadella M, Clotet B, Gatell JM, de Zoledronic acid is superior to tenofovir Gram-Negative Microorganisms from a Lazzari E, Martinez E, DOLAM Study Team . disoproxil fumarate-switching for low 25-Year Prospective Observational Study. Dolutegravir-based maintenance bone mineral density in adults with HIV. ANTIMICROBIAL AGENTS AND monotherapy versus dual therapy with AIDS. 32(14):1967-1975. I.F.: 4.914 CHEMOTHERAPY. 62(11). I.F.: 4.256 lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial. 26. De la Calle C, Ternavasio-de la Vega H, 31. García-de-la-Mària C, Gasch O, JOURNAL OF ANTIMICROBIAL Morata L, Marco F, Cardozo C, García-Vidal C, García-Gonzalez J, Soy D, Shaw E, CHEMOTHERAPY. 73(7):1965-1971. I.F.: 5.217 Del Rio A, Cilloniz C, Torres A, Martínez J, Ambrosioni J, Almela M, Pericàs JM, Tellez A, Mensa J, Soriano A. Effectiveness of Falces C, Hernandez-Meneses M, Sandoval E, 21. Pettit A, Giganti M, Ingle S, May M, combination therapy versus monotherapy Quintana E, Vidal B, Tolosana JM, Fuster D, Shepherd B, Gill M, Fätkenheuer G, Abgrall S, with a third-generation cephalosporin in Llopis J, Pujol M, Moreno A, Marco F, Miró JM . Saag M, Del Amo J, Justice A, Miro J, bacteraemic pneumococcal pneumonia: A The Combination of Daptomycin plus Cavasinni M, Dabis F, Monforte A, Reiss P, propensity score analysis. JOURNAL OF Fosfomycin has Synergistic, Potent and Guest J, Moore D, Shepherd L, Obel N, Crane INFECTION. 76(4):342-347. I.F.: 4.603 Rapid Bactericidal Activity against H, Smith C, Teira R, Zangerle R, Sterne J, Methicillin-ResistantStaphylococcus Sterling T. Study group: Antiretroviral 27. Tort O, Escribà T, Egaña-Gorroño L, de aureus(MRSA) in a Rabbit Model of Therapy Cohort Collaboration (ART-CC) Lazzari E, Cofan M, Fernandez E, Gatell JM, Experimental Endocarditis (EE). investigators. Increased non-AIDS Martinez E, Garcia F, Arnedo M . Cholesterol ANTIMICROBIAL AGENTS AND mortality among persons with efflux responds to viral load and CD4 CHEMOTHERAPY. 62(6). I.F.: 4.256 AIDS-deﬁning events after antiretroviral counts in HIV+ patients and is dampened in therapy initiation. JOURNAL OF THE HIV-exposed. JOURNAL OF LIPID 32. Wouthuyzen-Bakker M, Tornero E, INTERNATIONAL AIDS SOCIETY. 21(1). RESEARCH. 59(11):2108-2115. I.F.: 4.505 Morata L, Nannan Panday PV, Jutte PC, Bori I.F.: 5.135 G, Kampinga GA, Soriano A . Moxiﬂoxacin

70 INFECTIOUS DISEASES AND AIDS 1.3

plus rifampin as an alternative for 37. Perelló R, Aused M, Saubí N, Quirós C, 43. Young J, Smith C, Teira R, Reiss P, Jarrín levofloxacin plus rifampin in the treatment Blanco J, Martínez-Rebollar M, Galicia M, Vera I, Crane H, Miro J, D'Arminio Monforte A, of a prosthetic joint infection with Salgado E, Nogué S. Acute street drug Saag M, Zangerle R, Bucher H, Boulle A, staphylococcus aureus. INTERNATIONAL poisoning in the patient with human Stephan C, Cavassini M, del Amo J, JOURNAL OF ANTIMICROBIAL AGENTS. immunodeficiency virus infection: The role Fätkenheuer G, Gill J, Guest J, Hans-Ulrich 51(1):38-42. I.F.: 4.253 of chemsex. EMERGENCIAS. Haerry D, Hogg R, Justice A, Shepherd L, Obel 30(6):405-407. I.F.: 3.608 N, Sterling T, Williams M. Antiretroviral pill 33. Bouza E, Valerio M, Soriano A, Morata L, count and clinical outcomes in Carus E, Rodríguez-González C, 38. Bori G, Navarro G, Morata L, treatment-naïve patients with HIV Hidalgo-Tenorio M, Plata A, Muñoz P, Vena A, Fernández-Valencia JA, Soriano A, Gallart X . infection. HIV MEDICINE. 19(2):132-142. Alvarez-Uria A, Fernández-Cruz A, Nieto A, Preliminary Results After Changing From I.F.: 2.932 Artero A, Allende J, Morell E, González F, Two-Stage to One-Stage Revision Castelo L, Cobo J, del Carmen Gálvez Arthroplasty Protocol Using Cementless 44. Gonzalez-Cordon, A.; Domenech, M.; Contreras M, Fernández R, Horcajada J, Arthroplasty for Chronic Infected Hip Camafort, M.; Martinez-Rebollar, M.; Torres, B.; Guisado-Vasco P, Losa J, Hervás R, Iftimie S, Replacements. JOURNAL OF Laguno, M.; Rojas, J.; Lonca, M.; Blanco, J. L.; Mejías M, Jover F, Ferreiro J, Serrano A, ARTHROPLASTY. 33(2):527-532. I.F.: 3.339 Mallolas, J.; Gatell, J. M.; de Lazzari, E.; Malmierca E, Masiá M, Sempere M, Martinez, E. Subclinical cardiovascular Rodriguez-Pardo D, Alvarez S, San Juan R, 39. Löwik CAM, Jutte PC, Tornero E, disease in patients starting contemporary Cepeda C, Berrocal M, Sobrino B, Sorlí L. Ploegmakers JJW, Knobben BAS, de Vries AJ, protease inhibitors. HIV MEDICINE. Dalbavancin in the treatment of different Zijlstra WP, Dijkstra B, Soriano A, 19(7):497-503. I.F.: 2.932 gram-positive infections: A real-life Wouthuyzen-Bakker M, Northern Infection experience. INTERNATIONAL JOURNAL OF Network Joint Arthroplasty (NINJA). 45. Cuervo G, Garcia-Vidal C, Puig-Asensio ANTIMICROBIAL AGENTS. 51(4):571-577. Predicting Failure in Early Acute M, Merino P, Vena A, Martín-Peña A, Montejo I.F.: 4.253 Prosthetic Joint Infection Treated With JM, Ruiz A, Lázaro-Perona F, Fortún J, Debridement, Antibiotics, and Implant Fernández-Ruiz M, Suarez AI, Castro C, 34. Bermejo M, Ambrosioni J, Bautista G, Retention: External Validation of the KLIC Cardozo C, Gudiol C, Aguado JM, Paño JR, Climent N, Mateos E, Rovira C, Score. JOURNAL OF ARTHROPLASTY. Pemán J, Salavert M, Garnacho-Montero J, Rodríguez-Mora S, López-Huertas MR, 33(8):2582-2587. I.F.: 3.339 Cisneros JM, Soriano A, Muñoz P, Almirante B, García-Gutiérrez V, Steegmann JL, Duarte R, Carratalà J, REIPI, the GEMICOMED (SEIMC) Cervantes F, Plana M, Miró JM, Alcamí J, 40. Ambrosioni J, Martinez-Garcia C, Llopis J, and the Spanish CANDI-Bundle Group. Coiras M . Evaluation of resistance to HIV-1 Garcia-de-la-Maria C, Hernández-Meneses Usefulness of guideline recommendations infection ex vivo of PBMCs isolated from M, Tellez A, Falces C, Almela M, Vidal B, for prognosis in patients with candidemia. patients with chronic myeloid leukemia Sandoval E, Fuster D, Quintana E, Tolosana MEDICAL MYCOLOGY. I.F.: 2.799 treated with different tyrosine kinase JM, Marco F, Moreno A, Miró JM, Hospital inhibitors. BIOCHEMICAL Clinic Infective Endocarditis Investigators. 46. Cillóniz C, Liapikou A, Martin-Loeches I, PHARMACOLOGY. 156:248-264. I.F.: 4.235 HACEKinfective endocarditis: García-Vidal C, Gabarrús A, Ceccato A, epidemiology, clinical features outcome: A Magdaleno D, Mensa J, Marco F, Torres A . 35. Regueiro A, Falces C, Pericás JM, Muñoz case-control study. INTERNATIONAL Twenty-year trend in mortality among P, Martínez-Sellés M, Valerio M, Sousa JOURNAL OF INFECTIOUS DISEASES. hospitalized patients with pneumococcal Regueiro D, Castelo L, de Alarcón A, Cobo 76:120-125. I.F.: 3.202 community-acquired pneumonia. PLOS Belaustegui M, Goenaga MA, Hidalgo-Tenorio ONE. 13(7):e0200504. I.F.: 2.766 C, Martínez-Marcos FJ, Gainzarain Arana JC, 41. Rakotoarivelo R, Ambrosioni J, Rasolofo V, Miro JM, y los investigadores del Grupo de Raberahona M, Rakotosamimanana N, 47. Garcia-Vidal C, Cardozo-Espinola C, Apoyo al Manejo de la Endocarditis Infecciosa Andrianasolo R, Ramanampamonjy R, Tiaray Puerta-Alcalde P, Marco F, Tellez A, Agüero D, en España (GAMES). Risk factors of M, Razafimahefa J, Rakotoson J, Randria M, Romero-Santana F, Díaz-Beyá M, Giné E, pericardial effusion in native valve Bonnet F, Calmy A. Evaluation of the Xpert Morata L, Rodríguez-Núñez O, Martinez JA, infective endocarditis and its influence on MTB/RIF assay for diagnosis of Mensa J, Esteve J, Soriano A . Risk factors outcome: A multicenter prospective smear-negative pulmonary and for mortality in patients with acute cohort study. INTERNATIONAL JOURNAL extrapulmonary tuberculosis in leukemia and bloodstream infections in OF CARDIOLOGY. 273:193-198. I.F.: 4.034 Madagascar. INTERNATIONAL JOURNAL the era of multiresistance. PLOS ONE. OF INFECTIOUS DISEASES. 69:20-25. 13(6):e0199531. I.F.: 2.766 36. Bowles H, Ambrosioni J, Mestres G, I.F.: 3.202 Hernández-Meneses M, Sánchez N, Llopis J, 48. Pericàs JM, Cervera C, Moreno A, Yugueros X, Almela M, Moreno A, Riambau V, 42. Bodro M, Linares L, Chiang D, Moreno A, Garcia-de-la-Mària C, Almela M, Falces C, Fuster D, Miró JM, Hospital Clinic Endocarditis Cervera C . Managing recurrent urinary Quintana E, Vidal B, Llopis J, Fuster D, Mestres Study Group. Diagnostic yield of 18F-FDG tract infections in kidney transplant CA, Marco F, Miró JM, Hospital Clinic PET/CT in suspected diagnosis of vascular patients. EXPERT REVIEW OF Endocarditis Study Group. Outcome of graft infection: A prospective cohort study. ANTI-INFECTIVE THERAPY. 16(9):723-732. Enterococcus faecalis infective JOURNAL OF NUCLEAR CARDIOLOGY. I.F.: 3.141 endocarditis according to the length of I.F.: 4.011 antibiotic therapy: Preliminary data from a

71 AREA 1 BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

cohort of 78 patients. PLOS ONE. Resino S, Rallón N, Benito JM, Vallejo A, ECRIS MJ, Muñoz J, Soriano A, Trilla A, Vila J, Marcos 13(2):e0192387. I.F.: 2.766 Network integrated in the Spanish AIDS MÁ. Definitive diagnosis in suspected Research Network. Lower expression of Middle East Respiratory Syndrome 49. Beltran-Pavez C, Ferreira C, plasma-derived exosome miR-21 levels in Coronavirus cases. JOURNAL OF TRAVEL Merino-Mansilla A, Fabra-Garcia A, Casadella HIV-1 elite controllers with decreasing CD4 MEDICINE. 25(1). I.F.: 1.800 M, Noguera-Julian M, Paredes R, Olvera A, T cell count. JOURNAL OF MICROBIOLOGY, Haro I, Brander C, Garcia F, Gatell J, Yuste E, IMMUNOLOGY AND INFECTION. I.F.: 2.094 61. Ramos-Martínez A, Muñoz Serrano A, de Sanchez-Merino V. Guiding the humoral Alarcón González A, Muñoz P, response against HIV-1 toward a MPER 55. Cristelli M., Trullàs J., Cofán F., Rico N., Fernández-Cruz A, Valerio M, Fariñas MC, adjacent region by immunization with a Manzardo C., Ambrosioni J., Bedini J., Moreno Gutiérrez-Cuadra M, Miró JM, Ruiz-Morales J, VLP-formulated antibody-selected A., Diekmann F., Miro J. Prevalence and risk Sousa-Regueiro D, Montejo JM, envelope variant. PLOS ONE. factors of mild chronic renal failure in Gálvez-Acebal J, HidalgoTenorio C, 13(12):e0208345. I.F.: 2.766 HIV-infected patients: influence of female Domínguez F, Spanish Collaboration on gender and antiretroviral therapy. Endocarditis – Grupo de Apoyo al Manejo de 50. Muñoz-Mahamud E, Molinas I, Lozano L, BRAZILIAN JOURNAL OF INFECTIOUS la Endocarditis Infecciosa en España Bosch J, Morata L, Combalia A, Soriano Á, Bori DISEASES. 22(3):193-201. I.F.: 2.083 (GAMES). Gentamicin may have no effect G . Usefulness of Culturing the on mortality of staphylococcal prosthetic Periprosthetic Membrane or Neosynovium 56. Xipell M, Paredes S, Fresco L, Bodro M, valve endocarditis. JOURNAL OF for the Diagnosis of Infection During Hip Marco F, Martínez JA, Soriano A . Clinical INFECTION AND CHEMOTHERAPY. and Knee Revision Arthroplasty. JOURNAL experience with ceftolozane/tazobactam 24(7):555-562. I.F.: 1.777 OF THE AMERICAN ACADEMY OF in patients with serious infections due to ORTHOPAEDIC SURGEONS, THE. resistant pseudomonas aeruginosa. 62. Llibre JM, de Lazzari E, Molina JM, Gallien 26(20):e442-e447. I.F.: 2.638 JOURNAL OF GLOBAL ANTIMICROBIAL S, Gonzalez-García J, Imaz A, Podzamczer D, RESISTANCE. 13:165-170. I.F.: 2.022 Clotet B, Domingo P, Gatell JM . 51. Caro-Vega Y, Schultze A, W Efsen AM, Cost-effectiveness of initial antiretroviral Post FA, Panteleev A, Skrahin A, Miro JM, 57. Rodríguez-Núñez O, Ripa M, Morata L, de treatment administered as single vs. Girardi E, Podlekareva DN, Lundgren JD, la Calle C, Cardozo C, Fehér C, Pellicé M, multiple tablet regimens with the same or Sierra-Madero J, Toibaro J, Valcárcel A, Puerta-Alcalde P, Marco F, different components. ENFERMEDADES Andrade-Villanueva J, Tetradov S, Fehr J, García-Vidal C, Del Río A, Soriano A, INFECCIOSAS Y MICROBIOLOGIA CLINICA. Caylà J, Losso MH, Miller RF, Mocroft A, Kirk Martínez-Martínez JA. Evaluation of 36(1):16-20. I.F.: 1.707 O, Crabtree-Ramírez B . Differences in ceftazidime/avibactam for serious response to antiretroviral therapy in infections due to multidrug-resistant and 63. Rivero A, Pérez-Molina JA, Blasco AJ, HIV-positive patients being treated for extensively drug-resistant Pseudomonas Arribas JR, Asensi V, Crespo M, Domingo P, tuberculosis in Eastern Europe, Western aeruginosa. JOURNAL OF GLOBAL Iribarren JA, Lázaro P, López-Aldeguer J, Europe and Latin America. BMC ANTIMICROBIAL RESISTANCE. 15:136-139. Lozano F, Martínez E, Moreno S, Palacios R, INFECTIOUS DISEASES. 18(1):191. I.F.: 2.620 I.F.: 2.022 Pineda JA, Pulido F, Rubio R, Santos J, de la Torre J, Tuset M, Gatell JM. Costs and 52. Camon, S.; Quiros, C.; Saubi, N.; Moreno, A.; 58. Ruiz-Ruigómez M, Dueñas C, Hernandez cost-efficacy analysis of the 2017 Marcos, M. A.; Eto, Y.; Rofael, S.; Monclus, E.; C, Vinuesa D, Coronado-Álvarez N, GESIDA/Spanish National AIDS Plan Brown, J.; McHugh, T. D.; Mallolas, J.; Perello, R. Portillo-Tuñón V, Cardozo C, Muñoz-Medina recommended guidelines for initial Full blood count values as a predictor of L, Cabo-Magadán R, Luna J, Mensa J, antiretroviral therapy in HIV-infected poor outcome of pneumonia among Parra-Ruiz J. Clinical predictors of adults. ENFERMEDADES INFECCIOSAS Y HIV-infected patients. BMC INFECTIOUS candidemia in medical non-neutropenic, MICROBIOLOGIA CLINICA. 36(5):268-276. DISEASES. 18(1):189. I.F.: 2.620 non-ICU patients. The CaMed score. I.F.: 1.707 INTERNATIONAL JOURNAL OF CLINICAL 53. Reyes-Urueña JM, Campbell CNJ, Vives PRACTICE. 72(12):e13275. I.F.: 2.000 64. Bodro M, Ferrer J, Ricart MJ, Sanclemente N, Esteve A, Ambrosioni J, Tural C, Ferrer E, G, Linares L, Cervera C, Cofan F, Navarro G, Force L, García I, Masabeu À, 59. Cristelli MP, Mazolin MA, Manzardo C, Ventura-Aguiar P, Lopez-Boado MÁ, Marco F, Vilaró JM, García de Olalla P, Caylà JA, Miró Ribeiro MSJ, Cofán F, Santos DWC, Castel Fuster J, García-Valdecasas JC, Moreno A . JM, Casabona J, PISCIS investigators. MA, Tedesco-Silva H, Moreno A, Diekman F, Epidemiology, risk factors, and impact of Estimating the HIV undiagnosed Miro JM, Medina-Pestana JO . Sexual bacterial infections on outcomes for population in Catalonia, Spain: descriptive acquisition of HIV infection after solid pancreatic grafts. CLINICAL and comparative data analysis to identify organ transplantation: late presentation TRANSPLANTATION. 32(8):e13333. I.F.: 1.518 differences in MSM stratified by migrant and potentially fatal complications. and Spanish-born population. BMJ OPEN. TRANSPLANT INFECTIOUS DISEASE. 65. Bodro M, Londoño MC, Esforzado N, 8(2):e018533-e018533. I.F.: 2.413 20(4):e12894. I.F.: 1.869 Sanclemente G, Linares L, Solano MF, Cofan F, Marcos MA, Diekmann F, Moreno A . 54. Ruiz-de-León MJ, Jiménez-Sousa MA, 60. Rubio E, Martínez MJ, Gonzalo V, Hepatitis C viremia as a risk factor for Moreno S, García M, Gutiérrez-Rivas M, León Barrachina J, Torner N, Martínez AI, Jané M, opportunistic infections in kidney A, Montero-Alonso M, González-García J, Vilella A, Del Rio A, Rodriguez-Valero N, Pinazo transplant recipients. CLINICAL

72 INFECTIOUS DISEASES AND AIDS 1.3

TRANSPLANTATION. 32(10):e13382. I.F.: 1.518 5. Roncero C, Villegas J, Martínez-Rebollar M, Vancomycin for Complicated Bacteremia Buti M. The pharmacological interactions and Endocarditis Due to 66. Peacock JE, Stafford JM, Le K, Sohail MR, between direct-acting antivirals for the Methicillin-Resistant Staphylococcus Baddour LM, Prutkin JM, Danik SB, Vikram HR, treatment of chronic hepatitis c and aureus: A Randomized Clinical Trial. Hernandez-Meneses M, Miró JM, Blank E, psychotropic drugs. EXPERT REVIEW OF CLINICAL MICROBIOLOGY AND INFECTION. Naber CK, Carrillo RG, Greenspon AJ, Tseng CLINICAL PHARMACOLOGY. 24(6):673-676. I.F.: 5.394 CH, Uslan DZ . Attempted salvage of 11(10):999-1030. I.F.: 2.758 infected cardiovascular implantable 6. Ripa M, Rodríguez-Nuñez O, Cardozo C, electronic devices: Are there clinical 6. Aguado J, Silva J, Fernández-Ruiz M, Naharro-Abellán A, Almela M, Marco F, factors that predict success? PACE- Cordero E, Fortún J, Gudiol C, Morata L, De La Calle C, Del Río A, PACING AND CLINICAL Martínez-Martínez L, Vidal E, Almenar L, Garcia-Vidal C, Ortega MDM, Guerrero-León ELECTROPHYSIOLOGY. 41(5):524-531. Almirante B, Cantón R, Carratalá J, Caston J, MLA, Fehér C, Torres B, Puerta-Alcalde P, I.F.: 1.441 Cercenado E, Cervera C, Cisneros J, Mensa J, Soriano A, Martínez JA . Inﬂuence of Crespo-Leiro M, Cuervas-Mons V, empirical double-active combination 67. Zapata B, Alvarez DN, Farah S, Elizalde-Fernández J, Fariñas M, Gavaldà J, antimicrobial therapy compared with Garcia-de-la-Maria C, Miro JM, Sakoulas G, Goyanes M, Gutiérrez-Gutiérrez B, Hernández active monotherapy on mortality in Bayer AS, Mishra NN . Prevention of D, Len O, López-Andujar R, López-Medrano F, patients with septic shock: a propensity High-Level Daptomycin-Resistance Martín-Dávila P, Montejo M, Moreno A, Oliver score-adjusted and matched Emergence In Vitro in Streptococcus A, Pascual A, Pérez-Nadales E, Román-Broto analysis-authors' response. JOURNAL OF mitis-oralis by Using Combination A, San-Juan R, Serón D, Solé-Jover A, Valerio ANTIMICROBIAL CHEMOTHERAPY. Antimicrobial Strategies. CURRENT M, Muñoz P, Torre-Cisneros J. Management 73(6):1732-1733. I.F.: 5.217 MICROBIOLOGY. 75(8):1062-1067. I.F.: 1.373 of multidrug resistant Gram-negative bacilli infections in solid organ transplant 68. Carvalho E, Castro P, León E, Del Río A, recipients: SET/GESITRA-SEIMC/REIPI Editorial / I.F.: 1.707 Crespo F, Trigo L, Fernández S, Trilla A, Varela recommendations. TRANSPLANTATION P, Nicolás JM. Multi-professional simulation REVIEWS. 32(1):36-57. I.F.: 2.364 1. Martìnez E, Pulido F. Introducción. and risk perception of health care workers Darunavir, cobicistat, emtricitabina y caring for Ebola-infected patients. tenofovir alafenamida coformulados en el NURSING IN CRITICAL CARE. 12396. I.F.: 1.173 Letters / I.F.: 129.76 tratamiento de la infección por el VIH. ENFERMEDADES INFECCIOSAS Y 1. Rieg S., Kern W., Soriano A. Rifampicin in MICROBIOLOGIA CLINICA. 36:1-2. I.F.: 1.707 Review / I.F.: 19.436 treating S aureus bacteraemia. LANCET. 392(10147):554-555. I.F.: 53.254 1. Kilpeläinen A, Maya-Hoyos M, Saubí N, Soto Case Reports / I.F.: 1.494 CY, Joseph Munne J. Advances and 2. Ambrosioni J; Mosquera M; Miro JM. challenges in recombinant Mycobacterium Baseline Genotype Testing to Assess Drug 1. Medaglia A, Marco-Hernández J, de Ossó bovis BCG-based HIV vaccine development: Resistance Before Beginning HIV Acuña J, Hermida Lama E, Martínez-Rebollar Lessons learned. EXPERT REVIEW OF Treatment. JAMA-JOURNAL OF THE M, Caballero M, Rodríguez-Carunchio L, VACCINES. 17(11):1005-1020. I.F.: 4.271 AMERICAN MEDICAL ASSOCIATION. García F. Fusarium keratoplasticum 320(20):2153-2154. I.F.: 47.661 infection in an HIV-infected patient. 2. Blanco JL, Marcelin AG, Marcelin AG, INTERNATIONAL JOURNAL OF STD AND Katlama C, Katlama C, Martinez E. 3. Ambrosioni J, Urra X, Llopis J, Moreno A, AIDS. 29(10):1039-1042. I.F.: 1.494 Dolutegravir resistance mutations: lessons Chamorro A, Miró JM, Hospital Clinic Infective from monotherapy studies. CURRENT Endocarditis Investigators. Reply to OPINION IN INFECTIOUS DISEASES. author. CLINICAL INFECTIOUS DISEASES. Clinical Guidelines / I.F.: 6.346 31(3):237-245. I.F.: 3.782 67(7):1146-1147. I.F.: 9.117 1. Ryom L, Boesecke C, Bracchi M, 3. Cillóniz C, García-Vidal C, Moreno A, Miro 4. Ambrosioni J, Tellez A, Ambrosioni J, Pozniak A, Arribas J, Behrens G, JM, Torres A . Community-acquired Hernandez-Meneses M, Llopis J, Moreno A, Mallon P, Puoti M, Rauch A, Miro JM, Kirk O, bacterial pneumonia in adult HIV-infected Miró JM, Hospital Clinic Infective Endocarditis Marzolini C, Lundgren JD, Battegay M, EACS patients. EXPERT REVIEW OF Investigators. Reply to Garcia-Granja, et al. Governing Board. Highlights of the 2017 ANTI-INFECTIVE THERAPY. 16(7):579-588. CLINICAL INFECTIOUS DISEASES. European AIDS Clinical Society (EACS) I.F.: 3.141 67(11):1801-1801. I.F.: 9.117 Guidelines for the treatment of adult HIV-positive persons version 9.0. HIV 4. Cillóniz C, Dominedò C, Garcia-Vidal C, 5. Pericàs JM, Moreno A, Almela M, MEDICINE. 19(5):309-315. I.F.: 2.932 Torres A . Community-acquired pneumonia García-de-la-Mària C, Marco F, Muñoz P, as an emergency condition. CURRENT Peña C, de Alarcón A, Del Río A, Eworo A, 2. Garcia-Vidal C, Alastruey-Izquierdo A, OPINION IN CRITICAL CARE. 24(6):531-539. Cruceta A, Paré JC, Mestres CA, Miró JM, Aguilar-Guisado M, Carratalà J, Castro C, I.F.: 3.120 FOSIMI Investigators. Efficacy and Safety of Fernández-Ruiz M, Aguado JM, Fernández Fosfomycin Plus Imipenem vs. JM, Fortún J, Garnacho-Montero J, Gavaldà J,

73 AREA 1 BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

Gudiol C, Guinea J, Gómez-López A, Muñoz P, GRANTS FOR RESEARCH IN PROGRESS Garcia F. EHVA: European HIV Vaccine Pemán J, Rovira M, Ruiz-Camps I, Alliance: a EU platform for the discovery Cuenca-Estrella M. Executive summary of Arnedo M. Implicación del colesterol y and evaluation of novel prophylactic and clinical practice guideline for the ácidos grasos en macrofagos infectados therapeutic vaccine candidates. management of invasive diseases caused por VIH. Una aproximación lipidómica en el Sponsored by: European Comission. by Aspergillus: 2018 Update by the campo de la aterosclerosis y la infección CE_H2020-PHCRTD-15 (681032) GEMICOMED-SEIMC/REIPI. por el VIH. Duration: 01/01/2016-31/12/2020 ENFERMEDADES INFECCIOSAS Y Sponsored by: Instituto de Salud Carlos III MICROBIOLOGIA CLINICA. I.F.: 1.707 (ISCIII). PI15/00708 García F. EmERGE: Evaluating mHealth Duration: 01/01/2016-31/12/2018 technology in HIV to improve 3. Rivero, Antonio; Polo, Rosa; Lopez Empowerment and healthcare utilisation: Aldeguer, Jose; Lozano, Fernando; Antela, Blanco JL. Papel de la determinación de Research and innovation to Generate Antonio; Ramon Arribas, Jose; Asensi, Victor; resistencias en PMBC mediante Evidence for personalised care. Berenguer, Juan; Ramon Blanco, Jose; Luis secuenciación masica del DNA proviral Sponsored by: European Comission. Casado, Jose; Clotet, Bonaventura; Crespo, integrado en sujetos VIH+ con fracaso CE_H2020-PHC-2014-1s (643736) Manuel; Domingo, Pere; Duenas, Carlos; Maria virológico con viremias bajas (50-200 Duration: 01/05/2015-30/04/2020 Gatell, Jose; Luis Gomez-Sirvent, Juan; copias/mL). Gonzalez-Garcia, Juan; Antonio Iribarren, Sponsored by: Instituto de Salud Carlos III León A. Evaluación clínica y de consumo Jose; Bernaldo de Quiros, Juan Carlos Lopez; (ISCIII). PI17/01562 sanitario del seguimiento telemático de Lopez Cortes, Luis Fernando; Emilio Losa, Duration: 01/01/2018-31/12/2020 una cohorte de pacientes infectados por el Juan; Mallolas, Josep; Marino, Ana; Martinez, VIH. Esteban; Miro, Jose M.; Moreno, Santiago; García C. Impacto de un paquete de Sponsored by: Instituto de Salud Carlos III Palacios, Rosario; Pasquau, Juan; Antonio intervenciones basadas en la evidencia en (ISCIII). PI17/00726 Pineda, Juan; Podzamczer, Daniel; Portilla, la calidad de la atención y el pronóstico de Duration: 01/01/2018-31/12/2020 Joaquin; Poveda, Eva; Pulido, Federico; Rubio, la candidemia. Rafael; Santos, Jesus; Sanz Moreno, Jose; Sponsored by: Instituto de Salud Carlos III Mallolas J. Grup de Recerca VIH/SIDA. Sanz Sanz, Jesus; Jesus Tellez, Maria; de la (ISCIII). PI15/00744 Sponsored by: Generalitat de Catalunya. Torre, Javier; Tuset, Montserrat; Perez Molina, Duration: 05/07/2016-31/12/2019 AGAUR_SGR17_00615 Jose A.; AIDS Study Grp GESIDA Span. Duration: 01/01/2017-31/12/2020 Executive summary of the Garcia F. Red Temática de Investigación GESIDA/National AIDS Plan Consensus Cooperativa en Salud - SIDA. Mallolas J. Inmunoterapia frente al VIH con Document on Antiretroviral Therapy in Sponsored by: Instituto de Salud Carlos III una vacuna terapéutica más interferón Adults Infected by the Human (ISCIII). RD16/0025/0002 para modificar el reservorio viral y Immunodeficiency Virus (Updated Duration: 01/01/2017-31/12/2021 eventualmente alcanzar una remisión sin January 2017). ENFERMEDADES antiretrovirales. INFECCIOSAS Y MICROBIOLOGIA CLINICA. García F. Utilización de medicina de Sponsored by: Instituto de Salud Carlos III 36(7):435-445. I.F.: 1.707 sistemas para la predicción de la (ISCIII). PI15/00641 inmunogenicidad y eficacia de vacunas Duration: 01/01/2016-31/12/2018 terapéuticas frente a VIH. Consortium Publications / I.F.: 4.541 Sponsored by: Ministerio de Economia y Martínez EJ. Seguridad, tolerabilidad y Competitividad (MINECO). SAF2015-66193-R eficacia de dos estrategias de 1. Marent B, Henwood F, Darking M, Leon A, Duration: 01/01/2016-31/12/2018 simplificación basadas en dolutegravir en West B, Lockhart D, Garcia D, Fatz D, Wallitt E, pacientes infectados por VIH con Beck E, Gomez E, Teofilo E, Gonzalez E, García F. HIVACAR: Evaluating a supresión virológica sostenida. Garcia F, Rodrigues G, Whetham J, Begovac Combination of Immune-based Therapies Sponsored by: Instituto de Salud Carlos III J, Block K, Pereira L, Apers L, Borges M, to Achieve a Functional Cure of HIV (ISCIII). PI16/01085 Chausa P, Zekan S, Bremner S, Hoornaert S, Infection. Duration: 01/01/2017-31/12/2019 Mandalia S. Development of an mHealth Sponsored by: European Comission. platform for HIV care: Gathering user H2020-SC1-2016-RTD. (731626) Martínez EJ. Predictive Metabolomics perspectives through co-design Duration: 01/09/2017-31/08/2020 biomarkers for cardiovascular disease risk workshops and interviews. JMIR MHEALTH in ART-HIV+ population. AND UHEALTH. 6(10):e184. I.F.: 4.541 García F. INTEGRATE: Joint Action on Sponsored by: Gilead Sciences. integrating prevention, testing and linkage Gilead_Fellowship16 to care strategies acros HIV, viral hepatitis, Duration: 14/12/2016- TB and STIs in Europe. Sponsored by: European Comission. Miró JM. Estudi clínic i experimental de la CE_HP-JA-2016 (761319) relació entre la CMI a la vancomicina en Duration: 01/01/2017-31/12/2021 Staphylococcus aureus sensibles a la meticil·lina (MSSA) i el pronòstic de la endocarditis infecciosa esquerra per MSSA.

74 INFECTIOUS DISEASES AND AIDS 1.3

Sponsored by: Fundació la Marató de TV3. Garcia F. Marcadores de inflamación en TV3_Cor_15 pacientes infectados por el virus de la inmunodeficiencia humana en tratamiento Miro JM. Eficacia de nuevas pautas de antirretroviral. tratamiento antibiótico de la andocarditis PhD student: Berta Torres Murillo enterocòcica evaluadas in vitro y en el modelo de endocarditis experimental. Miró JM, Cofan F. Renal disease among Sponsored by: Instituto de Salud Carlos III patients with hiv infection: prevalence, risk (ISCIII). PI17/01251 factors, and evolution after renal Duration: 01/01/2018-31/12/2020 transplantation. PhD student: Marina Pontello Cristelli Miro JM. Estudio clínico y experimental de la asociación entre la CMI de vancomicina en Staphylococcus aureus sensible a meticilina (SASM) y el pronóstico de la endocarditis infecciona (EI) izquierda causada por dicho microorganismo. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI14/00603 Duration: 01/01/2015- 31/03/2019

Plana M. Desarrollo de una vacuna terapéutica frente al VIH basada en una nueva formulación de mRNA con nanopartículas. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI15/00480 Duration: 01/01/2016-31/09/2019

Plana M. Design of Human Inﬂuenza vaccines using multifunctional micelles harnessing innate immunity. Sponsored by: Instituto de Salud Carlos III (ISCIII). AC16/00051 Duration: 01/01/2017-31/12/2019

Soriano A. Estudio de estabilidad y viabilidad de la microbiota intestinal lioﬁlizada y su utilidad en el tratamiento de la infección por Clostridium difficile. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI16/01023 Duration: 01/01/2017-31/12/2019

DOCTORAL THESES

Garcia F. Evaluación de la seguridad, tolerabilidad y adherencia a la proﬁlaxis post-exposición como estrategia para la prevención de la infección por el virus de la inmunodeﬁciencia humana. PhD student: Lorna Leal Alexander

Garcia F. Pacientes infectados por VIH con buen control inmunovirológico: prevalencia de eventos no-SIDA y marcadores de evolución. PhD student: María Constanza Lucero

75 AREA 1 BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

Immune receptors of the 1.4 innate and adaptive system

STRATEGIC OBJECTIVES

LOCATION 1. Identiﬁcation and characterization of CEK building, ﬂoor 1 functionally relevant genetic variations of immunoreceptors regulating innate and/or adaptive immune responses.

2. Functional characterization of the ligand-receptor interactions responsible for KEYWORDS intercellular communication between 1. Innate and adaptive immune TEAM LEADER components from the innate and adaptive response Francisco Lozano (HCB/UB) immune system. 2. Immune receptor-ligand interactions T. 93 227 42 17 3. 3. Immunomodulation and ﬂ[email protected] Understanding of host-pathogen immunotherapy interactions mediated by lymphoid and 4. Host-pathogen interaction non-lymphoid receptors. 5. Immunevasion 4. Development of novel immunomodulatory RESERACHERS strategies in experimental models of Ana Angulo (UB) autoimmunity, infection and cancer. Pablo Engel (UB) Carles Serra (HCB-UB) 5. Characterization of cytomegalovirus (CMV) biology and pathogenesis. Original publications POST-DOCTORAL RESEARCHERS from 2016 to 2018 Fernando Aranda (IDIBAPS) Esther Carreras (IDIBAPS) YEAR I.F. TOTAL Q1 Q2 Pablo Martínez (UB) MAIN LINES OF RESEARCH 2016 42.52 7 6 1 2017 57.10 11 10 1 PRE-DOCTORAL RESEARCHERS 1. Molecular and functional characterization Guillem Angulo (UB) 2018 56.61 10 91 of the SLAM (Signaling Lymphocytic Sergi Casadó (IDIBAPS) Activation Molecule) and SAP Cristina Català (IDIBAPS) (SLAM-Associated Protein) leukocyte Joan Puñet (UB) receptor families. Manuel Sáez (UB) María Velasco (IDIBAPS) TEAM INVOLVED IN 2. Study of the molecules that intervene in Infect-ERA (SRecognite project) leukocyte adhesion and inﬂammation. TECHNICIANS AGAUR_SGR17: 1582 Noelia Armiger (IDIBAPS) HCDM 3. Immunogenetics of receptors and Adriana Lázaro (UB) molecules implicated in the regulation of innate and adaptive immune responses. Francisco Lozano TEAM

76 IMMUNE RECEPTORS OF THE INNATE AND ADAPTIVE SYSTEM 1.4

4. Study of the role of the lymphoid sjögren's syndrome. FRONTIERS IN Review / I.F.: 28.181 scavenger-like receptors CD5 and CD6 as IMMUNOLOGY. 9(NOV):2661. I.F.: 5.511 immunomodulators in infection, 1. Retamozo, Soledad; Flores-Chavez, autoimmunity and cancer. 5. Agod Z., Pazmandi K., Bencze D., Vereb G., Alejandra; Consuegra-Fernandez, Marta; Biro T., Szabo A., Rajnavolgyi E., Bacsi A., Engel Lozano, Francisco; Ramos-Casals, Manuel; 5. Molecular and functional characterization P., Lanyi A. Signaling lymphocyte activation Brito-Zeron, Pilar. Cytokines as therapeutic of nonlymphoid members of the molecule family 5 enhances autophagy targets in primary Sjögren syndrome. superfamily of receptors with extracellular and fine-tunes cytokine response in PHARMACOLOGY AND THERAPEUTICS. domains rich in cysteine (SRCR, Scavenger monocyte-derived dendritic cells via 184:81-97. I.F.: 10.376 Receptor Cysteine-Rich) residues. stabilization of interferon regulatory factor 8. FRONTIERS IN IMMUNOLOGY. 26(9):62. 2. Consuegra-Fernandez, Marta; Lin, Feng; 6. Characterization of the mechanisms that I.F.: 5.511 Fox, David A.; Lozano, Francisco. Clinical and regulate CMV gene expression and experimental evidence for targeting CD6 identification of functions encoded by CMV. 6. Martínez-Florensa M., Català C., in immune-based disorders. Velasco-de Andrés M., Cañadas O., AUTOIMMUNITY REVIEWS. 17(5):493-503. 7. Study of CMV modulation of the immune Fraile-ágreda V., Casadó-Llombart S., I.F.: 8.745 response and viral immune evasion Armiger-Borràs N., Consuegra-Fernández M., strategies Casals C., Lozano F. Conserved 3. Garcia-Martinez, Elena; Smith, Melody; bacterial-binding peptides of the Buque, Aitziber; Aranda, Fernando; Ayala de la scavenger-like human lymphocyte Pena, Francisco; Ivars, Alejandra; Sanchez receptor CD6 protect from mouse Canovas, Manuel; Vicente Conesa, Ma PUBLICATIONS experimental sepsis. FRONTIERS IN Angeles; Fucikova, Jitka; Spisek, Radek; IMMUNOLOGY. 12(9):627. I.F.: 5.511 Zitvogel, Laurence; Kroemer, Guido; Galluzzi, Originals / I.F.: 56.614 Lorenzo. Trial Watch: Immunostimulation 7. Aranda F., Chaba K., Bloy N., Garcia P., with recombinant cytokines for cancer 1. Consuegra-Fernández M, Julià M, Bordenave C., Martins I., Stoll G., Tesniere A., therapy. ONCOIMMUNOLOGY. Martínez-Florensa M, Aranda F, Català C, Kroemer G., Senovilla L. Immune effectors 7(6):e1433982. I.F.: 5.503 Armiger-Borràs N, Arias MT, Santiago F, responsible for the elimination of Guilabert A, Esteve A, Muñoz C, Ferrándiz C, hyperploid cancer cells. 4. Cuenca M, Sintes J, Lányi Á, Engel P. Carrascosa JM, Pedrosa E, Romaní J, Alsina ONCOIMMUNOLOGY. 7(8):e1463947. CD84 cell surface signaling molecule: An M, Mascaró-Galy JM, Lozano F, Lozano F, I.F.: 5.503 emerging biomarker and target for cancer Lozano F. Genetic and experimental and autoimmune disorders. CLINICAL evidence for the involvement of the CD6 8. Perez-Carmona, Natalia; Martinez-Vicente, IMMUNOLOGY. I.F.: 3.557 lymphocyte receptor in psoriasis. Pablo; Farre, Domenec; Gabaev, Ildar; CELLULAR AND MOLECULAR Messerle, Martin; Engel, Pablo; Angulo, Ana. IMMUNOLOGY. 15(10):898-906. I.F.: 7.551 A prominent role of the human Letters / I.F.: 3.675 cytomegalovirus UL8 glycoprotein 2. Aljutaily T, Consuegra-Fernández M, restraining pro-inflammatory cytokine 1. Julià M, Consuegra-Fernández M, Guilabert Aranda F, Lozano F, Huarte E. Gut microbiota production by myeloid cells at late times A, Muñoz C, Esteve A, Armiger-Borràs N, metabolites for sweetening type I during infection. JOURNAL OF VIROLOGY. Santiago F, Arias MT, Romaní J, Ferrándiz C, diabetes. CELLULAR AND MOLECULAR 92(9). I.F.: 4.368 Carrascosa JM, Pedrosa E, Alsina-Gibert M, IMMUNOLOGY. 15(2):92-95. I.F.: 7.551 Lozano F, Mascaró-Galy JM . Genetically 9. Mourglia-Ettlin G, Miles S, defined variants of toll-like receptors 3, 7 3. Lombardo-Quezada J, Sanclemente G, Velasco-De-Andrés M, Armiger-Borràs N, and 9 as phenotype and risk modifier Colmenero J, Español-Rego M, Arias MT, Ruiz Cucher M, Dematteis S, Lozano F, Lozano F, factors for psoriasis. JOURNAL OF P, Mauro E, Sastre L, Crespo G, Rimola A, Lozano F. The ectodomains of the DERMATOLOGICAL SCIENCE. Moreno A, Lozano F, Navasa M. lymphocyte scavenger receptors CD5 and 89(3):301-304. I.F.: 3.675 Mannose-binding lectin deficient donors CD6 interact with tegumental antigens increase the risk of bacterial infection and from Echinococcus granulosus sensu lato bacterial infection-related mortality after and protect mice against secondary cystic liver transplantation. AMERICAN JOURNAL echinococcosis. PLOS NEGLECTED GRANTS FOR RESEARCH IN PROGRESS OF TRANSPLANTATION. 18(1):197-206. TROPICAL DISEASES. 12(11):e0006891. I.F.: 6.493 I.F.: 4.367 Lozano F. Combined CD6 therapy for treatment of infectious diseases and 4. Puñet-Ortiz J., Moya M., Cuenca M., 10. Cuenca M., Puñet-Ortiz J., Ruart M., related inflammatory processes. Caleiras E., Lazaro A., Engel P. Ly9 (CD229) Terhorst C., Engel P. Ly9 (SLAMF3) receptor Sponsored by: Fundació Institució Centres de antibody targeting depletes marginal zone differentially regulates iNKT cell Recerca de Catalunya (CERCA). 2017-03-14 and germinal center b cells in lymphoid development and activation in mice. Duration: 18/04/2017-17/04/2022 tissues and reduces salivary gland EUROPEAN JOURNAL OF IMMUNOLOGY. inflammation in a mouse model of 48(1):99-105. I.F.: 4.248

77 AREA 1 BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

Lozano F. Aproximaciones experimentales al estudio de las propiedades inmunomoduladores de receptores linfocitarios tipo scavenger en patología inmunomediada. Sponsored by: Ministerio de Economía y Competitividad (MINECO). SAF2016-80535-R Duration: 30/12/2016-29/12/2019

Lozano F. Proteínas SRCR como receptores reconocedores de microorganismos: un amplio rastreo de interacciones con bacterias patogénicas. Sponsored by: Ministerio de Economía y Competitividad (MINECO). PCIN-2015-070 Duration: 01/12/2015- 31/05/2019

78 IMMUNOGENETICS OF THE AUTOINFLAMMATORY RESPONSE 1.6

Immunogenetics of the 1.6 autoinﬂammatory response

STRATEGIC OBJECTIVES

LOCATION In the field of autoinflammatory diseases: HCB building Promotion of basic, clinical and translation CELLEX building, floor 4B research in the physiopathology of autoinflammatory and immunomediated diseases as a model for gaining in-depth knowledge of the regulation of the normal inflammatory response, its dysfunctions, and KEYWORDS its effects upon the immune response. 1. Autoinflammation TEAM LEADER 2. Immunogenetics Jordi Yagüe (HCB) In the field of immune response: 3. Inflammasome T. 93 227 54 00 (Ext.: 2155) Determination of the components of immune 4. Immunotherapy [email protected] response is essential for modulating the 5. Immunodeficiencies specific recognition phenomena and developing products of immunotherapy (CART, DCs and TILs therapies). RESEARCHERS Juan Ignacio Aróstegui (HCB) Manel Juan (HCB) Original publications MAIN LINES OF RESEARCH from 2016 to 2018 POST-DOCTORAL RESEARCHERS Anna Mensa (HCB) In the field of autoinflammatory diseases: YEAR I.F. TOTAL Q1 Q2 - Determination of the genetic and molecular 2016 59.39 15 8 2 PRE-DOCTORAL RESEARCHERS bases of the autoinflammatory process. Berta Marzal (IDIBAPS) - Characterization of the regulatory 2017 90.93 15 10 1 mechanisms of the inflammasome and its 2018 108.30 13 10 3 COLLABORATORS dysfunction. Daniel Benítez (HCB) - Characterization of the specific Miguel Caballero (HCB) transcriptional profiles of autoinflammatory Azucena Europa (HCB) diseases. Eva González (HCB) - Isolation of new genes responsible for TEAM INVOLVED IN Eduard Palou (HCB) hereditary autoinflammatory diseases and AGAUR_SGR17: 1539 Estíbaliz Ruiz (HCB) identification of genetic susceptibility factors for the development of polygenic autoinflammatory processes. - Definition of new therapeutic targets for the treatment of autoinflammatory diseases. Jordi Yagüe TEAM

79 AREA 1 BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

In the field of immune responses: 32(6):1427-1434. I.F.: 10.023 cells pulsed with an allogenic tumoral - Assessing the role of HLA loci in the cell-lines lysate in patients with newly immune response against infection, 5. Van Gijn ME, Ceccherini I, Shinar Y, Carbo diagnosed diffuse intrinsic pontine glioma. transplantation, cancer and autoimmune EC, Slofstra M, Arostegui JI, Sarrabay G, FRONTIERS IN ONCOLOGY. 8(APR):167. responses. Rowczenio D, Omoy?mn? E, I.F.: 4.416 - Cell immunotherapy (mainly in cancer): Balci-Peynircioglu B, Hoffman HM, Milhavet F, CAR Ts, DCs and TILs. Swertz MA, Touitou I. New workflow for 10. Inciarte-Mundo J, Ramirez J, Hernández classification of genetic variants' MV, Ruiz-Esquide V, Cuervo A, pathogenicity applied to hereditary Cabrera-Villalba SR, Pascal M, Yagüe J, recurrent fevers by the International Study Cañete JD, Sanmarti R. Calprotectin PUBLICATIONS Group for Systemic Autoinflammatory strongly and independently predicts Diseases (INSAID). JOURNAL OF MEDICAL relapse in rheumatoid arthritis and Originals / I.F.: 108.301 GENETICS. 55(8):530-537. I.F.: 5.751 polyarticular psoriatic arthritis patients treated with tumor necrosis factor 1. Armangue T, Spatola M, Vlagea A, Mattozzi 6. De Valles-Ibáñez G., Esteve-Solé A., Piquer inhibitors: a 1-year prospective cohort S, Cárceles-Cordon M, Martinez-Heras E, M., Azucena González-Navarro E., study. ARTHRITIS RESEARCH AND Llufriu S, Muchart J, Erro ME, Abraira L, Moris Hernandez-Rodriguez J., Laayouni H., THERAPY. 20(1):275. I.F.: 4.269 G, Monros-Giménez L, Corral-Corral Í, González-Roca E., Plaza-Martin A., Montejo C, Toledo M, Bataller L, Secondi G, Deyà-Martínez á., Martín-Nalda A., 11. Esteve-Sole A, Sánchez-Dávila SP, Ariño H, Martínez-Hernández E, Juan M, Martínez-Gallo M., García-Prat M., del Deyà-Martínez A, Freeman AF, Zelazny AM, Marcos MA, Alsina L, Saiz A, Rosenfeld MR, Pino-Molina L., Cuscó I., Codina-Solà M., Dekker JP, Khil PP, Holland SM, Noguera-Julian Graus F, Dalmau J,. Frequency, symptoms, Batlle-Masó L., Solís-Moruno M., A, Bustamante J, Casanova JL, Juan M, Cordova risk factors, and outcomes of autoimmune Marquès-Bonet T., Bosch E., López-Granados W, Alsina L. Severe BCG-osis Misdiagnosed encephalitis after herpes simplex E., Aróstegui J., Soler-Palacín P., Colobran R., as Multidrug-Resistant Tuberculosis in an encephalitis: a prospective observational Yagüe J., Alsina L., Juan M., Casals F. IL-12Rβ1-Deficient Peruvian Girl. JOURNAL study and retrospective analysis. LANCET Evaluating the genetics of common OF CLINICAL IMMUNOLOGY. 38(6):712-716. I.F.: NEUROLOGY, THE. 17(9):760-772. I.F.: 27.144 variable immunodeficiency: Monogenetic 4.227 model and beyond. FRONTIERS IN 2. Rowczenio DM, Pathak S, Arostegui JI, IMMUNOLOGY. 9:636. I.F.: 5.511 12. Deyà-Martínez A, Esteve-Solé A, Mensa-Vilaro A, Omoyinmi E, Brogan P, Vélez-Tirado N, Celis V, Costa J, Cols M, Jou C, Lipsker D, Scambler T, Owen R, Trojer H, 7. De la Guardia R., Correa J., López-Millán B., Vlagea A, Plaza-Martin AM, Juan M, Alsina L. Baginska A, Gillmore JD, Wechalekar AD, Juan M., Bueno C., Cervantes F., Menéndez P. Sirolimus as an alternative treatment in Lane T, Williams R, Youngstein T, Hawkins PN, Detection of inflammatory monocytes but patients with granulomatous-lymphocytic Savic S, Lachmann HJ. Molecular genetic not mesenchymal stem/stromal cells in lung disease and humoral investigation, clinical features, and peripheral blood of patients with immunodeficiency with impaired regulatory response to treatment in 21 patients with myelofibrosis. BRITISH JOURNAL OF T cells. PEDIATRIC ALLERGY AND Schnitzler syndrome. BLOOD. HAEMATOLOGY. 181(1):133-137. I.F.: 5.128 IMMUNOLOGY. 29(4):425-432. I.F.: 4.137 131(9):974-981. I.F.: 15.132 8. Sarens IL, Casteels I, Anton J, 13. Bastida C, Ruiz-Esquide V, Pascal M, de Vries 3. Paré L, Pascual T, Seguí E, Teixidó C, Bader-Meunier B, Brissaud P, Chédeville G, Schultink AHM, Yagüe J, Sanmartí R, Huitema Gonzalez-Cao M, Galván P, Rodríguez A, Cimaz R, Dick AD, Espada G, ADR, Soy D. Fixed dosing of intravenous González B, Cuatrecasas M, Pineda E, Torné Fernandez-Martin J, Guly CM, Hachulla E, tocilizumab in rheumatoid arthritis. Results A, Crespo G, Martin-Algarra S, Pérez-Ruiz E, Harjacek M, Khubchandani R, Mackensen F, from a population pharmacokinetic Reig Ò, Viladot M, Font C, Adamo B, Vidal M, Merino R, Modesto C, Naranjo A, analysis. BRITISH JOURNAL OF CLINICAL Gaba L, Muñoz M, Victoria I, Ruiz G, Viñolas N, Oliveira-Knupp S, Özen S, Pajot C, Ramanan PHARMACOLOGY. 84(4):716-725. I.F.: 3.838 Mellado B, Maurel J, Garcia-Corbacho J, AV, Russo R, Susic G, Thatayatikom A, Molina-Vila MÁ, Juan M, Llovet JM, Reguart N, Thomée C, Vastert S, Bertin J, Arostegui JI, Arance A, Prat A. Association between PD1 Rose CD, Wouters CH. Blau Syndrome - Review / I.F.: 12.504 mRNA and response to anti-PD1 Associated Uveitis: Preliminary Results monotherapy across multiple from an International Prospective 1. Esteve-Solé A., Sologuren I., cancer-types. ANNALS OF ONCOLOGY. Interventional Case Series. AMERICAN Martínez-Saavedra M., Deyà-Martínez À., 29(10):2121-2128. I.F.: 13.930 JOURNAL OF OPHTHALMOLOGY. Oleaga-Quintas C., Martinez-Barricarte R., 187:158-166. I.F.: 4.795 Martin-Nalda A., Juan M., Casanova J., 4. De Larrea C., Isola I., Pereira A., Cibeira M., Rodriguez-Gallego C., Alsina L., Bustamante J. Magnano L., Tovar N., Rodríguez-Lobato L., 9. Benitez-Ribas D., Cabezón R., Flórez-Grau Laboratory evaluation of the IFN-? circuit Calvo X., Aróstegui J., Díaz T., Lozano E., G., Molero M., Puerta P., Guillen A., Paco S., for the molecular diagnosis of Mendelian Rozman M., Yagüe J., Bladé J., Rosiñol L. Carcaboso A., Lopez V., Cruz O., de Torres C., susceptibility to mycobacterial disease. Evolving M-protein pattern in patients with Salvador N., Juan M., Mora J., La Madrid A. CRITICAL REVIEWS IN CLINICAL smoldering multiple myeloma: impact on Immune response generated with the LABORATORY SCIENCES. 55(3):184-204. early progression. LEUKEMIA. administration of autologous dendritic I.F.: 6.481

80 IMMUNOGENETICS OF THE AUTOINFLAMMATORY RESPONSE 1.6

2. Esteve-Solé A, Luo Y, Vlagea A, DOCTORAL THESES Deyà-Martínez Á, Yagüe J, Plaza-Martín AM, Juan M, Alsina L. B Regulatory Cells: Players Juan M, Alsina L. Primary and secondary in Pregnancy and Early Life. immunodeﬁciencies of the IL-12/IFN-y INTERNATIONAL JOURNAL OF axis. MOLECULAR SCIENCES. 19(7). I.F.: 3.687 PhD student: Ana Esteve Solé

3. Hernández-Rodríguez J, Ruiz-Ortiz E, Aróstegui JI. Implicació del mosaïcisme Yagüe J. Monogenic autoinﬂammatory genètic en les immunodeﬁciències diseases: General concepts and primàries. presentation in adult patients. MEDICINA PhD student: Anna Mensa Vilaró CLINICA. 150(2):67-74. I.F.: 1.168

4. José Hernández Rodríguez; Estíbaliz Ruiz Ortiz; Jordi Yagüe. Enfermedades autoinﬂamatorias monogénicas: conceptos generales y presentación en pacientes adultos. MEDICINA CLINICA. 150(2):67-74. I.F.: 1.168

Letters / I.F.: 6.129

1. Podlipnik S, Morgado-Carrasco D, Fustà-Novell X, Mensa-Vilaró A, Arostegui JI, Alsina-Gibert M, Mascaró JM. Dynamics of plasma cytokines in a patient with deﬁciency of interleukin-36 receptor antagonist successfully treated with anakinra. BRITISH JOURNAL OF DERMATOLOGY. 178(4):e258-e260. I.F.: 6.129

Case Reports / I.F.: 5.386

1. Gargallo V., Menis D., Márquez A., Aróstegui J., Martín R. Short-term efficacy of adalimumab in a patient with pyrin-associated autoinﬂammation with neutrophilic dermatosis. JDDG - JOURNAL OF THE GERMAN SOCIETY OF DERMATOLOGY. 16(6):756-759. I.F.: 2.743

2. Podlipnik S, Castellanos-Moreira R, Florez-Enrich H, Arostegui JI, Mascaró JM. Acute generalized exanthematous pustulosis and polyarthritis associated with a novel CARD14 mutation. AUSTRALASIAN JOURNAL OF DERMATOLOGY. 59(1):e70-e73. I.F.: 1.602

3. Latour I., Noguera-Morel L., Colmenero I., Clemente D., Hernández-Martín A., López-Robledillo J., Arostegui J., Torrelo A. Chronic urticaria in infants as the ﬁrst manifestation of autoinﬂammatory disease. PEDIATRIC DERMATOLOGY. 35(6):e337-e340. I.F.: 1.041

81 AREA 1 BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

Emergencies: 1.7 processes and pathologies

PRE-DOCTORAL RESEARCHERS Sira Aguiló (HCB) LOCATION Pablo Burbano (UB) HCB building Javier Dario Cabrera (UB) Francesc Xavier Escalada (UB) Inés María Fernández (UB) Lluís Llauger (UB) Javier López (UB) Sònia Moreno (UB) KEYWORDS

1. Emergency department NURSING STAFF TEAM LEADER 2. Organization Òscar Miró (HCB) Sofía Calderón (HCB) Helena Morera (HCB) 3. Toxicology T. 93 227 54 00 (Ext.: 3153) 4. Chest pain [email protected] 5. Arrhythmia COLLABORATORS Ana García (HCB)

RESERACHERS Blanca Coll-Vinent (HCB) Sònia Jiménez (HCB) STRATEGIC OBJECTIVES Santiago Nogué (HCB) Original publications Mar Ortega-Romero (HCB) The study of all processes and pathologies from 2016 to 2018 Rafael Perelló (HCB) inherent to the emergency setting, with a

YEAR I.F. TOTAL Q1 Q2 Miguel Sánchez (HCB) patient-centred approach and focusing on the acute process leading to emergency 2016 37.46 14 8 5 POST-DOCTORAL RESEARCHERS consultation. The ﬁrst few hours of emergency 2017 235.95 39 29 8 Josep Ramon Alonso (HCB) disease conditions are exclusively addressed 2018 267.50 41 24 8 Montserrat Amigó (HCB) by the Emergency Department, where clinical Albert Antolín (HCB) research has not classically been considered. Ernest Bragulat (HCB) This makes this group unique in Catalonia and Rosa Escoda (HCB) Spain. Miguel Galicia (HCB)

TEAM INVOLVED IN Victor Gil (HCB) AGAUR_SGR17: 1424 Elisenda Gómez (HCB) Carolina Inostoza (HCB) MAIN LINES OF RESEARCH Francesc Xavier Jiménez (UB) Beatriz López (HCB) 1. Functional aspects of Hospital Emergency Mar Ortega-Aramburu (HCB) Departments. Emilio Salgado (HCB)

AWARDS Pepe Millá Award Institution: Sociedad Española de Medicina de Urgencias y Emergencias (SEMES) Awardee/s: Òscar Miró Òscar Miró TEAM

82 EMERGENCIES: PROCESSES AND PATHOLOGIES 1.7

2. Clinical aspects of intoxicated patients. 3. Gimenez, Maria Rubini; Badertscher, EUROPEAN RESPIRATORY JOURNAL. 51(2). Patrick; Twerenbold, Raphael; Boeddinghaus, I.F.: 12.244 3. Treatment of arrhythmias in the Jasper; Nestelberger, Thomas; Wussler, emergency room. Desiree; Miro, Oscar; Javier Martin-Sanchez, 8. Gayat E, Arrigo M, Littnerova S, Sato N, F.; Reichlin, Tobias; Mueller, Christian. Impact Parenica J, Ishihara S, Spinar J, Müller C, 4. Evaluation of chest pain in the Emergency of the US Food and Drug Administration- Harjola VP, Lassus J, Miró Ò, Maggioni AP, Department. Approved Sex-Speciﬁc Cutoff Values for AlHabib KF, Choi DJ, Park JJ, Zhang Y, Zhang High-Sensitivity Cardiac Troponin T to J, Januzzi JL, Kajimoto K, Cohen-Solal A, 5. Thromboembolic diseases. Diagnose Myocardial Infarction. Mebazaa A, GREAT Network. Heart failure CIRCULATION. 137(17):1867-1869. I.F.: 18.881 oral therapies at discharge are associated 6. Emergency medical care for problems with better outcome in acute heart failure: caused by drug abuse. 4. Van der Linden N, Wildi K, Twerenbold R, A propensity-score matched study. Pickering JW, Than M, Cullen L, Greenslade J, EUROPEAN JOURNAL OF HEART FAILURE. 7. Acute heart failure. Parsonage W, Nestelberger T, Boeddinghaus 20(2):345-354. I.F.: 10.683 J, Badertscher P, Rubini Giménez M, 8. Attention to infectious diseases in Klinkenberg LJJ, Bekers O, Schöni A, Keller DI, 9. Miró Ò, Tost J, Gil V, Martín-Sánchez FJ, Emergency Departments. Sabti Z, Puelacher C, Cupa J, Schumacher L, Llorens P, Herrero P, Mebazaa A, Harjola VP, Kozhuharov N, Grimm K, Shrestha S, Flores D, Ríos J, Marco-Hernández J, Collins SP, 9. Dynamics of teaching and research in Freese M, Stelzig C, Strebel I, Miró Ò, Rentsch Peacock WF, Hollander JE, Lorca MT, Jacob Emergency Medicine. K, Morawiec B, Kawecki D, Kloos W, J, ICA-SEMES Research Group. The Lohrmann J, Richards AM, Troughton R, BRONCH-AHF study: effects on Pemberton C, Osswald S, van Dieijen-Visser short-term outcome of nebulized MP, Mingels AM, Reichlin T, Meex SJR, bronchodilators in emergency department PUBLICATIONS Mueller C . Combining High Sensitivity patients diagnosed with acute heart Cardiac Troponin I and Cardiac Troponin T failure. EUROPEAN JOURNAL OF HEART Originals / I.F.: 267.499 in the Early Diagnosis of Acute Myocardial FAILURE. 20(4):822-826. I.F.: 10.683 Infarction. CIRCULATION. 138(10):989-999. 1. Boeddinghaus J, Nestelberger T, I.F.: 18.881 10. Akiyama E, Van Aelst LNL, Arrigo M, Twerenbold R, Neumann JT, Lindahl B, Lassus J, Miró Ò, Čelutkienė J, Choi DJ, Giannitsis E, Sörensen NA, Badertscher P, 5. Badertscher P, Boeddinghaus J, Cohen-Solal A, Ishihara S, Kajimoto K, Laribi S, Jann JE, Wussler D, Puelacher C, Rubini Twerenbold R, Nestelberger T, Wildi K, Maggioni AP, Motiejunaite J, Mueller C, Giménez M, Wildi K, Strebel I, Du Fay de Wussler D, Schwarz J, Puelacher C, Rubini Parenica J, Park JJ, Sato N, Spinar J, Zhang J, Lavallaz J, Selman F, Sabti Z, Kozhuharov N, Giménez M, Kozhuharov N, du Fay de Lavallaz Zhang Y, Kimura K, Tamura K, Gayat E, Potlukova E, Rentsch K, Miró Ò, J, Cerminara SE, Potlukova E, Rentsch K, Miró Mebazaa A, GREAT (Global Research on Martin-Sanchez FJ, Morawiec B, Parenica J, Ò, López B, Martin-Sanchez FJ, Morawiec B, Acute Conditions Team) Network. East Asia Lohrmann J, Kloos W, Buser A, Geigy N, Keller Muzyk P, Keller DI, Reichlin T, Mueller C, may have a better 1-year survival following DI, Osswald S, Reichlin T, Westermann D, APACE Investigators. Direct Comparison of an acute heart failure episode compared Blankenberg S, Mueller C, APACE, BACC, and the 0/1h and 0/3h Algorithms for Early with Europe: results from an international TRAPID-AMI Investigators. Impact of age on Rule-Out of Acute Myocardial Infarction. observational cohort. EUROPEAN the performance of the ESC CIRCULATION. 137(23):2536-2538. I.F.: 18.881 JOURNAL OF HEART FAILURE. 0/1h-algorithms for early diagnosis of 20(6):1071-1075. I.F.: 10.683 myocardial infarction. EUROPEAN HEART 6. Twerenbold R, Neumann JT, Sörensen NA, JOURNAL. 39(42):3780-3794. I.F.: 23.425 Ojeda F, Karakas M, Boeddinghaus J, 11. Boeddinghaus J, Twerenbold R, Nestelberger T, Badertscher P, Rubini Nestelberger T, Badertscher P, Wildi K, 2. Twerenbold, Raphael; Badertscher, Patrick; Giménez M, Puelacher C, Wildi K, Kozhuharov Puelacher C, du Fay de Lavallaz J, Keser E, Boeddinghaus, Jasper; Nestelberger, N, Breitenbuecher D, Biskup E, du Fay de Rubini Giménez M, Wussler D, Kozhuharov N, Thomas; Wildi, Karin; Puelacher, Christian; Lavallaz J, Flores D, Wussler D, Miró Ò, Martín Rentsch K, Miró Ò, Martin-Sanchez FJ, Sabti, Zaid; Gimenez, Maria Rubini; Tschirky, Sánchez FJ, Morawiec B, Parenica J, Geigy N, Morawiec B, Stefanelli S, Geigy N, Keller DI, Sandra; de Lavallaz, Jeanne du Fay; Keller DI, Zeller T, Reichlin T, Blankenberg S, Reichlin T, Mueller C, APACE Investigators. Kozhuharov, Nikola; Sazgary, Lorraine; Westermann D, Mueller C . Prospective Clinical Validation of a Novel Mueller, Deborah; Breidthardt, Tobias; Strebel, Validation of the 0/1-h Algorithm for Early High-Sensitivity Cardiac Troponin I Assay Ivo; Widmer, Dayana Flores; Shrestha, Diagnosis of Myocardial Infarction. for Early Diagnosis of Acute Myocardial Samyut; Miro, Oscar; Javier Martin-Sanchez, JOURNAL OF THE AMERICAN COLLEGE OF Infarction. CLINICAL CHEMISTRY. F.; Morawiec, Beata; Parenica, Jiri; Geigy, CARDIOLOGY. 72(6):620-632. I.F.: 16.834 64(9):1347-1360. I.F.: 8.636 Nicolas; Keller, Dagmar I.; Rentsch, Katharina; von Eckardstein, Arnold; Osswald, Stefan; 7. Vergara A, Cilloniz C, Luque N, Garcia-Vidal 12. Badertscher P, Boeddinghaus J, Reichlin, Tobias; Mueller, Christian. 0/1-Hour C, Tejero J, Perelló R, Lucena CM, Torres A, Nestelberger T, Twerenbold R, Wildi K, Sabti Z, Triage Algorithm for Myocardial Infarction Marcos MA. Detection of human Puelacher C, Rubini Giménez M, Pfäffli J, in Patients With Renal Dysfunction. cytomegalovirus in bronchoalveolar Flores D, du Fay de Lavallaz J, Miró Ò, CIRCULATION. 137(5):436-451. I.F.: 18.881 lavage of intensive care unit patients. Martin-Sanchez FJ, Morawiec B, Lohrmann J,

83 AREA 1 BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

Buser A, Keller DI, Geigy N, Reichlin T, Mueller Harjola V., Müller C., Parissis J., Peacock W., Meissner K, Kulangara C, Hartmann B, Ferel I, C. Effect of Acute Coronary Syndrome Llorens P., Fuentes M., Gil C., Pérez-Durá M., Sabti Z, Greenslade J, Hawkins T, Rentsch K, Probability on Diagnostic and Prognostic Salvo E., Xipell C., Sánchez C., Gaytan J., Noval von Eckardstein A, Buser A, Kloos W, Performance of High-Sensitivity Cardiac A., Torres J., López-Grima M., Valero A., Lohrmann J, Osswald S BASEL IX Troponin. CLINICAL CHEMISTRY. Aguirre A., Pedragosa M., Torres-Gárate R., Investigators. Prospective validation of 64(3):515-525. I.F.: 8.636 Alonso M., Ruiz F., Franco J., Sánchez S., Rizzi prognostic and diagnostic syncope scores M., Herrera S., Richard F., Lucas F., Cabello I., in the emergency department. 13. Miro, Oscar; Estruch, Ramon; Roset Á., Miró Ò., Gil V., Martín-Sánchez F., INTERNATIONAL JOURNAL OF Martin-Sanchez, Francisco J.; Gil, Victor; Jacob J., Herrero P., Alquézar A., Llauger L., CARDIOLOGY. 269:114-121. I.F.: 4.034 Jacob, Javier; Herrero-Puente, Pablo; Herrera Aguiló S., Martínez G., Ríos J., Mateo, Sergio; Aguirre, Alfons; Andueza, Juan Domínguez-Rodríguez A., Harjola V., Müller C., 20. Monclús Cols E, Ugarte Ramos A, Gabara A.; Llorens, Pere; ICA-SEMES Res Grp. Parissis J., Peacock W., Llorens P., Fuentes M., Xanco C, Ladino Vasquez A, Padrosa Pulido J, Adherence to Mediterranean Diet and Gil C., Pérez-Durá M., Salvo E., Xipell C., Ortega Romero M. Comparison of the Quick All-Cause Mortality After an Episode of Sánchez C., Gaytan J., Noval A., Torres J., Sepsis-related Organ Dysfunction score Acute Heart Failure. JACC: HEART López-Grima M., Valero A., Aguirre A., and severity levels assigned with the FAILURE. 6(1):52-62. I.F.: 8.202 Pedragosa M., Torres-Gárate R., Alonso M., Andorran Triage Model in an urban tertiary Ruiz F., Franco J. Short-term outcomes of care hospital emergency department. 14. Miró Ò., Hazlitt M., Escalada X., Llorens P., heart failure patients with reduced and EMERGENCIAS. 30(6):400-404. I.F.: 3.608 Gil V., Martín-Sánchez F., Harjola P., Rico V., preserved ejection fraction after acute Herrero-Puente P., Jacob J., Cone D., Möckel decompensation according to the ﬁnal 21. Miró Ò., Yates C., Dines A., Wood D., M., Christ M., Freund Y., di Somma S., Laribi S., destination after emergency department Dargan P., Galán I., Jerez A., Puiguriguer J., Mebazaa A., Harjola V., Fuentes M., Gil C., care. CLINICAL RESEARCH IN Waring W., Moughty A., O’connor N., Alonso H., Garmila P., Adrada E., Escoda R., CARDIOLOGY. 107(8):698-710. I.F.: 4.455 Heyerdahl F., Hovda K., Vallersnes O., Paasma Xipell C., Sánchez C., Gaytan J., Salvo E., R., Põld K., Jürgens G., Megarbane B., Anand J., Pérez-Durá M., Noval A., Torres J., 17. Llorens P, Javaloyes P, Martín-Sánchez FJ, Liakoni E., Liechti M., Eyer F., Zacharov S., Juan-Gómez M., López-Grima M., Valero A., Jacob J, Herrero-Puente P, Gil V, Garrido JM, Caganova B., Giraudon I., Galicia M. Aguirre A., Pedragosa M., Alonso M., Ruiz F., Salvo E, Fuentes M, Alonso H, Richard F, Emergencies related to recreational drug Franco J., Diaz E., Miró Ò., Hazlitt M., Escalada Lucas FJ, Bueno H, Parissis J, Müller CE, Miró abuse in Spain compared to emergencies X., Llorens P., Gil V., Martín-Sánchez F., Harjola Ò, ICA-SEMES Research Group. Time attended in 3 European areas. P., Rico V., Herrero-Puente P., Jacob J., Cone trends in characteristics, clinical course, EMERGENCIAS. 30(6):384-394. I.F.: 3.608 D., Möckel M., Christ M., Freund Y., di Somma and outcomes of 13,791 patients with acute S., Laribi S., Mebazaa A., Harjola V., Fuentes M., heart failure. CLINICAL RESEARCH IN 22. Perelló R., Aused M., Saubí N., Quirós C., Gil C., Alonso H., Garmila P., Adrada E., Escoda CARDIOLOGY. 107(10):897-913. I.F.: 4.455 Blanco J., Martínez-Rebollar M., Galicia M., R., Xipell C., Sánchez C., Gaytan J., Salvo E., Salgado E., Nogué S. Acute street drug Pérez-Durá M., Noval A., Torres J., 18. Wildi K, Singeisen H, Twerenbold R, poisoning in the patient with human Juan-Gómez M., López-Grima M. Effects of Badertscher P, Wussler D, Klinkenberg LJJ, immunodeﬁciency virus infection: The role the intensity of prehospital treatment on Meex SJR, Nestelberger T, Boeddinghaus J, of chemsex. EMERGENCIAS. short-term outcomes in patients with Miró Ò, Martin-Sanchez FJ, Morawiec B, 30(6):405-407. I.F.: 3.608 acute heart failure: the SEMICA-2 study. Muzyk P, Parenica J, Keller DI, Geigy N, CLINICAL RESEARCH IN CARDIOLOGY. Potlukova E, Sabti Z, Kozhuharov N, Puelacher 23. Díaz N., Sánchez M., Miró Ò. Analysis of 107(4):347-361. I.F.: 4.455 C, du Fay de Lavallaz J, Rubini Gimenez M, 15 years of emergency service interaction Shrestha S, Marzano G, Rentsch K, Osswald with schools. EMERGENCIAS. 15. Legrand M., Ludes P., Massy Z., Rossignol S, Reichlin T, Mueller C, APACE Investigators. 30(6):424-432. I.F.: 3.608 P., Parenica J., Park J., Ishihara S., AlHabib K., Circadian rhythm of cardiac troponin I and Maggioni A., Miró Ò., Sato N., Cohen-Solal A., its clinical impact on the diagnostic 24. Jacob J., Gené E., Alonso G., Rimbau P., Fairman E., Lassus J., Harjola V., Mueller C., accuracy for acute myocardial infarction. Zorrilla J., Casarramona F., Netto C., Sánchez Peacock F., Choi D., Plaisance P., Spinar J., INTERNATIONAL JOURNAL OF P., Hernández R., Escalada X., Miró Ò. Kosiborod M., Mebazaa A., Gayat E. GREAT CARDIOLOGY. 270:14-20. I.F.: 4.034 SUHCAT study, Part 5: Comparison of staff (Global Research on Acute Conditions Team) and chiefs’ perceptions of emergency Network and INI-CRCT (Investigation 19. Du Fay de Lavallaz J, Badertscher P, department quality in catalonia. Network Initiative-Cardiovascular and Renal Nestelberger T, Isenrich R, Miró Ò, Salgado E, EMERGENCIAS. 30(1):45-49. I.F.: 3.608 Clinical Trialists) network. Association Geigy N, Christ M, Cullen L, Than M, between hypo- and hyperkalemia and Martin-Sanchez FJ, Bustamante Mandrión J, 25. Gómez-Angelats E, Miró Ò, Bragulat Baur outcome in acute heart failure patients: the Di Somma S, Peacock WF, Kawecki D, E, Antolín Santaliestra A, Sánchez Sánchez M . role of medications. CLINICAL RESEARCH Boeddinghaus J, Twerenbold R, Puelacher C, Triage level assignment and nurse IN CARDIOLOGY. 107(3):214-221. I.F.: 4.455 Wussler D, Strebel I, Keller DI, Poepping I, characteristics and experience. Kühne M, Mueller C, Reichlin T,, Giménez MR, EMERGENCIAS. 30(3):163-168. I.F.: 3.608 16. Miró Ò., Gil V., Martín-Sánchez F., Jacob J., Walter J, Kozhuharov N, Shrestha S, Mueller D, Herrero P., Alquézar A., Llauger L., Aguiló S., Sazgary L, Morawiec B, Muzyk P, 26. Martín-Sánchez FJ, Rodríguez-Adrada E, Martínez G., Ríos J., Domínguez-Rodríguez A., Nowalany-Kozielska E, Freese M, Stelzig C, Vidán MT, Díez Villanueva P, Llopis García G,

84 EMERGENCIES: PROCESSES AND PATHOLOGIES 1.7

González Del Castillo J, Alberto Rizzi M, Martín-Sánchez FJ, Jacob J, Ríos J, Romero R, 37. Cupa J, Strebel I, Badertscher P, Abächerli Alquézar A, Herrera Mateo S, Piñera P, Gil V, Gayat É, Llorens P, Mebazaa A . The R, Twerenbold R, Schumacher L, Sánchez Nicolás JA, Lázaro Aragues P, subset of patients with acute heart failure Boeddinghaus J, Nestelberger T, Maechler P, Llorens P, Herrero P, Jacob J, Gil V, Fernández able to secrete relaxin-2 at pregnancy Kozhuharov N, Giménez MR, Wildi K, du Fay C, Bueno H, Miró Ò . Impact of geriatric concentrations could have a longer de Lavallaz J, Sabti Z, Sazgary L, Puelacher C, assessment variables on 30-day mortality survival: a pilot study. BIOMARKERS. Mueller D, Bianci C, Miró Ò, Fuenzalida C, among older patients with acute heart 23(6):573-579. I.F.: 1.976 Calderón S, Martín-Sánchez FJ, Iglesias SL, failure. EMERGENCIAS. 30(3):149-155. Morawiec B, Kawecki D, Parenica J, Keller DI, I.F.: 3.608 33. Ruiz-Artacho P, Piñera P, Antolin A, Casal Geigy N, Osswald S, Mueller C, Reichlin T . JR, Sanchez M, Suero C, Merlo M, Carriel J, Diagnostic and prognostic value of QRS 27. Miró Ò, Nayla Brizzi B, Aguiló S, Alemany X, Genis M, Jimenez S . Therapeutic approach duration and QTc interval in patients with Jacob J, Llorens P, Herrero Puente P, for patients with venous suspected myocardial infarction. González Ramón B, Castro Jiménez V, Torres thromboembolism attended in emergency CARDIOLOGY JOURNAL. 25(5):601-610. Machado V, Cenjor R, Gil A, Rico V, Martínez departments during routine clinical I.F.: 1.339 Nadal G, Lázaro Del Nogal M, Martín-Sánchez practice: the EDITH study. JOURNAL OF FJ . Profile of older patients attended in the COMPARATIVE EFFECTIVENESS 38. Martín-Sánchez F., Brizzi B., González del emergency department after falls: a RESEARCH. 7(4):319-330. I.F.: 1.906 Castillo J., Cantó Blázquez V., González FALL-ER registry study of the magnitude Jiménez C., Aguilo Mir S., Torres Machado V., of the problem and opportunities for 34. Martín-Sánchez F., Llopis García G., Gil A., Cenjor R., Miró O., Jacob Rodríguez J., improving hospital emergency care. González-Colaço Harmand M., Fernandez Llorens P., Herrero Puente P., Fernández EMERGENCIAS. 30(4):231-240. I.F.: 3.608 Pérez C., González del Castillo J., Llorens P., Pérez C., Lázaro del Nogal M. Characteristics Herrero P., Jacob J., Gil V., Domínguez- and outcomes of older adults presented to 28. Fernández-Guerrero IM, Rodriguez A., Rossello X., Miró O., Adrada E., Spanish emergency departments after a Hidalgo-Rodríguez A, de Las Mercedes Santos M., Salgado L., Brizzi B., Docavo M., fall. EUROPEAN GERIATRIC MEDICINE. Leal-Lobato M, Rivilla-Doce C, Cadenas M., Xipell C., Sánchez C., Aguiló S., 9(5):631-640. I.F.: 1.169 Martín-Sánchez FJ, Miró Ò . Presentations at Gaytan J., Jerez A., Pérez-Durá M., Gil P., 29 conferences of the Spanish Society of López-Grima M., Valero A., Aguirre A., 39. Broto-Sumalla A, Rabanal-Tornero M, Emergency Medicine (SEMES) from 1988 Pedragosa M., Piñera P., Aragues P., Nicolás J., García-Peláez M, Aguilar-Salmerón R, to 2017: a descriptive analysis. Rizzi M., Mateo S., Alquezar A., Roset A., Ferrer Fernández de Gamarra-Martínez E, EMERGENCIAS. 30(5):303-314. I.F.: 3.608 C., Llopis F., Pérez J., Diez M., Martín-Sánchez Martínez-Sánchez L, Gaspar-Caro MJ, F., Llopis García G., González-Colaço Nogué-Xarau S. Availability of antidotes in 29. Miró Ò, Martínez G, Masip J, Gil V, Harmand M., Fernandez Pérez C., González 70 hospitals in Catalonia. MEDICINA Martín-Sánchez FJ, Llorens P, Herrero-Puente del Castillo J., Llorens P., Herrero P., Jacob J., CLINICA. 150(1):16-19. I.F.: 1.168 P, Sánchez C, Richard F, Lucas-Invernón J, Gil V., Domínguez-Rodriguez A., Rossello X., Garrido JM, Mebazaa A, Ríos J, Peacock WF, Miró O., Adrada E., Santos M. Identification of 40. Miró Ò., Gil V., Martín-Sánchez F., Herrero Hollander JE, Jacob J, ICA-SEMES Research Senior At Risk scale predicts 30-day P., Jacob J., Sánchez C., Xipell C., Aguiló S., Group Researchers. Effects on short term mortality among older patients with acute Llorens P. Short-term reconsultation, outcome of non-invasive ventilation use in heart failure. MEDICINA INTENSIVA. hospitalisation, and death rates after the emergency department to treat :30218-3. I.F.: 1.755 discharge from the emergency patients with acute heart failure: A department in patients with acute heart propensity score-based analysis of the 35. Jacob J., Zorrilla J., Gené E., Alonso G., failure and analysis of the associated EAHFE Registry. EUROPEAN JOURNAL OF Rimbau P., Casarramona F., Netto C., Sánchez factors. The ALTUR-ICA Study. MEDICINA INTERNAL MEDICINE. 53:45-51. I.F.: 3.282 P., Hernández R., Escalada X., Miró. CLINICA. 150(5):167-177. I.F.: 1.168 Non-invasive ventilation in emergency 30. Camon, S.; Quiros, C.; Saubi, N.; Moreno, departments in public hospitals in 41. Miró Ò., Javaloyes P., Gil V., Jacob J., A.; Marcos, M. A.; Eto, Y.; Rofael, S.; Monclus, E.; Catalonia. The VENUR-CAT study. Herrero-Puente P., Martín-Sánchez F., Salvo Brown, J.; McHugh, T. D.; Mallolas, J.; Perello, R. MEDICINA INTENSIVA. 42(3):141-150. I.F.: 1.755 E., Alonso H., Juan Gómez M., Parissis J., Full blood count values as a predictor of Llorens P. Mortality after an episode of poor outcome of pneumonia among 36. Gil, Victor; Miro, Oscar; Schull, Michael J.; acute heart failure in a cohort of patients HIV-infected patients. BMC INFECTIOUS Llorens, Pere; Herrero-Puente, Pablo; Jacob, with intermediate ventricular function: DISEASES. 18(1):189. I.F.: 2.620 Javier; Rios, Jose; Lee, Douglas S.; Global analysis and relationship with Martin-Sanchez, Francisco J.; ICA-SEMES admission department. MEDICINA CLINICA. 31. Sánchez M, Suárez M, Asenjo M, Bragulat Res Grp. Emergency Heart Failure 151(6):223-230. I.F.: 1.168 E. Improvement of emergency department Mortality Risk Grade score performance patient flow using lean thinking. for 7-day mortality prediction in patients INTERNATIONAL JOURNAL FOR QUALITY with heart failure attended at the Review / I.F.: 1.168 IN HEALTH CARE. 30(4):250-256. I.F.: 2.554 emergency department: validation in a Spanish cohort. EUROPEAN JOURNAL OF 1. Llauger L, Jacob J, Miró Ò . Renal function 32. Miró Ò, Herrero-Puente P, Prieto B, EMERGENCY MEDICINE. 25(3):169-177. and acute heart failure outcome. MEDICINA García-García M, García-Hernández P, I.F.: 1.729 CLINICA. 151(7):281-290. I.F.: 1.168

85 AREA 1 BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

Letters / I.F.: 71.948 failure 2016. REVISTA CLINICA ESPANOLA. M, Platz E, McMurray J, DiSomma S, Zeymer 218(3):158-159. I.F.: 1.184 U, Bueno H, Gale CP, Lettino M, Tavares M, 1. Miró Ó, Pocock SJ . Predicting 30-Day Ruschitzka F, Mebazaa A, Harjola VP, Mueller Mortality for Patients With Acute Heart 9. Miró Ò, Javaloyes P, Llorens P . C, Acute Heart Failure Study Group of the Failure in the Emergency Department. Relationship between systolic blood Acute Cardiovascular Care Association and ANNALS OF INTERNAL MEDICINE. pressure on arrival at Emergency the Committee on Acute Heart Failure of the 168(12):899-900. I.F.: 19.384 Department and mortality after an episode Heart Failure Association of the European of acute heart failure. MEDICINA CLINICA. Society of Cardiology. Indications and 2. Kaier, Thomas E.; Twerenbold, Raphael; 151(8):e43-e44. I.F.: 1.168 practical approach to non-invasive Puelacher, Christian; Marjot, Jack; ventilation in acute heart failure. Imambaccus, Nazia; Boeddinghaus, Jasper; EUROPEAN HEART JOURNAL. 39(1):17-25. Nestelberger, Thomas; Badertscher, Patrick; Editorial / I.F.: 41.465 I.F.: 23.425 Sabti, Zaid; Gimenez, Maria Rubini; Wildi, Karin; Hillinger, Petra; Grimm, Karin; Loeffel, Sarah; 1. Miró Ò, Takagi K, Crespo-Leiro MG, 2. Harjola V., Parissis J., Brunner-La Rocca H., Shrestha, Samyut; Widmer, Dayana Flores; Mebazaa A. Left ventricular assist devices: ?elutkien? J., Chioncel O., Collins S., De Backer Cupa, Janosch; Kozhuharov, Nikola; Miro, let's move toward better quality of D., Filippatos G., Gayat E., Hill L., Lainscak M., Oscar; Javier Martin-Sanchez, F.; Morawiec, extended life, away from hospital. Lassus J., Masip J., Mebazaa A., Miró Ò., Beata; Rentsch, Katharina; Lohrmann, Jens; EUROPEAN HEART JOURNAL. Mortara A., Mueller C., Mullens W., Nieminen Kloos, Wanda; Osswald, Stefan; Reichlin, 39(37):3461-3463. I.F.: 23.425 M., Rudiger A., Ruschitzka F., Seferovic P., Tobias; Weber, Ekkehard; Marber, Michael; Sionis A., Vieillard-Baron A., Weinstein J., de Mueller, Christian. Response by Kaier et al to 2. Ortega Romero M. Antibiotic use in the Boer R., Crespo-Leiro M., Piepoli M., Riley J.. Letter Regarding Article, Direct emergency department: Is there room for Comprehensive in-hospital monitoring in Comparison of Cardiac Myosin-Binding improvement? EMERGENCIAS. acute heart failure: Applications for clinical Protein C With Cardiac Troponins for the 30(5):292-294. I.F.: 3.608 practice and future directions for research. Early Diagnosis of Acute Myocardial A statement from the Acute Heart Failure Infarction. CIRCULATION. 138(5):544-545. 3. Miró Ò. Emergencias’ impact factor from Committee of the Heart Failure I.F.: 18.881 2010 to 2017: A detailed analysis of our Association (HFA) of the European Society journal’s metrics. EMERGENCIAS. of Cardiology (ESC). EUROPEAN JOURNAL 3. Miró Ò., Estruch R., Gil V., Llorens P.. Reply: 30(5):289-291. I.F.: 3.608 OF HEART FAILURE. 20(7):1081-1099. I.F.: The Mediterranean Diet to Treat Heart Failure: 10.683 A Potential Powerful Tool in the Hand of 4. Òscar Miró Andreu. Mutatis mutandis: el Providers. JACC: HEART FAILURE. cambio como motor de crecimiento de 3. Alquézar-Arbé A, Sanchís J, Guillén E, 6(3):201-208. I.F.: 8.202 emergencias. EMERGENCIAS. 30(1):1-2. Bardají A, Miró Ò, Ordóñez-Llanos J . Cardiac I.F.: 3.608 troponin measurement and interpretation 4. Miró Ò., Gil V. Response. CHEST. in the diagnosis of acute myocardial 153(3):766-766. I.F.: 7.652 5. Miro, Oscar. Change: a driver of growth infarction in the emergency department: a for emergencias. EMERGENCIAS. 30(1):1-2. consensus statement. EMERGENCIAS. 5. Vinson D., Kea B., Coll-Vinent B., Barrett T., I.F.: 3.608 30(5):336-349. I.F.: 3.608 Atzema C. Enlisting Emergency Medicine Clinicians to Help Reduce Strokes in 6. Miro O. Emergencias' impact factor from High-Risk Patients With Atrial Fibrillation 2010 to 2017: a detailed analysis of our Consortium Publications / I.F.: 5.166 and Flutter. CLIN PHARMACOL THER. journal's metrics. EMERGENCIAS. 104(4):613-614. I.F.: 6.544 30(5):289-291. I.F.: 3.608 1. SEC Working Group for the 2018 ESC Guidelines for Syncope, Expert Reviewers for 6. Domínguez-Rodríguez A, González-Colaço the 2018 ESC Guidelines for Syncope, and the Harmand M, Martín-Sánchez FJ, Baez-Ferrer Case Reports / I.F.: 1.53 SEC Guidelines Committee, SEC Working N, Gil V, Miró Ò, Abreu-González P . Utility of Group for the 2018 ESC Guidelines for the the Identiﬁcation of Seniors at Risk Score 1. Giavedoni P, Velasco V, Morgado-Carrasco Diagnosis and Management of Syncope, to Predict In-Hospital Mortality in Older D, Nogué S, Galy J. Delayed allergic Expert Reviewers for the ESC Guidelines for Patients With Heart Failure. JOURNAL OF reactions to jelly ﬁsh stings: Usefulness of the Diagnosis and Management of Syncope, THE AMERICAN MEDICAL DIRECTORS ultrasonographic evaluation. JOURNAL OF SEC Guidelines Committee. Comments on ASSOCIATION. 19(12):1137-1138. I.F.: 5.325 ULTRASOUND IN MEDICINE. the 2018 ESC Guidelines for the Diagnosis 37(11):2721-2724. I.F.: 1.530 and Management of Syncope. REVISTA 7. Martín-Sierra C, Nogué-Xarau S, Pinillos ESPAÑOLA DE CARDIOLOGIA. Echeverría MÁ, Rey Pecharromán JM. 71(10):787-793. I.F.: 5.166 Snakebite poisoning in Spain. Clinical Guidelines / I.F.: 37.716 EMERGENCIAS. 30(2):126-132. I.F.: 3.608 1. Masip J, Peacock WF, Price S, Cullen L, 8. Miro, O.; Gil, V.; Javaloyes, R.; Llorens, P. Martin-Sanchez FJ, Seferovic P, Maisel AS, About European guidelines for heart Miro O, Filippatos G, Vrints C, Christ M, Cowie

86 EMERGENCIES: PROCESSES AND PATHOLOGIES 1.7

GRANTS FOR RESEARCH IN PROGRESS

Miró O. Identificació a urgències dels pacients amb insuficiència cardiaca aguda de baix risc i desenvolupament d'una escala per identificar-los i millorar l'evolució dels que són donats d'alta des d'urgències. Sponsored by: Fundació la Marató de TV3. TV3_Cor_15 Duration: 09/03/2016-31/12/2019

Miró O. Diseño de programas de intervención y escalas de riesgo con marcadores y biológicos de fragilidad para la insuﬁciencia cardiaca aguda en los servicios de urgencia españoles. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI15/01019 Duration: 01/01/2016-31/12/2019

DOCTORAL THESES

Miró Ò, Llorens P. Identiﬁcación y prevalencia de factores precipitantes de insuﬁciencia cardíaca aguda en los servicios de urgencias españoles y su relación con el pronóstico a corto y medio plazo. PhD student: Alfons Aguirre Tejedo

87 AREA 1 BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

Molecular and cellular bases of inﬂammation. Structural and 1.8 biological mass spectrometry

STRATEGIC OBJECTIVES

LOCATION 1. Molecular and cellular bases of IIBB-CSIC labs inflammation: Study of inflammatory response in experimental models of acute pancreatitis, lung fibrosis and pancreatic cancer.

2. Structural and biological mass KEYWORDS spectrometry: 1. Inﬂammation TEAM LEADER Development of techniques for the analysis 2. Fibrosis Daniel Closa (IIBB-CSIC ) of biomolecules by mass spectrometry and 3. Proteomics T. 93 363 83 43 more especially for proteomics studies. 4. Macrophages [email protected] Application to the characterization of post-translational modiﬁcations involved in signal transduction and of therapeutic targets and markers of disease.

RESEARCHERS MALDI-imaging. Joaquín Abián (IIBB-CSIC) Original publications Montserrat Carrascal (IIBB-CSIC) from 2016 to 2018 Anna Serrano (IIBB-CSIC) MAIN LINES OF RESEARCH

YEAR I.F. TOTAL Q1 Q2 POST-DOCTORAL RESEARCHER 1. Molecular and cellular bases of 2016 28.35 6 6- Albert Casanovas (IIBB-CSIC) inflammation: 2017 18.57 4 4 - TECHNICIAN - Mechanisms involved in the development 2018 37.45 7 4 3 Laura López (IIBB-CSIC) of systemic inflammatory processes. Roberto Pinto (IIBB-CSIC) - New therapies for idiopathic pulmonary Luis Ignacio Sánchez (IIBB-CSIC) fibrosis. - Study of cell communication in pancreatic cancer. - Exosomes in inflammatory diseases.

2. Structural and biological mass spectrometry: - Phosphoproteome, acetylome, ubiquitinome and modiﬁcation crosstalking on the human t-lymphocyte. Daniel Closa TEAM

88 MOLECULAR AND CELLULAR BASES OF INFLAMMATION. STRUCTURAL AND BIOLOGICAL MASS SPECTROMETRY 1.8

- Diagnostic and prognostic markers in 6. De Madaria, Enrique; Herrera-Marante, DOCTORAL THESES cancer and other diseases. Ivan; Gonzalez-Camacho, Veronica; Bonjoch, - External scientific-technical services. Laia; Quesada-Vazquez, Noe; Abian J, Avilés FX. Development of a - MALDI-Imaging. Almenta-Saavedra, Isabel; Miralles-Macia, formulation and stable pharmaceutical Cayetano; Acevedo-Piedra, Nelly G.; form for adenoviral vectors. Roger-Ibanez, Manuela; Sanchez-Marin, PhD student: Lluna Mª López Ortiz Claudia; Osuna-Ligero, Rosa; Gracia, Angel; PUBLICATIONS Llorens, Pere; Zapater, Pedro; Singh, Vikesh K.; Closa D, Lorente J. Papel de los exosomas Moreu-Martin, Rocio; Closa, Daniel. Fluid en la comunicación entre las células Originals / I.F.: 37.449 resuscitation with lactated Ringer's tumorales y los macrófagos en el solution vs normal saline in acute carcinoma laríngeo. 1. Guillamat-Prats R, Puig F, pancreatitis: A triple-blind, randomized, PhD student: Àngela Bellmunt Fontanet Camprubí-Rimblas M, Herrero R, controlled trial. UNITED EUR GASTROENT. Serrano-Mollar A, Gómez MN, Tijero J, 6(1):63-72. I.F.: 3.477 Matthay MA, Blanch L, Artigas A . Intratracheal instillation of alveolar type II 7. Guillén-Gómez E, Bardají-de-Quixano B, cells enhances recovery from acute lung Ferrer S, Brotons C, Knepper MA, Carrascal M, injury in rats. JOURNAL OF HEART AND Abian J, Mas JM, Calero F, Ballarín JA, LUNG TRANSPLANTATION. 37(6):782-791. Fernández-Llama P . Urinary Proteome I.F.: 7.955 Analysis Identified Neprilysin and VCAM as Proteins Involved in Diabetic Nephropathy. 2. Baulies A, Montero J, Matías N, Insausti N, JOURNAL OF DIABETES RESEARCH. Terrones O, Basañez G, Vallejo C, Conde de 2018(6165303). I.F.: 2.885 La Rosa L, Martinez L, Robles D, Morales A, Abian J, Carrascal M, Machida K, Kumar DBU, Tsukamoto H, Kaplowitz N, Garcia-Ruiz C, Fernández-Checa JC . The 2-oxoglutarate GRANTS FOR RESEARCH IN PROGRESS carrier promotes liver cancer by sustaining mitochondrial GSH despite cholesterol Abián J. Plataforma de recursos loading. REDOX BIOLOGY. 14:164-177. biomoleculares PRB3 (Plataforma de I.F.: 7.126 proteómica, genotipado y líneas celulares) Sponsored by: Instituto de Salud Carlos III 3. Schmitt C, Lenglet H, Yu A, Delaby C, (ISCIII). PT17/0019/0008 Benecke A, Lefebvre T, Letteron P, Paradis V, Duration: 01/01/2018-31/12/2020 Wahlin S, Sandberg S, Harper P, Sardh E, Sandvik AK, Hov JR, Aarsand AK, Chiche L, Closa D. Importancia de los microRNAs Bazille C, Scoazec JY, To-Figueras J, transportados por exosomas en la Carrascal M, Abian J, Mirmiran A, Karim Z, progresión de la inflamación sistémica Deybach JC, Puy H, Peoc'h K, Manceau H, durante la pancreatitis aguda. Gouya L . Recurrent attacks of acute Sponsored by: Asociación Española de hepatic porphyria: major role of the chronic Gastroenterología. AEG_BecaGonMiño_17 inflammatory response in the liver. Duration 09/03/2017-09/03/2020 JOURNAL OF INTERNAL MEDICINE. 284(1):78-91. I.F.: 6.754 Closa D. Exosomas como mediadores de la progresión sistémica en la pancreatitis 4. Casanovas A, Gallardo Ó, Carrascal M, aguda; Papel fisiopatológico y potencial Abian J. TCellXTalk facilitates the como marcadores pronóstico. detection of co-modified peptides for the Sponsored by: Instituto de Salud Carlos III study of protein post-translational (ISCIII). PI16/00060 modification cross-talk in T cells. Duration: 01/01/2017-31/12/2019 BIOINFORMATICS. I.F.: 5.481

5. De Madaria, Enrique; Molero, Xavier; Bonjoch, Laia; Casas, Joseﬁna; Cardenas-Jaen, Karina; Montenegro, Andrea; Closa, Daniel. Oleic acid chlorohydrin, a new early biomarker for the prediction of acute pancreatitis severity in humans. ANNALS OF INTENSIVE CARE. 8(1):1. I.F.: 3.771

89 AREA 1 BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

Ocular inﬂammation: clinical and experimental 1.9 studies

NURSING STAFF Victoria Hernández (FCRB) LOCATION MATERNITAT building

STRATEGIC OBJECTIVES

The research of the Ocular Inﬂammation Group focuses on how the retina responds to

KEYWORDS injury, inflammation and degeneration. 1. Uveitis Our main goal is to promote the investigation TEAM LEADER on ocular inflammatory diseases with special 2. Inflammation Alfredo Adán (HCB) 3. Immunology interest in the study of pathological T. 93 227 56 67 mechanisms, immune response, and 4. Biomarkers [email protected] development of new therapies. 5. Biological therapies

RESEARCHERS MAIN LINES OF RESEARCH Víctor Llorens (HCB) Elena Millá (HCB) 1. Prognostic factors in patients with Original publications Maria Teresa Sáinz (HCB) macular edema associated with from 2016 to 2018 Javier Zarranz (HCB) non-infectious uveitis: Assessment of the clinical, biological and imaging YEAR I.F. TOTAL Q1 Q2 POST-DOCTORAL RESEARCHERS factors involved in the pathogenesis of 2016 38.31 13 66 Marc Figueras (HCB) uveitic macular edema and its response 2017 40.96 8 7 - Marina Mesquida (HCB) to treatment. Blanca Molins (FCRB) 2018 40.62 9 8 - Marta Pazos (HCB) 2. New biologic therapies for the Anna Sala (HCB) treatment of non-infectious uveitis: Assessment of the efficacy and safety of PRE-DOCTORAL RESEARCHERS new biologic therapies including Jessica Matas (HCB) anti-TNF-alpha, anti-IL-1beta, and TEAM INVOLVED IN Sara Romero (FCRB) anti-IL-6 receptor monoclonal antibodies OFTARED (RETIC) for treating patients with non-infectious TECHNICIANS uveitis. Jesus Gascon (FCRB) Anna Montasell (FCRB) Alfredo Adán TEAM

90 OCULAR INFLAMMATION: CLINICAL AND EXPERIMENTAL STUDIES 1.9

3. Genetic polymorphisms predisposing OPHTHALMOLOGY. 125(9):1444-1451. Optical Coherence Tomography. PLOS to uveitis: Multicentric study that I.F.: 7.479 ONE. 13(7):e0200819-e0200819. I.F.: 2.766 investigates genetic polymorphisms as potential risk factors for developing uveitis 3. Fernandez-Robredo, Patricia; Recalde, 9. Berasategui B, Fonollosa A, Artaraz J, and its complications. Sergio; Hernandez, Maria; Zarranz-Ventura, Ruiz-Arruza I, Ríos J, Ríos J, Matas J, Llorenç V, Javier; Molins, Blanca; Casaroli-Marano, Diaz-Valle D, Sastre-Ibañez M, Arriola- 4. Tuberculosis-related uveitis: Ricardo P.; Adan, Alfredo; Saenz-de-Viteri, Villalobos P, Adan A. Behavior of Development of epidemiological, clinical Manuel; Garcia-Layana, Alfredo. Novel hyperreﬂective foci in non-infectious and experimental studies Association of High c-Reactive Protein uveitic macular edema, a 12-month Levels and A69S at Risk Alleles in Wet follow-up prospective study. BMC 5. Macular pathology in diabetic patients: Age-Related Macular Degeneration OPHTHALMOLOGY. 18(1):179. I.F.: 1.770 Development of clinical and experimental Women. FRONTIERS IN IMMUNOLOGY. studies to investigate the pathogenesis of 9(1862):1862. I.F.: 5.511 diabetic macular edema, as well as its Review / I.F.: 12.006 response to different therapeutic 4. Kuiper, Jonas J. W.; van Setten, Jessica; approaches. Devall, Matthew; Cretu-Stancu, Mircea; 1. Molins B., Romero-Vázquez S., Hiddingh, Sanne; Ophoff, Roel A.; Missotten, Fuentes-Prior P., Adan A., Dick A. C-reactive 6. Molecular basis of age-related macular Tom O. A. R.; van Velthoven, Mirjam; Den protein as a therapeutic target in degeneration (AMD): Study of the Hollander, Anneke, I; Hoyng, Carel B.; James, age-related macular degeneration. contribution of chronic inﬂammation and in Edward; Reeves, Emma; Cordero-Coma, FRONTIERS IN IMMUNOLOGY. 9:808. particular, C-reactive protein and Miguel; Fonollosa, Alejandro; Adan, Alfredo; I.F.: 5.511 complement Factor H to the progression Martin, Javier; Koeleman, Bobby P. C.; de Boer, of AMD. Joke H.; Pulit, Sara L.; Marquez, Ana; Radstake, 2. Palmou-Fontana N, Calvo-Río V, Timothy R. D. J. Functionally distinct ERAP1 Martín-Varillas JL, Fernández-Díaz C, and ERAP2 are a hallmark of Mesquida M, Adán A, Hernández MV, HLA-A29-(Birdshot) Uveitis. HUMAN Cordero-Coma M, Maiz Alonso O, Díaz-Valle PUBLICATIONS MOLECULAR GENETICS. 27(24):4333-4343. D, Fernández-Cid C, Ruiz-Moreno O, I.F.: 4.902 Hernández JL, González-Gay MA, Blanco R. Originals / I.F.: 40.616 Golimumab in refractory uveitis 5. Mesquida M, Molins B, Llorenç V, associated to juvenile idiopathic arthritis: 1. Suhler E., Adán A., Brézin A., Fortin E., Goto Hernández MV, Espinosa G, Sainz de la Maza multicentre study of 7 cases and literature H., Jaffe G., Kaburaki T., Kramer M., Lim L., M, Adán A. Twenty-four month follow-up of review. CLINICAL AND EXPERIMENTAL Muccioli C., Nguyen Q., Van Calster J., Cimino tocilizumab therapy for refractory RHEUMATOLOGY. 36(4):652-657. I.F.: 3.201 L., Kron M., Song A., Liu J., Pathai S., Camez A., uveitis-related macular edema. RETINA. Schlaen A., van Velthoven M., Vitale A., Zierhut 38(7):1361-1370. I.F.: 4.013 3. Navarro M., Vazquez M., Zarranz-Ventura J., M., Tari S., Dick A. Safety and Efficacy of Barrio-Barrio J. OCT angiography: A Adalimumab in Patients with 6. Miserocchi E, Iuliano L, Fogliato G, Modorati technique for the assessment of retinal Noninfectious Uveitis in an Ongoing G, Couto C, Schlaen A, Hurtado E, Llorenç V, and optic nerve diseases in the pediatric Open-Label Study: VISUAL III. Adan A, Bandello F. Bilateral Acute Retinal population. APPLIED SCIENCES-BASEL. OPHTHALMOLOGY. 125(7):1075-1087. I.F.: 7.479 Necrosis: Clinical Features and Outcomes 8(12). I.F.: 1.689 in a Multicenter Study. OCULAR 2. Martín-Varillas J., Calvo-Río V., Beltrán E., IMMUNOLOGY AND INFLAMMATION. :1-9. 4. García-Layana A, Figueroa MS, Arias L, Sánchez-Bursón J., Mesquida M., Adán A., I.F.: 3.348 Adán A, Cabrera F, Abraldes M, Hernandez M., Garfella M., Pascual E., Fernández-Vega Á, Navarro R, Cervera E, Martínez-Costa L., Sellas-Fernández A., 7. Llorenç V, Benejam G, Mesquida M, Sainz Silva R, Silva R, Silva R, Armadá F, Donate J, Cordero-Coma M., Díaz-Llopis M., Gallego R., de la Maza M, Molins B, Alba C, Pelegrin L, Ruiz-Moreno JM, Ruiz-Moreno JM. Clinical Salom D., Ortego N., García-Serrano J., Martínez JA, Adán A. Antituberculous Decision-Making when Treating Diabetic Callejas-Rubio J., Herreras J., García-Aparicio Treatment Itself Might Prevent Visual Macular Edema Patients with Á., Maíz O., Blanco A., Torre I., Díaz-Valle D., Impairment in Presumed Tuberculosis- Dexamethasone Intravitreal Implants. Pato E., Aurrecoechea E., Caracuel M., Related Uveitis. OCULAR IMMUNOLOGY INTERNATIONAL JOURNAL OF Gamero F., Minguez E., Carrasco-Cubero C., AND INFLAMMATION. 5:1-8. I.F.: 3.348 OPHTHALMOLOGY. 240(2):61-72. I.F.: 1.605 Olive A., Vázquez J., Ruiz-Moreno O., Manero J., Muñoz-Fernández S., Martinez M., 8. Sala-Puigdollers A, Sala-Puigdollers A, Rubio-Romero E., Toyos-Sáenz de Miera F., Sala-Puigdollers A, Figueras-Roca M, López Longo F., Nolla J., Martín-Varillas J., Figueras-Roca M, Hereu M, Hernández T, Letters / I.F.: 1.168 Calvo-Río V., Beltrán E., Sánchez-Bursón J., Morató M, Adán A, Adán A, Zarranz-Ventura J, Mesquida M., Adán A., Hernandez M., Garfella Zarranz-Ventura J. Repeatability and 1. Mesquida M., Llorenc V., Adan A. Reply. M. Successful Optimization of reproducibility of retinal and choroidal MEDICINA CLINICA. 151(8):336-337. I.F.: 1.168 Adalimumab Therapy in Refractory Uveitis thickness measurements in Diabetic Due to Behçet's Disease. Macular Edema using Swept-source

91 AREA 1 BIOLOGICAL AGGRESSION AND RESPONSE MECHANISMS

Editorial / I.F.: 5.511 Adán A. Diseño y validación de un índice de actividad objetivo compuesto para la 1. Slevin M., Molins B. Editorial: C-reactive uveítis basado en la tomografía de protein in age-related disorders. coherencia óptica Swept-Source. FRONTIERS IN IMMUNOLOGY. 9(NOV):2745. Sponsored by: Instituto de Salud Carlos III I.F.: 5.511 (ISCIII). PI17/00316 Duration: 01/01/2018-31/12/2020

Case Reports / I.F.: 3.348 Adán A. Prevención, detección precoz y tratamiento de la patología ocular 1.-Llorenç V., Mesquida M., Molins B., prevalente degenerativa y crónica. González-Martín J., Sainz de la Maza M., Adán Sponsored by: Instituto de Salud Carlos III A. Bacillus Calmette–Guérin Infection and (ISCIII). RD16/0008/0013 Cytotoxicity in the Retinal Pigment Duration: 01/01/2017-31/12/2021 Epithelium. OCULAR IMMUNOLOGY AND INFLAMMATION. 26(5):786-792. I.F.: 3.348 Zarranz J. Evaluation of microvascular changes in the perifoveal vascular network using Optical Coherence Tomography Consortium Publications / I.F.: 22.437 Angiography (OCT-A) in type I Diabetes Mellitus. 1. Bonini S, Lambiase A, Rama P, Sinigaglia F, Sponsored by: Fundació la Marató de TV3. Allegretti M, Chao W, Mantelli F; REPARO TV3_Diabet_16 Study Group. Phase II Randomized, Duration: 24/02/2017-23/02/2020 Double-Masked, Vehicle-Controlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis. OPHTHALMOLOGY. 125(9):1332-1343. DOCTORAL THESES I.F.: 7.479 Adán A. Caracterització dels Factors 2. Bonini S, Lambiase A, Rama P, Filatori I, Clínics i Biològics associats a l'Edema Allegretti M, Chao W, Mantelli F; REPARO Macular Diabètic en la Diabetis Mellitus Study Group. Phase I Trial of Recombinant Tipus II. Human Nerve Growth Factor for PhD student: Marc Figueras Roca Neurotrophic Keratitis. OPHTHALMOLOGY. 125(9):1468-1471. Adán A, Zarranz J. Estudio de repetibilidad y I.F.: 7.479 reproductuvidad del grosor retiniano y coroideo mediante tomografía de 3. Dick AD, Rosenbaum JT, Al-Dhibi HA, coherencia óptica de dominio swept Belfort R Jr, Brézin AP, Chee SP, Davis JL, source y comparación con dominio Ramanan AV, Sonoda KH, Carreño E, espectral en el Edema Macular Diabético. Nascimento H, Salah S, Salek S, Siak J, PhD student: Anna Sala Puigdollers Steeples L; Fundamentals of Care for Uveitis International Consensus Group. Guidance on Adán A, Villoslada P. Biomarcadores de Noncorticosteroid Systemic calidad visual percibida en pacientes con Immunomodulatory Therapy in neuritis óptica aguda y esclerosis multiple. Noninfectious Uveitis: Fundamentals Of PhD student: Bernardo Francisco Sánchez Care for UveitiS (FOCUS) Initiative. Dalmau OPHTHALMOLOGY. 125(5):757-773. I.F.: 7.479

GRANTS FOR RESEARCH IN PROGRESS

Adán A. Grup de recerca de malalties inﬂamatòries oculars. Sponsored by: Gerenalitat de Catalunya. AGAUR_SGR17_701 Duration: 01/01/2017-31/12/2020

92 OCULAR INFLAMMATION: CLINICAL AND EXPERIMENTAL STUDIES 1.9

93 ANNUAL SCIENTIFIC REPORT 2018

AREA 2 2

RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

2.1 Atherosclerosis, coronary disease and heart failure 96 Manel Sabaté

2.2 Arrhythmias, resynchronization and cardiac imaging 104 Josep Brugada

2.3 Nephro-urological diseases and kidney transplantation 114 Fritz Diekmann

2.4 Cardiovascular, nutrition and aging unit 118 Ramon Estruch

2.5 Respiratory biophysics and bioengineering 124 Ramon Farré

2.6 Applied research in infectious respiratory diseases, critically 127 ill patients and lung cancer Antoni Torres

2.7 Physiopathological mechanisms of respiratory illnesses 133 Joan Albert Barberà

2.8 Clinical and experimental respiratory immunoallergy 138 Joaquim Mullol

2.9 Inﬂammation and repair in respiratory illnesses 145 Alvar Agustí

2.10 Genetic and urological tumors 148 Antonio Alcaraz

95 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

Atherosclerosis, coronary 2.1 disease and heart failure

Marco Hernández (FCRB) Gustavo Jiménez (FCRB) LOCATION Luis Gabriel Ortega (HCB) CELLEX building, ﬂoor 2A Pedro Ramón Pérez (FCRB) Margarida Pujol (HCB)

ADMINISTRATIVE STAFF Eva Maria Trelliso (FCRB)

KEYWORDS NURSING STAFF 1. Acute myocardial infarction TEAM LEADER Anna Barrabés (FCRB) 2. Percutaneous coronary Manel Sabaté (HCB) Elisabet Codina (FCRB) intervention. Stent. Biodegrada T. 93 227 55 19 Elisabet de Mingo (FCRB) ble device [email protected] 3. Therapeutic hypothermia COLLABORATORS 4. Stem cell therapy Marta Farrero (HCB) 5. Heart failure Susanna Prat (HCB) RESEARCHERS Ander Regueiro (HCB) 6. Structural heart disease Xavier Bosch (HCB) Salvatore Brugaletta (HCB) Carles Falces (HCB) Ana García (HCB) STRATEGIC OBJECTIVES Victoria Martín (HCB) Mònica Masotti (HCB) - To identify the pathophysiological Original publications Joan Carles Paré (HCB) mechanisms of accelerated from 2016 to 2018 Felix Pérez (HCB) atherosclerosis.

YEAR I.F. TOTAL Q1 Q2 Josep Lluis Pomar (HCB) Montserrat Rigol (FCRB) - To evaluate the safety and efficacy of 2016 336.25 43 27 13 Mercè Roqué (HCB) regenerative cell therapy. 2017 277.20 39 26 11 Ana Paula Villela (IDIBAPS) - To increase the understanding of genetics, 2018 577.02 68 43 21 POST-DOCTORAL RESEARCHERS pathophysiology, diagnosis and treatment Laura Novensa (IDIBAPS) of heart failure and ischaemic heart disease. PRE-DOCTORAL RESEARCHERS - To evaluate the clinical implications of TEAM INVOLVED IN Ioannis Andreou (FCRB) AGAUR_SGR17 Joaquim Bobi (FCRB) diagnostic imaging techniques and types Eduardo Josue Flores (HCB) of treatment in structural heart disease and Manuel Garabito (IDIBAPS) heart failure. John García (FCRB) Manel Sabaté TEAM

96 ATHEROSCLEROSIS, CORONARY DISEASE AND HEART FAILURE 2.1

MAIN LINES OF RESEARCH Ferrante G., Santarelli A., Sardella G., de Akkerhuis KM, Karagiannis A, Windecker S, Cesare N., Tosi P., van ‘t Hof A., Omerovic E., Valgimigli M, HI-TECH investigators. - To study the regulatory mechanisms Brugaletta S., Windecker S., Heg D., Jüni P., Adenosine and Ticagrelor Plasma Levels in and efficacy of stem cell therapy in Campo G., Uguccioni L., Tamburino C., Patients With and Without experimental models and in clinical Presbitero P., Zavalloni-Parenti D., Ferrari F., Ticagrelor-Related Dyspnea. contexts. Valgimigli M., Frigoli E., Leonardi S., Vranckx P., CIRCULATION. 138(6):646-648. I.F.: 18.881 Rothenbühler M., Tebaldi M., Varbella F., - To perform experimental models of Calabrò P., Garducci S., Rubartelli P., Briguori 6. Zegri-Reiriz I, de Alarcón A, Muñoz P, neointimal hyperplasia, endothelialization, C., Andó G., Ferrario M., Limbruno U., Garbo R., Martínez Sellés M, González-Ramallo V, Miro vascular inflammation and thrombosis. Sganzerla P., Russo F., Nazzaro M., Lupi A., JM, Falces C, Gonzalez Rico C, Kortajarena Cortese B. Radial versus femoral access Urkola X, Lepe JA, Rodriguez Alvarez R, - To evaluate the influence of hormonal and bivalirudin versus unfractionated Reguera Iglesias JM, Navas E, Dominguez F, factors, gender and aging in ischemic heart heparin in invasively managed patients Garcia-Pavia P, Spanish Collaboration on disease. with acute coronary syndrome (MATRIX): Endocarditis—Grupo de Apoyo al Manejo de final 1-year results of a multicentre, la Endocarditis infecciosa en España - To design experimental and clinical studies randomised controlled trial. LANCET. (GAMES). Infective Endocarditis in to evaluate the performance of novel 392(10150):835-848. I.F.: 53.254 Patients With Bicuspid Aortic Valve or devices and strategies to treat coronary Mitral Valve Prolapse. JOURNAL OF THE artery disease, including chronic and acute 2. Varenne, Olivier; Cook, Stephane; Sideris, AMERICAN COLLEGE OF CARDIOLOGY. coronary syndromes, cardiogenic shock Georgios; Kedev, Sasko; Cuisset, Thomas; 71(24):2731-2740. I.F.: 16.834 and cardiac arrest. Carrie, Didier; Hovasse, Thomas; Garot, Philippe; El Mahmoud, Rami; Spaulding, 7. Ariotti S., van Leeuwen M., Brugaletta S., - To evaluate neurohormonal activation, Christian; Helft, Gerard; Diaz Fernandez, Jose Leonardi S., Akkerhuis K., Rimoldi S., Janssens fibrotic process, genetic and environmental F.; Brugaletta, Salvatore; Pinar-Bermudez, G., Ortega-Paz L., Gianni U., van den Berge J., factors associated with ventricular Eduardo; Mauri Ferre, Josepa; Commeau, Karagiannis A., Windecker S., Valgimigli M. remodeling in dilated cardiomyopathy. Philippe; Teiger, Emmanuel; Bogaerts, Kris; Effects of Ticagrelor, Prasugrel, or Sabate, Manel; Morice, Marie-Claude; Clopidogrel at Steady State on Endothelial - To determine the safety, efficacy and Sinnaeve, Peter R. Drug-eluting stents in Function. JOURNAL OF THE AMERICAN efficiency of new transcatheter and elderly patients with coronary artery COLLEGE OF CARDIOLOGY. minimally invasive devices to treat disease (SENIOR): a randomised 71(11):1289-1291. I.F.: 16.834 structural and congenital heart disease single-blind trial. LANCET. 391(10115):41-50. and the role of imaging techniques. I.F.: 53.254 8. Gargiulo G, Carrara G, Frigoli E, Vranckx P, Leonardi S, Ciociano N, Campo G, Varbella F, - To evaluate new pharmacological and 3. Lansky A, Wijns W, Xu B, Kelbæk H, van Calabrò P, Garducci S, Iannone A, Briguori C, invasive treatments for pulmonary Royen N, Zheng M, Morel MA, Knaapen P, Andò G, Crimi G, Limbruno U, Garbo R, hypertension. Slagboom T, Johnson TW, Vlachojannis G, Sganzerla P, Russo F, Lupi A, Cortese B, Arkenbout KE, Holmvang L, Janssens L, Ausiello A, Ierna S, Esposito G, Zavalloni D, Ochala A, Brugaletta S, Naber CK, Anderson Santarelli A, Sardella G, Tresoldi S, de Cesare R, Rittger H, Berti S, Barbato E, Toth GG, N, Sciahbasi A, Zingarelli A, Tosi P, van 't Hof A, PUBLICATIONS Maillard L, Valina C, Buszman P, Thiele H, Omerovic E, Brugaletta S, Windecker S, Schächinger V, Baumbach A, TARGET All Valgimigli M. Bivalirudin or Heparin in Originals / I.F.: 577.021 Comers Investigators. Targeted therapy Patients Undergoing Invasive with a localised abluminal groove, Management of Acute Coronary 1. Valgimigli M., Frigoli E., Leonardi S., Vranckx low-dose sirolimus-eluting, biodegradable Syndromes. JOURNAL OF THE AMERICAN P., Rothenbühler M., Tebaldi M., Varbella F., polymer coronary stent (TARGET All COLLEGE OF CARDIOLOGY. Calabrò P., Garducci S., Rubartelli P., Briguori Comers): a multicentre, open-label, 71(11):1231-1242. I.F.: 16.834 C., Andó G., Ferrario M., Limbruno U., Garbo R., randomised non-inferiority trial. LANCET. Sganzerla P., Russo F., Nazzaro M., Lupi A., 392(10153):1117-1126. I.F.: 53.254 9. Collet, Carlos; Miyazaki, Yosuke; Ryan, Cortese B., Ausiello A., Ierna S., Esposito G., Nicola; Asano, Taku; Tenekecioglu, Erhan; Ferrante G., Santarelli A., Sardella G., de 4. Asano T, Serruys PW, Collet C, Miyazaki Y, Sonck, Jeroen; Andreini, Daniele; Sabate, Cesare N., Tosi P., van ‘t Hof A., Omerovic E., Takahashi K, Chichareon P, Katagiri Y, Modolo Manel; Brugaletta, Salvatore; Stables, Rodney Brugaletta S., Windecker S., Heg D., Jüni P., R, Tenekecioglu E, Morel MA, Garg S, H.; Bartorelli, Antonio; de Winter, Robbert J.; Campo G., Uguccioni L., Tamburino C., Wykrzykowska J, Piek JJ, Sabate M, Morice Katagiri, Yuki; Chichareon, Ply; De Maria, Presbitero P., Zavalloni-Parenti D., Ferrari F., MC, Chevalier B, Windecker S, Onuma Y. Giovanni Luigi; Suwannasom, Pannipa; Valgimigli M., Frigoli E., Leonardi S., Vranckx P., Angiographic late lumen loss revisited: Cavalcante, Rafael; Jonker, Hans; Morel, Rothenbühler M., Tebaldi M., Varbella F., impact on long-term target lesion Marie-angele; Cosyns, Bernard; Kappetein, Calabrò P., Garducci S., Rubartelli P., Briguori revascularization. EUROPEAN HEART Arie P.; Taggart, David T.; Farooq, Vasim; C., Andó G., Ferrario M., Limbruno U., Garbo R., JOURNAL. 39(36):3381-3389. I.F.: 23.425 Escaned, Javier; Banning, Adrian; Onuma, Sganzerla P., Russo F., Nazzaro M., Lupi A., Yoshinobu; Serruys, Patrick W. Fractional Cortese B., Ausiello A., Ierna S., Esposito G., 5. Ortega-Paz L, Brugaletta S, Ariotti S, Flow Reserve Derived From Computed

97 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

Tomographic Angiography in Patients Berge J., Karagiannis A., Windecker S., Cook CM, Dehbi HM, Alegria-Barrero E, With Multivessel CAD. JOURNAL OF THE Valgimigli M., Frigoli E., Monti M., Ciociano N., Alghamdi A, Al-Lamee R, Altman J, Ambrosia AMERICAN COLLEGE OF CARDIOLOGY. Heg D., Van Royen N., Rizzotti D., Mandurino A, Baptista SB, Bertilsson M, Bhindi R, 71(24):2756-2769. I.F.: 16.834 Mirizzi A., Räber L., Rexhaj E., Sabaté M. Birgander M, Bojara W, Brugaletta S, Buller C, Effects of Ticagrelor, Prasugrel, or Calais F, Silva PC, Carlsson J, Christiansen EH, 10. Acosta J, Fernández-Armenta J, Borràs R, Clopidogrel on Endothelial Function and Danielewicz M, Di Mario C, Doh JH, Erglis A, Anguera I, Bisbal F, Martí-Almor J, Tolosana Other Vascular Biomarkers: A Erlinge D, Gerber RT, Going O, JM, Penela D, Andreu D, Soto-Iglesias D, Randomized Crossover Study. JACC: Gudmundsdottir I, Härle T, Hauer D, Hellig F, Evertz R, Matiello M, Alonso C, Villuendas R, de CARDIOVASCULAR INTERVENTIONS. Indolﬁ C, Jakobsen L, Janssens L, Jensen J, Caralt TM, Perea RJ, Ortiz JT, Bosch X, Serra 11(16):1576-1586. I.F.: 9.881 Jeremias A, Kåregren A, Karlsson AC, L, Planes X, Greiser A, Ekinci O, Lasalvia L, Kharbanda RK, Khashaba A, Kikuta Y, Mont L, Berruezo A. Scar Characterization 15. Alfonso, Fernando; Jose Perez-Vizcayno, Krackhardt F, Koo BK, Koul S, Laine M, to Predict Life-Threatening Arrhythmic Maria; Cuesta, Javier; Garcia del Blanco, Lehman SJ, Lindroos P, Malik IS, Maeng M, Events and Sudden Cardiac Death in Bruno; Garcia-Touchard, Arturo; Ramon Matsuo H, Meuwissen M, Nam CW, Niccoli G, Patients With Cardiac Resynchronization Lopez-Minguez, Jose; Masotti, Monica; Zueco, Nijjer SS, Olsson H, Olsson SE, Omerovic E, Therapy: The GAUDI-CRT Study. JACC: Javier; Cequier, Angel; Velazquez, Maite; Panayi G, Petraco R, Piek JJ, Ribichini F, CARDIOVASCULAR IMAGING. 11(4):561-572. Moreno, Raul; Mainar, Vicente; Dominguez, Samady H, Samuels B, Sandhall L, Sapontis J, I.F.: 10.247 Antonio; Moris, Cesar; Molina, Eduardo; Sen S, Seto AH, Sezer M, Sharp ASP, Shin ES, Rivero, Fernando; Jimenez-Quevedo, Pilar; Singh J, Takashima H, Talwar S, Tanaka N, 11. Katagiri Y, Serruys PW, Macaya C, Gonzalo, Nieves; Fernandez-Perez, Tang K, Van Belle E, van Royen N, Varenhorst Ormiston JA, Hill J, Lang IM, Egred M, Fajadet Cristina;RIBS IV Study Investigators; Spanish C, Vinhas H, Vrints CJ, Walters D, Yokoi H, J, Lesiak M, Wykrzykowska JJ, Piek JJ, Soc Cardiology. 3-Year Clinical Follow-Up Fröbert O, Patel MR, Serruys P, Davies JE, Sabaté M, Windecker S, Chevalier B, Onuma of the RIBS IV Clinical Trial A Prospective Götberg M. Safety of the Deferral of Y. The Long-Term Impact of Randomized Study of Drug-Eluting Coronary Revascularization on the Basis Post-Procedural Asymmetry and Balloons Versus Everolimus-Eluting of Instantaneous Wave-Free Ratio and Eccentricity of Bioresorbable Stents in Patients With In-Stent Restenosis Fractional Flow Reserve Measurements in Everolimus-Eluting Scaffold and Metallic in Coronary Arteries Previously Treated Stable Coronary Artery Disease and Acute Everolimus-Eluting Stent on Clinical With Drug-Eluting Stents. JACC: Coronary Syndromes. JACC: Outcomes in the ABSORB II Trial. CARDIOVASCULAR INTERVENTIONS. CARDIOVASCULAR INTERVENTIONS. JACC-CARDIOVASCULAR 11(10):981-991. I.F.: 9.881 11(15):1437-1449. I.F.: 9.881 INTERVENTIONS. 11(10):1013-1015. I.F.: 9.881 16. Ellis, Stephen G.; Gori, Tommaso; Serruys, 19. Nombela-Franco L, Rodés-Cabau J, 12. Lefèvre T., Haude M., Neumann F., Stangl Patrick W.; Nef, Holger; Steffenino, Giuseppe; Cruz-Gonzalez I, Freixa X, Asmarats L, K., Skurk C., Slagboom T., Sabaté M., Goicolea Brugaletta, Salvatore; Munzel, Thomas; Feliz, Gutiérrez H, Sahay S, Rodriguez-Gabella T, J., Barragan P., Cook S., Macia J., Windecker S. Cordula; Schmidt, Goetz; Sabate, Manel; Moreno-Samos JC, Tirado-Conte G, Comparison of a Novel Biodegradable Onuma, Yoshinobu; van Geuns, R. J.; Gao, Goncalves-Ramirez LR, Rama-Merchan JC, Polymer Sirolimus-Eluting Stent With a Run-Lin; Menichelli, Maurizio; Kereiakes, Dean Amat-Santos IJ, O'Hara G, Martín-Yuste V, Durable Polymer Everolimus-Eluting J.; Stone, Gregg W.; Testa, Luca; Kimura, Bethencourt A, Jimenez-Quevedo P, Macaya Stent: 5-Year Outcomes of the Takeshi; Abizaid, Alexandre. Clinical, C. Incidence, Predictors, and Prognostic Randomized BIOFLOW-II Trial. JACC: Angiographic, and Procedural Correlates Value of Acute Kidney Injury Among CARDIOVASCULAR INTERVENTIONS. of Very Late Absorb Scaffold Thrombosis Patients Undergoing Left Atrial 11(10):995-1002. I.F.: 9.881 Multistudy Registry Results. JACC: Appendage Closure. JACC: CARDIOVASCULAR INTERVENTIONS. CARDIOVASCULAR INTERVENTIONS. 13. Gomez-Lara J., Brugaletta S., Ortega-Paz 11(7):638-644. I.F.: 9.881 11(11):1074-1083. I.F.: 9.881 L., Vandeloo B., Moscarella E., Salas M., Romaguera R., Roura G., Ferreiro J., Teruel L., 17. Serruys, Patrick W.; Cavalcante, Rafael; 20. Ambrosioni J, Urra X, Hernández- Gracida M., Windecker S., Serruys P., Collet, Carlos; Kappetein, Arie Pieter; Sabik, Meneses M, Almela M, Falces C, Tellez A, Gomez-Hospital J., Sabaté M., Cequier A. Joseph F., III; Banning, Adrian P.; Taggart, Quintana E, Fuster D, Sandoval E, Vidal B, Long-Term Coronary Functional David P.; Sabate, Manel; Pomar, Jose; Tolosana JM, Moreno A, Chamorro A, Miró Assessment of the Infarct-Related Artery Boonstra, Piet W.; Lembo, Nicholas J.; Onuma, JM, Hospital Clínic Infective Endocarditis Treated With Everolimus-Eluting Yoshinobu; Simonton, Charles A.; Morice, Study Group . Mechanical thrombectomy Bioresorbable Scaffolds or Marie-Claude; McAndrew, Thomas; Dressler, for acute ischemic stroke secondary to Everolimus-Eluting Metallic Stents: Ovidiu; Stone, Gregg W. Outcomes After infective endocarditis. CLINICAL Insights of the TROFI II Trial. JACC: Coronary Stenting or Bypass Surgery for INFECTIOUS DISEASES. 66(8):1286-1289. CARDIOVASCULAR INTERVENTIONS. Men and Women With Unprotected Left I.F.: 9.117 11(16):1559-1571. I.F.: 9.881 Main Disease The EXCEL Trial. JACC: CARDIOVASCULAR INTERVENTIONS. 21. Téllez A, Ambrosioni J, Llopis J, Pericàs JM, 14. Ariotti S., Ortega-Paz L., van Leeuwen M., 11(13):1234-1243. I.F.: 9.881 Falces C, Almela M, Garcia de la Mària C, Brugaletta S., Leonardi S., Akkerhuis K., Hernandez-Meneses M, Vidal B, Sandoval E, Rimoldi S., Janssens G., Gianni U., Van den 18. Escaned J, Ryan N, Mejía-Rentería H, Quintana E, Fuster D, Tolosana JM, Marco F,

98 ATHEROSCLEROSIS, CORONARY DISEASE AND HEART FAILURE 2.1

Moreno A, Miro JM, Hospital Clínic Infective 27. Cruz-González I, Freixa X, Fernández-Díaz 33. Hernández-Enríquez M; Freixa X; Endocarditis Investigators . Epidemiology, JA, Moreno-Samos JC, Martín-Yuste V, Quintana E; Pereda D; Sandoval E; Sabate M. clinical features and outcome of infective Goicolea J. Left Atrial Appendage Paravalvular Leak Correction: Searching endocarditis due to Abiotrophia spp. and Occlusion With the LAmbre Device: Initial for a Balance Between Surgical and Granulicatella spp.: Report of 76 cases Experience. REVISTA ESPAÑOLA DE Percutaneous Techniques. REVISTA (2000-2015). CLINICAL INFECTIOUS CARDIOLOGIA. 71(9):755-756. I.F.: 5.166 ESPAÑOLA DE CARDIOLOGIA. DISEASES. 66(1):104-111. I.F.: 9.117 71(8):679-681. I.F.: 5.166 28. Vilardell P., Brugada J., Aboal J., 22. Almendro-Delia M, Núñez-Gil IJ, Lobo M, Loma-Osorio P., Falces C., Andrea R., 34. Cubero-Gallego H., Romaguera R., Andrés M, Vedia O, Sionis A, Martin-García A, Figueras-Coll M., Brugada R. Gómez-Lara J., Gómez-Hospital J., Sabaté M., Cruz Aguilera M, Pereyra E, Martín de Miguel I, Characterization of Electrocardiographic Pinar E., Gracida M., Roura G., Ferreiro J., Linares Vicente JA, Corbí-Pascual M, Bosch X, Findings in Young Students. REVISTA Teruel L., Tebé-Codorni C., Jiménez-Quevedo Fabregat Andrés O, Sánchez Grande Flecha ESPAÑOLA DE CARDIOLOGIA. . I.F.: 5.166 P., Montanya E., Alfonso F., Cequier Á. In Vivo A, Pérez-Castellanos A, Pais JL, De Mora Evaluation of the Synergic Effect of Martín M, Escudier Villa JM, Martín Asenjo R, 29. Sanchis J., García-Blas S., Ortega-Paz L., Metformin and mTOR Inhibitors on the Guillen Marzo M, Rueda Sobella F, Aceña Á, Dantas A., Rodríguez E., Abellán L., Brugaletta Endothelial Healing of Drug-eluting Stents García Acuña JM, García-Rubira JC, RETAKO S., Valero E., Miñana G., Garabito M., Corchón in Diabetic Patients. REVISTA ESPAÑOLA Investigators. Short- and Long-Term Á., Núñez J., Carratalá A., Sabaté M. Cell-free DE CARDIOLOGIA. 71(11):917-925. I.F.: 5.166 Prognostic Relevance of Cardiogenic DNA and Microvascular Damage in Shock in Takotsubo Syndrome: Results ST-segment Elevation Myocardial 35. Barge-Caballero E., González-Vílchez F., From the RETAKO Registry. JACC. HEART Infarction Treated With Primary Delgado J., Mirabet-Pérez S., González- FAILURE. 6(11):928-936. I.F.: 8.202 Percutaneous Coronary Intervention. Costello J., Pérez-Villa F., Martínez-Sellés M., REVISTA ESPAÑOLA DE CARDIOLOGIA. Segovia-Cubero J., Hervás-Sotomayor D., 23. Sanchis L., Andrea R., Falces C., Poyatos 72(4):317-323. I.F.: 5.166 Blasco-Peiró T., De la Fuente-Galán L., S., Vidal B., Sitges M. Differential Clinical Lambert-Rodríguez J., Rangel-Sousa D., Implications of Current Recommendations 30. González-Vílchez F., Almenar-Bonet L., Almenar-Bonet L., Garrido-Bravo I., for the Evaluation of Left Ventricular Crespo-Leiro M., Alonso-Pulpón L., Rábago-Juan-Aracil G., Muñiz J., Crespo-Leiro Diastolic Function by Echocardiography. González-Costelo J., Sobrino-Márquez J., M. Use of Intra-aortic Balloon Pump as a JOURNAL OF THE AMERICAN SOCIETY OF Arizón del Prado J., Sousa-Casasnovas I., Bridge to Heart Transplant in Spain: ECHOCARDIOGRAPHY. 31(11):1203-1208. Delgado-Jiménez J., Pérez-Villa F. On behalf Results From the ASIS-TC Study. REVISTA I.F.: 6.827 of the Spanish Heart Transplant Teams. ESPAÑOLA DE CARDIOLOGIA. . I.F.: 5.166 Spanish Heart Transplant Registry. 29th 24. Spitaleri G, Tebaldi M, Biscaglia S, Westra Official Report of the Spanish Society of 36. Soto-Iglesias D, Acosta J, Penela D, J, Brugaletta S, Erriquez A, Passarini G, Brieda Cardiology Working Group on Heart Fernández-Armenta J, Cabrera M, Martínez A, Leone AM, Picchi A, Ielasi A, Girolamo DD, Failure. REVISTA ESPAÑOLA DE M, Vassanelli F, Alcaine A, Linhart M, Jáuregui Trani C, Ferrari R, Reiber JHC, Valgimigli M, CARDIOLOGIA. 71(11):952-960. I.F.: 5.166 B, Efimova E, Perea RJ, Prat-González S, Sabatè M, Campo G. Quantitative Flow Ortiz-Pérez JT, Bosch X, Mont L, Camara O, Ratio Identifies Nonculprit Coronary 31. de la Torre Hernández J., Rumoroso J., Berruezo A. Image-Based Criteria to Lesions Requiring Revascularization in Ojeda S., Brugaletta S., Cascón J., Ruisánchez Identify the Presence of Epicardial Patients With ST-Segment-Elevation C., Sánchez Gila J., Roa J., Tizón H., Gutiérrez arrhythmogenic Substrate in Patients with Myocardial Infarction and Multivessel H., Larman M., García Camarero T., Pinar E., Transmural Myocardial Infarction. HEART Disease. CIRCULATION: Díaz J., Pan M., Morillas Bueno M., Oyonarte J., RHYTHM. 15(6):814-821. I.F.: 4.743 CARDIOVASCULAR INTERVENTIONS. Ruiz Guerrero L., Ble M., Rubio Patón R., Arnold 11(2):e006023. I.F.: 6.504 R., Echegaray K., de la Morena G., Sabate M. 37. Asano T., Katagiri Y., Collet C., Angina and Ischemia at 2 Years With Tenekecioglu E., Miyazaki Y., Sotomi Y., 25. Vidal-Gómez X, Pérez-Cremades D, Bioresorbable Vascular Scaffolds and Amoroso G., Aminian A., Brugaletta S., Vrolix Mompeón A, Dantas AP, Novella S, Metallic Drug-eluting Stents. ESTROFA M., Hernandez-Antolín R., Van De Harst P., Hermenegildo C. MicroRNA as Crucial Ischemia BVS-mDES Study. REVISTA Iñiguez A., Janssens L., Smits P., Wykrzkowska Regulators of Gene Expression in ESPAÑOLA DE CARDIOLOGIA. J., Ribeiro V., Pereira H., Da Silva P., Piek J., Estradiol-Treated Human Endothelial 71(5):327-334. I.F.: 5.166 Reiber J., Von Birgelen C., Sabate M., Onuma Cells. CELLULAR PHYSIOLOGY AND Y., Serruys P. Functional comparison BIOCHEMISTRY. 45(5):1878-1892. I.F.: 5.500 32. Regueiro A, Fernández-Rodríguez D, between the BuMA Supreme Freixa X, Bosch X, Martín-Yuste V, Brugaletta biodegradable polymer sirolimus-eluting 26. Jiménez Brítez G, Sabaté M, Robles C, S, Roqué M, Sabaté M, Masotti M. False stent and a durable polymer García-Granja PE, Amat-Santos IJ, Brugaletta Positive STEMI Activations in a Regional zotarolimus-eluting coronary stent using S. Functional and Morphological Network: Comprehensive Analysis and quantitative flow ratio: PIONEER QFR Assessment of Left Anterior Descending Clinical Impact. Results From the substudy. EUROINTERVENTION. Artery in Patients With Tako-tsubo Catalonian Codi Infart Network. REVISTA 14(5):e570-e579. I.F.: 4.417 Syndrome. REVISTA ESPAÑOLA DE ESPAÑOLA DE CARDIOLOGIA. 7(4):243-249. CARDIOLOGIA. 71(11):986-988. I.F.: 5.166 I.F.: 5.166 38. Von Birgelen C., Asano T., Amoroso G.,

99 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

Aminian A., Brugaletta S., Vrolix M., in patients with ST-segment elevation Experimental Endocarditis (EE). Hernandez-Antolín R., Van De Harst P., Iñiguez myocardial infarction: insights from ANTIMICROBIAL AGENTS AND A., Janssens L., Smits P., Wykrzykowska J., five-year follow-up of the EXAMINATION CHEMOTHERAPY. 62(6):1-8. I.F.: 4.256 Ribeiro V., Pereira H., Da Silva P., Piek J., trial. EUROINTERVENTION. 13(16):1939-1945. Onuma Y., Serruys P., Sabaté M. First-in-man I.F.: 4.417 47. Serafín V., Torrente-Rodríguez R., randomised comparison of the BuMA González-Cortés A., García de Frutos P., Supreme biodegradable polymer 43. Kochman, Janusz; Koltowski, Lukasz; Sabaté M., Campuzano S., Yáñez-Sedeño P., sirolimus-eluting stent versus a durable Tomaniak, Mariusz; Jakala, Jacek; Pingarrón J. An electrochemical polymer zotarolimus-eluting coronary Proniewska, Klaudia; Legutko, Jacek; Roleder, immunosensor for brain natriuretic stent: the PIONEER trial. Tomasz; Pietrasik, Arkadiusz; Rdzanek, Adam; peptide prepared with screen-printed EUROINTERVENTION. 13(17):2026-2035. Kochman, Waclaw; Brugaletta, Salvatore; carbon electrodes nanostructured with I.F.: 4.417 Opolski, Grzegorz; Regar, Evelyn. First serial gold nanoparticles grafted through aryl optical coherence tomography diazonium salt chemistry. TALANTA. 39. Abizaid A, Kedev S, Kedhi E, Talwar S, assessment at baseline, 12 and 24 months 179:131-138. I.F.: 4.244 Erglis A, Hlinomaz O, Masotti M, in STEMI patients treated with the Fath-Ordoubadi F, Lemos P, Milewski K, second-generation Absorb bioresorbable 48. Brugaletta S, Gomez-Lara J, Caballero J, Botelho R, Costa R, Bangalore S. vascular scaffold.EUROINTERVENTION. Ortega-Paz L, Teruel L, Fernandez MJ, Randomised comparison of a 13(18):E2201-E2209. I.F.: 4.417 Romaguera R, Martinez VA, Ñato M, Navarro biodegradable polymer ultra-thin EM, Gomez-Hospital JA, Vilches CC, Joyera sirolimus-eluting stent versus a durable 44. Katagiri, Yuki; Onuma, Yoshinobu; Asano, M, Cequier A, Angiolillo DJ, Sabate M. polymer everolimus-eluting stent in Taku; Iniguez, Andres; Jensen, Lisette Okkels; Ticagrelor versus clopidogrel for recovery patients with de novo native coronary Cequier, Angel; Hofma, Sjoerd H.; of vascular function immediately after artery lesions: The meriT-V trial. Christiansen, Evald H.; Suttorp, Maarten; successful chronic coronary total EUROINTERVENTION. 14(11):e1207-e1214. Brugaletta, Salvatore; Raeber, Lorenz; Sabate, occlusion recanalization: A randomized I.F.: 4.417 Manel; Windecker, Stephan; Serruys, Patrick clinical trial. AMERICAN HEART JOURNAL. W. Three-year follow-up of the randomised 204:205-209. I.F.: 4.171 40. Sotomi Y., Onuma Y., Liu S., Asano T., comparison between an everolimus- Eggermont J., Katagiri Y., Cavalcante R., De eluting bioresorbable scaffold and a 49. Fernández-Barat L, Ben-Aicha S, Motos Winter R., Wykrzykowska J., Brugaletta S., durable polymer everolimus-eluting A, Vila J, Marco F, Rigol M, Muñoz L, Li Bassi G, Räber L., Sabaté M., Windecker S., Dijkstra J., metallic stent in patients with ST-segment Ferrer M, Torres A. Assessment of in vivo Serruys P. Quality difference of neointima elevation myocardial infarction (TROFI II versus in vitro biofilm formation of clinical following the implantation of everolimus- trial). EUROINTERVENTION. 14(11):1224-1226. methicillin-resistant Staphylococcus eluting bioresorbable scaffolds and I.F.: 4.417 aureus isolates from endotracheal tubes. metallic stents in patients with SCIENTIFIC REPORTS. 8(1):11906. I.F.: 4.122 ST-elevation myocardial infarction: 45. de la Torre Hernandez, Jose M.; Gonzalo, Quantitative assessments by light Nieves; Otaegui, Imanol; Rumoroso, Jose R.; 50. Regueiro A, Falces C, Pericás JM, Muñoz intensity, light attenuation, and Gutierrez, Hipolito; Alfonso, Fernando; Marti, P, Martínez-Sellés M, Valerio M, Sousa backscatter on optical coherence Gerard; Serrador Frutos, Ana; Brugaletta, Regueiro D, Castelo L, de Alarcón A, Cobo tomography in the TROFI II trial. Salvatore; Gomez Menchero, Antonio; Garcia Belaustegui M, Goenaga MA, Hidalgo-Tenorio EUROINTERVENTION. 14(6):678-685. Camarero, Tamara; Biagioni, Corina; Escaned, C, Martínez-Marcos FJ, Gainzarain Arana JC, I.F.: 4.417 Javier. Device specificity of vascular Miro JM, y los investigadores del Grupo de healing following implantation of Apoyo al Manejo de la Endocarditis Infecciosa 41. Paoletti G, Gomez-Lara J, Brugaletta S, bioresorbable vascular scaffolds and en España (GAMES). Risk factors of Ñato M, Romaguera R, Roura G, Ferreiro JL, bioabsorbable polymer metallic pericardial effusion in native valve Teruel L, Gracida M, Ortega-Paz L, drug-eluting stents in human coronary infective endocarditis and its influence on Gomez-Hospital JA, Sabaté M, Cequier À . arteries: the ESTROFA OCT BVS vs. outcome: A multicenter prospective Association between coronary BP-DES study. EUROINTERVENTION. cohort study. INTERNATIONAL JOURNAL atherosclerosis progression and in-stent 14(12):E1295-E1303. I.F.: 4.417 OF CARDIOLOGY. 273:193-198. I.F.: 4.034 neoatherosclerosis in patients with ST-elevation myocardial infarction at 46. García-de-la-Mària C, Gasch O, 51. Costa T., Ceravolo G., Echem C., 5-years follow-up. EUROINTERVENTION. García-Gonzalez J, Soy D, Shaw E, Hashimoto C., Costa B., Santos-Eichler R., 14(2):206-214. I.F.: 4.417 Ambrosioni J, Almela M, Pericàs JM, Tellez A, Oliveira M., Jiménez-Altayó F., Akamine E., Falces C, Hernandez-Meneses M, Sandoval E, Dantas A., Carvalho M. Detrimental effects 42. Spitaleri G, Moscarella E, Brugaletta S, Quintana E, Vidal B, Tolosana JM, Fuster D, of testosterone addition to estrogen Pernigotti A, Ortega-Paz L, Gomez-Lara J, Llopis J, Pujol M, Moreno A, Marco F, Miró JM . therapy involve cytochrome Cequier A, Iñiguez A, Serra A, Jiménez- The Combination of Daptomycin plus P-450-induced 20-HETE synthesis in aorta Quevedo P, Mainar V, Campo G, Tespili M, den Fosfomycin has Synergistic, Potent and of ovariectomized spontaneously Heijer P, Bethencourt A, Vazquez N, Valgimigli Rapid Bactericidal Activity against hypertensive rat (SHR), a model of M, Serruys PW, Sabaté M. Correlates of Methicillin-ResistantStaphylococcus postmenopausal hypertension. FRONTIERS non-target vessel-related adverse events aureus(MRSA) in a Rabbit Model of IN PHYSIOLOGY. 9:490. I.F.: 3.394

100 ATHEROSCLEROSIS, CORONARY DISEASE AND HEART FAILURE 2.1

52. Bosch X., Sanclemente-Ansó C., Escoda Campo G, Tespili M, den Heijer P, Bethencourt with diabetes mellitus treated with Absorb O., Monclús E., Franco-Vanegas J., Moreno P., A, Vazquez N, Valgimigli M, Serruys PW, bioresorbable vascular scaffolds: a Guerra-García M., Guasch N., López-Soto A. Ademi Z, Schwenkglenks M, Sabaté M . subanalysis of the European Multicentre Time to diagnosis and associated costs of Cost-effectiveness of everolimus-eluting GHOST-EU Registry. CATHETERIZATION an outpatient vs inpatient setting in the versus bare-metal stents in ST-segment AND CARDIOVASCULAR INTERVENTIONS. diagnosis of lymphoma: A retrospective elevation myocardial infarction: An 91(3):444-453. I.F.: 2.602 study of a large cohort of major lymphoma analysis from the EXAMINATION subtypes in Spain. BMC CANCER. 18(1):276. randomized controlled trial. PLOS ONE. 62. Baquet M, Nef H, Gori T, Latib A, I.F.: 3.288 13(8):e0201985. I.F.: 2.766 Capodanno D, Di Mario C, Sabate M, Colombo A, Tamburino C, Mehilli J. Restenosis 53. Andrea R., López-Giraldo A., Falces C., 58. Hernández-Enríquez M, Regueiro A, patterns after bioresorbable vascular López T., Sanchis L., Gistau C., Sabaté M., Romaguera R, Andrea R, Gómez-Hospital JA, scaffold implantation: Angiographic Sitges M., Brugada J., Agustí À. Pulmonary Pujol-López M, Ferreiro-Gutiérrez JL, substudy of the GHOST-EU registry. function predicts mortality and Brugaletta S, Roura G, Freixa X, Gómez-Lara CATHETERIZATION AND hospitalizations in outpatients with heart J, Martín-Yuste V, Gracida M, Cequier Á, CARDIOVASCULAR INTERVENTIONS. failure and preserved ejection fraction. Sabaté M. Thrombocytopenia after 92(2):276-282. I.F.: 2.602 RESPIRATORY MEDICINE. 134:124-129. transcatheter aortic valve implantation. I.F.: 3.230 A comparison between balloon- 63. Ribera A., Slof J., Ferreira-González I., expandable and self-expanding valves. Serra V., García-del Blanco B., Cascant P., 54. Ambrosioni J, Martinez-Garcia C, Llopis J, CATHETERIZATION AND Andrea R., Falces C., Gutiérrez E., del Garcia-de-la-Maria C, Hernández-Meneses CARDIOVASCULAR INTERVENTIONS. Valle-Fernández R., Morís-de laTassa C., Mota M, Tellez A, Falces C, Almela M, Vidal B, 93(7):1344-1351. I.F.: 2.602 P., Oteo J., Tornos P., García-Dorado D. The Sandoval E, Fuster D, Quintana E, Tolosana impact of waiting for intervention on costs JM, Marco F, Moreno A, Miró JM, Hospital 59. Brugaletta S, Gomez-Lara J, Caballero J, and effectiveness: the case of Clinic Infective Endocarditis Investigators. Ortega-Paz L, Teruel L, Jimenez Fernandez M, transcatheter aortic valve replacement. HACEKinfective endocarditis: Romaguera R, Alcalde Martinez V, Ñato M, EUROPEAN JOURNAL OF HEALTH epidemiology, clinical features outcome: Molina Navarro E, Gomez-Hospital JA, Correa ECONOMICS. 19(7):945-956. I.F.: 2.601 A case-control study. INTERNATIONAL Vilches C, Joyera M, Cequier A, Sabate M . JOURNAL OF INFECTIOUS DISEASES. TIcaGrEloR and Absorb bioresorbable 64. Amat-Santos, Ignacio J.; Catala, Pablo; 76:120-125. I.F.: 3.202 vascular scaffold implantation for Diez del Hoyo, Felipe; Fernandez-Diaz, Jose recovery of vascular function after A.; Alonso-Briales, Juan H.; Del Trigo, Maria; 55. Spitaleri G., Brugaletta S., Scalone G., successful chronic total occlusion Regueiro, Ander; Juan-Salvadores, Pablo; Moscarella E., Ortega-Paz L., Pernigotti A., recanalization (TIGER-BVS trial): Rationale Serra, Vicenc; Gutierrez-Ibanes, Enrique; Gomez-Lara J., Cequier A., Iñiguez A., Serra A., and study design. CATHETERIZATION AND Munoz-Garcia, Antonio J.; Nombela-Franco, Jiménez-Quevedo P., Mainar V., Campo G., CARDIOVASCULAR INTERVENTIONS. Luis; Sabate, Manel; Jimenez-Diaz, Victor A.; Tespili M., den Heijer P., Bethencourt A., 91(1):1-6. I.F.: 2.602 Garcia del Blanco, Bruno; Lopez, Javier; Vazquez N., Valgimigli M., Serruys P., Sabaté Varela-Falcon, Luis H.; Sevilla, Teresa; Arnold, M. Role of ST-Segment Resolution in 60. Puri R, Otaegui I, Sabaté M, Roman; Revilla, Ana; Alberto San Roman, J. Patients With ST-Segment Elevation Serra-Peñaranda A, Puigfel M, Perez de Prado Impact of renin-angiotensin system Myocardial Infarction Treated With A, Nombela-Franco L, de la Torre Hernandez inhibitors on clinical outcomes and Primary Percutaneous Coronary JM, Ortas Nadal R, Iniguez-Romo A, Jiménez ventricular remodelling after transcatheter Intervention (from the 5-Year Outcomes of G, Fernandez-Vazquez F, Cuellas-Ramon C, aortic valve implantation: rationale and the EXAMINATION [Evaluation of the Gonzalo N, Alfonso Jiménez Diaz V, design of the RASTAVI randomised Xience-V Stent in Acute Myocardial Duocastella L, Molina M, Amoros M, Perez I, multicentre study. BMJ OPEN. Infarction] Trial). AMERICAN JOURNAL OF Barria Perez A, Pelletier Beaumont E, Nicholls 8(2):e020255. I.F.: 2.413 CARDIOLOGY. 121(9):1039-1045. I.F.: 3.171 SJ, Garcia Del Blanco B, Rodés-Cabau J. Three- and 6-month optical coherence 65. Brito-Zerón P., Acar-Denizli N., 56. Pericàs JM, Cervera C, Moreno A, tomographic surveillance following Sisó-Almirall A., Bosch X., Hernández F., Garcia-de-la-Mària C, Almela M, Falces C, percutaneous coronary intervention with Vilanova S., Villalta M., Kostov B., Paradela M., Quintana E, Vidal B, Llopis J, Fuster D, Mestres the Angiolite® drug-eluting stent: The Sanchez M., Ramírez J., Muxí A., Berruezo A., CA, Marco F, Miró JM, Hospital Clinic ANCHOR study. CATHETERIZATION AND Galceran-Chaves C., Xaubet A., Agustí C., Endocarditis Study Group. Outcome of CARDIOVASCULAR INTERVENTIONS. Sellarés J., Ramos-Casals M. The Burden of Enterococcus faecalis infective 91(3):435-443. I.F.: 2.602 Comorbidity and Complexity in endocarditis according to the length of Sarcoidosis: Impact of Associated Chronic antibiotic therapy: Preliminary data from a 61. Capranzano P, Capodanno D, Brugaletta Diseases. LUNG. 196(2):239-248. I.F.: 2.101 cohort of 78 patients. PLOS ONE. S, Latib A, Mehilli J, Nef H, Gori T, Lesiak M, 13(2):e0192387. I.F.: 2.766 Geraci S, Pyxaras S, Mattesini A, Münzel T, 66. Santiago-Vacas E., Farrero M., Araszkiewicz A, Caramanno G, Naber C, Di Ivey-Miranda J., Castel M., García-Álvarez A., 57. Schur N, Brugaletta S, Cequier A, Iñiguez Mario C, Sabatè M, Colombo A, Wiebe J, Rios J., Perez-Villa F. Initial experience with A, Serra A, Jiménez-Quevedo P, Mainar V, Tamburino C . Clinical outcomes of patients bosentan for the management of

101 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

pulmonary hypertension after heart System: First Implant in Spain. REVISTA tomography. JOURNAL OF NUCLEAR transplantation. CLINICAL ESPAÑOLA DE CARDIOLOGIA. CARDIOLOGY. 25(5):1514-1518. I.F.: 4.011 TRANSPLANTATION. 32(9):e13364. I.F.: 1.518 71(11):976-977. I.F.: 5.166

67. Ivey-Miranda J, Flores-Umanzor E, Consortium Publications / I.F.: 14.905 Farrero-Torres M, Santiago E, Cepas-Guillen Editorial / I.F.: 47.668 P, Perez-Villa F. Predictors of renal 1. Rivoisy C, Vena A, Schaeffer L, Charlier C, replacement therapy after heart 1. Sabaté M., Brugaletta S. Thrombectomy Fontanet A, Delahaye F, Bouza E, Lortholary transplantation and its impact on and Stroke: Guilty or Innocent Bystander? O, Munoz P, Lefort A, French Mycoses Study long-term survival. CLINICAL JOURNAL OF THE AMERICAN COLLEGE OF Group and Grupo de Apoyo al Manejo de las TRANSPLANTATION. 32(10):e13401. I.F.: 1.518 CARDIOLOGY. 72(14):1597-1599. I.F.: 16.834 Endocarditis en España (GAMES) . Prosthetic Valve Candida spp. 68. Tomaniak M., Kochman J., Ko?towski ?., 2. García-Alvarez A. Myocardial Delayed Endocarditis: New Insights Into Long-term Pietrasik A., Rdzanek A., Jaka?a J., Enhancement in Chagas Heart Disease: Prognosis-The ESCAPE Study. CLINICAL Proniewska K., Malinowski K., Ochijewicz D., Ready for the Clinical Arena? JOURNAL OF INFECTIOUS DISEASES. 66(6):825-832. Filipiak K., Brugaletta S., Opolski G. A serial THE AMERICAN COLLEGE OF I.F.: 9.117 three- and nine-year optical coherence CARDIOLOGY. 72(21):2588-2590. I.F.: 16.834 tomography evaluation of 2. Bowles H, Ambrosioni J, Mestres G, neoatherosclerosis progression after 3. Costa F, Brugaletta S. Antithrombotic Hernández-Meneses M, Sánchez N, Llopis J, sirolimus- and paclitaxel- -eluting stent Therapy in Acute Coronary Syndrome: Yugueros X, Almela M, Moreno A, Riambau V, implantation. KARDIOLOGIA POLSKA. Striking a Happy Medium. REVISTA Fuster D, Miró JM, Hospital Clinic Endocarditis 76(8):1251-1256. I.F.: 1.213 ESPAÑOLA DE CARDIOLOGIA. Study Group. Diagnostic yield of 18F-FDG 71(10):782-786. I.F.: 5.166 PET/CT in suspected diagnosis of vascular graft infection: A prospective Review / I.F.: 12.094 4. Chevalier B., Cequier A., Dudek D., Haude cohort study. JOURNAL OF NUCLEAR M., Carrie D., Sabaté M., Windecker S., Reith S., CARDIOLOGY. :1-9. I.F.: 4.011 1. Ortega-Paz L, Brugaletta S, Sabaté M. De Sousa Almeida M., Campo G., Iñiguez A., Impact of PSP Technique on Clinical Onuma Y., Serruys P. Four-year follow-up of 3. Ramos-Martínez A, Muñoz Serrano A, de Outcomes Following Bioresorbable the randomised comparison between an Alarcón González A, Muñoz P, Scaffolds Implantation. J CLIN MED. 7(2). everolimus-eluting bioresorbable scaffold Fernández-Cruz A, Valerio M, Fariñas MC, I.F.: 5.583 and an everolimus-eluting metallic stent Gutiérrez-Cuadra M, Miró JM, Ruiz-Morales J, for the treatment of coronary artery Sousa-Regueiro D, Montejo JM, 2. Sabate M. The future of vascular stenosis (ABSORB II Trial). Gálvez-Acebal J, HidalgoTenorio C, restoration therapy. EUROINTERVENTION. EUROINTERVENTION. 13(13):1561-1564. Domínguez F, Spanish Collaboration on 14(9):e976-e979. I.F.: 4.417 I.F.: 4.417 Endocarditis – Grupo de Apoyo al Manejo de la Endocarditis Infecciosa en España 3. Moscarella E., Brugaletta S., Sabaté M. 5. Brugaletta S. Moving fast towards the (GAMES). Gentamicin may have no effect Latest STEMI treatment: a focus on future: the role of #SoMe in learning on mortality of staphylococcal prosthetic current and upcoming devices. EXPERT cardiology. EUROINTERVENTION. valve endocarditis. JOURNAL OF REVIEW OF MEDICAL DEVICES. 13(16):1874-1875. I.F.: 4.417 INFECTION AND CHEMOTHERAPY. 15(11):807-817. I.F.: 2.094 24(7):555-562. I.F.: 1.777

Case Reports / I.F.: 8.428 Letters / I.F.: 10.56 1. Fallesen, Christian Oliver; Antonsen, Lisbeth; GRANTS FOR RESEARCH IN PROGRESS 1. Pericàs JM, Moreno A, Almela M, Thayssen, Per; Jensen, Lisette Okkels; Lee, Pil García-de-la-Mària C, Marco F, Muñoz P, Hyung; Lee, Seung-Whan; Park, Seung-Jung; Bosch X. Papel del sistema GAS-6-TAM en Peña C, de Alarcón A, Del Río A, Eworo A, Moscarella, Elisabetta; Spitaleri, Giosafat; la diferenciación ﬁbroblástica y el Cruceta A, Paré JC, Mestres CA, Miró JM, Brugaletta, Salvatore. How should I treat a remodelado ventricular tras el infarto FOSIMI Investigators. Efficacy and Safety of bioresorbable vascular scaffold edge agudo de miocardio. Fosfomycin Plus Imipenem vs. Vancomycin restenosis and intra-scaffold dissection? Sponsored by: Instituto de Salud Carlos III for Complicated Bacteremia and EUROINTERVENTION. 13(14):1730-1732. (ISCIII). PI15/00531 Endocarditis Due to Methicillin-Resistant I.F.: 4.417 Duration: 01/01/2016-31/12/2019 Staphylococcus aureus: A Randomized Clinical Trial. CLINICAL MICROBIOLOGY 2. Pujol-López M, Flores-Umanzor E, San Dantas AP. Potential prognostic and AND INFECTION. 24(6):673-676. I.F.: 5.394 Antonio R, Lomeña F, Quintana E, Bosch X, therapeutic role of exosomal miRNAs Vidal B. What is This Image? 2018: Image 2 derived from circulating cells (Endothelial 2. Freixa X, Hernández-Enríquez M, Sanchís L, Result: Early infective endocarditis with Progenitor, Platelets and Neutrophils) in Regueiro A, Sabaté M, Sitges M. Tricuspid aorto-left atrial ﬁstula: Unmasking the acute coronary syndrome. Percutaneous Repair With the MitraClip underlying disease with positron emission Sponsored by: Instituto de Salud Carlos III.

102 ATHEROSCLEROSIS, CORONARY DISEASE AND HEART FAILURE 2.1

PI16/00742 Roqué M. Effects of combined treatment of Duration: 01/01/2017-31/12/2019 apixaban at different concentrations with current antiplatelet therapies on fibrin and Dantas AP. Targeting endothelial platelet components of hemostasis. An dysfunction in highly prevalent diseases: ex-vivo exploratory study in patients characterization and validation of exposed to various antiplatelet agents. prognostic biomarkers and identification Sponsored by: Bristol-Myers-Squibb of potential therapeutic strategies. (ERISTA). CV 185-700 Sponsored by: Instituto de Salud Carlos III Duration: 09/07/2018-31/12/2020 (ISCIII). PIE15/00027. Duration: 01/01/2016-31/12/2019 Roqué M. Acute myocardical infarction in young patients. Analysis of prothrombotic, García A. Tractament agonista adrenèrgic inflammatory and epigenetic factors. en la hipertensió pulmonar crònica Effect of miRNA expressión modulation in secundària a insuficiència cardíaca: assaig a porcine model. clínic fase 2 aleatoritzat i controlat amb Sponsored by: Instituto de Salud Carlos III. placebo. PI15/00553 Sponsored by: Fundació la Marató de TV3. Duration: 01/01/2016-31/12/2018 TV3_Cor_15 Duration: 21/07/2016-20/07/2019 Roqué M. Inhibición de la hiperplasia de la íntima con PAP-1, un inhibidor selectivo de García A. Estudio de los mecanismos los canales de potasio. Desarollo de un fisiopatológicos que conducen a la stent farmacoactivo liberador de PAP-1 y hipertrofia maladaptativa del ventrículo aplicación en un modelo experimental de derecho en la hipertensión pulmonar restenosis. crónica. Sponsored by: Fundación Casa del Corazon. Sponsored by: Instituto de Salud Carlos III SEC_InvTraslaciona15 (2) (ISCIII). PI17/00995 Duration: 24/10/2015- Duration: 01/01/2018-31/12/2020 Sabaté M. Aterosclerosi, malaltia coronària Pomar JL. Aortic Valve Replacement using i insuficiència cardíaca. Individualised Regenerative Allografts: Sponsored by: Generalitat de Catalunya. Bridging the Therapeutic Gap. AGAUR_SGR17_ 01525 Sponsored by: European Comission. Duration: 01/01/2017-31/12/2020 CE_H2020-PHC-2014-1s (643597) Duration: 01/01/2015-31/03/2019 Sabaté M. Desarrollo de biosensores sobre tecnología flexible y rígida para la Rigol M. Terapia con células madre detección de marcadores cardíacos. mesenquimales derivadas del tejido Sponsored by: Ministerio de Economía y adiposo alogénicas en un modelo porcino Competitividad (MINECO). RTC-2015-4184-1 de infarto de miocardio:mecanismos Duration: 01/07/2015-30/06/2018 paracrinos, respuesta inmunológica y efectos funcionales a corto y largo plazo. Sabaté M. EURO SHOCK. Assessment of Sponsored by: Fundación Española del up-front use of Mechanical Support Device Corazón. SEC_InvBasica17 in Cardiogenic Shock: The EURO. Duration: 26/10/2017- Sponsored by: European Comission. CE_H2020-SC1_17_2s (754946-1) Rigol M. Estrategias para optimizar el Duration: 01/01/2018-31/12/2022 potencial terapéutico de las células progenitoras endoteliales: terapia combinada y rejuvenecimiento. Sponsored by: Fundación Casa del Corazon. SEC_InvBasica17 (1) Duration: 26/10/2017

103 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

Arrhythmias, resynchronization 2.2 and cardiac imaging

RESEARCHERS Elena Arbelo (HCB) LOCATION Antonio Berruezo (HCB) HCB building M. Angeles Castel (HCB) CELLEX building, ﬂoor 2A Mª Teresa de Caralt (HCB) Silvia Montserrat (HCB) José Tomás Ortiz (HCB) Rosario Jesus Perea (HCB) Susana Prat (HCB) José M Tolosana (HCB) KEYWORDS Bárbara Vidal (HCB) TEAM LEADER 1. Atrial ﬁbrillation Josep Brugada (HCB) POST-DOCTORAL RESEARCHERS 2. Ventricular tachycardia T. 93 227 17 78 Cristina Arce (UB) 3. Sudden death [email protected] Montserrat Batlle (IDIBAPS) 4. Cardiac imaging Adelina Doltra (HCB) 5. Resynchronization therapy Gonzalo Grazioli (FCRB) Laura Sanchís (HCB) GROUP LEADERS Gemma Sangüesa (CIBER) Gustavo Egea (UB) Maria Sanz (HCB) T. 93 402 19 09 David Soto (IDIBAPS) [email protected] PRE-DOCTORAL RESEARCHERS Original publications Francisco Alarcón (HCB) from 2016 to 2018 Eduard Guasch (HCB-IDIBAPS) T. 93 227 48 05 Eva Benito (HCB) YEAR I.F. TOTAL Q1 Q2 [email protected] Fabio Bonorino (UB) Gal.la Caixal (IDIBAPS) 2016 275.53 47 31 14 Lluis Mont (HCB) Glara Gunturiz (CIBER) 2017 315.23 56 42 8 T.93 227 17 78 Beatriz Jáuregui (IDIBAPS) 2018 335.64 53 36 14 [email protected] Paloma Jorda (FCRB) Markus Linhart (IDIBAPS) Marta Sitges (HCB) Filip Loncaric (IDIBAPS) T. 93 227 17 94 Maria Elisa Matiello (HCB) [email protected] Loredana Nunno (IDIBAPS) TEAM INVOLVED IN Isaac Rodriguez (UB) AGAUR_ SGR17 Rodolfo San Antonio (CIBER) CIBERCV Paula Sánchez (HCB) Antonia Vaquer (FCRB) Josep Brugada TEAM

104 TECHNICIANS research groupsandenterprises. international collaborativenetworkwith This isperformedwithinanationaland cardiovascular diseases. the prevention,diagnosisandtherapyof (from benchtobedside),eventuallyaimingat vessels throughatranslationalperspective biochemical remodellingoftheheartand the electrophysiological,mechanicaland Our researchteamfocusesonthestudyof STRATEGIC OBJECTIVES Omar Trotta(Argentina) Norihiro Enomoto(Japó) Fredy Chipa(Perú) Marc Abuli(FCRB) VISITING SCIENTISTS Fatima Zaraket(FCRB) Vladimir Syrovnev(FCRB) Mikel Martinez(HCB-IDIBAPS) Paz Garre(HCB) Hael Fernández(FCRB) Jennifer Cozzari(IDIBAPS) José AlejandroApolo(FCRB) COLLABORATORS Silvia Vidorreta(HCB-FCRB) Miriam Sanchez(IDIBAPS) Sílvia Poyatos(FCRB) Mireia Niebla(HCB) Laura Merino(HCB-IDIBAPS) Rebeca Domingo(HCB) Alba Cano(HCB) NURSING STAFF Carolina Sanroman(FCRB) M NeusPortella(FCRB) Laura González(FCRB) Mariona deTorres(FCRB) ADMINISTRATIVE STAFF Nadia Castillo(IDIBAPS) Laura Barbera(UB) Anna Alcarraz(FCRB)

GROUP Gustavo Egea - defibrillators. asleadlesspacingandsubcutaneous method.Wetestinnovativedevicessuch multipointpacingandthefusion-optimized atimprovingsuccessratethrough - newtherapeuticsforAF. theSteeringCommitteeoftrialsassessing onimagingtechniques.Weparticipate in individualizedablationapproachesbased - models. extremetraininginclinicalandmurine remodellingandthedeleteriouseffectsof sport - ablationforBrugadasyndrome. arrhythmias,andtheefficacyofepicardial geneticsandprognosisofinherited - MAIN LINESOFRESEARCH tutrladfntoa eoeln n structuralandfunctionalremodellingin - antiarrhythmic andcomparetheefficacyofablation with drugs. remodellingregressionafterPVCablation analysisinmagneticresonance,evaluate predictsuddencardiacdeathbysubstrate Inremodellinginheartdisease, In ventriculartachycardia In resynchronizationandpacing In atrialfibrillation In adaptationandconsequencesof In geneticdiseases , westudyexercise-inducedcardiac edvlp , wedevelop efcso h , wefocusonthe , weworkto ARRHYTHMIAS, RESYNCHRONIZATION ANDCARDIAC IMAGING westudy , weaim syndrome. aneurysm inmousemodelsofMarfan repurposing totreatascendingaorta and performpreclinicalassaysfordrug associated toMarfansyndrome,and associated stress, stress, In thisrespect,wearefocuson: particularly inMarfansyndrome. syndromic thoracicaortaaneurysms impaired intheformationandprogressionof understand whicharethemolecularbases The mainobjectiveofthisgroupisto Gustavo Egea GROUP LEADER VASCULAR CELLBIOLOGY RESEARCH GROUP aneurysm signalling,andmechanicalforcesin progression. biology,membranetrafficking,cell Marfan syndrome - characteristics. valveheartdisease,andfailure In vascularcellandmolecularbiologyof (2) theendoplasmicreticulum- (UB) (3) behavioural alterations eadesrdx , weaddressredox (1) theredox (4) 2.2 105 106 novel drugs. testing differenttherapeutic strategiesand We alsoparticipateinmulticenterstudies ablation tailoring. can helpintherapypersonalization and identification incardiacmagneticresonance Furthermore, weaimattestinghow fibrosis balance. relationship betweenstatureandautonomic parasympathetic balancetoanalyzethe association ofthesympathetic/ In thisregard,weareassessingthe mechanisms andpreventitsdevelopment. factors ofatrialfibrillationtounderstandits Our group Lluis Mont GROUP LEADER BIOPATHOLOGY ANDTHERAPY ATRIAL FIBRILLATION RESEARCH GROUP fibrillation. diseases, includingarrhythmiassuchasatrial an emergingcauseofcardiovascular intensity exercise(regardedasexcessive) special interestinthestudyofextreme In thisregard,thegrouphasdevelopeda and studiesinhumans. animal models,exvivoandinvitrotechniques through amultifactorialapproachinvolving cardiac atrialandventriculararrhythmias etiology, pathophysiologyandtherapyof Main researchtopicsincludethestudyof program. established in2015undertheIDIBAPS50/50 led The Eduard Guasch GROUP LEADER ACTIVITY ARRYTHMIAS ANDPHYSICAL RESEARCH GROUP AREA 2 byDr.EduardGuaschwasofficially Arrhythmias andPhysicalActivitygroup

RESPIRATORY, CARDIOVASCULAR ANDRENALPATHOBIOLOGY ANDBIOENGINEERING focuses inthestudyofetiologic (HCB) (HCB-IDIBAPS)

GROUP Marta Sitges GROUP Lluís Mont GROUP Eduard Guasch ARRHYTHMIAS, RESYNCHRONIZATION AND CARDIAC IMAGING 2.2

This work is performed within UFA (Unitat de Franco; Brignole, M.; Oddone, D.; Donateo, C, Villuendas R, de Caralt TM, Perea RJ, Fibril·lació Auricular), a multidisciplinary unit led O.; Maggi, R.; Croci, F.; Solano, A.; Pentimalli, Ortiz JT, Bosch X, Serra L, Planes X, Greiser by Dr. Mont including clinicians and F.; Palmisano, P.; Landolina, M.; Chieffo, E.; A, Ekinci O, Lasalvia L, Mont L, Berruezo A . researchers (https://ufaclinic.cat/ca). Taravelli, E.; Occhetta, E.; Quartieri, F.; Scar Characterization to Predict Bottoni, N.; Iori, M.; Calo, L.; Sgueglia, M.; Life-Threatening Arrhythmic Events and Pieragnoli; Giorni, A.; Nesti, M.; Giannini, I.; Sudden Cardiac Death in Patients With Ungar, A.; Padeletti, L.; Pokushalov, E.; Cardiac Resynchronization Therapy: The RESEARCH GROUP Romanov, A.; Peregudov, I.; Vidorreda, S.; GAUDI-CRT Study. JACC: CARDIAC IMAGING Nunez, R.; Mont, L.; APAF-CRT CARDIOVASCULAR IMAGING. 11(4):561-572. Investigators. A randomized controlled I.F.: 10.247 trial of atrioventricular junction ablation and cardiac resynchronization therapy in 7. Ambrosioni J, Urra X, Hernández-Meneses patients with permanent atrial fibrillation M, Almela M, Falces C, Tellez A, Quintana E, and narrow QRS. EUROPEAN HEART Fuster D, Sandoval E, Vidal B, Tolosana JM, JOURNAL. 39(45):3999-4008. Moreno A, Chamorro A, Miró JM, Hospital I.F.: 23.425 Clínic Infective Endocarditis Study Group . GROUP LEADER Mechanical thrombectomy for acute Marta Sitges (HCB) 3. Kirchhof, Paulus; Haeusler, Karl Georg; ischemic stroke secondary to infective Blank, Benjamin; De Bono, Joseph; Callans, endocarditis. CLINICAL INFECTIOUS Our group has a pluridisciplinary team of David; Elvan, Arif; Fetsch, Thomas; Van DISEASES. 66(8):1286-1289. I.F.: 9.117 people dedicated to non-invasive cardiac Gelder, Isabelle C.; Gentlesk, Philip; Grimaldi, imaging and its application in the knowledge Massimo; Hansen, Jim; Hindricks, Gerhard; 8. Téllez A, Ambrosioni J, Llopis J, Pericàs JM, and research into cardiovascular Al-Khalidi, Hussein R.; Massaro, Tyler; Mont, Falces C, Almela M, Garcia de la Mària C, pathophysiology and therapy within the field Lluis; Nielsen, Jens Cosedis; Noelker, Georg; Hernandez-Meneses M, Vidal B, Sandoval E, of cardiac mechanics and remodelling in Piccini, Jonathan P.; De Potter, Tom; Scherr, Quintana E, Fuster D, Tolosana JM, Marco F, cardiovascular diseases. Daniel; Schotten, Ulrich; Themistoclakis, Moreno A, Miro JM, Hospital Clínic Infective Our lines of research include the application Sakis; Todd, Derick; Vijgen, Johan; Di Biase, Endocarditis Investigators . Epidemiology, of cardiac imaging in the study of cardiac Luigi;. Apixaban in patients at risk of clinical features and outcome of mechanics and function and analysis of stroke undergoing atrial fibrillation infective endocarditis due to Abiotrophia cardiac remodelling in order to detect latent ablation. EUROPEAN HEART JOURNAL. spp. and Granulicatella spp.: Report of 76 cardiac dysfunction. 39(32):2942-2955. I.F.: 23.425 cases (2000-2015). CLINICAL Additionally, our collaboration with INFECTIOUS DISEASES. 66(1):104-111. I.F.: bioengineering groups allows for better 4. Pappone C., Ciconte G., Manguso F., 9.117 quantification and identification of patterns Vicedomini G., Mecarocci V., Conti M., of cardiac adaptations to disease and Giannelli L., Pozzi P., Borrelli V., Menicanti L., 9. López-Guimet J., Peña-Pérez L., Bradley understanding of their underlying Calovic Z., Della Ratta G., Brugada J., R., García-Canadilla P., Disney C., Geng H., physiopathology. Santinelli V. Assessing the Malignant Bodey A., Withers P., Bijnens B., Sherratt M., Ventricular Arrhythmic Substrate in Egea G. MicroCT imaging reveals Patients With Brugada Syndrome. differential 3D micro-scale remodelling JOURNAL OF THE AMERICAN COLLEGE of the murine aorta in ageing and marfan PUBLICATIONS OF CARDIOLOGY. 71(15):1631-1646. I.F.: syndrome. THERANOSTICS. 16.834 8(21):6038-6052. I.F.: 8.537 Originals / I.F.: 335.638 5. Tayal, Bhupendar; Gorcsan, John, III; Bax, 10. Ramos J; Monteagudo JM; 1. Chan, Xin Hui S.; Win, Yan Naung; Mawer, Jeroen J.; Risum, Niels; Olsen, Niels Thue; Gonzàlez-Alujas T; Fuentes ME; Sitges M; Laura J.; Tan, Jireh Y.; Brugada, Josep; Singh, Jagmeet P.; Abraham, William T.; Peña ML; Carrasco-Chinchilla F; Echeverría White, Nicholas J. Risk of sudden Borer, Jeffrey S.; Dickstein, Kenneth; Gras, T; Bouzas A; Forteza Alberti JF; Mesa D; De unexplained death after use of Daniel; Krum, Henry; Brugada, Josep; La Hera JM; Zamorano JL. Large-scale dihydroartemisinin- piperaquine for Robertson, Michele; Ford, Ian; Holzmeister, assessment of aortic stenosis: facing the malaria: a systematic review and Johannes; Ruschitzka, Frank; Sogaard, next cardiac epidemic? EUROPEAN Bayesian meta-analysis. LANCET Peter. Cardiac Resynchronization HEART JOURNAL-CARDIOVASCULAR INFECTIOUS DISEASES, THE. Therapy in Patients With Heart Failure IMAGING. 19(10):1142-1148. I.F.: 8.336 18(8):913-923. I.F.: 25.148 and Narrow QRS Complexes. JOURNAL OF THE AMERICAN COLLEGE OF 11. Bisbal F, Alarcón F, Ferrero de Loma 2. Brignole, Michele; Pokushalov, Evgeny; CARDIOLOGY. 71(12):1325-1333. I.F.: 16.834 Osorio A, González-Ferrer JJ, Alonso C, Pentimalli, Francesco; Palmisano, Pietro; Pachón M, Tizón H, Cabanas-Grandío P, Chieffo, Enrico; Occhetta, Eraldo; Quartieri, 6. Acosta J, Fernández-Armenta J, Borràs Sanchez M, Benito E, Teis A, Ruiz-Granell R, Fabio; Calo, Leonardo; Ungar, Andrea; Mont, R, Anguera I, Bisbal F, Martí-Almor J, Pérez-Villacastín J, Viñolas X, Arias MA, Lluis; Menozzi, Carlo; Alboni, Paolo; Bertero, Tolosana JM, Penela D, Andreu D, Vallés E, García-Campo E, Giovanni; Klersy, Catherine; Noventa, Soto-Iglesias D, Evertz R, Matiello M, Alonso Fernández-Lozano I, Villuendas R, Mont L.

107 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

Left atrial geometry and outcome of identified by late gadolinium enhancement Carlosena A, Vassanelli F, Alarcón F, atrial fibrillation ablation: results from the cardiac magnetic resonance in patients Soto-Iglesias D, Korshunov V, Borras R, multicentre LAGO-AF study. EUROPEAN with atrial fibrillation. EUROPACE. Linhart M, Martínez M, Fernández-Armenta J, HEART JOURNAL-CARDIOVASCULAR 20(12):1959-1965. I.F.: 5.231 Mont L, Berruezo A. Multielectrode vs. IMAGING. 19(9):1002-1009. I.F.: 8.336 point-by-point mapping for ventricular 17. Calkins, Hugh; Hindricks, Gerhard; tachycardia substrate ablation: a 12. Monteagudo Ruiz JM, Galderisi M, Cappato, Riccardo; Kim, Young-Hoon; Saad, randomized study. EUROPACE. Buonauro A, Badano L, Aruta P, Swaans MJ, Eduardo B.; Aguinaga, Luis; Akar, Joseph G.; 20(3):512-519. I.F.: 5.231 Sanchis L, Saraste A, Monaghan M, Badhwar, Vinay; Brugada, Josep; Camm, Theodoropoulos KC, Papitsas M, Liel-Cohen John; Chen, Peng-Sheng; Chen, Shih-Ann; 21. Vilardell P., Brugada J., Aboal J., N, Kobal S, Bervar M, Berlot B, Filippatos G, Chung, Mina K.; Nielsen, Jens Cosedis; Curtis, Loma-Osorio P., Falces C., Andrea R., Ikonomidis I, Katsanos S, Tanner FC, Cassani Anne B.; Davies, D. Wyn; Day, John D.; d'Avila, Figueras-Coll M., Brugada R.. D, Faletra FF, Leo LA, Martinez A, Matabuena Andre; de Groot, N. M. S. (Natasja); Di Biase, Characterization of Electrocardiographic J, Grande-Trillo A, Alonso-Rodriguez D, Mesa Luigi; Duytschaever, Mattias; Edgerton, James Findings in Young Students. REVISTA D, Gonzalez-Alujas T, Sitges M, R.; Ellenbogen, Kenneth A.; Ellinor, Patrick T.; ESPAÑOLA DE CARDIOLOGIA. . I.F.: 5.166 Carrasco-Chinchilla F, Li CH, Fernandez- Ernst, Sabine; Fenelon, Guilherme; Golfin C, Zamorano JL, Zamorano JL. Gerstenfeld, Edward P.; Haines, David E.; 22. García-Fernández F., Ibáñez Criado J., Overview of mitral regurgitation in Europe: Haissaguerre, Michel; Helm, Robert H.; Hylek, Quesada Dorador A., Álvarez-López M., results from the European Registry of Elaine; Jackman, Warren M.; Jalife, Jose; Almendral J., Alonso C., Alonso-Fernández P., mitral regurgitation (EuMiClip). EUROPEAN Kalman, Jonathan M.; Kautzner, Josef; Alvaralenga N., Álvarez-Acosta L., Anguera I., HEART JOURNAL-CARDIOVASCULAR Kottkamp, Hans; Kuck, Karl Heinz; Kumagai, Arcocha M., Arias M., Asso A., IMAGING. 19(5):503-507. I.F.: 8.336 Koichiro; Lee, Richard; Lewalter, Thorsten; Barrera-Cordero A., Ballesteros G., Lindsay, Bruce D.; Macle, Laurent; Mansour, Benezet-Mazuecos J., Bodegas-Cañas A., 13. Sanchis L., Andrea R., Falces C., Poyatos Moussa; Marchlinski, Francis E.; Michaud, Brugada J., Cano-Calabria C., Caballero-Dorta S., Vidal B., Sitges M. Differential Clinical Gregory F.; Nakagawa, Hiroshi; Natale, E., Cabanas-Grandío P., Cabrera S., Castro V., Implications of Current Recommendations Andrea; Nattel, Stanley; Okumura, Ken; Cózar R., Díaz-Infante E., Doblado M., Elices J., for the Evaluation of Left Ventricular Packer, Douglas; Pokushalov, Evgeny; Expósito-Pineda M., Fernández-Gómez J., Diastolic Function by Echocardiography. Reynolds, Matthew R.; Sanders, Prashanthan; Fidalgo M., Fontenla A., García-Alberola A., JOURNAL OF THE AMERICAN SOCIETY OF Scanavacca, Mauricio; Schilling, Richard; Gil-Ortega I., Gómez-Pulido F., ECHOCARDIOGRAPHY. 31(11):1203-1208. Tondo, Claudio; Tsao, Hsuan-Ming; Verma, González-Vasserot M., Grande Á., I.F.: 6.827 Atul; Wilber, David J.; Yamane, Teiichi. 2017 Guerra-Ramos J., Hernández-Afonso J., HRS/EHRA/ECAS/APHRS/SOLAECE Heras-Herreros S., Hidalgo-Olivares V., 14. Jiménez-Altayó F, Meirelles T, expert consensus statement on catheter García-Fernández F., Ibáñez Criado J., Crosas-Molist E, Sorolla MA, Del Blanco DG, and surgical ablation of atrial fibrillation: Quesada Dorador A., Álvarez-López M., López-Luque J, Mas-Stachurska A, Siegert Executive summary. EUROPACE. Almendral J., Alonso C., Alonso-Fernández P., AM, Bonorino F, Barberà L, García C, Condom 20(1):157-208. I.F.: 5.231 Alvaralenga N., Álvarez-Acosta L., Anguera I., E, Sitges M, Rodríguez-Pascual F, Laurindo F, Arcocha M., Arias M., Asso A., Schröder K, Ros J, Fabregat I, Egea G . Redox 18. Delise, Pietro; Probst, Vincent; Allocca, Barrera-Cordero A., Ballesteros G., stress in marfan syndrome: dissecting the Giuseppe; Sitta, Nadir; Sciarra, Luigi; Brugada, Benezet-Mazuecos J., Bodegas-Cañas A., role of the nadph oxidase nox4 in aortic Josep; Kamakura, Shiro; Takagi, Masahiko; Brugada J., Cano-Calabria C., Caballero-Dorta aneurysm. FREE RADICAL BIOLOGY AND Giustetto, Carla; Calo, Leonardo. Clinical E., Cabanas-Grandío P., Cabrera S., Castro V., MEDICINE. 118:44-58. I.F.: 6.020 outcome of patients with the Brugada type Cózar R., Díaz-Infante E., Doblado M., Elices J., 1 electrocardiogram without prophylactic Expósito-Pineda M., Fernández-Gómez J., 15. Valenzuela-Alcaraz B, Cruz-Lemini M, implantable cardioverter defibrillator in Fidalgo M., Fontenla A., García-Alberola A., Rodríguez-López M, Goncé A, García-Otero primary prevention: a cumulative analysis Gil-Ortega I., Gómez-Pulido F., L, Ayuso H, Sitges M, Bijnens B, Balasch J, of seven large prospective studies. González-Vasserot M., Grande Á., Gratacós E, Crispi F. Fetal cardiac EUROPACE. 20(FI1):F77-F85. I.F.: 5.231 Guerra-Ramos J., Hernández-Afonso J., remodeling in twin pregnancies conceived Heras-Herreros S., Hidalgo-Olivares V., by assisted reproductive technologies. 19. Acosta J, Andreu D, Penela D, Cabrera M, García-Fernández F., Ibáñez Criado J., ULTRASOUND IN OBSTETRICS AND Carlosena A, Korshunov V, Vassanelli F, Quesada Dorador A., Álvarez-López M., GYNECOLOGY. 51(1):94-100. I.F.: 5.654 Borras R, Martínez M, Fernández-Armenta J, Almendral J., Alonso C., Alonso-Fernández P., Linhart M, Tolosana JM, Mont L, Berruezo A. Alvaralenga N.. Spanish Catheter Ablation 16. Benito EM, Cabanelas N, Nuñez-Garcia M, Elucidation of hidden slow conduction by Registry. 17th Official Report of the Spanish Alarcón F, Figueras I Ventura RM, double ventricular extrastimuli: a method Society of Cardiology Working Group on Soto-Iglesias D, Guasch E, Prat-Gonzalez S, for further arrhythmic substrate Electrophysiology and Arrhythmias (2017). Perea RJ, Borràs R, Butakoff C, Camara O, identification in ventricular tachycardia REVISTA ESPAÑOLA DE CARDIOLOGIA. Bisbal F, Arbelo E, Tolosana JM, Brugada J, ablation procedures. EUROPACE. 71(11):941-951. I.F.: 5.166 Berruezo A, Mont L . Preferential regional 20(2):337-346. I.F.: 5.231 distribution of atrial fibrosis in posterior 23. Wangüemert Pérez F, Hernández Afonso wall around left inferior pulmonary vein as 20. Acosta J, Penela D, Andreu D, Cabrera M, JS, Groba Marco MDV, Caballero Dorta E,

108 ARRHYTHMIAS, RESYNCHRONIZATION AND CARDIAC IMAGING 2.2

Álvarez Acosta L, Campuzano Larrea O, Brugada R, Calo L, Priori SG, Takagi M, Behr Length in Wide Circumferential Pulmonary Pérez G, Brugada Terradellas J, Brugada ER, Gaita F, Yan GX, Brugada J, Leenhardt A, Vein Ablation Lesions Is Associated With Terradellas R. Flecainide Reduces Wilde AAM, Brugada P, Kusano KF, Hirao K, Recurrence of Atrial Fibrillation. Ventricular Arrhythmias in Patients With Nam GB, Probst V, Belhassen B. CIRCULATION. ARRHYTHMIA AND Genotype RYR2-positive Fever-Related Arrhythmic Events in the ELECTROPHYSIOLOGY. 11(12):e006659. I.F.: Catecholaminergic Polymorphic Multicenter Survey on Arrhythmic 4.728 Ventricular Tachycardia. REVISTA Events in Brugada Syndrome (SABRUS). ESPAÑOLA DE CARDIOLOGIA. 71(3):185-191. HEART RHYTHM. 15(9):1394-1401. I.F.: 4.743 32. Kuck, Karl-Heinz; Brugada, Josep; I.F.: 5.166 Fuernkranz, Alexander; Chun, K. R. Julian; 28. Milman A, Gourraud JB, Andorin A, Metzner, Andreas; Ouyang, Feifan; Schlueter, 24. Siegert A., Serra-Peinado C., Postema PG, Sacher F, Mabo P, Conte G, Michael; Elvan, Arif; Braegelmann, Kendra M.; Gutiérrez-Martínez E., Rodríguez-Pascual F., Giustetto C, Sarquella-Brugada G, Kueffer, Fred J.; Arentz, Thomas; Albenque, Fabregat I., Egea G. Altered TGF-β Hochstadt A, Kim SH, Juang JJM, Maeda S, Jean-Paul; Kuhne, Michael; Sticherling, endocytic trafficking contributes to the Takahashi Y, Kamakura T, Aiba T, Leshem Christian; Tondo, Claudio; FIRE ICE increased signaling in Marfan syndrome. E, Michowitz Y, Rahkovich M, Mizusawa Y, Investigators. Impact of Female Sex on BIOCHIMICA ET BIOPHYSICA ACTA - Arbelo E, Huang Z, Denjoy I, Wijeyeratne YD, Clinical Outcomes in the FIRE AND ICE MOLECULAR BASIS OF DISEASE. Napolitano C, Brugada R, Casado-Arroyo R, Trial of Catheter Ablation for Atrial 1864(2):554-562. I.F.: 5.108 Champagne J, Calo L, Tfelt-Hansen J, Priori Fibrillation. CIRCULATION. ARRHYTHMIA SG, Takagi M, Veltmann C, Delise P, AND ELECTROPHYSIOLOGY. 11(5):e006204. 25. Soto-Iglesias D, Acosta J, Penela D, Corrado D, Behr ER, Gaita F, Yan GX, I.F.: 4.728 Fernández-Armenta J, Cabrera M, Martínez Brugada J, Leenhardt A, Wilde AAM, M, Vassanelli F, Alcaine A, Linhart M, Jáuregui Brugada P, Kusano KF, Hirao K, Nam GB, 33. De Jong M., Hoogerwaard A., Adiyaman B, Efimova E, Perea RJ, Prat-González S, Probst V, Belhassen B. Gender Differences A., Smit J., Ramdat Misier A., Heeg J., van Ortiz-Pérez JT, Bosch X, Mont L, Camara O, in Patients with Brugada Syndrome and Hasselt B., Van Gelder I., Crijns H., Lozano I., Berruezo A. Image-Based Criteria to Arrhythmic Events: Data from a Survey Toquero Ramos J., Javier Alzueta F., Ibañez B., Identify the Presence of Epicardial on Arrhythmic Events in 678 Patients. Rubio J., Arribas F., Porres Aracama J., arrhythmogenic Substrate in Patients with HEART RHYTHM. 15(10):1457-1465. I.F.: Brugada J., Mont L., Elvan A.. Treatment of Transmural Myocardial Infarction. HEART 4.743 atrial fibrillation in patients with enhanced RHYTHM. 15(6):814-821. I.F.: 4.743 sympathetic tone by pulmonary vein 29. Andreu D, Fernández-Armenta J, isolation or pulmonary vein isolation and 26. Milman A, Andorin A, Gourraud JB, Acosta J, Penela D, Jáuregui B, renal artery denervation: clinical Postema PG, Sacher F, Mabo P, Kim SH, Soto-Iglesias D, Syrovnev V, Arbelo E, background and study design: The ASAF Juang JJM, Maeda S, Takahashi Y, Tolosana JM, Berruezo A. A QRS trial: ablation of sympathetic atrial Kamakura T, Aiba T, Conte G, Axis-Based Algorithm to Identify the fibrillation. CLINICAL RESEARCH IN Sarquella-Brugada G, Leshem E, Rahkovich Origin of Scar-Related Ventricular CARDIOLOGY. 107(7):539-547. I.F.: 4.455 M, Hochstadt A, Mizusawa Y, Arbelo E, Tachycardia in an American Heart Huang Z, Denjoy I, Giustetto C, Wijeyeratne Association 17-Segment Model. HEART 34. Varma, Niraj; Sogaard, Peter; Bax, Jeroen YD, Napolitano C, Michowitz Y, Brugada R, RHYTHM. 15(10):1491-1497. I.F.: 4.743 J.; Abraham, William T.; Borer, Jeffrey S.; Casado-Arroyo R, Champagne J, Calo L, Dickstein, Kenneth; Singh, Jagmeet P.; Gras, Tfelt-Hansen J, Priori SG, Takagi M, 30. Chinitz, Larry; Ritter, Philippe; Khelae, Daniel; Holzmeister, Johannes; Brugada, Veltmann C, Delise P, Corrado D, Behr ER, Surinder Kaur; Iacopino, Saverio; Garweg, Josep; Ruschitzka, Frank. Interaction of Left Gaita F, Yan GX, Brugada J, Leenhardt A, Christophe; Grazia-Bongiorni, Maria; Neuzil, Ventricular Size and Sex on Outcome of Wilde AAM, Brugada P, Kusano KF, Hirao K, Petr; Johansen, Jens Brock; Mont, Lluis; Cardiac Resynchronization Therapy Nam GB, Probst V, Belhassen B. Profile of Gonzalez, Efrain; Sagi, Venkata; Duray, Among Patients With a Narrow QRS patients with Brugada syndrome Gabor Z.; Clementy, Nicolas; Sheldon, Todd; Duration in the EchoCRT Trial. JOURNAL presenting with their first documented Splett, Vincent; Stromberg, Kurt; Wood, OF THE AMERICAN HEART ASSOCIATION. arrhythmic event: Data from the Survey Nicole; Steinwender, Clemens. 7(11). I.F.: 4.450 on Arrhythmic Events in Brugada Accelerometer- based atrioventricular Syndrome. HEART RHYTHM. 15(5):716-724. synchronous pacing with a ventricular 35. Kuck, Karl-Heinz; Brugada, Josep; I.F.: 4.743 leadless pacemaker: Results from the Schlueter, Michael; Braegelmann, Kendra M.; Micra atrioventricular feasibility studies. Kueffer, Fred J.; Chun, K. R. Julian; Albenque, 27. Michowitz Y, Milman A, Sarquella-Brugada HEART RHYTHM. 15(9):1363-1371. I.F.: 4.743 Jean-Paul; Tondo, Claudio; Calkins, Hugh; G, Andorin A, Champagne J, Postema PG, Metzner, Andreas; Ouyang, Feifan; Chun, Julian; Casado-Arroyo R, Leshem E, Juang JJM, 31. Linhart M., Alarcon F., Borràs R., Benito E., Fuernkranz, Alexander; Elvan, Arif; Arentz, Giustetto C, Tfelt-Hansen J, Wijeyeratne YD, Chipa F., Cozzari J., Caixal G., Enomoto N., Thomas; Kuehne, Michael; Sticherling, Veltmann C, Corrado D, Kim SH, Delise P, Carlosena A., Guasch E., Arbelo E., Tolosana J., Christian; Geller, Laszlo; Busch, Matthias; Mont, Maeda S, Gourraud JB, Sacher F, Mabo P, Prat-Gonzalez S., Perea R., Doltra A., Sitges M., Lluis; Barrera, Alberto; Deneke, Thomas; Takahashi Y, Kamakura T, Aiba T, Conte G, Brugada J., Berruezo A., Mont L. Delayed Kuehlkamp, Volker; Ruiz-Granell, Ricardo; Neuzil, Hochstadt A, Mizusawa Y, Rahkovich M, Gadolinium Enhancement Magnetic Peter; Perez-Castellano, Nicasio; FIRE ICE Trial Arbelo E, Huang Z, Denjoy I, Napolitano C, Resonance Imaging Detected Anatomic Gap Investigators. The FIRE AND ICE Trial: What

109 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

We Know, What We Can Still Learn, and 40. Scumaci D, Oliva A, Concolino A, Curcio Prat-Gonzalez S, Perea RJ, Borràs R, Chipa What We Need to Address in the Future. A, Fiumara CV, Tammè L, Campuzano O, F, Arbelo E, Tolosana JM, Brugada J, JOURNAL OF THE AMERICAN HEART Pascali VL, Coll M, Iglesias A, Berne P, Casu Berruezo A, Mont L . Post-procedural ASSOCIATION. 7(24):e010777. I.F.: 4.450 G, Olivo E, Ausania F, Ricci P, Indolfi C, LGE-CMR comparison of laser and Brugada J, Brugada R, Cuda G . Integration radiofrequency ablation lesions after 36. García de la Mària C, Gasch O, of "Omics" Strategies for Biomarkers pulmonary vein isolation. JOURNAL OF García-Gonzalez J, Soy D, Shaw E, Discovery and for the Elucidation of CARDIOVASCULAR Ambrosioni J, Almela M, Pericàs JM, Tellez Molecular Mechanisms Underlying ELECTROPHYSIOLOGY. 29(8):1065-1072. A, Falces C, Hernandez-Meneses M, Brugada Syndrome. PROTEOMICS - I.F.: 2.873 Sandoval E, Quintana E, Vidal B, Tolosana CLINICAL APPLICATIONS. 12(6):e1800065. JM, Fuster D, Llopis J, Pujol M, Moreno A, I.F.: 3.567 46. Pericàs JM, Cervera C, Moreno A, Marco F, Miró JM . The Combination of Garcia-de-la-Mària C, Almela M, Falces C, Daptomycin plus Fosfomycin has 41. Vicent L; Saldivar HG; Bouza E; Muñoz P; Quintana E, Vidal B, Llopis J, Fuster D, Synergistic, Potent and Rapid Cuerpo G; De Alarcón A; Vidal B; Cobo M; Mestres CA, Marco F, Miró JM, Hospital Bactericidal Activity against Goenaga MÁ; Carrasco-Chinchilla F; Clinic Endocarditis Study Group. Outcome Methicillin-ResistantStaphylococcus Montejo M; Gálvez-Acebal J; of Enterococcus faecalis infective aureus(MRSA) in a Rabbit Model of Hidalgo-Tenorio C; Vinuesa-Garcia D; endocarditis according to the length of Experimental Endocarditis (EE). Martinez-Selles M; NULL NULL. Prognostic antibiotic therapy: Preliminary data from ANTIMICROBIAL AGENTS AND implications of a negative a cohort of 78 patients. PLOS ONE. CHEMOTHERAPY. 62(6):1-8. I.F.: 4.256 echocardiography in patients with 13(2):e0192387. I.F.: 2.766 infective endocarditis. EUROPEAN 37. Rupérez C, Lerin C, Ferrer-Curriu G, JOURNAL OF INTERNAL MEDICINE. 47. Hohnloser, Stefan H.; Camm, John; Cairo M, Mas-Stachurska A, Sitges M, 52:40-48. I.F.: 3.282 Cappato, Riccardo; Diener, Hans-Christoph; Villarroya J, Giralt M, Villarroya F, Planavila A. Heidbuchel, Hein; Lanz, Hans-Joachim; Autophagic control of cardiac steatosis 42. Andrea R., López-Giraldo A., Falces C., Mont, Lluis; Morillo, Carlos A.; Smolnik, through FGF21 in obesity-associated López T., Sanchis L., Gistau C., Sabaté M., Ruediger; Yin, Ophelia Q. P.; Kautzner, Josef. cardiomyopathy. INTERNATIONAL Sitges M., Brugada J., Agustí À. Pulmonary Uninterrupted administration of JOURNAL OF CARDIOLOGY. 260:163-170. function predicts mortality and edoxaban vs vitamin K antagonists in I.F.: 4.034 hospitalizations in outpatients with heart patients undergoing atrial fibrillation failure and preserved ejection fraction. catheter ablation: Rationale and design 38. Mates J., Mademont-Soler I., Del Olmo RESPIRATORY MEDICINE. 134:124-129. of the ELIMINATE-AF study. CLINICAL B., Ferrer-Costa C., Coll M., Pérez-Serra A., I.F.: 3.230 CARDIOLOGY. 41(4):440-449. Picó F., Allegue C., Fernandez-Falgueras A., I.F.: 2.733 Álvarez P., Yotti R., Espinosa M., 43. Ambrosioni J, Martinez-Garcia C, Llopis Sarquella-Brugada G., Cesar S., Carro E., J, Garcia-de-la-Maria C, 48. Caminal P., Sola F., Gomis P., Guasch E., Brugada J., Arbelo E., Garcia-Pavia P., Hernández-Meneses M, Tellez A, Falces C, Perera A., Soriano N., Mont L. Validity of the Borregan M., Tizzano E., López-Granados Almela M, Vidal B, Sandoval E, Fuster D, Polar V800 monitor for measuring heart A., Mazuelos F., Díaz De Bustamante A., Quintana E, Tolosana JM, Marco F, Moreno rate variability in mountain running route Darnaude M., González-Hevia J., A, Miró JM, Hospital Clinic Infective conditions. EUROPEAN JOURNAL OF Díaz-Flores F., Trujillo F., Iglesias A., Endocarditis Investigators. APPLIED PHYSIOLOGY. 118(3):669-677. Fernandez-Aviles F., Campuzano O., HACEKinfective endocarditis: I.F.: 2.401 Brugada R. Role of copy number variants epidemiology, clinical features outcome: in sudden cardiac death and related A case-control study. INTERNATIONAL 49. Gabrielli L, Gabrielli L, Herrera S, Herrera diseases: genetic analysis and JOURNAL OF INFECTIOUS DISEASES. S, Contreras-Briceño F, Vega J, Ocaranza translation into clinical practice. 76:120-125. I.F.: 3.202 MP, Ocaranza MP, Yáñez F, Yáñez F, EUROPEAN JOURNAL OF HUMAN Fernández R, Saavedra R, Sitges M, García GENETICS. 26(7):1014-1025. 44. Den Uijl, Dennis W.; Cabanelas, Nuno; L, Chiong M, Lavandero S, Lavandero S, I.F.: 3.636 Benito, Eva M.; Figueras, Rosa; Alarcon, Castro PF, Castro PF. Increased active Francisco; Borras, Roger; Prat, Susanna; phase atrial contraction is related to 39. Vicent L, Ariza-Solé A, Guasch, Eduard; Perea, Rosario; Sitges, marathon runner performance. González-Juanatey JR, Uribarri A, Ortiz J, Marta; Brugada, Josep; Berruezo, Antonio; EUROPEAN JOURNAL OF APPLIED López de Sá E, Sans-Roselló J, Querol CT, Mont, Lluis. Impact of left atrial volume, PHYSIOLOGY. 118(9):1931-1939. Codina P, Sousa-Casasnovas I, sphericity and fibrosis on the outcome of I.F.: 2.401 Martínez-Sellés M, Cardiac Arrest and catheter ablation for atrial fibrillation. Myocardial Infarction Notified After JOURNAL OF CARDIOVASCULAR 50. Barberan-Garcia A., Gimeno-Santos E., Marathon Or Similar effort (CAMINAMOS) ELECTROPHYSIOLOGY. 29(5):740-746. Blanco I., Cano I., Martínez-Pallí G., Burgos registry. Exercise-related severe cardiac I.F.: 2.873 F., Miralles F., Coca M., Murillo S., Sanz M., events. SCANDINAVIAN JOURNAL OF Steblin A., Ubré M., Benavent J., Vidal J., MEDICINE AND SCIENCE IN SPORTS. 45. Figueras I Ventura RM, M?rgulescu AD, Sitges M., Roca J. Protocol for regional 28(4):1404-1411. I.F.: 3.623 Benito EM, Alarcón F, Enomoto N, implementation of collaborative

110 ARRHYTHMIAS, RESYNCHRONIZATION AND CARDIAC IMAGING 2.2

self-management services to promote patients. MEDICINA CLINICA. Editorial / I.F.: 9.265 physical activity. BMC HEALTH SERVICES 151(10):402-411. I.F.: 1.168 RESEARCH. 18(1):560. I.F.: 1.843 1. Brugada, Josep; Hindricks, Gerhard. Primary electrical disorders and 51. Conde-Mir I., Miranda-Rius J., Trucco E., Letters / I.F.: 28.931 arrhythmogenic right ventricular Lahor-Soler E., Brunet-Llobet L., Domingo cardiomyopathy: new research insights R., Tolosana J., Mont L. In-vivo 1. Pericàs JM, Moreno A, Almela M, with clinical implications. EUROPACE. compatibility between pacemakers and García-de-la-Mària C, Marco F, Muñoz P, 20(FI1):F1-F2. I.F.: 5.231 dental equipment. EUROPEAN JOURNAL Peña C, de Alarcón A, Del Río A, Eworo A, OF ORAL SCIENCES. 126(4):307-315. I.F.: Cruceta A, Paré JC, Mestres CA, Miró JM, 2. Penela, Diego; Mont, Lluis. VT ablation 1.655 FOSIMI Investigators. Efficacy and Safety and survival: A solved question? of Fosfomycin Plus Imipenem vs. INTERNATIONAL JOURNAL OF 52. Berruezo A, Linhart M, Auricchio A, Vancomycin for Complicated CARDIOLOGY. 267:118-119. I.F.: 4.034 Zamorano JL, Santamaria P, Borràs R, Bacteremia and Endocarditis Due to Burgos F, Brugada J. Rationale and design Methicillin- Resistant Staphylococcus of the TRICHAMPION trial: Triple aureus: Case Reports / I.F.: 6.587 Chamber Pacing in Hypertrophic A Randomized Clinical Trial. CLINICAL Obstructive Cardiomyopathy Patients. MICROBIOLOGY AND INFECTION. 1. Dallaglio P., Anguera I., García-Alberola A., JOURNAL 24(6):673-676. I.F.: 5.394 Sabaté X., Cequier Á., Brugada J. OF INTERVENTIONAL CARDIAC Antitachycardia Pacing Effectiveness for ELECTROPHYSIOLOGY. 51(2):117-124. 2. Freixa X, Hernández-Enríquez M, Sanchís Monomorphic Ventricular Tachycardia in I.F.: 1.522 L, Regueiro A, Sabaté M, Sitges M. Brugada Syndrome After Quinidine Tricuspid Percutaneous Repair With the Administration. REVISTA ESPAÑOLA DE 53. Santiago-Vacas E., Farrero M., MitraClip System: First Implant in Spain. CARDIOLOGIA. 71(5):403-406. I.F.: 5.166 Ivey-Miranda J., Castel M., García-Álvarez REVISTA ESPAÑOLA DE CARDIOLOGIA. A., Rios J., Perez-Villa F. Initial experience 71(11):976-977. I.F.: 5.166 2. Soto-Iglesias D., Andreu D., Jáuregui B., with bosentan for the management of Linhart M., Mont L., Berruezo A. pulmonary hypertension after heart 3. Loma-Osorio P., Nuñez M., Aboal J., Mini-electrodes help identifying hidden transplantation. CLINICAL Bosch D., Batlle P., Ruiz de Morales E., slow conduction during ventricular TRANSPLANTATION. 32(9):e13364. I.F.: Ramos R., Brugada J., Onaga H., Morales A., tachycardia substrate ablation. 1.518 Olivet J., Brugada R. The Girona Territori JOURNAL OF ELECTROCARDIOLOGY. Cardioprotegit Project: Performance 51(6):1011-1013. I.F.: 1.421 Evaluation of Public Defibrillators. Review / I.F.: 22.351 REVISTA ESPAÑOLA DE CARDIOLOGIA. 71(2):79-85. I.F.: 5.166 Clinical Guidelines / I.F.: 10.462 1. Brugada J., Campuzano O., Arbelo E., Sarquella-Brugada G., Brugada R. Present 4. Benito E., Mont L. Selection of the Best 1. Calkins, Hugh; Hindricks, Gerhard; Status of Brugada Syndrome: JACC of 2017 in Catheter Ablation. REVISTA Cappato, Riccardo; Kim, Young-Hoon; Saad, State-of-the-Art Review. JOURNAL OF ESPAÑOLA DE CARDIOLOGIA. Eduardo B.; Aguinaga, Luis; Akar, Joseph G.; THE AMERICAN COLLEGE OF 71(4):303-304. I.F.: 5.166 Badhwar, Vinay; Brugada, Josep; Camm, CARDIOLOGY. 72(9):1046-1059. I.F.: 16.834 John; Chen, Peng-Sheng; Chen, Shih-Ann; 5. Jiménez Brítez G., Sanchis L., Regueiro A., Chung, Mina K.; Nielsen, Jens Cosedis; 2. Mascia G., Arbelo E., Solimene F., Sabate M., Sitges M., Freixa X. Curtis, Anne B.; Davies, D. Wyn; Day, John D.; Giaccardi M., Brugada R., Brugada J. The Minimally-invasive Transesophageal d'Avila, Andre; de Groot, N. M. S. (Natasja); Di long-QT syndrome and exercise Echocardiography for Left Atrial Biase, Luigi; Duytschaever, Mattias; practice: The never-ending debate. Appendage Occlusion With a Edgerton, James R.; Ellenbogen, Kenneth A.; JOURNAL OF CARDIOVASCULAR Latest-generation Microprobe. Initial Ellinor, Patrick T.; Ernst, Sabine; Fenelon, ELECTROPHYSIOLOGY. 29(3):489-496. Experience. REVISTA ESPAÑOLA DE Guilherme; Gerstenfeld, Edward P.; Haines, I.F.: 2.873 CARDIOLOGIA. 72(6):511-512. I.F.: 5.166 David E.; Haissaguerre, Michel; Helm, Robert H.; Hylek, Elaine; Jackman, Warren M.; Jalife, 3. Guasch E, Mont L, Sitges M . 6. Den Uijl DW, Mont L. Response to the Jose; Kalman, Jonathan M.; Kautzner, Josef; Mechanisms of atrial fibrillation in letter to the editor on 'impact of left atrial Kottkamp, Hans; Kuck, Karl Heinz; Kumagai, athletes: what we know and what we do volume, sphericity and fibrosis on the Koichiro; Lee, Richard; Lewalter, Thorsten; not know. NETHERLANDS HEART outcome of catheter ablation for atrial Lindsay, Bruce D.; Macle, Laurent; Mansour, JOURNAL. 26(3):133-145. I.F.: 1.476 fibrillation'. JOURNAL OF Moussa; Marchlinski, Francis E.; Michaud, CARDIOVASCULAR Gregory F.; Nakagawa, Hiroshi; Natale, 4. Alventosa-Zaidin M, Roca Saumell C, ELECTROPHYSIOLOGY. 29(7):E15-E15. Andrea; Nattel, Stanley; Okumura, Ken; Brugada Terradellas J. Right bundle I.F.: 2.873 Packer, Douglas; Pokushalov, Evgeny; branch block and cardiovascular Reynolds, Matthew R.; Sanders, morbidity and mortality in healthy Prashanthan; Scanavacca, Mauricio;

111 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

Schilling, Richard; Tondo, Claudio; Tsao, Sponsored by: Ministerio de Economía y Mont JL. Arítmies, Resincronització i Hsuan-Ming; Verma, Atul; Wilber, David J.; Competitividad (MINECO). imatge cardíaques. Yamane, Teiichi; EHRA; AHA; Soc RTC-2016-5445-1 Sponsored by: Generalitat De Catalunya. Latinoamer Estimulacion; APHRS; ACC; Duration: 08/03/2016-31/08/2019 AGAUR_SGR17_01548 ECAS; STS; CHRS; JHRS; Soc Brasileira Duration: 01/01/2017- 31/12/2020 Arritmias Cardiacas. 2017 Berruezo A. Caracterización automática HRS/EHRA/ECAS/APHRS/SOLAECE del sustrato arrítmico y evaluación de su expert consensus statement on utilidad para la prevención de la muerte Mont L. Ablación de fibrilación auricular catheter and surgical ablation of atrial súbita cardíaca y guiado de los guiada por resonancia magnética. fibrillation. EUROPACE. 20(1):E1-E160. procedimientos de arritmias (ADAS). Estudio randomizado de la eficacia de la I.F.: 5.231 Sponsored by: Ministerio de Economía y identificación y aislamiento de las zonas Competitividad (MINECO). de fibrosis. 2. Kotecha D, Breithardt G, Camm AJ, Lip RTC-2015-3515-1 Sponsored by: Instituto de Salud Carlos III GYH, Schotten U, Ahlsson A, Arnar D, Atar Duration:01/11/2015-30/06/2018 (ISCIII). PI16/00435 D, Auricchio A, Bax J, Benussi S, Duration: 01/01/2017-31/12/2019 Blomstrom-Lundqvist C, Borggrefe M, Brugada J. Comparative Effectiveness Boriani G, Brandes A, Calkins H, Casadei B, Research to Assess the Use of Primary Mont L. Characterizing Atrial fibrillation Castellá M, Chua W, Crijns H, Dobrev D, ProphylacTic Implantable Cardioverter by Translating its Causes into Health Fabritz L, Feuring M, Freedman B, Gerth A, Defibrillators in EUrope. Modifiers in the Elderly. Goette A, Guasch E, Haase D, Hatem S, Sponsored by: European Commission. Sponsored by: European Commission. Haeusler KG, Heidbuchel H, Hendriks J, CE_FP7_HEALTH_IN1_13 (602299-2) CE_H2020-PHC-2014-2s (633196) Hunter C, Kääb S, Kespohl S, Landmesser U, Duration: 01/10/2013-30/09/2018 Duration: 01/05/2015-30/04/2019 Lane DA, Lewalter T, Mont L, Nabauer M, Nielsen JC, Oeff M, Oldgren J, Oto A, Pison Egea G. Apolinker p144, a potential Ortiz JT. Paper dels macròfags i L, Potpara T, Ravens U, Richard-Lordereau I, anti-tTGFgf-beta therapeutic tool to fight fibroblastes residents a la remodelació Rienstra M, Savelieva I, Schnabel R, Sinner against aortic aneurysms in marfan miocàrdica i la regeneració tisular tras MF, Sommer P, Themistoclakis S, Van syndrome. l'infart de miocardi: contribució del Gelder IC, Vardas PE, Verma A, Wakili R, Sponsored by: The National Marfan sistema GAS6-TAM. Weber E, Werring D, Willems S, Ziegler A, Foundation. INT_NMarfanF_15 Sponsored by: Fundació la Marató de TV3. Hindricks G, Kirchhof P . Integrating new (NMARFANF_15_01) TV3_Cor_15 approaches to atrial fibrillation Duration: 01/01/2016-31/12/2018 Duration: 26/04/2016-31/12/2019 management: the 6th AFNET/EHRA Consensus Conference. EUROPACE. Egea G. Impacto fisiopatológico de un Ortiz JT. Papel del sistema GAS6-TAM en 20(3):395-407. I.F.: 5.231 péptido anti-TGF-beta, del ejercicio la diferenciación fibroblástica y el físico y del humo de los cigarrillos en la remodelado ventricular tras el infarto de formación del anuerisma aórtico en el miocardio. síndrome de Marfan. Sponsored by: Instituto de Salud Carlos III GRANTS FOR RESEARCH IN Sopnsored by: Ministerio de Economía y (ISCIII). PI15/00531 PROGRESS Competitividad (MINECO). Duration: 01/01/2016-31/12/2019 SAF2017-83039-R Arbelo E. Estudio ANVERSO: análisis Duration: 01/01/2018-31/12/2020 Sitges M. Predicció personalitzada i continuo y automático de variables oprecoç de fibrilació auricular en electrocardiográficas en relación al Guasch E. Caracterización del subjectes en risc. PREDICTAF. riesgo de muerte súbita en pacientes con remodelado a dosis crecientes de Sponsored by: Fundació la Marató de TV3. síndrome de Brugada. ejercicio físico como sustrato para el TV3_Cor_15 Sponsored by: Instituto de Salud Carlos III desarrollo de patología inducida por el Duration: 10/05/2016-09/05/2019 (ISCIII). PI16/01203 ejercicio. Duration: 01/01/2017-31/12/2019 Sponsored by: Instituto de Salud Carlos III Sitges M. Personalized In-Silico (ISCIII). PI16/00703 Cardiology. Batlle M. Acidosis asociada al ejercicio Duration: 01/01/2017-31/12/2019 Sponsored by: European Commission. extremo y su efecto en la función CE_H2020-MSCA-ITN-17 (764738) mitocondrial vascular. Mont JL. Caracterització no invasiva dels Duration: 01/09/2017-31/08/2021 Sponsored by: Sociedad Española de teixits de l'aurícula esquerra per guiar Cardiologia (SEC). SEC_BASICA_02 l'ablació de la fibril·lació auricular i per Duration: 26/10/2017-31/12/2018 predir els resultats del procediment així com la progressió de la malaltia. Berruezo A. ABLAVIEW: Un sistema Sponsored by: Fundació la Marató de TV3. innovador de ablación por TV3_Cor_15 radiofrecuencia guiado por imagen para Duration: 29/06/2016-28/06/2019 el tratamiento de la fibrilación auricular.

112 ARRHYTHMIAS, RESYNCHRONIZATION AND CARDIAC IMAGING 2.2

DOCTORAL THESES

Berruezo A.Técnicas de imagen y mapeo electroanatómico para la identicación y caracterización del sustrato de las arritmias ventriculares. Implicaciones en la ablación con catéter y en la estratiﬁcación de riesgo de arritmias ventriculares malignas. PhD student: Juan Acosta Martínez

Ortiz JT, Bosch X. Paper del sistema GAS6-TAM en el remodelat ventricular postinfart agut de miocardi. PhD student: Guillem R. Caldentey Adrover

Mont L, Miranda J. Compatibilitat clínica entre marcapassos cardíacs i aparells electrònics odontològics: Estudi in vivo. PhD student: Isabel Conde Mir

Egea G. Technological insights into a histopathological and protein composition analysis of aortic aneurysms in Marfan syndrome. PhD student: Júlia López Guimet

113 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

Nephro-urological diseases 2.3 and kidney transplantation

TEAM LEADER Ana Teresa Menjivar (FCRB) Fritz Diekmann (HCB) Olga Millan (HCB) LOCATION T. 93 227 54 00 (Ext.: 5444) Alicia Molina (HCB) CELLEX building, ﬂoor 2B [email protected] Carlos Nicolau (HCB) Raquel Ojeda (HCB) Eduard Palou (HCB)

GROUP LEADER David Parades (HCB) Ignacio Revuelta (HCB-IDIBAPS) Maria José Ricart (HCB) T.93 227 54 00 (Ext.: 4410) Lida Rodas (HCB) KEYWORDS [email protected] Rafael Salvador (HCB) 1. Renal transplantation Clara San Bartolome (HCB) 2. Dialysis Manel Solé (HCB) 3. Transplant immunology Belen Suarez (HCB) Posttransplant cancer 4. RESEARCHERS Vicenç Torregrosa (HCB) 5. Renal regeneration Josep M. Campistol (HCB) Ana Paula Villela (HCB) 6. Pancreas transplantation Aleix Cases (HCB) Marc Xipell (HCB) 7. Transplant registries Martí Manyalich (HCB) Federico Oppenheimer (HCB) Esteban Poch (HCB) Luis F. Quintana (HCB) STRATEGIC OBJECTIVES Jordi Rovira (IDIBAPS) LENIT performs translational research of renal diseases. Our focus is pathophysiology of Original publications POST-DOCTORAL RESEARCHERS kidney diseases and optimization of renal from 2016 to 2018 Elisenda Bañon (FCRB) Maria Jose Ramirez (FCRB) replacement therapy (RT) (dialysis or YEAR I.F. TOTAL Q1 Q2 transplantation) as well as pancreas transplantation. 2016 171.98 23 15 4 PRE-DOCTORAL RESEARCHERS Marta Arias (HCB) However, we also focus on regenerative 2017 116.82 19 11 3 Sergi Betriu (FCRB) treatment as an alternative establishing a cure 2018 216.07 17 10 3 Miquel Blasco (HCB) and thus avoiding the need for conventional David Cucchiari (HCB) organ replacement therapy. Miquel Gómez (FCRB) Gastón Julio (HCB) Valeria Tubita (IDIBAPS-FCRB) TEAM INVOLVED IN Pedro Ventura (HCB) MAIN LINES OF RESEARCH REDinREN Manel Vera (HCB) AGAUR_SGR17-1331 In order to achieve these challenges, we are a

TECHNICIANS team with well-balanced collaboration Natalia Hierro (IDIBAPS) between clinicians and medical researchers, Marta Lazo (IDIBAPS) biologists, biochemists, veterinarians and specialist technicians.

ADMINISTRATIVE STAFF This expertise enables us to personalize and Mireia Collado (IDIBAPS) improve current therapies and to discover new ways of action. Scientiﬁc objectives of

COLLABORATORS LENIT are focused on the following areas of Ramon Adalia (HCB) research: Joan Albert Barberà (HCB) Mercedes Brunet (HCB) Federico Cofan (HCB) 1. Immunology of transplantationCell therapy Erika de (HCB) and renal regeneration. Maribel Diaz (HCB) Ginés Escolar (HCB) 2. Role of immunosuppression and Nuria Esforzado (HCB) immunosuppressive medications in M Angeles Garcia (HCB) posttransplantation oncogenesis. Juan Carlos García-Pagán (HCB) Eduard Gratacós (HCB) 3. Advanced therapies in renal Georgina Hotter (IIBB-CSIC) transplantation. Miguel Ángel Lopez-Boado (HCB) Fracesc Maduell (HCB) 4. Pancreas Transplantation. Jaume Martorell (HCB)

114 NEPHRO-UROLOGICAL DISEASES AND KIDNEY TRANSPLANTATION 2.3

5. Renal living donor psychosocial follow-up.

6. Glomerular diseases and endothelial disfunction.

7. Identiﬁcation of new uremic toxins.

8. Artiﬁcial inteloigence and big data in nephrology and kidney transplant.

50/50 PROGRAM TRANSLATIONAL RESEARCH IN POSTTRASPLANT NEOPLASIA Ignacio Revuelta GROUP

GROUP LEADER with Hereditary transthyretin amyloidosis. pregnancy-associated atypical hemolytic Ignacio Revuelta (HCB-IDIBAPS) NEW ENGLAND JOURNAL OF MEDICINE. uremic syndrome. KIDNEY 379(1):22-31. I.F.: 79.260 INTERNATIONAL. 93(2):450-459. I.F.: 8.429 Alloimmunity and tumor immunity is a challenge in transplantation. The effect of the 2. Adams D., Gonzalez-Duarte A., O'Riordan W., 5. Vera M, Torramade-Moix S, Martin-Rodriguez immunosuppressive therapy in tumor immune Yang C., Ueda M., Kristen A., Tournev I., Schmidt S, Cases A, Cruzado JM, Rivera J, Escolar G, escape and oncologic pathways lead to tumor H., Coelho T., Berk J., Lin K., Vita G., Attarian S., Palomo M, Diaz-Ricart M . Antioxidant and progression and metastasis development. Planté-Bordeneuve V., Mezei M., Campistol J., Anti-Inflammatory Strategies Based on the Exosomes released from cancer cells (CaEx) Buades J., Brannagan T., Kim B., Oh J., Parman Y., Potentiation of Glutathione Peroxidase or immune cells (InmEx) are crucial for Sekijima Y., Hawkins P., Solomon S., Polydefkis Activity Prevent Endothelial Dysfunction in intercellular communication, and their role in M., Dyck P., Gandhi P., Goyal S., Chen J., Strahs A., Chronic Kidney Disease. CELLULAR transplant settings is unknown. Nochur S., Sweetser M., Garg P., Vaishnaw A., PHYSIOLOGY AND BIOCHEMISTRY. We aim to characterize CaEx and InmEx Gollob J., Suhr O. Patisiran, an RNAi 51(3):1287-1300. I.F.: 5.500 under different transplant situations. However, therapeutic, for hereditary transthyretin recent immune risk classifications and kind of amyloidosis. NEW ENGLAND JOURNAL OF 6. Ocak G., Noordzij M., Rookmaaker M., Cases rejection are not representing the real MEDICINE. 379(1):11-21. I.F.: 79.260 A., Couchoud C., Heaf J., Jarraya F., De Meester scenario. J., Groothoff J., Waldum-Grevbo B., Palsson R., New technology tools based on big data 3. Lefaucheur C, Viglietti D, Hidalgo LG, Ratner Resic H., Remón C., Finne P., Stendahl M., and/or artifitial intelligence are needed for LE, Bagnasco SM, Batal I, Aubert O, Orandi BJ, Verhaar M., Massy Z., Dekker F., Jager K. better characterization of the transplant Oppenheimer F, Bestard O, Rigotti P, Reisaeter Mortality due to bleeding, myocardial population. AV, Kamar N, Lebranchu Y, Duong Van Huyen infarction and stroke in dialysis patients. JP, Bruneval P, Glotz D, Legendre C, Empana JP, JOURNAL OF THROMBOSIS AND Jouven X, Segev DL, Montgomery RA, Zeevi A, HAEMOSTASIS. 16(10):1953-1963. I.F.: 4.899 Halloran PF, Loupy A . Complement- PUBLICATIONS Activating Anti-HLA Antibodies in Kidney 7. Ventura-Aguiar P, Ferrer J, Revuelta I, Paredes Transplantation: Allograft Gene D, de Sousa-Amorim E, Rovira J, Esmatjes E, Originals / I.F.: 216.068 Expression Profiling and Response to Garcia-Valdecasas JC, Campistol JM, Treatment. JOURNAL OF THE AMERICAN Oppenheimer F, Diekmann F, Ricart MJ . 1. Benson M., Waddington-Cruz M., Berk J., SOCIETY OF NEPHROLOGY : JASN. Pancreas outcomes between living and Polydefkis M., Dyck P., Wang A., 29(2):620-635. I.F.: 8.655 deceased kidney donor in pancreas after Planté-Bordeneuve V., Barroso F., Merlini G., kidney transplantation patients. Obici L., Scheinberg M., Brannagan T., Litchy W., 4. Huerta A., Arjona E., Portoles J., NEPHROLOGY, DIALYSIS AND Whelan C., Drachman B., Adams D., Heitner S., Lopez-Sanchez P., Rabasco C., Espinosa M., TRANSPLANTATION. 33(11):2052-2059. Conceição I., Schmidt H., Vita G., Campistol J., Cavero T., Blasco M., Cao M., Manrique J., I.F.: 4.602 Gamez J., Gorevic P., Gane E., Shah A., Solomon Cabello-Chavez V., Suñer M., Heras M., S., Monia B., Hughes S., Jesse Kwoh T., McEvoy Fulladosa X., Belmar L., Sempere A., Peralta C., 8. Ceretta ML, Noordzij M, Luxardo R, De B., Jung S., Baker B., Ackermann E., Gertz M., Castillo L., Arnau A., Praga M., Rodriguez de Meester J, Abad Diez JM, Finne P, Heaf JG, Coelho T. Inotersen treatment for patients Cordoba S. A retrospective study of Couchoud C, Kramar R, Collart F, Cases A,

115 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

Palsson R, Reisæter AV, Rydell H, Massy ZA, DISEASES. 22(3):193-201. I.F.: 2.083 (HCV) treated donors for kidney Jager KJ, Kramer A. Changes in co-morbidity transplantation (KT) excluding occult HCV pattern in patients starting renal 15. Bodro M, Londoño MC, Esforzado N, infection through kidney biopsies. replacement therapy in Europe-data from Sanclemente G, Linares L, Solano MF, Cofan F, TRANSPLANT INTERNATIONAL. the ERA-EDTA Registry. NEPHROLOGY, Marcos MA, Diekmann F, Moreno A . Hepatitis 31(8):938-939. I.F.: 3.196 DIALYSIS AND TRANSPLANTATION. C viremia as a risk factor for opportunistic 33(10):1794-1804. I.F.: 4.602 infections in kidney transplant recipients. CLINICAL TRANSPLANTATION. Case Reports / I.F.: 5.503 9. Rovira J, Ramírez-Bajo MJ, Banon-Maneus E, 32(10):e13382. I.F.: 1.518 Lazo-Rodríguez M, Moya-Rull D, Hierro-Garcia 1. Xipell M., Victoria I., Hoffmann V., Villarreal J., N, Tubita V, Piñeiro GJ, Revuelta I, Ventura- 16. Maduell F., Ojeda R., Arias-Guillén M., García-Herrera A., Reig O., Rodas L., Blasco M., Aguiar P, Cucchiari D, Oppenheimer F, Brunet M, Fontseré N., Vera M., Rodas L., Gómez M., Poch E., Mellado B., Quintana L. Acute Campistol JM, Diekmann F . Tofacitinib halts Huablocho K., Esquivel F., Mori P., Hoffmann V., tubulointerstitial nephritis associated with progression of graft dysfunction in a rat Ugalde J., Rico N. A new generation of atezolizumab, an anti-programmed model of mixed cellular and humoral cellulose triacetate suitable for online death-ligand 1 (pd-l1) antibody therapy. rejection. TRANSPLANTATION. haemodiaﬁltration. NEFROLOGIA. ONCOIMMUNOLOGY. 7(7):e1445952. 102(7):1075-1084. I.F.: 3.960 38(2):161-168. I.F.: 1.167 I.F.: 5.503

10. Menjivar A, Torres X, Paredes D, Avinyo N, 17. Maduell F, Ojeda R, Belmar L, Munguía P, Peri JM, De Sousa-Amorim E, Oppenheimer F, Sango C, Martinez-Díaz A, Arias-Guillén M, Vera Manyalich M, Diekmann F, Revuelta I. M, Fontseré N, Gómez M, Rodas L, Rico N. GRANTS FOR RESEARCH IN PROGRESS Assessment of donor satisfaction as an Evaluation of the dialyser inner diameter in essential part of living donor kidney online haemodiafiltration. NEFROLOGIA. Diekmann F. Laboratori Experimental de transplantation: an eleven-year 38(1):34-40. I.F.: 1.167 Nefrologia i Trasplantament Renal retrospective study. TRANSPLANT (LENIT). INTERNATIONAL. 31(12):1332-1344. I.F.: 3.196 Sponsored by: Generalitat de Catalunya. Review / I.F.: 2.65 AGAUR_SGR17 (01331) 11. Perelló J., Gómez M., Ferrer M., Rodríguez N., Duration: 01/01/2017-31/12/2020 Salcedo C., Buades J., Pérez M., Torregrosa J., 1. Cases A, Gorriz JL. Sodium zirconium Martín E., Maduell F. SNF472, a novel inhibitor of cyclosilicate: a new potassium binder for Diekmann F. Inmunoterapia para el control vascular calcification, could be administered the treatment of hyperkalemia. DRUGS OF del rechazo del riñon trasplantado: uso de during hemodialysis to attain potentially TODAY. 54(10):601-613. I.F.: 1.325 células T modificadas genéticamente con therapeutic phytate levels. JOURNAL OF receptores quiméricos del antígeno. NEPHROLOGY. 31(2):287-296. I.F.: 2.724 2. Poch E, Rodas L, Blasco M, Molina A, Sponsored by: Instituto de Salud Carlos III (ISCIII). Quintana L. An update on tolvaptan for PI17/00078 12. Arias-Guillén M., Perez E., Herrera P., autosomal dominant polycystic kidney Duration: 01/01/2018-31/12/2020 Romano B., Ojeda R., Vera M., Ríos J., Fontseré disease. DRUGS OF TODAY. 54(9):519-533. N., Maduell F. Bioimpedance Spectroscopy I.F.: 1.325 Diekmann F. Red de Investigación renal. as a Practical Tool for the Early Detection Sponsored by: Instituto de Salud Carlos III and Prevention of Protein-Energy Wasting (ISCIII). RD16/0009/0023 in Hemodialysis Patients. JOURNAL OF Letters / I.F.: 7.798 Duration: 01/01/2017-31/12/2021 RENAL NUTRITION. 28(5):324-332. I.F.: 2.651 1. Jager KJ, Stel VS, Branger P, Guijt M, Busic M, Diekmann F. Extracellular Vesicles and 13. Piñeiro G., De Sousa-Amorim E., Solé M., Ríos Dragovic M, Diekmann F, Manyalich M, Di exosomes from adult stem cells in the J., Lozano M., Cofán F., Ventura-Aguiar P., Ciaccio P, Nanni Costa A, Collett D, Mumford L, regeneration of organ injury. Cucchiari D., Revuelta I., Cid J., Palou E., Haase B, Hemke A, Deme O, Mihály S, Murphy Sponsored by: European Commission. Campistol J., Oppenheimer F., Rovira J., M, Couchoud C, Massy Z, Massy Z, Massy Z, CE_PEOPLE-2013-IAPP (612224) Diekmann F. Rituximab, plasma exchange Lingemann M, Rahmel A. The effect of Duration: 01/02/2014-31/01/2018 and immunoglobulins: An ineffective differing kidney disease treatment treatment for chronic active modalities and organ donation and Campistol JM. Targeting endothelial antibody-mediated rejection. BMC transplantation practices on health dysfunction in highly prevalent diseases: NEPHROLOGY. 19(1):261. I.F.: 2.395 expenditure and patient outcomes. characterization and validation of NEPHROLOGY, DIALYSIS AND prognostic biomarkers and identification 14. Cristelli M., Trullàs J., Cofán F., Rico N., TRANSPLANTATION. 33(4):560-562. of potential therapeutic strategies. Manzardo C., Ambrosioni J., Bedini J., Moreno A., I.F.: 4.602 Sponsored by: Instituto de Salud Carlos III (ISCIII). Diekmann F., Miro J. Prevalence and risk PIE15/00027 factors of mild chronic renal failure in 2. Gelpi R, Rodríguez-Villar C, Paredes D, Roque Duration: 01/01/2016-31/12/2019 HIV-infected patients: influence of female R, Ruiz A, Adalia R, de Sousa E, Revuelta I, Sole M, gender and antiretroviral therapy. Martinez M, Navarro M, Lens S, Oppenheimer F, Manyalich M. Evolución psicosocial del BRAZILIAN JOURNAL OF INFECTIOUS Diekmann F . Safety of Hepatitis C Virus donante vivo renal. Estudio de cohortes.

116 NEPHRO-UROLOGICAL DISEASES AND KIDNEY TRANSPLANTATION 2.3

Sponsored by: Instituto de Salud Carlos III (ISCIII). PI14/00693 Duration: 01/01/2015-30/06/2019

Manyalich M. EDITH: The Effect of Differing Kidney Disease Treatment Modalities and Organ Donation and Transplantation Practices on Health Expenditure and Patient Outcomes. Sponsored by: European Commission. HP-PP16 (739495) Duration: 01/01/2017-31/12/2019

Quintana LF. Papel de la patología digital y la Resonancia nuclear magnética en la detección precoz de la ﬁbrosis intersticial en la enfermedad renal crónica. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI17/00080 Duration: 01/01/2018-31/12/2020

Revuelta I. Papel de los exosomas de células inmunes de memoria (InmEx) en la activación del endotelio y desarrollo precoz del rechazo mediado por anticuerpos en el trasplante renal Sponsored by: Instituto de Salud Carlos III (ISCIII). PI16/00115 Duration: 01/01/2017-31/12/2019

Ricart MJ. Trasplante de páncreas – monitorización de poblaciones linfocitarias y aplicación de ecografía con contraste y elastograﬁa como preditores de rechazo y sobrevida. Sponsored by: Instituto de Salud Carlos III. PI16/00167 Duration: 01/01/2017-31/12/2019

117 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

Cardiovascular, nutrition 2.4 and aging unit

NURSING STAFF Maria Gual (IDIBAPS) LOCATION Ana Jordán (HCB) CELLEX building, ﬂoor 4B Rosa Soriano (HCB) Internal Medicine Service, HCB COLLABORATORS Rosa Lamuela-Raventós (UB) Marina Puig (IDIBAPS) Javier Sobrino (UB) KEYWORDS Conxa Viñas (CIBEROBN) 1. Nutrition TEAM LEADER 2. Mediterranean diet Ramon Estruch (HCB) 3. Cardiovascular disease T. 93 227 23 33 STRATEGIC OBJECTIVES 4. Cardiovascular risk factors [email protected] 5. Cognition To deep in the knowledge of the effects of the lifestyle (Effect of diet, alcohol and physical EMERITUS exercise) in the different stages of life Emilio Ros (HCB) (adolescence, pregnancy, elderly ...) and its role in the prevention of chronic diseases RESEARCHERS (hypertension, diabetes, dyslipidemia, Original publications Antonio Coca (HCB) cognitive impairment ...) and cancer. from 2015 to 2017 Ferran Masanés (HCB)

YEAR I.F. TOTAL Q1 Q2 Emilio Sacanella (HCB) Cristina Sierra (HCB) 2016 143.83 32 21 8 MAIN LINES OF RESEARCH 2017 188.02 41 25 11 POST-DOCTORAL RESEARCHERS 2018 308.12 44 35 6 Miguel Camafort (HCB) 1. Protective Effects of Mediteranean Diet on Rosa Casas (CIBEROBN) cardiovascular and cerebrovascular Mónica Doménech (FCRB) prevention ( chronic diseases, Dolors Estrada (HCB) neurodegenerative diseases and cáncer). Alfonso López (HCB)

TEAM INVOLVED IN Margarita Navarro (HCB) 2. Effects of alcohol (beer or wine) CIBEROBN compsumption on health. AGAUR_SRG17 PRE-DOCTORAL RESEARCHERS Sara Castro (IDIBAPS) 3. Effects of other diet components on Tania Freitas (IDIBAPS) healthy: olive oil, nuts, cocoa, fatty-acids, Ana M. Ruiz (CIBEROBN) tomatoes….

AWARDS Excellence in Research Award Institution: International Nut and Dried Fruit Foundation Awardee/s: Ramon Estruch

Premis DOP Catalanes d’Oli Institution: Denominacions d’Origen Catalanes d’Oli Awardee/s: Ramon Estruch Ramon Estruch TEAM

118 CARDIOVASCULAR, NUTRITION AND AGING UNIT 2.4

4. Assesment on cardiovascular risk factors case–cohort study. CLINICAL CHEMISTRY. Toledo E., Clish C., Corella D., Estruch R., Ros on primary prevention, specially blood 64(8):1211-1220. I.F.: 8.636 E., Fitó M., Arós F., Fiol M., Lapetra J., pressure management. Serra-Majem L., Gómez-Gracia E., Liang L., 5. Martínez-González MA, Buil-Cosiales P, Fragkiadakis G., Razquin C., Hu F., 5. Hair failure physiopathology. Corella D, Bulló M, Fitó M, Vioque J, Salas-Salvadó J. Plasma Romaguera D, Martínez JA, Wärnberg J, trimethylamine-N-oxide and related 6. Aging. López-Miranda J, Estruch R, Bueno- metabolites are associated with type 2 Cavanillas A, Arós F, Tur JA, Tinahones F, diabetes risk in the Prevención con Dieta 7. Thrombosis. Serra-Majem L, Martín V, Lapetra J, Vázquez Mediterránea (PREDIMED) trial. C, Pintó X, Vidal J, Daimiel L, AMERICAN JOURNAL OF CLINICAL Delgado-Rodríguez M, Matía P, Ros E, NUTRITION. 108(1):163-173. I.F.: 6.549 Fernández-Aranda F, Botella C, Portillo MP, PUBLICATIONS Lamuela-Raventós RM, Marcos A, Sáez G, 10. García-Gavilán JF; Bullo M; Gómez-Gracia E, Ruiz-Canela M, Toledo E, Camacho-Barcia L; Rosique-Esteban N; Originals / I.F.: 318.019 Alvarez-Alvarez I, Díez-Espino J, Sorlí JV, Hernández-Alonso P; Basora J; Basora J, Castañer O, Schröder H, Martinez-Gonzalez MA; Estruch R; Fito M; 1. Estruch R, Ros E, Salas-Salvadó J, Covas Navarrete-Muñoz EM, Zulet MA, García-Rios Salas-Salvado J. Higher dietary glycemic MI, Corella D, Arós F, Gómez-Gracia E, A, Salas-Salvadó J, PREDIMED-Plus index and glycemic load values increase Ruiz-Gutiérrez V, Fiol M, Lapetra J, Investigators. Cohort Proﬁle: Design and the risk of osteoporotic fracture in the Lamuela-Raventos RM, Serra-Majem L, Pintó methods of the PREDIMED-Plus PREvención con DIeta MEDiterránea X, Basora J, Muñoz MA, Sorlí JV, Martínez JA, randomized trial. INTERNATIONAL (PREDIMED)-Reus trial. AMERICAN Fitó M, Gea A, Hernán MA, Martínez-González JOURNAL OF EPIDEMIOLOGY. JOURNAL OF CLINICAL NUTRITION. MA, PREDIMED Study Investigators. Primary 48(2):387-388o. I.F.: 8.360 107(6):1035-1042. I.F.: 6.549 Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with 6. Wang D., Zheng Y., Toledo E., Razquin C., 11. Ruiz-Canela M; Guasch-Ferré M; Toledo E; Extra-Virgin Olive Oil or Nuts. NEW Ruiz-Canela M., Guasch-Ferré M., Yu E., Clish C; Razquin C; Liang L; Wang D; Corella D; ENGLAND JOURNAL OF MEDICINE. Corella D., Gómez-Gracia E., Fiol M., Estruch Hernáez Á; Yu E; Gómez-Gracia E; Zheng Y; 378(25):e34. I.F.: 79.260 R., Ros E., Lapetra J., Fito M., Aros F., Arós F; Romaguera D; Dennis C; Ros E; Serra-Majem L., Clish C., Salas-Salvadó J., Lapetra J; Serra-Majem L; Papandreou C; 2. Paynter, Nina P.; Balasubramanian, Raji; Liang L., Martínez-González M., Hu F. Lipid Portolés O; Fito M; Hu F; Martínez-González Giulianini, Franco; Wang, Dong D.; Tinker, metabolic networks, Mediterranean diet M. Plasma branched chain/aromatic amino Lesley F.; Gopal, Shuba; Deik, Amy A.; Bullock, and cardiovascular disease in the acids, enriched Mediterranean diet and Kevin; Pierce, Kerry A.; Scott, Justin; PREDIMED trial. INT J EPIDEMIOL. risk of type 2 diabetes: case-cohort study Martinez-Gonzalez, Miguel A.; Estruch, 47(6):1830-1845. I.F.: 8.360 within the PREDIMED Trial. Ramon; Manson, JoAnn E.; Cook, Nancy R.; DIABETOLOGIA. 61(7):1560-1571. I.F.: 6.023 Albert, Christine M.; Clish, Clary B.; Rexrode, 7. Miro, Oscar; Estruch, Ramon; Kathryn M. Metabolic Predictors of Incident Martin-Sanchez, Francisco J.; Gil, Victor; 12. Schröder H, Cárdenas-Fuentes G, Coronary Heart Disease in Women. Jacob, Javier; Herrero-Puente, Pablo; Herrera Martínez-González MA, Corella D, Vioque J, CIRCULATION. 137(8):841-853. I.F.: 18.881 Mateo, Sergio; Aguirre, Alfons; Andueza, Juan Romaguera D, Alfredo Martínez J, Tinahones A.; Llorens, Pere; ICA-SEMES Res Grp. FJ, Miranda JL, Estruch R, Bueno-Cavanillas 3. Razquin C., Toledo E., Clish C., Ruiz-Canela Adherence to Mediterranean Diet and A, Arós F, Marcos A, Tur JA, Warnberg J, M., Dennis C., Corella D., Papandreou C., Ros All-Cause Mortality After an Episode of Serra-Majem L, Martín V, Vázquez C, Lapetra E., Estruch R., Guasch-Ferré M., Acute Heart Failure. JACC: HEART J, Pintó X, Vidal J, Daimiel L, Gaforio JJ, Gómez-Gracia E., Fitó M., Yu E., Lapetra J., FAILURE. 6(1):52-62. I.F.: 8.202 Matía-Martín P, Ros E, Castañer O, Lassale C, Wang D., Romaguera D., Liang L., Ruiz-Canela M, Asensio EM, Basora J, Alonso-Gómez A., Deik A., Bullo M., 8. Barrubés L, Babio N, Mena-Sánchez G, Torres-Collado L, Garcia-Rios A, Abete I, Serra-Majem L., Salas-Salvadó J., Hu F., Toledo E, Ramírez-Sabio JB, Estruch R, Ros E, Toledo E, Buil-Cosiales P, Bullo M, Goday A, Martínez-González M. Plasma Lipidomic Fitó M, Arós F, Fiol M, Santos-Lozano JM, Fitó M, Salas-Salvadó J, PREDIMED-Plus Proﬁling and Risk of Type 2 Diabetes in the Serra-Majem L, Pintó X, Martínez-González investigators. Effectiveness of the physical PREDIMED Trial. DIABETES CARE. MÁ, Sorlí JV, Basora J, Salas-Salvadó J, activity intervention program in the 41(12):2617-2624. I.F.: 13.397 PREvención con DIeta MEDiterránea Study PREDIMED-Plus study: a randomized Investigators. Dairy product consumption controlled trial. INTERNATIONAL JOURNAL 4. Yu E., Papandreou C., Ruiz-Canela M., and risk of colorectal cancer in an older OF BEHAVIORAL NUTRITION AND Guasch-Ferre M., Clish C., Dennis C., Liang L., Mediterranean population at high PHYSICAL ACTIVITY. 15(1):110. I.F.: 5.548 Corella D., Fitó M., Razquin C., Lapetra J., cardiovascular risk. INTERNATIONAL Estruch R., Ros E., Cofán M., Arós F., Toledo E., JOURNAL OF CANCER. 143(6):1356-1366. 13. Pérez-Heras A., Mayneris-Perxachs J., Serra-Majem L., Sorlí J., Hu F., Martinez- I.F.: 7.360 Cofán M., Serra-Mir M., Castellote A., Gonzalez M., Salas-Salvado J. Association of López-Sabater C., Fitó M., Salas-Salvadó J., tryptophan metabolites with incident type 9. Papandreou C., Bulló M., Zheng Y., Martínez-González M., Corella D., Estruch R., 2 diabetes in the PREDIMED trial: A Ruiz-Canela M., Yu E., Guasch-Ferré M., Ros E., Sala-Vila A. Long-chain n-3 PUFA

119 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

supplied by the usual diet decrease plasma related to atherosclerosis in men with high 24. Amor AJ, Cofán M, Mateo-Gallego R, stearoyl-CoA desaturase index in cardiovascular risk: Randomized Cenarro A, Civeira F, Ortega E, Ros E, non-hypertriglyceridemic older adults at intervention trial. CLINICAL NUTRITION. Sala-Vila A. Dietary polyunsaturated fatty high vascular risk. CLINICAL NUTRITION. I.F.: 5.496 acids mediate the inverse association of 37(1):157-162. I.F.: 5.496 stearoyl-CoA desaturase activity with the 20. Álvarez-Álvarez I, Martínez-González MÁ, risk of fatty liver in dyslipidaemic 14. Cantero I., Abete I., Babio N., Arós F., Sánchez-Tainta A, Corella D, Díaz-López A, individuals. EUROPEAN JOURNAL OF Corella D., Estruch R., Fitó M., Hebert J., Fitó M, Vioque J, Romaguera D, Martínez JA, NUTRITION. I.F.: 4.423 Martínez-González M., Pintó X., Portillo M., Wärnberg J, López-Miranda J, Estruch R, Ruiz-Canela M., Shivappa N., Wärnberg J., Bueno-Cavanillas A, Arós F, Tur JA, Tinahones 25. Cárdenas-Fuentes G, Subirana I, Gómez-Gracia E., Tur J., Salas-Salvadó J., FJ, Serra-Majem L, Martín V, Lapetra J, Más Martinez-Gonzalez MA, Salas-Salvadó J, Zulet M., Martínez J. Dietary Inflammatory Fontao S, Pintó X, Vidal J, Daimiel L, Gaforio JJ, Corella D, Estruch R, Fíto M, Muñoz-Bravo C, Index and liver status in subjects with Matía P, Ros E, Ruiz-Canela M, Sorlí JV, Fiol M, Lapetra J, Aros F, Serra-Majem L, Tur different adiposity levels within the Becerra-Tomás N, Castañer O, Schröder H, JA, Pinto X, Ros E, Coltell O, Díaz-López A, PREDIMED trial. CLINICAL NUTRITION. Navarrete-Muñoz EM, Zulet MÁ, García-Ríos Ruiz-Canela M, Schröder H. Multiple 37(5):1736-1743. I.F.: 5.496 A, Salas-Salvadó J, Díez-Espino J, Toledo E. approaches to associations of physical Adherence to an Energy-restricted activity and adherence to the 15. Konieczna J, Abete I, Galmés AM, Babio N, Mediterranean Diet Score and Prevalence Mediterranean diet with all-cause mortality Colom A, Zulet MA, Estruch R, Vidal J, Toledo of Cardiovascular Risk Factors in the in older adults: the PREvención con DIeta E, Díaz-López A, Fiol M, Casas R, Vera J, PREDIMED-Plus: A Cross-sectional Study. MEDiterránea study. EUROPEAN JOURNAL Buil-Cosiales P, Martín V, Goday A, REVISTA ESPAÑOLA DE CARDIOLOGIA. OF NUTRITION. I.F.: 4.423 Salas-Salvadó J, Martínez JA, Romaguera D, I.F.: 5.166 PREDIMED-Plus Investigators. Body 26. Sánchez-Villegas A., Álvarez-Pérez J., adiposity indicators and cardiometabolic 21. Rosique-Esteban N, Papandreou C, Toledo E., Salas-Salvadó J., Ortega-Azorín C., risk: Cross-sectional analysis in Romaguera D, Warnberg J, Corella D, Zomeño M., Vioque J., Martínez J., Romaguera participants from the PREDIMED-Plus trial. Martínez-González MÁ, Díaz-López A, D., Pérez-López J., López-Miranda J., Estruch CLINICAL NUTRITION. . I.F.: 5.496 Estruch R, Vioque J, Arós F, Garcia-Rios A, R., Bueno-Cavanillas A., Arós F., Tur J., Bueno-Cavanillas A, Vidal J, Serra-Majem L, Tinahones F., Lecea O., Martín V., Ortega- 16. Castro Salomó, Antoni; Becerra-Tomás N; Sibai AA, Tinahones FJ, Martínez JA, Ordovás Calvo M., Vázquez C., Pintó X., Vidal J., Daimiel Díaz-López A; Rosique-Esteban N; Ros E; JM, Tur JA, Ellacuría MT, Sanllorente A, Pintó L., Delgado-Rodríguez M., Matía P., Corella D., Buil-Cosiales P; Corella D; Estruch R; Fito M; X, Buil-Cosiales P, Fernández-Carrion R, Díaz-López A., Babio N., Muñoz M., Fitó M., de Serra-Majem L; Arós F; Lamuela-Raventos Castañer O, Bulló M, Ruiz-Canela M, la Hera M., Abete I., García-Rios A., Ros E., RM; Fiol M; Santos-Lozano JM; Diez-Espino J; Garcia-de la Hera M, Pérez-Farinós N, Ruíz-Canela M., Martínez-González M., Portolés O; PREDIMED Study Investigators. Barón-López FJ, Colom A, Abete I, Ros E, Izquierdo M., Serra-Majem L. Seafood Legume consumption is inversely Salas-Salvadó J . Cross-sectional consumption, omega-3 fatty acids intake, associated with type 2 diabetes incidence associations of objectively-measured and life-time prevalence of depression in in adults: A prospective assessment from sleep characteristics with obesity and type the PREDIMED-plus trial. NUTRIENTS. the PREDIMED study. CLINICAL 2 diabetes in the PREDIMED-Plus trial. 10(12). I.F.: 4.196 NUTRITION. 37(3):906-913. I.F.: 5.496 SLEEP. 41(12). I.F.: 5.135 27. Cano-Ibáñez N, Bueno-Cavanillas A, 17. García-Gavilán J., Bulló M., Canudas S., 22. López-Laguna N, Martínez-González MA, Martínez-González MA, Corella D, Martínez-González M., Estruch R., Giardina S., Toledo E, Babio N, Sorlí JV, Ros E, Muñoz MÁ, Salas-Salvadó J, Zomeño MD, Fitó M., Corella D., Ros E., Salas-Salvadó J. Estruch R, Lapetra J, Muñoz-Bravo C, Fiol M, García-de-la-Hera M, Romaguera D, Martínez Extra virgin olive oil consumption reduces Serra-Majem L, Pintó X, González JI, Fitó M, JA, Barón-López FJ, García-Ríos A, Estruch R, the risk of osteoporotic fractures in the Basora J, Arós F, Ruiz-Canela M . Risk of García-Molina L, Alonso Gómez Á, Tur JA, PREDIMED trial. CLINICAL NUTRITION. peripheral artery disease according to a Tinahones F, Serra-Majem L, Cubelos- 37(1):329-335. I.F.: 5.496 healthy lifestyle score: The PREDIMED Fernández N, Lapetra J, Vázquez C, Pintó X, study. ATHEROSCLEROSIS. 275:133-140. Vidal J, Daimiel L, Gaforio JJ, Matía P, Ros E, 18. Roth I., Casas R., Medina-Remón A., I.F.: 4.467 Diez-Espino J, Fernández-Carrión R, Basora J, Lamuela-Raventós R., Estruch R. Fitó M, Zazo JM, Colom A, Toledo E, Consumption of aged white wine 23. Lindholt JS; Kristensen KL; Burillo E; Díaz-López A, Muñoz MÁ, Ruiz-Canela M, Gea modulates cardiovascular risk factors via Martínez-López D; Calvo C; Ros E; A . Dietary Intake in Population with circulating endothelial progenitor cells and Martin-Ventura JL; Sala-Vila A. Arachidonic Metabolic Syndrome: Is the Prevalence of inflammatory biomarkers. CLINICAL Acid, but Not Omega-3 Index, Relates to Inadequate Intake Influenced by NUTRITION. 38(3):1036-1044. I.F.: 5.496 the Prevalence and Progression of Geographical Area? Cross-Sectional Abdominal Aortic Aneurysm in a Analysis from PREDIMED-Plus Study. 19. Roth I, Casas R, Ribó-Coll M, Doménech M, Population-Based Study of Danish Men. NUTRIENTS. 10(11). I.F.: 4.196 Lamuela-Raventós RM, Estruch R. Acute JOURNAL OF THE AMERICAN HEART consumption of Andalusian aged wine and ASSOCIATION. 7(3). I.F.: 4.450 28. Beulen Y., Martínez-González M., van de gin decreases the expression of genes Rest O., Salas-Salvadó J., Sorlí J.,

120 CARDIOVASCULAR, NUTRITION AND AGING UNIT 2.4

Gómez-Gracia E., Fiol M., Estruch R., D, Pardo-Cea MA, García-Martín ML, Crovetto 38. Gonzalez-Cordon, A.; Domenech, M.; Santos-Lozano J., Schröder H., F, Fuertes-Martin R, Domenech M, Camafort, M.; Martinez-Rebollar, M.; Torres, B.; Alonso-Gómez A., Serra-Majem L., Pintó X., Gómez-Roig MD, Eixarch E, Estruch R, Laguno, M.; Rojas, J.; Lonca, M.; Blanco, J. L.; Ros E., Becerra-Tomas N., González J., Fitó M., Hansson SR, Amigó N, Cañellas N, Crispi F, Mallolas, J.; Gatell, J. M.; de Lazzari, E.; Martínez J., Gea A. Quality of dietary fat Gratacós E . Metabolic profiling and Martinez, E. Subclinical cardiovascular intake and body weight and obesity in a targeted lipidomics reveals a disturbed disease in patients starting contemporary mediterranean population: Secondary lipid profile in mothers and fetuses with protease inhibitors. HIV MEDICINE. analyses within the PREDIMED trial. intrauterine growth restriction. SCIENTIFIC 19(7):497-503. I.F.: 2.932 NUTRIENTS. 10(12). I.F.: 4.196 REPORTS. 8(1):13614. I.F.: 4.122 39. Cardenas Fuentes, Gabriela; Ahmed 29. Bitok E., Rajaram S., Jaceldo-Siegl K., Oda 34. Razquin C., Liang L., Toledo E., Clish C., Bawaked, Rowaedh; Martinez Gonzalez, K., Sala-Vila A., Serra-Mir M., Ros E., Sabaté J. Ruiz-Canela M., Zheng Y., Wang D., Corella D., Miguel Angel; Corella, Dolores; Subirana Effects of long-term walnut Castaner O., Ros E., Aros F., Gomez-Gracia E., Cachinero, Isaac; Salas-Salvado, Jordi; supplementation on body weight in Fiol M., Santos-Lozano J., Guasch-Ferre M., Estruch, Ramon; Serra-Majem, Lluis; Ros, free-living elderly: Results of a randomized Serra-Majem L., Sala-Vila A., Buil-Cosiales P., Emilio; Lapetra Peralta, Jose; Fiol, Miguel; controlled trial. NUTRIENTS. 10(9). I.F.: 4.196 Bullo M., Fito M., Portoles O., Estruch R., Rekondo, Javier; Gomez-Gracia, Enrique; Tur Salas-Salvado J., Hu F., Martinez-Gonzalez M. Mari, Josep Antoni; Pinto Sala, Xavier; Babio, 30. Arpón A., Milagro F., Razquin C., Corella D., Plasma lipidome patterns associated with Nancy; Ortega, Carolina; Alfredo Martinez, Estruch R., Fitó M., Marti A., Martínez-González cardiovascular risk in the PREDIMED trial: Jose; Schroeder, Helmut. Association of M., Ros E., Salas-Salvadó J., Riezu-Boj J., A case-cohort study. INTERNATIONAL physical activity with body mass index, Martínez J. Impact of consuming JOURNAL OF CARDIOLOGY. 253:126-132. waist circumference and incidence of extra-virgin olive oil or nuts within a I.F.: 4.034 obesity in older adults. EUROPEAN mediterranean diet on DNA methylation in JOURNAL OF PUBLIC HEALTH. peripheral white blood cells within the 35. Corella D., Ramírez-Sabio J., Coltell O., 28(5):944-950. I.F.: 2.782 PREDIMED-navarra randomized Ortega-Azorín C., Estruch R., controlled trial: A role for dietary lipids. Martínez-González M., Salas-Salvadó J., Sorlí 40. Galilea-Zabalza I, Buil-Cosiales P, NUTRIENTS. 10(1). I.F.: 4.196 J., Castañer O., Arós F., Garcia-Corte F., Salas-Salvadó J, Toledo E, Ortega-Azorín C, Serra-Majem L., Gómez-Gracia E., Fiol M., Díez-Espino J, Vázquez-Ruiz Z, Zomeño MD, 31. Freitas-Simoes TM; Cofán M; Blasco MA; Pintó X., Saez G., Toledo E., Basora J., Fitó M., Vioque J, Martínez JA, Romaguera D, Soberon N; Foronda M; Serra-Mir M; Roth I; Cofán M., Ros E., Ordovas J. Effects of the Perez-Farinos N, López-Miranda J, Estruch R, Valls-Pedret C; Domenech M; Ser326Cys Polymorphism in the DNA Bueno-Cavanillas A, Arós F, Tur JA, Tinahones Ponferrada-Ariza E; Calvo C; Rajaram S; Repair OGG1 Gene on Cancer, F, Serra-Majem L, Marcos-Delgado A, Sabaté J; Ros E; Sala-Vila A. Walnut Cardiovascular, and All-Cause Mortality in Ortega-Calvo M, Vázquez C, Pintó X, Vidal J, Consumption for Two Years and the PREDIMED Study: Modulation by Diet. Daimiel L, Delgado-Rodríguez M, Matía P, Leukocyte Telomere Attrition in JOURNAL OF THE ACADEMY OF Corella D, Diaz-López A, Babio N, Muñoz MA, Mediterranean Elders: Results of a NUTRITION AND DIETETICS. 118(4):589-605. Fitó M, González-Palacios S, Abete I, Randomized Controlled Trial. NUTRIENTS. I.F.: 4.021 García-Rios A, Ros E, Martínez-González MÁ, 10(12). I.F.: 4.196 PREDIMED-PLUS Study Investigators. 36. Mena-Sánchez G, Babio N, Mediterranean diet and quality of life: 32. Mallorquí-Bagué N., Lozano-Madrid M., Martínez-González MÁ, Corella D, Schröder H, Baseline cross-sectional analysis of the Toledo E., Corella D., Salas-Salvadó J., Vioque J, Romaguera D, Martínez JA, PREDIMED-PLUS trial. PLOS ONE. Cuenca-Royo A., Vioque J., Romaguera D., Lopez-Miranda J, Estruch R, Wärnberg J, 13(6):e0198974. I.F.: 2.766 Martínez J., Wärnberg J., López-Miranda J., Bueno-Cavanillas A, Serra-Majem L, Tur JA, Estruch R., Bueno-Cavanillas A., Arós F, Tinahones FJ, Sánchez VM, Lapetra J, 41. De la Sierra A, Pareja J, Yun S, Acosta E, Alonso-Gómez Á., Tur J., Tinahones F., Pintó X, Vidal J, Vázquez C, Ordovás JM, Aiello F, Oliveras A, Vázquez S, Armario P, Serra-Majem L., Martín V., Lapetra J., Vázquez Delgado-Rodriguez M, Matía-Martín P, Basora Blanch P, Sierra C, Calero F, Fernández-Llama C., Pintó X., Vidal J., Daimiel L., Gaforio J., Matía J, Buil-Cosiales P, Fernandez-Carrion R, Fitó P. Central blood pressure variability is P., Ros E., Granero R., Buil-Cosiales P., M, Salas-Salvadó J, PREDIMED-PLUS increased in hypertensive patients with Barragán R., Bulló M., Castañer O., investigators. Fermented dairy products, target organ damage. JOURNAL OF García-de-la-Hera M., Yáñez A., Abete I., diet quality, and cardio–metabolic profile CLINICAL HYPERTENSION. 20(2):266-272. García-Ríos A., Ruiz-Canela M., Díaz-López A., of a Mediterranean cohort at high I.F.: 2.629 Jiménez-Murcia S., Martínez-González M., De cardiovascular risk. NUTRITION, la Torre R. Type 2 diabetes and cognitive METABOLISM AND CARDIOVASCULAR 42. Parati G, Agabiti-Rosei E, Bakris GL, Bilo impairment in an older population with DISEASES. 28(10):1002-1011. I.F.: 3.318 G, Branzi G, Cecchi F, Chrostowska M, De la overweight or obesity and metabolic Sierra A, Domenech M, Dorobantu M, Faria T, syndrome: baseline cross-sectional 37. Vilarnau C, Stracker D, Funtikov A, da Silva Huo Y, Jelaković B, Kahan T, Konradi A, analysis of the PREDIMED-plus study. R, Estruch R, Bach-Faig A. Worldwide Laurent S, Li N, Madan K, Mancia G, McManus SCIENTIFIC REPORTS. 8(1):16128. I.F.: 4.122 adherence to Mediterranean Diet between RJ, Modesti PA, Ochoa JE, Octavio JA, 1960 and 2011. EUROPEAN JOURNAL OF Omboni S, Palatini P, Park JB, Pellegrini D, Perl 33. Miranda J, Simões RV, Paules C, Cañueto CLINICAL NUTRITION. . I.F.: 2.954 S, Podoleanu C, Pucci G, Redon J, Renna N,

121 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

Rhee MY, Rodilla Sala E, Sanchez R, AND METABOLIC CARE. 21(6):498-504. MOLECULAR SCIENCES. 19(12). I.F.: 3.687 Schmieder R, Soranna D, Stergiou G, I.F.: 4.534 Stojanovic M, Tsioufis K, Valsecchi MG, Veglio 11. Cofan M, Ros E. Use of plant sterol and F, Waisman GD, Wang JG, Wijnmaalen P, 5. Freitas-Simoes T., Ros E., Sala-Vila A. stanol fortified foods in clinical practice. Zambon A, Zanchetti A, Zhang Y. Telomere length as a biomarker of CURRENT MEDICINAL CHEMISTRY. MASked-unconTrolled hypERtension accelerated aging: is it influenced by I.F.: 3.469 management based on office BP or on dietary intake? CURRENT OPINION IN ambulatory blood pressure measurement CLINICAL NUTRITION AND METABOLIC 12. Barrios, Vivencio; Almendro-Delia, Manuel; (MASTER) Study: a randomised controlled CARE. 21(6):430-436. I.F.: 4.534 Facila, Lorenzo; Garcia-Moll, Xavier; Mazon, trial protocol. BMJ OPEN. 8(12):e021038. Pilar; Camafort, Miguel; Maria Cepeda, Jose; I.F.: 2.413 6. Castro-Barquero S, Castro-Barquero S, Mediavilla Garcia, Juan Diego; Pose Reino, Lamuela-Raventós RM, Lamuela-Raventós Antonio; Suarez Fernandez, Carmen. 43. Rehm J., Gmel G., Sierra C., Gual A. RM, Doménech M, Doménech M, Doménech Rivaroxaban: searching the integral Reduction of mortality following better M, Estruch R, Estruch R, Estruch R, Estruch R. vascular protection. EXPERT REVIEW OF detection of hypertension and alcohol Relationship between Mediterranean CLINICAL PHARMACOLOGY. 11(7):719-728. problems in primary health care in Spain. Dietary Polyphenol Intake and Obesity. I.F.: 2.758 ADICCIONES. 30(1):9-18. I.F.: 2.021 NUTRIENTS. 10(10). I.F.: 4.196 13. Marfany A, Sierra C, Camafort M, 44. Doménech M, Sastre E, Camafort M, 7. Casas R, Casas R, Estruch R, Estruch R, Doménech M, Coca A. High blood pressure, Sierra C, Coca A. Misdiagnosis of resistant Sacanella E, Sacanella E. Influence of Alzheimer disease and antihypertensive hypertension: Real frequency of true Bioactive Nutrients on the Atherosclerotic treatment. PANMINERVA MEDICA. resistant hypertension in patients with Process: A Review. NUTRIENTS. 10(11). 60(1):8-16. I.F.: 2.102 suspected resistance to treatment. I.F.: 4.196 MEDICINA CLINICA. 150(1):20-23. I.F.: 1.168 14. Casas, Rosa; Estruch, Ramon; Sacanella, 8. Kotsis V, Tsioufis K, Antza C, Seravalle G, Emilio. The Protective Effects of Extra Coca A, Sierra C, Lurbe E, Lurbe E, Stabouli S, Virgin Olive Oil on Immune-mediated Review / I.F.: 68.686 Jelakovic B, Redon J, Redon P, Nilsson PM, Inflammatory Responses. ENDOCRINE, Jordan J, Micic D, Finer N, Leitner DR, Toplak METABOLIC AND IMMUNE DISORDERS - 1. Freeman A., Morris P., Aspry K., Gordon N., H, Tokgozoglu L, Athyros V, Elisaf M, Filippatos DRUG TARGETS. 18(1):23-35. I.F.: 2.013 Barnard N., Esselstyn C., Ros E., Devries S., TD, Grassi G, Grassi G. Obesity and O'Keefe J., Miller M., Ornish D., Williams K., cardiovascular risk: a call for action from Batts T., Ostfeld R., Litwin S., Aggarwal M., the European Society of Hypertension Letters / I.F.: 99.259 Werner A., Allen K., White B., Kris-Etherton P. Working Group of Obesity, Diabetes and A Clinician's Guide for Trending the High-risk Patient and European 1. Martínez-González MA, Ros E, Estruch R. Cardiovascular Nutrition Controversies: Association for the Study of Obesity: part Primary Prevention of Cardiovascular Part II. JOURNAL OF THE AMERICAN B: obesity-induced cardiovascular Disease with a Mediterranean Diet COLLEGE OF CARDIOLOGY. 72(5):553-568. disease, early prevention strategies and Supplemented with Extra-Virgin Olive Oil I.F.: 16.834 future research directions. JOURNAL OF or Nuts. NEW ENGLAND JOURNAL OF HYPERTENSION. 36(7):1441-1455. I.F.: 4.099 MEDICINE. 379(14):1388-1389. I.F.: 79.260 2. Medina-Remón A, Medina-Remón A, Kirwan R, Lamuela-Raventós RM, 9. Kotsis V, Jordan J, Micic D, Finer N, Leitner 2. Miró Ò., Estruch R., Gil V., Llorens P. Reply: Lamuela-Raventós RM, Estruch R, Estruch R. DR, Toplak H, Tokgozoglu L, Athyros V, Elisaf The Mediterranean Diet to Treat Heart Dietary Patterns and the Risk of Obesity, M, Filippatos TD, Redon J, Redon J, Redon P, Failure: A Potential Powerful Tool in the Type 2 Diabetes Mellitus, Cardiovascular Antza C, Tsioufis K, Grassi G, Grassi G, Hand of Providers. JACC: HEART FAILURE. Diseases, Asthma, and Mental Health Seravalle G, Coca A, Sierra C, Lurbe E, Lurbe 6(3):201-208. I.F.: 8.202 Problems. CRITICAL REVIEWS IN FOOD E, Stabouli S, Jelakovic B, Nilsson PM. Obesity SCIENCE AND NUTRITION. 58(2):262-296. and cardiovascular risk: a call for action 3. O'Keefe, James H.; DiNicolantonio, James I.F.: 6.202 from the European Society of J.; Sigurdsson, Axel F.; Ros, Emilio. Evidence, Hypertension Working Group of Obesity, Not Evangelism, for Dietary 3. Jacobs DR, Petersen KS, Svendsen K, Ros Diabetes and the High-risk Patient and Recommendations. MAYO CLINIC E, Sloan CB, Steffen LM, Tapsell LC, European Association for the Study of PROCEEDINGS. 93(2):138-144. I.F.: 7.199 Kris-Etherton PM. Considerations to Obesity: part A: mechanisms of obesity facilitate a US study that replicates induced hypertension, diabetes and 4. Ros E. Editorial commentary: PREDIMED. METABOLISM: CLINICAL AND dyslipidemia and practice guidelines for Plant-based diets: More than meets the EXPERIMENTAL. 85:361-367. I.F.: 5.963 treatment. JOURNAL OF HYPERTENSION. eye. TRENDS IN CARDIOVASCULAR 36(7):1427-1440. I.F.: 4.099 MEDICINE. 28(7):442-444. I.F.: 4.598 4. Ros E., Izquierdo-Pulido M., Sala-Vila A. Beneficial effects of walnut consumption 10. Casas R; Castro-Barquero S; Estruch R; on human health: role of micronutrients. Sacanella E. Nutrition and Cardiovascular CURRENT OPINION IN CLINICAL NUTRITION Health. INTERNATIONAL JOURNAL OF

122 CARDIOVASCULAR, NUTRITION AND AGING UNIT 2.4

Editorial / I.F.: 10.488 Estruch R. Efecto de una pérdida de peso con dieta mediterránea hipocalórica y 1. Estruch R, Sacanella E. Keys to a Long and promoción de la actividad física en Healthy Life. REVISTA ESPAÑOLA DE prevención primaria cardiovascular: CARDIOLOGIA. 71(12):993-995. I.F.: 5.166 Estudio PREDIMED-PLUS. Sponsored by: Instituto de Salud Carlos III 2. Estruch R, Bach-Faig A. Mediterranean (ISCIII). PI16/00381 diet as a lifestyle and dynamic food Duration: 01/01/2017-31/12/2019 pattern. EUROPEAN JOURNAL OF CLINICAL NUTRITION. I.F.: 2.954 Estruch R. Efecto de una pérdida de peso con dieta mediterránea hipocalórica y 3. Sobrino, J.; Domenech, M. The clinical promoción de la actividad física en la value of an exaggerated hypertensive prevención primaria cardiovascular: response to exercise. REVISTA CLINICA Estudio PREDIMED-PLUS. ESPANOLA. 218(1):13-14. I.F.: 1.184 Sponsored by: Instituto de Salud Carlos III (ISCIII). PI044504 4. Ros E. The Mediterranean diet, optimal Duration:01/01/2017-31/12/2019 against cardiovascular disease but adopted by few survivors of an ischemic Estruch R. The Moderate Alcohol and coronary event in a Mediterranean Cardiovascular Health Trial. country. REVISTA CLINICA ESPANOLA. Sponsored by: National Institutes of Health. 218(5):241-243. I.F.: 1.184 NIH_PAR-16-363 (38685) Duration: 30/09/2016-31/07/2021

Clinical Guidelines / I.F.: 8.636 Sacanella E. Morbi-mortalidad cardiovascular, adherencia a la dieta 1. Langlois MR; Chapman MJ; Cobbaert C; mediterranea y efecto legado en 1000 Mora S; Remaley AT; Ros E; Watts GF; Borén pacientes con dieta mediterranea (Estudio J; Baum H; Bruckert E; Catapano A; PREDIMED). Descamps OS; Von Eckardstein A; Kamstrup Sponsored by: Fundación Española de PR; Kolovou G; Kronenberg F; Langsted A; Medicina Interna. FEMI_Proyectos15 Pulkki K; Rifai N; Sypniewska G; Wiklund O; Duration: 24/12/2015- Nordestgaard BRG; NULL NULL. Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. CLINICAL CHEMISTRY. 64(7):1006-1033. I.F.: 8.636

GRANTS FOR RESEARCH IN PROGRESS

Estruch R. Nous predictors de la cardiopatía coronaria: micropartículas endotelials circulants, funcionalitat de les partícules d'HDL i composició en àcids grassos de les membranes cel·lulars. Sponsored by: Fundació la Marató de TV3. TV3_Cor_15 Duration: 29/06/2016-28/06/2019

Estruch R. Cardiovascular, Nutrition and Aging Group. Sponsored by: Generalitat de Catalunya. AGAUR_SGR17_01717 Duration: 01/01/2017-31/12/2020

123 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

Respiratory biophysics 2.5 and bioengineering

COLLABORATORS Aida Niñerola (HCB-UB) LOCATION Jorge Otero (UB) UB School of Medicine Roser Sala (UB)

STRATEGIC OBJECTIVES WEB www.ub.edu/bioﬁsica The general objectives are the study of the biophysical mechanisms determining TEAM LEADER respiratory function, and the development of Ramon Farré (UB) models and methods for the processing of T. 93 402 45 15 biomedical images and signals. The work of [email protected] the group is based on an interdisciplinary KEYWORDS scientiﬁc approach, promoting industrial 1. Respiratory mechanics transfer of the technological advances derived Lung bioengineering 2. RESEARCHERS from the research work. 3. Neuroimaging in refractory epilepsy Isaac Almendros (UB) 4. Neuroimaging in Parkinson’s disease Daniel Navajas (UB) Javier Pavia (HCB-UB) Domenec Ros (UB) MAIN LINES OF RESEARCH

POST-DOCTORAL RESEARCHERS 1. Respiratory mechanics. Noelia Campillo (UB) To investigate the viscoelastic properties of Original publications Maria José Menal (UB) the airways and lung tissues. The work from 2016 to 2018 Aida Niñerola (UB) focuses on the study of upper airway collapsibility in obstructive YEAR I.F. TOTAL Q1 Q2 PRE-DOCTORAL RESEARCHERS apnea-hypopnea and in the monitoring 2016 51.56 12 9 3 Jair Asir (UB) noninvasive mechanical ventilation. We aim Ignacio Cabrera (UB) to improve noninvasive diagnostic 2017 82.69 18 13 4 Bryan Falcones (UB) techniques and to optimize the treatments. 2018 77.30 13 10 3 Ignasi Jorba (UB) Esther Marhuenda (UB) 2. Molecular and cellular nanomechanics. To use atomic force microscopy, magnetic TECHNICIANS microspheres and traction force Miguel Angel Rodriguez (UB) microscopy to study cell adhesion and TEAM INVOLVED IN Elisabet Urrea (UB) mechanics of lung cells. We study the CIBERES mechanical properties of stem cells and of CIBER-BBN Ramon Farré TEAM

124 RESPIRATORY BIOPHYSICS AND BIOENGINEERING 2.5

the way in which mechanical stimuli Montserrat JM, Carrera C, Corral J, Masa JF, properties, endothelial function and enhance differentiation. We also work on de Terreros JG, Abad J, Boada A, Mediano O, treatment of obesity hypoventilation lung regeneration, focusing on recreating de Eusebio E, Chiner E, Landete P, Mayos M, syndrome: A proof of concept study. the mechanical pulmonary micro-nano Fortuño A, Barbé F, Sánchez de la Torre M, JOURNAL OF CLINICAL SLEEP MEDICINE. environment to optimize cell differentiation. Sanchez de la Torre A, Cano I, Gonzalez C, 14(5):797-807. I.F.: 3.396 Pérez-Gil A, Gómez-García T, Cullen D, 3. Biomedical imaging analysis. Somoza M, Formigón M, Aizpuru F, Navarro C, 9. Suarez-Giron, Monique C.; Castro-Grattoni, Imaging analysis focused on the Selma-Ferrer MJ, Garcia-Ortega A, de Anabel; Torres, Marta; Farre, Ramon; Barbe, processing of photon emission Unamuno B, Almendros I, Farré R, Gozal D, Ferran; Sanchez-de-la-Torre, Manuel; Gozal, tomography (SPECT) and positron Spanish Sleep Network. Sleep-Disordered David; Picado, Cesar; Montserrat, Josep M.; emission tomography (PET) images aimed Breathing is Independently Associated Almendros, Isaac. Acetylsalicylic Acid at securing more precise quantification of with Increased Aggressiveness of Prevents Intermittent Hypoxia-Induced gammagraphic (scintigraphic) studies. Cutaneous Melanoma. A multicentre Vascular Remodeling in a Murine Model of Iterative algorithms are being developed for observational study in 443 patients. Sleep Apnea. FRONTIERS IN PHYSIOLOGY. the three-dimensional reconstruction of CHEST. 154(6):1348-1358. I.F.: 7.652 9(MAY):600. I.F.: 3.394 images and for the fusion of SPECT and magnetic resonance imaging (MRI) images. 5. Perea-Gil I, Gálvez-Montón C, Prat-Vidal C, 10. Farré N., Otero J., Falcones B., Torres M., Jorba I, Segú-Vergés C, Roura S, Soler-Botija Jorba I., Gozal D., Almendros I., Farré R., C, Iborra-Egea O, Revuelta-López E, Navajas D. Intermittent hypoxia mimicking Fernández MA, Farré R, Navajas D, sleep apnea increases passive stiffness of PUBLICATIONS Bayes-Genis A. Head-to-head comparison myocardial extracellular matrix. A of two engineered cardiac grafts for multiscale study. FRONTIERS IN Originals / I.F.: 77.301 myocardial repair: From scaffold PHYSIOLOGY. 9(AUG):1143. I.F.: 3.394 characterization to pre-clinical testing. 1. Walker PP, Pompilio PP, Zanaboni P, SCIENTIFIC REPORTS. 8(1):6708. I.F.: 4.122 11. Farré N, Jorba I, Torres M, Falcones B, Bergmo TS, Prikk K, Malinovschi A, Montserrat Martí-Almor J, Farré R, Almendros I, Navajas D. JM, Middlemass J, Šonc S, Munaro G, Maruši? 6. Menal, Maria Jose; Jorba, Ignasi; Torres, Passive Stiffness of Left Ventricular D, Sepper R, Rosso R, Siriwardena AN, Janson Marta; Montserrat, Josep M.; Gozal, David; Myocardial Tissue Is Reduced by C, Farré R, Calverley PMA, Dellaca' RL. Colell, Anna; Pinol-Ripoll, Gerard; Navajas, Ovariectomy in a Post-menopause Mouse Telemonitoring in COPD: The CHROMED Daniel; Almendros, Isaac; Farre, Ramon. Model. FRONTIERS IN PHYSIOLOGY. Study, a Randomized Clinical Trial. Alzheimer's Disease Mutant Mice Exhibit 9(NOV):1545. I.F.: 3.394 AMERICAN JOURNAL OF RESPIRATORY Reduced Brain Tissue Stiffness Compared AND CRITICAL CARE MEDICINE. to Wild-type Mice in both Normoxia and 12. Zhu K, Farré R, Katz I, Hardy S, Escourrou 198(5):620-628. I.F.: 15.239 following Intermittent Hypoxia Mimicking P. Mimicking a flow-limited human upper Sleep Apnea. FRONTIERS IN NEUROLOGY. airway using a collapsible tube: 2. Santamaria-Martos F; Benítez I; Girón C; 9(JAN):1. I.F.: 3.508 Relationships between flow patterns and Barbe F; Martinez-Garcia MA; Hernandez L; pressures in a respiratory model. JOURNAL Montserrat JM; Nagore E; Martorell-Calatayud 7. Almendros, Isaac; Angel Martinez-Garcia, OF APPLIED PHYSIOLOGY. 125(2):605-614. A; Campos-Rodriguez F; Corral J; Cabriada V; Miguel; Campos-Rodriguez, Francisco; I.F.: 3.256 Abad J; Mediano O; Troncoso MF; Riveiro-Falkenbach, Erica; Rodriguez-Peralto, Cano-Pumarega I; Gutierrez AMF; Jose L.; Nagore, Eduardo; Martorell- 13. Da Palma RK, Fratini P, Schiavo Matias GS, Díaz-Cambriles T; Somoza-González M; Calatayud, Antonio; Hernandez Blasco, Luis; Cereta AD, Guimarães LL, Anunciação ARA, Almendros I; Farré R; Gozal D; Sanchez de la Banuls Roca, Jose; Chiner Vives, Eusebi; de Oliveira LVF, Farre R, Miglino MA. Equine Torre M. Biomarkers of carcinogenesis and Sanchez-de-la-Torre, Alicia; Abad-Capa, lung decellularization: a potential tumour growth in patients with cutaneous Jorge; Maria Montserrat, Josep; Perez-Gil, approach for in vitro modeling the role of melanoma and obstructive sleep apnoea. Amalia; Cabriada-Nuno, Valentin; the extracellular matrix in asthma. EUROPEAN RESPIRATORY JOURNAL. 51(3). Cano-Pumarega, Irene; Corral-Penafiel, Jaime; JOURNAL OF TISSUE ENGINEERING. 9:1-11. I.F.: 12.244 Diaz-Cambriles, Trinidad; Mediano, Olga; I.F.: 2.683 Dalmau-Arias, Joan; Farre, Ramon; Gozal, 3. Notari M, Ventura-Rubio A, Bedford-Guaus David;Spanish Sleep Network. Intermittent SJ, Jorba I, Mulero L, Navajas D, Martí M, Raya Hypoxia Is Associated With High Hypoxia Review / I.F.: 31.109 Á. The local microenvironment limits the Inducible Factor-1 alpha but Not High regenerative potential of the mouse Vascular Endothelial Growth Factor Cell 1. Randerath W, Bassetti CL, Bonsignore MR, neonatal heart. SCIENCE ADVANCES. Expression in Tumors of Cutaneous Farre R, Ferini-Strambi L, Grote L, Hedner J, 4(5):eaao5553. I.F.: 11.511 Melanoma Patients. FRONTIERS IN Kohler M, Martinez-Garcia MA, Mihaicuta S, NEUROLOGY. 9(APR):272. I.F.: 3.508 Montserrat J, Pepin JL, Pevernagie D, Pizza F, 4. Martinez-Garcia MA, Campos-Rodriguez F, Polo O, Riha R, Ryan S, Verbraecken J, Nagore E, Martorell A, Rodriguez-Peralto JL, 8. Bhattacharjee R., Khalyfa A., Mokhlesi B., McNicholas WT. Challenges and Riveiro-Falkenbach E, Hernandez L, Bañuls J, Kheirandish-Gozal L., Almendros I., Peris E., Perspectives in Obstructive Sleep Apnoea: Arias E, Ortiz P, Cabriada V, Gardeazabal J, Malhotra A., Gozal D. Exosomal cargo Report by an ad hoc working group of the

125 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

Sleep Disordered Breathing Group of the Obstructive Sleep Apnea. ARCHIVOS DE Farré R. Efectos de la hipoxia/hipercapnia European Respiratory Society and the BRONCONEUMOLOGIA. 55(6):334. I.F.: 2.633 en la interacción biomecánica European Sleep Research Society. célula-matriz pulmonar en la progresión de EUROPEAN RESPIRATORY JOURNAL. 52(3). las enfermedades respiratorias. I.F.: 12.244 Editorial / I.F.: 29.287 Sponsored by: Ministerio de Economía y Competitividad (MINECO). 2. Farré N, Farré R, Gozal D. Sleep Apnea 1. Farré R, Navajas D, Montserrat JM. Is SAF2017-85574-R Morbidity: A Consequence of Telemedicine a Key Tool for Improving Duration: 01/01/2018-31/12/2020 Microbial-Immune Cross-Talk? CHEST. Continuous Positive Airway Pressure 154(4):754-759. I.F.: 7.652 Adherence in Patients with Sleep Apnea? Farré R. Global self-management telematic AMERICAN JOURNAL OF RESPIRATORY support for patients with obstructive sleep 3. Farré R, Montserrat JM, Gozal D, AND CRITICAL CARE MEDICINE. 197(1):12-14. apneahypopnea syndrome and CPAP Almendros I, Navajas D. Intermittent I.F.: 15.239 treatment. Pilot study on patients with Hypoxia Severity in Animal Models of severe obstructive sleep apnea-hypopnea Sleep Apnea. FRONTIERS IN PHYSIOLOGY. 2. Farre, Ramon; Hiemstra, Pieter S.; syndrome that are provided bad fulﬁllers. 9(NOV):1556. I.F.: 3.394 Dinh-Xuan, Anh Tuan. Basic and Sponsored by: Proyectos Inter-CIBER. translational research in the European CIBERER-FES2018-01 4. Farré R, Almendros I, Montserrat JM, Gozal Respiratory Journal. EUROPEAN Duration: 21/05/2018-30/04/2021 D, Navajas D. Gas Partial Pressure in RESPIRATORY JOURNAL. 51(5). I.F.: 12.244 Cultured Cells: Patho-Physiological Farré R. Sleep Apnea diagnostic and Importance and Methodological 3. Almendros I, Aliverti A. Clinical physiology monitoring (ApneaBand). Approaches. FRONTIERS IN PHYSIOLOGY. and sleep: highlights from the European Sponsored by: European Commission. 9(1803):1803. I.F.: 3.394 Respiratory Society Congress 2018 H2020_EIT Health (RFP2018KC) presented by early career members. Duration: 01/01/2018-31/12/2018 5. Farre, Ramon; Otero, Jordi; Almendros, J THORAC DIS. 10(Suppl 25):S2988-S2991. Isaac; Navajas, Daniel. Bioengineered Lungs: I.F.: 1.804 A Challenge and An Opportunity. ARCHIVOS DE BRONCONEUMOLOGIA. DOCTORAL THESES 54(1):31-38. I.F.: 2.633 Consortium Publications / I.F.: 21.466 Almendros I, Montserrat JM. New 6. Almendros I., Gozal D. Intermittent 1. McNicholas WT, Bassetti CL, Ferini-Strambi Therapeutic approaches for obstructive hypoxia and cancer: Undesirable bed L, Pépin JL, Pevernagie D, Verbraecken J, sleep apnea. partners? RESPIRATORY PHYSIOLOGY Randerath W, Baveno Working Group PhD student: Monique Carolina Suarez Giróna AND NEUROBIOLOGY. 256:79-86. I.F.: 1.792 members. Challenges in obstructive sleep apnoea. THE LANCET. RESPIRATORY MEDICINE. 6(3):170-172. I.F.: 21.466 Letters / I.F.: 33.111

1. Villanueva JA, Isetta V, Montserrat JM, Navajas D, Farré R. A Portable Continuous GRANTS FOR RESEARCH IN PROGRESS Positive Airway Pressure Device That Can Perform Optimally Under Strenuous Almendros I. Alteraciones del citoesqueleto Conditions. AMERICAN JOURNAL OF y de la matriz extracelular cerebral RESPIRATORY AND CRITICAL CARE caracteristicas de la nefermedad de MEDICINE. 198(7):956-958. I.F.: 15.239 Allzheimer en un modelo celular y animal de apnea obstructiva del sueño. 2. Torres, Marta; Campillo, Noelia; Nonaka, Sponsored by: Sociedad Española de Paula N.; Montserrat, Josep M.; Gozal, David; Neumología y Cirugía Torácica (SEPAR). Angel Martinez-Garcia, Miguel; Campos- SEPAR-139/2015 Rodriguez, Francisco; Navajas, Daniel; Farre, Duration: 01/10/2016-30/09/2019 Ramon; Almendros, Isaac. Aging Reduces Intermittent Hypoxia-induced Lung Farré R. Impacte de l’apnea obstructiva del Carcinoma Growth in a Mouse Model of son en la progressió de la malaltia Sleep Apnea. AMERICAN JOURNAL OF d’Alzheimer. Paper de la hipòxia i la RESPIRATORY AND CRITICAL CARE fragmentació del son. MEDICINE. 198(9):1234-1236. I.F.: 15.239 Sponsored by: Fundació la Marató de TV3. Neuro_14 3. Suarez-Giron M., Almendros I., Roca-Ferrer Duration: 03/06/2015-31/12/2020 J., Picado C. Overnight Change in Urinary Prostacyclin and Thromboxane in

126 APPLIED RESEARCH IN INFECTIOUS RESPIRATORY DISEASES, CRITICALLY ILL PATIENTS AND LUNG CANCER 2.6

Applied research in infectious respiratory diseases, critically 2.6 ill patients and lung cancer

PRE-DOCTORAL RESEARCHERS Victòria Alcaraz (FCRB) LOCATION Enric Barbeta (HCB) CELLEX building, ﬂoor 2B Adrian Ceccato (HCB) Onintza Garmendia (CIBER) Ruben López (FCRB) Anna Motos (FCRB)

WEB Carmen Rosa Vargas (HCB) www.idibapsrespiratoryresearch.org Hua Yang (FCRB) Minlan Yang (FCRB)

TEAM LEADER Antoni Torres (HCB) NURSING STAFF Mª Concepción Ruiz (HCB) T. 93 227 54 00 (Ext.: 3037)

[email protected] COLLABORATORS KEYWORDS Joaquim Bobi (FCRB) 1. Respiratory infections Montserrat Rigol (FCRB) 2. Mechanical ventilation 3. Pneumonia GROUP LEADER Josep Mª Montserrat (HCB) VISITING SCIENTISTS 4. COPD, bronchiectasis T. 93 227 57 46 Denise Battaglini Breathing disturbances in sleep 5. [email protected] (Hospital Políclínic, San Martino Genoa, Italy) Cristina Dominedó (Fondazione Policlinico Universitario Agostino Gemelli, Milan, Italy) RESEARCHERS Carles Agustí (HCB) Andrea Meli Joan Ramon Badia (HCB) (Hospital San Paolo de Milano) Original publications Laia Fernández (CIBER) Francesco Pagliara from 2016 to 2018 Miquel Ferrer (HCB) (Università degli Studi di Genova, Italy) Nestor Soler (HCB) Giulia Scioscia YEAR I.F. TOTAL Q1 Q2 Dolors Soy (HCB) (University of Foggia, Italy) 2016 134.54 32 22 7 Giacomo Tanzella (University of Genova, Italy) 2017 160.19 30 20 9 POST-DOCTORAL RESEARCHERS Rosanel Amaro (HCB) 2018 312.13 46 32 10 Roberto Cabrera (CIBER) Catia Cillóniz (CIBER) Pamela Conde (FCRB) STRATEGIC OBJECTIVES Gianluigi Li (HCB-FCRB) 1. To study respiratory infections, invasive TEAM INVOLVED IN Carmen Lucena (HCB) Monique Carolina Suárez (HCB) and noninasive mechanical ventilation, CIBERES exacerbations of chronic obstructive AGAUR_SGR17: 00787 Marta Torres (CIBER) Antoni Torres TEAM

127 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

pulmonary disease (COPD), Specifically, the two most important lines are Depends on Time since Onset of bronchiectasis. the following: the study of diagnostic methods Symptoms. AMERICAN JOURNAL OF and effects of treatment in a population of RESPIRATORY AND CRITICAL CARE 2. Physiopathological and treatment studies apneic patients in which the indication is not MEDICINE. 198(3):370-378. I.F.: 15.239 in animals and humans with ventilator clear; and the study of animal models for associated pneumonia and or ARDS . exploring the mechanisms underlying the 5. Moreno G, Rodríguez A, Reyes LF, Gomez origin and consequences of the disorder. J, Sole-Violan J, Díaz E, Bodí M, Trefler S, 3. Human and animal model research in sleep Both lines are carried out in the context of Guardiola J, Yébenes JC, Soriano A, apnea syndrome. Telemedicine and national multicenter clinical trials. Garnacho-Montero J, Socias L, Del Valle Ortíz multcentre studies. Finally, the envelopment of a visrtual sleep unit M, Correig E, Marín-Corral J, Vallverdú-Vidal is one of the major topic during last year as well M, Restrepo MI, Torres A, Martín-Loeches I, as other telemedicine procedures to improve GETGAG Study Group. Corticosteroid the patient management and the cost treatment in critically ill patients with MAIN LINES OF RESEARCH effectivenes. severe influenza pneumonia: a propensity score matching study. INTENSIVE CARE 1. Epidemiology, prevention and new MEDICINE. 44(9):1470-1482. I.F.: 15.008 treatments of: pneumonia associated with artificial ventilation, community-acquired PUBLICATIONS 6. Welte T, Dellinger RP, Ebelt H, Ferrer M, pneumonia. New treatments. Resistances Opal SM, Singer M, Vincent JL, Werdan K, of microorganisms. Local and systemic Originals / I.F.: 312.132 Martin-Loeches I, Almirall J, Artigas A, Ignacio inflammatory response. Ayestarán J, Nuding S, Ferrer R, Sirgo 2. Etiopathogenesis, bronchial infection and 1. Torres A., Zhong N., Pachl J., Timsit J., Kollef Rodríguez G, Shankar-Hari M, Álvarez-Lerma inflammation in the patient with chronic M., Chen Z., Song J., Taylor D., Laud P., Stone F, Riessen R, Sirvent JM, Kluge S, obstructive pulmonary disease (COPD). G., Chow J. Ceftazidime-avibactam versus Zacharowski K, Bonastre Mora J, Lapp H, 3. Chronic pulmonary infections: meropenem in nosocomial pneumonia, Wöbker G, Achtzehn U, Brealey D, Kempa A, bronchiectasis not associated with cystic including ventilator-associated Sánchez García M, Brederlau J, Kochanek M, fibrosis, immune deficiencies and cystic pneumonia (REPROVE): A randomised, Reschreiter HP, Wise MP, Belohradsky BH, fibrosis in the adult. double-blind, phase 3 non-inferiority trial. Bobenhausen I, Dälken B, Dubovy P, Langohr 4. Invasive and noninvasive mechanical LANCET INFECTIOUS DISEASES, THE. P, Mayer M, Schüttrumpf J, Wartenberg- ventilation: epidemiology, cost- 18(3):285-295. I.F.: 25.148 Demand A, Wippermann U, Wolf D, Torres A . effectiveness and physiopathology. Efficacy and safety of trimodulin, a novel Weaning from mechanical ventilation: role 2. Ekren PK, Ranzani OT, Ceccato A, Li Bassi polyclonal antibody preparation, in of the inflammatory response and G, Muñoz Conejero E, Ferrer M, Niederman patients with severe community-acquired respiratory failure following extubation. MS, Torres A. Evaluation of the 2016 pneumonia: a randomized, 5. Study of the pharmacokinetics of Infectious Diseases Society of placebo-controlled, double-blind, antibiotics and other drugs in the ventilated America/American Thoracic Society multicenter, phase II trial (CIGMA study). and non-ventilated patient. Guideline Criteria for Risk of Multi-drug INTENSIVE CARE MEDICINE. 44(4):438-448. 6. Porcine model of acute pulmonary damage Resistant Pathogens in Hospital-acquired I.F.: 15.008 due to methicillinresistant P. aeruginosa, S. and Ventilator-associated Pneumonia aureus and S. pneumoniae. Patients in the Intensive Care Unit. 7. Cilloniz C, Ferrer M, Liapikou A, Garcia-Vidal 7. Translational research laboratory for the AMERICAN JOURNAL OF RESPIRATORY C, Gabarrus A, Ceccato A, Puig de La microbiology diagnosis and pathogen-host AND CRITICAL CARE MEDICINE. Bellacasa J, Blasi F, Torres A . Acute response in respiratory infections. 197(6):826-830. I.F.: 15.239 Respiratory Distress Syndrome in 8. Chronic sleep apnea models. Mechanically-Ventilated Patients with 9. Multicenter Study to assess the effect of 3. Walker PP, Pompilio PP, Zanaboni P, Community-Acquired Pneumonia. CPAP on cardiovascular diseases in Bergmo TS, Prikk K, Malinovschi A, Montserrat EUROPEAN RESPIRATORY JOURNAL. 51(3). patients with sleep apnea. JM, Middlemass J, Šonc S, Munaro G, Maruši? I.F.: 12.244 10. Telematic control of CPAP treatment in D, Sepper R, Rosso R, Siriwardena AN, Janson sleep apnea syndrome. C, Farré R, Calverley PMA, Dellaca' RL. 8. Vergara, Andrea; Cilloniz, Catia; Luque, Telemonitoring in COPD: The CHROMED Nestor; Garcia-Vidal, Carolina; Tejero, Javier; Study, a Randomized Clinical Trial. Perello, Rafael; Maria Lucena, Carmen; Torres, AMERICAN JOURNAL OF RESPIRATORY Antoni; Angeles Marcos, Maria. Detection of RESEARCH GROUP AND CRITICAL CARE MEDICINE. human cytomegalovirus in BREATHING DISTURBANCES IN SLEEP 198(5):620-628. I.F.: 15.239 bronchoalveolar lavage of intensive care unit patients. EUROPEAN RESPIRATORY GROUP LEADER 4. Méndez R, Menéndez R, Cillóniz C, JOURNAL. 51(2). I.F.: 12.244 Josep M. Montserrat (HCB) Amara-Elori I, Amaro R, González P, Posadas T, Gimeno A, España PP, Almirall J, Torres A. 9. Santamaria-Martos F; Benítez I; Girón C; The main research line of this group is the Initial Inflammatory Profile in Barbe F; Martinez-Garcia MA; Hernandez L; analysis of respiratory disturbances in sleep. Community-acquired Pneumonia Montserrat JM; Nagore E; Martorell-

128 APPLIED RESEARCH IN INFECTIOUS RESPIRATORY DISEASES, CRITICALLY ILL PATIENTS AND LUNG CANCER 2.6

Calatayud A; Campos-Rodriguez F; Corral J; Sandra; Aldoma, Albina; Worner, Fernando; Hypertension: Relationship Between Cabriada V; Abad J; Mediano O; Troncoso MF; Valls, Joan; Lee, Chi-Hang; Turino, Cecilia; Refractory Hypertension and Obstructive Cano-Pumarega I; Gutierrez AMF; Galera, Estefania; de Batlle, Jordi; Sanchez de Sleep Apnea. HYPERTENSION. Díaz-Cambriles T; Somoza-González M; la Torre, Manuel. Cardiac Troponin Values in 72(3):618-624. I.F.: 6.823 Almendros I; Farré R; Gozal D; Sanchez de la Patients With Acute Coronary Syndrome Torre M. Biomarkers of carcinogenesis and and Sleep Apnea A Pilot Study. CHEST. 19. Li Bassi, G.; Chiurazzi, C.; Aguilera, E.; tumour growth in patients with cutaneous 153(2):329-338. I.F.: 7.652 Travierso, C.; Battaglini, D.; Yang, M.; Motos, A.; melanoma and obstructive sleep apnoea. Yang, H.; Meli, A.; Marti, D.; Ranzani, O. T.; Blasi, EUROPEAN RESPIRATORY JOURNAL. 51(3). 15. Martinez-Garcia MA; Campos-Rodriguez F.; Pelosi, P.; Chiumello, D.; Torres, A. In-vitro I.F.: 12.244 F; Nagore E; Martorell A; Rodríguez-Peralto analysis of a novel "add-on' silicone cuff to JL; Riveiro-Falkenbach E; Hernandez L; improve sealing properties of tracheal 10. Restrepo MI; Babu BL; Reyes LF; Bañuls J; Arias E; Ortiz P; Cabriada V; tubes. ANAESTHESIA. 73(11):1372-1381. Chalmers JD; Soni NJ; Sibila O; Faverio P; Gardeazabal J; Montserrat JM; Carreres C; I.F.: 5.431 Cilloniz C; Rodriguez-Cintron W; Aliberti S; Corral J; Masa JF; Gomez De Terreros J; Abad GLIMP. Burden and risk factors for J; Boada A; Mediano O; De Eusebio E; Chiner 20. Aldasoro E; Posada E; Requena-Méndez Pseudomonas aeruginosa E; Landete P; Mayos M; Fortuño A; Barbe F; A; Calvo-Cano A; Serret N; Casellas A; Sanz S; community-acquired pneumonia: a Sánchez de la Torre M; Sanchez de la Torre A; Soy D; Pinazo MJ; Gascon J. What to expect multinational point prevalence study of Cano I; Gonzalez C; Pe?ez-Gil A; and when: benznidazole toxicity in chronic hospitalised patients. EUROPEAN Gómez-García T; Cullen D; Somoza M; Chagas' disease treatment. JOURNAL OF RESPIRATORY JOURNAL. 52(2):1701190. Formigon M; Aizpuru F; Navarro C; ANTIMICROBIAL CHEMOTHERAPY. I.F.: 12.244 Selma-Ferrer MJ; García-Ortega A; de 73:1060-1067. I.F.: 5.217 Unamuno B. Sleep-Disordered Breathing is 11. Briel M, Spoorenberg SMC, Snijders D, Independently Associated with Increased 21. De la Calle C., Ternavasio-de la Vega H., Torres A, Fernandez-Serrano S, Meduri GU, Aggressiveness of Cutaneous Melanoma. Morata L., Marco F., Cardozo C., García-Vidal Gabarrús A, Blum CA, Confalonieri M, A multicentre observational study in 443 C., Del Rio A., Cilloniz C., Torres A., Martínez J., Kasenda B, Siemieniuk RAC, Boersma W, Bos patients. CHEST. 154(6):1348-1358. I.F.: 7.652 Mensa J., Soriano A. Effectiveness of WJW, Christ-Crain M, Ovidius Study Group, combination therapy versus monotherapy Capisce Study Group, STEP Study Group. 16. Bedi P., Chalmers J., Goeminne P., Mai C., with a third-generation cephalosporin in Corticosteroids in patients hospitalized Saravanamuthu P., Velu P., Cartlidge M., bacteraemic pneumococcal pneumonia: A with community-acquired pneumonia: Loebinger M., Jacob J., Kamal F., Schembri N., propensity score analysis. JOURNAL OF systematic review and individual patient Aliberti S., Hill U., Harrison M., Johnson C., INFECTION. 76(4):342-347. I.F.: 4.603 data meta-analysis. CLINICAL INFECTIOUS Screaton N., Haworth C., Polverino E., Rosales DISEASES. 66(3):346-354. I.F.: 9.117 E., Torres A., Benegas M., Rossi A., Patel D., Hill 22. Polverino E, Rosales-Mayor E, Benegas M, A. The BRICS (Bronchiectasis Menendez R, Alcaraz-Serrano V, Ansotegui E, 12. Cillóniz C, Miguel-Escuder L, Pedro-Bonet Radiologically Indexed CT Score): A Montull B, Girón RM, Cisneros C, Vendrell M, ML, Falcó V, Lopez Y, García-Vidal C, Multicenter Study Score for Use in Muñoz G, Marcos MA, Sanchez M, Torres A . Gabarrús A, Moreno A, Torres A, Miró JM, Idiopathic and Postinfective Pneumonic and non-pneumonic Legionella-HIV Researchers. Community- Bronchiectasis. CHEST. 153(5):1177-1186. exacerbations in bronchiectasis: clinical Acquired Legionella Pneumonia in I.F.: 7.652 and microbiological differences. JOURNAL HIV-Infected Adult Patients: A Matched OF INFECTION. 77(2):99-106. I.F.: 4.603 Case-Control Study. CLINICAL INFECTIOUS 17. Schumann DM, Leeming D, DISEASES. 67(6):958-961. I.F.: 9.117 Papakonstantinou E, Blasi F, Kostikas K, 23. García de la Mària C, Gasch O, Boersma W, Louis R, Milenkovic B, Aerts J, García-Gonzalez J, Soy D, Shaw E, 13. Huang DB, O'Riordan W, Overcash JS, Sand JMB, Wouters EFM, Rohde G, Prat C, Ambrosioni J, Almela M, Pericàs JM, Tellez A, Heller B, Amin F, File TM, Wilcox MH, Torres A, Torres A, Welte T, Tamm M, Karsdal M, Stolz Falces C, Hernandez-Meneses M, Sandoval E, Dryden M, Holland TL, McLeroth P, Shukla R, D. Collagen degradation and formation are Quintana E, Vidal B, Tolosana JM, Fuster D, Corey GR . A Phase 3, Randomized, elevated in exacerbated COPD compared Llopis J, Pujol M, Moreno A, Marco F, Miró JM . Double-Blind, Multicenter Study to to stable disease. CHEST. 154(4):798-807. The Combination of Daptomycin plus Evaluate the Safety and Efficacy of I.F.: 7.652 Fosfomycin has Synergistic, Potent and Intravenous Iclaprim Vs Vancomycin for Rapid Bactericidal Activity against the Treatment of Acute Bacterial Skin and 18. Martinez-Garcia, Miguel-Angel; Methicillin-ResistantStaphylococcus Skin Structure Infections Suspected or Navarro-Soriano, Cristina; Torres, Gerard; aureus(MRSA) in a Rabbit Model of Conﬁrmed to be Due to Gram-Positive Barbe, Ferran; Caballero-Eraso, Candela; Experimental Endocarditis (EE). Pathogens: REVIVE-1. CLINICAL Lloberes, Patricia; Diaz-Cambriles, Teresa; ANTIMICROBIAL AGENTS AND INFECTIOUS DISEASES. 66(8):1222-1229. Somoza, Maria; Masa, Juan F.; Gonzalez, CHEMOTHERAPY. 62(6). I.F.: 4.256 I.F.: 9.117 Monica; Manas, Eva; de la Pena, Monica; Garcia-Rio, Francisco; Maria Montserrat, 24. Holland TL, O'Riordan W, McManus A, 14. Sanchez-de-la-Torre, Alicia; Soler, Xavier; Josep; Muriel, Alfonso; Jose Selma-Ferrer, Shin E, Borghei A, File TM, Wilcox MH, Torres Barbe, Ferran; Flores, Marina; Maisel, Alan; Maria; Garcia Ortega, Alberto; Campos- A, Dryden M, Lodise T, Oguri T, Corey GR, Malhotra, Atul; Rue, Montserrat; Bertran, Rodriguez, Francisco. Beyond Resistant McLeroth P, Shukla R, Huang DB. A Phase 3,

129 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

Randomized, double-blind, multicenter risk of a hospital stay for longer than 7 days Hospitalizations due to exacerbations of study to EValuate the safety and efficacy in patients with severe acute COPD: A big data perspective. of intravenous Iclaprim versus exacerbations of chronic obstructive RESPIRATORY MEDICINE. 145:219-225. Vancomycin for the treatment of acute pulmonary disease: a prospective study. I.F.: 3.230 bacterial skin and skin structure infections RESPIRATORY RESEARCH. 19(1):261. suspected or confirmed to be due to I.F.: 3.751 36. López-Aguilar J, Bassi GL, Quilez ME, Gram-positive pathogens: REVIVE-2. Martí JD, Tavares OR, Xiol EA, Rigol M, Luque ANTIMICROBIAL AGENTS AND 31. Almendros, Isaac; Angel Martinez-Garcia, N, Guillamat R, Ferrer I, Torres A, Blanch L . CHEMOTHERAPY. 62(5):e02580. I.F.: 4.256 Miguel; Campos-Rodriguez, Francisco; Hippocampal Damage During Mechanical Riveiro-Falkenbach, Erica; Rodriguez-Peralto, Ventilation in Trendelenburg Position: A 25. Huang DB, Corey GR, Holland TL, Lodise Jose L.; Nagore, Eduardo; Martorell- Secondary Analysis of an Experimental T, O'Riordan W, Wilcox MH, File TM, Dryden M, Calatayud, Antonio; Hernandez Blasco, Luis; Study on the Prevention of Ventilator- Balser B, Desplats E, Torres A . Pooled Banuls Roca, Jose; Chiner Vives, Eusebi; Associated Pneumonia. SHOCK. . I.F.: 3.005 analysis of the phase 3 REVIVE trials: Sanchez-de-la-Torre, Alicia; Abad-Capa, randomised, double-blind studies to Jorge; Maria Montserrat, Josep; Perez-Gil, 37. Herrero-Cortina, Beatriz; Alcaraz, Victoria; evaluate the safety and efficacy of iclaprim Amalia; Cabriada-Nuno, Valentin; Vilaro, Jordi; Torres, Antoni; Polverino, Eva. versus vancomycin for treatment of acute Cano-Pumarega, Irene; Corral-Penafiel, Jaime; Impact of Hypertonic Saline Solutions on bacterial skin and skin-structure Diaz-Cambriles, Trinidad; Mediano, Olga; Sputum Expectoration and Their Safety infections. INTERNATIONAL JOURNAL OF Dalmau-Arias, Joan; Farre, Ramon; Gozal, Profile in Patients with Bronchiectasis: A ANTIMICROBIAL AGENTS. 52(2):233-240. David. Intermittent Hypoxia Is Associated Randomized Crossover Trial. JOURNAL OF I.F.: 4.253 With High Hypoxia Inducible Factor-1 alpha AEROSOL MEDICINE AND PULMONARY but Not High Vascular Endothelial Growth DRUG DELIVERY. 31(5):281-289. I.F.: 2.927 26. Crisafulli E., Guerrero M., Ielpo A., Ceccato Factor Cell Expression in Tumors of A., Huerta A., Gabarrús A., Soler N., Chetta A., Cutaneous Melanoma Patients. 38. Cillóniz C, Liapikou A, Martin-Loeches I, Torres A. Impact of bronchiectasis on FRONTIERS IN NEUROLOGY. 9(APR):272. García-Vidal C, Gabarrús A, Ceccato A, outcomes of hospitalized patients with I.F.: 3.508 Magdaleno D, Mensa J, Marco F, Torres A . acute exacerbation of chronic obstructive Twenty-year trend in mortality among pulmonary disease: A propensity matched 32. Menal, Maria Jose; Jorba, Ignasi; Torres, hospitalized patients with pneumococcal analysis. SCIENTIFIC REPORTS. 8(1):9236. Marta; Montserrat, Josep M.; Gozal, David; community-acquired pneumonia. PLOS I.F.: 4.122 Colell, Anna; Pinol-Ripoll, Gerard; Navajas, ONE. 13(7):e0200504. I.F.: 2.766 Daniel; Almendros, Isaac; Farre, Ramon. 27. Fernández-Barat L, Ben-Aicha S, Motos A, Alzheimer's Disease Mutant Mice Exhibit 39. Ferrer M., Travierso C., Cilloniz C., Vila J, Marco F, Rigol M, Muñoz L, Li Bassi G, Reduced Brain Tissue Stiffness Compared Gabarrus A., Ranzani O., Polverino E., Liapikou Ferrer M, Torres A. Assessment of in vivo to Wild-type Mice in both Normoxia and A., Blasi F., Torres A. Severe versus in vitro biofilm formation of clinical following Intermittent Hypoxia Mimicking community-acquired pneumonia: methicillin-resistant Staphylococcus Sleep Apnea. FRONTIERS IN NEUROLOGY. Characteristics and prognostic factors in aureus isolates from endotracheal tubes. 9(JAN):1. I.F.: 3.508 ventilated and non-ventilated patients. SCIENTIFIC REPORTS. 8(1):11906. I.F.: 4.122 PLOS ONE. 13(1):e0191721. I.F.: 2.766 33. Suarez-Giron, Monique C.; 28. Bastida C, Ruiz-Esquide V, Pascal M, de Castro-Grattoni, Anabel; Torres, Marta; Farre, 40. Egli A, Egli A, Mandal J, Schumann DM, Vries Schultink AHM, Yagüe J, Sanmartí R, Ramon; Barbe, Ferran; Sanchez-de-la-Torre, Roth M, Thomas B, Lorne Tyrrell D, Blasi F, Huitema ADR, Soy D . Fixed dosing of Manuel; Gozal, David; Picado, Cesar; Kostikas K, Boersma W, Milenkovic B, Lacoma intravenous tocilizumab in rheumatoid Montserrat, Josep M.; Almendros, Isaac. A, Rentsch K, Rohde GGU, Louis R, Aerts JG, arthritis. Results from a population Acetylsalicylic Acid Prevents Intermittent Welte T, Torres A, Tamm M, Stolz D. IFN?3/4 pharmacokinetic analysis. BRITISH Hypoxia-Induced Vascular Remodeling in locus polymorphisms and IFN?3 JOURNAL OF CLINICAL PHARMACOLOGY. a Murine Model of Sleep Apnea. circulating levels are associated with 84(4):716-725. I.F.: 3.838 FRONTIERS IN PHYSIOLOGY. 9(MAY):600. COPD severity and outcomes. BMC I.F.: 3.394 PULMONARY MEDICINE. 18(1):51. I.F.: 2.721 29. Estirado C, Ceccato A, Guerrero M, Huerta A, Cilloniz C, Vilaró O, Gabarrús A, Gea 34. Faner R., Noell G., Badia J., López-Giraldo 41. Garmendia O., Suarez-Giron M., Torres M., J, Crisafulli E, Soler N, Torres A, Torres A. A., Bakke P., Silverman E., Tal-Singer R., Agustí Montserrat J. Telemedicine in Sleep Apnea: Microorganisms resistant to conventional A. Distribution, temporal stability and A Simple Approach for Nasal Pressure antimicrobials in acute exacerbations of association with all-cause mortality of the (CPAP) Treatment. ARCHIVOS DE chronic obstructive pulmonary disease. 2017 GOLD groups in the ECLIPSE cohort. BRONCONEUMOLOGIA. 54(9):491-492. RESPIRATORY RESEARCH. 19(1):119. RESPIRATORY MEDICINE. 141:14-19. I.F.: 2.633 I.F.: 3.751 I.F.: 3.230 42. Bongard E, van der Velden AW, Cook J, 30. Crisafulli E, Ielpo A, Barbeta E, Ceccato A, 35. Serra-Picamal X., Roman R., Escarrabill J., Saville B, Beutels P, Munck Aabenhus R, Huerta A, Gabarrús A, Soler N, Chetta A, García-Altés A., Argimón J., Soler N., Faner R., Brugman C, Chlabicz S, Coenen S, Colliers A, Torres A. Clinical variables predicting the Carbonell E., Trilla A., Agusti A.. Davies M, De Paor M, De Sutter A, Francis NA,

130 APPLIED RESEARCH IN INFECTIOUS RESPIRATORY DISEASES, CRITICALLY ILL PATIENTS AND LUNG CANCER 2.6

Glinz D, Godycki-wirko M, Goossens H, Review / I.F.: 62.694 9. Cillóniz C, Dominedò C, Garcia-Vidal C, Holmes J, Ieven M, de Jong M, Lindbaek M, Torres A. Community-acquired pneumonia Little P, Martinón-Torres F, Moragas A, Pauer 1. Randerath W, Bassetti CL, Bonsignore MR, as an emergency condition. CURRENT J, Pfeiferová M, Radzeviciene-Jurgute R, Farre R, Ferini-Strambi L, Grote L, Hedner J, OPINION IN CRITICAL CARE. 24(6):531-539. Sundvall PD, Torres A, Touboul P, Varthalis D, Kohler M, Martinez-Garcia MA, Mihaicuta S, I.F.: 3.120 Verheij T, Butler CC. Antivirals for Montserrat J, Pepin JL, Pevernagie D, Pizza F, influenza-Like Illness? A randomised Polo O, Riha R, Ryan S, Verbraecken J, 10. Ferrer M, Torres A. Epidemiology of Controlled trial of Clinical and Cost McNicholas WT. Challenges and ICU-acquired pneumonia. CURRENT effectiveness in primary CarE (ALIC4 E): Perspectives in Obstructive Sleep OPINION IN CRITICAL CARE. 24(5):325-331. the ALIC4 E protocol. BMJ OPEN. Apnoea: Report by an ad hoc working I.F.: 3.120 8(7):e021032. I.F.: 2.413 group of the Sleep Disordered Breathing Group of the European Respiratory 11. Martin-Loeches I, Rodriguez AH, Torres A. 43. Mandala, Jyotshna; Roth, Michael; Society and the European Sleep Research New guidelines for hospital-acquired Papakonstantinou, Eleni; Sun, Qingzhu; Costa, Society. EUROPEAN RESPIRATORY pneumonia/ventilator-associated Luigi; Boeck, Lucas; Scherr, Andreas; Rakic, JOURNAL. 52(3). I.F.: 12.244 pneumonia: USA vs. Europe. CURRENT Janko; Louis, Renaud; Milenkovic, Branislava; OPINION IN CRITICAL CARE. 24(5):347-352. Boersma, Wim; Kostikas, Konstantinos; Blasi, 2. Torres A., Motos A., Battaglini D., Li Bassi G. I.F.: 3.120 Francesco; Aerts, Joachim; Rohde, Gernot; Inhaled amikacin for severe Lacoma, Alicia; Torres, Antoni; Welte, Tobias; Gram-negative pulmonary infections in 12. Ranzani OT, Taniguchi LU, Torres A. Tamm, Michael; Stolz, Daiana. Treatment the intensive care unit: Current status and Severity scoring systems for pneumonia: with long acting muscarinic antagonists future prospects. CRITICAL CARE. current understanding and next steps. stimulates serum levels of irisin in patients 22(1):343. I.F.: 6.425 CURRENT OPINION IN PULMONARY with COPD. PULMONARY MEDICINE. 24(3):227-236. I.F.: 3.000 PHARMACOLOGY AND THERAPEUTICS. 3. Ceccato A., Ferrer M., Barbeta E., Torres A. 48:111-116. I.F.: 2.406 Adjunctive Therapies for Community- 13. Amaro R, Panagiotaraka M, Alcaraz V, Acquired Pneumonia. CLINICS IN CHEST Torres A. The efficacy of inhaled antibiotics 44. Huang D., Duncan L., Flamm R., Dryden M., MEDICINE. 39(4):753-764. I.F.: 4.347 in non-cystic fibrosis bronchiectasis. Corey G., Wilcox M., Torres A., File T. The EXPERT REVIEW OF RESPIRATORY effect of pulmonary surfactant on the in 4. Farré R, Montserrat JM, Gozal D, MEDICINE. 12(8):1-9. I.F.: 2.607 vitro activity of Iclaprim against common Almendros I, Navajas D. Intermittent respiratory bacterial pathogens. Hypoxia Severity in Animal Models of 14. Crisafulli E., Torres A. COPD 2017: A Year DIAGNOSTIC MICROBIOLOGY AND Sleep Apnea. FRONTIERS IN PHYSIOLOGY. in Review. COPD: JOURNAL OF CHRONIC INFECTIOUS DISEASE. 90(1):64-66. I.F.: 2.341 9:1556. I.F.: 3.394 OBSTRUCTIVE PULMONARY DISEASE. 15(2):1-5. I.F.: 2.604 45. Huang D., File T., Dryden M., Corey G., 5. Torres A., Cillóniz C., Blasi F., Chalmers J., Torres A., Wilcox M. Surveillance of iclaprim Gaillat J., Dartois N., Schmitt H., Welte T. 15. Cillóniz C, Ielpo A, Torres A . Treating activity: In vitro susceptibility of Burden of pneumococcal HIV-Positive/Non-AIDS Patients for gram-positive pathogens collected from community-acquired pneumonia in adults Community-Acquired Pneumonia with 2012 to 2014 from the United States, Asia across Europe: A literature review. ART. CURRENT INFECTIOUS DISEASE Pacific, Latin American and Europe. RESPIRATORY MEDICINE. 137:6-13. I.F.: 3.230 REPORTS. 20(11):46. I.F.: 2.085 DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE. 90(4):329-334. 6. Liapikou A, Cilloniz C, Torres A. Drugs that 16. Cillóniz C., Rodríguez-Hurtado D., Nicolini I.F.: 2.341 increase the risk of community-acquired A., Torres A. Clinical Approach to pneumonia: a narrative review. EXPERT Community-acquired Pneumonia. 46. Brito-Zeron, Pilar; Acar-Denizli, Nihan; OPINION ON DRUG SAFETY. 17(10):991-1003. JOURNAL OF THORACIC IMAGING. Siso-Almirall, Antoni; Bosch, Xavier; I.F.: 3.156 33(5):273-281. I.F.: 1.624 Hernandez, Fernanda; Vilanova, Sergi; Villalta, Mireia; Kostov, Belchin; Paradela, Marina; 7. Cillóniz C, García-Vidal C, Moreno A, Miro 17. Sampol Rubio G; Macías Escalada E; Sanchez, Marcelo; Ramirez, Jose; Muxi, Africa; JM, Torres A. Community-acquired Montserrat Canal J; Terán Santos J. Mandibular Berruezo, Antonio; Galceran-Chaves, Celeste; bacterial pneumonia in adult HIV-infected advancement devices in the treatment of Xaubet, Antoni; Agusti, Carles; Sellares, patients. EXPERT REVIEW OF obstructive sleep apnea. A necessary and Jacobo; Ramos-Casals, Manuel. The Burden ANTI-INFECTIVE THERAPY. 16(7):579-588. effective option.MEDICINA CLINICA. of Comorbidity and Complexity in I.F.: 3.141 151(1):34-38. I.F.: 1.168 Sarcoidosis: Impact of Associated Chronic Diseases. LUNG. 196(2):239-248. I.F.: 2.101 8. Martin-Loeches I, Dale GE, Torres A . 18. Gabriel Sampol; Emilio Macías Escalada; Murepavadin: a new antibiotic class in the Josep María Montserrat; Joaquín Terán Santos. pipeline. EXPERT REVIEW OF Los dispositivos de avance mandibular en el ANTI-INFECTIVE THERAPY. 16(4):259-268. tratamiento de la apnea obstructiva del I.F.: 3.141 sueño. Una opción necesaria y eficaz. MEDICINA CLINICA. 151(1):34-38. I.F.: 1.168

131 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

Letters / I.F.: 48.119 Case Reports / I.F.: 3.831 Torres A. Eﬁcacia y caracterización de los efectos de los corticosteroides asociados 1. Villanueva JA, Isetta V, Montserrat JM, 1. Luisa Imaz M., Oriolo G., Torra M., Soy D., a antibióticos en un modelo animal de Navajas D, Farré R. A Portable Continuous García-Esteve L., Martin-Santos R. Clozapine neumonía grave por streptococcus Positive Airway Pressure Device That Can use during pregnancy and lactation: A pneumoniae. Perform Optimally Under Strenuous case-series report. FRONTIERS IN Sponsored by: Instituto de Salud Carlos III. Conditions. AMERICAN JOURNAL OF PHARMACOLOGY. 9:264. I.F.: 3.831 PI15/00506 RESPIRATORY AND CRITICAL CARE Duration: 01/01/2016-31/12/2019 MEDICINE. 198(7):956-958. I.F.: 15.239 Consortium Publications / I.F.: 5.394 Torres A. COMBACTE_APC: Academic 2. Ranzani OT, Torres A, on behalf of all Partners of COMBACTE. authors. Reply to: Sepsis-3 in 1. Pericàs JM, Moreno A, Almela M, Sponsored by: European Commission. Community-acquired Pneumonia: How García-de-la-Mària C, Marco F, Muñoz P, IMI12_8th_2stg Reliable is It? AMERICAN JOURNAL OF Peña C, de Alarcón A, Del Río A, Eworo A, Duration: 01/01/2013-31/12/2021 RESPIRATORY AND CRITICAL CARE Cruceta A, Paré JC, Mestres CA, Miró JM, MEDICINE. 197(4):537-538. I.F.: 15.239 FOSIMI Investigators. Efficacy and Safety of Torres A. COMBACTE-MAGNET: Fosfomycin Plus Imipenem vs. Combatting Bacterial Resistance in 3. Torres A, Ferrer M, Niederman MS. Vancomycin for Complicated Bacteremia Europe - Molecules Against Gram Adjuvant therapies in critical care: steroids and Endocarditis Due to Methicillin- Negative Infections. in community-acquired pneumonia. Resistant Staphylococcus aureus: A Sponsored by: European Commission. INTENSIVE CARE MEDICINE. 44(4):478-481. Randomized Clinical Trial. CLINICAL IMI13_11th_2stg I.F.: 15.008 MICROBIOLOGY AND INFECTION. Duration: 01/01/2015-31/12/2021 24(6):673-676. I.F.: 5.394 4. Onintza Garmendia; Monique C. Suarez Giron; Marta Torres López; Josep María Montserrat. Telemedicine in sleep apnea : DOCTORAL THESES A simple approach for nasal pressure GRANTS FOR RESEARCH IN PROGRESS (CPAP) treatment. ARCHIVOS DE Agustí C. Análisis del impacto clínico, BRONCONEUMOLOGIA. 54(9):491-492. Montserrat JM. Telemedicina en pacientes pronóstico y económico de los pacientes I.F.: 2.633 con "sleep APNEA" que no cumplen con bronquiectasias y EPOC. adecuadamente el tratamiento con CPAP. PhD student: David de la Rosa Carrillo Cumplidores mínimos vs cumplidores Editorial / I.F.: 45.842 óptimos. Montserrat JM. New therapeutic Sponsored by: Instituto de Salud Carlos III approaches for obstructive sleep apnea. 1. Farré R, Navajas D, Montserrat JM. Is (ISCIII). PI17/01068 PhD student: Monique Carolina Suarez Girón Telemedicine a Key Tool for Improving Duration: 01/01/2018-31/12/2020 Continuous Positive Airway Pressure Adherence in Patients with Sleep Apnea? Montserrat JM. Aplicabilidad y coste AMERICAN JOURNAL OF RESPIRATORY eﬁciencia de un modelo de gestión para el AND CRITICAL CARE MEDICINE. 197(1):12-14. síndrome de apneas durante el sueño I.F.: 15.239 basado en el trabajo en red y telemedicina. Sponsored by: Instituto de Salud Carlos III 2. Torres A. New Insights in the Regulation (ISCIII). PI14/00416 of the Endothelial Lung Permeability in Duration: 01/01/2015-30/06/2019 Pneumonia: The Interplay between Angiopoietins 1 and 2. AMERICAN Soler N. Dinámica del microbioma JOURNAL OF RESPIRATORY AND CRITICAL pulmonar en la agudización neumónica y CARE MEDICINE. 198(2):149-150. I.F.: 15.239 no neumónica de la EPOC y uso como potencial diana terapéutica: estudio 3. Froes F., Blasi F., Torres A. Achoo, achis, discriminativo con TAC torácica de baja ATCHIN! Vaccine you. EUROPEAN radiación. RESPIRATORY JOURNAL. 51(3):1702558. I.F.: Sponsored by: Instituto de Salud Carlos III 12.244 (ISCIII). PI16/00803 Duration: 01/01/2017-31/12/2019 4. Torres A. ICU-acquired pneumonia: is it time to use this term? CURRENT OPINION Torres A. Fisiopatologia i tractament de les IN CRITICAL CARE. 24(5):323-324. I.F.: 3.120 malalties respiratòries. Sponsored by: Generalitat de Catalunya. AGAUR_SGR17_00787 Duration: 01/01/2017-31/12/2020

132 PHYSIOPATHOLOGICAL MECHANISMS OF RESPIRATORY ILLNESSES 2.7

Physiopathological mechanisms of 2.7 respiratory illnesses

Jessica Garcia (FCRB) Elena Gimeno (IDIBAPS) LOCATION Maria Isabel Marquina (IDIBAPS) HCB Víctor Ivo Peinado (CIBER) CELLEX building, ﬂoor 2A Akos Tenyi (IDIBAPS)

WEB PRE-DOCTORAL RESEARCHERS www.clinicbarcelona.org/en/ Eric Baltaxe (IDIBAPS) idibaps/research-areas Tanya Elisa Orizaga (FCRB) Jeisson Osorio (CIBER)

TEAM LEADER Laura Sebastian (IDIBAPS) Joan Albert Barberà (HCB) Valerie Smolders (UB) T. 93 227 57 79 Yolanda Torralba (HCB) [email protected] KEYWORDS TECHNICIANS 1. Pulmonary hypertension Cristina Bonjoch (IDIBAPS) 2. COPD GROUP LEADER Cristina Rodríguez (IDIBAPS) 3. Systems medicine Isabel Blanco (HCB-IDIBAPS) 4. Endothelium T. 93 227 57 47 ADMINISTRATIVE STAFF 5. Stem cells [email protected] Julio Tomas Mas (FCRB) Mària Sánchez (IDIBAPS) Maria Dolores Sanz (FCRB) EMERITUS Robert Rodríguez-Roisin (HCB) NURSING STAFF Original publications Xavier Alsina (HCB) from 2016 to 2018 RESEARCHERS Concepción Gistau (HCB) Felip Burgos (HCB) María Palomo (HCB) YEAR I.F. TOTAL Q1 Q2 Carme Hernández (HCB) Ana Maria Ramírez (HCB) 2016 141.51 28 19 5 Graciela Martínez-Pallí (HCB) Josep Roca (HCB) COLLABORATORS 2017 86.75 16 13 - Olga Tura (IDIBAPS) Albert Alonso (HCB) 2018 109.71 26 13 8 Elizabeth Zavala (HCB) Mª José Arguis (HCB) Xavier Borrat (HCB) POST-DOCTORAL RESEARCHERS Marta Cascante (UB) Anael Barberan (UB) Jorge Moisés (HCB) TEAM INVOLVED IN Isaac Cano (IDIBAPS) Lucilla Piccari (FCRB) CIBERES Ivan Guillermo Dueñas (IDIBAPS) Jordi Vilaró (FCRB) RETIC Biobancos AGAUR_SGR17: 00617

AWARDS Best Clinical Trajectory in Rare Diseases Institution: Asociación Española de Laboratorios de Medicamentos Huérfanos y Ultrahuérfanos (AELMHU) Awardee/s: Joan A. Barberà

Fellow of the European Respiratory Society (excellence in research, education and clinical leadership) Institution: European Respiratory Society Awardee/s: Felip Burgos Joan Albert Barberà TEAM

133 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

STRATEGIC OBJECTIVES vasoconstriction contributes, especially in TRANSPLANTATION. 37(12):1410-1417. earlier stages, the obstructive vascular I.F.: 7.955 Understanding of the molecular mechanisms remodelling is the major cause of the elevated involved in the development of pulmonary PVR and ultimately the right heart failure. 5. Papi, Alberto; Ryan, Dermot; Soriano, Joan vascular diseases. Identification of biomarkers There is a need to identify new signaling B.; Chrystyn, Henry; Bjermer, Leif; and therapeutic targets for pulmonary pathways in the pathogenesis of PAH. We Rodriguez-Roisin, Roberto; Dolovich, Myrna hypertension. Characterization of propose going from the bench to the bed side B.; Harris, Mark; Wood, Lucy; Batsiou, Maria; extrapulmonary disorders in COPD. studying potential biomarkers of the disease Thornhill, Susannah I.; Price, David B. Determination of intra-and extrapulmonary activity and progression; as well as potential Relationship of Inhaled Corticosteroid manifestations of severe obesity. Role of stem new drugs to reverse the proliferative Adherence to Asthma Exacerbations in cells in lung injury and repair mechanisms. remodelling phenotype in PAH. Patients with Moderate-to-Severe Personalized medical care for chronic Asthma. JOURNAL OF ALLERGY AND respiratory diseases from a systems medicine CLINICAL IMMUNOLOGY-IN PRACTICE. strategy. 6(6):1989-1998.e3. I.F.: 6.966 PUBLICATIONS 6. Selga E., Sendfeld F., Martinez-Moreno R., Originals / I.F.: 109.705 Medine C., Tura-Ceide O., Wilmut S., Pérez G., MAIN LINES OF RESEARCH Scornik F., Brugada R., Mills N. Sodium 1. Ramon MA, Ter Riet G, Carsin AE, channel current loss of function in induced - Clinical research in pulmonary Gimeno-Santos E, Agustí A, Antó JM, pluripotent stem cell-derived hypertension: biomarkers and new Donaire-Gonzalez D, Ferrer J, Rodríguez E, cardiomyocytes from a Brugada therapies. Rodriguez-Roisin R, Puhan MA, syndrome patient. JOURNAL OF - Endothelial dysfunction and vascular Garcia-Aymerich J, PAC-COPD Study Group. MOLECULAR AND CELLULAR remodeling. The dyspnoea-inactivity vicious circle in CARDIOLOGY. 114:10-19. I.F.: 5.296 - Experimental models of COPD and COPD: Development and external pulmonary hypertension. validation of a conceptual model. 7. Tényi Á, Cano I, Marabita F, Kiani N, Kalko - Stem and progenitor cells. EUROPEAN RESPIRATORY JOURNAL. SG, Barreiro E, de Atauri P, Cascante M, - Interaction between airway, lung and 52(3):1800079. I.F.: 12.244 Gomez-Cabrero D, Roca J. Network systemic inflammation in COPD and modules uncover mechanisms of skeletal severe obesity. 2. Arbillaga-Etxarri A., Gimeno-Santos E., muscle dysfunction in COPD patients. - Pathophysiology of pulmonary gas Barberan-Garcia A., Balcells E., Benet M., JOURNAL OF TRANSLATIONAL MEDICINE. exchange. Borrell E., Celorrio N., Delgado A., Jané C., 16(1):34. I.F.: 4.197 - Systems medicine. Marin A., Martín-Cantera C., Monteagudo M., Montellà N., Muñoz L., Ortega P., Rodríguez D., 8. Jacobs, Susan S.; Lindell, Kathleen O.; Rodríguez-Roisin R., Simonet P., Collins, Eileen G.; Garvey, Chris M.; Hernandez, Torán-Monserrat P., Torrent-Pallicer J., Carme; McLaughlin, Sally; Schneidman, Ann 50/50 PROGRAM Vall-Casas P., Vilaró J., Garcia-Aymerich J. M.; Meek, Paula M. Patient Perceptions of TRANSLATIONAL RESEARCH IN Long-term efficacy and effectiveness of a the Adequacy of Supplemental Oxygen PULMONARY VASCULAR DISEASES: behavioural and community-based Therapy Results of the American Thoracic CELL PROLIFERATION AND exercise intervention (Urban Training) to Society Nursing Assembly Oxygen APOPTOTIC MECHANISMS IN increase physical activity in patients with Working Group Survey. ANNALS OF THE PULMONARY ARTERIAL COPD: a randomised controlled trial. AMERICAN THORACIC SOCIETY. 15(1):24-32. HYPERTENSION EUROPEAN RESPIRATORY JOURNAL. 52(4). I.F.: 4.006 I.F.: 12.244 9. Velickovski, Filip; Ceccaroni, Luigi; Marti, 3. Barberan-Garcia A, Ubré M, Roca J, Lacy Robert; Burgos, Felip; Gistau, Concepcion; AM, Burgos F, Risco R, Momblán D, Balust J, Alsina-Restoy, Xavier; Roca, Josep. Blanco I, Martínez-Pallí G . Personalised Automated Spirometry Quality Assurance: Prehabilitation in High-risk Patients Supervised Learning From Multiple Undergoing Elective Major Abdominal Experts. IEEE JOURNAL OF BIOMEDICAL GROUP LEADER Surgery: A Randomized Blinded AND HEALTH INFORMATICS. 22(1):276-284. Isabel Blanco (HCB-IDIBAPS) Controlled Trial. ANNALS OF SURGERY. I.F.: 3.850 267(1):50-56. I.F.: 9.203 Pulmonary arterial hypertension (PAH) is a 10. Musri MM, Coll-Bonfill N, Maron BA, disease of small pulmonary arteries, 4. Frost A., Hoeper M., Barberá J., Vachiery J., Peinado VI, Wang RS, Altirriba J, Blanco I, characterized by gradual obliteration of the Blair C., Langley J., Rubin L. Risk-stratified Oldham WM, Tura-Ceide O, García-Lucio J, arterial lumen due to the enlargement of the outcomes with initial combination therapy de la Cruz-Thea B, Meister G, Loscalzo J, vessel wall. It results in a progressive increase in pulmonary arterial hypertension: Barberà JA. MicroRNA Dysregulation in of pulmonary vascular resistance (PVR) and, Application of the REVEAL risk score. Pulmonary Arteries from COPD: finally, right ventricular failure and death. While JOURNAL OF HEART AND LUNG Relationships with Vascular Remodeling.

134 PHYSIOPATHOLOGICAL MECHANISMS OF RESPIRATORY ILLNESSES 2.7

AMERICAN JOURNAL OF RESPIRATORY J, Rodríguez Chiaradía D, Pascual-Guardia S, MAKING. 18(1):85. I.F.: 2.134 CELL AND MOLECULAR BIOLOGY. Marcos Rodríguez PJ, Alvarez Martinez CJ, 59(4):490-499. I.F.: 3.785 Casanova Macario C, López-Campos JL, 23. Barberan-Garcia A., Gimeno-Santos E., Carrasco Hernández L, Martínez-González C, Blanco I., Cano I., Martínez-Pallí G., Burgos F., 11. Watz H, Tetzlaff K, Magnussen H, Mueller A, Santos-Pérez S, Peces-Barba G, Molina Paris Miralles F., Coca M., Murillo S., Sanz M., Steblin Rodriguez-Roisin R, Wouters EFM, J, Román Rodríguez M, Barberà JA, Faner R, A., Ubré M., Benavent J., Vidal J., Sitges M., Vogelmeier C, Calverley PMA. Spirometric Agustí A, Cosío BG, en representación del Roca J. Protocol for regional changes during exacerbations of COPD: a Grupo Investigador del estudio EARLY COPD. implementation of collaborative post hoc analysis of the WISDOM trial. Determinants of the Appearance and self-management services to promote RESPIRATORY RESEARCH. 19(1):251. Progression of Early-Onset Chronic physical activity. BMC HEALTH SERVICES I.F.: 3.751 Obstructive Pulmonary Disease in Young RESEARCH. 18(1):560. I.F.: 1.843 Adults. ARCHIVOS DE 12. Rodriguez-Perez, Raquel; Cortes, Roldan; BRONCONEUMOLOGIA. 55(6):312-318. 24. Rutten-van Mölken M; Leijten F; Guaman, Ana; Pardo, Antonio; Torralba, I.F.: 2.633 Hoedemakers M; Tsiachristas A; Verbeek N; Yolanda; Gomez, Federico; Roca, Josep; Karimi M; Bal R; de Bont A; Islam K; Askildsen Albert Barbera, Joan; Cascante, Marta; Marco, 18. Del Corral T., Cebrià Iranzo M., JE; Czypionka T; Kraus M; Huic M; Pitter JG; Santiago. Instrumental drift removal in López-de-Uralde-Villanueva I., Vogt V; Stokes J; Baltaxe E; SELFIE GC-MS data for breath analysis: the Martínez-Alejos R., Blanco I., Vilaró J. consortium. Strengthening the short-term and long-term temporal Effectiveness of a Home-Based Active evidence-base of integrated care for validation of putative biomarkers for Video Game Programme in Young Cystic people with multi-morbidity in Europe COPD. JOURNAL OF BREATH RESEARCH. Fibrosis Patients. RESPIRATION; using Multi-Criteria Decision Analysis 12(3):036007. I.F.: 3.489 INTERNATIONAL REVIEW OF THORACIC (MCDA). BMC HEALTH SERVICES DISEASES. 95(2):87-97. I.F.: 2.591 RESEARCH. 18(1):576. I.F.: 1.843 13. Ferguson G., Rodriguez-Roisin R., Reisner C., Maes A., Siddiqui S., Martin U. 19. Vela E, Tényi Á, Cano I, Monterde D, Cleries 25. Hernández C, Aibar J, Seijas N, Puig I, Pharmacokinetics of glycopyrronium/ M, Garcia-Altes A, Hernandez C, Escarrabill J, Alonso A, Garcia-Aymerich J, Roca J. formoterol fumarate dihydrate delivered Roca J. Population-based analysis of Implementation of Home Hospitalization via metered dose inhaler using patients with COPD in Catalonia: a cohort and Early Discharge as an Integrated Care co-suspension delivery technology in study with implications for clinical Service: A Ten Years Pragmatic patients with moderate-to-very severe management. BMJ OPEN. 8(3):e017283. Assessment. INTERNATIONAL JOURNAL COPD. INTERNATIONAL JOURNAL OF I.F.: 2.413 OF INTEGRATED CARE. 18(2):12. I.F.: 1.837 COPD. 13:945-953. I.F.: 2.917 20. Gaveikaite V, Fischer C, Schonenberg H, 26. Berruezo A, Linhart M, Auricchio A, 14. Paul T., Salazar-Degracia A., Peinado V., Pauws S, Kitsiou S, Chouvarda I, Maglaveras Zamorano JL, Santamaria P, Borràs R, Burgos Tura-Ceide O., Blanco I., Barreiro E., Barberà J. N, Roca J. Telehealth for patients with F, Brugada J. Rationale and design of the Soluble guanylate cyclase stimulation chronic obstructive pulmonary disease TRICHAMPION trial: Triple Chamber reduces oxidative stress in experimental (COPD): a systematic review and Pacing in Hypertrophic Obstructive Chronic Obstructive Pulmonary Disease. meta-analysis protocol. BMJ OPEN. Cardiomyopathy Patients. JOURNAL OF PLOS ONE. 13(1):e0190628. I.F.: 2.766 8(9):e021865. I.F.: 2.413 INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY. 51(2):117-124. I.F.: 1.522 15. García-Lucio J, Peinado VI, de Jover L, Del 21. Folch Ayora A, Macia-Soler L, Orts-Cortés Pozo R, Blanco I, Bonjoch C, Coll-Bonﬁll N, Paul MI, Hernández C, Seijas-Babot N. T, Tura-Ceide O, Barberà JA. Imbalance Comparative analysis of the psychometric Review / I.F.: 35.084 between endothelial damage and repair parameters of two quality-of-life capacity in chronic obstructive pulmonary questionnaires, the SGRQ and CAT, in the 1. Kovacs G, Agusti A, Barberà JA, Celli B, disease. PLOS ONE. assessment of patients with COPD Criner G, Humbert M, Sin DD, Voelkel N, 13(4):e0195724-e0195724. I.F.: 2.766 exacerbations during hospitalization: A Olschewski H. Pulmonary Vascular multicenter study. CHRONIC Involvement in COPD - Is There a 16. Chamorro, Virginia; Morales-Cano, Daniel; RESPIRATORY DISEASE. 15(4):374-383. Pulmonary Vascular Phenotype? Milara, Javier; Barreira, Bianca; Moreno, Laura; I.F.: 2.275 AMERICAN JOURNAL OF RESPIRATORY Callejo, Maria; Mondejar-Parreno, Gema; AND CRITICAL CARE MEDICINE. Esquivel-Ruiz, Sergio; Cortijo, Julio; Cogolludo, 22. Natsiavas P; Rasmussen J; Voss-Knude 198(8):1000-1011. I.F.: 15.239 Angel; Barbera, Joan A.; Perez-Vizcaino, M; Votis ?; Coppolino L; Campegiani P; Cano I; Francisco. Riociguat versus sildenaﬁl on Marí D; Faiella G; Clemente F; Nalin M; Grivas 2. Huertas A, Guignabert C, Barberà JA, hypoxic pulmonary vasoconstriction and E; Stan O; Gelenbe E; Dumortier J; Petersen J; Bärtsch P, Bhattacharya J, Bhattacharya S, ventilation/perfusion matching. PLOS Tzovaras D; Romano L; Komnios I; Koutkias V. Bonsignore MR, Dewachter L, Dinh-Xuan AT, ONE. 13(1):e0191239. I.F.: 2.766 Comprehensive user requirements Dorfmüller P, Gladwin MT, Humbert M, engineering methodology for secure and Kotsimbos T, Vassilakopoulos T, Sanchez O, 17. Borràs-Santos A, Garcia-Aymerich J, interoperable health data exchange. BMC Savale L, Testa U, Wilkins MR. Pulmonary Soler-Cataluña JJ, Vigil Giménez L, Gea Guiral MEDICAL INFORMATICS AND DECISION vascular endothelium: the orchestra

135 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

conductor in respiratory diseases: Recommendations on 5. Vincent JL, Jaschinski U, Wittebole X, Highlights from basic research to therapy. non-Pharmacological Treatment in Lefrant JY, Jakob SM, Almekhlafi GA, Pellis T, EUROPEAN RESPIRATORY JOURNAL. Chronic Obstructive Pulmonary Disease Tripathy S, Rubatto Birri PN, Sakr Y, ICON 51(4):467. I.F.: 12.244 From the Spanish COPD Guidelines Investigators. Worldwide audit of blood (GesEPOC 2017). ARCHIVOS DE transfusion practice in critically ill patients. 3. Rodríguez-Roisin R., Krowka M., Agustí A. BRONCONEUMOLOGIA. 54(11):568-575. CRITICAL CARE. 22(1):102. I.F.: 6.425 Hepatopulmonary disorders: Gas I.F.: 2.633 exchange and vascular manifestations in 6. Sakr Y, Jaschinski U, Wittebole X, Szakmany chronic liver disease. COMPR PHYSIOL. T, Lipman J, Ñamendys-Silva SA, 8(2):711-729. I.F.: 5.797 Consortium Publications / I.F.: 76.155 Martin-Loeches I, Leone M, Lupu MN, Vincent JL, ICON Investigators. Sepsis in Intensive 4. Sanchez-Lorente D, Navarro-Ripoll R, 1. Ferrando C, Soro M, Unzueta C, Care Unit Patients: Worldwide Data From Guzman R, Moises J, Gimeno E, Boada M, Suarez-Sipmann F, Canet J, Librero J, Pozo N, the Intensive Care over Nations Audit. Molins L. Prehabilitation in thoracic surgery. Peiró S, Llombart A, León I, India I, Aldecoa C, OPEN FORUM INFECTIOUS DISEASES. JOURNAL OF THORACIC DISEASE. 10(Suppl Díaz-Cambronero O, Pestaña D, Redondo F, 5(12):ofy313-ofy313. I.F.: 3.240 22):S2593-S2600. I.F.: 1.804 Garutti I, Balust J, García J, Ibáñez M, Granell M, Rodríguez A, Gallego L, de la Matta M, Gonzalez R, Brunelli A, García J, Rovira L, Letters / I.F.: 40.209 Barrios F, Torres V, Hernández S, Gracia E, GRANTS FOR RESEARCH IN PROGRESS Giné M, García M, García N, Miguel L, Sánchez 1. Agusti A, Faner R, Celli B, Rodriguez-Roisin S, Piñeiro P, Pujol R, García-del-Valle S, Barberà JA. Recerca traslacional en R. Precision medicine in COPD Valdivia J, Hernández MJ, Padrón O, Colás A, malalties pulmonars. exacerbations. THE LANCET. Puig J, Azparren G, Tusman G, Villar J, Belda J; Sponsored by: Generalitat de Catalunya. RESPIRATORY MEDICINE. 6(9):657-659. Individualized PeRioperative Open-lung AGAUR_SGR17_00617 I.F.: 21.466 VEntilation (iPROVE) Network. Individualised Duration: 01/01/2017-31/12/2020 perioperative open-lung approach versus 2. Demeyer, Heleen; Costilla-Frias, Marcos; standard protective ventilation in Barberà JA. Caracterització de la Louvaris, Zafeiris; Gimeno-Santos, Elena; abdominal surgery (iPROVE): A hipertensió pulmonar greu a les malalties Tabberer, Maggie; Rabinovich, Roberto A.; de randomised controlled trial. THE LANCET. respiratòries cròniques. Jong, Corina; Polkey, Michael I.; Hopkinson, RESPIRATORY MEDICINE. 6(3):193-203. I.F.: Sponsored by: Fundació Acadèmia de les Nicholas S.; Karlsson, Niklas; Serra, Ignasi; 21.466 Ciències Mèdiques. SOCAP_TemaLliure16 Vogiatzis, Ioannis; Troosters, Thierry; Duration: 01/09/2016-31/12/2018 Garcia-Aymerich, Judith; PROactive 2. Vincent J, Lefrant J, Kotfis K, Nanchal R, Consortium. Both moderate and severe Martin-Loeches I, Wittebole X, Sakka S, Barberà JA. GERAR: Gestión en red de exacerbations accelerate physical activity Pickkers P, Moreno R, Sakr Y, ICON and pacientes con Enfermedades Raras: la decline in COPD patients. EUROPEAN SOAP investigators; SOAP investigators. Hipertensión Pulmonar como caso de uso. RESPIRATORY JOURNAL. 51(1). I.F.: 12.244 Comparison of European ICU patients in Sponsored by: Ministerio de Economía y 2012 (ICON) versus 2002 (SOAP). Competitividad (MINECO). RTC-2015-4137-1 3. Coca-Martinez M, Barberan-Garcia A, INTENSIVE CARE MEDICINE. 44(3):337-344. Duration: 01/09/2015-31/08/2018 Risco R, Lopez-Baamonde M, Martinez-Palli I.F.: 15.008 G. Fit for surgery? Evidence supporting Barberà JA. Proliferación celular en la prehabilitation programs. BRITISH 3. Haas LEM, Karakus A, Fijen JW, de Lange hipertensión pulmonar: detección y JOURNAL OF ANAESTHESIA. DW, Vincent JL, Sakr Y, ICON and SOAP mecanismos de regulación epigenética. 120(6):1429-1429. I.F.: 6.499 Investigators. True changes in patient Sponsored by: Instituto de Salud Carlos III characteristics and outcomes or partially a (ISCIII). PI15/00582 reflection of different study populations? : Duration: 01/01/2016-30/06/2019 Clinical Guidelines / I.F.: 5.266 Discussion on "Comparison of European ICU patients in 2012 (ICON) versus 2002 Barberà JA. Plataformas de apoyo a la 1. Barberà JA, Román A, Gómez-Sánchez MÁ, (SOAP)". INTENSIVE CARE MEDICINE. Investigación en Ciencias y Tecnologías de Blanco I, Otero R, López-Reyes R, Otero I, 44(7):1195-1196. I.F.: 15.008 la Salud. Red de Biobanco. Pérez-Peñate G, Sala E, Escribano P. Sponsored by: Instituto de Salud Carlos III Guidelines on the Diagnosis and 4. Mahla RS, Vincent JL, Sakr Y, ICON and (ISCIII). PT13/0010/0011 Treatment of Pulmonary Hypertension: SOAP Investigators. Sepsis is a global Duration: 01/01/2014-30/06/2018 Summary of Recommendations. burden to human health: incidences are ARCHIVOS DE BRONCONEUMOLOGIA. underrepresented : Discussion on " Blanco I. Efectos del entrenamiento físico 54(4):205-215. I.F.: 2.633 Comparison of European ICU patients in sobre la función vascular como diana 2012 (ICON) versus 2002 (SOAP)". terapéutica en la hipertensión pulmonar. 2. Pleguezuelos E., Gimeno-Santos E., INTENSIVE CARE MEDICINE. 44(7):1197-1198. Sponsored by: Fundació Acadèmia de les Hernández C., Mata M., Palacios L., Piñera P., I.F.: 15.008 Ciències Mèdiques. SOCAP_TemaLliure18 Molina J., Chiner E., Miravitlles M. Duration: 19/06/2018-31/12/2018

136 PHYSIOPATHOLOGICAL MECHANISMS OF RESPIRATORY ILLNESSES 2.7

Blanco I. Efectos del entrenamiento físico Duration: 01/01/2018-31/12/2018 sobre la función vascular como diana terapéutica en la hipertensión pulmonar. Tura O. New targets of Chronic Sponsored by Instituto de Salud Carlos III Thromboembolic Pulmonary (ISCIII). PI17/01515 Hypertension (CTEPH): the root cause and Duration: 01/01/2018-31/12/2020 an in vivo model of CTEPH endothelial pathology. Martínez G. Implementación de un Sponsored by: Instituto de Salud Carlos III programa de prehabilitación trimodal (ISCIII). CP17/00114 (PI) como estrategia de optimización Duration: 01/01/2018-31/12/2020 prequirúrgica en cirugía cardíaca. Sponsored by Instituto de Salud Carlos III (ISCIII). PI17/00852 Duration: 01/01/2018-31/12/2020 DOCTORAL THESES

Roca J. Atenció personalitzada del malalt Roca J, Cano I. A Systems Medicine crònic en un marc de salut digital. approach to multimorbidity -Towards Sponsored by: Fundació Eurecat. personalised care for patients with Chronic COMRDI15-1-0016-08 Obstructive Pulmonary Disease. Duration: 15/10/2016-15/10/2019 PhD student: Ákos Tényi

Roca J. Plataforma de innovación en telemedicina y e-salud: TIC para los retos de I+i en servicios de salud. PITES-TliSS. Sponsored by: Instituto de Salud Carlos III. PI15/00576 Duration: 01/01/2016-30/06/2019

Roca J. SELFIE: Sustainable intEgrated care modeLs for multi-morbidity: delivery, FInancing and performance. Sponsored by: European commission. H2020-PHC-2014-2s (634288) Duration: 01/09/2015-31/08/2019

Roca J. ACT-at-Scale: Advancing Care Coordination and Telehealth deployment at Scale. Sponsored by: European commission. HP-PJ-2015 (709770) Duration: 04/03/2016-03/04/2019

Roca J. CONNECARE: Personalised Connected Care for Complex Chronic Patients. Sponsored by: European commission. H2020-PHC-2015-1s (689802) Duration: 01/04/2016-31/12/2019

Roca J. KONFIDO: Secure and Trusted Paradigm for Interoperable eHealth Services. Sponsored by: European commission. H2020-DS-16 (727528) Duration: 01/11/2016-31/10/2019

Roca J. MTiH: Master Technological Innovation in Health. Sponsored by: European commission. EITHealth_2018 (18284)

137 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

Clinical and experimental 2.8 respiratory immunoallergy

Alfonso Santamaría (HCB) Eva Serrano (FCRB) LOCATION Meritxell Valls (UB) CELLEX building, ﬂoor 2B

PRE-DOCTORAL RESEARCHERS Giovanna Araujo (FCRB) WEB Marina Bantulà (FCRB) www.clinicbarcelona.org/en/ Rocío Casas (IDIBAPS) idibaps/research-areas Federico de la Roca (FCRB) Alba García (UB)

TEAM LEADER Sònia Gelis (HCB) Joaquim Mullol (IDIBAPS) Adriana Izquierdo (UB) T. 93 227 98 72 Francesca Jaume (UB) Cristobal Langdon (HCB) [email protected] Eduardo Lehrer (HCB) KEYWORDS 1. Upper airway inﬂammatory diseases Mauricio López (HCB) Paula Mackers (UB) (rhinitis, rhinosinusitis) RESEARCHERS Carla Merma (UB) 2. NSAID-exacerbated respiratory Isam Alobid (HCB) Arnau Navinés-Ferrer (UB) disease (N-ERD) Joan Bartra (HCB) Paula Ribó (HCB) 3. Drug & food allergy Joaquim Enseñat (HCB) Maria Rueda (UB) 4. Olfactory disorders Maria Concepció Marín (IDIBAPS) Clara San Bartolomé (HCB) 5. Urticaria and mast cells Margarita Martin (UB) Sònia Vicens (IDIBAPS) 6. Endoscopic & skull base surgery Rosa Maria Muñoz-Cano (HCB-IDIBAPS) Mariona Pascal (HCB) TECHNICIANS César Picado (UB) Sílvia Centellas (HCB) Laura Pujols (IDIBAPS) Rosa Cortés (HCB) Antonio Valero (HCB) Rossó de Lluís (FCRB) Original publications Mireya Fuentes (IDIBAPS) from 2016 to 2018 POST-DOCTORAL RESEARCHERS Gemma Lopez (FCRB) Ebymar Arismendi (CIBER) María Pérez (FCRB) YEAR I.F. TOTAL Q1 Q2 Joan Berenguer (HCB) Ma Carmen Sánchez (HCB) 2016 151.13 26 14 5 Manuel Bernal (HCB) Irina Bobolea (HCB) ADMINISTRATIVE STAFF 2017 152.51 35 22 9 Francisco de Borja (IDIBAPS) Paola Cucagna (FCRB) 2018 154.28 39 20 15 Josep Maria Guilemany (HCB) Jordi Roca-Ferrer (FCRB)

TEAM INVOLVED IN AGAUR_SGR17: 01090 CIBER_CIBERES RETIC_RIRAAF RETIC_ARADYAL Joquim Mullol TEAM

138 CLINICAL AND EXPERIMENTAL RESPIRATORY IMMUNOALLERGY 2.8

VISITING SCIENTISTS 6. Pathophysiology of eosinophils, mast PUBLICATIONS Carla Pereira (Hospital Santiago (Chile) cells, and basophils. Silvia Quarta (Hospital Italia) Anaphylactic reactions (mastocytosis, Originals / I.F.: 154.281 Silvia Riggioni (London Imperial College (UK) adapter molecules in the signaling of IgE). Antiinflammatory drugs in eosinophils and 1. Mariño-Sanchez F, Valls-Mateus M, Haag O, epithelial cells (corticosteroids, MP-AzeFlu, Alobid I, Bousquet J, Mullol J . Smell loss is anti-PAF), and mast cell and basophils associated with severe and uncontrolled STRATEGIC OBJECTIVES (omalizumab). disease in children and adolescents with persistent allergic rhinitis. J ALLERGY CLIN 1. To investigate mechanisms regulating 7. Skull Base tumours. IMMUNOL PRACT. 6(5):1752-1755.e3. inflammatory response and remodelling in Impact of skull base tumours in quality of life I.F.: 13.258 asthma, rhinitis, rhinosinusitis/polyposis. and olfaction. Different surgical approaches. 2. Vennera MDC, Sabadell C, Picado C. 2. To investigate mechanisms underlying Duration of the efficacy of omalizumab food and drug allergies. after treatment discontinuation in 'real life' RESEARCH GROUP severe asthma. THORAX. 73(8):782-784. 3. To investigate mechanisms involved in SINONASAL INFLAMMATORY AND I.F.: 9.655 anaphylaxis and mast cell physiology. OLFACTORY RESEARCH GROUP (INGENIO) 3. Bousquet J, Agache I, Aliberti MR, Angles R, 4. To investigate mechanisms of smell loss: Annesi-Maesano I, Anto JM, Arnavielhe S, sinonasal inflammation, Traumatic Brain Asayag E, Bacci E, Bedbrook A, Bachert C, Injury, Parkinson Disease, iatrogenic, Baroni I, Barreto BA, Bedolla-Barajas M, idiopathic. Bergmann KC, Bertorello L, Bewick M, Bieber T, Birov S, Bindslev-Jensen C, Blua A, Bochenska Marciniak M, Bogus-Buczynska I, Bosnic-Anticevich S, Bosse I, Bourret R, Bucca MAIN LINES OF RESEARCH GROUP LEADER C, Buonaiuto R, Burguete Cabanas MT, Joaquim Mullol (IDIBAPS) Caillaud D, Caimmi DP, Caiazza D, Camargos 1. Inflammation of the Upper and P, Canfora G, Cardona V, Carriazo AM, Cartier Lower respiratory mucosa. 1. Upper airway diseases (rhinitis, C, Castellano G, Chavannes NH, Cecci L, Mechanisms involved in sinonasal and rhinosinusitis, nasal polyps): A) regulation of Ciaravolo MM, Cingi C, Ciceran A, Colas L, bronchial development, inflammation, mucins and MUC genes; and B) impact on Colgan E, Coll J, Conforti D, Correia de Sousa and remodelling. quality of life. J, Cortés-Grimaldo RM, Corti F, Costa E, Courbis AL, Cousein E, Cruz AA, Custovic A, 2. Sense of smell in health and disease. 2. Olfactory disorders and their mechanisms Cvetkovski B, Dario C, da Silva J, Dauvilliers Y, Mechanisms involved in olfactory of action: A) validation of new adult (BOT-8) De Blay F, Dedeu T, De Feo G, De Martino B, dysfunctions (rhinitis, rhinosinusitis) and children (pBOT-6) olfactometries; and B) Demoly P, De Vries G, Di Capua Ercolano S, Di and neurogenesis of sinonasal diseases, validation of an olfactory training test Carluccio N, Doulapsi M, Dray G, Dubakiene R, Traumatic Brain Injury, and (BASTAT-6) in post-viral and post-TBI Eller E, Emuzyte R, Espinoza-Contreras JG, neurodegenerative (Parkinson) olfactory loss; and C) mechanisms of smell Estrada-Cardona A, Farrell J, Farsi A, Ferrero diseases (cell and animal models). loss and its recovery in sinonasal diseases, J, Fokkens WJ, Fonseca J, Fontaine JF, Forti traumatic brain injury, and neurodegenerative S, Gálvez-Romero JL, García-Cobas CI, 3. Food and drug allergy. diseases. Garcia Cruz MH, Gemicioglu B, Gerth van Wijk Genetic, immunological, and biochemical R, Guidacci M, Gómez-Vera J, Guldemond NA, mechanisms of respiratory, food, and drug 3. Human in vitro model of eosinophilic Gutter Z, Haahtela T, Hajjam J, Hellings PW, allergy. inflammation to test / compare the Hernández-Velázquez L, Illario M, Ivancevich antiinflammatory effects of medications: JC, Jares E, Joos G, Just J, Kalayci O, 4. Glucocorticoid resistance. corticosteroids, antihistamines, anti-PAF, Kalyoncu AF, Karjalainen J, Keil T, Khaltaev N, Mechanisms and biomarkers involved in antileukotrienes, MP-AzeFlu, biologics. Klimek L, Kritikos V, Kull I, Kuna P, Kvedariene glucocorticoid resistance of respiratory and V, Kolek V, Krzych-Fa?ta E, Kupczyk M, non-respiratory diseases. 4. Stem/progenitor respiratory epithelial / Lacwik P, La Grutta S, Larenas-Linnemann D, neuroepithelial cell differentiation and Laune D, Lauri D, Lavrut J, Lessa M, Levato G, 5. Aspirin and Non-Steroidal regenerative medicine in ALI culture model. Lewis L, Lieten I, Lipiec A, Louis R, Luna-Pech Antiinflammatory Drug (NSAID) JA, Magnan A, Malva J, Maspero JF, intolerance. Matta-Campos JJ, Mayora O, Medina-Ávalos Mechanisms of allergy and cofactors, MA, Melén E, Menditto E, Millot-Keurinck J, regulation of cyclooxygenase, leukotriene Moda G, Morais-Almeida M, Mösges R, and prostaglandins (PGE2) and their Mota-Pinto A, Mullol J, Muraro A, Murray R, receptors. Noguès M, Nalin M, Napoli L, Neffen H, O'Hehir RE, Onorato GL, Palkonen S, Papadopoulos

139 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

NG, Passalacqua G, Pépin JL, Pereira AM, Haahtela T, Papadopoulos NG, SH3BP2 reduces KIT/PDGFRA receptors Persico M, Pfaar O, Pozzi AC, Prokopakis E, Annesi-Maesano I, Bewick M, expression and impairs gastrointestinal Pugin B, Raciborski F, Rimmer J, Rizzo JA, Bosnic-Anticevich S, Cruz AA, De Vries G, stromal tumors growth. MOL ONCOL. Robalo-Cordeiro C, Rodríguez-González M, Gemicioglu B, Larenas-Linnemann D, Laune 12(8):1383-1397. I.F.: 5.264 Rolla G, Roller-Wirnsberger RE, Romano A, D, Mathieu-Dupas E, O'Hehir RE, Pfaar O, Romano M, Romano MR, Salimäki J, Portejoie F, Siroux V, Spranger O, Valovirta E, 10. Courbis AL, Murray RB, Arnavielhe S, Samolinski B, Serpa FS, Shamai S, Sierra M, VandenPlas O, Yorgancioglu A. Treatment of Caimmi D, Bedbrook A, Van Eerd M, De Vries Sova M, Sorlini M, Stellato C, Stelmach R, allergic rhinitis using mobile technology G, Dray G, Agache I, Morais-Almeida M, Strandberg T, Stroetmann V, Stukas R, with real world data: The MASK Bachert C, Bergmann KC, Bosnic-Anticevich Szylling A, Tan R, Tibaldi V, Todo-Bom A, observational pilot study. ALLERGY. S, Brozek J, Bucca C, Camargos P, Canonica Toppila-Salmi S, Tomazic P, Trama U, 73(9):1763-1774. I.F.: 6.048 GW, Carr W, Casale T, Fonseca JA, Haahtela Triggiani M, Valero A, Valovirta E, Valiulis A, van T, Kalayci O, Klimek L, Kuna P, Kvedariene V, Eerd M, Vasankari T, Vatrella A, Ventura MT, 6 . Samreth D, Arnavielhe S, Ingenrieth F, Larenas Linnemann D, Lieberman P, Mullol J, Verissimo MT, Viart F, Williams S, Wagenmann Bedbrook A, Onorato GL, Murray R, Almeida Ohehir R, Papadopoulos N, Price D, Ryan D, M, Wanscher C, Westman M, Wickman M, R, Mizani MA, Fonseca J, Costa E, Malva J, Samolinski B, Simons FE, Tomazic P, Triggiani Young I, Yorgancioglu A, Zernotti E, Zuberbier Morais-Almeida M, Pereira AM, Todo-Bom A, M, Valiulis A, Valovirta E, Wagenmann M, T, Zurkuhlen A, De Oliviera B, Senn A. Menditto E, Stellato C, Ventura MT, Wickman M, Yorgancioglu A, Bousquet J. Transfer of innovation on allergic rhinitis Larenas-Linnemann D, Fuentes-Pérez JM, Electronic Clinical Decision Support and asthma multimorbidity in the elderly Huerta-Villalobos YR, Cruz AA, Stelmach R, da System for allergic rhinitis management. (MACVIA-ARIA) - Reference Site Twinning Silva J, Emuzyte R, Kvedariene V, Valiulis A, CLINICAL AND EXPERIMENTAL ALLERGY. (EIP on AHA). ALLERGY. 73(1):77-92. I.F.: Annesi-Maesano I, Bosse I, Demoly P, Devillier 48(12):1640-1653. I.F.: 5.158 6.048 P, Fontaine JF, Kuna P, Samolinski B, Klimek L, Mösges R, Pfaar O, Shamai S, Bewick M, Ryan 11. Langdon C, Lehrer E, Berenguer J, Laxe S, 4. Bousquet J, Arnavielhe S, Bedbrook A, D, Sheikh A, Anto JM, Cardona V, Mullol J, Alobid I, Quintó L, Mariño-Sánchez F, Fonseca J, Morais Almeida M, Todo Bom A, Valero A, Chavannes NH, Fokkens WJ, Bernabeu M, Marin C, Mullol J. Olfactory Annesi-Maesano I, Caimmi D, Demoly P, Reitsma S, Roller-Wirnsberger RE, Tomazic training in posttraumatic smell Devillier P, Siroux V, Menditto E, Passalacqua PV, Haahtela T, Toppila-Salmi S, Valovirta E, impairment: mild improvement in G, Stellato C, Ventura MT, Cruz AA, Sarquis Makris M, Papadopoulos NG, Prokopakis EP, threshold performances - results from a Serpa F, da Silva J, Larenas-Linnemann D, Psarros F, Gemicioglu B, Yorgancioglu A, randomized controlled trial. JOURNAL OF Rodriguez Gonzalez M, Burguete Cabañas Bindslev-Jensen C, Eller E, Kull I, Wickman M, NEUROTRAUMA. 35(22):2641-2652. MT, Bergmann KC, Keil T, Klimek L, Mösges R, Bachert C, Hellings PW, Pugin B, I.F.: 5.002 Shamai S, Zuberbier T, Bewick M, Price D, Bosnic-Anticevich S, O'Hehir RE, Kolek V, Ryan D, Sheikh A, Anto JM, Mullol J, Valero A, Sova M, Wehner K, De Vries G, van Eerd M, 12. García S, Torné R, Hoyos JA, Haahtela T, Valovirta E, Fokkens WJ, Kuna P, Laune D, Wittmann J, Bousquet J, Poncelet P, Rodríguez-Hernández A, Amaro S, Llull L, Samolinski B, Bindslev-Jensen C, Eller E, MASK study group. Geolocation with López-Rueda A, Enseñat J. Quantitative Bosnic-Anticevich S, O'Hehir RE, Tomazic PV, respect to personal privacy for the Allergy versus qualitative blood amount Yorgancioglu A, Gemicioglu B, Bachert C, Diary app - A MASK study. WORLD assessment as a predictor for Hellings PW, Kull I, Melén E, Wickman M, van ALLERGY ORGANIZATION JOURNAL. shunt-dependent hydrocephalus following Eerd M, De Vries G, MASK study group. The 11(1):15. I.F.: 5.676 aneurysmal subarachnoid hemorrhage. Allergic Rhinitis and its Impact on Asthma JOURNAL OF NEUROSURGERY. 21:1-8. (ARIA) score of allergic rhinitis using 7. Bandara G, Muñoz-Cano R, Tobío A, Yin Y, I.F.: 4.319 mobile technology correlates with quality Komarow HD, Desai A, Metcalfe DD, Olivera A. of life: The MASK study. ALLERGY. Targeting Sphingosine Kinase Isoforms 13. Di Somma A, Torales J, Cavallo LM, Pineda 73(2):505-510. I.F.: 6.048 Effectively Reduces Growth and Survival J, Solari D, Gerardi RM, Frio F, Enseñat J, of Neoplastic Mast Cells With D816V-KIT. Prats-Galino A, Cappabianca P. Deﬁning the 5. Bousquet J, Devillier P, Arnavielhe S, FRONTIERS IN IMMUNOLOGY. 28(9):631. lateral limits of the endoscopic endonasal Bedbrook A, Alexis-Alexandre G, van Eerd M, I.F.: 5.511 transtuberculum transplanum approach: Murray R, Canonica GW, Illario M, Menditto E, anatomical study with pertinent Passalacqua G, Stellato C, Triggiani M, 8. Baos S, Calzada D, Cremades-Jimeno L, quantitative analysis. JOURNAL OF Carreiro-Martins P, Fonseca J, Morais Sastre J, Picado C, Quiralte J, Florido F, Lahoz NEUROSURGERY. 1(1):13. I.F.: 4.319 Almeida M, Nogueira-Silva L, Pereira AM, C, Cárdaba B. Non-allergic asthma and its Todo Bom A, Bosse I, Caimmi D, Demoly P, severity: Biomarkers for its discrimination 14. Inciarte-Mundo J, Ramirez J, Hernández Fontaine JF, Just J, Onorato GL, Kowalski ML, in peripheral samples. FRONTIERS IN MV, Ruiz-Esquide V, Cuervo A, Cabrera- Kuna P, Samolinski B, Anto JM, Mullol J, Valero IMMUNOLOGY. 9(JUN):1416. I.F.: 5.511 Villalba SR, Pascal M, Yagüe J, Cañete JD, A, Tomazic PV, Bergmann KC, Keil T, Klimek L, Sanmarti R . Calprotectin strongly and Mösges R, Shamai S, Zuberbier T, Murphy E, 9. Serrano-Candelas E, Ainsua-Enrich E, independently predicts relapse in McDowall P, Price D, Ryan D, Sheikh A, Navinés-Ferrer A, Rodrigues P, rheumatoid arthritis and polyarticular Chavannes NH, Fokkens WJ, Kvedariene V, García-Valverde A, Bazzocco S, Macaya I, psoriatic arthritis patients treated with tumor Valiulis A, Bachert C, Hellings PW, Kull I, Melen Arribas J, Serrano C, Sayós J, Arango D, necrosis factor inhibitors: a 1-year E, Wickman M, Bindslev-Jensen C, Eller E, Martin M . Silencing of adaptor protein prospective cohort study. ARTHRITIS

140 CLINICAL AND EXPERIMENTAL RESPIRATORY IMMUNOALLERGY 2.8

RESEARCH AND THERAPY. 20(1):275. MT, Ryan D, Sheikh A, Anto JM, Mullol J, asthma-COPD overlap: a network I.F.: 4.269 Valero A, Kowalski ML, Kuna P, Samolinski B, approach. INTERNATIONAL JOURNAL OF Tomazic PV, Bosnic-Anticevich S, O Hehir RE, COPD. 13:591-601. I.F.: 2.917 15. Navinés-Ferrer A, Serrano-Candelas E, De Vries G, Laune D. Work Productivity and Lafuente A, Muñoz-Cano R, Martín M, Activity Impairment Allergic Speciﬁc 27. Muñoz X, Álvarez-Puebla MJ, Arismendi E, Gastaminza G. MRGPRX2-mediated mast (WPAI-AS) Questionnaire using Mobile Arochena L, Ausín MDP, Barranco P, Bobolea cell response to drugs used in perioperative Technology: The MASK study. JOURNAL I, Cañas JA, Cardaba B, Crespo A, Del Pozo V, procedures and anaesthesia. SCIENTIFIC OF INVESTIGATIONAL ALLERGOLOGY AND Domínguez-Ortega J, Fernandez-Nieto MDM, REPORTS. 8(1):11628. I.F.: 4.122 CLINICAL IMMUNOLOGY. 28(1):42-44. Giner J, González-Barcala FJ, Luna JA, Mullol I.F.: 3.457 J, Ojanguren I, Olaguibel JM, Picado C, Plaza V, 16. Schiener M, Hilger C, Eberlein B, Pascal M, Quirce S, Ramos D, Rial M, Romero-Mesones Kuehn A, Revets D, Planchon S, Pietsch G, 21. Suarez-Girón MC, Castro-Grattoni A, C, Salgado FJ, San-José ME, Sánchez-Diez S, Serrano P, Moreno-Aguilar C, De La Roca F, Torres M, Farré R, Barbe F, Sánchez de la Sastre B, Sastre J, Soto L, Torrejón M, Biedermann T, Darsow U, Schmidt-Weber C, Torre M, Gozal D, Picado C, Montserrat JM, Urnadoz M, Valdes L, Valero A, Cruz MJ . The Ollert M, Blank S. The high molecular weight Almendros I. Acetylsalicylic Acid Prevents MEGA Project: A Study of the Mechanisms dipeptidyl peptidase IV Pol d 3 is a major Intermittent Hypoxia-Induced Vascular Involved in the Genesis and Disease allergen of Polistes dominula venom. Remodeling in a Murine Model of Sleep Course of Asthma. Asthma Cohort SCIENTIFIC REPORTS. 8(1):1318. I.F.: 4.122 Apnea. FRONTIERS IN PHYSIOLOGY. Creation and Long-Term Follow-Up. 9(MAY):600. I.F.: 3.394 ARCHIVOS DE BRONCONEUMOLOGIA. 17. Bastida C, Ruiz-Esquide V, Pascal M, de 54(7):378-385. I.F.: 2.633 Vries Schultink AHM, Yagüe J, Sanmartí R, 22. Bobolea I, Del Pozo V, Sanz V, Cabañas R, Huitema ADR, Soy D . Fixed dosing of Fiandor A, Alfonso-Carrillo C, Salcedo MÁ, 28. Valls-Mateus M, Nogués-Sabaté A, intravenous tocilizumab in rheumatoid Heredia Revuelto R, Quirce S. Aspirin Blanch J, Bernal-Sprekelsen M, Avilés-Jurado arthritis. Results from a population desensitization in aspirin-exacerbated F, Vilaseca I. Narrow band imaging for head pharmacokinetic analysis. BRITISH respiratory disease: New insights into the and neck malignancies: Lessons learned JOURNAL OF CLINICAL PHARMACOLOGY. molecular mechanisms. RESPIRATORY from mistakes. HEAD AND NECK. 84(4):716-725. I.F.: 3.838 MEDICINE. 143:39-41. I.F.: 3.230 40(6):1164-1173. I.F.: 2.471

18. Schriever VA, Agosin E, Altundag A, Avni H, 23. Martínez-Rivera C, Crespo A, 29. Van Gerven L, Langdon C, Cordero A, Cao Van H, Cornejo C, de Los Santos G, Pinedo-Sierra C, García-Rivero J, Cardelús S, Mullol J, Alobid I. Lack of Fishman G, Fragola C, Guarneros M, Gupta N, Pallarés-Sanmartín A, Marina-Malanda N., long-term add-on effect by montelukast in Hudson R, Kamel R, Knaapila A, Konstantinidis Pascual-Erquicia S, Padilla A, Mayoralas- postoperative chronic rhinosinusitis I, Landis BN, Larsson M, Lundström JN, Alises S, Plaza V, López-Viña A, Picado C. patients with nasal polyps. Macchi A, Mariño-Sánchez F, Martinec Mucus hypersecretion in asthma is LARYNGOSCOPE. 128(8):1743-1751. I.F.: 2.442 Nováková L, Mori E, Mullol J, Nord M, Parma V, associated with rhinosinusitis, polyps and Philpott C, Propst EJ, Rawan A, Sandell M, exacerbations. RESPIRATORY MEDICINE. 30. Alobid I, Langdon C, López-Chacon M, Sorokowska A, Sorokowski P, Sparing- 135:22-28. I.F.: 3.230 Enseñat J, Carrau R, Bernal-Sprekelsen M, Paschke LM, Stetzler C, Valder C, Vodicka J, Santamaría A. Total septal perforation Hummel T . Development of an 24. Aranda G, Fernández-Ruiz R, Palomo M, repair with a pericranial flap: International Odor Identification Test for Romo M, Mora M, Halperin I, Casals G, Radio-anatomical and clinical findings. Children: The Universal Sniff Test. Enseñat J, Vidal O, Diaz-Ricart M, Hanzu F. LARYNGOSCOPE. 128(6):1320-1327. JOURNAL OF PEDIATRICS. 198:265-272.e3. Translational evidence of prothrombotic I.F.: 2.442 I.F.: 3.667 and inflammatory endothelial damage in Cushing syndrome after remission. 31. Jaume F, Quintó L, Alobid I, Mullol J. 19. Muñoz-Cano R, Ribó P, Araujo G, Giralt E, CLINICAL ENDOCRINOLOGY. 88(3):415-424. Overuse of diagnostic tools and Sánchez-López J, Valero A. Severity of I.F.: 3.077 medications in acute rhinosinusitis in allergic rhinitis impacts sleep and anxiety: Spain: a population-based study (the Results from a large Spanish cohort. 25. Santamaria-Gadea A, López-Chacón M, PROSINUS study). BMJ OPEN. 8(1):e018788. CLINICAL AND TRANSLATIONAL ALLERGY. Langdon C, Van Gerven L, Valls-Mateus M, I.F.: 2.413 8(1):23. I.F.: 3.539 Bernal-Sprekelsen M, Alobid I. Modified nasal floor and inferior meatus flap for septal 32. Alobid I, Langdon C, Santamaría A. 20. Bousquet J, VandenPlas O, Bewick M, perforation repair. Extension and limits. Technique to Repair Total Septal Arnavielhe S, Bedbrook A, Murray R, van Eerd RHINOLOGY. 56(4):386-392. I.F.: 2.931 Perforation With a Pericranial Flap: The M, Fonseca J, Morais-Almeida M, Todo Bom Money Box Approach. JAMA FACIAL A, Cruz AA, Sarquis Serpa F, da Silva J, 26. De Llano LP, Cosío BG, Iglesias A, de Las PLAST SU. 20(4):324-325. I.F.: 2.388 Menditto E, Passalacqua G, Stellato C, Cuevas N, Soler-Cataluña JJ, Izquierdo JL, Ventura MT, Caimmi D, Demoly P, Bergmann López-Campos JL, Calero C, Plaza V, 33. Plaza V, Giner J, Calle M, Rytilä P, Campo KC, Keil T, Klimek L, Mösges R, Shamai S, Miravitlles M, Torrego A, Martinez-Moragon E, C, Ribó P, Valero A. Impact of patient Zuberbier T, Larenas-Linnemann D, Soriano JB, Viña AL, Bobolea I. Mixed Th2 satisfaction with his or her inhaler on Rodriguez Gonzalez M, Burguete Cabañas and non-Th2 inflammatory pattern in the adherence and asthma control. ALLERGY

141 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

AND ASTHMA PROCEEDINGS. Review / I.F.: 61.688 L, Mösges R, Pfaar O, Shamai S, Zuberbier T, 39(6):437-444. I.F.: 2.213 Mullol J, Valero A, Spranger O, Tomazic PV, 1. Vandenplas O, Vinnikov D, Blanc P, Agache I, Kowalski ML, Kuna P, Kupczyk M, Raciborski 34. Roca-Ferrer J, Pujols L, Pérez-González Bachert C, Bewick M, Cardell L, Cullinan P, F, Samolinski B, Toppila-Salmi SK, Valovirta E, M, Alobid I, Callejas B, Vicens-Artés S, Fuentes Demoly P, Descatha A, Fonseca J, Haahtela T, Cruz AA, Sarquis-Serpa F, da Silva J, M, Valero A, Picado C, Castor D, Nguyen D, Hellings P, Jamart J, Jantunen J, Kalayci Ö, Stelmach R, Larenas-Linnemann D, Rodriguez Mullol J. Superior effect of MP-AzeFlu than Price D, Samolinski B, Sastre J, Tian L, Valero Gonzalez M, Burguete Cabañas MT, azelastine or fluticasone propionate alone A, Zhang X, Bousquet J. Impact of Rhinitis on Kvedariene V, Valiulis A, Chavannes NH, on reducing inflammatory markers. Work Productivity: A Systematic Review. Fokkens WJ, Ryan D, Sheikh A, Bachert C, ALLERGY ASTHMA AND CLINICAL JOURNAL OF ALLERGY AND CLINICAL Hellings PW, VandenPlas O, Ballardini N, Kull I, IMMUNOLOGY. 14(1):86. I.F.: 2.051 IMMUNOLOGY: IN PRACTICE. Melén E, Westman M, Wickman M, 6(4):1274-1286.e9. I.F.: 6.966 Bindslev-Jensen C, Eller E, Bosnic-Anticevich 35. Di Somma A, Andaluz N, Cavallo LM, S, O'Hehir RE, Agache I, Bieber T, Casale T, Topczewski TE, Frio F, Gerardi RM, Pineda J, 2. Bosnic-Anticevich S, Costa E, Menditto E, Gemicioğlu B, Ivancevich JC, De Vries G, Solari D, Enseñat J, Prats-Galino A, Lourenço O, Novellino E, Bialek S, Briedis V, Sorensen M, Yorgancioglu A, Laune D, Cappabianca P. Endoscopic transorbital Buonaiuto R, Chrystyn H, Cvetkovski B, Di MACVIA working group. Daily allergic route to the petrous apex: a feasibility Capua S, Kritikos V, Mair A, Orlando V, Paulino multimorbidity in rhinitis using mobile anatomic study. ACTA E, Salimäki J, Söderlund R, Tan R, Williams DM, technology: a novel concept of the MASK NEUROCHIRURGICA. 160(4):707-720. Wroczynski P, Agache I, Ansotegui IJ, Anto study. ALLERGY. 73(8):1622-1631. I.F.: 6.048 I.F.: 1.929 JM, Bedbrook A, Bachert C, Bewick M, Bindslev-Jensen C, Brozek JL, Canonica GW, 4. Pascal M, Pérez-Gordo M, Caballero T, 36. Torné R, Reyes L, Rodríguez-Hernández Cardona V, Carr W, Casale TB, Chavannes Escribese MM, Lopez Longo MN, Luengo O, A, Urra X, Sanroman L, Enseñat J. Anatomical NH, Correia de Sousa J, Cruz AA, Czarlewski Manso L, Matheu V, Seoane, E, Zamorano M, Variations of Brain Venous Sinuses in W, De Carlo G, Demoly P, Devillier P, Dykewicz Labrador M, Mayorga C. Microbiome and Patients with Arteriovenous MS, Gaga M, El-Gamal Y, Fonseca J, Fokkens Allergic Diseases. FRONTIERS IN Malformations: Incidental Finding or WJ, Guzmán MA, Haahtela T, Hellings PW, IMMUNOLOGY. 9(JUL):1584. I.F.: 5.511 Causative Factor? WORLD Illario M, Ivancevich JC, Just J, Kaidashev I, NEUROSURGERY. 113:e465-e470. I.F.: 1.924 Khaitov M, Khaltaev N, Keil T, Klimek L, 5. Bartra J, Araújo G, Muñoz-Cano R. Kowalski ML, Kuna P, Kvedariene V, Interaction between foods and 37. Nogués-Sabaté A, Aviles-Jurado F, Larenas-Linnemann DE, Laune D, Le LTT, nonsteroidal anti-inflammatory drugs and Ruiz-Sevilla L, Lehrer E, Santamaría-Gadea A, Lodrup Carlsen KC, Mahboub B, Maier D, exercise in the induction of anaphylaxis. Valls-Mateus M, Vilaseca I. Intra and Malva J, Manning PJ, Morais-Almeida M, CURRENT OPINION IN ALLERGY AND interobserver agreement of narrow band Mösges R, Mullol J, Münter L, Murray R, CLINICAL IMMUNOLOGY. 18(4):310-316. imaging for the detection of head and neck Naclerio R, Namazova-Baranova L, Nekam K, I.F.: 3.544 tumors. EUROPEAN ARCHIVES OF Nyembue TD, Okubo K, O'Hehir RE, Ohta K, OTO-RHINO-LARYNGOLOGY. Okamoto Y, Onorato GL, Palkonen S, Panzner 6. Bousquet J, Arnavielhe S, Bedbrook A, 275(9):2349-2354. I.F.: 1.546 P, Papadopoulos NG, Park HS, Pawankar R, Bewick M, Laune D, Mathieu-Dupas E, Murray Pfaar O, Phillips J, Plavec D, Popov TA, Potter R, Onorato GL, Pépin JL, Picard R, Portejoie F, 38. Lopatin AS, Ivanchenko OA, Soshnikov PC, Prokopakis EP, Roller-Wirnsberger RE, Costa E, Fonseca J, Lourenço O, SS, Mullol J. Cyclamen europaeum Rottem M, Ryan D, Samolinski B, Morais-Almeida M, Todo-Bom A, Cruz AA, da improves the effect of oral antibiotics on Sanchez-Borges M, Schunemann HJ, Sheikh Silva J, Serpa FS, Illario M, Menditto E, Cecchi exacerbations and recurrences of chronic A, Sisul JC, Somekh D, Stellato C, To T, L, Monti R, Napoli L, Ventura MT, De Feo G, rhinosinusitis: a real-life observational Todo-Bom AM, Tomazic PV, Toppila-Salmi S, Larenas-Linnemann D, Fuentes Perez M, study (CHRONOS). ACTA Valero A, Valiulis A, Valovirta E, Ventura MT, Huerta Villabolos YR, Rivero-Yeverino D, OTORHINOLARYNGOLOGICA ITALICA. Wagenmann M, Wallace D, Waserman S, Rodriguez-Zagal E, Amat F, Annesi-Maesano 38:115-123. I.F.: 1.196 Wickman M, Yiallouros PK, Yorgancioglu A, I, Bosse I, Demoly P, Devillier P, Fontaine JF, Yusuf OM, Zar HJ, Zernotti ME, Zhang L, Just J, Kuna TP, Samolinski B, Valiulis A, 39. Montoro V, Asensio C, Martínez Á, Lorente Zidarn M, Zuberbier T, Bousquet J . ARIA Emuzyte R, Kvedariene V, Ryan D, Sheikh A, J, Rodríguez FJ, Montojo J, Gavilanes J, Sarría pharmacy 2018 Allergic rhinitis care Schmidt-Grendelmeier P, Klimek L, Pfaar O, P, Langdon C, Prades E. Efficacy and safety pathways for community pharmacy. Bergmann KC, Mösges R, Zuberbier T, of fluocinolone acetonide 0.025% otic ALLERGY. I.F.: 6.048 Roller-Wirnsberger RE, Tomazic P, Fokkens solution in patients with otic eczema: a WJ, Chavannes NH, Reitsma S, Anto JM, randomized, double-blind, 3. Bousquet J, Devillier P, Anto JM, Bewick M, Cardona V, Dedeu T, Mullol J, Haahtela T, placebo-controlled clinical trial. JOURNAL Haahtela T, Arnavielhe S, Bedbrook A, Murray Salimäki J, Toppila-Salmi S, Valovirta E, OF INTERNATIONAL MEDICAL RESEARCH. R, van Eerd M, Fonseca JA, Morais Almeida M, Gemicioğlu B, Yorgancioglu A, Papadopoulos 46(10):4050-4060. I.F.: 1.023 Todo Bom A, Menditto E, Passalacqua G, N, Prokopakis EP, Bosnic-Anticevich S, Stellato C, Triggiani M, Ventura MT, Vezzani G, O'Hehir R, Ivancevich JC, Neffen H, Zernotti E, Annesi-Maesano I, Bourret R, Bosse I, Caimmi Kull I, Melen E, Wickman M, Bachert C, Hellings D, Cartier C, Demoly P, Just J, Portejoie F, P, Palkonen S, Bindslev-Jensen C, Eller E, Siroux V, Viart F, Bergmann KC, Keil T, Klimek Waserman S, Sova M, De Vries G, van Eerd M,

142 CLINICAL AND EXPERIMENTAL RESPIRATORY IMMUNOALLERGY 2.8

Agache I, Casale T, Dykewickz M, Naclerio 13. Quijada-Manuitt MA, Escamilla Y, Vallano modiﬁcations? ACTA NEUROCHIRURGICA. RN, Okamoto Y, Wallace DV, MASK study A, Cardesín A, Bernal-Sprekelsen M, Pontes C. 160(8):1585-1586. I.F.: 1.929 group. MASK 2017: ARIA digitally-enabled, Use of α2-Adrenergic Agonists to Improve integrated, person-centred care for Surgical Field Visibility in Endoscopy Sinus 3. Di Somma A, Andaluz N, Cavallo LM, rhinitis and asthma multimorbidity using Surgery: A Systematic Review of Enseñat J, Prats-Galino A, Cappabianca P. real-world-evidence. CLINICAL AND Randomised Controlled Trials. CLINICAL Reply to letter: "Endoscopic transorbital TRANSLATIONAL ALLERGY. 8:45. I.F.: 3.539 THERAPEUTICS. 40(1):136-149.e19. I.F.: 3.185 route to the petrous apex: a feasibility anatomic study". ACTA 7. Bobolea I, Arismendi E, Valero A, Agustí A. 14. Seys SF, Bousquet J, Bachert C, Fokkens NEUROCHIRURGICA. 160(11):2251-2253 Early Life Origins of Asthma: A Review of WJ, Agache I, Bernal-Sprekelsen M, Callebaut I.F.: 1.929 Potential Effectors. JOURNAL OF I, Cardel LO, Carrie S, Castelnuovo P, Cathcart INVESTIGATIONAL ALLERGOLOGY AND R, Constantinidis J, Cools L, Cornet M, CLINICAL IMMUNOLOGY. 29(3):0-179. Clement G, de Sousa JC, Cox T, Doulaptsi M, Editorial / I.F.: 2.633 I.F.: 3.457 Gevaert P, Hopkins C, Hox V, Hummel T, Hosemann W, Jacobs R, Jorissen M, Landis 1. Picado C, Pernigotti A, Arismendi E. 8. Valero A, Olaguibel J, Delgado J, Plaza V, BN, Leunig A, Lund VJ, Mullol J, Onerci M, Asthma: A New Cardiovascular Risk Álvarez F, Molina J, Mascarós E, Quirce S. Palkonen S, Proano I, Prokopakis E, Ryan D, Factor? ARCHIVOS DE Re-evolution of asthma management: Riechelmann H, Saevels J, Segboer C, BRONCONEUMOLOGIA. I.F.: 2.633 dilemmas and new paradigms. JOURNAL Speleman K, Steinsvik EA, Surda P, Tomazic OF INVESTIGATIONAL ALLERGOLOGY PV, Vanderveken O, Van Gerven L, Van Zele T, AND CLINICAL IMMUNOLOGY. 29(1):15-23. Verhaeghe B, Vierstraete K, Vlaminck S, Clinical Guidelines / I.F.: 8.502 I.F.: 3.457 Wilkinson J, Williams S, Pugin B, Hellings PW. mySinusitisCoach: patient empowerment 1. Augé J, Vent J, Agache I, Airaksinen L, 9. Vidal, C.; Antolin, D.; Reano, M.; Valero, A.; in chronic rhinosinusitis using mobile Campo Mozo P, Chaker A, Cingi C, Durham S, Sastre, J. Safety and Quality technology. RHINOLOGY. 56(3):209-215. Fokkens W, Gevaert P, Giotakis A, Hellings P, Recommendations in Allergy Medicine I.F.: 2.931 Herknerova M, Hox V, Klimek L, La Melia C, (Spanish acronym, RESCAL). JOURNAL Mullol J, Muluk NB, Muraro A, Naito K, Pfaar O, OF INVESTIGATIONAL ALLERGOLOGY 15. Serra-Baldrich E, de Frutos J, Jáuregui I, Riechelmann H, Rondon C, Rudenko M, AND CLINICAL IMMUNOLOGY. 28(1):1-39. Armario-Hita J, Silvestre J, Herraez L, Samolinski B, Tasca I, Tomazic P, Vogt K, I.F.: 3.457 Martín-Santiago A, Valero A, Sastre J. Wagenmann M, Yeryomenko G, Zhang L, Changing perspectives in atopic Mösges R. Position Paper on the 10. Valero A, Navarro AM, Del Cuvillo A, Alobid dermatitis. ALLERGOLOGIA ET Standardization of Nasal Allergen I, Benito JR, Colás C, de Los Santos G, IMMUNOPATHOLOGIA. 46(4):397-412. Challenges. ALLERGY. 73(8):1597-1608. Fernández Liesa R, García-Lliberós A, I.F.: 1.644 I.F.: 6.048 González-Pérez R, Izquierdo-Domínguez A, Jurado-Ramos A, Lluch-Bernal MM, 16. Guntinas-Lichius O, Silver CE, Thielker J, 2. Wise SK, Lin SY, Toskala E, Orlandi RR, Montserrat Gili JR, Mullol J, Puiggròs Casas A, Bernal-Sprekelsen M, Bradford CR, De Bree R, Akdis CA, Alt JA, Azar A, Baroody FM, Bachert Sánchez-Hernández MC, Vega F, Villacampa Kowalski LP, Olsen KD, Quer M, Rinaldo A, C, Canonica GW, Chacko T, Cingi C, Ciprandi JM, Armengot-Carceller M, Dordal MT, SEAIC Rodrigo JR, Sanabria A, Shaha AR, Takes RP, G, Corey J, Cox LS, Creticos PS, Custovic A, Rhinoconjunctivitis Committee & SEORL Vander Poorten V, Zbären P, Ferlito A. Damask C, DeConde A, DelGaudio JM, Ebert Rhinology, Allergy, and Skull Base Committee. Management of the facial nerve in parotid CS, Eloy JA, Flanagan CE, Fokkens WJ, Position paper on nasal obstruction: cancer: preservation or resection and Franzese C, Gosepath J, Halderman A, evaluation and treatment. JOURNAL OF reconstruction. EUROPEAN ARCHIVES OF Hamilton RG, Hoffman HJ, Hohlfeld JM, INVESTIGATIONAL ALLERGOLOGY AND OTO-RHINO-LARYNGOLOGY. Houser SM, Hwang PH, Incorvaia C, Jarvis D, CLINICAL IMMUNOLOGY. 28(2):67-90. 275(11):2615-2626. I.F.: 1.546 Khalid AN, Kilpeläinen M, Kingdom TT, Krouse I.F.: 3.457 H, Larenas-Linnemann D, Laury AM, Lee SE, Levy JM, Luong AU, Marple BF, McCoul ED, 11. Pereira C, Santamaría A, Langdon C, Letters / I.F.: 6.491 McMains KC, Melén E, Mims JW, Moscato G, López-Chacón M, Hernández-Rodríguez J, Mullol J, Nelson HS, Patadia M, Pawankar R, Alobid I. Nasoseptal Perforation: from 1. Suarez-Giron M, Almendros I, Roca-Ferrer J, Pfaar O, Platt MP, Reisacher W, Rondón C, Etiology to Treatment. CURRENT Picado C. Overnight Change in Urinary Rudmik L, Ryan M, Sastre J, Schlosser RJ, ALLERGY AND ASTHMA REPORTS. 18(1):5. Prostacyclin and Thromboxane in Settipane RA, Sharma HP, Sheikh A, Smith TL, I.F.: 3.449 Obstructive Sleep Apnea. ARCHIVOS DE Tantilipikorn P, Tversky JR, Veling MC, Wang BRONCONEUMOLOGIA. 55(6):334. I.F.: 2.633 Y, Westman M, Wickman M, Zacharek M. 12. Marin C, Vilas D, Langdon C, Alobid I, International Consensus Statement on López-Chacón M, Haehner A, Hummel T, 2. Di Somma A, Andaluz N, Cavallo LM, Allergy and Rhinology: Allergic Rhinitis. INT Mullol J. Olfactory Dysfunction in Enseñat J, Prats-Galino A, Cappabianca P. FORUM ALLERGY RH. 8(2):108-352. Neurodegenerative Diseases. CURRENT Reply to letter: Endoscopic transpalpebral I.F.: 2.454 ALLERGY AND ASTHMA REPORTS. 18(8):42. transorbital anterior petrosectomy: does I.F.: 3.449 safer surgical freedoms necessitates

143 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

Consortium Publications / I.F.: 13.258 Sponsored by: SEPAR - BECAS ‘18 Duration: 1/01/2018-31/12/2021 Duration: 1/04/2018-31/12/2021 1. Sastre J, Crespo A, Fernandez-Sanchez A, Ribó P. Prevalencia y mecanismos Rial M, Plaza V, investigators of the De la Roca F. Perﬁl de sensibilización a responsables de la clínica respiratorias CONCORD Study Group. Anxiety, alérgenos del D. pteronyssinus en sujetos inducida por bebidas alcohólicas: Papel de depression, and asthma control: Changes adultos con alergia a ácaros del polvo los Receptores de Potenciales after standardized treatment. J ALLERGY doméstico y su relación con la presencia de Transitorios. CLIN IMMUNOL PRACT. 6(6):1953-1959. asma y la gravedad de los síntomas Sponsored by: Fundación SEAIC - AYUDAS I.F.: 13.258 respiratorios (rinitis/conjuntivitis y asma). _17-27 Sponsored by: Fundación SEAIC - AYUDAS ‘17 Duration: 1/01/2018-31/12/2021 Duration: 1/01/2017-31/12/2019

GRANTS FOR RESEARCH IN PROGRESS De la Roca F. Perfil de sensibilización a DOCTORAL THESES alérgenos del D. pteronyssinus en sujetos Alobid I. El impacto de la inflamación sobre adultos con alergia a ácaros del polvo Alobid I, Enseñat J. Uso endoscópico del el sentido del olfato en pacientes con doméstico y su relación con las colgajo pericraneal para la reconstrucción poliposis nasal: el rol de los eosinófilos características del asma y su respuesta a nasal y de base de cráneo. sobre la neurogenesis del neuroepitelio la inmunoterapia especifica. PhD student: Alfonso Santamaría Gadea olfatorio. Sponsored by: FUCAP - AJUTS ‘17 Sponsored by: Instituto de Salud Carlos III Duration: 1/01/2017-31/12/2019 Mullol J, Mariño F. Impacte de les alteracions (ISCIII). PI15/00262 anatòmiques intranasals sobre els Duration: 01/01/2016-31/12/2019 Mullol J. Función reguladora de los símptomes, la resposta al tractament microRNA sobre los genes diana mèdic i la qualitat de vida en nens i Araujo G. El papel de la prueba de involucrados en la diferenciación epitelial de adolescents amb rinitis al·lèrgica provocación nasal alérgeno específica con la mucosa nasosinusal en la poliposis nasal. persistent. Pru p3 para el diagnóstico de alergia a Sponsored by: Instituto de Salud Carlos III (ISCIII). PhD student: Meritxell Valls Mateus alimentos por proteína de transferencia de PI15/00046 lípidos del melocotón. Duration: 01/01/2016-31/12/2019 Sponsored by: Societat Catalana d'Al·lèrgia i Immunologia Clínica (SCAIC). Mullol J, Roca-Ferrer J. Expression of BECA_SCAIC2017 Rupatadine on PAF-induced inflammation in Duration: 1/01/2018-31/12/2019 blood eosinophils and epithelial cells from nasal polyps and healthy nasal mucosa Bartra J. ARADYAL: Asma, reacciones (RINOPAF-2 Study). adversas y alérgicas. Sponsored by: URIACH – RINOPAF-02-2018 Sponsored by: Instituto de Salud Carlos III Duration: 1/01/2018-31/12/2020 (ISCIII). RD16/0006/0007 Duration: 01/01/2017-31/12/2021 Muñoz-Cano R. Estudios de los mecanismos patogénicos en la anafilaxia inducida por Bartra J. Mecanismos y predicción de alimentos y exacerbada oir antiinflamatorios reacciones adversas medicamentosas y no esteroideos (AINEs). enfermedad alérgica. Sponsored by: Instituto de Salud Carlos III (ISCIII). Sponsored by: Fundación SEAIC. PI16/00696 AYUDAS_18-01 Duration: 01/01/2017-31/12/2019 Duration: 25/06/2018-31/12/2018 Pascal M. Síndrome LTP: identificación y Bobolea I. Identificación de biomarcadores caracterización clínica de los epítopos no invasivos asociados a los distintos inmunodominantes B y T y su presentación fenotipos y endotipos de asma descritos. antigénica HLA. Utilidad clínica y valor pronóstico de la Sponsored by: Instituto de Salud Carlos III (ISCIII). periostina, en vistas al tratamiento PI16/00344 personalizado. Duration: 01/01/2017-31/12/2019 Sponsored by: Instituto de Salud Carlos III (ISCIII). PI14/00711 Picado C. Estudio de la prevalencia y de los Duration: 06/06/2017-31/12/2019 mecanismos responsables de las manifestaciones clínicas respiratorias Bobolea I. Estudio de los mecanismos por los inducidas por las bebidas alcohólicas: cuales el Omalizumab es capaz de mejorar el Papel de los Receptores de Potenciales asma persistente asociada a la Enfermedad Transitorios. Respiratoria Exacerbada por AINES (EREA). Sponsored by: SEPAR - BECAS ‘17

144 INFLAMMATION AND REPAIR IN RESPIRATORY ILLNESSES 2.9

Inﬂammation and repair 2.9 in respiratory illnesses

STRATEGIC OBJECTIVES

LOCATION The objective of the group is to investigate the CELLEX building, floor 2A biological processed underling the clinical heterogeneity and complexity of chronic obstructive pulmonary disease (COPD) and lung cancer. To investigate the clinical functional correlation and the diagnostic, prognostic and therapeutic value the group KEYWORDS uses systems network methods. 1. COPD TEAM LEADER 2. Emphysema Alvar Agustí (HCB) 3. Inflammation T. 93 227 17 01 MAIN LINES OF RESEARCH 4. Networks [email protected] 5. Systems biology 1. Mechanism of abnormal repair in COPD related to the inflammation present in RESEARCHERS COPD patients. Eugenio Ballester (HCB) Maria Rosa Faner (CIBER) 2. Mechanisms of oncogenesis in COPD. Original publications Abel Gómez-Caro (HCB) Ramón Marrades (HCB) from 2016 to 2018 3. Application systems biology to COPD to Jacobo Sellarés (HCB) understand its natural history. YEAR I.F. TOTAL Q1 Q2 PRE-DOCTORAL RESEARCHERS 2016 111.89 18 11 4 Sandra Casas (CIBER) Sandra Cuerpo (HCB) 2017 93.59 15 12 2 PUBLICATIONS Angela Guirao (HCB) 2018 112.11 18 8 9 Fernanda Hernández (HCB) Originals / I.F.: 112.113 Alejandra Lopez (HCB) Núria Mendoza (IDIBAPS) 1. Jones PW, Mullerova H, Agusti A, Decramer Guillaume Noel (IDIBAPS) M, Adamek L, Raillard A, Zhu CQ, Wedzicha TEAM INVOLVED IN TECHNICIANS JA. Cardiovascular Disease Does Not CIBERES Tamara Garcia (CIBER) Predict Exacerbation Rate or Mortality in Gemma Sunyer (CIBER) COPD. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE COLLABORATORS MEDICINE. 197(3):400-403. I.F.: 15.239 Laureano Molins (HCB)

AWARDS Premio Fundación Lilly de Investigación Clínica 2018 Institution: Fundación Lilly Awardee/s: Dr. Àlvar Agustí

Honorary membership Institution: European Respiratory Society Awardee/s: Dr. Àlvar Agustí Alvar Agustí TEAM

145 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

2. Almagro P, De la Sierra A, Acosta E, Navarro 8. Obeidat M., Dvorkin-Gheva A., Li X., Bossé Á, Saco A, Cuerpo S, Ramirez J, Agustí Á, A, Garcia ME, Valdivieso S, Castañeda T, Y., Brandsma C., Nickle D., Hansbro P., Faner Faner R. Characterization, localization and Agustí A. Spirometrically Confirmed COPD R., Agusti A., Paré P., Stampfli M., Sin D. The comparison of c-Kit+ lung cells in never Worsens Long-term Prognosis After Overlap of Lung Tissue Transcriptome of smokers and smokers with and without Percutaneous Coronary Intervention. Smoke Exposed Mice with Human COPD. BMC PULMONARY MEDICINE. AMERICAN JOURNAL OF RESPIRATORY Smoking and COPD. SCIENTIFIC REPORTS. 18(1):123. I.F.: 2.721 AND CRITICAL CARE MEDICINE. 8(1):11881. I.F.: 4.122 197(6):824-826. I.F.: 15.239 16. Borràs-Santos A, Garcia-Aymerich J, 9. Yoon JH, Nouraie M, Chen X, Zou RH, Soler-Cataluña JJ, Vigil Giménez L, Gea Guiral 3. Ramon MA, Ter Riet G, Carsin AE, Sellares J, Veraldi KL, Chiarchiaro J, Lindell K, J, Rodríguez Chiaradía D, Pascual-Guardia S, Gimeno-Santos E, Agustí A, Antó JM, Wilson DO, Kaminski N, Burns T, Trejo Bittar H, Marcos Rodríguez PJ, Alvarez Martinez CJ, Donaire-Gonzalez D, Ferrer J, Rodríguez E, Yousem S, Gibson K, Kass DJ. Casanova Macario C, López-Campos JL, Rodriguez-Roisin R, Puhan MA, Characteristics of lung cancer among Carrasco Hernández L, Martínez-González C, Garcia-Aymerich J, PAC-COPD Study Group. patients with idiopathic pulmonary fibrosis Santos-Pérez S, Peces-Barba G, Molina Paris The dyspnoea-inactivity vicious circle in and interstitial lung disease - analysis of J, Román Rodríguez M, Barberà JA, Faner R, COPD: Development and external institutional and population data. Agustí A, Cosío BG, en representación del validation of a conceptual model. RESPIRATORY RESEARCH. 19(1):195. Grupo Investigador del estudio EARLY COPD. EUROPEAN RESPIRATORY JOURNAL. I.F.: 3.751 Determinants of the Appearance and 52(3):1800079. I.F.: 12.244 Progression of Early-Onset Chronic 10. Toledo-Pons N., Noell G., Jahn A., Iglesias Obstructive Pulmonary Disease in Young 4. Alcázar-Navarrete B, Ruiz Rodríguez O, A., Duran M., Iglesias J., Rios A., Scrimini S., Adults. ARCHIVOS DE Conde Baena P, Romero Palacios PJ, Agusti Faner R., Gigirey O., Agustí A., Cosío B. Bone BRONCONEUMOLOGIA. 55(6):312-318. A. Persistently elevated exhaled nitric marrow characterization in COPD: A I.F.: 2.633 oxide fraction is associated with increased multi-level network analysis. risk of exacerbation in COPD. EUROPEAN RESPIRATORY RESEARCH. 19(1):118. 17. Breyer-Kohansal R, Hartl S, Burghuber OC, RESPIRATORY JOURNAL. 51(1). I.F.: 12.244 I.F.: 3.751 Urban M, Schrott A, Agusti A, Sigsgaard T, Vogelmeier C, Wouters E, Studnicka M, Breyer 5. Celli, Bartolome R.; Locantore, Nicholas; 11. Olloquequi J, Jaime S, Parra V, MK. The LEAD (Lung, Heart, Social, Body) Tal-Singer, Ruth; Riley, John; Miller, Bruce; Cornejo-Córdova E, Valdivia G, Agustí À, Silva Study: Objectives, Methodology, and Vestbo, Jorgen; Yates, Julie C.; Silverman, O R. Comparative analysis of COPD External Validity of the Population-Based Edwin K.; Owen, Caroline A.; Divo, Miguel; associated with tobacco smoking, Cohort Study. JOURNAL OF Pinto-Plata, Victor; Wouters, Emiel F. M.; Faner, biomass smoke exposure or both. EPIDEMIOLOGY. I.F.: 2.518 Rosa; Agusti, Alvar; ECLIPSE Study RESPIRATORY RESEARCH. 19(1):13. I.F.: 3.751 Investigators. Emphysema and 18. Brito-Zerón P., Acar-Denizli N., extrapulmonary tissue loss in COPD: a 12. Faner R., Noell G., Badia J., López-Giraldo Sisó-Almirall A., Bosch X., Hernández F., multi-organ loss of tissue phenotype. A., Bakke P., Silverman E., Tal-Singer R., Agustí Vilanova S., Villalta M., Kostov B., Paradela M., EUROPEAN RESPIRATORY JOURNAL. 51(2). A. Distribution, temporal stability and Sanchez M., Ramírez J., Muxí A., Berruezo A., I.F.: 12.244 association with all-cause mortality of the Galceran-Chaves C., Xaubet A., Agustí C., 2017 GOLD groups in the ECLIPSE cohort. Sellarés J., Ramos-Casals M. The Burden of 6. Cardenes N; Álvarez D; Sellarés J; Peng Y; RESPIRATORY MEDICINE. 141:14-19. I.F.: Comorbidity and Complexity in Corey C; Wecht S; Nouraie SM; Shanker S; 3.230 Sarcoidosis: Impact of Associated Chronic Sembrat J; Bueno M; Shiva S; Mora AL; Rojas Diseases. LUNG. 196(2):239-248. I.F.: 2.101 M. Senescence of bone marrow-derived 13. Andrea R., López-Giraldo A., Falces C., mesenchymal stem cells from patients López T., Sanchis L., Gistau C., Sabaté M., with idiopathic pulmonary fibrosis. STEM Sitges M., Brugada J., Agustí À. Pulmonary Review / I.F.: 94.729 CELL RESEARCH & THERAPY. 9(1):257. function predicts mortality and I.F.: 4.963 hospitalizations in outpatients with heart 1. Pavord ID, Beasley R, Agusti A, Anderson failure and preserved ejection fraction. GP, Bel E, Brusselle G, Cullinan P, Custovic A, 7. Qiao D; Ameli A; Prokopenko D; Chen H; RESPIRATORY MEDICINE. 134:124-129. Ducharme FM, Fahy JV, Frey U, Gibson P, Kho AT; Parker MM; Morrow J; Hobbs BD; Liu I.F.: 3.230 Heaney LG, Holt PG, Humbert M, Lloyd CM, Y; Beaty TH; Crapo JD; Barnes KC; Nickerson Marks G, Martinez FD, Sly PD, von Mutius E, DA; Bamshad M; Hersh CP; Lomas DA; Agustí 14. Serra-Picamal X., Roman R., Escarrabill J., Wenzel S, Zar HJ, Bush A . After asthma: A; Make BJ; Calverley PMA; Donner CF; García-Altés A., Argimón J., Soler N., Faner R., redefining airways diseases. LANCET. Wouters EF; Vestbo J; Paré PD; Levy RD; Carbonell E., Trilla A., Agusti A. 391(10118):350-400. I.F.: 53.254 Rennard SI; Tal-Singer R; Spitz MR; Sharma A; Hospitalizations due to exacerbations of Ruczinski I; Lange C; Silverman EK; Cho MH. COPD: A big data perspective. 2. Kovacs G, Agusti A, Barberà JA, Celli B, Whole exome sequencing analysis in RESPIRATORY MEDICINE. 145:219-225. Criner G, Humbert M, Sin DD, Voelkel N, severe chronic obstructive pulmonary I.F.: 3.230 Olschewski H. Pulmonary Vascular disease. HUMAN MOLECULAR GENETICS. Involvement in COPD - Is There a 27(21):3801-3812. I.F.: 4.902 15. López-Giraldo A, Cruz T, Molins L, Guirao Pulmonary Vascular Phenotype?

146 INFLAMMATION AND REPAIR IN RESPIRATORY ILLNESSES 2.9

AMERICAN JOURNAL OF RESPIRATORY RESPIRATORY AND CRITICAL CARE (ISCIII). PI15/00799 AND CRITICAL CARE MEDICINE. MEDICINE. 198(7):973-973. I.F.: 15.239 Duration: 01/01/2016-31/12/2018 198(8):1000-1011. I.F.: 15.239 Agustí A. Valoración de la heterogeneidad y 3. Agusti A, Fabbri LM, Singh D, Vestbo J, Celli Editorial / I.F.: 53.238 progresión de la EPOC en base a B, Franssen FME, Rabe KF, Papi A. Inhaled biomarcadores moleculares y de imagen. corticosteroids in COPD: Friend or foe? 1. Agustí A, Faner R. The Changing Sponsored by: Sociedad Española de EUROPEAN RESPIRATORY JOURNAL. 52(6). Landscape of COPD. AMERICAN JOURNAL Neumología y Cirugía Torácica (SEPAR) I.F.: 12.244 OF RESPIRATORY AND CRITICAL CARE Duration: 01/01/2018-31/12/2020 MEDICINE. 198(8):978-981. I.F.: 15.239 4. Rodríguez-Roisin R., Krowka M., Agustí A. Fané R. Toward a new understanding and Hepatopulmonary disorders: Gas 2. Agusti A. The disease model: implications clinical stratiﬁcation of COPD through the exchange and vascular manifestations in for clinical practice. EUROPEAN molecular mechanisms underlying chronic liver disease. COMPR PHYSIOL. RESPIRATORY JOURNAL. 51(4):467. different vital lung function trajectories. 8(2):711-729. I.F.: 5.797 I.F.: 12.244 Sponsored by: Instituto de Salud Carlos III (ISCIII). 5. Bobolea I, Arismendi E, Valero A, Agustí A. 3. Singh, Dave; Barnes, Peter J.; Stockley, Duration: 01/01/2017-31/12/2019 Early Life Origins of Asthma: A Review of Robert; Lopez Valera, Maria Victorina; Potential Effectors.JOURNAL OF Vogelmeier, Claus; Agusti, Alvar. Fané R. Abnormal lung development vs. INVESTIGATIONAL ALLERGOLOGY AND Pharmacological treatment of COPD: the Accelerated aging in COPD: a multilevel CLINICAL IMMUNOLOGY. 29(3):0-179. devil is always in the detail. EUROPEAN network analysis approach. I.F.: 3.457 RESPIRATORY JOURNAL. 51(4). I.F.: 12.244 Sponsored by: Instituto de Salud Carlos III (ISCIII). PI17/000369 6. Sanchez-Lorente D, Guzman R, Boada M, 4. Boaventura R, Sibila O, Agusti A, Chalmers Duration: 01/01/2018-31/12/2020 Guirao A, Carriel N, Molins L. N2 disease in JD . Treatable traits in bronchiectasis. non-small-cell lung cancer: straight to EUROPEAN RESPIRATORY JOURNAL. 52(3). Fané R. Respiratory Microbiome and COPD surgery? FUTURE ONCOLOGY. 14(6s):13-16. I.F.: 12.244 Exacerbations. I.F.: 2.369 Sponsored by: Fundació Ramón Pla i 5. Sellares J., Strambu I., Crouser E., Armengol 7. Sanchez-Lorente D, Guzman R, Boada M, Freudenberg M., Gulati M., Hart S., Herzog E., Duration: 01/01/2015-31/12/2018 Carriel N, Guirao A, Molins L. Is it appropriate Kolb M., Weichhart T., Drake W., Spitzer G., to perform video-assisted thoracoscopic Singh N., Culver D. New advances in the Hernández F. Integrative network surgery for advanced lung cancer? development of sarcoidosis models: A genomics approach to address molecular FUTURE ONCOLOGY. 14(6s):29-31. I.F.: 2.369 synopsis of a symposium sponsored by the differences and commonalities in COPD Foundation for Sarcoidosis Research. and IPF. SARCOIDOSIS VASCULITIS AND DIFFUSE Sponsored by: Sociedad Española de Letters / I.F.: 132.891 LUNG DISEASES. 35(1):2-4. I.F.: 1.267 Neumología y Cirugía Torácica (SEPAR) Duration: 01/12/2017-30/06/2019 1. Agusti A. Filling the gaps in COPD: The TRIBUTE study. LANCET. Case Reports / I.F.: 2.633 Sellarés J. Caracterización de las 391(10125):1004-1006. I.F.: 53.254 enfermedades pulmonares instersticiales 1. Martin-Deleon R, Llabrés de Prada M, difusas asociadas al tabaquismo mediante 2. Agusti A, Faner R, Celli B, Rodriguez-Roisin López-Giraldo A. Diffuse Idiopathic la biología de sistemas: estudio del R. Precision medicine in COPD Pulmonary Neuroendocrine Cell radio-transcripto-proteoma. exacerbations. THE LANCET. Hyperplasia Causing Chronic Cough. Sponsored by: Fundació Catalana de RESPIRATORY MEDICINE. 6(9):657-659. ARCHIVOS DE BRONCONEUMOLOGIA. Pneumologia (FUCAP) I.F.: 21.466 54(11):577. I.F.: 2.633 Duration: 01/01/2018-31/12/2021

3. Agustí A, Faner R. COPD beyond Sellarés J. Caracterización y uso smoking: new paradigm, novel terapéutico de las células progenitoras opportunities. THE LANCET. RESPIRATORY GRANTS FOR RESEARCH IN PROGRESS mesenquimales residentes en el pulmón MEDICINE. 6(5):324-326. I.F.: 21.466 en la fibrosis pulmonar. Agustí A. Análisis multinivel en red de las Sponsored by: Sociedad Española de 4. Agusti A, Pavord ID. Do we really need a similitudes y diferencias moleculares entre Neumología i Cirugía Torácica (SEPAR) new classification of airway diseases? THE enfisema y cáncer de pulmón en pacientes Duration: 01/01/2018-31/12/2021 LANCET. RESPIRATORY MEDICINE. con enfermedad pulmonar obstructiva 6(12):891-893. I.F.: 21.466 crónica: papel de la respuesta inmune y de las células madre mesenquimales 5. Agusti A, Faner R. How to Define Early pulmonares. COPD. AMERICAN JOURNAL OF Sponsored by: Instituto de Salud Carlos III

147 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

Genetics 2.10 and urologic tumors

TEAM LEADER STRATEGIC OBJECTIVES Antonio Alcaraz (HCB) LOCATION T. 93 227 55 45 The group is focused on the translational CELLEX building, ﬂoor 2B [email protected] research in urological oncology, aimed at generating knowledge that provides a direct beneﬁt to patients.

RESEARCHERS 1. Develop non-invasive tools for the Laura Izquierdo (HCB-IDIBAPS) diagnosis and prognosis of bladder, upper KEYWORDS Lourdes Mengual (IDIBAPS-FCRB) urinary tract and prostate cancer. 1. Bladder cancer Mireia Musquera (HCB-IDIBAPS) 2. Prostate cancer María José Ribal (HCB-IDIBAPS) 2. Identify biomarkers to predict the response 3. Upper tract urothelial carcinoma to chemotherapy in bladder cancer. 4. Renal cell carcinoma PRE-DOCTORAL RESEARCHERS 5. Biomarkers for diagnosis, Raquel Carrasco (FCRB) 3. Determine molecular prognostic factors in prognosis and treatment response Maria Mercedes Ingelmo (IDIBAPS) bladder, upper urinary tract, kidney and Ruth Montalbo (FCRB) prostate cancer.

ADMINISTRATIVE STAFF Maria Teresa Dalet (FCRB) MAIN LINES OF RESEARCH Original publications COLLABORATORS Agustín Franco (HCB) from 2016 to 2018 1. Non-invasive diagnosis and prognosis Francisco Lozano (HCB-UB) of bladder tumors. YEAR I.F. TOTAL Q1 Q2 Begoña Mellado (HCB-UB) - Development of a gene/miRNA expression Aleix Prat (HCB-UB) 2016 28.18 10 42 signatures in urine samples. - Identification of DNA aneuploidies in urine 2017 64.02 12 62 VISITING SCIENTISTS samples by FISH. 2018 51.24 12 61 Marco Franco - Determination of methylation profiles of (Università Degli Studi di Napoli “Federico II”, urine samples. Napoles, Italia) - Identification of somatic mutations in circulating tumor cells and tumor cell free DNA (liquid biopsy) . TEAM INVOLVED IN AGAUR_SGR17: 01801 2. Predictive biomarkers of prognosis and response to treatments. - Markers of disseminated cells from bladder tumours in lymph nodes and peripheral blood. - Markers of response to neoadjuvant chemotherapy in bladder cancer patients. - Prognostic markers in bladder, kidney and upper urinary tract tumors. - Radiogenomics in prostate cancer and renal cell carcinoma

3. Non-invasive diagnosis and prognosis of prostate tumours. - Development of a gene/miRNA expression signature in post-prostatic massage urine samples. - Prognostic biomrakers for prostate cancer.

148 GENETICS AND UROLOGIC TUMORS 2.10

PUBLICATIONS robot-assisted kidney transplantation: Review / I.F.: 3.78 minimum of 1-year follow-up. BJU Originals / I.F.: 51.241 INTERNATIONAL. 122(2):255-262. I.F.: 4.688 1. Linares-Espinós E, Hernández V, 6. Mateu Arrom L, Peri Cusi L, Franco de Castro Domínguez-Escrig JL, Fernández-Pello S, Hevia 1. Breda A, Territo A, Gausa L, Tuğcu V, Alcaraz A, López-Fando L, Jiménez Cidre MÁ, Alcaraz V, Mayor J, Padilla-Fernández B, Ribal MJ. A, Musquera M, Decaestecker K, Desender L, Asensio A. Development and feasibility Methodology of a systematic review. Stockle M, Janssen M, Fornara P, Mohammed N, assessment of a 3 day electronic bladder 42(8):499-506. I.F.: 1.260 Siena G, Serni S, Guirado L, Facundo C, diary as an app for smart-phone. Doumerc N. Robot-assisted Kidney NEUROUROLOGY AND URODYNAMICS. 2. E. García Cruz; J. Romero Otero; M. Fode; Transplantation: The European 37(5):1717-1723. I.F.: 3.263 Antonio Alcaraz Asensio. El entorno digital en Experience. EUROPEAN UROLOGY. los trastornos sexuales masculinos: 73(2):273-281. 7. Mengual L., Kang B., Lozano J., Yang X., Zhang revisión sistemática. ACTAS UROLOGICAS I.F.: 17.581 C., Alcaraz A., Liang J., Ye D. Validation of ESPANOLAS. 42(6):365-374. I.F.: 1.260 urine-based gene classifiers for detecting 2. Van der Heijden, Antoine G.; Mengual, bladder cancer in a Chinese study. 3. Gomez-Veiga, F.; Alcaraz-Asensio, A.; Lourdes; Ingelmo-Torres, Mercedes; Lozano, JOURNAL OF CANCER. 9(17):3208-3215. Burgos-Revilla, J.; Cozar-Olmo, J. Juan J.; van Rijt-van de Westerlo, Cindy C. M.; I.F.: 3.249 Developments in urologic oncology Baixauli, Montserrat; Geavlete, Bogdan; "OncoForum": The best of 2017. ACTAS Moldoveanud, Cristian; Ene, Cosmin; Dinney, 8. Unda-Urzaiz M, Cozar-Olmos JM, UROLOGICAS ESPANOLAS. 42(8):488-498. Colin P.; Czerniak, Bogdan; Schalken, Jack A.; Miñana-Lopez B, Camarero-Jimenez J, I.F.: 1.260 Kiemeney, Lambertus A. L. M.; Ribal, Maria J.; Brugarolas-Rossello X, Zubiaur-Libano C, Witjes, J. Alfred; Alcaraz, Antonio. Urine Ribal-Caparros MJ, Suarez-Charneco AJ, cell-based DNA methylation classifier for Rodriguez-Tesedo V, Chantada-Abal V, Letters / I.F.: 20.562 monitoring bladder cancer. CLINICAL Ruiz-de-Leon C, Carrillo-George C, EPIGENETICS. 10(1):71. I.F.: 6.091 Carballido-Rodriguez J, Villacampa-Auba F, en 1. Alcaraz A, Mengual L. Re: Role of Genetic representación del Grupo Español del Registro Testing for Inherited Prostate Cancer Risk: 3. Castelló A, Boldo E, Amiano P, de Cepas de BCG en representación del Grupo Philadelphia Prostate Cancer Consensus Castaño-Vinyals G, Aragonés N, Gómez-Acebo Español del Registro de Cepas de BCG. Safety Conference 2017. EUROPEAN UROLOGY. I, Peiró R, Jimenez-Moleón JJ, Alguacil J, Tardón and efficacy of various strains of bacille 74(3):397. I.F.: 17.581 A, Cecchini L, Lope V, Dierssen-Sotos T, Calmette-Guérin in the treatment of Mengual L, Kogevinas M, Pollán M, bladder tumours in standard clinical 2. Borgmann H, Musquera M, May M, Pérez-Gómez B, MCC-Spain Researchers. practice. 42(4):238-248. I.F.: 1.260 Brookman-May SD. Answer to comment on Mediterranean Dietary Pattern is manuscript Prognostic significance of Associated with Low Risk of Aggressive 9. Carrion, A.; D'Anna, M.; Costa-Grau, M.; Luque, Fuhrman grade and age for Prostate Cancer: MCC-Spain Study. P.; Garcia-Cruz, E.; Franco, A.; Alcaraz, A. Office cancer-specific and overall survival in JOURNAL OF UROLOGY. 199(2):430-437. stent placement under local anesthesia is a patients with papillary renal cell I.F.: 5.381 safe and efficient procedure for the carcinoma: results of an international management of multiple ureteral multi-institutional study on 2189 patients. 4. Vela-Navarrete R, Alcaraz A, disorders. ACTAS UROLOGICAS WORLD JOURNAL OF UROLOGY. Rodríguez-Antolín A, Miñana López B, ESPANOLAS. 42(2):126-132. I.F.: 1.260 36(12):2091-2092. I.F.: 2.981 Fernández-Gómez JM, Angulo JC, Castro Díaz D, Romero-Otero J, Brenes FJ, Carballido J, 10. García-Cruz E, Carrión A, Ajami T, Álvarez M, Molero García JM, Fernández-Pro Ledesma A, Correas MÁ, García B, García JV, González C, Clinical Guidelines / I.F.: 17.581 Cózar Olmos JM, Manasanch Dalmau J, Portillo JA, Romero-Otero J, Simón C, Subirana Cachinero I, Herdman M, Ficarra V. Torremadé J, Vigués F, Alcaraz A. The 1. Borgmann H, Cooperberg M, Murphy D, Loeb Efficacy and safety of a hexanic extract of Patient's Comorbidity Burden Correlates S, N'Dow J, Ribal MJ, Woo H, Rouprêt M, Serenoa repens (Permixon® ) for the with the Erectile Dysfunction Severity. Winterbottom A, Wijburg C, Wirth M, Catto J, treatment of lower urinary tract symptoms ACTAS UROLOGICAS ESPANOLAS. Kutikov A. Online Professionalism-2018 associated with benign prostatic 42(1):57-63. I.F.: 1.260 Update of European Association of hyperplasia (LUTS/BPH): Systematic Urology (@Uroweb) Recommendations on review and meta-analysis of randomized 11. García-Cruz E, Bretonnet A, Alcaraz A. the Appropriate Use of Social Media. controlled trials and observational studies. Testing Smart Glasses in urology: Clinical 74(5):644-650. I.F.: 17.581 BJU INTERNATIONAL. 122(6):1049-1065. and surgical potential applications. ACTAS I.F.: 4.688 UROLOGICAS ESPANOLAS. 42(3):207-211. I.F.: 1.260 Consortium Publications / I.F.: 131.091 5. Territo A, Gausa L, Alcaraz A, Musquera M, Doumerc N, Decaestecker K, Desender L, 12. Mateu L, Peri L, Franco A, Roldán F, Musquera 1. Smith MR, Saad F, Chowdhury S, Oudard S, Stockle M, Janssen M, Fornara P, Mohammed N, M, Ribal MJ. Functional outcomes after Hadaschik BA, Graff JN, Olmos D, Mainwaring Siena G, Serni S, Sahin S, Tu?cu V, Basile G, prostatic cryosurgery. ACTAS UROLOGICAS PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel Breda A. European experience of ESPANOLAS. 42(5):338-343. I.F.: 1.260 GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu

149 AREA 2 RESPIRATORY, CARDIOVASCULAR AND RENAL PATHOBIOLOGY AND BIOENGINEERING

MK, Small EJ, SPARTAN Investigators Genome) Consortium, Cancer of the Prostate in GRANTS FOR RESEARCH IN PROGRESS SPARTAN Investigators. Apalutamide Sweden (CAPS), Prostate Cancer Treatment and Metastasis-free Survival in Genome-wide Association Study of Uncommon Alcaraz A. Validación Clínica Robot Prostate Cancer. 378(15):1408-1418. I.F.: Susceptibility Loci (PEGASUS), Genetic Quirúrgico. 79.260 Associations and Mechanisms in Oncology Sponsored by: Ministerio de Economía y (GAME-ON)/Elucidating Loci Involved in Competitividad (MINECO). RTC-2015-3926-1 2. Schumacher FR, Al Olama AA, Berndt SI, Prostate Cancer Susceptibility (ELLIPSE) Duration: 01/03/2015- 30/06/2018 Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Consortium Profile Study, Australian Prostate Leongamornlert D, Anokian E, Cieza-Borrella C, Cancer BioResource (APCB), IMPACT Study, Mengual L. Identificación de biomarcadores Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Canary PASS Investigators, Breast and Prostate pronósticos del tumor vesical músculo Tyrer J, Muir K, Lophatananon A, Stevens VL, Cancer Cohort Consortium (BPC3), invasivo y su inferencia en la biopsia Gapstur SM, Carter BD, Tangen CM, Goodman PRACTICAL (Prostate Cancer Association líquida. PJ, Thompson IM, Batra J, Chambers S, Moya L, Group to Investigate Cancer-Associated Sponsored by: Instituto de Salud Carlos III (ISCIII). Clements J, Horvath L, Tilley W, Risbridger GP, Alterations in the Genome) Consortium, Cancer PI17/01343 Gronberg H, Aly M, Nordström T, Pharoah P, of the Prostate in Sweden (CAPS), Prostate Duration: 01/01/2018-31/12/2020 Pashayan N, Schleutker J, Tammela TLJ, Sipeky Cancer Genome-wide Association Study of C, Auvinen A, Albanes D, Weinstein S, Wolk A, Uncommon Susceptibility Loci (PEGASUS), Håkansson N, West CML, Dunning AM, Burnet Genetic Associations and Mechanisms in N, Mucci LA, Giovannucci E, Andriole GL, Oncology (GAME-ON)/Elucidating Loci DOCTORAL THESES Cussenot O, Cancel-Tassin G, Koutros S, Beane Involved in Prostate Cancer Susceptibility Freeman LE, Sorensen KD, Orntoft TF, Borre M, (ELLIPSE) Consortium. Association analyses Mengual L, Izquierdo L. Estudi del Carcinoma Maehle L, Grindedal EM, Neal DE, Donovan JL, of more than 140,000 men identify 63 new Urotelial. Identificació de biomarcadors Hamdy FC, Martin RM, Travis RC, Key TJ, prostate cancer susceptibility loci. amb valor diagnòstic i pronòstic. Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, NATURE GENETICS. 50(7):928-936. I.F.: 27.125 PhD student: Ruth Montalbo Calafell Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, 3. Matejcic M, Saunders E, Dadaev T, Brook M, Sun Z, Giles GG, Southey MC, MacInnis RJ, Wang K, Sheng X, Olama A, Schumacher F, FitzGerald LM, Kibel AS, Drake BF, Vega A, Ingles S, Govindasami K, Benlloch S, Berndt S, Gómez-Caamaño A, Szulkin R, Eklund M, Albanes D, Koutros S, Muir K, Stevens V, Gapstur Kogevinas M, Llorca J, Castaño-Vinyals G, S, Tangen C, Batra J, Clements J, Gronberg H, Penney KL, Stampfer M, Park JY, Sellers TA, Lin Pashayan N, Schleutker J, Wolk A, West C, HY, Stanford JL, Cybulski C, Wokolorczyk D, Mucci L, Kraft P, Cancel-Tassin G, Sorensen K, Lubinski J, Ostrander EA, Geybels MS, Maehle L, Grindedal E, Strom S, Neal D, Hamdy Nordestgaard BG, Nielsen SF, Weischer M, F, Donovan J, Travis R, Hamilton R, Rosenstein B, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk Lu Y, Giles G. Germline variation at 8q24 and K, Holleczek B, Maier C, Luedeke M, Schnoeller prostate cancer risk in men of European T, Kim J, Logothetis CJ, John EM, Teixeira MR, ancestry. NATURE COMMUNICATIONS. Paulo P, Cardoso M, Neuhausen SL, Steele L, 9(1):4616. I.F.: 12.353 Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, 4. Dadaev T; Saunders EJ; Newcombe PJ; Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani Anokian E; Leongamornlert DA; Brook MN; N, Singhal S, Slavov C, Mitev V, Parliament M, Cieza-Borrella C; Mijuskovic M; Wakerell S; Claessens F, Joniau S, Van den Broeck T, Larkin Olama AAA; Schumacher FR; Berndt SI; S, Townsend PA, Aukim-Hastie C, Benlloch S; Ahmed M; Goh C; Sheng X; Zhang Z; Gago-Dominguez M, Castelao JE, Martinez ME, Muir K; Govindasami K; Lophatananon A; Roobol MJ, Jenster G, van Schaik RHN, Stevens VL; Gapstur SM; Carter BD; Tangen Menegaux F, Truong T, Koudou YA, Xu J, Khaw CM; Goodman P; Thompson IM; Batra J; KT, Cannon-Albright L, Pandha H, Michael A, Chambers S; Moya L; Clements J; Horvath L; Thibodeau SN, McDonnell SK, Schaid DJ, Tilley W; Risbridger G; Grönberg H; Aly M; Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Nordström T; Pharoah P; Pashayan N; Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Schleutker J; Tammela TLJ. Fine-mapping of Hoover RN, Machiela MJ, Cui Z, Kraft P, Amos CI, prostate cancer susceptibility loci in a large Conti DV, Easton DF, Wiklund F, Chanock SJ, meta-analysis identifies candidate causal Henderson BE, Kote-Jarai Z, Haiman CA, Eeles variants. NATURE COMMUNICATIONS. RA, Profile Study, Australian Prostate Cancer 9(1):2256-2256. I.F.: 12.353 BioResource (APCB), IMPACT Study, Canary PASS Investigators, Breast and Prostate Cancer Cohort Consortium (BPC3), PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the

150 GENETICS AND UROLOGIC TUMORS 2.10

151 ANNUAL SCIENTIFIC REPORT 2018

AREA 3

LIVER, DIGESTIVE SYSTEM AND METABOLISM 3

LIVER, DIGESTIVE SYSTEM AND METABOLISM

3.1 Gynecological endocrinology and human reproduction 154 María Ángeles Martínez Zamora

3.2 Fetal and perinatal medicine 156 Eduard Gratacós

3.3 Viral, toxic and metabolic hepatopathies 162 Xavier Forns

3.4 Mechanisms of liver disease and complications of cirrhosis 166 Pere Ginès

3.5 Hepatic oncology 172 Jordi Bruix

3.6 Hepatic hemodynamics and portal hypertension. Hemorrhage from ruptured gastroesophageal varices 177 Juan Carlos García-Pagán

3.7 Inﬂammatory bowel disease 182 Julià Panés

3.8 Cholestasis and bone pathology 186 Albert Parés / Núria Guañabens

3.9 Mitochondrial regulation of cell death and steatohepatitis 189 José Carlos Fernández-Checa

3.10 Liver transplantation and graft viability 192 Miquel Navasa

3.11 Gastrointestinal and pancreatic oncology 197 Antoni Castells

3.12 Inherited metabolic diseases 203 Antonia Ribes 3.13 Genomic programming of beta cells and diabetes 205 Jorge Ferrer

3.14 Diabetes: metabolic and molecular networks 207 Josep Vidal

3.15 Pathogenesis and prevention of diabetes 214 Anna Novials

153 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

Gynecological endocrinology 3.1 and human reproduction

TEAM LEADER 3. Optimization of the surgical María Ángeles Martínez Zamora (HCB) management of diseases of LOCATION T. 93 227 54 36 the reproductive apparatus. HCB building [email protected] To analyze the role of the surgical variables allowing improvement of the results and reduction of the morbidity in the surgical RESEARCHERS treatment of benign and malignant Immaculada Alonso (HCB) gynaecological disorders. To deﬁne the Francesc Carmona (HCB) prognostic value of human papillomavirus KEYWORDS Camil Castelo-Branco (HCB) detection and viral typing as progression 1. Human papillomavirus Marta del Pino (HCB) markers of precancerous lesions of the 2. Endometrial cancer Francisco J. Fábregues (HCB) cervix, vagina and vulva. 3. Assisted reproductive technologies Dolors Manau (HCB) 4. Recurrent miscarriage Aureli Torné (HCB)

5. Gynecological laparoscopy 6. Endometriosis PRE-DOCTORAL RESEARCHERS PUBLICATIONS Meritxell Gracia (HCB) Mariona Rius (HCB) Originals / I.F.: 38.684

NURSING STAFF 1. Paré L, Pascual T, Seguí E, Teixidó C, Ana Carrión (HCB) Gonzalez-Cao M, Galván P, Rodríguez A, Original publications González B, Cuatrecasas M, Pineda E, Torné from 2016 to 2018 A, Crespo G, Martin-Algarra S, Pérez-Ruiz E, Reig Ò, Viladot M, Font C, Adamo B, Vidal M, YEAR I.F. TOTAL Q1 Q2 STRATEGIC OBJECTIVES Gaba L, Muñoz M, Victoria I, Ruiz G, Viñolas N, 2016 30.28 10 5 1 Mellado B, Maurel J, Garcia-Corbacho J, The global aim of this research group for Molina-Vila MÁ, Juan M, Llovet JM, Reguart N, 2017 68.24 19 10 5 the coming years is to advance in the Arance A, Prat A . Association between 2018 38.68 9 4 3 knowledge of different aspects relating to the PD1 mRNA and response to anti-PD1 physiopathology of human reproduction: from monotherapy across multiple endocrinological considerations to the most cancer-types. ANNALS OF ONCOLOGY. important benign and malignant pathological 29(10):2121-2128. I.F.: 13.930 processes of the female reproductive system, as well as the investigation and treatment of 2. Rakislova N, Alemany L, Clavero O, Del Pino human reproduction failure. M, Saco A, Quirós B, Lloveras B, Alejo M, Halec G, Quint W, de Sanjosé S, Ordi J, VVAP study group. Differentiated Vulvar MAIN LINES OF RESEARCH Intraepithelial Neoplasia-like and Lichen Sclerosus-like Lesions in HPV- 1. Reproductive failure markers. associated Squamous Cell Carcinomas To ﬁnd new markers of hemostasis of the Vulva. AMERICAN JOURNAL OF alterations in early and advanced SURGICAL PATHOLOGY. 42(6):828-835. pregnancy in patients with or without I.F.: 5.878 antiphospholipid syndrome and in endometriosis patients. To assess the 3. Fabregues F, González-Foruria I, usefulness of immunohistochemical and Peñarrubia J, Carmona F. Ovarian response proteomic parameters in the human is associated with anogenital distance in endometrium as markers of endometrial patients undergoing controlled ovarian receptiveness. stimulation for IVF. HUMAN REPRODUCTION. 33(9):1696-1704. I.F.: 4.990 2. Ovarian dysfunction and stimulation/ hyperstimulation . 4. Gracia M, Alcalà M, Ferreri J, Rius M, Ros C, Investigation of the possibilities of Saco MA, Martínez-Zamora MÁ, Carmona F. ultrasound, hormonal, endocrinemetabolic Ulipristal Acetate Improves Clinical and genetic markers in relation to the Symptoms in Women with Adenomyosis prediction of ovarian response. To assess and Uterine Fibroids. JOURNAL OF the role of the ovarian follicular cells in the MINIMALLY INVASIVE GYNECOLOGY. pathogenesis of ovarian hyperstimulation 25(7):1274-1280. I.F.: 3.061 syndrome in order to improve the results of assisted reproduction techniques.

154 GYNECOLOGICAL ENDOCRINOLOGY AND HUMAN REPRODUCTION 3.1

5. Rodríguez-Trujillo A, Fusté P, Paredes P, literature review. JOURNAL OF OVARIAN Mensión E, Agustí N, Gil-Ibáñez B, Del Pino M, RESEARCH. 11(76). I.F.: 2.367 González-Bosquet E, Torné A . Long-term oncological outcomes of patients with negative sentinel lymph node in vulvar Case Reports / I.F.: 1.453 cancer. Comparative study with conventional lymphadenectomy. ACTA 1. Garrido Oyarzún MF, Saco A, Castelo- OBSTETRICIA ET GYNECOLOGICA Branco C. Anterior abdominal wall SCANDINAVICA. 97(12):1427-1437. I.F.: 2.649 parasitic leiomyoma: case report. GYNECOLOGICAL ENDOCRINOLOGY. 6. Rodríguez-Trujillo A, Martí C, Angeles MA, 34(2):103-106. I.F.: 1.453 Sierra A, Esteve R, Saco A, Barnadas E, Marimón L, Nicolás I, Torné A, Ordi J, Del Pino M. Value of HPV 16/18 Genotyping and p16/Ki-67 Dual Staining to Predict GRANTS FOR RESEARCH IN PROGRESS Progression to HSIL/CIN2+ in Negative Cytologies From a Colposcopy Referral Del Pino M. Valor de la detección del Population. AMERICAN JOURNAL OF ARNm de los biomarcadores CDKN2A, CLINICAL PATHOLOGY. 150(5):432-440. MKi67, TOP2A en la prevención I.F.: 2.413 secundaria del cáncer de cuello de útero. Sponsored by: Instituto de Salud Carlos III 7. Del Valle Aguilera, Maria; Rovirosa, Angeles; (ISCIII). PI17/00772 Ascaso, Carlos; Herreros, Antonio; Sanchez, Duration: 01/01/2018-31/12/2020 Joan; Garcia-Miguel, Julia; Cortes, Stephania; Agusti, Eduardo; Camacho, Cristina; Zhang, Torné A. Estudi multicèntric sobre el Yaowen; Li, Yan; Sabater, Sebastia; Torne, procés assistencial del càncer d'ovari a Aureli; Arenas, Meritxell. Late G2 vagina l'atenció primària de Catalunya: toxicity in post-operative endometrial Avaluació de dues intervencions per carcinoma is associated with a 68 Gy reduir el retard diagnòstic. dose equivalent to 2 Gy per fraction Sponsored by: Generalitat de Catalunya. (α/β=3Gy) at 2 cm3 of vagina. JOURNAL PERIS_Projectes Atenció Primària OF CONTEMPORARY BRACHYTHERAPY. (SLT002/16/00200) 10(1):40-46. I.F.: 2.146 Duration: 27/03/2017-31/12/2019

8. Lopez, Noelia; Torne, Aureli; Franco, Agustin; San-Martin, Maria; Viayna, Elisabet; Barrull, Carmen; Perulero, Nuria. DOCTORAL THESES Epidemiologic and economic burden of HPV diseases in Spain: implication of Carmona F, Chapron C . additional 5 types from the 9-valent Endometriosis pathogenesis: The vaccine. INFECTIOUS AGENTS AND relationship between oxidative stress, CANCER. 13(15). I.F.: 2.123 ﬁbrosis and immunological dysfunction. PhD student: Iñaki González Foruria 9. Munmany M, Torné A, Nonell R, Barnadas E, Luqui N, Ordi J, Del Pino M. Colposcopy Torné A, Del Pino M. Detecció de la Evaluation at the Time of Loop regressió post-biòpsia de la neoplàsia Electrosurgical Excision Procedure May cervical intraepitelial. Valor de la Avoid Unnecessary Treatment. JOURNAL colposcòpia immediata preconització. OF LOWER GENITAL TRACT DISEASE. PhD student: Meritxell Munmany Delgado 22(4):367-374. I.F.: 1.494 Torné A, Del Pino M. Utilidad de la determinación VPH, genotipado y Review / I.F.: 2.367 tinción dual p16/Ki67 en la prevención secundaria del cáncer de cuello de útero. 1. Fabregues F., Ferreri J., Calafell J., Moreno PhD student: Adriano Rodríguez Trujillo V., Borrás A., Manau D., Carmona F. Pregnancy after drug-free in vitro activation of follicles and fresh tissue autotransplantation in primary ovarian insufficiency patient: A case report and

155 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

Fetal and perinatal 3.2 medicine

PRE-DOCTORAL RESEARCHERS Paz Ahumada (UB) LOCATION Maria Laura Boutet (UB) Maternitat building Laura Garcia (HCB) Nadine Margit Hahner (UB) Eduardo Herreros (UB) Mari Kinoshita (UB) WEB Talita Micheletti (UB) www.fetalmedbarcelona.org Lucas Monteiro (UB) Ana Moreno (UB) Cristina Paules (IDIBAPS) TEAM LEADER Eduard Gratacós (HCB) Sergio Quesada (IDIBAPS) Marta Rial (IDIBAPS) T. 93 227 99 46 Alvaro Sepulveda (UB) [email protected] KEYWORDS Ximena Francisca Torres (HCB) 1. Prenatal diseases Kilian Vellvé (FCRB) 2. Intrauterine growth restriction Lina Youssef (UB) 3. Fetal programming RESEARCHERS 4. Fetal brain damage Antoni Borrell (HCB) TECHNICIANS 5. Prematurity Francesc Botet (HCB) Carla Loreiro (FCRB) Elena Casals (HCB) 6. Environment and pregnancy Miriam Osorio (FCRB) Maria Teresa Cobo (HCB) Nuria Rierola (FCRB) complications Fátima Crispi (HCB-IDIBAPS) Ana Belén Sánchez (FCRB) 7. Neonatal risk factors for impaired Elisenda Eixarch (HCB-IDIBAPS) neurodevelopment outcome Josep Figueras (HCB) ADMINISTRATIVE STAFF Francesc Figueras (HCB) Maite Aguilera (FCRB) Oscar García (HCB) María Mercedes Alonso (FCRB) Olga Gomez (HCB) Estefanía Callado (FCRB) Anna Gonce (HCB) Ester Cardet (FCRB) Original publications Jose Mª Martinez (HCB) Marta Dacal (FCRB) from 2016 to 2018 Montserrat Palacio (HCB) Luis Enrique Enciso (FCRB) Pedro Lorente (FCRB) YEAR I.F. TOTAL Q1 POST-DOCTORAL RESEARCHERS Q2 Paula Navarro (FCRB) 2016 149.32 44 33 5 Ángela Arranz (HCB-FCRB) Isil Tekeli (FCRB) Francesca Crovetto (CIBER) Nathalia Torrico (FCRB) 2017 182.64 51 28 18 Narcís Masoller (HCB) 2018 119.25 41 13 8 Mónica Zamora (FCRB)

TEAM INVOLVED IN CIBERER AGAUR_SGR17: 01531, 01734

AWARDS Premi extraordinari de doctorat per la tesi: “Development of combined screening test for the prediction of preeclampsia and intrauterine growth restriction in the ﬁrst trimester of pregnancy” Intitution: Universitat de Barcelona Awardee/s: Francesca Crovetto TEAM Eduard Gratacós

156 FETAL AND PERINATAL MEDICINE 3.2

NURSING STAFF impairment related to fetal growth Murillo-Bravo C, Coronado D, Gratacós E, Alba Camacho (FCRB) restriction and to develop new Deprest J, Palacio M. Quantitative analysis Nadia Rojas (FCRB) technological solutions for fetal surgery. of the cervical texture by ultrasound in the mid-pregnancy is associated with VISITING SCIENTISTS 6. Environment and pregnancy spontaneous preterm birth. Ayako Nakaki (National Hospital Organization complications. This research line studies ULTRASOUND IN OBSTETRICS AND Kyoto Medical Center) the effect of exposure to environmental GYNECOLOGY. 51(5):637-643. I.F.: 5.654 pollutants during pregnancy and evaluates their impact and drug abuse impact during 6. Caradeux J, Eixarch E, Mazarico E, Basuki pregnancy. TR, Gratacós E, Figueras F. Second to third STRATEGIC OBJECTIVES trimester longitudinal growth 7. Neonatal risk factors for impaired assessment for the prediction of SGA Our main objectives are to develop new neurodevelopment outcome. This line and late FGR. ULTRASOUND IN imaging and molecular tools for early focuses on epigenetic, toxic and OBSTETRICS AND GYNECOLOGY. diagnosis and prenatal disease monitoring, environmental risk factors for abnormal 51(2):219-224. I.F.: 5.654 to provide new clinical solutions and neurodevelopmental, nutritional and interventions for improving fetal growth, to metabolic outcome. 7. Guirado L, Crispi F, Masoller N, Bennasar M, develop and validate new technological Marimon E, Carretero J, Gratacós E, Martínez solutions for fetal surgery and to consolidate JM, Friedberg MK, Gómez O. Biventricular animal models to better characterise fetal impact of mild to moderate pulmonary programming. PUBLICATIONS valve stenosis in fetal life. ULTRASOUND IN OBSTETRICS AND GYNECOLOGY. Originals / I.F.: 119.253 51(3):349-356. I.F.: 5.654

MAIN LINES OF RESEARCH 1. Caradeux J, Eixarch E, Mazarico E, Basuki 8. Spencer R, Rossi C, Lees M, Peebles D, TR, Gratacos E, Figueras F . Longitudinal Brocklehurst P, Martin J, Hansson S, Hecher 1. Prematurity. This line focuses on patients growth assessment for the prediction of K, Marsal K, Figueras F, Gratacos E, David A. at risk of preterm labor, investigating adverse perinatal outcome in SGA- Achieving orphan designation for non-invasive diagnostic tools such as suspected fetuses. ULTRASOUND IN placental insufficiency: annual incidence quantitative ultrasound textures analysis OBSTETRICS AND GYNECOLOGY. estimations in Europe. BJOG: AN and biomarkers for intraamniotic 52(3):325-331. I.F.: 5.654 INTERNATIONAL JOURNAL OF inflammation and infection. OBSTETRICS AND GYNAECOLOGY. 2. Valenzuela-Alcaraz B, Cruz-Lemini M, I.F.: 4.876 2. Placental Disease. We aim to identify Rodríguez-López M, Goncé A, García-Otero suboptimal fetal growth before birth L, Ayuso H, Sitges M, Bijnens B, Balasch J, 9. Miranda J, Simões RV, Paules C, Cañueto providing new diagnosis tools for the Gratacós E, Crispi F. Fetal cardiac D, Pardo-Cea MA, García-Martín ML, correct classification of small babies at remodeling in twin pregnancies Crovetto F, Fuertes-Martin R, Domenech M, highest perinatal risk and optimal timing to conceived by assisted reproductive Gómez-Roig MD, Eixarch E, Estruch R, delivery. technologies. ULTRASOUND IN Hansson SR, Amigó N, Cañellas N, Crispi F, OBSTETRICS AND GYNECOLOGY. Gratacós E . Metabolic profiling and 3. Fetal Brain Development. We aim to 51(1):94-100. I.F.: 5.654 targeted lipidomics reveals a develop quantitative imaging biomarkers disturbed lipid profile in mothers and for early diagnosis of neurodevelopmental 3. Migliorelli F, Rueda C, Angeles MA, Baños fetuses with intrauterine growth disorders of prenatal origin based on N, Posadas DE, Gratacós E, Palacio M. restriction. SCIENTIFIC REPORTS. ultrasound and magnetic resonance. Cervical consistency index and risk of 8(1):13614. I.F.: 4.122 cesarean delivery after induction of 4. Fetal Programming. We focus on the labor at term. ULTRASOUND IN 10. Benkarim OM, Hahner N, Piella G, long-term impact of prenatal conditions OBSTETRICS AND GYNECOLOGY. Gratacos E, González Ballester MA, Eixarch E, such as fetal growth restriction, 53(6):798-803. I.F.: 5.654 Sanroma G. Cortical folding alterations in preeclampsia, assisted reproductive fetuses with isolated non-severe technologies, perinatal infections or 4. Baños N, Murillo-Bravo C, Julià C, Migliorelli ventriculomegaly. NEUROIMAGE: congenital heart disease, providing a F, Perez-Moreno A, Ríos J, Gratacós E, CLINICAL. 18:103-114. I.F.: 3.869 better phenotypic characterization and Valentin L, Palacio M. Mid-trimester testing preventive strategies for fetal sonographic Cervical Consistency Index 11. Guitart-Mampel M, Gonzalez-Tendero A, growth restriction. to predict spontaneous preterm birth in Niñerola S, Morén C, Catalán-Garcia M, a low-risk population. ULTRASOUND IN González-Casacuberta I, Juárez-Flores DL, 5. Fetal Therapy and Surgery. This OBSTETRICS AND GYNECOLOGY. Ugarteburu O, Matalonga L, Cascajo MV, Tort research line aims to characterize 51(5):629-636. I.F.: 5.654 F, Cortés A, Tobias E, Milisenda JC, Grau JM, neuroprotective therapies that could Crispi F, Gratacós E, Garrabou G, Cardellach mitigate the neurodevelopmental 5. Baños N, Perez-Moreno A, Julià C, F . Cardiac and placental mitochondrial

157 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

characterization in a rabbit model of segmentation. COMPUTERIZED MEDICAL Dysfunction and Damage in Term intrauterine growth restriction. BBA IMAGING AND GRAPHICS. 69:52-59. Growth-Restricted Fetuses Classified BIOCHIMICA ET BIOPHYSICA ACTA. I.F.: 2.435 by Severity Criteria. FETAL DIAGNOSIS 1862(5):1157-1167. I.F.: 3.679 AND THERAPY. 44(4):271-276. I.F.: 1.813 19. Kulkarni A, Garcia-Cañadilla P, Khan A, 12. Wald N, Bestwick J, Huttly W, Aldis J, Lorenzo JM, Beckerman K, Valenzuela- 27. Torres X., Bennasar M., Eixarch E., Rueda Borrell A, Goodburn S, Mills I. Prenatal Alcaraz B, Cruz-Lemini M, Gomez O, C., Goncé A., Muñoz M., Marimón E., Martínez screening for Down syndrome in twin Gratacos E, Crispi F, Bijnens B. Remodeling J., Gratacós E., Figueras F. Gender-Specific pregnancies: Estimates of screening of the cardiovascular circulation in Antenatal Growth Reference Charts in performance based on 61 affected and fetuses of mothers with diabetes: A fetal Monochorionic Twins. FETAL DIAGNOSIS 7302 unaffected twin pregnancies. computational model analysis. AND THERAPY. 44(3):202-209. I.F.: 1.813 PRENATAL DIAGNOSIS. 38(13):1079-1085. PLACENTA. 63:1-6. I.F.: 2.434 I.F.: 2.779 28. Cobo T, Palacio M, Grande M, 20. Miranda J., Paules C., Nair S., Lai A., Palma Sánchez-García AB, Estanyol JM, López M, 13. Hahner N, Puerto B, Perez-Cruz M, C., Scholz-Romero K., Rice G., Gratacos E., Bosch J, Martí C, Gratacós E. Cervical Policiano C, Monterde E, Crispi F, Gratacos E, Crispi F., Salomon C. Placental exosomes Alpha-Actinin-4 Is Upregulated in Eixarch E. Altered cortical development profile in maternal and fetal circulation in Women with Threatened Preterm Labor in fetuses with isolated non-severe intrauterine growth restriction - Liquid and Microbial Invasion of the Amniotic ventriculomegaly assessed by biopsies to monitoring fetal growth. Cavity. FETAL DIAGNOSIS AND THERAPY. neurosonography. PRENATAL PLACENTA. 64:34-43. I.F.: 2.434 44(1):36-43. I.F.: 1.813 DIAGNOSIS. 38(5):365-375. I.F.: 2.779 21. Sabra S., Malmqvist E., Almeida L., 29. Kacerovsky, Marian; Musilova, Ivana; 14. Cruz-Lemini M, Valenzuela-Alcaraz B, Gratacos E., Gomez Roig M. Differential Bestvina, Tomas; Stepan, Martin; Cobo, Granados-Montiel J, Martínez JM, Crispi F, correlations between maternal hair Teresa; Jacobsson, Bo. Preterm Prelabor Gratacós E, Cruz-Martínez R. levels of tobacco and alcohol with fetal Rupture of Membranes between 34 and Characterizing cardiac dysfunction in growth restriction clinical subtypes. 37 Weeks: A Point-of-Care Test of fetuses with left congenital ALCOHOL. 70:43-49. I.F.: 2.425 Vaginal Fluid Interleukin-6 diaphragmatic hernia. PRENATAL Concentrations for a Noninvasive DIAGNOSIS. 38(6):422-427. I.F.: 2.779 22. Gomez-Roig M., Marchei E., Sabra S., Detection of Intra-Amniotic Busardò F., Mastrobattista L., Pichini S., Inflammation. FETAL DIAGNOSIS AND 15. Kammoun M., Souche E., Brady P., Ding J., Gratacós E., Garcia-Algar O. Maternal hair THERAPY. 43(3):175-183. I.F.: 1.813 Cosemans N., Gratacos E., Devriendt K., testing to disclose self-misreporting in Eixarch E., Deprest J., Vermeesch J. drinking and smoking behavior during 30. Basuki TR, Triunfo S, Caradeux J, Eixarch Genetic profile of isolated congenital pregnancy. ALCOHOL. 67:1-6. I.F.: 2.425 E, Hansson S, Gratacos E, Figueras F. diaphragmatic hernia revealed by Third-Trimester Conditional Reference targeted next-generation sequencing. 23. Crispi F., Crovetto F., Gratacos E. Values for Longitudinal Fetal Growth PRENATAL DIAGNOSIS. 38(9):654-663. Intrauterine growth restriction and later Assessment. FETAL DIAGNOSIS AND I.F.: 2.779 cardiovascular function. EARLY HUMAN THERAPY. 43(1):34-39. I.F.: 1.813 DEVELOPMENT. 126:23-27. I.F.: 2.025 16. Gumus H., Illa M., Pla L., Zamora M., Crispi 31. Cobo T., Munrós J., Ríos J., Ferreri J., F., Gratacos E. Nutritional intra-amniotic 24. Blazquez A, García D, Vassena R, Migliorelli F., Baños N., Gratacós E., Palacio M. therapy increases survival in a rabbit Figueras F, Rodriguez A. Risk of Contribution of Amniotic Fluid along model of fetal growth restriction. PLOS preeclampsia in pregnancies resulting Gestation to the Prediction of Perinatal ONE. 13(2):e0193240. I.F.: 2.766 from double gamete donation and from Mortality in Women with Early Preterm oocyte donation alone. PREGNANCY Premature Rupture of Membranes. 17. Simoes, Rui V.; Cabanas, Miquel E.; HYPERTENSION. 13:133-137. I.F.: 2.011 FETAL DIAGNOSIS AND THERAPY. Loreiro, Carla; Illa, Miriam; Crispi, Fatima; 43(2):105-112. I.F.: 1.813 Gratacos, Eduard. Assessment of prenatal 25. Illa M., Brito V., Pla L., Eixarch E., cerebral and cardiac metabolic changes Arbat-Plana A., Batallé D., Muñoz-Moreno E., 32. Palacio M., Caradeux J., Sánchez M., in a rabbit model of fetal growth Crispi F., Udina E., Figueras F., Ginés S., Cobo T., Figueras F., Coll O., Gratacós E., restriction based on C-13-labelled Gratacós E. Early Environmental Cararach V. Uterine Cervical Length substrate infusions and ex vivo Enrichment Enhances Abnormal Brain Measurement to Reduce Length of Stay multinuclear HRMAS. PLOS ONE. Connectivity in a Rabbit Model of in Patients Admitted for Threatened 13(12):e0208784. I.F.: 2.766 Intrauterine Growth Restriction. FETAL Preterm Labor: A Randomized Trial. DIAGNOSIS AND THERAPY. 44(3):184-193. FETAL DIAGNOSIS AND THERAPY. 18. Sanroma G., Benkarim O., Piella G., I.F.: 1.813 43(3):184-190. I.F.: 1.813 Lekadir K., Hahner N., Eixarch E., González Ballester M. Learning to combine 26. Pérez-Cruz M; Crispi F; Fernandez M; 33. Caradeux J, Eixarch E, Mazarico E, complementary segmentation methods Parra J; Valls A; Gomez Roig M; Gratacos E. Basuki TR, Gratacós E, Figueras F. Second- for fetal and 6-month infant brain MRI Cord Blood Biomarkers of Cardiac to Third-Trimester Longitudinal Growth

158 FETAL AND PERINATAL MEDICINE 3.2

Assessment for the Prediction of annular displacement in fetal growth 5. Pauta M, Grande M, Rodriguez-Revenga Largeness for Gestational Age and restriction. THE JOURNAL OF L, Kolomietz E, Borrell A. Added value of Macrosomia in an Unselected MATERNAL-FETAL & NEONATAL Chromosomal Microarray Analysis Population. FETAL DIAGNOSIS AND MEDICINE. 31(14):1845-1850. I.F.: 1.493 (CMA) over karyotyping in Early THERAPY. 43(4):284-290. I.F.: 1.813 Pregnancy Loss - a Systematic Review 40. Nuruddin R., Urpi-Sarda M., and Meta-Analysis. ULTRASOUND IN 34. Ortiz J., Torres X., Eixarch E., Bennasar M., Rodriguez-Lopez M., Garcia-Arenas D., OBSTETRICS AND GYNECOLOGY. Cruz-Lemini M., Gómez O., Lobmaier S., Gratacos E., Crispi F., Acosta-Rojas R. 51(4):453-462. I.F.: 5.654 Martínez J., Gratacós E., Crispi F. Differential Macronutrient and ﬁbre intake of Changes in Myocardial Performance young Spanish children with reference 6. Sebastiani G, Borrás-Novell C, Casanova Index and Its Time Intervals in Donors to their in utero growth status: Are they M, Tutusaus M, Martínez S, Roig M, and Recipients of Twin-to-Twin eating a healthy diet? JOURNAL OF García-Algar O. The effects of alcohol and Transfusion Syndrome before and after PAEDIATRICS AND CHILD HEALTH. drugs of abuse on maternal nutritional Laser Therapy. FETAL DIAGNOSIS AND 54(5):563-571. I.F.: 1.449 proﬁle during pregnancy. NUTRIENTS. THERAPY. 44(4):305-310. I.F.: 1.813 10(8). I.F.: 4.196 41. Gumus HG, Illa M, Pla L, Gonzalez A, 35. Migliorelli F, Baños N, Angeles MA, Rueda Demicheva E, Ley D, Crispi F, Gratacos E. 7. Palma-Gudiel H., Cirera F., Crispi F., Eixarch C, Salazar L, Gratacós E, Palacio M. Clinical Ultrasound-Guided Intrauterine E., Fañanás L. The impact of prenatal and Sonographic Model to Predict Labeling of Rat Fetuses. insults on the human placental Cesarean Delivery after Induction of GYNECOLOGIC AND OBSTETRIC epigenome: A systematic review. Labor at Term. FETAL DIAGNOSIS AND INVESTIGATION. 83(2):116-123. I.F.: 1.183 NEUROTOXICOLOGY AND TERATOLOGY. THERAPY. 1-9. I.F.: 1.813 66:80-93. I.F.: 2.811

36. Blazquez, Anna; Garcia, Desiree; Review / I.F.: 17.204 8. Borrell A., Grande M., Pauta M., Vassena, Rita; Figueras, Francesc; Rodriguez, Rodriguez-Revenga L., Figueras F. Amelia. Risk of pre-eclampsia after fresh 1. Figueras F., Caradeux J., Crispi F., Eixarch Chromosomal Microarray Analysis in or frozen embryo transfer in patients E., Peguero A., Gratacos E. Diagnosis and Fetuses with Growth Restriction and undergoing oocyte donation. EUROPEAN surveillance of late-onset fetal growth Normal Karyotype: A Systematic Review JOURNAL OF OBSTETRICS, GYNECOLOGY restriction. AMERICAN JOURNAL OF and Meta-Analysis. FETAL DIAGNOSIS AND REPRODUCTIVE BIOLOGY. 227:27-31. OBSTETRICS AND GYNECOLOGY. AND THERAPY. 44(1):1-9. I.F.: 1.813 I.F.: 1.809 218(2):S790-S802. I.F.: 5.732

37. Musilova I; Andrys C; Holeckova M; 2. McCowan L, Figueras F, Anderson N. Letters / I.F.: 10.447 Kolarova V; Pliskova L; Drahosova M; Evidence-based national guidelines for Bolehovska R; Pilka R; Huml K; Cobo T; the management of suspected fetal 1. Kumar S, Figueras F, Ganzevoort W, Turner Jacobsson B; Kacerovsky M. growth restriction: comparison, J, McCowan L. Using cerebroplacental Interleukin-6 measured using the consensus, and controversy. ratio in non-SGA fetuses to predict automated electrochemiluminescence AMERICAN JOURNAL OF OBSTETRICS adverse perinatal outcome: Caution is immunoassay method for the AND GYNECOLOGY. 218(2):S855-S868. required. ULTRASOUND IN OBSTETRICS & identification of intra-amniotic I.F.: 5.732 GYNECOLOGY. 52(4):427-429. I.F.: 5.654 inflammation in preterm prelabor rupture of membranes. THE JOURNAL 3. Crispi F., Miranda J., Gratacós E. 2. Figueras F. Response to comment on OF MATERNAL-FETAL & NEONATAL Long-term cardiovascular “First Trimester screening for early and MEDICINE. 1-131. I.F.: 1.493 consequences of fetal growth late preeclampsia based on maternal restriction: biology, clinical implications, characteristics, biophysical parameters, 38. Hallingström M, Cobo T, Kacerovsky M, and opportunities for prevention of adult and angiogenic factors”. PRENATAL Skogstrand K, Hougaard D, Holst R, disease. AMERICAN JOURNAL OF DIAGNOSIS. 38(11):892-892. I.F.: 2.779 Tsiartas P, Bullarbo M, Carlsson Y, Nilsson OBSTETRICS AND GYNECOLOGY. S, Jacobsson B. The association 218(2):S869-S879. I.F.: 5.732 3. Borrell A., Grande M., Meler E., Sabrià J., between selected mid-trimester Mazarico E., Muñoz A., Rodriguez-Revenga L., amniotic fluid candidate proteins and 4. Caradeux J., Martinez-Portilla R., Basuki Badenas C., Figueras F. Genomic Microarray spontaneous preterm delivery. T., Kiserud T., Figueras F. Risk of fetal in Fetuses with Early Growth Restriction: JOURNAL OF MATERNAL-FETAL & death in growth-restricted fetuses A Multicenter Study. OBSTETRICAL AND NEONATAL MEDICINE. 10:1-10. I.F.: 1.493 with umbilical and/or ductus venosus GYNECOLOGICAL SURVEY. 73(2):73-74. absent or reversed end-diastolic I.F.: 2.014 39. Tanis JC, Mohammed N, Bennasar M, velocities before 34 weeks of Martinez JM, Bijnens B, Crispi F, Gratacos gestation: A systematic review and E. Online versus offline spatiotemporal meta-analysis. AMERICAN JOURNAL OF image correlation (STIC) M-mode for OBSTETRICS AND GYNECOLOGY. the evaluation of cardiac longitudinal 218(2):S774-S782. I.F.: 5.732

159 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

Editorial / I.F.: 5.654 Sponsored by: Instituto de Salud Carlos III (ISCIII). PI15/00130 (ISCIII). PI17/00675 Duration: 01/01/2016-31/12/2019 1. Borrell A. A new comprehensive Duration: 01/01/2018-31/12/2020 paradigm for prenatal diagnosis: seeing Gratacós E. Targeting endothelial the forest through the trees. Eixarch E. Desarrollo de herramientas dysfunction in highly prevalent diseases: ULTRASOUND IN OBSTETRICS AND predictivas para la identiﬁcación precoz characterization and validation of GYNECOLOGY. 52(5):563-568. I.F.: 5.654 de las alteraciones del neurodesarrollo prognostic biomarkers and de origen prenatal basadas en el estudio identiﬁcation of potential therapeutic del desarrollo cortical fetal. strategies. Clinical Guidelines / I.F.: 5.654 Sponsored by: Instituto de Salud Carlos III Sponsored by: Instituto de Salud Carlos III (ISCIII). PI16/00861 (ISCIII). PIE15/00027 1. Coelho Neto M, Ludwin A, Borrell A, Duration: 01/01/2017-31/12/2019 Duration: 01/01/2016-31/12/2019 Benacerraf B, Dewailly D, da Silva Costa F, Condous G, Alcazar J, Jokubkiene L, Figueras F. Papel del factor de Gratacós E. EVERREST - Does vascular Guerriero S, Van den Bosch T, Martins W. crecimineto placentario en el manejo de endothelial growth factor gene therapy Counting ovarian antral follicles by la preeclampsia no severa: estudio safely improve outcome in severe ultrasound: a practical guide. aleatorizado. Estudio MAP. early-onset fetal growth restriction? ULTRASOUND IN OBSTETRICS AND Sponsored by: Instituto de Salud Carlos III Sponsored by: European Commission. GYNECOLOGY. 51(1):10-20. I.F.: 5.654 (ISCIII). PI15/00903 FP7_Health_12 (305823) Duration: 01/01/2016-31/12/2019 Duration: 01/01/2013-31/12/2018

Garcia Algar O. Alteraciones epigenéticas Palacio M. Impacto de la detección y GRANTS FOR RESEARCH IN PROGRESS generadas por exposición prenatal al tratamiento precoz de las gestantes alcohol en pacientes con SAF (síndrome portadoras asintomáticas de vaginosis Borrell A. Pérdida gestacional precoz: alcohol fetal). Antioxidante bacteriana, en la tasa de parto causas genéticas y riesgo de epigalocatequina (EGCG) como pretérmino (VB-PREM): ensayo clínico recurrencia. herramienta terapéutica. multicéntrico. Sponsored by: Instituto de Salud Carlos III Sponsored by: Instituto de Salud Carlos III Sponsored by: Instituto de Salud Carlos III (ISCIII). PI14/00588 (ISCIII). PI16/00566 (ISCIII). PI17/00975 Duration: 01/01/2015-31/12/2018 Duration: 17/03/2017-31/12/2019 Duration: 01/01/2018-31/12/2020

Borrell A. Secuenciación del exoma Garcia Algar O. Red de Salud Paules C. Development of prenatal completo (SEC) en fetos con anomalías Materno-Infantil y del desarrollo. biomarkers for the prediction of fetales estructurales. Sponsored by: Instituto de Salud Carlos III neurological impairment at early stages Sponsored by: Instituto de Salud Carlos III (ISCIII). RD16/0022/0002 of life. (ISCIII). PI17/01153 Duration: 04/01/2017-31/12/2021 Sponsored by: Fundació Santiago Dexeus Duration: 01/01/2018-31/12/2020 Font 2017. Gomez del Rincón O. Evaluación Duration: 01/01/2018-31/12/2018 Cobo T. Validación de biomarcadores pronóstica de las cardiopatías proteómicos y metabolómicos de congénitas desde la etapa prenatal inﬂamación intraamniótica en el parto mediante ecocardiografía avanzada y prematuro en muestras biomarcadores plasmáticos. DOCTORAL THESES cervico-vaginales y desarrollo de Sponsored by: Instituto de Salud Carlos III algoritmos clínicos predictores. (ISCIII). PI15/00263 Crispi F, López M. Fetal cardiovascular Sponsored by: Instituto de Salud Carlos III Duration: 01/01/2016-31/12/2019 remodelling in HIV pregnancies. (ISCIII). PI15/00344 PhD student: Laura García Otero Duration: 01/01/2016-31/12/2019 Gratacós E. Grup de medicina Maternofetal i Reproductiva mixta Crispi F, Ley D. Intrauterine therapy for Crispi F. Impacto de la restricción de Hospital Clínic de Barcelona i Hospital fetal growth restriction. crecimiento intrauterino en la dinámica Sant Joan de Déu. PhD student: Hatice Gulcin Gumus del remodelado cardiovascular en las Sponsored by: Generalitat de Catalunya. diferentes etapas de la vida. AGAUR_SGR17_01531 Figueras F, Vassena R. Donation of Sponsored by: Instituto de Salud Carlos III Duration: 01/01/2017-31/12/2020 gametes and Risk of Preeclampsia. (ISCIII). PI14/00226 PhD student: Anna Blazquez Ventura Duration: 01/01/2015-31/12/2018 Gratacós E. Identiﬁcación de moduladores y dianas terapéuticas Figueras F. Longitudinal assessment for Crispi F. Impacto de las técnicas de en el remodelado y enfermedad the prediction of abnormal fetal growth. reproducción asistida en la cardiovascular del adulto asociada a PhD student: Javier Caradeux Bull programación cardiovascular fetal, retraso de crecimiento intrauterino. resultado perinatal y epigenética fetal. Sponsored by: Instituto de Salud Carlos III

160 FETAL AND PERINATAL MEDICINE 3.2

Gratacós E, Figueras F. Longitudinal Study of Fetal Growth in Low-Risk Population. PhD student: Tri Rahmat Basuki

Gratacós E, Crispi F. Phenomapping of fetal growth restriction. PhD student: Jezid Enrique Miranda Quintero

Gratacós E, Gómez MD. Maternal Heavy Metals and Toxins Exposure and their inﬂuences on Fetal Growth Restriction Clinical Subtypes. PhD student: Sally Sabra

161 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

Viral, toxic and 3.3 metabolic hepatopathies

NURSING STAFF Concepció Bartres (HCB) LOCATION Anna Miralpeix (FCRB-IDIBAPS) CEK building, ﬂoor 4

STRATEGIC OBJECTIVES

- Inﬂuence of virological and immunological KEYWORDS factors on the natural history and treatment 1. Hepatitis C virus response in chronic hepatitis B. TEAM LEADER - 2. Direct-acting antivirals (DAA) Xavier Forns (HCB) Strategies of hepatitis C microelimination in 3. Hepatitis B virus our geographical area. T. 93 227 54 99 - 4. Antiviral immune responses Evaluation of the impact of HCV [email protected] eradication on clinical follow-up. 5. Wilson’s disease - 6. DILI Clinical and biological characterization of patients with Wilson’s disease. RESEARCHERS Josep Costa (HCB) Sabela Lens (HCB) Maria Carlota Londoño (HCB) MAIN LINES OF RESEARCH Zoe Mariño (HCB) Original publications Sofía Pérez del Pulgar (CIBER) - Characterization of virological biomarkers from 2016 to 2018 in the natural history of chronic HBV POST-DOCTORAL RESEARCHERS YEAR I.F. TOTAL Q1 Q2 infection. Georgios Koutsoudakis (FCRB) - Molecular mechanisms and clinical 2016 135.49 22 18 2 signiﬁcance of cccDNA persistence in HBV 2017 175.86 25 20 3 PRE-DOCTORAL RESEARCHERS infection.

2018 182.38 19 16 1 Mireia Garcia-López (IDIBAPS) - Inﬂuence of viral and host factors in the Elena Perpiñán (CIBER) natural history and response to treatment in Sergio Rodríguez-Tajes (HCB) chronic hepatitis B. - Microelimination of HCV infection in TECHNICIANS persons who inject drugs.

TEAM INVOLVED IN Patricia González (CIBER) - Neurocognitive and cerebral connectivity CIBEREHD Thais Leonel (FCRB) changes in HCV patients after viral AGAUR_SGR17: 01753 eradication. TEAM Xavier Forns

162 VIRAL, TOXIC AND METABOLIC HEPATOPATHIES 3.3

- Incidence of hepatic and extrahepatic Weeks in Genotype 1-4 HCV-Infected neuroimaging in hepatitis C chronic cancer and tumoral characterization after Liver Transplant Recipients. JOURNAL infection. ALIMENTARY PHARMACOLOGY HCV cure. OF HEPATOLOGY. 69(3):603-607. I.F.: 15.040 AND THERAPEUTICS. 47(9):1238-1252. - Long term impact of HCV eradication on I.F.: 7.357 portal and systemic pressures in cirrhotic 5. Londoño M., Souza L., Lozano J., Miquel R., patients. Abraldes J., Llovet L., Quaglia A., Rimola A., 11. Manzardo C, Londoño MC, Castells L, - Study of immune responses against Navasa M., Sánchez-Fueyo A. Molecular Testillano M, Luis Montero J, Peñafiel J, hepatitis C after viral eradication, as a profiling of subclinical inflammatory Subirana M, Moreno A, Aguilera V, Luisa vaccine development strategy. lesions in long-term surviving adult liver González-Diéguez M, Calvo-Pulido J, Xiol X, - Interplay between HBV, HDV and host transplant recipients. JOURNAL OF Salcedo M, Cuervas-Mons V, Manuel Sousa J, factors: impact on liver disease HEPATOLOGY. 69(3):626-634. I.F.: 15.040 Suarez F, Serrano T, Ignacio Herrero J, progression. Jiménez M, Fernandez JR, Giménez C, Del - Clinical and functional characterization of a 6. Ampuero J., Jimeno C., Quiles R., Rosales J., Campo S, Esteban-Mur JI, Crespo G, de la cohort of patients with Wilson’s disease. Llerena S., Palomo N., Cordero P., Serrano F., Rosa G, Rimola A, Miro JM,and the FIPSE - Development of a Wilson’s disease Urquijo J., Moreno-Planas J., Ontanilla G., LT-HIV investigators. Direct-acting database in Catalonia. Hernández M., Ortega-Alonso A., Maraver M., antivirals are effective and safe in Bonacci M., Rojas Á., Figueruela B., Forns X., HCV/HIV-coinfected liver transplant Andrade R., Calleja J., Diago M., Carmona I., de recipients who experience recurrence of la Mata M., Buti M., Crespo J., Pascasio J., hepatitis C: A prospective nationwide Navarro J., Salmerón J., Romero-Gómez M. cohort study. AMERICAN JOURNAL OF PUBLICATIONS Impact of comorbidities on patient TRANSPLANTATION. 18(10):2513-2522. outcomes after interferon-free I.F.: 6.493 Originals / I.F.: 182.379 therapy-induced viral eradication in hepatitis C. JOURNAL OF HEPATOLOGY. 12. Mingorance L, Castro V, Ávila-Pérez G, 1. Bonacci M, Lens S, Mariño Z, Londoño MC, 68(5):940-948. I.F.: 15.040 Calvo G, Rodriguez MJ, Carrascosa JL, Rodriguez-Tajes S, Sánchez-Tapias JM, Pérez-Del-Pulgar S, Forns X, Gastaminza P . Ramos-Casals M, Hernández-Rodríguez J, 7. Reau N, Kwo PY, Rhee S, Brown RS, Host phosphatidic acid phosphatase Forns X . Long-Term Outcomes of Agarwal K, Angus P, Gane E, Kao JH, Mantry lipin1 is rate limiting for functional Patients With HCV-Associated PS, Mutimer D, Reddy KR, Tran TT, Hu YB, hepatitis C virus replicase complex Cryoglobulinemic Vasculitis After Gulati A, Krishnan P, Dumas EO, Porcalla A, formation. PLOS PATHOGENS. Virologic Cure. GASTROENTEROLOGY. Shulman NS, Liu W, Samanta S, Trinh R, Forns 14(9):e1007284. I.F.: 6.158 155(2):311-315. I.F.: 20.773 X . Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With 13. Nicolás D, Ambrosioni J, de Lazzari E, 2. Esteban R, Pineda JA, Calleja JL, Casado M, Hepatitis C Virus Infection. Suarez A, Manzardo C, Agüero F, Mosquera Rodríguez M, Turnes J, Morano Amado LE, HEPATOLOGY. 68(4):1298-1307. I.F.: 14.079 MM, Costa J, Ligero C, Marcos MÁ, Morillas RM, Forns X, Pascasio Acevedo JM, Sánchez-Palomino S, Fernández E, Plana M, Andrade RJ, Rivero A, Carrión JA, Lens S, 8. Mauro E, Crespo G, Montironi C, Londoño Yerly S, Gatell JM, Miró JM, Hospital Clinic Riveiro-Barciela M, McNabb B, Zhang G, MC, Hernández-Gea V, Ruiz P, Sastre L, Acute/Recent HIV Study Group. Camus G, Stamm LM, Brainard DM, Lombardo J, Mariño Z, Díaz A, Colmenero J, Epidemiological changes of Subramanian GM, Buti M . Efficacy of Rimola A, Garcia-Pagán JC, Brunet M, Forns acute/recent HIV-1 infection in Sofosbuvir and Velpatasvir, With and X, Navasa M. Portal pressure and liver Barcelona, Spain (1997-2015): A Without Ribavirin, in Patients With HCV stiffness measurements in the prediction prospective cohort study. CLINICAL genotype 3 Infection and Cirrhosis. of fibrosis regression after SVR in MICROBIOLOGY AND INFECTION. GASTROENTEROLOGY. 155(4):1120-1127. recurrent hepatitis C. HEPATOLOGY. 25(7):878-884. I.F.: 5.394 I.F.: 20.773 67(5):1683-1694. I.F.: 14.079 14. Lens S, García-Eliz M, Fernández I, 3. Crespo G., Trota N., Londoño M., Mauro E., 9. Bonacci M, Lens S, Mariño Z, Londoño MC, Castells L, Bonacci M, Mas A, Crespo G, Buti Baliellas C., Castells L., Castellote J., Tort J., Rodríguez-Tajes S, Mas A, García-López M, M, Prieto M, Forns X . Shorter HBIG Forns X., Navasa M. The efficacy of direct Pérez-Del-Pulgar S, Sánchez-Tapias JM, administration is not associated to HBV anti-HCV drugs improves early post-liver Forns X. Anti-viral therapy can be delayed recurrence when receiving combined transplant survival and induces or avoided in a significant proportion of prophylaxis after liver transplantation. significant changes in waiting list HBeAg-negative Caucasian patients in LIVER INTERNATIONAL. 38(11):1940-1950. composition. JOURNAL OF HEPATOLOGY. the Grey Zone. ALIMENTARY I.F.: 4.500 69(1):11-17. I.F.: 15.040 PHARMACOLOGY AND THERAPEUTICS. 47(10):1397-1408. I.F.: 7.357 15. Rodríguez-Tajes S, Perpiñán E, Caballol B, 4. Agarwal K, Castells L, Müllhaupt B, Lens S, Mariño Z, Costa J, Vilella A, Rosenberg WMC, McNabb B, Arterburn S, 10. Oriolo G, Egmond E, Mariño Z, Cavero M, Pérez-Del-Pulgar S, Forns X, Koutsoudakis G. Camus G, McNally J, Stamm LM, Brainard DM, Navines R, Zamarrenho L, Solà R, Pujol J, Hepatitis A outbreak in Barcelona among Mani Subramanian G, Mariño Z, Dufour JF, Bargallo N, Forns X, Martin-Santos R . men who have sex with men (MSM), Forns X . Sofosbuvir/Velpatasvir for 12 Systematic review with meta-analysis: January-June 2017: A hospital

163 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

perspective. LIVER INTERNATIONAL. treatment of hepatitis C virus infection in and VI nerve paralysis. LIVER 38(4):588-593. I.F.: 4.500 chronic kidney disease: a position INTERNATIONAL. 38(9):1696-1697. I.F.: 4.500 statement by the Spanish association of 16. Perpiñán E, Caro-Pérez N, the liver and the kidney. JOURNAL OF 2. Carpio, Adria; Merino, Anna; García-González N, Gregori J, González P, NEPHROLOGY. 31(1):1-13. I.F.: 2.724 Rodriguez-Tajes, Sergio; Reverter, Enric; Bartres C, Soria ME, Perales C, Lens S, Mariño Bruguera, Miquel; Forns, Xavier; Fernandez, Z, Londoño MC, Ariza X, Koutsoudakis G, Javier. Massive hemolysis complicating Quer J, González-Candelas F, Forns X, Letters / I.F.: 62.305 acute granulomatous hepatitis. ANNALS Pérez-Del-Pulgar S . Hepatitis C virus early OF HEMATOLOGY. 97(9):1741-1742. I.F.: 2.845 kinetics and resistance-associated 1. Lens S., Forns X., García-Pagán J. Reply. substitution dynamics during antiviral GASTROENTEROLOGY. 154(5):1551-1552. therapy with direct-acting antivirals. I.F.: 20.773 Clinical Guidelines / I.F.: 1.078 JOURNAL OF VIRAL HEPATITIS. 25(12):1515-1525. I.F.: 4.237 2. Londoño M., Forns X., Pascasio J. Reply to: 1. Calleja, Jose L.; Macias, Juan; Forns, Xavier; Extended DAA indications for hepatitis C Garcia, Federico; Berenguer, Marina; Garcia 17. González-Colominas E., Londoño M., patients awaiting liver transplantation Deltoro, Miguel; Buti, Maria; Granados, Rafael; Morillas R., Torras X., Mojal S., Lens S., López and further statistical considerations. Carrion, Jose A.; Morano, Luis; Fernandez, D., Gallego A., Mariño Z., Ardèvol M., Pagès N., JOURNAL OF HEPATOLOGY. 68(3):627-628. Inmaculada; Coste, Pablo; Pineda, Juan A. Solà R., Carrión J. Potential drug-drug I.F.: 15.040 Guidelines on treatment of hepatitis C interactions of OMBITASVIR, virus infection. Spanish Association for PARITAPREVIR/ritonavir ± DASABUVIR 3. Forns X, Sarrazin C . Treatment of the Study of the Liver (AEEH). ± ribavirin in clinical practice. JOURNAL chronic hepatitis C. JOURNAL OF GASTROENTEROLOGIA Y HEPATOLOGIA. OF GASTROENTEROLOGY AND HEPATOLOGY. 69(2):544-546. I.F.: 15.040 41(9):597-608. I.F.: 1.078 HEPATOLOGY. 33(5):1100-1107. I.F.: 3.483 4. Gratacós-Ginès J, Jung G, Díaz A, Forns X . 18. Bodro M, Londoño MC, Esforzado N, An uncommon presentation of alcoholic Sanclemente G, Linares L, Solano MF, Cofan liver disease. LIVER INTERNATIONAL. GRANTS FOR RESEARCH IN PROGRESS F, Marcos MA, Diekmann F, Moreno A . 38(8):1514-1514. I.F.: 4.500 Hepatitis C viremia as a risk factor for Forns X. Hepatopaties víriques, tòxiques opportunistic infections in kidney 5. Mauro E, Crespo G, Montironi C, Londoño i metabòliques. transplant recipients. CLINICAL MC, Díaz A, Forns X, Navasa M . Viral Sponsored by: Generalitat de Catalunya. TRANSPLANTATION. 32(10):e13382. I.F.: 1.518 eradication and fibrosis resolution in AGAUR_SGR17_01753 post liver transplant cholestatic hepatitis Duration: 01/01/2017-31/12/2020 19. Kerbert AJC, Reverter E, Verbruggen L, C. LIVER TRANSPLANTATION. Tieleman M, Navasa M, Mertens BJA, 24(5):703-707. I.F.: 3.756 Forns X. Estudio de los factores Rodríguez-Tajes S, de Vree M, Metselaar HJ, virológicos e inmunológicos Chiang FWT, Verspaget HW, van Hoek B, 6. Gelpi R, Rodríguez-Villar C, Paredes D, relacionados con la recurrencia de la Bosch J, Coenraad MJ. Impact of hepatic Roque R, Ruiz A, Adalia R, de Sousa E, infección por los virus de la hepatitis C encephalopathy on liver transplant Revuelta I, Sole M, Martinez M, Navarro M, y B tras la interrupción del tratamiento waiting list mortality in regions with Lens S, Oppenheimer F, Diekmann F . Safety antiviral. different transplantation rates. CLINICAL of Hepatitis C Virus (HCV) treated donors Sponsored by: Instituto de Salud Carlos III TRANSPLANTATION. 32(11):e13412. I.F.: 1.518 for kidney transplantation (KT) (ISCIII). PI15/00151 excluding occult HCV infection through Duration: 01/01/2016-31/12/2018 kidney biopsies. TRANSPLANT Review / I.F.: 7.224 INTERNATIONAL. 31(8):938-939. I.F.: 3.196 Forns X. Virological and immunological factors associated with hepatitis C and 1. Fernández-Carrillo C., Pérez-Vilaró G., Díez hepatitis B virus infection recurrence J., Pérez-del-Pulgar S. Hepatitis C virus Editorial / I.F.: 7.357 after treatment discontinuation. plays with fire and yet avoids getting Sponsored by: Gilead Sciences. burned. A review for clinicians on 1. Bonacci M., Lens S. Editorial: STAT-4 GLD15/00274 processing bodies and stress granules. polymorphism - a tool to personalise Duration: 07/03/2016-31/12/2018 LIVER INTERNATIONAL. 38(3):388-398. clinical practice in chronic HBV infection. I.F.: 4.500 ALIMENTARY PHARMACOLOGY AND Londoño MC. Identificación de THERAPEUTICS. 48(7):768-769. I.F.: 7.357 biomarcadores para predecir el éxito 2. Aoufi-Rabih S, García-Agudo R, Londoño de la retirada de la inmunosupresión en MC, Fraga-Fuentes MD, Barril-Cuadrado G, pacientes con hepatitis autoinmune. On behalf on the Spanish Association of the Case Reports / I.F.: 7.345 Sponsored by: Instituto de Salud Carlos III Liver and the Kidney (AEHR) On behalf on the (ISCIII). PI17/00955 Spanish Association of the Liver and the 1. Jung G., Olivas P., Díaz A., Lens S. Hepatitis Duration: 01/01/2018-31/12/2020 Kidney (AEHR). Recommendations for the E-induced acute-on-chronic liver failure

164 VIRAL, TOXIC AND METABOLIC HEPATOPATHIES 3.3

Mariño Z. Brain metabolic and functional connectivity dysfunction in patients with chronic hepatitis C and reversibility after viral eradication with direct acting antivirals. Sponsored by: Gilead Sciences. GLD17/00273 Duration: 18/01/2018-31/12/2018

Pérez del Pulgar S. Estudio de la persistencia del cccDNA durante la infección por el VHB in vivo, e in vitro mediante un bioreactor que simula el microambiente hepático. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI16/00111 Duration: 01/01/2017-31/12/2019

DOCTORAL THESES

Forns X, Lens S. Historia natural de la infección crónica por el VHB en Portadores Inactivos y Pacientes en Zona Gris e Impacto Virológico, Inmunológico y Clínico del Tratamiento con Antivirales de Acción Directa sobre la Vasculitis Crioglobulinémica asociada al VHC. PhD student: Martin Sebastian Bonacci

165 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

Mechanisms of liver disease 3.4 and complications of cirrhosis

Marina Parra-Robert (HCB) Meritxell Perramón (IDIBAPS) LOCATION Irene Portolés (IDIBAPS) CEK building, ﬂoor 3 Jose Alcaraz (HCB) Mireia Casulleras (FCRB) Marta Duran (FCRB) Roger Flores (FCRB) Beatriz Aguilar (IDIBAPS) Silvia Ariño (IDIBAPS) KEYWORDS Delia Blaya (IDIBAPS) 1. Cirrhosis TEAM LEADER Luis Perea (IDIBAPS) 2. Non-alcoholic steatohepatitis Pere Ginès (HCB) Julia Vallverdu (IDIBAPS) 3. Liver stem cells T. 93 227 17 13 4. Kidney failure [email protected] TECHNICIANS 5. Chronic liver diseases Montserrat Bernat (HCB) 6. Alcoholic liver disease Carmen Cano (HCB) Cristina Diez (HCB) GROUP LEADERS Ana Isabel Martinez (FCRB) Joan Clària (HCB) Mònica Romo (IDIBAPS) T. 93 227 54 00 (Ext.: 4784) Albert Salvatella (FCRB) [email protected] Sílvia Sanz (FCRB) Pau Bosch (IDIBAPS) Original publications Pere Ginès (HCB) Ana Teresa Rubio (IDIBAPS) from 2016 to 2018 T. 93 227 17 13 [email protected] ADMINISTRATIVE STAFF YEAR I.F. TOTAL Q1 Q2 Rosario Poblet (IDIBAPS) 2016 182.19 25 21 2 Wladimiro Jiménez (HCB) Nicki Van Berckel (HCB-FCRB) 2017 140.22 23 17 2 T. 93 227 54 00 (Ext.: 2199) NURSING STAFF 2018 196.66 23 18 3 [email protected] Marta Carol (IDIBAPS) Pau Sancho-Bru (IDIBAPS) Marta Cervera (HCB) T. 93 227 54 00 (Ext.: 3371) Gloria de Prada (HCB) [email protected]

TEAM INVOLVED IN COLLABORATORS CIBEREHD Enric Reverter (HCB) AGAUR_SGR17: 01449, 01281, EMERITUS Bernardino González (HCB) 00858, 01456 Vicente Arroyo (HCB) Silvia Sandalinas (HCP) Esther Titos (HCB) RESEARCHERS Núria Fabrellas (UB) Javier Fernández-Gómez (HCB) Isabel Graupera (HCB) STRATEGIC OBJECTIVES Elsa Solà (HCB) Gregori Casals (HCB) To investigate new therapeutic and diagnostic Guillermo Fernández-Varo (CIBER) strategies in the most common complications Manuel Morales-Ruiz (HCB) present in chronic liver diseases. The basic and translational studies investigate POST-DOCTORAL RESEARCHERS the mechanisms implicated in disease Martin Bonacci (IDIBAPS-FCRB) progression of chronic liver diseases as well as Pedro Melgar-Lesmes (IDIBAPS) the role of progenitor cells in liver regeneration Jordi Ribera (CIBER) and tissue repair. Cristina Lopez (FCRB) To assess the role of bioactive lipid mediators Maria del Mar Coll (CIBER) on the onset and resolution of systemic and tissue inﬂammatory responses in chronic liver PRE-DOCTORAL RESEARCHERS disease. Laura Napoleone (IDIBAPS) Elisa Pose (IDIBAPS) Cristina Sole (HCB) Silvia Carvajal (FCRB) Bernat Córdoba (IDIBAPS)

166 MECHANISMS OF LIVER DISEASE AND COMPLICATIONS OF CIRRHOSIS 3.4

MAIN LINES OF RESEARCH systemic inflammation. Our research is on chronic liver diseases The ultimate goal of our group is to translate (CLD) and progression to advance disease 1. To explore new therapeutic targets the in vitro and in vivo findings into novel via bench to beside studies. useful in the treatment of endothelial therapeutic approaches to fight persistent 1. End-stage CLD: Role of urine biomarkers dysfunction, vascular remodeling, inflammation in chronic liver disease. in diagnosis and treatment of renal hepatic fibrosis and the characteristic dysfunction in cirrhosis. Inflammatory hemodynamic disturbances of chronic biomarkers and disease progression. liver diseases. RESEARCH GROUP Intestinal microbiome in patients with 2. To search for molecular strategies to CHRONIC LIVER DISEASES: different stages of liver cirrhosis, particularly stimulate a functional liver regeneration. MOLECULAR MECHANISMS AND in ACLF. Efficacy and safety of rifaximin and 3. To identify novel serum biomarkers of liver CLINICAL CONSEQUENCES simvastatin as a treatment for prevention of disease progression and complications of ACLF. Analysis of liver transcriptome at cirrhosis. varying stages of disease to assess molecular 4. To investigate molecular pathways of networks relevant to disease progression. acute-on-chronic liver failure development 2. Role of systemic inflammation in (ACLF) and identify new biomarkers of progression of end-stage CLD. ACLF. 3. Screening of CLD: Referral pathways 5. To investigate the role of liver cell plasticity from general population to specialist. and progenitor cells in liver disease. GROUP LEADER 4. Non alcoholic liver disease: Role of 6. Mechanisms of liver inflammation, with Pere Ginès (HCB) adipose tissue in NAFLD development and particular emphasis on the role of lipid progression. mediators generated from both omega-6 and omega-3 polyunsaturated fatty acids. 7. Mechanisms of resolution of inflammation in adipose tissue and its relationship with obesity-associated complications, particularly non-alcoholic steatohepatitis. 8. To study the role of systemic inflammation in Acute-on-Chronic Liver Failure. 9. To explore the potential of iPSC-derived liver cells for disease modeling.

RESEARCH GROUP INFLAMMATION AND LIVER DISEASE GROUP Pere Ginès

GROUP LEADER Joan Clària (HCB)

Our group is interested in the study of the molecular mechanisms underlying the inﬂammatory process commonly observed in patients with chronic liver disease. Our main priorities are:

1. To discern the mechanisms that trigger the activation of innate immunity; 2. To profile the inflammatory lipid mediators, especially the so-called pro-resolving lipid mediators, which have the ability to promote resolution without inducing immunosuppression; 3. To characterize genetic modifiers of GROUP Joan Clària

167 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

RESEARCH GROUP TRANSLATIONAL RESEARCH GROUP IN NEW THERAPEUTIC AND DIAGNOSTIC STRATEGIES IN LIVER DISEASES

GROUP LEADER Wladimiro Jiménez (HCB)

Our group have an extensive research experience on the pathophysiological and molecular bases of the most common complications present in patients with chronic liver disease. The projects have a profound translational character, with special interest in

identifying new therapeutic tools to stop or GROUP Wladimiro Jiménez reverse the progression of the ﬁbroproliferative events. We also intend that the knowledge generated in these studies result in substantial improvements in the biochemical diagnosis of patients, which also constitutes a substantial part of our activity. This would represent an improvement from the point of view of comfort, diagnosis, monitoring and treatment of patients with liver disease.

RESEARCH GROUP PLASTICITAT I REPARACIÓ TISSULAR EN MALALTIES HEPÀTIQUES GROUP LEADER GROUP Pau Sánchez-Bru GROUP LEADER Pau Sancho-Bru (IDIBAPS)

Liver regeneration and tissue repair are exploring the potential of iPSC-derived liver Blaya D., Rodrigo-Torres D., Graupera I., complex and well-orchestrated processes cells for the generation of multicellular in vitro Aguilar-Bravo B., Chesne C., Najimi M., Sokal that become deregulated in chronic liver models of liver disease. E., Lozano J., van Grunsven L., Verfaillie C., disease. By using human samples, animal Sancho-Bru P. Generation of Hepatic models as well as primary and stem cell-based Stellate Cells from Human Pluripotent in vitro approaches we aim at identifying those Stem Cells Enables In Vitro Modeling of factors leading to deﬁcient liver regeneration PUBLICATIONS Liver Fibrosis. CELL STEM CELL. and tissue repair and to develop means to 23(1):101-113. I.F.: 23.290 enhance liver function in chronic liver disease. Originals / I.F.: 196.662 Our group is particularly interested in 2. Fernández J., Acevedo J., Wiest R., Gustot understanding cell plasticity and inﬂammatory 1. Coll M., Perea L., Boon R., Leite S., Vallverdú T., Amoros A., Deulofeu C., Reverter E., responses in chronic liver injury, as well as J., Mannaerts I., Smout A., El Taghdouini A., Martínez J., Saliba F., Jalan R., Welzel T., Pavesi

168 MECHANISMS OF LIVER DISEASE AND COMPLICATIONS OF CIRRHOSIS 3.4

M., Hernández-Tejero M., Ginès P., Arroyo V. Targeted Macrophage Overexpression Currie M., Masferrer J., Clària J. The soluble Bacterial and fungal infections in of Metalloproteinase 9 and Hepatic guanylate cyclase stimulator IW-1973 acute-on-chronic liver failure: Fibrosis Precision Therapy. NANO prevents inflammation and fibrosis in Prevalence, characteristics and impact LETTERS. 18(9):5839-5845. I.F.: 12.080 experimental non-alcoholic on prognosis. GUT. 67(10):1870-1880. steatohepatitis. BRITISH JOURNAL OF I.F.: 17.016 9. Caballería L, Pera G, Arteaga I, Rodríguez L, PHARMACOLOGY. 175(6):953-967. I.F.: 6.810 Alumà A, Morillas RM, de la Ossa N, Díaz A, 3. Solà E, Solé C, Simón-Talero M, Expósito C, Miranda D, Sánchez C, Prats RM, 14. Carracedo M, Artiach G, Witasp A, Clària J, Martín-Llahí M, Castellote J, Garcia-Martínez Urquizu M, Salgado A, Alemany M, Martinez A, Carlström M, Laguna-Fernandez A, Stenvinkel R, Moreira R, Torrens M, Márquez F, Fabrellas Majeed I, Fabrellas N, Graupera I, Planas R, P, Bäck M. The G-protein coupled N, de Prada G, Huelin P, Lopez Benaiges E, Ojanguren I, Serra M, Torán P, Caballería J, receptor ChemR23 determines smooth Ventura M, Manríquez M, Nazar A, Ariza X, Ginès P . High Prevalence of Liver Fibrosis muscle cell phenotypic switching to Suñé P, Graupera I, Pose E, Colmenero J, Among European Adults with Unknown enhance high phosphate-induced Pavesi M, Guevara M, Navasa M, Xiol X, Liver Disease. A Population-Based vascular calcification. CARDIOVASCULAR Córdoba J, Vargas V, Ginès P . Midodrine Study. CLINICAL GASTROENTEROLOGY RESEARCH. I.F.: 6.290 &albumin for preventing complications AND HEPATOLOGY. 16(7):1138-1145. in patients with cirrhosis awaiting liver I.F.: 7.683 15. Melgar-Lesmes, Pedro; Sanchez-Herrero, transplantation. JOURNAL OF Alvaro; Lozano-Juan, Ferran; de la Torre HEPATOLOGY. 69(6):1250-1259. I.F.: 15.040 10. Piano S, Schmidt HH, Ariza X, Amoros A, Hernandez, Jose Maria; Montell, Eulalia; Romano A, Hüsing-Kabar A, Solà E, Gerbes A, Jimenez, Wladimiro; Edelman, Elazer R.; 4. Blasi A, Calvo A, Prado V, Reverter E, Bernardi M, Alessandria C, Scheiner B, Tonon Balcells, Mercedes. Chondroitin Sulphate Reverter JC, Hernández-Tejero M, Aziz F, M, Maschmeier M, Solè C, Trebicka J, Gustot Attenuates Atherosclerosis in ApoE Amoros A, Cardenas A, Fernández J. T, Nevens F, Arroyo V, Gines P, Angeli P, EASL Knockout Mice Involving Cellular Coagulation failure in patients with CLIF Consortium, European Foundation for Regulation of the Inflammatory Acute-on-Chronic Liver Failure (ACLF) the Study of Chronic Liver Failure (EF Clif). Response. THROMBOSIS AND and decompensated cirrhosis: beyond Association Between Grade of Acute on HAEMOSTASIS. 118(7):1329-1339. I.F.: 4.952 INR. HEPATOLOGY. 68(6):2325-2337. Chronic Liver Failure and Response to I.F.: 14.079 Terlipressin and Albumin in Patients 16. Artiach G., Carracedo M., Clària J., With Hepatorenal Syndrome. CLINICAL Laguna-Fernandez A., Bäck M. Opposing 5. Alcaraz-Quiles J., Casulleras M., Oettl K., GASTROENTEROLOGY AND effects on vascular smooth muscle cell Titos E., Flores-Costa R., Duran-Güell M., HEPATOLOGY. 16(11):1792-1800. I.F.: 7.683 proliferation and macrophage -induced López-Vicario C., Pavesi M., Stauber R., Arroyo inflammation reveal a protective role for V., Clària J. Oxidized Albumin Triggers a 11. Medina-Caliz I, Garcia-Cortes M, the proresolving lipid mediator receptor Cytokine Storm in Leukocytes Through Gonzalez-Jimenez A, Cabello MR, ChemR23 in intimal hyperplasia. P38 Mitogen-Activated Protein Kinase: Robles-Diaz M, Sanabria-Cabrera J, FRONTIERS IN PHARMACOLOGY. 9:1327. Role in Systemic Inflammation in Sanjuan-Jimenez R, Ortega-Alonso A, I.F.: 3.831 Decompensated Cirrhosis. García-Muñoz B, Moreno I, Jimenez-Perez M, HEPATOLOGY. 68(5):1937-1952. I.F.: 14.079 Fernandez MC, Ginés P, Prieto M, Conde I, 17. Llovet JM, Pavel M, Rimola J, Diaz MA, Hallal H, Soriano G, Roman E, Castiella A, Colmenero J, Saavedra-Perez D, Fondevila C, 6. Delia Blaya; Beatriz Aguilar-Bravo; Fengie Blanco-Reina E, Montes MR, Quiros-Cano M, Ayuso C, Fuster J, Ginès P, Bruix J, Garcia- Hao; Silvia Casacuberta-Serra; Mar Coll; Luis Martin-Reyes F, Lucena MI, Andrade RJ, Valdecasas JC . Pilot study of living donor Perea; Julia Vallverdu; Isabel Graupera; Elisa Spanish DILI Registry. Herbal and Dietary liver transplantation for patients with Pose; Barquinero Mañez, Jordi; Francisco Supplement-Induced Liver Injuries in the HCC exceeding Milan criteria (BCLC Javier Cubero; Juan Caballería; Pere Ginès; Spanish DILI Registry. CLINICAL extended criteria). LIVER Pau Sancho-Bru. Expression of GASTROENTEROLOGY AND TRANSPLANTATION. 24(3):369-379. microRNA-155 in inflammatory cells HEPATOLOGY. 16(9):1495-1502. I.F.: 7.683 I.F.: 3.756 modulates liver injury. HEPATOLOGY. 68(2):691-706. I.F.: 14.079 12. Bonacci M, Lens S, Mariño Z, Londoño MC, 18. Auge J., Rodriguez C., Espanyol O., Rivero Rodríguez-Tajes S, Mas A, García-López M, L., Sandalinas S., Grau J., Jimenez W., Castells 7. Macdonald S, Andreola F, Bachtiger P, Pérez-Del-Pulgar S, Sánchez-Tapias JM, A. An evaluation of the SENTiFIT 270 Amoros A, Pavesi M, Mookerjee R, Zheng YB, Forns X. Anti-viral therapy can be delayed analyser for quantitation of faecal Gronbaek H, Gerbes AL, Sola E, Caraceni P, or avoided in a significant proportion of haemoglobin in the investigation of Moreau R, Gines P, Arroyo V, Jalan R . Cell HBeAg-negative Caucasian patients in patients with suspected colorectal death markers in cirrhotic patients with the Grey Zone. ALIMENTARY cancer. CLINICAL CHEMISTRY AND acute decompensation. HEPATOLOGY. PHARMACOLOGY AND THERAPEUTICS. LABORATORY MEDICINE. 56(4):625-633. 67(3):989-1002. I.F.: 14.079 47(10):1397-1408. I.F.: 7.357 I.F.: 3.556

8. Melgar-Lesmes P, Luquero A, Parra-Robert 13. Flores-Costa R., Alcaraz-Quiles J., Titos E., 19. Massey V., Qin L., Cabezas J., Caballeria J., M, Mora A, Ribera J, Edelman ER, Jiménez W. López-Vicario C., Casulleras M., Duran-Güell Sancho-Bru P., Bataller R., Crews F. Graphene-Dendrimer Nanostars for M., Rius B., Diaz A., Hall K., Shea C., Sarno R., TLR7-let-7 Signaling Contributes to

169 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

Ethanol-Induced Hepatic Inflammatory 3. Laleman W., Claria J., Van Der Merwe S., Guidelines for the management of Response in Mice and in Alcoholic Moreau R., Trebicka J. Systemic patients with decompensated cirrhosis. Hepatitis. ALCOHOLISM: CLINICAL AND Inflammation and Acute-on-Chronic JOURNAL OF HEPATOLOGY. EXPERIMENTAL RESEARCH. Liver Failure: Too Much, Not Enough. 69(2):406-460. I.F.: 15.040 42(11):2107-2122. I.F.: 3.183 CANADIAN JOURNAL OF GASTROENTEROLOGY AND 20. Aranda G., Fernandez-Ruiz R., Palomo M., HEPATOLOGY. 2018: 1027152. I.F.: 1.622 Romo M., Mora M., Halperin I., Casals G., GRANTS FOR RESEARCH IN PROGRESS Enseñat J., Vidal O., Diaz-Ricart M., Hanzu F. Translational evidence of prothrombotic Editorial / I.F.: 60.16 Casals G. Evaluación de las propiedades and inflammatory endothelial damage in antioxidantes y antiinflamatorias de las Cushing syndrome after remission. 1. Graupera I., Lammert F. Screening is nanopartículas de óxido de cerio como CLINICAL ENDOCRINOLOGY. 88(3):415-424. caring: Community-based non-invasive nueva estrategia terapéutica en la I.F.: 3.077 diagnosis and treatment strategies for esteatosis hepática. hepatitis C to reduce liver disease Sponsored by: Instituto de Salud Carlos III 21. Fabrellas N, Hernández R, Graupera I, Solà burden. JOURNAL OF HEPATOLOGY. (ISCIII). PI15/00777 E, Ramos P, Martín N, Sáez G, Simón C, Pérez 69(3):562-563. I.F.: 15.040 Duration: 01/01/2016-31/12/2019 A, Graell T, Larrañaga A, Garcia M, de la Arada A, Juanola A, Coiduras A, Duaso I, Casado A, 2. Fernández J, Saliba F. Liver Claria J. Investigació hepàtica: recerca Martin J, Ginès M, Moreno N, Gema Perez A, transplantation in patients with ACLF bàsica i experimental. Marti L, Bernat M, Sola M, Olivé C, Solé C, and multiple organ failure: Time for Sponsored by: Generalitat de Catalunya. Ginès P. Prevalence of hepatic steatosis priority after initial stabilization. AGAUR_SGR17_01449 as assessed by controlled attenuation JOURNAL OF HEPATOLOGY. Duration: 01/01/2017-31/12/2020 parameter (CAP) in subjects with 69(5):1004-1006. I.F.: 15.040 metabolic risk factors in primary care. A Claria J. Mecanismos moleculares population-based study. PLOS ONE. 3. Arroyo V, Clària J . Acute-On-Chronic determinantes de la resolución 13(9):e0200656. I.F.: 2.766 Liver Failure, Human Serum Albumin and inadecuada de la inflamación en tejido Immune-Modulation: The Beginning of an adiposo obeso. Nuevas oportunidades 22. Fernández-Galán E., Massana N., Exciting Adventure. CLINICAL en la prevención de comorbilidades Parra-Robert M., Hidalgo S., Casals G., Esteve GASTROENTEROLOGY AND metabólicas. J., Jiménez W. Validation of a routine gas HEPATOLOGY. 16(5):633-636. I.F.: 7.683 Sponsored by: Ministerio de Economía y chromatography mass spectrometry Competitividad (MINECO). method for 2-hydroxyglutarate 4. Ginès P, Sarin S . More Than Meets the SAF2015-63674-R quantification in human serum as a Eye in Using Interleukin 6 as a Marker of Duration: 01/01/2016-31/12/2019 screening tool for detection of idh Inflammation and Prognostic Factor for mutations. JOURNAL OF Patients With Cirrhosis. CLINICAL Fernández Gómez J. Impacto clínico y CHROMATOGRAPHY B: ANALYTICAL GASTROENTEROLOGY AND coste/eficacia de estrategias de TECHNOLOGIES IN THE BIOMEDICAL AND HEPATOLOGY. 16(5):630-632. I.F.: 7.683 vigilancia epidemiológica y de LIFE SCIENCES. 1083:28-34. I.F.: 2.441 optimización farmacoterapéutica 5. Bonacci M., Lens S. Editorial: STAT-4 antibiótica en la cirrosis 23. Blasi A, Hernandez V, Fernandez J, polymorphism - a tool to personalise descompensada. Colmenero J, Beltran J, Garcia-Valdecasas clinical practice in chronic HBV infection. Sponsored by: Instituto de Salud Carlos III JC, Reverter JC . Venous Thrombotic ALIMENTARY PHARMACOLOGY AND (ISCIII). PI16/00885 Events After Liver Transplantation. THERAPEUTICS. 48(7):768-769. I.F.: 7.357 Duration: 01/01/2017-31/12/2019 CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS. 24(2):317-322. 6. Solé C, Pose E, Solà E. Editorial: Ginés P. Grup de Hepatologia Recerca I.F.: 1.852 macrophage activation markers predict Clínica. prognosis and decompensation in Sponsored by: Generalitat de Catalunya. patients with cirrhosis-linking gut AGAUR_SGR17_01281 Review / I.F.: 22.193 permeability, inflammation and cirrhosis Duration: 01/01/2017-31/12/2020 progression. ALIMENTARY 1. Ginès P., Solà E., Angeli P., Wong F., Nadim PHARMACOLOGY AND THERAPEUTICS. Ginés P. Insuficiencia hepática crónica M., Kamath P. Hepatorenal syndrome. 47(6):851-853. I.F.: 7.357 agudizada y disfunción multiorgánica: NATURE REVIEWS DISEASE PRIMERS. Mecanismos moleculares y evaluación 4(1):23. I.F.: 16.071 de nuevos métodos diagnósticos y Clinical Guidelines / I.F.: 15.04 terapéuticos. 2. Solé C, Pose E, Solà E, Ginès P . Sponsored by: Instituto de Salud Carlos III Hepatorenal syndrome in the era of 1. Angeli P., Bernardi M., Villanueva C., Francoz (ISCIII). PI12/00330 Acute Kidney injury. LIVER C., Mookerjee R., Trebicka J., Krag A., Laleman Duration: 01/01/2013-31/12/2018 INTERNATIONAL. 38(11):1891-1901. I.F.: 4.500 W., Gines P. EASL Clinical Practice Ginés P. Síndrome de insuficiencia

170 MECHANISMS OF LIVER DISEASE AND COMPLICATIONS OF CIRRHOSIS 3.4

hepática crónica agudizada en la cirrosis. Duration: 01/01/2018-31/12/2020 Relación con el microbioma y la inﬂamación. Sancho-Bru P. InTeam: Molecular Sponsored by: Instituto de Salud Carlos III subtypes for targeted therapies in (ISCIII). FIS PI16/00043 alcoholic hepatitis. Duration: 01/01/2017 -31/12/2019 Sponsored by: National Institutes of Health, NIH (U01AA021908) Ginés P. CARBALIVE: Clinical evaluation Duration: 01/06/2017-31/12/2018 of carbons of controlled porosity as a new therapy for the treatment of liver Sancho-Bru P. LiverTF: Liver-enriched cirrhosis and non-alcoholic fatty liver transcription factors as prognostic disease. markers and therapeutic targets in Sponsored by: European Commission. alcoholic hepatitis. H2020_PHC2014 (634579-2). Sponsored by: National Institutes of Health, Duration: 01/05/2015-31/10/2019 NIH (1U01AA026972-01) Duration: 22/09/2018-30/06/2019 Ginés P. LIVERHOPE: SIMVASTIN and RIFAXIMIN as New Therapy for patients Sancho-Bru P. Role of liver progenitor with decompensated cirrhosis. cells in the progression of alcoholic liver Sponsored by: European Commission. disease. H2020_SC1 ( 731875) Sponsored by: The European Foundation for Duration: 01/01/2017-31/12/2021 Alcohol Research (ERAB) Duration: 01/01/2017-31/12/2018 Ginés P. LIVERSCREEN: Screening for Chronic Liver Diseases in the Population. Sponsored by: EIT Health_2018 Duration: 01/01/2018-31/12/2019 DOCTORAL THESES

Jiménez W, Fernández-Varo G. Utilidad Clària J. Influencia de factores séricos y terapéutica de las Nanopartículas de genéticos en la respuesta inflamatoria Óxido de Cerio en las enfermedades sistémica en pacientes cirróticos hepáticas. descompensados. Sponsored by: Ministerio de Economía y PhD student: José Alcaraz Quiles Competitividad (MINECO). SAF2015-64126-R Duration: 01/01/2016-31/03/2019 Ginés P, Guevara M. Insuficiencia renal en la cirrosis: Validación de los criterios akin Morales M. Estimulación de la y utilidad de la Ngal en el diagnóstico regeneración funcional de hígados diferencial. cirróticos mediante la normalización PhD student: Cláudia Gonçalves Fagundes vascular intrahepática y la modulación Pereira de dianas de Akt. Sponsored by: Ministerio de Economia y Ginés P. Valoración de la función Competitividad (MINECO). ventricular izquierda en la cirrosis SAF2016-75358-R hepática: relación con la hemodinámica Duration: 30/12/2016-29/12/2019 sistémica y la disfunción renal. PhD student: Andrè Nogueira Nazar Sancho-Bru P. Papel de las células progenitoras hepáticas en la hepatitis Sancho-Bru P. Las células estrelladas alcohólica y su potencial como nueva hepáticas en las enfermedades del diana terapéutica. hígado y el desarrollo de nuevos Sponsored by: Instituto de Salud Carlos III modelos de fibrosis. (ISCIII). PI14/00320 PhD student: Luis Perea Sanchez Duration: 01/01/2015-30/06/2018

Sancho-Bru P. Mecanismos implicados en la deﬁciente reparación tisular del hígado en enfermedades crónicas hepáticas. Nuevas dianas terapéuticas. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI17/00673

171 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

Hepatic 3.5 oncology

PRE-DOCTORAL RESEARCHERS Álvaro Díaz-González (FCRB) LOCATION Marco Sanduzzi-Zamparelli (FCRB) HCB Carmen Andreu (IDIBAPS) CEK building, ﬂoor 3 Roger Esteban (IDIBAPS) IIBB-CSIC labs Robert Montal (IDIBAPS) Carla Montironi (HCB) Sara Torrecilla (CIBER) Laura Torrens (IDIBAPS) WEB www.bclc.cat Blanca Cucarull (IIBB-CSIC)

TEAM LEADER TECHNICIANS Jordi Bruix (HCB) Josep Corominas (FCRB) T. 93 227 98 03 Cristina Millan (FCRB) [email protected] Maragda Quintas (FCRB) Esther Samper (FCRB) KEYWORDS Victor Sapena (CIBER)

1. Hepatocellular carcinoma GROUP LEADERS Judit Peix (CIBER) 2. Intrahepatic cholangiocarcinoma Josep M. Llovet (ICREA-IDIBAPS) 3. Biomarker proﬁling ADMINISTRATIVE STAFF T 93 227 91 55 Nuria Perez (FCRB) 4. Treatment [email protected] Celia Cortez (IDIBAPS) 5. Outcomes research Ariadna Farré (IDIBAPS) Albert Morales (IIBB-CSIC) T 93 363 83 00 (Ext.: 363) NURSING STAFF [email protected] Neus Llarch (HCB)

COLLABORATORS Original publications RESEARCHERS Jordi Abril (IDIBAPS) Mari Carmen Ayuso (HCB) from 2016 to 2018 Marta Piqué (IDIBAPS) Loreto Boix (CIBER) Milica Stefanovic (IIBB-CSIC) YEAR I.F. TOTAL Q1 Q2 Alejandro Forner (HCB) Josep Fuster (HCB) 2016 186.48 17 16 1 María Reig (HCB-FCRB) 2017 186.91 22 12 2 Ramon Vilana (HCB) STRATEGIC OBJECTIVES 2018 165.22 17 15 1 POST-DOCTORAL RESEARCHERS It is a multidisciplinary team, known Laia Bassaganyas (IDIBAPS) internationally as “Barcelona Clinic Liver Agrin Moeini (IDIBAPS) Cancer (BCLC) group”, which develops an Roser Pinyol (IDIBAPS) intense clinical and translational research in TEAM INVOLVED IN Catherine Willoughby (IDIBAPS) liver cancer. The aim of the team is to CIBEREHD Anna Tutusaus (IDIBAPS) AGAUR_SGR17: 01465, 01358 TEAM Jordi Bruix

172 HEPATIC ONCOLOGY 3.5

investigate the efficacy of clinical and several others. These explore: - molecular RESEARCH GROUP therapeutic interventions as well as the classiﬁcation of hepatocellular carcinoma and HEPATOCELULAR SIGNALING mechanisms regulating the disease Intrahepatic cholangiocarcinoma. - drivers AND CANCER progression. and signalling pathways, - role of co-morbidities in the pathogenesis of HCC (EU-grant HEP-CAR), - characterization of MAIN LINES OF RESEARCH immune subclasses in HCC and the impact of checkpoint inhibitor in treatment response. The team investigates how to reﬁne the selection criteria for potentially curative treatment (surgical resection, transplantation, GROUP LEADER percutaneous approach with ablation) with Albert Morales (IIBB-CSIC) the aim of ensuring maximum efficacy in terms of survival. Evaluations are made of Our work is focused on identifying cellular the options for improving the efficacy of targets with therapeutic potential in liver non-curative therapies which have been cancer and the development of prognostic shown to improve survival (arterial markers of antitumor efficacy for the chemoembolization, sorafenib, regorafenib). treatment of the hepatocellular carcinoma In this sense, phase 1, 2 and 3 studies are carried out and led at international level together with the Biomedical Industry, with a view to determining the efficacy of new molecular agents in phase 1, 2 and 3. The team is also actively involved in studies about diagnosis and treatment of cholangiocarcinoma. Major projects in clinical research are developed as investigator initiated trials or in collaboration with the pharmaceutical industry. These include clinical and translational activity using BCLC human cell lines, while the two subgroups coordinated by JM Llovet and A Morales base their activity in bench studies to advance knowledge in the pathogenesis and signalling pathways in hepatocyte and cholangiocte proliferation and liver cancer.

RESEARCH GROUP TRANSLATIONAL RESEARCH IN HEPATIC ONCOLOGY

GROUP LEADER Josep M. Llovet (ICREA-IDIBAPS)

The group aims to identify new therapeutic targets and biomarkers of response/resistance to systemic therapies. There are several lines of research within two international consortiums involving the BCLC-IDIBAPS, the Mount Sinai School of Medicine, the Dana-Farber Cancer Institute, the Broad Institute (Boston), INSERM (Paris),

the National Tumor Institute (Milan), and GROUP Josep Maria Llobet GROUP Albert Morales

173 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

(HCC). In particular, mitochondrial-directed HEPATOLOGY. 67(2):612-622. I.F.: 14.079 La Rosa L, Martinez L, Robles D, Morales A, and lipid-based therapies that may improve Abian J, Carrascal M, Machida K, Kumar DBU, current HCC management, and help to 5. Paré L, Pascual T, Seguí E, Teixidó C, Tsukamoto H, Kaplowitz N, Garcia-Ruiz C, overcome sorafenib/regorafenib resistance, Gonzalez-Cao M, Galván P, Rodríguez A, Fernández-Checa JC . The 2-oxoglutarate are under present evaluation. Protein and RNA González B, Cuatrecasas M, Pineda E, Torné carrier promotes liver cancer by signatures that categorize potential A, Crespo G, Martin-Algarra S, Pérez-Ruiz E, sustaining mitochondrial GSH despite candidates for each specific treatment Reig Ò, Viladot M, Font C, Adamo B, Vidal M, cholesterol loading. REDOX BIOLOGY. represent another area of interest in our Gaba L, Muñoz M, Victoria I, Ruiz G, Viñolas N, 14:164-177. I.F.: 7.126 research. Mellado B, Maurel J, Garcia-Corbacho J, Molina-Vila MÁ, Juan M, Llovet JM, Reguart N, 10. Labgaa I, Villacorta-Martin C, D'Avola D, Arance A, Prat A . Association between Craig AJ, von Felden J, Martins-Filho SN, Sia PD1 mRNA and response to anti-PD1 D, Stueck A, Ward SC, Fiel MI, Mahajan M, PUBLICATIONS monotherapy across multiple Tabrizian P, Thung SN, Ang C, Friedman SL, cancer-types. ANNALS OF ONCOLOGY. Llovet JM, Schwartz M, Villanueva A . A pilot Originals / I.F.: 165.223 29(10):2121-2128. I.F.: 13.930 study of ultra-deep targeted sequencing of plasma DNA identifies driver 1. Rimassa L, Assenat E, Peck-Radosavljevic 6. Barbero-Camps E, Roca-Agujetas V, mutations in hepatocellular carcinoma. M, Pracht M, Zagonel V, Mathurin P, Rota Bartolessis I, de Dios C, Fernández-Checa JC, ONCOGENE. 37(27):3740-3752. I.F.: 6.854 Caremoli E, Porta C, Daniele B, Bolondi L, Marí M, Morales A, Hartmann T, Colell A. Mazzaferro V, Harris W, Damjanov N, Cholesterol impairs 11. Pulido Á., de Gregorio E., Chandra S., Colell Pastorelli D, Reig M, Knox J, Negri F, Trojan J, autophagy-mediated clearance of A., Morales A., Kronenberg M., Marí M. López López C, Personeni N, Decaens T, amyloid beta while promoting its Differential role of cathepsins S and B Dupuy M, Sieghart W, Abbadessa G, Schwartz secretion. AUTOPHAGY. 14(7):1129-1154. in hepatic APC-mediated NKT cell B, Lamar M, Goldberg T, Shuster D, Santoro A, I.F.: 11.100 activation and cytokine secretion. Bruix J . Tivantinib for second-line FRONTIERS IN IMMUNOLOGY. 9(391):391. treatment of MET-high, advanced 7. Piulats JM, Vidal A, García-Rodríguez FJ, I.F.: 5.511 hepatocellular carcinoma (METIV-HCC): Muñoz C, Nadal M, Moutinho C, a final analysis of a phase 3, randomised, Martínez-Iniesta M, Mora J, Figueras A, Guinó 12. Kamath, Geetanjali R.; Taioli, Emanuela; placebo-controlled study. LANCET E, Padullés L, Aytés À, Molleví DG, Puertas S, Egorova, Natalia N.; Llovet, Josep M.; ONCOLOGY. 19(5):682-693. I.F.: 36.421 Martínez-Fernández C, Castillo W, Juliachs M, Perumalswami, Ponni V.; Weiss, Jeffrey J.; Moreno V, Muñoz P, Stefanovic M, Pujana MA, Schwartz, Myron; Ewala, Stanley; Bickell, Nina 2. Finn R., Merle P., Granito A., Huang Y., Condom E, Esteller M, Germà JR, Capella G, A. Liver Cancer Disparities in New York Bodoky G., Pracht M., Yokosuka O., Farré L, Morales A, Viñals F, García-Del-Muro City: A Neighborhood View of Risk and Rosmorduc O., Gerolami R., Caparello C., X, Cerón J, Villanueva A . Orthoxenografts Harm Reduction Factors. FRONTIERS IN Cabrera R., Chang C., Sun W., LeBerre M., of testicular germ cell tumors ONCOLOGY. 8(220):220. I.F.: 4.416 Baumhauer A., Meinhardt G., Bruix J. demonstrate genomic changes Outcomes of sequential treatment with associated with cisplatin resistance and 13. García-Pérez R, Ferrer Fábrega J, sorafenib followed by regorafenib for identify PDMP as a re-sensitizing agent. Varona-Bosque A, Martínez CM, Revilla-Nuin HCC: Additional analyses from the phase CLINICAL CANCER RESEARCH. B, Cabellos L, Pena R, Vilana R, III RESORCE trial. JOURNAL OF 24(15):3755-3766. I.F.: 10.199 Gonzalez-Abós C, García-Valdecasas JC, HEPATOLOGY. 69(2):353-358. I.F.: 15.040 Fuster Obregón J. Role of Kupffer cells in 8. Lim, Ho Yeong; Merle, Philippe; Weiss, Karl the progression of CRC liver metastases 3. Mauro E, Crespo G, Montironi C, Londoño Heinz; Yau, Thomas; Ross, Paul; Mazzaferro, after the first stage of ALPPS. SCIENTIFIC MC, Hernández-Gea V, Ruiz P, Sastre L, Vincenzo; Blanc, Jean-Frederic; Ma, Yuk Ting; REPORTS. 8(1):8089. I.F.: 4.122 Lombardo J, Mariño Z, Díaz A, Colmenero J, Yen, Chia Jui; Kocsis, Judit; Choo, Su Pin; Rimola A, Garcia-Pagán JC, Brunet M, Forns Sukeepaisarnjaroen, Wattana; Gerolami, 14. Llovet JM, Pavel M, Rimola J, Diaz MA, X, Navasa M . Portal pressure and liver Rene; Dufour, Jean-Francois; Gane, Edward Colmenero J, Saavedra-Perez D, Fondevila C, stiffness measurements in the prediction J.; Ryoo, Baek-Yeol; Peck-Radosavljevic, Ayuso C, Fuster J, Ginès P, Bruix J, of fibrosis regression after SVR in Markus; Thong Dao; Yeo, Winnie; Lamlertthon, Garcia-Valdecasas JC . Pilot study of living recurrent hepatitis C. HEPATOLOGY. Wisut; Thongsawat, Satawat; Teufel, Michael; donor liver transplantation for patients 67(5):1683-1694. I.F.: 14.079 Roth, Katrin; Reis, Diego; Childs, Barrett H.; with HCC exceeding Milan criteria (BCLC Krissel, Heiko; Llovet, Josep M. Phase II extended criteria). LIVER 4. Rimola J, Díaz-González Á, Darnell A, Varela Studies with Refametinib or Refametinib TRANSPLANTATION. 24(3):369-379. I.F.: 3.756 M, Pons F, Hernandez-Guerra M, Delgado M, plus Sorafenib in Patients with Castroagudin J, Matilla A, Sangro B, Rodriguez RAS-Mutated Hepatocellular Carcinoma. 15. Hessheimer AJ, Vendrell M, Muñoz J, Ruíz de Lope C, Sala M, Gonzalez C, Huertas C, CLINICAL CANCER RESEARCH. Á, Díaz A, Sigüenza LF, Lanzilotta JR, Delgado Minguez B, Ayuso C, Bruix J, Reig M . Complete 24(19):4650-4661. I.F.: 10.199 Oliver E, Fuster J, Navasa M, García- response under sorafenib in patients with Valdecasas JC, Taurá P, Fondevila C. hepatocellular carcinoma. Relationship 9. Baulies A, Montero J, Matías N, Insausti N, Heparin but not tissue plasminogen with dermatologic adverse events. Terrones O, Basañez G, Vallejo C, Conde de activator improves outcomes in DCD

174 HEPATIC ONCOLOGY 3.5

liver transplantation in a porcine model. GASTROENTEROLOGY. 24(32):3626-3636. 2. Caballol B, Ruiz P, Ferrer-Fàbrega J, Diaz A, LIVER TRANSPLANTATION. 24(5):665-676. I.F.: 3.300 Forner A. A rare cause of systemic I.F.: 3.756 inflammatory response syndrome. 7. Ayuso C., Rimola J., Vilana R., Burrel M., GASTROENTEROLOGIA Y HEPATOLOGIA. . 16. Molina V., Sampson-Dávila J., Ferrer J., Darnell A., García-Criado Á., Bianchi L., I.F.: 1.078 Fondevila C., Díaz del Gobbo R., Calatayud D., Belmonte E., Caparroz C., Barrufet M., Bruix J., Bruix J., García-Valdecasas J., Fuster J. Brú C. Diagnosis and staging of Benefits of laparoscopic liver resection hepatocellular carcinoma (HCC): current Clinical Guidelines / I.F.: 30.048 in patients with hepatocellular guidelines. EUROPEAN JOURNAL OF carcinoma and portal hypertension: a RADIOLOGY. 101:72-81. I.F.: 2.843 1. Galle, Peter R.; Forner, Alejandro; Llovet, case-matched study. SURGICAL Josep M.; Mazzaferro, Vincenzo; Piscaglia, ENDOSCOPY. 32(5):2345-2354. I.F.: 3.117 Fabio; Raoul, Jean-Luc; Schirmacher, Peter; Letters / I.F.: 55.217 Vilgrain, Valerie. EASL Clinical Practice 17. Bodro M, Ferrer J, Ricart MJ, Sanclemente Guidelines: Management of G, Linares L, Cervera C, Cofan F, 1. Llovet JM, Finn R. Negative phase 3 study hepatocellular carcinoma. JOURNAL OF Ventura-Aguiar P, Lopez-Boado MÁ, Marco F, of 90Y microspheres versus sorafenib in HEPATOLOGY. 69(1):182-236. I.F.: 15.040 Fuster J, García-Valdecasas JC, Moreno A . HCC. LANCET ONCOLOGY. 19(2):e69-E69. Epidemiology, risk factors, and impact of I.F.: 36.421 2. Vogel A, Cervantes A, Chau I, Daniele B, bacterial infections on outcomes for Llovet J, Meyer T, Nault JC, Neumann U, Ricke pancreatic grafts. CLINICAL 2. Bruix J, Lii Cheng A, Llovet JM. Predictors J, Sangro B, Schirmacher P, Verslype C, Zech TRANSPLANTATION. 32(8):e13333. I.F.: 1.518 of Sorafenib Benefit in Patients with CJ, Arnold D, Martinelli E, ESMO Guidelines Hepatocellular Carcinoma. JOURNAL OF Committee. Hepatocellular carcinoma: HEPATOLOGY. 68(3):620-621. I.F.: 15.040 ESMO Clinical Practice Guidelines for Review / I.F.: 124.228 diagnosis, treatment and follow-up. 3. Mauro E, Crespo G, Montironi C, Londoño ANNALS OF ONCOLOGY. 29(4):iv238-iv255. 1. Forner A., Reig M., Bruix J. Hepatocellular MC, Díaz A, Forns X, Navasa M . Viral I.F.: 13.930 carcinoma. LANCET. 391(10127):1301-1314. eradication and fibrosis resolution in post I.F.: 53.254 liver transplant cholestatic hepatitis C. 3. Aller R., Fernández-Rodríguez C., lo Iacono LIVER TRANSPLANTATION. 24(5):703-707. O., Bañares R., Abad J., Carrión J., 2. Llovet J., Montal R., Sia D., Finn R. I.F.: 3.756 García-Monzón C., Caballería J., Berenguer M., Molecular therapies and precision Rodríguez-Perálvarez M., Miranda J., medicine for hepatocellular carcinoma. Vilar-Gómez E., Crespo J., García-Cortés M., NATURE REVIEWS CLINICAL ONCOLOGY. Editorial / I.F.: 82.407 Reig M., Navarro J., Gallego R., Genescà J., 15(10):599-616. I.F.: 24.653 Arias-Loste M., Pareja M., Albillos A., Muntané 1. Reig, Maria; Bruix, Jordi. Lenvatinib: can a J., Jorquera F., Solà E., Hernández-Guerra M., 3. Gerbes, Alexander; Zoulim, Fabien; Tilg, non-inferiority trial change clinical Rojo M., Salmerón J., Caballería L., Diago M., Herbert; Dufour, Jean-Francois; Bruix, Jordi; practice? LANCET. 391(10126):1123-1124. Molina E., Bataller R., Romero-Gómez M. Paradis, Valerie; Salem, Riad; Peck- I.F.: 53.254 Consensus document. Management of Radosavljevic, Markus; Galle, Peter R.; Greten, non-alcoholic fatty liver disease Tim F.; Nault, Jean-Charles; Avila, Matias A. 2. Sanduzzi-Zamparelli, Marco; Bruix, Jordi. (NAFLD). Clinical practice guideline. Gut roundtable meeting paper: selected Locoregional versus systemic therapy - GASTROENTEROLOGIA Y HEPATOLOGIA. recent advances in hepatocellular robust positive data remain elusive. 41(5):328-349. I.F.: 1.078 carcinoma. GUT. 67(2):380-388. I.F.: 17.016 NATURE REVIEWS CLINICAL ONCOLOGY. 15(9):537-538. I.F.: 24.653 4. Reig M, da Fonseca LG, Faivre S. New trials and results in systemic treatment 3. Da Fonseca L., Forner A. Carbon-ion GRANTS FOR RESEARCH IN PROGRESS of HCC. JOURNAL OF HEPATOLOGY. radiotherapy for HCC-A potential tool to 69(2):525-533. I.F.: 15.040 fulfil an unmet gap in the treatment Bruix J. Influencia de la heterogeneidad algorithms? LIVER INTERNATIONAL. del micro-ambiente tumoral en la 5. Raoul J., Kudo M., Finn R., Edeline J., 38(12):2132-2133. I.F.: 4.500 respuesta terapéutica del carcinoma Reig M., Galle P. Systemic therapy for hepatocelular humano (CHC). intermediate and advanced Sponsored by: Instituto de Salud Carlos III hepatocellular carcinoma: Sorafenib and Case Reports / I.F.: 15.157 (ISCIII). PI14/00962 beyond. CANCER TREATMENT REVIEWS. Duration: 01/01/2015-31/12/2018 68:16-24. I.F.: 8.122 1. Díaz-González Á, Monclús E, Darnell A, Solé M, Bruix J. Liver metastases from gastric Bruix J. Molecular regulation of the 6. Pavel M., Fuster J. Expansion of the adenocarcinoma mimicking progression from hepatic steatosis to hepatocellular carcinoma Milan criteria multinodular hepatocellular carcinoma. cirrhosis and hepatocellular carcinoma: in liver transplantation: Future HEPATOLOGY. 68(5):2042-2044. I.F.: 14.079 Role and therapeutic potential of CPEB directions. WORLD JOURNAL OF proteins.

175 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

Sponsored by: Asociación Española Contra el Reig M. Evaluación clínica prospectiva del Cáncer. AECC_Grupo Estable15 perfil genético-inmuno/inflamatorio en Duration: 01/09/2015-31/08/2020 el tratamiento del carcinoma hepatocelular con sorafenib para Bruix J. Role and therapeutic potential of predecir tolerancia y supervivencia. CPEB proteins in the transition from Sponsored by: Instituto de Salud Carlos III cirrhosis to hepatocellular carcinoma. (ISCIII). PI115/00145 Sponsored by:World Wide Cancer Research Duration: 23/05/2016-31/12/2019 (WCR). 16-0026 Duration: 01/01/2016-31/12/2018 Reig M. Prospective clinical evaluation of the genetic-immuno / inflammatory Llovet JM. Laboratori de Recerca profile in the treatment of hepatocellular Translacional en Oncología Hepàtica. carcinoma with sorafenib to predict Sponsored by: Generalitat de Catalunya. tolerance and survival. AGAUR_SGR17_01358 Sponsored by: Asociación Española Contra el Duration: 01/01/2017-31/12/2020 Cáncer. AECC_Clínico18 Duration: 01/08/2018- Llovet JM. Mecanismos de resistencia adquirida a sorafenib en el carcinoma hepatocelular. Sponsored by: Ministerio de Economía y DOCTORAL THESES Competitividad (MINECO). SAF2016-76390-R Llovet JM. Characterization of novel Duration: 30/12/2016-29/12/2019 actionable molecular subgroups in Hepatocellular Carcinoma: Immune Llovet JM. Integrative molecular class and IGF2-driven tumors. classification of extrahepatic PhD student: Iris Martínez Quetglas cholangiocarcinoma. Sponsored by: Sociedad Española de Marí M, Morales A. Identificación de dianas Oncología Médica. SEOM_Retorno18 terapéuticas en fibrosis hepáticas y Duration:26/10/2018-30/10/2019 cáncer. PhD student: Anna Tutusaus López Llovet JM. HUNTER: Hepatocellular Carcinoma Expediter Network. Sponsored by: Asociación Española Contra el Cáncer. AECC_Accelerator Award17 Duration: 01/12/2018-30/11/2023

Llovet JM. HEP-CAR: Mechanisms underlying hepatocellular carcinoma pathogenesis and impact of co-morbidities. Sponsored by: European Commission. H2020_PHC_2015 (667273-1) Duration: 01/01/2016-31/12/2019

Llovet JM. CRISH-2: Co-cReating Innovative Solutions for Health 2.0. Sponsored by: European Commission. EITHealth_2018 (18053-IDBPS) Duration: 01/01/2018-31/12/2019

Morales A. Regulación terapéutica de la transición EMT/MET y la quimioresistencia en enfermedad hepática crónica. Sponsored by: Ministerio de Economía y Competitividad (MINECO). SAF2015-66515-R Duration: 01/01/2016-30/06/2019

176 HEPATIC HEMODYNAMICS AND PORTAL HYPERTENSION. HEMORRHAGE FROM RUPTURED GASTROESOPHAGEAL VARICES 3.6

Hepatic hemodynamics and portal hypertension. 3.6 Hemorrhage from ruptured gastroesophageal varices

Nuria Pell (IDIBAPS) LOCATION Marta Ramírez (IDIBAPS) CEK building, ﬂoor 4 Laia Abad (IDIBAPS) Raquel Maeso-Díaz (IDIBAPS) Nico Manicardi (IDIBAPS) Martí Ortega-Ribera (IDIBAPS)

TECHNICIANS KEYWORDS Héctor García-Calderó (CIBER-FCRB) 1. Portal hypertension TEAM LEADER Montserrat Monclús (IDIBAPS) 2. Cirrhosis of the liver Juan Carlos García-Pagán (HCB) T. 93 227 54 00 (Ext.: 5790) 3. Angiogenesis ADMINISTRATIVE STAFF [email protected] 4. Obesity Oliva Ros (IDIBAPS) 5. Liver sinusoidal endothelial cells 6. Vascular liver diseases NURSING STAFF GROUP LEADERS Lara Orts-Salvador (CIBER) Mercedes Fernández Lobato (IDIBAPS) T. 606 958 606 [email protected] STRATEGIC OBJECTIVES Juan Carlos García-Pagán (HCB) Original publications T. 93 227 54 00 (Ext.: 5790) Translational research aimed at advancing from 2016 to 2018 [email protected] in the knowledge of the pathophysiology of

YEAR I.F. TOTAL Q1 Q2 portal hypertension, which represents the Jordi Gracia-Sancho (IDIBAPS) main complication of chronic liver diseases. 2016 151.24 16 16 - T. 93 227 54 00 (Ext.: 4306) Discovery of new therapeutic targets, 2017 219.10 27 22 4 [email protected] introduction of new treatments for this 2018 191.41 17 15 - syndrome, and development of new non-invasive techniques for its clinical evaluation. EMERITUS In addition, the group is active in the ﬁelds of Jaume Bosch (IDIBAPS) vascular liver diseases, angiogenesis

TEAM INVOLVED IN abnormalities in liver disease and on organ RESEARCHERS preservation. CIBEREHD Ramón Deulofeu (HCB) AGAUR_SGR17: 00517 Àngels Escorsell (HCB) M. Rosa Gilabert (HCB) Virginia Hernández-Gea (HCB) MAIN LINES OF RESEARCH Montserrat Marí (IIBB-CSIC) 1. Factors regulating liver microcirculation POST-DOCTORAL RESEARCHERS under normal conditions and in cirrhosis, Genís Campreciós (CIBER) based on isolated liver perfusion studies Anabel Fernández-Iglesias (CIBER) and studies in isolated liver sinusoid Javier Gallego (CIBER) endothelial cells. Ester Garcia-Pras (CIBER) 2. Regulation of the phenotype of liver Marc Mejias (CIBER) sinusoidal endothelial cells: relevance in the Salvador Naranjo-Suárez (IDIBAPS) pathophysiology of chronic liver disease, Dinesh Mani Tripathi (IDIBAPS) portal hypertension, liver preservation, and Marina Vilaseca (IDIBAPS) in the complications of cirrhosis. 3. Liver protection from external injury in PRE-DOCTORAL RESEARCHERS healthy and cirrhotic livers. Anna Baiges (HCB-FCRB) 4. Angiogenesis in chronic liver disease: Michel Ble (HCB) function, regulation/dysregulation and Estefanía de Gregorio (IDIBAPS) therapeutic potential. Jose Alberto Ferrusquía (IDIBAPS) 5. Impact of obesity on chronic liver disease: Erica Lafoz (FCRB) pathogenic mechanisms and therapeutic Marta Magaz-Martínez (HCB) implications. Maria Ruart (IDIBAPS) 6. Molecular regulation of the progression Fanny Turon (HCB) from liver steatosis to cirrhosis and liver

177 178 AREA 3 implications. pathogenicmechanismsandtherapeutic cirrhosis. 10. 9. 8. 7. targets. cancer.Identificationofnewtherapeutic targets. cancer:identificationofnewtherapeutic fromliversteatosistocirrhosisand 3. 2. 1. Our specificresearchprojectsinclude: avenues toimprovehumanhealth. facilitate theidentificationofnoveltherapeutic pathogenetic mechanismsofdisease,andto This isessentialtofullyelucidateunresolved death andlivertransplantationworldwide. humans beingsandareleadingcausesof liver andcancer,whichaffectmillionsof chronic liverdiseases,includingcirrhosisofthe on identifyingthecausesanddriversof (www.mercedesfernandezlab.com) focuses Our research Mercedes FernándezLobato GROUP LEADER ANGIOGENESIS INLIVERDISEASES RESEARCH GROUP fibrosis. 12. risk-stratification. idiopathicportalhypertensionandfor 11. Idiopathicnon-cirrhoticportalhypertension). syndrome,PortalVeinThrombosis; treatmentsforportalhypertension. cirrhosis. ucin euaindseuainad therapeutic function,regulation/dysregulationand potential. Agoeei ncrnclvrdsae Angiogenesisinchronicliverdisease: Impact ofobesityonchronic liverdisease: admzdciia tde fnvl Randomized clinicalstudiesofnovel Hepatic vasculardiseases(Budd-Chiari Molecular regulationoftheprogression Discovery ofdiagnosticbiomarkersfor New non-invasivemethodsforevaluating Mcaim nlvriflmainad Mechanismsinliverinflammationand rvnino eopnaino Prevention ofdecompensation

LIVER, DIGESTIVE SYSTEM ANDMETABOLISM (IDIBAPS)

GROUP Juan Carlos García-Pagán GROUP Mercedes Fernández Lobato AND HEPATICVASCULARDISEASES MICROCIRCULATION INCIRRHOSIS REGULATION OFLIVER RESEARCH GROUP Juan CarlosGarcía-Pagán GROUP LEADER

(HCB) (prognosis, diagnosis and illne group hasservedas areferencecenterforthese portal hypertension.Foranumberof yearsour portal hypertension,areinfrequent causes of non-cirrhotic portalthrombosisand idiopathic disorders, particularlyBudd-Chiarisyndrome, treatment ofportalhypertension.Liver vascular us todesignnewtherapeuticstrategies forthe cirrhosis andtheirpotentialmodulationwillallow in theincreasedintrahepaticresistance Better understandingthemechanismsinvolved development ofportalhypertensionincirrhosis. the mainmechanismsresponsiblefor Increased hepaticvascularresistanceisoneof sses allowingustoadvance intheir treatment). knowledge 1. Originals / PUBLICATIONS big data. liver-on-a-chip technology,andanalysisof disease, cellco-culturebymeansof and rodents,invivo/invitromodelsofliver tissues andprimarycells,bothfromhuman range ofexperimentalmethodsthatinclude order toachieveourgoals,weuseawide microcirculation, ﬁbrosisandfunction.In of newtherapiestoimproveliver Our resultsarethebasisfordevelopment and fattyliver),inageing. liver damage,inchronicdisease(cirrhosis mechanisms, inhealth,responsetoacute hepatic intercellularcommunication phenotype ofthesesinusoidalcells,andthe biomechanical processesthatregulatethe Our researchgroupstudiesthemolecularand with liverdamage. the treatmentandimprovementofpatients represent animportanttherapeutictargetfor progression ofliverdiseases,andtherefore cells), playakeyroleinthedevelopmentand cells andresidentmacrophages(Kupffer principally sinusoidalendothelialcells,stellate The cellsofthelivermicrocirculation, Jordi Gracia-Sancho GROUP LEADER VASCULAR BIOLOGYOFTHELIVER RESEARCH GROUP Abraldes JG,Lopez M,KukukG,KragA, Majumdar A,Picón C,TothD,DarnellA, Vangrinsven G,Garcia-MartinezR, DamA, Praktiknjo M,MaurerMH,ZipprichA, TrioloM, Lampichler K,BaigesA,LowG,Llop E, 2. I.F.: 20.773 GASTROENTEROLOGY. With CirrhosisandPortalHypertension. Acute onChronicLiverFailureinRats Simvastatin PreventsProgressionof García-Pagán JC,BoschJ,Gracia-SanchoJ. Fernández-Iglesias A,RodriguesdeOliveiraJ, Garcia-Calderó H,ViegasHauteG, Tripathi DM,VilasecaM,LafozE, Simón-TaleroM,RoccarinaD,Martínez J, I.F.:191.414 (IDIBAPS) 155(5):1564-1577. HEPATIC HEMODYNAMICS ANDPORTAL HYPERTENSION. HEMORRHAGE FROMRUPTUREDGASTROESOPHAGEAL VARICES

GROUP Jordi Gracia-Sancho 5. HEPATOLOGY. Management andOutcome. Study onMaternalandFetal Portal Hypertension:AMulticentric Pregnancy inIdiopathicNon-Cirrhotic A, RautouPE,VALDIGinvestigators. PF, deRaucourtE,PayancéA,Valla D,Plessier Turon F,ObertiTripathiD,RouxO,Ceccaldi D'Alteroche L,HeurguéA,Garcia-PaganJC, 4. 20.773 GASTROENTEROLOGY. Nonalcoholic Steatohepatitis. Compensated CirrhosisCausedby for PatientswithBridgingFibrosisor Investigators. SimtuzumabIsIneffective GS-US-321-0105GS-US-321-0106 Goodman Z;BoschJ;SanyalAJ; RP; YounossiZ;RatziuV;MuirAJ;AfdhalNH; Mchutchison JG;SubramanianGM;Myers Rockey DC;SchallRA;JiaC;McColganBJ; Shiffman ML;DiehlAM;GhalibR;LawitzEJ; 3. 154(6):1694-1705.e4. I.F.:20.773 With Cirrhosis. Complications andMortalityinPatients Portosystemic ShuntsandIncreased Cooperation. Baveno VI-SPSSgroupfromthe Tsochatzis EA,AugustinS,GenescàJ, Hernandez-Gea V,ReibergerT,AlbillosA, Berzigotti A,TrebickaJ,CallejaJL,TandonP, Bañares R,LalemanW,LaMuraV,RipollC, Harrison SA;AbdelmalekMF;CaldwellS; De ChiaraF,Heebøll S,MarroneG,Montoliu Andrade F,ShuklaA,BureauC,SenzoloM, Association Between 69(6):1242-1249. I.F.: 15.040 GASTROENTEROLOGY. 155(4):1140-1153. I.F.: JOURNAL OF 68(3):1140-1153. I.F.: 14.079 hepatic stellate cells. pro-ﬁbrogenic phenotype ofhuman axis: Akeyregulatorofthe Rombouts K. Viollet B,PinzaniM, M, Fernández-IglesiasA,HallLuong TV, Dhar D,LongatoL,MazzaG,Zhang Z,Marrali 8. 67(5):1683-1694. I.F.:14.079 recurrent hepatitisC. of ﬁbrosisregressionafterSVRin stiffness measurementsintheprediction X, NavasaM. Rimola A,Garcia-PagánJC,BrunetM,Forns Lombardo J,MariñoZ,DíazA,Colmenero MC, Hernández-GeaV,RuizP,SastreL, 7. 69(6):1365-1370. I.F.:15.040 JOURNAL OFHEPATOLOGY. outcomes withouttreatmentoptions. cryptogenic cirrhosis:Adverse N., BoschJ.,GoodmanZ. B., SubramanianG.,MyersR.,MuirA.,Afdhal Caldwell S.,ShiffmanM.,SchallR.,McColgan Harrison S.,RatziuV.,AbdelmalekM.,DiehlA., 6. 69(4):905-915. I.F.:15.040 disease. dysregulation innon-alcoholicfattyliver Jalan R,ThomsenKL. Gracia-Sancho J,MookerjeeRP,VilstrupH, Rombouts K,GrønbækH,FelipoV, C, Hamilton-DutoitS,FerrandezA,AndreolaF, MauroE,CrespoG,MontironiC,Londoño Marrone G,DeChiaraF,BöttcherK, LeviA, Younossi Z.,StepanovaM.,SanyalA., JOURNALOFHEPATOLOGY. The AMPK-v-ATPase-pH Portal pressureandliver Urea cycle HEPATOLOGY.

HEPATOLOGY The conundrumof . 3.6 179 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

9. Payancé A, Silva-Junior G, Bissonnette J, pharmaceutical applications. Requiring Both Liver Regeneration and Tanguy M, Pasquet B, Levi C, Roux O, BIOTECHNOLOGY AND BIOENGINEERING. Vascular Occlusion. INTERNATIONAL Nekachtali O, Baiges A, Hernández-Gea V, 115(10):2585-2594. I.F.: 3.952 JOURNAL OF MOLECULAR SCIENCES. Laouénan C, Lebrec D, Albuquerque M, 19(11):3395. I.F.: 3.687 Paradis V, Moreau R, Valla D, Durand F, 16. Klinger C, Riecken B, Schmidt A, De Boulanger CM, Garcia-Pagan JC, Rautou PE. Gottardi A, Meier B, Bosch J, Caca K. 7. Turon F, Hernández-Gea V, García-Pagán Hepatocyte microvesicle levels improve Transjugular portal vein recanalization JC . Portal vein thrombosis: yes or no on prediction of mortality in patients with with creation of intrahepatic anticoagulation therapy. CURRENT cirrhosis. HEPATOLOGY. 68(4):1508-1518. portosystemic shunt (PVR-TIPS) in OPINION IN ORGAN TRANSPLANTATION. I.F.: 14.079 patients with chronic non-cirrhotic, 23(2):250-256. I.F.: 2.869 non-malignant portal vein thrombosis. 10. Barbero-Camps E, Roca-Agujetas V, ZEITSCHRIFT FUR GASTROENTEROLOGIE. Bartolessis I, de Dios C, Fernández-Checa JC, 56(3):221-237. I.F.: 1.612 Letters / I.F.: 49.892 Marí M, Morales A, Hartmann T, Colell A. Cholesterol impairs autophagy- 17. Kerbert AJC, Reverter E, Verbruggen L, 1. Lens S., Forns X., García-Pagán J. Reply. mediated clearance of amyloid beta Tieleman M, Navasa M, Mertens BJA, GASTROENTEROLOGY. 154(5):1551-1552. while promoting its secretion. Rodríguez-Tajes S, de Vree M, Metselaar HJ, I.F.: 20.773 AUTOPHAGY. 14(7):1129-1154. I.F.: 11.100 Chiang FWT, Verspaget HW, van Hoek B, Bosch J, Coenraad MJ. Impact of hepatic 2. Gracia-Sancho J, Guixé-Muntet S. The 11. Maeso-Díaz R., Ortega-Ribera M., encephalopathy on liver transplant many-faced role of autophagy in liver Fernández-Iglesias A., Hide D., Muñoz L., waiting list mortality in regions with diseases. JOURNAL OF HEPATOLOGY. Hessheimer A., Vila S., Francés R., Fondevila different transplantation rates. CLINICAL 68(3):593-594. I.F.: 15.040 C., Albillos A., Peralta C., Bosch J., Tacke F., TRANSPLANTATION. 32(11):e13412. I.F.: 1.518 Cogger V., Gracia-Sancho J. Effects of 3. Berzigotti, Annalisa; Bosch, Jaime; Spordiet aging on liver microcirculatory function Study Investigators. Balancing Exercise- and sinusoidal phenotype. AGING CELL. Review / I.F.: 37.154 Induced Weight Loss With Protein 17(6):e12829. I.F.: 7.627 Caloric Requirement Remains a 1. Hernández-Gea V, Baiges A, Turon F, Challenge in Overweight Patients With 12. Moya A, Ortega-Ribera M, Guimerà X, Garcia-Pagán JC. Idiopathic Portal Cirrhosis Reply. HEPATOLOGY. Sowade E, Zea M, Illa X, Ramon E, Villa R, Hypertension. HEPATOLOGY. 67(4):1645-1646. I.F.: 14.079 Gracia-Sancho J, Gabriel G. Online oxygen 68(6):2413-2423. I.F.: 14.079 monitoring using integrated inkjet- printed sensors in a liver-on-a-chip 2. Vilaseca M., Guixé-Muntet S., Editorial / I.F.: 38.334 system. LAB ON A CHIP - Fernández-Iglesias A., Gracia-Sancho J. MINIATURISATION FOR CHEMISTRY AND Advances in therapeutic options for 1. Fernandez M. Placental Growth Factor: BIOLOGY. 18(14):2023-2035. I.F.: 5.995 portal hypertension. THERAPEUTIC New Treatment Target Bringing Hope in ADVANCES IN GASTROENTEROLOGY. Hepatopulmonary Syndrome. 13. Pulido Á., de Gregorio E., Chandra S., Colell 11:1-19. I.F.: 4.168 HEPATOLOGY. 68(2):404-407. I.F.: 14.079 A., Morales A., Kronenberg M., Marí M. Differential role of cathepsins S and B in 3. Baiges A., Hernández-Gea V., Bosch J. 2. Hernandez-Gea, Virginia; Bureau, hepatic APC-mediated NKT cell Pharmacologic prevention of variceal Christophe. Practice makes better: TIPS activation and cytokine secretion. bleeding and rebleeding. HEPATOLOGY procedures in referral centers. FRONTIERS IN IMMUNOLOGY. 9(391):391. INTERNATIONAL. 12(1):S68-S80. HEPATOLOGY. 67(2):473-475. I.F.: 14.079 I.F.: 5.511 I.F.: 4.117 3. Bosch, J.; Berzigotti, A. Editorial: use of 14. Gómez-Hurtado I, Zapater P, Portune K, 4. Hernández-Gea V, Berbel C, Baiges A, beta-blockers and of band ligation in Juanola O, Fernández-Iglesias A, García-Pagán JC. Acute variceal bleeding: preventing first and recurrent variceal González-Navajas JM, Gracia-Sancho J, Sanz risk stratification and management bleeding-"real life" vs evidence-based Y, Francés R. Improved hemodynamic and (including TIPS). HEPATOLOGY decisions. ALIMENTARY PHARMACOLOGY liver function in portal hypertensive INTERNATIONAL. 12(1):81-90. I.F.: 4.117 AND THERAPEUTICS. 47(8):1222-1223. cirrhotic rats after administration of B. I.F.: 7.357 pseudocatenulatum CECT 7765. 5. Bosch J, Iwakiri Y. The portal EUROPEAN JOURNAL OF NUTRITION. hypertension syndrome: etiology, 4. Escorsell À., García-Pagán J., Bosch J. 58(4):1-12. I.F.: 4.423 classification, relevance, and animal Esophageal Stents for Acute Variceal models. HEPATOLOGY INTERNATIONAL. Bleeding: Expanding the Possibilities. 15. Ortega-Ribera M, Fernández-Iglesias A, Illa 12(1):S1-S10. I.F.: 4.117 DIGESTIVE DISEASES AND SCIENCES. X, Moya A, Molina V, Maeso-Díaz R, Fondevila 63(2):275-276. I.F.: 2.819 C, Peralta C, Bosch J, Villa R, Gracia-Sancho J. 6. Álvarez-Mercado A., Bujaldon E., Resemblance of the human liver sinusoid Gracia-Sancho J., Peralta C. The Role of in a fluidic device with biomedical and Adipokines in Surgical Procedures

180 HEPATIC HEMODYNAMICS AND PORTAL HYPERTENSION. HEMORRHAGE FROM RUPTURED GASTROESOPHAGEAL VARICES 3.6

GRANTS FOR RESEARCH IN PROGRESS García-Pagán JC. Hipertensión Portal Duration: 01/01/2018-31/12/2020 Idiopática. Fisiopatología e identificación Bosch J. CLEVER: Contrast-enhanced de dianas terapéuticas. Marí M. Actuacíón sobre el eje uLtrasound for livEr-disease eValuation: Sponsored by: Ministerio de Economía y sirtuina-1/catepsina como terapia development and validation of a novel Competitividad (MINECO). antiinflamatoria en esteatohepatitis no E-Health-software for Risk-stratification. SAF2016-75767-R alcohólica y obesidad. Sponsored by: European Commission. Duration: 30/12/2016-29/12/2019 Sponsored by: Instituto de Salud Carlos III FP7_People_2013_IAPP (612273) (ISCIII). PI16/00930 Duration: 01/10/2013-30/09/2018 García-Pagán JC. Estudio prospectivo Duration: 01/01/2017-31/12/2019 multicéntrico, aleatorizado del efecto de Escorsell A. Eficacia de la derivación Rivaroxaban sobre la supervivencia y el portosistémica intrahepática (TIPS) en el desarrollo de complicaciones de la tratamiento de la hemorragia aguda por hipertensión portal en pacientes con DOCTORAL THESES varices gástricas: estudio aleatorizado y cirrosis. controlado vs tratamiento convencional. Sponsored by: Instituto de Salud Carlos III Fernández M. Mecanismes moleculars i Sponsored by: Instituto de Salud Carlos III (ISCIII). ICI14/00133 cel·lulars de la neovascularització (ISCIII). PI14/00392 Duration: 01/01/2015-31/12/2019 associada a la hipertensió portal i la Duration: 01/01/2015-31/12/2018 cirrosi hepàtica. García-Pagán JC. Proyecto Integrado de PhD student: Ester Garcia Pras Fernández M. Mecanismos moleculares y Excelencia. Targeting endothelial celulares implicados en la interacción dysfunction in highly prevalent diseases: Fernández M. Mecanismos reguladores de entre obesidad y enfermedad hepática characterization and validation of la angiogénesis mediada por la vía del crónica: papel y potencial terapéutico de prognostic biomarkers and identification factor de crecimiento endotelial (VEGF) la angiogénesis y proteínas CPEB. of potential therapeutic strategies. en hipertensión portal i cirrosis. Sponsored by: Ministerio de Economía y Sponsored by: Instituto de Salud Carlos III PhD student: Javier Gallego Pinos Competitividad (MINECO). (ISCIII). PIE15/00027 SAF2014-55473-R Duration: 01/01/2016-31/12/2019 Marí M, Morales A. Identificación de dianas Duration: 01/01/2015-31/12/2018 terapéuticas en fibrosis hepáticas y Gracia-Sancho J. Capilarización del cáncer. Fernández M. UPROLC: Papel y potencial endotelio sinusoidal hepático en la PhD student: Anna Tutusaus López terapéutico de la respuesta a proteínas cirrosis: caracterización integral para el desplegadas en el cáncer de hígado descubrimiento de nuevas dianas asociado a la obesidad. terapéuticas. Sponsored by: Ministerio de Economía y Sponsored by: Instituto de Salud Carlos III Competitividad (MINECO). (ISCIII). PI17/00012 SAF2017-87988-R Duration: 01/01/2018-31/12/2020 Duration: 01/01/2018-31/12/2020 Gracia-Sancho J. ExoLiver: Liver on a Chip Fernández M. Molecular regulation of the platform for toxicology and drug progression from hepatic steatosis to development. cirrhosis and hepatocellular carcinoma: Sponsored by: Fundació La Caixa. Role and therapeutic potential of CPEB CI16-00052 proteins. Duration: 01/05/2017-31/12/2018 Sponsored by: Asociación Española Contra el Cáncer (AECC). Grupo Estable_2015 Gracia-Sancho J. Capillarization of the Duration: 01/09/2015-31/08/2020 liver sinusoidal endothelium: Orchestration by miRNAs. Fernández M. Role and therapeutic Sponsored by: Gilead Sciences. International potential of CPEB proteins in the Research Scholars Program in Liver Disease. transition from cirrhosis to GILEAD_IRS_16_02 hepatocellular carcinoma. Duration: 02/08/2016-01/08/2019 Sponsored by: Worldwide Cancer Research (WCR). 16-0026 Hernandez-Gea V. La autofagia endotelial Duration: 01/01/2016-31/12/2018 gobierna la respuesta de la célula hepática estrellada al daño hepático: Garcia-Pagán JC. Hemodinàmica hepàtica regeneración o fibrosis? Análisis del i hipertensió portal. secretoma endotelial para el desarrollo Sponsored by: Generalitat de Catalunya. de nuevos tratamientos antifibroticos. AGAUR_SGR17_00517 Sponsored by: Instituto de Salud Carlos III Duration: 01/01/2017-31/12/2020 (ISCIII). FIS PI17/00398

181 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

Inﬂammatory 3.7 bowel disease

TECHNICIANS Montserrat Arroyes (IDIBAPS) LOCATION Miriam Esteller (CIBER) CEK building, ﬂoor 3 Alba Garrido (CIBER) Maria Carme Masamunt (CIBER)

NURSING STAFF

WEB Rebeca Barastegui (HCB) www.clinicbarcelona.org/ Marta Gallego (HCB) en/idibaps/research-areas Àngel Giner (FCRB) TEAM LEADER Julián Panés (HCB) T. 93 227 54 18 STRATEGIC OBJECTIVES [email protected] This IDIBAPS research team has a KEYWORDS 1. Inflammatory bowel diseases translational orientation, aimed at generating RESEARCHERS knowledge in the area of inflammatory bowel 2. Crohn’s disease Faust Feu (HCB) diseases to provide a benefit to patients 3. Ulcerative colitis Glòria Lacima (HCB) suffering from Crohn’s disease or ulcerative 4. Cell therapy Josep Llach (HCB) colitis in the near future, with a special 5. Cross-sectional imaging Ingrid Ordás (HCB) emphasis on the discovery of disease Elena Ricart (HCB) biomarkers, new molecular and cellular María Azucena Salas (IDIBAPS) targets, as well as imaging techniques for diagnosis and monitoring. POST-DOCTORAL RESEARCHERS Helena Bassolas (IDIBAPS) Original publications Isabella Dotti (IDIBAPS) MAIN LINES OF RESEARCH from 2016 to 2018 Elena Ferrer (IDIBAPS) Marisol Veny (IDIBAPS) 1. Autologous hematopoietic stem cell YEAR I.F. TOTAL Q1 Q2 transplantation in refractory Crohn’s 2016 229.49 20 17 2 PRE-DOCTORAL RESEARCHERS disease. Role of host, immune and

2017 247.99 17 13 3 Jesús Castro (HCB) intestinal microbiota related factors on Ana Maria Corraliza (IDIBAPS) the therapeutic response. 2018 198.52 23 19 2 Agnès Fernández (IDIBAPS) Aida Mayorgas (IDIBAPS) 2. Efficacy of mesenchymal stem cells for Lluís Revilla (CIBER) treatment of ﬁstulizing Crohn’s disease.

TEAM INVOLVED IN CIBEREHD AGAUR_SGR17: 00992 TEAM Julián Panés

182 INFLAMMATORY BOWEL DISEASE 3.7

3. Development and optimization of intestinal Development of Anti-fibrosis Drugs for AMERICAN JOURNAL OF epithelial stem cells production. Application Treatment of Crohn's Disease. GASTROENTEROLOGY. 113(7):1009-1016. of the technology for characterization of GASTROENTEROLOGY. 155(1):76-87. I.F.: 10.231 pathobiological aspects of inflammatory I.F.: 20.773 bowel diseases and vitro drug testiing. 7. Sandborn WJ, Panés J, D'Haens GR, Sands 3. Carballal S, Maisterra S, López-Serrano A, BE, Su C, Moscariello M, Jones T, Pedersen R, 4. Transcriptional analysis in IBD as a tool to Gimeno-García AZ, Vera MI, Marín-Garbriel Friedman GS, Lawendy N, Chan G. Safety of understand the pathophysiology of IBD JC, Díaz-Tasende J, Márquez L, Álvarez MA, Tofacitinib for Treatment of Ulcerative and to evaluate therapeutic responses. Hernández L, De Castro L, Gordillo J, Puig I, Colitis, Based on 4. CLINICAL Vega P, Bustamante-Balén M, Acevedo J, GASTROENTEROLOGY AND 5. Microbial antigen specific responses in the Peñas B, López-Cerón M, Ricart E, HEPATOLOGY. S1542-3565(18):31278-3. pathophysiology of Crohn’s disease. Cuatrecasas M, Jimeno M, Pellisé M, I.F.: 7.683 EndoCAR group of the Spanish 6. Optimization of cross sectional imaging Gastroenterological Association and Spanish 8. Olivera P, Sandborn WJ, Panés J, Baumann techniques, for evaluation of the extent, Digestive Endoscopy Society. Real-life C, D'Haens G, Vermeire S, Danese S, severity and prognosis of the inflammatory chromoendoscopy for neoplasia detection Peyrin-Biroulet L . Physicians' perspective lesions in Crohn’s disease. Study and characterisation in long-standing IBD. on the clinical meaningfulness of permanent damage in ulcerative colitis. GUT. 67(1):70-78. I.F.: 17.016 inflammatory bowel disease trial results: an International Organization for the 7. Advanced endoscopic techniques for 4. Siegel C., Whitman C., Spiegel B., Feagan B., Study of Inflammatory Bowel Disease diagnosis and treatment of IBD. Sands B., Loftus E., Panaccione R., D'Haens G., (IOIBD) survey. ALIMENTARY Bernstein C., Gearry R., Ng S., Mantzaris G., PHARMACOLOGY AND THERAPEUTICS. Sartor B., Silverberg M., Riddell R., 47(6):773-783. I.F.: 7.357 Koutroubakis I., O'Morain C., Lakatos P., PUBLICATIONS McGovern D., Halfvarson J., Reinisch W., 9. Rieder, F.; Bettenworth, D.; Ma, C.; Parker, C. Rogler G., Kruis W., Tysk C., Schreiber S., E.; Williamson, L. A.; Nelson, S. A.; van Assche, Originals / I.F.: 198.52 Danese S., Sandborn W., Griffiths A., Moum B., G.; Di Sabatino, A.; Bouhnik, Y.; Stidham, R. W.; Gasche C., Pallone F., Travis S., Panes J., Dignass, A.; Rogler, G.; Taylor, S. A.; Stoker, J.; 1. Panés J., García-Olmo D., Van Assche G., Colombel J., Hanauer S., Peyrin-Biroulet L. Rimola, J.; Baker, M. E.; Fletcher, J. G.; Panes, J.; Colombel J., Reinisch W., Baumgart D., Development of an index to define Sandborn, W. J.; Feagan, B. G.; Jairath, V. An Dignass A., Nachury M., Ferrante M., overall disease severity in IBD. GUT. expert consensus to standardise Kazemi-Shirazi L., Grimaud J., de la Portilla F., 67(2):244-254. I.F.: 17.016 definitions, diagnosis and treatment Goldin E., Richard M., Diez M., Tagarro I., targets for anti-fibrotic stricture Leselbaum A., Danese S., Stift A., 5. Laharie D; Bourreille A; Branche J; Allez M; therapies in Crohn's disease. Tschmelitsch J., Mrak K., Tilg H., Kroberger I., Bouhnik Y; Filippi J; Zerbib F; Savoye G; ALIMENTARY PHARMACOLOGY AND D'Hoore A., De Looze D., Baert F., Pattyn P., Vuitton L; Moreau J; Amiot A; Cosnes J; Ricart THERAPEUTICS. 48(3):347-357. I.F.: 7.357 Zerbib P., Zerbib F., Viennot S., Dupas J., E; Dewit O; Lopez-Sanroman A; Fumery M; Orsoni P., Hebuterne X., Rahili A., Allez M., Carbonnel F; Bommelaer G; Coffin B; Roblin X; 10. Rimola J., Alfaro I., Fernández-Clotet A., Panis Y., Reinshagen M., Scherer R., Sturm A., Van Assche G; Esteve M; Färkkilä M; Gisbert Castro-Poceiro J., Vas D., Rodríguez S., Kruis W., Panés J., García-Olmo D., Van JP; Marteau P; Nahon S; De Vos M; Lambert J; Masamunt M., Ordás I., Ricart E., Panés J. Assche G., Colombel J., Reinisch W., Baumgart Mary JY; Louis E; Groupe d'Etudes Persistent damage on magnetic D., Dignass A., Nachury M., Ferrante M., Thérapeutiques des Affections Inflammatoires resonance enterography in patients with Kazemi-Shirazi L., Grimaud J., de la Portilla F., Digestives. Long-term outcome of Crohn’s disease in endoscopic Goldin E., Richard M., Diez M., Tagarro I., patients with steroid-refractory acute remission. ALIMENTARY Leselbaum A., Danese S., Stift A., severe UC treated with ciclosporin or PHARMACOLOGY AND THERAPEUTICS. Tschmelitsch J., Mrak K., Tilg H., Kroberger I., infliximab. GUT. 67(2):237-243. I.F.: 17.016 48(11-12):1232-1241. I.F.: 7.357 D'Hoore A., De Looze D., Baert F., Pattyn P., Zerbib P., Zerbib F., Viennot S., Dupas J., 6. Ordás I., Domènech E., Mañosa M., 11. Chaparro M, Garre A, Ricart E, Iborra M, Orsoni P. Long-term Efficacy and Safety García-Sánchez V., Iglesias-Flores E., Mesonero F, Vera I, Riestra S, García-Sánchez of Stem Cell Therapy (Cx601) for Rodríguez-Moranta F., Márquez L., Merino O., V, Luisa De Castro M, Martin-Cardona A, Complex Perianal Fistulas in Patients Fernández-Bañares F., Gomollón F., Vera M., Aldeguer X, Mínguez M, de-Acosta MB, Rivero With Crohn's Disease. Gutiérrez A., Llaó J., Gisbert J., Aguas M., Arias M, Muñoz F, Andreu M, Bargalló A, GASTROENTEROLOGY. 154(5):1334-1342. L., Rodríguez-Lago I., Muñoz C., Alcaide N., González-Muñoza C, Pérez Calle JL, I.F.: 20.773 Calvet X., Rodríguez C., Montoro M., García S., García-Sepulcre MF, Bermejo F, Huguet JM, De Castro M., Piqueras M., Pareja L., Ribes J., Cabriada JL, Gutiérrez A, Mañosa M, Villoria A, 2. Danese S, Bonovas S, Lopez A, Fiorino G, Panés J., Esteve M. Post-operative Carbajo AY, Lorente R, García-López S, Sandborn WJ, Rubin DT, Kamm MA, morbidity and mortality of a cohort of Piqueras M, Hinojosa E, Arajol C, Sicilia B, Colombel JF, Sands BE, Vermeire S, Panes J, steroid refractory acute severe Conesa AM, Sainz E, Almela P, Llaó J, Roncero Rogler G, D'Haens G, Peyrin-Biroulet L . ulcerative colitis: Nationwide multicenter O, Camo P, Taxonera C, Domselaar MV, Identification of Endpoints for study of the GETECCU ENEIDA Registry. Pajares R, Legido J, Madrigal R, Lucendo AJ,

183 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

Alcaín G, Doménech E, Gisbert JP, with active Crohn's disease: Results Gonzalo; Rodriguez de Miguel, Cristina; GETECCU study group GETECCU study from a randomised phase II biopsy Fondevila, Constantino; Llach, Josep; Navasa, group. Short and long-term effectiveness substudy. JOURNAL OF CROHN'S AND Miquel; Baron, Todd; Cardenas, Andres;. and safety of vedolizumab in COLITIS. 12(10):1170-1179. I.F.: 6.637 Endoscopic management of bile leaks inflammatory bowel disease: results after liver transplantation: An analysis of from the ENEIDA registry. ALIMENTARY 16. Sands BE, Sandborn WJ, Feagan BG, two high-volume transplant centers. PHARMACOLOGY AND THERAPEUTICS. Lichtenstein GR, Zhang H, Strauss R, Szapary UNITED EUR GASTROENT. 6(1):89-96 48(8):839-851. I.F.: 7.357 P, Johanns J, Panes J, Vermeire S, O'Brien CD, I.F.: 3.477 Yang Z, Bertelsen K, Marano C, Peficitinib-UC 12. Panes, Julian; Vermeire, Severine; Lindsay, Study Group. Peficitinib, an Oral Janus 21. Castro-Poceiro J, Fernández-Clotet A, James O.; Sands, Bruce E.; Su, Chinyu; Kinase Inhibitor, in Moderate-to-Severe Panés J . Mesenchymal stromal cells in Friedman, Gary; Zhang, Haiying; Yarlas, Aaron; Ulcerative Colitis: Results From a the treatment of perianal fistulas in Bayliss, Martha; Maher, Stephen; Cappelleri, Randomized, Phase 2 Study. JOURNAL Crohn's disease. IMMUNOTHERAPY. Joseph C.; Bushmakin, Andrew G.; Rubin, OF CROHN'S AND COLITIS. 12(10):1158-1169. 10(14):1203-1217. I.F.: 3.461 David T. Tofacitinib in Patients with I.F.: 6.637 Ulcerative Colitis: Health-Related Quality 22. Garcia-Planella E., Mañosa M., Chaparro of Life in Phase 3 Randomised 17. Bassolas-Molina, Helena; Raymond, M., Beltrán B., Barreiro-de-Acosta M., Gordillo Controlled Induction and Maintenance Ernest; Labadia, Mark; Wahle, Joseph; J., Ricart E., Bermejo F., García-Sánchez V., Studies. JOURNAL OF CROHN'S AND Ferrer-Picon, Elena; Panzenbeck, Mark; Piqueras M., Llaó J., Gisbert J., Cabré E., COLITIS. 12(2):145-156. I.F.: 6.637 Zheng, Jie; Harcken, Christian; Hughes, Domènech E. Serial semi-quantitative Robert; Turner, Michael; Smith, Dustin; measurement of fecal calprotectin in 13. Domènech E, Panés J, Hinojosa J, Annese Calderdon-Gomez, Elisabeth; Esteller, Miriam; patients with ulcerative colitis in V, Magro F, Sturniolo GC, Bossa F, Fernández Carrasco, Anna; Esteve, Maria; Dotti, Isabella; remission. SCANDINAVIAN JOURNAL OF F, González-Conde B, García-Sánchez V, Maria Corraliza, Ma; Carme Masamunt, Maria; GASTROENTEROLOGY. 53(2):152-157. Dignass A, Herrera JM, Cabriada JL, Guardiola Arajol, Claudia; Guardiola, Jordi; Ricart, Elena; I.F.: 2.629 J, Vecchi M, Portela F, Ginard D, ATTICA Nabozny, Gerald; Salas, Azucena. An ROR Study Group by the Grupo Español de gamma t Oral Inhibitor Modulates IL-17 23. Mira J, Lacima G, Cortés Gil X. Trabajo en Enfermedad de Crohn y Colitis Responses in Peripheral Blood and Perceptions of the public healthcare Ulcerosa [listed at the end of the article] . Intestinal Mucosa of Crohn's Disease system from private-care patients with Addition of granulocyte/monocyte Patients. FRONTIERS IN IMMUNOLOGY. irritable bowel syndrome with apheresis to oral prednisone for 9(2307):2307. I.F.: 5.511 constipation in Spain. REVISTA steroid-dependent ulcerative colitis: A ESPAÑOLA DE ENFERMEDADES randomized, multicentre, clinical trial. 18. Jairath, Vipul; Ordas, Ingrid; Zou, DIGESTIVAS. 110(10):612-620. I.F.: 1.632 JOURNAL OF CROHN'S AND COLITIS. Guangyong; Panes, Julian; Stoker, Jaap; 12(6):687-694. I.F.: 6.637 Taylor, Stuart A.; Santillan, Cynthia; Horsthuis, Karin; Samaan, Mark A.; Shackelton, Lisa M.; Review / I.F.: 35.738 14. Brierley, Charlotte K.; Castilla-Llorente, Stitt, Larry W.; Hindryckx, Pieter; Khanna, Cristina; Labopin, Myriam; Badoglio, Manuela; Reena; Sandborn, William J.; D'Haens, Geert; 1. Snowden J., Panés J., Alexander T., Allez M., Rovira, Montserrat; Ricart, Elena; Dierickx, Feagan, Brian G.; Levesque, Barrett G.; Rimola, Ardizzone S., Dierickx D., Finke J., Hasselblatt Daan; Vermeire, Severine; Hasselblatt, Peter; Jordi. Reliability of Measuring P., Hawkey C., Kazmi M., Lindsay J., Onida F., Finke, Juergen; Onida, Francesco; Cassinotti, Ileo-Colonic Disease Activity in Crohn's Salas A., Saccardi R., Vermeire S., Rovira M., Andrea; Satsangi, Jack; Kazmi, Majid; Disease by Magnetic Resonance Ricart E. Autologous haematopoietic Lopez-Sanroman, Antonio; Schmidt, Carsten; Enterography. INFLAMMATORY BOWEL stem cell transplantation (AHSCT) in Farge, Dominique; Travis, Simon P. L.; Hawkey, DISEASES. 24(2):440-449. I.F.: 4.347 severe Crohn's disease: A review on Chris J.; Snowdens, John A.; European Soc behalf of ECCO and EBMT. JOURNAL OF Blood Marrow Transpl. Autologous 19. González-Suárez B., Rodriguez S., Ricart CROHN'S AND COLITIS. 12(4):476-488. Haematopoietic Stem Cell E., Ordás I., Rimola J., Díaz-González Á., I.F.: 6.637 Transplantation for Crohn's Disease: A Romero C., De Miguel C., Jáuregui A., Araujo I., Retrospective Survey of Long-term Ramirez A., Gallego M., Fernández-Esparrach 2. Yarlas, Aaron; Rubin, David T.; Panes, Julian; Outcomes from the European Society G., Ginés Á., Sendino O., Llach J., Panés J. Lindsay, James O.; Vermeire, Severine; for Blood and Marrow Transplantation. Comparison of Capsule Endoscopy and Bayliss, Martha; Cappelleri, Joseph C.; Maher, JOURNAL OF CROHN'S AND COLITIS. Magnetic Resonance Enterography for Stephen; Bushmakin, Andrew G.; Chen, Lea 12(9):1097-1103. I.F.: 6.637 the Assessment of Small Bowel Lesions Ann; DiBonaventura, Marco. Burden of in Crohn's Disease. INFLAMMATORY Ulcerative Colitis on Functioning and 15. Visvanathan S, Baum P, Salas A, Vinisko R, BOWEL DISEASES. 24(4):775-780. I.F.: 4.347 Well-being: A Systematic Literature Schmid R, Grebe KM, Davis JW, Wallace K, Review of the SF-36 (R) Health Survey. Böcher WO, Padula SJ, Fine JS, Panés J . 20. Sendino, Oriol; Fernandez-Simon, JOURNAL OF CROHN'S AND COLITIS. Selective IL-23 inhibition by Alejandro; Law, Ryan; Abu Dayyeh, Barham; 12(5):600-609. I.F.: 6.637 risankizumab modulates the molecular Leise, Michael; Chavez-Rivera, Karina; profile in the colon and ileum of patients Cordova, Henry; Colmenero, Jordi; Crespo,

184 INFLAMMATORY BOWEL DISEASE 3.7

3. Panés J, Salas A . Past, Present and GASTROENTEROLOGY AND resposta a productes microbians en la Future of Therapeutic Interventions HEPATOLOGY. 16(7):1037-1039. I.F.: 7.683 malaltia inflamatòria intestinal. Targeting Leukocyte Trafficking in PhD student: Elena Ferrer Picón Inflammatory Bowel Disease. JOURNAL OF CROHN'S AND COLITIS. Salas A, Lozano JJ. Estudi transcripcional 12(2):S633-S640. I.F.: 6.637 GRANTS FOR RESEARCH IN PROGRESS de la Colitis Ulcerosa. Caracterizació i cerca de biomarcadors. 4. Dotti I, Salas A . Potential Use of Human Ricart E. Efficacy and safety of autologous PhD student: Núria Planell Picola Stem Cell-Derived Intestinal Organoids hematopoietic stem cells to Study Inflammatory Bowel Diseases. transplantation for refractory Crohn's INFLAMMATORY BOWEL DISEASES. disease after cyclophosphamide-free 24(12):2501-2509. I.F.: 4.347 mobilization. Sponsored by: Instituto de salud Carlos III 5. Fernández-Clotet A., Castro-Poceiro J., (ISCIII). PI17/00513 Panés J. Tofacitinib for the treatment of Duration: 01/01/2018-31/12/2020 ulcerative colitis. EXPERT REVIEW OF CLINICAL IMMUNOLOGY. 14(11):881-892. Salas A. Mecanismes cel·lulars i I.F.: 3.436 moleculars de la malaltia inflamatòria intestinal. 6. Panes J., Reinisch W., Rupniewska E., Khan Sponsored by: Generalitat de Catalunya. S., Forns J., Khalid J., Bojic D., Patel H. Burden AGAUR_SGR17_00992 and outcomes for complex perianal Duration: 01/01/2017-31/12/2020 fistulas in Crohn’s disease: Systematic review. WORLD JOURNAL OF Salas A. Panés J. Transplante autólogo de GASTROENTEROLOGY. 24(42):4821-4834. células madre hematopoyéticas en la I.F.: 3.300 enfermedad de Crohn: factores moleculares, inmunes y microbiológicos 7. Panés J., Ricart E. Can we monitor a implicados en el control de la patient with inflammatory bowel disease enfermedad. and adapt treatment without Sponsored by: Ministerio de Economía y endoscopy? CURRENT DRUG TARGETS. Competitividad (MINECO). 17(10):777-781. I.F.: 3.112 SAF2015-66379-R Duration: 01/01/2016 - 31/12/2018 8. Ciriza-de-los-Rios, Constanza; Minguez, Miguel; Maria Remes-Troche, Jose; Lacima, Salas A. New NEW DEAL: New siRNA Gloria. High-resolution and high-definition Nanotherapy for Inflammatory Bowel anorectal manometry: rediscovering Diseases, targeting Janus kinase 3. anorectal function. REVISTA ESPANOLA Sponsored by: European Commission. DE ENFERMEDADES DIGESTIVAS. H2020_NMBP16-17 (720905) 110(12):794-805. I.F.: 1.632 Duration: 01/01/2017-31/12/2020

Salas A. Cellular mechanisms in Crohn's Letters / I.F.: 1.078 Disease: unraveling new therapeutic avenues. 1. Uchima HI, Araujo IK, Ferrer J, Burrell M, Sponsored by: The Leona M & Harry B Sotomayor A, García-Criado Á, Feu F, Ricart Helmsley Charitable Trust MJ, Llach J, González-Suárez B. Superior Duration: 01/08/2014-31/03/2019 mesenteric artery pseudoaneurysm ﬁstulised to the small intestine in a pancreas-kidney transplant recipient: Can it be detected by capsule DOCTORAL THESES endoscopy? GASTROENTEROLOGIA Y HEPATOLOGIA. 41(2):109-111. I.F.: 1.078 Salas A. Resposta T especíﬁca contra antígens de la microbiota comensal en la malaltia de Crohn i inhibició de RORyt Editorial / I.F.: 7.683 com a estratègia terapèutica. PhD student: Helena Bassolas Molina 1. Panés J, Rimola J . Therapeutic objectives in Crohn's disease: mucosal Salas A, Dotti I. Ús d'organoides humans or transmural healing? CLINICAL per a l'estudi de la barrera epitelial i la

185 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

Cholestasis 3.8 and bone pathology

RESEARCHERS Lluisa Álvarez (HCB) LOCATION Ana Isabel Monegal (HCB) HCB building Pilar Peris (HCB)

POST-DOCTORAL RESEARCHERS Susana Jurado (FCRB)

PRE-DOCTORAL RESEARCHERS KEYWORDS Anna Reig (FCRB) 1. Primary biliary cholangitis TEAM LEADER 2. Primary sclerosing cholangitis Albert Parés (HCB) NURSING STAFF Pilar Sesé (HCP) 3. Autoimmune hepatitis T. 93 227 57 53 4. Osteoporosis [email protected] 5. Bone metabolism 6. Pruritus STRATEGIC OBJECTIVES

1. Epidemiology, natural history and treatment in cholestatic diseases. 2. Natural history diagnosis, prognosis and treatment of autoimmune hepatitis . Original publications 3. Phenotype and prognosis in primary from 2016 to 2018 sclerosing cholangitis.

YEAR I.F. TOTAL Q1 Q2 4. Itching of cholestasis. 5. Presentation forms of autoimmune 2016 41.48 7 6 1 hepatitis. 2017 87.79 11 6 4 6. Osteoporosis in cholestatic diseases. TEAM LEADER 7. 2018 76.1 10 5 1 Núria Guañabens (HCB) Osteoporosis in premenopausal women and men. T. 93 227 54 00 (Ext.: 2235) 8. Bone remodelling in liver transplantation. [email protected] 9. Management of vertebral fractures in osteoporosis.

TEAM INVOLVED IN 10. Rare bone diseases. CIBEREHD TEAM Albert Parés and Núria Guañabens

186 CHOLESTASIS AND BONE PATHOLOGY 3.8

MAIN LINES OF RESEARCH RESEARCH GROUP GN, Thorburn D, Hirschfield G, LaRusso NF, BONE METABOLIC DISEASE Lindor KD, Zachou K, Poupon R, Trivedi PJ, 1. Epidemiology, natural history and Verhelst X, Janssen HLA, Hansen BE, therapeutic response of chronic GLOBAL PBC Study Group. Milder disease cholestatic disorders in adults. stage in patients with primary biliary 2. Evaluation of the factors of treatment cholangitis over a 44-year period: A response, and new treatment regimens in changing natural history. HEPATOLOGY. patients withsuboptimal response to 67(5):1920-1930. I.F.: 14.079 ursodeoxycholic acid. 3. Development of new prognostic scores in GROUP LEADER 4. Harms MH, Lammers WJ, Thorburn D, primary biliary cholangitis. Núria Guañabens (HCB) Corpechot C, Invernizzi P, Janssen HLA, 4. Pruritus in chronic cholestasis: Battezzati PM, Nevens F, Lindor KD, Floreani Pathogenesis and treatment. The research group consists of A, Ponsioen CY, Mayo MJ, Dalekos GN, Bruns 5. Pathogenesis of osteoporosis and fracture rheumatologists specialized in metabolic bone T, Parés A, Mason AL, Verhelst X, Kowdley KV, development in primary biliary cholangitis disease, a specialist in clinical analysis and a Goet JC, Hirschfield GM, Hansen BE, van and other chronic cholestatic disorders. biologist who is dedicated specifically to Buuren HR, Global PBC Study Group. Major 6. Course and prognosis in primary studies in cell cultures. Hepatic Complications in Ursodeoxycholic sclerosing cholangitis. The group is a world leader in bone pathology Acid-Treated Patients With Primary Biliary 7. Presentation, course and prognosis of of liver diseases and liver transplantation, as Cholangitis: Risk Factors and Time Trends autoimmune hepatitis. well as in male osteoporosis and bone in Incidence and Outcome. AMERICAN 8. Osteoporosis in premenopausal women turnover markers. It has a close collaboration JOURNAL OF GASTROENTEROLOGY. and in males. Study of the clinical with the group of cholestasis. 113(2):254-264. I.F.: 10.231 characteristics and mechanisms involved in the development of the disorder. 5. Reig, Anna; Sese, Pilar; Pares, Albert. 9. Osteoporosis in primary biliary cholangitis. Effects of Bezafibrate on Outcome and Clinical and experimental evaluation. PUBLICATIONS Pruritus in Primary Biliary Cholangitis 10. Osteoporosis in liver transplantation. With Suboptimal Ursodeoxycholic Acid 11. Evaluation of bone remodelling regulators Originals / I.F.: 76.1 Response. AMERICAN JOURNAL OF in the pathogenesis of osteoporosis. GASTROENTEROLOGY. 113(1):49-55. I.F.: 10.231 12. Biomarkers in Paget disease. 1. Alberts R; de Vries EMG; Goode EC; Jiang X; Sampaziotis F; Rombouts K; Böttcher K; 6. Gifre L, Humbert L, Muxi A, Del Rio L, Vidal J, Folseraas T; Weismüller TJ; Mason AL; Wang Portell E, Monegal A, Guañabens N, Peris P. W; Alexander G; Alvaro D; Bergquist A; Analysis of the evolution of cortical and RESEARCH GROUP Björkström NK; Beuers U; Bjornsson E; trabecular bone compartments in the CHOLESTASIS Boberg KM; Bowlus CL; Bragazzi MC; proximal femur after spinal cord injury by Carbone M; Chazouillères O; Cheung A; 3D-DXA. OSTEOPOROSIS Dalekos G; Eaton J; Eksteen B; Ellinghaus D; INTERNATIONAL. 29(1):201-209. I.F.: 3.857 Färkkilä M; Festen EAM; Floreani A; Franceschet I; Gotthardt DN; Hirschfield GM; 7. Lemoinne S., Pares A., Reig A., Ben Hoek BV. Genetic association analysis Belkacem K., Kemgang Fankem A., Gaouar F., identifies variants associated with Poupon R., Housset C., Corpechot C., disease progression in primary Chazouillères O. Primary sclerosing GROUP LEADER sclerosing cholangitis. GUT. cholangitis response to the combination Albert Parés (HCB) 67(8):1517-1524. I.F.: 17.016 of fibrates with ursodeoxycholic acid: French–Spanish experience. CLINICS The research group consist of clinicians 2. Kowdley K., Luketic V., Chapman R., AND RESEARCH IN HEPATOLOGY AND (hepatologists) who follow a large number Hirschfield G., Poupon R., Schramm C., GASTROENTEROLOGY. 42(6):521-528. of patients with autoimmune cholestatic Vincent C., Rust C., Parés A., Mason A., I.F.: 2.623 diseases, basically primary biliary cholangitis, Marschall H., Shapiro D., Adorini L., Sciacca C., autoimmune hepatitis and primary sclerosing Beecher-Jones T., Böhm O., Pencek R., Jones 8. Parés A, Albillos A, Andrade RJ, Berenguer cholangitis. D. A randomized trial of obeticholic acid M, Crespo J, Romero-Gómez M, Vergara M, The group actively participates in international monotherapy in patients with primary Vendrell B, Gil A . Primary biliary cholangitis in research groups in these diseases and they biliary cholangitis. HEPATOLOGY. Spain. Results of a Delphi study of contribute in the knowledge of the phenotype, 67(5):1890-1902. I.F.: 14.079 epidemiology, diagnosis, follow-up and natural history, diagnosis, prognosis and treatment. REVISTA ESPAÑOLA DE treatment of these diseases. 3. Murillo Perez CF, Goet JC, Lammers WJ, ENFERMEDADES DIGESTIVAS. Close collaboration with the bone Gulamhusein A, van Buuren HR, Ponsioen CY, 110(10):641-649. I.F.: 1.632 pathology group. Carbone M, Mason A, Corpechot C, Invernizzi P, Mayo MJ, Battezzati PM, Floreani A, Pares 9. Redondo L, Puigoriol E, Rodríguez JR, Peris A, Nevens F, Kowdley KV, Bruns T, Dalekos P, Kanterewicz E. Usefulness of the

187 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

Trabecular Bone Score for assessing the la osteoclastogénesis. risk of osteoporotic fracture. REVISTA Sponsored by: Instituto de Salud Carlos III CLINICA ESPAÑOLA. 218(3):121-127. I.F.: 1.184 (ISCIII). PI17/00444 Duration: 01/01/2018-31/12/2020 10. Florez H., Mandelikova S., Filella X., Monegal A., Guañabens N., Peris P. Clinical Parés A. Efecto del bezafibrato sobre el significance of increased serum levels of prurito de la colestasis. Mecanismos FGF-23 in fibrous dysplasia. MEDICINA patogénicos. CLINICA. 151(2):65-67. I.F.: 1.168 Sponsored by: Instituto de Salud Carlos III (ISCIII). PI15/00797 Duration: 01/01/2016-30/06/2020 Review / I.F.: 10.468

1. Guañabens N, Parés A . Osteoporosis in chronic liver disease. LIVER DOCTORAL THESES INTERNATIONAL. 38(5):776-785. I.F.: 4.500 Parés A, Caballeria LL. Detección precoz de 2. Parés A., Guañabens N. Primary biliary ﬁbrosis hepática en población adulta. cholangitis and bone disease. PhD student: Ingrid Cecibel Arteaga Pillasagua BAILLIERE'S BEST PRACTICE AND RESEARCH IN CLINICAL GASTROENTEROLOGY. 34-35:63-70. I.F.: 3.632

3. Parés A. Primary biliary cholangitis. MEDICINA CLINICA. 151(6):242-249. I.F.: 1.168

4. Guañabens N., Blanch J., Martínez-Díaz-Guerra G., Muñoz Torres M. Identiﬁcation of hypophosphatasia in a clinical setting: Clinical manifestations and diagnostic recommendations in adult patients. MEDICINA CLINICA. 150(2):75-79. I.F.: 1.168

Case Reports / I.F.: 5.245

1. Fustà X, Combalia A, Guañabens N, Iranzo P. Uncommon local reaction at the injection site of subcutaneous methotrexate. RHEUMATOLOGY. 57(1):27. I.F.: 5.245

GRANTS FOR RESEARCH IN PROGRESS

Guañabens N. Efectos de la bilirrubina y ácidos biliares sobre las células reguladoras del remodelado óseo. Estudio in vitro en células osteocitarias MLO-A5/MLO-Y4. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI14/00478 Duration: 01/01/2015-30/06/2019

Guañabens N. Efectos de la bilirrubina y ácidos biliares sobre osteoclastos humanos in vitro y sobre el patrón de expresión de MicroRNAs implicados en

188 MITOCHONDRIAL REGULATION OF CELL DEATH AND STEATOHEPATITIS 3.9

Mitochondrial regulation of 3.9 cell death and steatohepatitis

STRATEGIC OBJECTIVES

LOCATION The overall aim is to examine the cell biology CEK building, ﬂoor 4 of lipids and cholesterol trafficking in liver diseases and neurodegeneration. This includes the role of mitochondrial cholesterol and sphingolipids in steatohepatitis, liver cancer, liver ﬁbrogenesis, hepatic ischemia/reperfusion injury, Alzheimer’s KEYWORDS disease and lysosomal storage disorders. 1. Cholesterol/sphingolipids TEAM LEADER 2. Mitochondrial death José Carlos Fernández-Checa (IIBB-CSIC) 3. Oxidative stress T. 93 227 57 09 4. Alcoholic and non-alcoholic [email protected] MAIN LINES OF RESEARCH

steatohepatitis (ASH/NASH) 5. Lipid therapies 1. Sphingolipid and mitochondrial RESEARCHERS oxidative-stress regulation of cell death. Joan Caballeria (HCB) 2. Mechanisms responsible for cholesterol Carmen García (IIBB-CSIC) transport to the mitochondria and role in NASH, hepatocellular carcinoma and POST-DOCTORAL RESEARCHERS Alzheimer’s disease. Original publications Laura Conde (CIBER) 3. Translational research in nonalcoholic from 2016 to 2018 Raquel Fucho (IIBB-CSIC) steatohepatitis (NASH): Development of Anna Moles (IIBB-CSIC) NASH in a humanized mouse model to YEAR I.F. TOTAL Q1 Q2 Vicente Ribas (IIBB-CSIC) identify potential targets in human NASH. 2016 62.32 8 7 1 Sandra Torres (IIBB-CSIC) 4. Contribution of acid sphingomyelinase in acetaminophen induced acute liver failure. 2017 101.61 10 10 - PRE-DOCTORAL RESEARCHERS 5. Development of non-invasive diagnostic 2018 111.64 12 10 2 Naroa Insausti (IIBB-CSIC) methods for diagnosis and prognosis in David Robles (IIBB-CSIC) alcohol-induced liver disease. Estel Solsona (IIBB-CSIC) 6. Mitochondrial cholesterol and glycosphingolipids in liver ﬁbrosis. TECHNICIANS Reciprocal regulation between HIF1a TEAM INVOLVED IN Gemma Gay (IIBB-CSIC) and StARD1 in steatohepatitis and CIBEREHD Susana Núñez (CIBER) hepatocellular carcinoma. AGAUR_SGR17: 01112 TEAM José Carlos Fernández-Checa

189 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

7. Establishment of a mouse model with a 5. Barbero-Camps E, Roca-Agujetas V, EXPERIMENTAL AND CLINICAL humanized liver to study ALD and NASH. Bartolessis I, de Dios C, Fernández-Checa JC, INVESTIGATION : THE OFFICIAL JOURNAL 8. ER stress-mitochondrial cholesterol axis in Marí M, Morales A, Hartmann T, Colell A. OF THE INTERNATIONAL SOCIETY OF obesity-associated insulin resistance and Cholesterol impairs autophagy- AMYLOIDOSIS. 25(2):75-78. I.F.: 4.048 comorbidities mediated clearance of amyloid beta while promoting its secretion. 10. Hadj Abdallah N, Baulies A, Bouhlel A, AUTOPHAGY. 14(7):1129-1154. I.F.: 11.100 Bejaoui M, Zaouali MA, Ben Mimouna S, Messaoudi I, Fernandez-Checa JC, García PUBLICATIONS 6. Caballería L, Pera G, Arteaga I, Rodríguez L, Ruiz C, Ben Abdennebi H. Zinc mitigates Alumà A, Morillas RM, de la Ossa N, Díaz A, renal ischemia-reperfusion injury in rats by Originals / I.F.: 101.614 Expósito C, Miranda D, Sánchez C, Prats RM, modulating oxidative stress, endoplasmic Urquizu M, Salgado A, Alemany M, Martinez A, reticulum stress, and autophagy. JOURNAL 1. Ouyang X, Han SN, Zhang JY, Dioletis E, Majeed I, Fabrellas N, Graupera I, Planas R, OF CELLULAR PHYSIOLOGY. Nemeth BT, Pacher P, Feng D, Bataller R, Ojanguren I, Serra M, Torán P, Caballería J, 233(11):8677-8690. I.F.: 3.923 Cabezas J, Stärkel P, Caballeria J, Pongratz Ginès P . High Prevalence of Liver Fibrosis RL, Cai SY, Schnabl B, Hoque R, Chen Y, Yang Among European Adults with Unknown 11. Hadj Abdallah N, Baulies A, Bouhlel A, WH, Garcia-Martinez I, Wang FS, Gao B, Liver Disease. A Population-Based Bejaoui M, Zaouali MA, Ben Mimouna S, Torok NJ, Kibbey RG, Mehal WZ. Digoxin Study. CLINICAL GASTROENTEROLOGY Messaoudi I, Fernandez-Checa JC, García Suppresses Pyruvate Kinase AND HEPATOLOGY. 16(7):1138-1145. Ruiz C, Ben Abdennebi H. The effect of zinc M2-Promoted HIF-1? Transactivation in I.F.: 7.683 acexamate on oxidative stress, Steatohepatitis. CELL METABOLISM. inflammation and mitochondria induced 27(2):339-350. I.F.: 20.565 7. Ampuero, Javier; Aller, Rocio; apoptosis in rat model of renal warm Gallego-Duran, Rocio; Banales, Jesus M.; ischemia. BIOMEDICINE AND 2. Estes C, Anstee QM, Arias-Loste MT, Crespo, Javier; Garcia-Monzon, Carmelo; PHARMACOTHERAPY. 105:573-581. I.F.: 3.457 Bantel H, Bellentani S, Caballeria J, Colombo Pareja, Maria Jesus; Vilar-Gomez, Eduardo; M, Craxi A, Crespo J, Day CP, Eguchi Y, Geier Caballeria, Juan; Escudero-Garcia, 12. Massey V., Qin L., Cabezas J., Caballeria J., A, Kondili LA, Kroy DC, Lazarus JV, Loomba R, Desamparados; Gomez-Camarero, Judith; Sancho-Bru P., Bataller R., Crews F. Manns MP, Marchesini G, Nakajima A, Negro Calleja, Jose Luis; Latorre, Mercedes; Albillos, TLR7-let-7 Signaling Contributes to F, Petta S, Ratziu V, Romero-Gomez M, Sanyal Agustin; Salmeron, Javier; Aspichueta, Ethanol-Induced Hepatic Inflammatory A, Schattenberg JM, Tacke F, Tanaka J, Patricia; Lo Iacono, Oreste; Frances, Ruben; Response in Mice and in Alcoholic Trautwein C, Wei L, Zeuzem S, Razavi H. Benlloch, Salvador; Fernandez-Rodriguez, Hepatitis. ALCOHOLISM: CLINICAL AND Modeling NAFLD disease burden in Conrado; Garcia-Samaniego, Javier; Estevez, EXPERIMENTAL RESEARCH. China, France, Germany, Italy, Japan, Pamela; Andrade, Raul J.; Turnes, Juan; 42(11):2107-2122. I.F.: 3.183 Spain, United Kingdom, and United Romero-Gomez, Manuel; HEPAmet Registry. States for the period 2016-2030. The effects of metabolic status on JOURNAL OF HEPATOLOGY. non-alcoholic fatty liver disease-related Review / I.F.: 3.831 69(4):896-904. I.F.: 15.040 outcomes, beyond the presence of obesity. ALIMENTARY PHARMACOLOGY 1. Moles A., Torres S., Baulies A., Garcia-Ruiz 3. Delia Blaya; Beatriz Aguilar-Bravo; Fengie AND THERAPEUTICS. 48(11-12):1260-1270. C., Fernandez-Checa J. Mitochondrial- Hao; Silvia Casacuberta-Serra; Mar Coll; Luis I.F.: 7.357 lysosomal axis in acetaminophen Perea; Julia Vallverdu; Isabel Graupera; Elisa hepatotoxicity. FRONTIERS IN Pose; Barquinero Mañez, Jordi; Francisco 8. Baulies A, Montero J, Matías N, Insausti N, PHARMACOLOGY. 9:453. I.F.: 3.831 Javier Cubero; Juan Caballería; Pere Ginès; Terrones O, Basañez G, Vallejo C, Conde de Pau Sancho-Bru. Expression of La Rosa L, Martinez L, Robles D, Morales A, microRNA-155 in inflammatory cells Abian J, Carrascal M, Machida K, Kumar DBU, Clinical Guidelines / I.F.: 1.078 modulates liver injury. HEPATOLOGY. Tsukamoto H, Kaplowitz N, Garcia-Ruiz C, 68(2):691-706. I.F.: 14.079 Fernández-Checa JC . The 2-oxoglutarate 1. Aller R., Fernández-Rodríguez C., lo Iacono carrier promotes liver cancer by O., Bañares R., Abad J., Carrión J., 4. Friedman S., Ratziu V., Harrison S., sustaining mitochondrial GSH despite García-Monzón C., Caballería J., Berenguer M., Abdelmalek M., Aithal G., Caballeria J., cholesterol loading. REDOX BIOLOGY. Rodríguez-Perálvarez M., Miranda J., Francque S., Farrell G., Kowdley K., Craxi A., 14:164-177. I.F.: 7.126 Vilar-Gómez E., Crespo J., García-Cortés M., Simon K., Fischer L., Melchor-Khan L., Vest J., Reig M., Navarro J., Gallego R., Genescà J., Wiens B., Vig P., Seyedkazemi S., Goodman Z., 9. Pané A, Ruiz S, Orois A, Martínez D, Arias-Loste M., Pareja M., Albillos A., Muntané J., Wong V., Loomba R., Tacke F., Sanyal A., Squarcia M, Sastre L, Ruiz P, Caballería J, Jorquera F., Solà E., Hernández-Guerra M., Rojo Lefebvre E. A randomized, Hanzu FA, Halperin I. Primary adrenal M., Salmerón J., Caballería L., Diago M., Molina E., placebo-controlled trial of cenicriviroc insufficiency due to hereditary Bataller R., Romero-Gómez M. Consensus for treatment of nonalcoholic apolipoprotein AI amyloidosis: document. Management of non-alcoholic steatohepatitis with fibrosis. endocrine involvement beyond fatty liver disease (NAFLD). Clinical HEPATOLOGY. 67(5):1754-1767. I.F.: 14.079 hypogonadism. AMYLOID : THE practice guideline. GASTROENTEROLOGIA INTERNATIONAL JOURNAL OF Y HEPATOLOGIA. 41(5):328-349. I.F.: 1.078

190 MITOCHONDRIAL REGULATION OF CELL DEATH AND STEATOHEPATITIS 3.9

GRANTS FOR RESEARCH IN PROGRESS

Fernández-Checa JC. Mitochondrial Regulation of Cell Death and Role in Liver Diseases. Sponsored by: Instituto de Salud Carlos III (ISCIII). CB06/04/0035 Duración: 01/01/2018-31/12/2018

Fernández-Checa JC. Regulation and contribution of HIF-1 and StARD1 to steatohepatitis and hepatocellular carcinoma. Sponsored by: Ministerio de Economía y Competitividad (MINECO). SAF2015-069944 Duration: 01/01/2016-31/12/2019

Fernández-Checa JC. COST Action CA17112 Prospective European Drug-Induced Liver Injury Network. Sponsored by: European Commission. H2020. Duration: 01/04/2018-31/03/2022

Fernández-Checa JC. Mechanisms and impact of StARD1 activation and mitochondrial cholesterol in ALD. Sponsored by: National Institute of Alcohol Abuse and Alcoholism Duration: 01/01/2014-31/12/2018

García-Ruiz C. Investigación traslacional en esteatohepatitis no alcohólica (ehna): desarrollo de Ehna en un modelo murino con hígado humanizado para la identiﬁcación de dianas Terapeuticas. Sponsored by: Ministerio de Economía y Competitividad (MINECO). SAF2017-85877-R Duration: 01/01/2018-31/12/2020

Ribas V. Papel de colesterol mitocondrial en carcinoma hepatocelular. Sponsored by: Ministerio de Economía y Competitividad (MINECO). SAF2015-735579-JIN Duration: 01/01/2017-31/12/2019

191 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

Liver transplantation 3.10 and graft viability

PRE-DOCTORAL RESEARCHERS Maryury Andrea Calvo (HCB) LOCATION Cindy Ávalos (IDIBAPS) CEK building, ﬂoor 3 Esther Bujaldon (IDIBAPS) Ana Teresa Menjivar (FCRB) Elsa Negrete (IDIBAPS)

TECHNICIANS Marta Martinez (IDIBAPS) KEYWORDS Xavier Muñoz (CIBER) 1. Liver transplantation TEAM LEADER David Sabater (CIBER) 2. Graft viability Miquel Navasa (HCB) 3. Immunosuppression T. 93 227 57 53 (Ext.: 4406) 4. Allograft tolerance [email protected]

5. Hepatic ischemia-reperfusion injury STRATEGIC OBJECTIVES

GROUP LEADER Carmen Peralta (IDIBAPS) Aloimmune response and T. 93 227 54 00 (Ext.: 4177) immunosuppression. Operational Tolerance. [email protected] Ischemic reperfussion injury. Evaluation of new ways of graft preservation. Ex-vivo perfusion devices. Original publications RESEARCHERS Complications of immunosuppression. from 2016 to 2018 Annabel Blasi (HCB) Prevention and treatment of cardiovascular YEAR I.F. TOTAL Q1 Q2 Mercedes Brunet (HCB) risk factors after liver transplantation. Jordi Felix Colmenero (HCB) 14 2016 106.38 22 3 Gonzalo Crespo (HCB) 2017 94.43 25 11 8 Constantino Fondevila (HCB) 2018 192.79 32 22 6 Juan Carlos García-Valdecasas (HCB) MAIN LINES OF RESEARCH Joan Rosello (IIBB-CSIC) 1. Evaluation of the impact of alloreactivity in POST-DOCTORAL RESEARCHERS graft outcome. Diferent studies are ongoing Amelia Judith Hessheimer (HCB) aimed at investigating the role of different TEAM INVOLVED IN Olga Millán (CIBER) markers of the immunosuppressive CIBEREHD Ana Isabel Álvarez (IDIBAPS) balance and graft outcome after LT. A AGAUR_SGR17: 00551 María Eugenia Cornide (IDIBAPS) prospective, multicentre, European trial has Jose Gulfo (CIBER) been started to translate the results of the Monica Bibiana Jimenez (IDIBAPS) studies done by the group in operational Floriana Rotondo (IDIBAPS) tolerance into clinical practice. TEAM Miquel Navasa

192 LIVER TRANSPLANTATION AND GRAFT VIABILITY 3.10

2. In the field of organ retrieval, we are Cirrhosis awaiting liver transplantation. decompensated cirrhosis: beyond INR. characterizing new targets based on JOURNAL OF HEPATOLOGY. HEPATOLOGY. 68(6):2325-2337. I.F.: 14.079 adipocytokines modulation and 69(6):1250-1259. I.F.: 15.040 investigating the protective effect of 6. Mauro E, Crespo G, Montironi C, Londoño polyethilenglycol in the preservation 2. Crespo G., Trota N., Londoño M., Mauro E., MC, Hernández-Gea V, Ruiz P, Sastre L, solutions. We are conducting several Baliellas C., Castells L., Castellote J., Tort J., Forns Lombardo J, Mariño Z, Díaz A, Colmenero J, studies evaluating ex-vivo perfusion X., Navasa M. The efficacy of direct anti-HCV Rimola A, Garcia-Pagán JC, Brunet M, Forns devices. drugs improves early post-liver transplant X, Navasa M . Portal pressure and liver survival and induces significant changes in stiffness measurements in the prediction 3. Prevention and treatment of cardiovascular waiting list composition. JOURNAL OF of fibrosis regression after SVR in risk factors after liver transplantation. HEPATOLOGY. 69(1):11-17. I.F.: 15.040 recurrent hepatitis C. HEPATOLOGY. Studies on cardiovascular risk factors in 67(5):1683-1694. I.F.: 14.079 patients with liver transplantation are 3. Londoño M., Souza L., Lozano J., Miquel R., ongoing. Abraldes J., Llovet L., Quaglia A., Rimola A., 7. Sánchez-Cabús S., Cherqui D., Rashidian N., Navasa M., Sánchez-Fueyo A. Molecular Pittau G., Elkrief L., Vanlander A., Toso C., profiling of subclinical inflammatory Fondevila C., Cunha A., Berney T., Castaing D., lesions in long-term surviving adult liver de Hemptinne B., Fuster J., Rogiers X., Adam RESEARCH GROUP transplant recipients. JOURNAL OF R., Majno P., García-Valdecasas J., Troisi R. PROTECTIVE STRATEGIES AGAINST HEPATOLOGY. 69(3):626-634. I.F.: 15.040 Left-liver Adult-to-Adult Living Donor Liver HEPATIC ISCHEMIA-REPERFUSION Transplantation: Can It Be Improved? A INJURY 4. Belli L, Perricone G, Adam R, Cortesi P, Retrospective Multicenter European Strazzabosco M, Facchetti R, Karam V, Study. ANNALS OF SURGERY. Salizzoni M, Andujar R, Fondevila C, De 268(5):876-884. I.F.: 9.203 Simone P, Morelli C, Fabregat-Prous J, Samuel D, Agarwaal K, Moreno Gonzales E, 8. Staiger RD, Cimino M, Javed A, Biondo S, Charco R, Zieniewicz K, De Carlis L, Duvoux C. Fondevila C, Périnel J, Aragão AC, Torzilli G, Impact of DAAs on liver transplantation: Wolfgang C, Adham M, Pinto-Marques H, major effects on the evolution of Dutkowski P, Puhan MA, Clavien PA . The GROUP LEADER indications and results. An ELITA study Comprehensive Complication Index Carmen Peralta (IDIBAPS) based on the ELTR registry. JOURNAL OF (CCI®) is a Novel Cost Assessment Tool for HEPATOLOGY. 69(4):810-817. I.F.: 15.040 Surgical Procedures. ANNALS OF The investigations led by Carmen Peralta are SURGERY. 268(5):784-791. I.F.: 9.203 pioneers in the study of experimental surgical, 5. Blasi A, Calvo A, Prado V, Reverter E, technological and pharmacological strategies Reverter JC, Hernández-Tejero M, Aziz F, 9. Maeso-Díaz R., Ortega-Ribera M., (in vivo pharmacological treatments, Amoros A, Cardenas A, Fernández J. Fernández-Iglesias A., Hide D., Muñoz L., improvements in preservation solutions, Coagulation failure in patients with Hessheimer A., Vila S., Francés R., Fondevila ischemic preconditioning, etc.) that protect Acute-on-Chronic Liver Failure (ACLF) and C., Albillos A., Peralta C., Bosch J., Tacke F., livers against damage induced by ischemia-reperfusion and increase the tolerance of steatotic livers and reduced-size liver grafts against the risk that show these liver types to damage and regenerative failure when they are submitted to transplantation or hepatic resections.

PUBLICATIONS

Originals / I.F.: 192.794

1. Solà E, Solé C, Simón-Talero M, Martín-Llahí M, Castellote J, Garcia-Martínez R, Moreira R, Torrens M, Márquez F, Fabrellas N, de Prada G, Huelin P, Lopez Benaiges E, Ventura M, Manríquez M, Nazar A, Ariza X, Suñé P, Graupera I, Pose E, Colmenero J, Pavesi M, Guevara M, Navasa M, Xiol X, Córdoba J, Vargas V, Ginès P . Midodrine &Albumin for preventing complications in patients with GROUP Carmen Peralta

193 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

Cogger V., Gracia-Sancho J. Effects of aging Fuster Obregón J. Role of Kupffer cells in INTERNATIONAL JOURNAL OF on liver microcirculatory function and the progression of CRC liver metastases MOLECULAR SCIENCES. 19(9):2479. sinusoidal phenotype. AGING CELL. after the first stage of ALPPS. SCIENTIFIC I.F.: 3.687 17(6):e12829. I.F.: 7.627 REPORTS. 8(1):8089. I.F.: 4.122 21. Sendino, Oriol; Fernandez-Simon, 10. Lombardo-Quezada J, Sanclemente G, 15. Rovira J, Ramírez-Bajo MJ, Alejandro; Law, Ryan; Abu Dayyeh, Barham; Colmenero J, Español-Rego M, Arias MT, Ruiz Banon-Maneus E, Lazo-Rodríguez M, Leise, Michael; Chavez-Rivera, Karina; P, Mauro E, Sastre L, Crespo G, Rimola A, Moya-Rull D, Hierro-Garcia N, Tubita V, Piñeiro Cordova, Henry; Colmenero, Jordi; Crespo, Moreno A, Lozano F, Navasa M. GJ, Revuelta I, Ventura-Aguiar P, Cucchiari D, Gonzalo; Rodriguez de Miguel, Cristina; Mannose-binding lectin deficient donors Oppenheimer F, Brunet M, Campistol JM, Fondevila, Constantino; Llach, Josep; Navasa, increase the risk of bacterial infection and Diekmann F . Tofacitinib halts progression Miquel; Baron, Todd; Cardenas, Andres. bacterial infection-related mortality after of graft dysfunction in a rat model of mixed Endoscopic management of bile leaks liver transplantation. AMERICAN JOURNAL cellular and humoral rejection. after liver transplantation: An analysis of OF TRANSPLANTATION. 18(1):197-206. TRANSPLANTATION. 102(7):1075-1084. two high-volume transplant centers. I.F.: 6.493 I.F.: 3.960 UNITED EUR GASTROENT. 6(1):89-96. I.F.: 3.477 11. Manzardo C, Londoño MC, Castells L, 16. Ortega-Ribera M, Fernández-Iglesias A, Illa Testillano M, Luis Montero J, Peñafiel J, X, Moya A, Molina V, Maeso-Díaz R, Fondevila 22. Pommergaard HC; Rostved AA; Adam R; Subirana M, Moreno A, Aguilera V, Luisa C, Peralta C, Bosch J, Villa R, Gracia-Sancho J. Thygesen LC; Salizzoni M; Gómez Bravo MA; González-Diéguez M, Calvo-Pulido J, Xiol X, Resemblance of the human liver sinusoid Cherqui D; De Simone P; Boudjema K; Salcedo M, Cuervas-Mons V, Manuel Sousa J, in a fluidic device with biomedical and Mazzaferro V; Soubrane O; Garcia- Suarez F, Serrano T, Ignacio Herrero J, pharmaceutical applications. Valdecasas JC; Fabregat Prous J; Pinna AD; Jiménez M, Fernandez JR, Giménez C, Del BIOTECHNOLOGY AND BIOENGINEERING. O'Grady J; Karam V; Duvoux C; Rasmussen A; Campo S, Esteban-Mur JI, Crespo G, de la 115(10):2585-2594. I.F.: 3.952 European Liver and Intestine Transplant Rosa G, Rimola A, Miro JM, and the FIPSE Association (ELITA). Locoregional LT-HIV investigators. Direct-acting antivirals 17. Llovet JM, Pavel M, Rimola J, Diaz MA, treatments before liver transplantation for are effective and safe in HCV/HIV- Colmenero J, Saavedra-Perez D, Fondevila C, hepatocellular carcinoma: A study from coinfected liver transplant recipients who Ayuso C, Fuster J, Ginès P, Bruix J, the European Liver Transplant Registry. experience recurrence of hepatitis C: A Garcia-Valdecasas JC . Pilot study of living TRANSPLANT INTERNATIONAL. 531-539. prospective nationwide cohort study. donor liver transplantation for patients I.F.: 3.196 AMERICAN JOURNAL OF with HCC exceeding Milan criteria (BCLC TRANSPLANTATION. 18(10):2513-2522. extended criteria). LIVER 23. Adam R; Karam V; Cailliez V; O Grady JG; I.F.: 6.493 TRANSPLANTATION. 24(3):369-379. I.F.: 3.756 Mirza D; Cherqui D; Klempnauer J; Salizzoni M; Pratschke J; Jamieson N; Hidalgo E; Paul A; 12. Ventura-Aguiar P, Ventura-Aguiar P, Ferrer 18. Hessheimer AJ, Vendrell M, Muñoz J, Ruíz Andujar RL; Lerut J; Fisher L; Boudjema K; J, Revuelta I, Revuelta I, Revuelta I, Paredes D, Á, Díaz A, Sigüenza LF, Lanzilotta JR, Delgado Fondevila C; Soubrane O; Bachellier P; Pinna de Sousa-Amorim E, Rovira J, Esmatjes E, Oliver E, Fuster J, Navasa M, García- AD; Berlakovich G; Bennet W; Pinzani M; Garcia-Valdecasas JC, Campistol JM, Valdecasas JC, Taurá P, Fondevila C. Heparin Schemmer P; Zieniewicz K; Romero CJ; De Campistol JM, Campistol JM, Oppenheimer F, but not tissue plasminogen activator Simone P; Ericzon BG; Schneeberger S; Diekmann F, Diekmann F, Diekmann F, Ricart improves outcomes in DCD liver Wigmore SJ; Prous JF; Colledan M; Porte RJ; MJ, Ricart MJ. Pancreas outcomes transplantation in a porcine model. LIVER Yilmaz S; Azoulay D; Pirenne J; Line PD; between living and deceased kidney donor TRANSPLANTATION. 24(5):665-676. Trune?ka P; Navarro F; Lopez AV. 2018 in pancreas after kidney transplantation I.F.: 3.756 Annual Report of the European Liver patients. NEPHROLOGY, DIALYSIS AND Transplant Registry (ELTR) - 50-year TRANSPLANTATION. 33(11):2052-2059. 19. Panisello-Roselló A., Verde E., Lopez A., evolution of liver transplantation. I.F.: 4.602 Flores M., Folch-Puy E., Rolo A., Palmeira C., TRANSPLANT INTERNATIONAL. Hotter G., Carbonell T., Adam R., 31(12):1293-1317. I.F.: 3.196 13. Lens S, García-Eliz M, Fernández I, Roselló-Catafau J. Cytoprotective Castells L, Bonacci M, Mas A, Crespo G, Buti mechanisms in fatty liver preservation 24. Pommergaard H; Rostved A; Adam R; M, Prieto M, Forns X . Shorter HBIG against cold ischemia injury: A comparison Thygesen L; Salizzoni M; Gómez Bravo M; administration is not associated to HBV between IGL-1 and HTK. INTERNATIONAL Cherqui D; Filipponi F; Boudjema K; recurrence when receiving combined JOURNAL OF MOLECULAR SCIENCES. Mazzaferro V; Soubrane O; prophylaxis after liver transplantation. 19(2):348. I.F.: 3.687 García-Valdecasas J; Prous J; Pinna A; LIVER INTERNATIONAL. 38(11):1940-1950. O'Grady J; Karam V; Duvoux C; Rasmussen A. I.F.: 4.500 20. Panisello-Roselló A, Alva N, Flores M, Vascular invasion and survival after liver Lopez A, Castro Benítez C, Folch-Puy E, Rolo transplantation for hepatocellular 14. García-Pérez R, Ferrer Fábrega J, A, Palmeira C, Adam R, Carbonell T, carcinoma: a study from the European Varona-Bosque A, Martínez CM, Revilla-Nuin Roselló-Catafau J. Aldehyde Liver Transplant Registry. HPB. B, Cabellos L, Pena R, Vilana R, Dehydrogenase 2 (ALDH2) in Rat Fatty 20(8):768-775. I.F.: 3.131 Gonzalez-Abós C, García-Valdecasas JC, Liver Cold Ischemia Injury.

194 LIVER TRANSPLANTATION AND GRAFT VIABILITY 3.10

25. Molina V., Sampson-Dávila J., Ferrer J., Rodríguez-Tajes S, de Vree M, Metselaar HJ, HEPATOLOGY RESEARCH. Fondevila C., Díaz del Gobbo R., Calatayud D., Chiang FWT, Verspaget HW, van Hoek B, 48(3):E379-E380. I.F.: 3.418 Bruix J., García-Valdecasas J., Fuster J. Bosch J, Coenraad MJ. Impact of hepatic Benefits of laparoscopic liver resection in encephalopathy on liver transplant waiting 3. Falgàs N., Alfaro I., Crespo G., Berenguer J., patients with hepatocellular carcinoma list mortality in regions with different García-Pagán J., Muñoz E. Aphasia in a and portal hypertension: a case-matched transplantation rates. CLINICAL patient with acute hepatic encephalopathy study. SURGICAL ENDOSCOPY. TRANSPLANTATION. 32(11):e13412. I.F.: 1.518 associated with multifocal cortical brain 32(5):2345-2354. I.F.: 3.117 lesions. NEUROLOGIA. 33(6):410-412. 32. Blasi, Annabel; Molina, Victor; I.F.: 1.938 26. Sabate A, Blasi A, Costa M, Reyes R, Sanchez-Cabus, Santiago; Balust, Jaume; Beltran J, Torres F . Assessment of Carlos Garcia-Valdecasas, J.; Taura, Pilar. rotational thromboelastometry for the Prediction of thromboembolic Consortium Publications / I.F.: 5.394 prediction of red blood cell requirements in complications after liver resection for orthotopic liver transplantation. MINERVA cholangiocarcinoma: is there a place for 1. Pericàs JM, Moreno A, Almela M, ANESTESIOLOGICA. 84(4):447-454. thromboelastometry? BLOOD García-de-la-Mària C, Marco F, Muñoz P, I.F.: 2.693 COAGULATION AND FIBRINOLYSIS. Peña C, de Alarcón A, Del Río A, Eworo A, 29(1):61-66. I.F.: 1.119 Cruceta A, Paré JC, Mestres CA, Miró JM, 27. Delgado-Oliver E, Vidal-Sicart S, Martínez FOSIMI Investigators. Efficacy and Safety of D, Squarcia M, Mora M, Hanzu FA, Halperin I, Fosfomycin Plus Imipenem vs. Vancomycin Fuster D, Fondevila C, Vidal-Perez Ó. Review / I.F.: 9.68 for Complicated Bacteremia and Applicability of sentinel lymph node biopsy Endocarditis Due to Methicillin-Resistant in papillary thyroid cancer. THE 1. Álvarez-Mercado A., Bujaldon E., Staphylococcus aureus: A Randomized QUARTERLY JOURNAL OF NUCLEAR Gracia-Sancho J., Peralta C. The Role of Clinical Trial. CLINICAL MICROBIOLOGY MEDICINE AND MOLECULAR IMAGING : Adipokines in Surgical Procedures AND INFECTION. 24(6):673-676. I.F.: 5.394 OFFICIAL PUBLICATION OF THE ITALIAN Requiring Both Liver Regeneration and ASSOCIATION OF NUCLEAR MEDICINE Vascular Occlusion. INTERNATIONAL (AIMN) [AND] THE INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. ASSOCIATION OF RADIOPHARMACOLOGY 19(11):3395. I.F.: 3.687 GRANTS FOR RESEARCH IN PROGRESS (IAR), [AND] SECTION OF THE SOCIETY OF RADIOPHARMACEUTICAL CHEMISTRY 2. Panisello-Roselló A, Lopez A, Folch-Puy E, Brunet M, Navasa M. Evaluación del impacto AND BIOLOGY. I.F.: 2.368 Carbonell T, Rolo A, Palmeira C, Adam R, Net de la aloreactividad en la evolución del M, Roselló-Catafau J. Role of aldehyde injerto y de la reversibilidad de la fibrosis 28. Gómez-Bravo MA, Apellaniz-Ruiz M, dehydrogenase 2 in ischemia reperfusion tras el tratamiento de la hepatitis C Salcedo M, Fondevila C, Suarez F, Castellote injury: An update. WORLD JOURNAL OF post-transplante hepático. J, Rufian S, Pons JA, Bilbao I, Alamo JM, Millán GASTROENTEROLOGY. 24(27):2984-2994. Sponsored by: Instituto de Salud Carlos III O, Brunet M, Rodríguez-Antona C . Influence I.F.: 3.300 (ISCIII). PI14/01055 of donor liver CYP3A4*20 loss-of-function Duration: 01/01/2015-30/06/2019 genotype on tacrolimus 3. Blasi A, Reverter JC . Time to change the pharmacokinetics in transplanted classical vision of coagulation in liver Fondevila C. Evaluación de la regeneración patients. PHARMACOGENETICS AND disease: from the balance disequilibrium to hepatocelular tras hepatectomía mayor en GENOMICS. 28(2):41-48. I.F.: 2.250 the systems biology network modelling. un modelo clínico y otro experimental. MINERVA ANESTESIOLOGICA. Utilidad del tratamiento con 29. Blasi A, Hernandez V, Fernandez J, 84(7):848-857. I.F.: 2.693 somatostanina y debutamina en un Colmenero J, Beltran J, Garcia-Valdecasas modelo porcino de cirugía hepática JC, Reverter JC . Venous Thrombotic extrema. Events After Liver Transplantation. Letters / I.F.: 9.112 Sponsored by: Instituto de Salud Carlos III CLINICAL AND APPLIED THROMBOSIS/ (ISCIII). PI15/01092 HEMOSTASIS. 24(2):317-322. I.F.: 1.852 1. Mauro E, Crespo G, Montironi C, Londoño Duration: 01/01/2016-30/06/2019 MC, Díaz A, Forns X, Navasa M . Viral 30. Bodro M, Ferrer J, Ricart MJ, eradication and fibrosis resolution in post García-Valdecasas JC. Evaluation of the Sanclemente G, Linares L, Cervera C, Cofan F, liver transplant cholestatic hepatitis C. feasibilty of normothermic regional Ventura-Aguiar P, Lopez-Boado MÁ, Marco F, LIVER TRANSPLANTATION. 24(5):703-707. perfusion followed by ex-vivo Fuster J, García-Valdecasas JC, Moreno A . I.F.: 3.756 normothermic machine perfusion in Type Epidemiology, risk factors, and impact of II DCD (Donation after Cardiac Death) Liver bacterial infections on outcomes for 2. Blasi, Annabel; Saner, Fuat; Biancofiore, Transplants. pancreatic grafts. CLINICAL Gianni; Lisman, Ton. Comment to Sponsored by: Fundacio La Caixa TRANSPLANTATION. 32(8):e13333. I.F.: 1.518 Antithrombin III administration for portal (ConvExcel15) vein thrombosis in patients with liver Duration: 01/05/2016-30/04/2019 31. Kerbert AJC, Reverter E, Verbruggen L, disease: A randomized double-blind Tieleman M, Navasa M, Mertens BJA, controlled trial.

195 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

Garcia-Valdecasas J.C. Consortium on organ preservation in Europe (COPE) Sponsored by: European Commission. COPE 305934 Duration: 01/09/2013-30/06/2018

Peralta C. Preservació del l'empelt hepatic (Hepatic graft perseveration). Sponsored by: Generalitat de Catalunya. AGAUR_SGR17_00551 Duration: 01/01/2017-31/12/2020

Peralta C. PROTECTRASPLANT: La hormona de crecimiento en el trasplante de injertos hepáticos esteatósicos y no esteatósicos procedentes de donantes con muerte cerebral. Sponsored by: Ministerio de Economía y Competitividad (MINECO). SAF2015-64857-R Duration: 01/01/2016-31/12/2018

Peralta C. Nuevas tecnologías de preservación y transporte de órganos abdominales – Proyecto ALBA (Retos-Colaboración 2015) Sponsored by: Ministerio de Economía y Competitividad (MINECO). RTC-2015-3859-1 Duration: 01/03/2015-30/06/2018

DOCTORAL THESES

Garcia-Valdecasas JC. Factores pronósticos para la supervivencia y recidiva en los pacientes con carcinoma hepatocelular sobrepasando los criterios de Milán sometidos a trasplante hepático de donante vivo. PhD student: Mihai Calin Pavel

Fondevila C. Garcia-Valdecasas JC. Evaluación de las alteraciones de la coagulación de los donantes a corazón parado, su relación con la viabilidad de los injertos hepáticos y posibles acciones terapéuticas. PhD student: Marina Vendrell Jordà

196 GASTROINTESTINAL AND PANCREATIC ONCOLOGY 3.11

Gastrointestinal 3.11 and pancreatic oncology

POST-DOCTORAL RESEARCHERS Josep Maria Augé (HCB) LOCATION Sabela Carballal (HCB) CEK building, ﬂoor 4 Henry Nelson Cordova (HCB) Eva Hernandez (FCRB) Irene Sangrador (CIBER) Oriol Sendino (HCB) Elena Vila (FCRB) Sabrina Gea (CIBER) KEYWORDS Jeronimo Luna (IDIBAPS) 1. Colorectal cancer TEAM LEADER Leticia Moreira (HCB) 2. Pancreatic cancer Antoni Castells (HCB) Laia Bonjoch (FCRB) 3. Genetics T. 93 227 57 03 4. Inherited disorders [email protected] PRE-DOCTORAL RESEARCHERS

5. Susceptibility to cancer Isis Karina Araujo (HCB) Coral Arnau-Colell (CIBER) GROUP LEADERS Pau Brugada (IDIBAPS) Sergi Castellví-Bel (IDIBAPS) Marcos Diaz-Gay (IDIBAPS) T. 93 227 54 00 (Ext.: 4183/2915) Saray Durán (IDIBAPS) [email protected] Sebastià Franch-Expósito (FCRB-CIBER) Claudia Galofre (CIBER) Original publications Cristina Fillat (IDIBAPS) Estela Nuñez (IDIBAPS) from 2016 to 2018 T. 93 227 54 00 (Ext.: 4579) Marc Otero (IDIBAPS)

YEAR I.F. TOTAL Q1 Q2 cﬁ[email protected] Giulia Raimondi (IDIBAPS) Liseth Rivero (IDIBAPS) 2016 295.29 44 39 3 Cristina Sanchez (IDIBAPS) 2017 261.86 49 32 10 RESEARCHERS Ariadna Sánchez (HCB) 2018 201.17 34 26 7 Juan Ramon Ayuso (HCB) Francesc Balaguer (HCB) TECHNICIANS Jordi Camps (IDIBAPS) Elena Asensio (IDIBAPS) José Ignacio Elizalde (HCB) Manuel Dominguez (CIBER) Gloria Fernández (HCB) Maria Marcuello (CIBER)

TEAM INVOLVED IN Mª Àngels Ginès (HCB) Lorena Moreno (HCB-FCRB) CIBEREHD Meritxell Gironella (CIBER) Jenifer Muñoz (CIBER) CIBERER Antonio Maria Lacy (HCB) AGAUR_SGR17: 01035, Maria Pellisé (HCB) ADMINISTRATIVE STAFF 00653, 00021, 00861 Santiago Sanchez (HCB) Diana Patricia Vargas (HCB) Eva Cristina Vaquero (HCB) Oscar Vidal (HCB) NURSING STAFF Santiago Sánchez (HCB) Mireia Diaz (HCB)

AWARDS Premi a l'Excel·lència Professional 2018 Intitution: Col·legi de Metges de Barcelona Awardee/s: Gloria Fernández Esparrach TEAM Antoni Castells

197 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

Teresa Ocaña (HCB) gastrointestinal cancer” is a research group RESEARCH GROUP Àngels Pozo (HCB) led by Sergi Castellví-Bel has the main GENE THERAPY AND CANCER GROUP Cristina Rodriguez (FCRB) objective of identifying genetic variants Anna Serradesanferm (HCB) involved in germline susceptibility to colorectal cancer (CRC) and gastric cancer (GC), and to explore its application in the clinical management of patients. STRATEGIC OBJECTIVES The main research lines are: The gaining of in-depth knowledge of the GROUP LEADER mechanisms underlying the development and 1. Next generation sequencing: new Cristina Fillat (IDIBAPS) progression of gastrointestinal and pancreatic predisposition genes for CRC and GC. premalignant and malignant lesions, with a view 2. Genetic association studies: new genetic Our group main research interests focus on to deﬁning new diagnostic, therapeutic and/or variants for CRC and advanced adenoma risk. pancreatic cancer and in the development of preventive strategies. 3. State-of-the-art Fine mapping and gene therapy strategies for rare diseases. functionality studies for genetic variants Main research lines: using gene editing in cellular models. 4. Genotype-phenotype correlation of the 1. Understand the contribution of speciﬁc MAIN LINES OF RESEARCH genetic variants with clinical characteristics molecules to pancreatic carcinogenesis. of patients, including their value in 2. Rationally design and preclinically evaluate The activity of the research group in establishing prognosis. therapeutic strategies based on engineered Gastrointestinal and Pancreatic Oncology is divided into four areas, and these in turn correspond to different lines of investigation:

1. Physiopathology of colorectal cancer: - Hereditary forms of colorectal cancer, screening and surveillance. - Genetic susceptibility in colorectal cancer. - Epigenetics of colorectal cancer. 2. Physiopathology of pancreatic cancer: - Implication of microRNAs in pancreatic cancer. - Epithelial-mesenchymal transition in the local and metastatic spread of pancreatic cancer. 3. Research and innovation in endoscopy: - Endoscopic ultrasound. - Advanced diagnostic techniques. - Endoscopic therapies. 4. Research and innovation in surgery: - Surgery for colorectal cancer. - Surgery for pancreatic cancer.

RESEARCH GROUP GENETIC PREDISPOSITION TO GASTROINTESTINAL CANCER

GROUP LEADER Sergi Castellví-Bel (IDIBAPS)

The “Genetic predisposition to colorectal GROUP Sergi Castellví -Bel GROUP Cristina Fillat

198 GASTROINTESTINAL AND PANCREATIC ONCOLOGY 3.11

oncolytic adenovirus. 5. Barberan-Garcia A, Ubré M, Roca J, Lacy 11. Companioni O, Bonet C, García N, 3. Understand the host AM, Burgos F, Risco R, Momblán D, Balust J, Ramírez-Lázaro MJ, Lario S, Mendoza J, contribution to the oncolytic virus effect and Blanco I, Martínez-Pallí G . Personalised Adrados MM, Poves E, Espinosa L, identify biological interfaces between Prehabilitation in High-risk Patients Pozo-Kreilinger JJ, Ortega L, Bujanda L, viruses and tumors to maximize Undergoing Elective Major Abdominal Cosme A, Ferrández A, Muñoz G, effective therapeutic viruses and/or Surgery: A Randomized Blinded Cuatrecasas M, Elizalde I, Andreu V, Paules chemical-biological combination therapies. Controlled Trial. ANNALS OF SURGERY. MJ, Madrigal B, Barrio J, Berdasco M, Calvet X, 4. Develop gene therapy and genome editing 267(1):50-56. I.F.: 9.203 Sanz-Anquela JM, Gisbert JP, González CA, strategies for metabolic defects . Sala N, Study Group. Genetic variation 6. Sánchez-Cabús S., Cherqui D., Rashidian N., analysis in a follow-up study of gastric Pittau G., Elkrief L., Vanlander A., Toso C., cancer precursor lesions confirms the Fondevila C., Sa Cunha A., Berney T., Castaing association of MUC2 variants with the PUBLICATIONS D., De Hemptinne B., Fuster J., Rogiers X., evolution of the lesions and identifies a Adam R., Majno P., García-Valdecasas J., significant association with NFKB1 and Originals / I.F.: 204.173 Troisi R. Left-liver Adult-to-Adult Living CD14. INTERNATIONAL JOURNAL OF Donor Liver Transplantation: Can It Be CANCER. 143(11):2777-2786. I.F.: 7.360 1. Luna J, Boni J, Cuatrecasas M, Bofill-De Ros Improved? A Retrospective Multicenter X, Núñez-Manchón E, Gironella M, Vaquero European Study. ANNALS OF SURGERY. 12. Vangala DB, Cauchin E, Balmaña J, EC, Arbones ML, de la Luna S, Fillat C. 268(5):876-884. I.F.: 9.203 Wyrwicz L, van Cutsem E, Güller U, Castells A, DYRK1A modulates c-MET in pancreatic Carneiro F, Hammel P, Ducreux M, van ductal adenocarcinoma to drive tumour 7. Sangrador I, Molero X, Campbell F, Laethem JL, Matysiak-Budnik T, Schmiegel growth. GUT. 316128. I.F.: 17.016 Franch-Expósito S, Rovira-Rigau M, Samper W. Screening and surveillance in E, Domínguez-Fraile M, Fillat C, Castells A, hereditary gastrointestinal cancers: 2. Carballal S, Maisterra S, López-Serrano A, Vaquero EC . Zeb1 in stromal Recommendations from the European Gimeno-García AZ, Vera MI, Marín-Garbriel myofibroblasts promotes Kras-driven Society of Digestive Oncology (ESDO) JC, Díaz-Tasende J, Márquez L, Álvarez MA, development of pancreatic cancer. expert discussion at the 20th European Hernández L, De Castro L, Gordillo J, Puig I, CANCER RESEARCH. 78(10):2624-2637. Society for Medical Oncology Vega P, Bustamante-Balén M, Acevedo J, I.F.: 9.130 (ESMO)/World Congress on Peñas B, López-Cerón M, Ricart E, Gastrointestinal Cancer, Barcelona, June Cuatrecasas M, Jimeno M, Pellisé M, 8. Paquet-Fifield S, Koh SL, Cheng L, Beyit 2018. EUROPEAN JOURNAL OF CANCER. EndoCAR group of the Spanish LM, Shembrey C, Mølck C, Behrenbruch C, 104:91-103. I.F.: 7.191 Gastroenterological Association and Spanish Papin M, Gironella M, Guelfi S, Nasr R, Grillet F, Digestive Endoscopy Society. Real-life Prudhomme M, Bourgaux JF, Castells A, 13. Perlaza P, Ortín J, Pagès M, Buxó E, chromoendoscopy for neoplasia detection Pascussi JM, Heriot AG, Puisieux A, Davis MJ, Fernández-Esparrach G, Colletti PM, Rubello and characterisation in long-standing IBD. Pannequin J, Hill AF, Sloan EK, Hollande F . D, Mayoral M, Sánchez N, Ruiz C, Ginés A, GUT. 67(1):70-78. I.F.: 17.016 Tight junction protein claudin-2 promotes Fuster D. Should 18F-FDG PET/CT Be self-renewal of human colorectal cancer Routinely Performed in the Clinical Staging 3. Murcia O, Jover R, Egoavil C, stem-like cells. CANCER RESEARCH. of Locally Advanced Gastric Perez-Carbonell L, Juárez M, Hernández-Illán 78(11):2925-2938. I.F.: 9.130 Adenocarcinoma? CLINICAL NUCLEAR E, Rojas E, Alenda C, Balaguer F, Andreu M, MEDICINE. 43(6):402-410. I.F.: 6.309 Llor X, Castells A, Boland CR, Goel A . 9. Rozen EJ, Roewenstrunk J, Barallobre MJ, TFAP2E Methylation and Expression Di Vona C, Jung C, Figueiredo AF, Luna J, Fillat 14. Gallardo-Gómez M; Páez de la Cadena M; Status Does Not Predict Response to C, Arbonés ML, Graupera M, Valverde MA, de Martínez-Zorzano V; Rodríguez-Berrocal F; 5FU-based Chemotherapy in Colorectal la Luna S. DYRK1A Kinase Positively Rodríguez-Girondo M; Cubiella J; Bujanda L; Cancer. CLINICAL CANCER RESEARCH. Regulates Angiogenic Responses in Balaguer F; Jover R; De Chiara L. A new 24(12):2820-2827. I.F.: 10.199 Endothelial Cells. CELL REPORTS. approach to epigenome-wide discovery of 23(6):1867-1878. I.F.: 8.032 non-invasive methylation biomarkers for 4. Reichert, Maximilian; Bakir, Basil; Moreira, colorectal cancer screening in circulating Leticia; Pitarresi, Jason R.; Feldmann, Karin; 10. López-Vicente J, Rodríguez-Alcalde D, cell-free DNA using pooled samples. Simon, Lauren; Suzuki, Kensuke; Maddipati, Hernández L, Pons FR, Vega P, Herrero Rivas CLINICAL EPIGENETICS. 10(53):53. I.F.: 6.091 Ravikanth; Rhim, Andrew D.; Schlitter, Anna M.; JM, Santiago García J, Salces Franco I, Kriegsmann, Mark; Weichert, Wilko; Wirth, Bustamante Balén M, López-Cerón Pinilla M, 15. Moreno V., Alonso M., Closa A., Vallés X., Matthias; Schuck, Kathleen; Schneider, Pellisé M, EndoCAR group of the Spanish Diez-Villanueva A., Valle L., Castellví-Bel S., Guenter; Saur, Dieter; Reynolds, Albert B.; Gastroenterological Association and Spanish Sanz-Pamplona R., Lopez-Doriga A., Cordero Klein-Szanto, Andres J.; Pehlivanoglu, Burcin; Digestive Endoscopy Society. D., Solé X. Colon-specific eQTL analysis to Memis, Bahar; Adsay, N. Volkan; Rustgi, Anil K. Panchromoendoscopy Increases inform on functional SNPs. BRITISH Regulation of Epithelial Plasticity Detection of Polyps in Patients With JOURNAL OF CANCER. 119(8):971-977. Determines Metastatic Organotropism in Serrated Polyposis Syndrome. CLINICAL I.F.: 5.922 Pancreatic Cancer. DEVELOPMENTAL GASTROENTEROLOGY AND CELL. 45(6):696-711. I.F.: 9.616 HEPATOLOGY. I.F.: 7.683 16. Wangsa D, Quintanilla I, Torabi K, Vila-

199 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

Casadesús M, Ercilla A, Klus G, Yuce Z, predisposition characterized by exome Morales R, Cano JM, Serrano R, Galofré C, Cuatrecasas M, Lozano JJ, Agell N, sequencing analysis. JOURNAL OF López-Ceballos MH, González-Santiago S, Cimini D, Castells A, Ried T, Camps J . GENETICS AND GENOMICS. 45(1):41-45. Juan-Fita MJ, Alonso-Cerezo C, Casas A, Near-tetraploid cancer cells show I.F.: 4.066 Graña B, Teulé A, Alba E, Antón A, chromosome instability triggered by Guillén-Ponce C, Sánchez-Heras AB, replication stress and exhibit enhanced 21. Auge J., Rodriguez C., Espanyol O., Rivero Alés-Martínez JE, Brunet J, Balaguer F, invasiveness. FASEB JOURNAL. L., Sandalinas S., Grau J., Jimenez W., Castells Balmaña J . Psychological impact of 32(7):3502-3517. I.F.: 5.595 A. An evaluation of the SENTiFIT 270 multi-gene cancer panel testing in patients analyser for quantitation of faecal with a clinical suspicion of hereditary 17. Benyamine, Audrey; Loncle, Celine; haemoglobin in the investigation of cancer across Spain. Foucher, Etienne; Blazquez, Juan-Luis; patients with suspected colorectal cancer. PSYCHO-ONCOLOGY. 27(6):1530-1537. Castanier, Celine; Chretien, Anne-Sophie; CLINICAL CHEMISTRY AND LABORATORY I.F.: 3.455 Modesti, Mauro; Secq, Veronique; Chouaib, MEDICINE. 56(4):625-633. I.F.: 3.556 Salem; Gironella, Meritxell; Vila-Navarro, Elena; 26. Jover R, Dekker E, Schoen RE, Hassan C, Montalto, Giuseppe; Dagorn, Jean-Charles; 22. Sendino, Oriol; Fernandez-Simon, Pellise M, Ladabaum U, WEO Expert Working Dusetti, Nelson; Iovanna, Juan; Olive, Daniel. Alejandro; Law, Ryan; Abu Dayyeh, Barham; Group of Surveillance after colonic neoplasm. BTN3A is a prognosis marker and a Leise, Michael; Chavez-Rivera, Karina; Colonoscopy quality requisites for promising target for V gamma 9V delta 2 T Cordova, Henry; Colmenero, Jordi; Crespo, selecting surveillance intervals: A World cells based-immunotherapy in pancreatic Gonzalo; Rodriguez de Miguel, Cristina; Endoscopy Organization Delphi ductal adenocarcinoma (PDAC). Fondevila, Constantino; Llach, Josep; Navasa, Recommendation. DIGESTIVE ONCOIMMUNOLOGY. 7(1):e1372080. Miquel; Baron, Todd; Cardenas, Andres;. ENDOSCOPY. 30(6):750-759. I.F.: 3.375 I.F.: 5.503 Endoscopic management of bile leaks after liver transplantation: An analysis of 27. De Lacy FB, van Laarhoven JJEM, Pena R, 18. De Batlle J., Gracia-Lavedan E., two high-volume transplant centers. Arroyave MC, Bravo R, Cuatrecasas M, Lacy Romaguera D., Mendez M., Castaño-Vinyals UNITED EUR GASTROENT. 6(1):89-96. AM. Transanal total mesorectal excision: G., Martín V., Aragonés N., Gómez-Acebo I., I.F.: 3.477 pathological results of 186 patients with Olmedo-Requena R., Jimenez-Moleon J., mid and low rectal cancer. SURGICAL Guevara M., Azpiri M., Llorens-Ivorra C., 23. Carot L, Castells A, Hernández C, ENDOSCOPY AND OTHER Fernandez-Tardon G., Lorca J., Huerta J., Alvarez-Urturi C, Balaguer F, Lanas A, Cubiella INTERVENTIONAL TECHNIQUES. Moreno V., Boldo E., Pérez-Gómez B., Castilla J, Tasende JD, Jover R, Hernandez V, Carballo 32(5):2442-2447. I.F.: 3.117 J., Fernández-Villa T., Barrio J., Andreu M., F, Bujanda L, Quintero E, Andreu M, Bessa X. Castells A., Dierssen T., Altzibar J., Kogevinas Detection of serrated lesions in proximal 28. Aranda G., Fernandez-Ruiz R., Palomo M., M., Pollán M., Amiano P. Meat intake, cooking colon by simulated sigmoidoscopy vs Romo M., Mora M., Halperin I., Casals G., methods and doneness and risk of faecal immunochemical testing in a Enseñat J., Vidal O., Diaz-Ricart M., Hanzu F. colorectal tumours in the Spanish multicentre, pragmatic, randomised Translational evidence of prothrombotic multicase-control study (MCC-Spain). controlled trial. UNITED EUROPEAN and inﬂammatory endothelial damage in EUROPEAN JOURNAL OF NUTRITION. GASTROENTEROLOGY JOURNAL. Cushing syndrome after remission. 57(2):1-11. I.F.: 4.423 6(10):1527-1537. I.F.: 3.477 CLINICAL ENDOCRINOLOGY. 88(3):415-424. I.F.: 3.077 19. González-Suárez B., Rodriguez S., Ricart 24. Mangas-Sanjuan, Carolina; Zapater, E., Ordás I., Rimola J., Díaz-González Á., Pedro; Cubiella, Joaquin; Murcia, Oscar; 29. Guardiola M, Buitrago S, Romero C., De Miguel C., Jáuregui A., Araujo I., Bujanda, Luis; Hernandez, Vicent; Fernández-Esparrach G, O'Callaghan JM, Ramirez A., Gallego M., Fernández-Esparrach Martinez-Ares, David; Pellise, Maria; Seoane, Romeu J, Cuatrecasas M, Córdova H, G., Ginés Á., Sendino O., Llach J., Panés J. Agustin; Lanas, Angel; Nicolas-Perez, David; González Ballester MÁ, Camara O . Dielectric Comparison of Capsule Endoscopy and Herreros-de-Tejada, Alberto; Chaparro, Maria; properties of colon polyps, cancer and Magnetic Resonance Enterography for the Cacho, Guillermo; Fernandez-Diez, Servando; normal mucosa: ex vivo measurements Assessment of Small Bowel Lesions in Marin-Gabriel, Jose-Carlos; Quintero, Enrique; from 0.5 to 20 GHz. MEDICAL PHYSICS. Crohn's Disease. INFLAMMATORY BOWEL Castells, Antoni; Jover, Rodrigo; 45(8):3768-3782. I.F.: 2.884 DISEASES. 24(4):775-780. I.F.: 4.347 COLONPREV study investigators. Importance of endoscopist quality metrics 30. Maurel J, Sánchez-Cabús S, Laquente B, 20. Franch-Expósito S., Esteban-Jurado C., for ﬁndings at surveillance colonoscopy: Gaba L, Visa L, Fabregat J, Povés I, Roselló S, Garre P., Quintanilla I., Duran-Sanchon S., The detection-surveillance paradox. Díaz-Beveridge R, Martín-Richard M, Díaz-Gay M., Bonjoch L., Cuatrecasas M., UNITED EUR GASTROENT. 6(4):622-629. Rodriguez J, Sabater L, Conill C, Cambray M, Samper E., Muñoz J., Ocaña T., Carballal S., I.F.: 3.477 Reig A, Ayuso JR, Valls C, Ferrández A, Bombí López-Cerón M., Castells A., Vila-Casadesús JA, Ginés A, García-Albéniz X, M., Derdak S., Laurie S., Beltran S., Carvajal J., 25. Esteban I, Vilaró M, Adrover E, Angulo A, Fernández-Cruz L . Outcomes after Bujanda L., Ruiz-Ponte C., Camps J., Gironella Carrasco E, Gadea N, Sánchez A, Ocaña T, neoadjuvant treatment with gemcitabine M., Lozano J., Balaguer F., Cubiella J., Caldés Llort G, Jover R, Cubiella J, Servitja S, Herráiz and erlotinib followed by gemcitabine- T., Castellví-Bel S. Rare germline copy M, Cid L, Martínez S, Oruezábal-Moreno MJ, erlotinib and radiotherapy for resectable number variants in colorectal cancer Garau I, Khorrami S, Herreros-de-Tejada A, pancreatic cancer (GEMCAD 10-03 trial).

200 GASTROINTESTINAL AND PANCREATIC ONCOLOGY 3.11

CANCER CHEMOTHERAPY AND cancer: Next enemy to beat. MEDICINA Consortium Publications / I.F.: 3.117 PHARMACOLOGY. 82(6):935-943. I.F.: 2.808 CLINICA. 150(1):24-25. I.F.: 1.168 1. Adamina M, Buchs NC, Penna M, Hompes R, 31. Murcia O, Juárez M, Rodríguez-Soler M, StGallen Colorectal Consensus Expert Group. Hernández-Illán E, Giner-Calabuig M, Alustiza Case Reports / I.F.: 4.756 St.Gallen consensus on safe M, Egoavil C, Castillejo A, Alenda C, Barberá V, implementation of transanal total Mangas-Sanjuan C, Yuste A, Bujanda L, 1. Martin-Perez B, Otero-Piñeiro A, Lacy AM. mesorectal excision. SURGICAL Clofent J, Andreu M, Castells A, Llor X, Zapater Purse-string rupture: pitfalls of transanal ENDOSCOPY AND OTHER P, Jover R. Colorectal cancer molecular total mesorectal excision (Cecil INTERVENTIONAL TECHNIQUES. classification using BRAF, KRAS, approach). TECHNIQUES IN 32(3):1091-1103. I.F.: 3.117 microsatellite instability and CIMP status: COLOPROCTOLOGY. 22(5):393-394. Prognostic implications and response to I.F.: 2.378 chemotherapy. PLOS ONE. 13(9):e0203051. I.F.: 2.766 2. Otero-Piñeiro AM, De Lacy FB, GRANTS FOR RESEARCH IN PROGRESS Martín-Pérez B, Lacy AM. Indications for a 32. Mizrahi I., de Lacy F., Abu-Gazala M., transanal approach in complicated Balaguer F. Análisis del defecto de campo Fernandez L., Otero A., Sands D., Lacy A., inflammatory bowel disease. TECHNIQUES mediado por metilación aberrante del ADN Wexner S. Transanal total mesorectal IN COLOPROCTOLOGY. 22(6):469-470. en el síndrome de poliposis serrada. excision for rectal cancer with indocyanine I.F.: 2.378 Sponsored by: Instituto de Salud Carlos III green fluorescence angiography. (ISCIII). PI16/00766 TECHNIQUES IN COLOPROCTOLOGY. Duration: 01/01/2017-31/12/2019 22(10):785-791. I.F.: 2.378 Clinical Guidelines / I.F.: 2.156 Balaguer F. Identificación de neoantígenos 33. Diaz-Gay, Marcos; Vila-Casadesus, Maria; 1. Albéniz E, Pellisé M, Gimeno García AZ, para desarrollar una inmunoterapia eficaz Franch-Exposito, Sebastia; Hernandez-Illan, Lucendo AJ, Alonso Aguirre PA, Herreros de para la prevención del cáncer en el Eva; Jose Lozano, Juan; Castellvi-Bel, Sergi. Tejada A, Álvarez MA, Fraile M, Herráiz Bayod síndrome de Lynch. Mutational Signatures in Cancer (MuSiCa): M, López Rosés L, Martínez Ares D, Ono A, Sponsored by: Asociación Española de a web application to implement mutational Parra Blanco A, Redondo E, Sánchez Yagüe Gastroenterología. signatures analysis in cancer samples. A, Soto S, Díaz Tasende J, Montes Díaz M, AEG_BecaGrupoOncología18 BMC BIOINFORMATICS. 19(1):224. I.F.: 2.213 Téllez MR, García O, Zuñiga Ripa A, Duration: 01/04/2018- Hernández Conde M, Alberca de Las Parras F, 34. García-Rodriguez A; Fernández- Gargallo C, Saperas E, Navas MM, Gordillo J, Camps J. Genòmica traslacional del càncer Esparrach G; Sendino O; Gines A; en Ramos Zabala F, Echevarría JM, Bustamante colorectal. representación del Grupo de Ecoendoscopia M, González Haba M, González Huix F, Sponsored by: Generalitat de Catalunya. de la SEED. State of endoscopic González Suárez B, Vila Costas JJ, Guarner AGAUR_SGR17_01035 ultrasonography in Spain in 2017. Argente C, Múgica F, Cobián J, Rodríguez Duration: 01/01/2017-31/12/2020 GASTROENTEROLOGIA Y HEPATOLOGIA. Sánchez J, López Viedma B, Pin N, Marín 41(10):672-678. I.F.: 1.078 Gabriel JC, Nogales Ó, de la Peña J, Navajas Camps J. Implicaciones de la León FJ, León Brito H, Remedios D, Esteban heterogeneidad intratumoral en la JM, Barquero D, Martínez Cara JG, Martínez respuesta al tratamiento de Review / I.F.: 1.549 Alcalá F, Fernández Urién I, Valdivielso E, en quimio-radioterapia neoadyuvante en nombre del Grupo Español de Resección pacientes con cáncer de recto. 1. De Lacy FB, Chadi SA, Berho M, Heald RJ, Endoscópica de la Sociedad Española de Sponsored by: Instituto de Salud Carlos III Khan J, Moran B, Panis Y, Perez R, Tekkis P, Endoscopia Digestiva. Clinical guidelines for (ISCIII). PI14/00783 Mortensen NJ, Lacy AM, Wexner SD, Chand endoscopic mucosal resection of Duration: 01/01/2015-30/06/2019 M. The Future of Rectal Cancer Surgery: A non-pedunculated colorectal lesions. Narrative Review of an International GASTROENTEROLOGIA Y HEPATOLOGIA. Camps J, Cuatrecasas M. Nuevas Symposium. SURGICAL INNOVATION. 41(3):175-190. I.F.: 1.078 estrategias para la estratificación del 25(5):525-535. I.F.: 1.549 riesgo de recidiva en pacientes con cáncer 2. Cubiella J., Marzo-Castillejo M., de colon en estadio II: Integración de Mascort-Roca J., Amador-Romero F., perfiles genómicos y carga tumoral Editorial / I.F.: 3.546 Bellas-Beceiro B., Clofent-Vilaplana J., ganglionar. Carballal S., Ferrándiz-Santos J., Sponsored by: Instituto de Salud Carlos III 1. Martin-Perez B, Bennis H, Lacy AM. Virtual Gimeno-García A., Jover R., Mangas-Sanjuán (ISCIII). PI17/01304 reality simulation for surgery: from video C., Moreira L., Pellisè M., Quintero E., Duration: 01/01/2018-31/12/2020 games to transanal total mesorectal Rodríguez-Camacho E., Vega-Villaamil P.. excision. TECHNIQUES IN Clinical practice guideline. Diagnosis and Castells A. Grup de recerca en Oncologia COLOPROCTOLOGY. 22(1):5-6. I.F.: 2.378 prevention of colorectal cancer. 2018 Gastrointestinal i Pancreàtica. Update. GASTROENTEROLOGIA Y Sponsored by: Generalitat de Catalunya. 2. Castells A. Post-colonoscopy colorectal HEPATOLOGIA. 41(9):585-596. I.F.: 1.078 AGAUR_SGR17_00653

201 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

Duration: 01/01/2017-31/12/2020 Duration: 01/01/2018-31/12/2020 DOCTORAL THESES

Castells A, Castellví S, Camps J. Prevenció Fernandez-Esparrach G. Validación Gironella M. MicroRNA biomarkers for del càncer colorectal en la població de risc preclínica de un dispositivo de endoscopia early detection of pancreatic ductal mitjà mitjançant biomarcadors genòmics i basado en microondas (MiWendo) para el adenocarcinoma and functional microbiòmics (CRIPREV). diagnóstico de neoplasias colorectales. characterization of miR-93 in the Sponsored by: Generalitat de Catalunya. Sponsored by: Instituto de Salud Carlos III pancreatic carcinogenesis. PERIS_Programes16 (SLT002/16/00398). (ISCIII). DTS17/00090 PhD student: Elena Vila Navarro Duration: 27/03/2017-31/12/2019 Duration: 01/01/2018-31/12/2019 Balaguer F, Pellisé M. Caracterización Castells A. Detección de miRNA en heces Fillat C. ONCO-SELEC: Oncoselective clínica y endoscópica de formas de alto con nueva estrategia de cribado del cancer mechanism for gene or viral therapy. riesgo de cáncer colorrectal. colorrectal: identificación y validación en Sponsored by: Generalitat de Catalunya. PhD student: Sabela Carballal Ramil población de riesgo medio. CERCA_Ginjol_16 Sponsored by: Ministerio de Economía y Duration: 24/04/2017-23/04/2022 De Lacy A. Abordaje transanal en patología Competitividad (MINECO). rectal. SAF2014-54453-R Fillat C. Increasing the efficacy of oncolytic PhD student: Marta María Tasende Presedo Duration: 01/01/2015-31/12/2018 adenovirus through replication enhancement strategies in pancreatic Fillat C. Boosting intravenous Castells A. Desarollo de un kit de tumors. administration of therapeutic viral vectors diagnóstico precoz de cáncer colorrectal Sponsored by: Ministerio de Economía y using an oligopeptide-modified poly mediante método no invsivo en plasma Competitividad (MINECO). (-amino ester)s-based coating technology. basado en la expresión de miRNAs. BIO2014-57716-C2-2-R PhD student: Pau Brugada Vilà Sponsored by: Ministerio de Economía y Duration: 01/01/2015-30/06/2018 Competitividad (MINECO). RTC-2015-3850-1 Ginés A, Fernandez G. Nuevas aplicaciones Duration: 25/02/2015-30/06/2019 Fillat C. Adenovirus oncolíticos protegidos de la ultrasonografía endoscópica (USE) frente anticuerpos neutralizantes y en oncología digestiva. Castells A, Pellisé M, Balaguer F, Camps J, optimizados para la expresión de PhD student: Nadia Alberghina Castellví S, Gironella M. Identificación de transgenes y reprogramación del estroma nuevos biomarcadores para la prevención de tumores pancreáticos. Vaquero EC. Zeb1 en las células estrelladas del cáncer colorrectal. Sponsored by: Ministerio de Economía y del páncreas: implicación en la Sponsored by: Asociación Española Contra el Competitividad (MINECO). oncogénesis pancreática dependientede Cáncer. AECC_Grupo Estable_2013 BIO2017-89754-C2-2-R Kras. Duration: 01/10/2013-30/09/2019 Duration: 01/01/2018-31/12/2020 PhD student: Irene Sangrador Escrig

Castellví-Bel S. Caracterización funcional Fillat C. Recubrimiento polimérico de variantes en nuevos genes candidatos multicapa de adenovirus oncolíticos para en la predisposición germinal al cáncer la regulación de su tropismo en el colorrectal y el síndrome de poliposis tratamiento del adenocarcinoma de serrada (FUNCTION4GENE). páncreas. Sponsored by: Instituto de Salud Carlos III Sponsored by: Ministerio de Economía y (ISCIII). PI17/00878 Competitividad (MINECO). RTC-2015-4189-1 Duration: 01/01/2018-31/12/2020 Duration: 01/09/2015-31/03/2018

Castellví-Bel S. Transcoloncan: Identifying Pellisé M. Utilidad de la Imagen de Color biomarkers through translational research Vinculada (Linked Color Imaging; LCI) en la for prevention and stratiﬁcation of vigilancia del Síndrome de Poliposis colorectal cancer. Serrada: Ensayo clínico Aleatorizado, Sponsored by: European Commission. H2020 Controlado, Paralelo y Multicéntrico. _COST17 (CA17118) Sponsored by: Fundación SEED Duration: 01/06/2013-29/09/2017 Duration: 21/12/2018-31/12/2019

Fernandez-Esparrach G. Validación clínica del primer sistema in-vivo de predicción histológica automática de los pólopis de colon integrando la visión del endoscopista con la visión por computador (HISINVIA). Sponsored by: Instituto de Salud Carlos III (ISCIII). PI17/00894

202 INHERITED METABOLIC DISEASES 3.12

Inherited metabolic 3.12 diseases

STRATEGIC OBJECTIVES

LOCATION The strategic objective of our group is to HCB building investigate the genetic and biochemical bases, as well as the physiopathological mechanisms, of a group of rare diseases called “inherited metabolic diseases or inborn errors of metabolism”. The ultimate aim is to develop new diagnostic and therapeutic KEYWORDS strategies. On the other hand, we conduct 1. Mitochondrial diseases TEAM LEADER translational research, stimulating the transfer 2. Mitochondrial cofactors Antonia Ribes (HCB) of knowledge from basic research to the 3. Lysosomal diseases T. 93 227 54 00 (Ext.: 9340) clinical practice, and vice versa. 4. Inherited metabolic diseases [email protected] 5. Inborn errors of metabolism 6. Organic acidurias MAIN LINES OF RESEARCH

Within the general line of inherited metabolic RESEARCHERS diseases, our specific research lines are: Mª José Coll (HCB) Judit Garcia-Villoria (HCB) 1. Identification of genes responsible for Original publications Laura Gort (HCB) Mendelian disorders, particularly in patients from 2016to 2018 Rosa Mª López-Galera (HCB) with defects of the mitochondrial energy metabolism. These patients are YEAR I.F. TOTAL Q1 Q2 POST-DOCTORAL RESEARCHERS preselected on the basis of their clinical and biochemical characteristics. Within this line 2016 51.81 11 7 4 Xènia Ferrer (FCRB) Laura Texido (CIBER) we aim to identify new defects to generate 2017 12.73 3 3 - Frederic Tort (CIBER) knowledge that could be implemented to 2018 14.28 3 3 - the diagnosis and to the design of PRE-DOCTORAL RESEARCHERS therapeutic options. Gerard Muñoz (IDIBAPS) Eulàlia Segur (FCRB ) 2. Physiopathology of the identified diseases. Olatz Ugarteburu (CIBER) In addition to the classical methodologies TEAM INVOLVED IN we aim to introduce the study of lipidomics, CIBERER COLLABORATORS organelle-organelle interaction, AGAUR_SGR17: 01428 Marisa Giros (HCB) mitochondrial dynamics, mitochondrial Sonia Pajares (HCB) supercomplexes and high resolution respirometry. TEAM Antonia Ribes

203 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

3. Therapeutic approaches. This line involves Case Reports / I.F.: 1.377 the testing of chemical and peptide libraries. Selection has been made of 1. Sisinni L., Pineda M., Coll M., Gort L., Turon E., disease-causing missense mutations Torrent M., Ey A., Tobajas E., Badell I. previously identiﬁed by our group in a wide Haematopoietic stem cell transplantation range of diseases. We are particularly for mucopolysaccharidosis type VII: A interested in compounds with chaperone case report. PEDIATRIC action and compounds capable of inducing TRANSPLANTATION. 22(7):e13278. I.F.: 1.377 lysosomal exocytosis and autophagy promotion. Clinical Guidelines / I.F.: 3.607

1. Geberhiwot T, Moro A, Dardis A, PUBLICATIONS Ramaswami U, Sirrs S, Marfa M, Vanier M, Walterfang M, Bolton S, Dawson C, Héron B, Originals / I.F.: 14.276 Stampfer M, Imrie J, Hendriksz C, Gissen P, Crushell E, Coll M, Nadjar Y, Klünemann H, 1. Guitart-Mampel M, Gonzalez-Tendero A, Mengel E, Hrebicek M, Jones S, Ory D, Bembi Niñerola S, Morén C, Catalán-Garcia M, B, Patterson M. Consensus clinical González-Casacuberta I, Juárez-Flores DL, management guidelines for Niemann-Pick Ugarteburu O, Matalonga L, Cascajo MV, Tort disease type C. ORPHANET JOURNAL OF F, Cortés A, Tobias E, Milisenda JC, Grau JM, RARE DISEASES. 13(1):50. I.F.: 3.607 Crispi F, Gratacós E, Garrabou G, Cardellach F. Cardiac and placental mitochondrial characterization in a rabbit model of intrauterine growth restriction. BBA GRANTS FOR RESEARCH IN PROGRESS BIOCHIMICA ET BIOPHYSICA ACTA. 1862(5):1157-1167. I.F.: 5.108 Ribes A. Implementació de la medicina personalitzada basada en la genómica en 2. Mir JF, Zagmutt S, Lichtenstein MP, malalties minoritaries neurologiques no García-Villoria J, Weber M, Gracia A, Fabriàs diagnosticades. G, Casas J, López M, Casals N, Ribes A, Suñol Sponsored by: Generalitat de Catalunya. C, Herrero L, Serra D . Ghrelin Causes a PERIS_Programes16 (SLT002/16/00174) Decline in GABA Release by Reducing Duration: 27/03/2017-31/12/2019 Fatty Acid Oxidation in Cortex. MOLECULAR NEUROBIOLOGY. Ribes A. Identificación y caracterización de 55(9):7216-7228. I.F.: 5.076 nuevos defectos del metabolismo energético mitocondrial asociados a 3. Batllori M, Molero-Luis M, Ormazabal A, aciduria 3-metilglutacónica. Montero R, Sierra C, Ribes A, Montoya J, Sponsored by: Instituto de Salud Carlos III Ruiz-Pesini E, O’Callaghan M, Pias L, (ISCIII). PI16/01048 Nascimento A, Palau F, Armstrong J, Yubero Duration: 01/01/ 2017-31/12/2019 D, Ortigoza-Escobar J, García-Cazorla A, Artuch R. Cerebrospinal fluid monoamines, pterins, and folate in patients with mitochondrial diseases: systematic review DOCTORAL THESES and hospital experience. JOURNAL OF INHERITED METABOLIC DISEASE. Ribes A. Identificació de mutacions en gens 41(6):1147-1158. I.F.: 4.092 implicats en el metabolisme de l’àcid lipòic en l’acidúrica 3- metilglutacònica. PhD student: Xènia Ferrer Cortès Letters / I.F.: 3.512

1. García-Villoria J, De Azua B, Tort F, Mosegaard S, Ugarteburu O, Texidó L, Morales-Romero B, Olsen RKJ, Ribes A . FLAD1, encoding FAD synthase, is mutated in a patient with myopathy, scoliosis and cataracts. CLINICAL GENETICS. 94(6):592-593. I.F.: 3.512

204 GENOMIC PROGRAMMING OF BETA CELLS AND DIABETES 3.13

Genomic programming 3.13 of beta cells and diabetes

STRATEGIC OBJECTIVES

LOCATION A study has been published that deﬁnes the CEK building, ﬂoor 5 function of long non-coding RNAs (lncRNAs) in genetic networks involved in type 2 diabetes

WEB www.crg.eu/en/programmes- MAIN LINES OF RESEARCH groups/ferrer-lab TEAM LEADER 1. Dissection of the genetic mechanisms Jorge Ferrer underlying the pathogenesis of human (IDIBAPS / Imperial College London) diabetes. T. 93 227 54 00 (Ext.: 4542) [email protected] 2. Understanding the epigenome of pancreatic beta cells and its implications for

KEYWORDS the development, plasticity and growth of 1. Epigenetics beta cells. 2. Mouse genetic analysis POST-DOCTORAL RESEARCHERS of beta cells regulation Edgar Bernardo (IDIBAPS) 3. Mouse genetic analysis of beta-cell gene Silvia Bonas (IDIBAPS) regulation. 3. Genomic regulation Miguel Angel Maestro (CIBER) of pancreatic beta cells Irene Miguel (IDIBAPS) 4. The regeneration of pancreatic beta cells. 4. Pancreas regeneration

5. Type 2 diabetes PRE-DOCTORAL RESEARCHERS Mar Armengol (IDIBAPS) Goutham Atla (IDIBAPS) PUBLICATIONS

TECHNICIANS Originals / I.F.: 15.119 Xavi García (CIBER) Original publications Vanessa Grau (CIBER) 1. Bonas-Guarch, Silvia; Guindo-Martinez, from 2016 to 2018 Marta; Miguel-Escalada, Irene; Grarup, Niels; ADMINISTRATIVE STAFF Sebastian, David; Rodriguez-Fos, Elias; YEAR I.F. TOTAL Q1 Q2 Carme Sanahuja (CIBER) Sanchez, Friman; Planas-Felix, Merce; 2016 16.03 2 2 - Cortes-Sanchez, Paula; Gonzalez, Santi; Timshel, Pascal; Pers, Tune H.; Morgan, Claire 2017 29.65 3 3 - C.; Moran, Ignasi; Atla, Goutham; Gonzalez, 2018 15.12 22 -

TEAM INVOLVED IN CIBERDEM TEAM Jorge Ferrer

205 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

Juan R.; Puiggros, Montserrat; Marti, Jonathan; Ferrer J. T2DSystems: Development of a Andersson, Ehm A.; Diaz, Carlos; Badia, Rosa systems biomedicine approach for risk M.; Udler, Miriam; Leong, Aaron; Kaur, identiﬁcation, prevention and treatment of Varindepal; Flannick, Jason; Jorgensen, type 2 diabetes. Torben; Linneberg, Allan; Jorgensen, Marit E.; Sponsored by: European Commission. Witte, Daniel R.; Christensen, Cramer; H2020_PHC_2015 (667191) Brandslund, Ivan; Appel, Emil V.; Scott, Robert Duration: 01/01/2016-30/09/2019 A.; Luan, Jian'an; Langenberg, Claudia; Wareham, Nicholas J.; Pedersen, Oluf; Ferrer J. Modeling three-dimensional Zorzano, Antonio; Florez, Jose C.; Hansen, chromosomal structure in beta cells to Torben; Ferrer, Jorge; Maria Mercader, Josep; identify genetic mechanisms underlying Torrents, David. Re-analysis of public type 2 diabetes. genetic data reveals a rare Sponsored by: Fundacio La Marató de TV3 X-chromosomal variant associated with (201611-30) type 2 diabetes. NATURE Duration: 31/03/2017-30/03/2020 COMMUNICATIONS. 9(1):321. I.F.: 12.353

2. Gudmundsdottir V., Pedersen H., Allebrandt K., Brorsson C., van Leeuwen N., Banasik K., Mahajan A., Groves C., de Bunt M., Dawed A., Fritsche A., Staiger H., Simonis-Bik A., Deelen J., Kramer M., Dietrich A., Hübschle T., Willemsen G., Häring H., de Geus E., Boomsma D., Eekhoff E., Ferrer J., McCarthy M., Pearson E., Gupta R., Brunak S., t Hart L. Integrative network analysis highlights biological processes underlying GLP-1 stimulated insulin secretion: A DIRECT study. PLOS ONE. 13(1):e0189886. I.F.: 2.766

GRANTS FOR RESEARCH IN PROGRESS

Ferrer J. Genome regulators as targets for enhancing beta cell regeneration and function / Evaluación de reguladores genómicos como dianas para estimular la regeneración y función de las células beta (Betareg). Sponsored by: Ministerio de Economía y competitividad (MINECO). BFU2014-54284-R Duration: 01/01/2015-31/12/2018

Ferrer J. DIRECT: DIabetes REsearCh on patient sTratiﬁcation. Sponsored by: European Commission. Innovative Medicines Initiative-2010 (IMI/115317) Duration: 01/02/2012-31/07/2019

Ferrer J. ZENCODE: Computational and functional annotation of genomic elements during development of the model vertebrate zebraﬁsh. Sponsored by: European Commission. H2020_MSCA_ITN_14 (643062) Duration: 01/01/2015-31/12/2018

206 DIABETES: METABOLIC AND MOLECULAR NETWORKS 3.14

Diabetes: metabolic 3.14 and molecular networks

Roberta Haddad-Tóvolli (IDIBAPS) Arnaud Obri (IDIBAPS) LOCATION Macarena Pozo (IDIBAPS) CEK building, ﬂoor 5 Sara Ramirez (IDIBAPS)

PRE-DOCTORAL RESEARCHERS Hugo Alves (FCRB) Diana Alicia Diaz (FCRB) Berta Serra (IDIBAPS) KEYWORDS Gloria Beatriz Aranda (IDIBAPS) 1. Type 1 diabetes TEAM LEADER Antonio Jesús Blanco (IDIBAPS) 2. Type 2 diabetes Josep Vidal (HCB) Josep Garnica (IDIBAPS) 3. Obesity T. 93 227 57 39 Javier Jose Montaño (IDIBAPS) 4. Autoimmunity [email protected] Daniel Parras (IDIBAPS) 5. Pancreatic islets Patricia Solé (IDIBAPS) 6. Steroids Guillermo Garcia (IDIBAPS) Iñigo Chivite (IDIBAPS) 7. Endocrine tumours GROUP LEADERS Marc Claret (IDIBAPS) TECHNICIANS T. 93 227 54 00 (Ext.: 4552) Ainhoa García (CIBER) [email protected] Original publications Juan Antonio Arranz (IDIBAPS) Luis Miguel Carrasco (IDIBAPS) from 2016 to 2018 Ramon Gomis (HCB-IDIBAPS) Immaculada Creus (IDIBAPS) T. 93 227 54 00 (Ext.: 4180) YEAR I.F. TOTAL Q1 Q2 Melek Denizli (IDIBAPS) [email protected] César Fandos (IDIBAPS) 2016 168.97 32 24 3 Oriol Giro (FCRB) Felicia A. Hanzu (HCB-IDIBAPS) 2017 153.32 18 12 3 Maria Milà (IDIBAPS) T. 93 227 54 00 (Ext.: 9846) 2018 144.02 27 22 4 [email protected] ADMINISTRATIVE STAFF Kimberly Katte (CIBER) Pere Santamaria (IDIBAPS) Mireia Ortega (IDIBAPS) T. 93 227 54 00 (Ext.: 4558) [email protected] TEAM INVOLVED IN NURSING STAFF CIBERDEM Alberto Fernández (IDIBAPS) AGAUR_SGR17: 00338, 01166 Josep Vidal (HCB) T. 93 227 57 39 REEM COLLABORATORS [email protected] Mattia Squarcia (HCB)

RESEARCHERS Ignasi Conget (HCB) AWARDS STRATEGIC OBJECTIVES Enrique Esmatjes (HCB) Premi Gaudí Gresol Margarita Gimenez (IDIBAPS) 1. To evaluate the molecular, genetic, and a la Notorietat i l’Excel·lència Amanda Jiménez (IDIBAPS) environmental contribution to the Awardee/s: Ramon Gomis Emilio Ortega (HCB) determinants of different endocrinological Rosa Maria Gasa (IDIBAPS) diseases. Pau Serra (IDIBAPS) 2. To understand the contribution and interaction of central and peripheral factors POST-DOCTORAL RESEARCHERS in the regulation of glucose homeostasis Montserrat Cofán (CIBER) and energy balance. Rebeca Fernandez (CIBER) 3. To translate new concepts in Garyfallia Kapravelou (CIBER) immunobiology into clinical studies. Violeta Moize (HCB) Óscar Osorio (CIBER) Marta Fontcuberta (IDIBAPS) Maria Nahir Garabatos (IDIBAPS) MAIN LINES OF RESEARCH Irene Gracia (IDIBAPS) Meritxell Tort (IDIBAPS) 1. Investigation of the mechanisms involved in Irene Halperin (HCB) the destruction, survival and proliferation of Mireia Mora (HCB) pancreatic beta-cells. Alicia Garcia (IDIBAPS)

207 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

2. Manipulation of defined populations of RESEARCH GROUP pancreatic beta-cell, the molecules that neurons in the central nervous system in PANCREATIC ISLETS: BIOMARKERS participate in these processes, and how the order to correlate the function of a particular AND FUNCTION activation or inhibition of these molecules may protein with specific physiological and help recover beta-cell mass as therapeutic behavioural outputs. targets for treating diabetes; the second one 3. Bariatric surgery and the resolution of seeks to obtain insulin-producing cells from comorbidites associated with obesity. human skin fibroblasts and to analyze their 4. Mediterranean dietary patterns and other function, revascularization process and nutritional strategies for the prevention of capacity for reversing diabetes when type 2 diabetes and cardiovascular disease. transplanted into experimental models of 5. Study of the molecular and epigenetic GROUP LEADER diabetes. mechanisms of cardiometabolic memory in Ramon Gomis (HCB-IDIBAPS) In addition, the group participates in research humans and animal models of projects in collaboration with Alícia Foundation hypercortisolism. Our team conducts two main research that focus on investigating different nutritional 6. Depiction of nanomedicine-based programs: the first one is aimed at strategies for preventing diabetes. strategies to efficiently suppress the investigating the mechanisms involved in the progression of several different destruction, survival and proliferation of the autoimmune disorders without compromising systemic immunity. 7. Translation of knowledge gained on immunobiology into clinical studies for chronic inflammatory disorders such as type 1 diabetes. 8. To improve algorithms of insulin delivery that may help reduce the burden of hyperglycemia in subjects with type 1 diabetes.

RESEARCH GROUP NEURONAL CONTROL OF METABOLISM (NEUCOME) GROUP Ramon Gomis

GROUP LEADER Marc Claret (IDIBAPS)

Our general research interests are focused on the study of the molecular mechanisms by which particular neurocircuits control food intake, body weight and glucose metabolism. To achieve this aim, our group uses a combination of neuroanatomy, molecular and genetic tools to manipulate defined populations of neurons in order to correlate the function of a particular protein with specific physiological and behavioural outputs. Understanding the physiological mechanisms controlling energy balance and the pathophysiological alterations leading to obesity and diabetes, are the first steps towards developing new and more effective therapeutic approaches for the treatment of these metabolic conditions. GROUP Marc Claret

208 DIABETES: METABOLIC AND MOLECULAR NETWORKS 3.14

50/50 PROGRAM ENDOCRINE DISORDERS: CROSSTALK BETWEEN MOLECULAR AND METABOLIC DETERMINANTS

GROUP LEADER Felicia A. Hanzu (HCB-IDIBAPS)

Our group study the molecular, metabolic and therapeutic aspects of complex endocrine tumors and steroids-induced disorders having as the principal aim the translation of the knowledge from basic research to the clinical practice. The steroids research focus on the cellular

and epigenetic deleterious effects of the GROUP Felicia Hanzu steroid hormones on target tissues. The endocrine tumor research line focus on genetic, molecular biomarkers with diagnostic and therapeutic porpoise.

RESEARCH GROUP PATHOGENESIS AND TREATMENT OF AUTOIMMUNITY

GROUP LEADER Pere Santamaria (IDIBAPS)

Our group pursues translational studies on the immunobiology of a novel therapeutic approach for chronic inﬂammatory disorders GROUP Josep Vidal based on nanomedicine. This therapeutic approach triggers the formation of extensive antigen- and RESEARCH GROUP The main aim of our research group is to gain a disease-speciﬁc networks of regulatory TRANSLATIONAL RESEARCH greater understanding of the mechanisms that T and B-cells that efficiently suppress the IN DIABETES, LIPIDS associate excess weight and dietary patterns progression of several different autoimmune AND OBESITY with the development of metabolic disorders. disorders without compromising systemic For this purpose, we develop clinical and basic immunity. lines of research that seek to analyze metabolic adaptation response to situations including weight gain, exposure to certain dietary patterns, and weight loss in human subjects and animal models. At present, our studies involving human subjects focus on the GROUP LEADER Mediterranean diet model, and also weight Josep Vidal (HCB) loss associated with bariatric surgery.

209 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

PUBLICATIONS uncontrolled type 2 diabetes. DIABETES, Wärnberg J, López-Miranda J, Estruch R, OBESITY AND METABOLISM. Bueno-Cavanillas A, Arós F, Tur JA, Originals / I.F.: 144.022 20(12):2821-2829. I.F.: 5.980 Tinahones FJ, Serra-Majem L, Martín V, Lapetra J, Más Fontao S, Pintó X, Vidal J, 1. Singha S; Shao K; Ellestad KK; Yang Y; 6. Schröder H, Cárdenas-Fuentes G, Daimiel L, Gaforio JJ, Matía P, Ros E, Santamaria P. Nanoparticles for Immune Martínez-González MA, Corella D, Vioque J, Ruiz-Canela M, Sorlí JV, Becerra-Tomás N, Stimulation Against Infection, Cancer, and Romaguera D, Alfredo Martínez J, Tinahones Castañer O, Schröder H, Navarrete-Muñoz Autoimmunity. ACS NANO. FJ, Miranda JL, Estruch R, Bueno-Cavanillas EM, Zulet MÁ, García-Ríos A, Salas-Salvadó J, 12(11):10621-10635. I.F.: 13.709 A, Arós F, Marcos A, Tur JA, Warnberg J, Díez-Espino J, Toledo E. Adherence to an Serra-Majem L, Martín V, Vázquez C, Lapetra Energy-restricted Mediterranean Diet 2. Gimenez M, Tannen AJ, Reddy M, J, Pintó X, Vidal J, Daimiel L, Gaforio JJ, Score and Prevalence of Cardiovascular Moscardo V, Conget I, Oliver N. Revisiting the Matía-Martín P, Ros E, Castañer O, Lassale C, Risk Factors in the PREDIMED-Plus: A Relationships Between Measures of Ruiz-Canela M, Asensio EM, Basora J, Cross-sectional Study. REVISTA Glycemic Control and Hypoglycemia in Torres-Collado L, Garcia-Rios A, Abete I, ESPAÑOLA DE CARDIOLOGIA. . I.F.: 5.166 Continuous Glucose Monitoring Data Sets. Toledo E, Buil-Cosiales P, Bullo M, Goday A, DIABETES CARE. 41(2):326-332. I.F.: 13.397 Fitó M, Salas-Salvadó J, PREDIMED-Plus 11. Boswell L, Jiménez A, Ortega E, Pané A, investigators. Effectiveness of the physical Hollanda A, Moizé V, Andreu A, Ibarzabal A, 3. Quiñones M., Al-Massadi O., Folgueira C., activity intervention program in the Flores L, Vidal J. Genetic background Bremser S., Gallego R., Torres-Leal L., PREDIMED-Plus study: a randomized influences weight-loss trajectories on the Haddad-Tóvolli R., García-Caceres C., controlled trial. INTERNATIONAL JOURNAL mid-term after bariatric surgery. Hernandez-Bautista R., Lam B., Beiroa D., OF BEHAVIORAL NUTRITION AND INTERNATIONAL JOURNAL OF OBESITY. Sanchez-Rebordelo E., Senra A., Malagon J., PHYSICAL ACTIVITY. 15(1):110. I.F.: 5.548 I.F.: 5.159 Valerio P., Fondevila M., Fernø J., Malagon M., Contreras R., Pfluger P., Brüning J., Yeo G., 7. Rosique-Esteban N, Babio N, Díaz-López A, 12. Rosique-Esteban N, Papandreou C, Tschöp M., Diéguez C., López M., Claret M., Romaguera D, Alfredo Martínez J, Sanchez Romaguera D, Warnberg J, Corella D, Kloppenburg P., Sabio G., Nogueiras R. p53 in VM, Schröder H, Estruch R, Vidal J, Martínez-González MÁ, Díaz-López A, AgRP neurons is required for protection Buil-Cosiales P, Konieczna J, Abete I, Estruch R, Vioque J, Arós F, Garcia-Rios A, against diet-induced obesity via JNK1. Salas-Salvadó J. Leisure-time physical Bueno-Cavanillas A, Vidal J, Serra-Majem L, NATURE COMMUNICATIONS. 9(1):3432. activity at moderate and high intensity is Sibai AA, Tinahones FJ, Martínez JA, Ordovás I.F.: 12.353 associated with parameters of body JM, Tur JA, Ellacuría MT, Sanllorente A, Pintó composition, muscle strength and X, Buil-Cosiales P, Fernández-Carrion R, 4. Martínez-González MA, Buil-Cosiales P, sarcopenia in aged adults with obesity and Castañer O, Bulló M, Ruiz-Canela M, Corella D, Bulló M, Fitó M, Vioque J, metabolic syndrome from the Garcia-de la Hera M, Pérez-Farinós N, Romaguera D, Martínez JA, Wärnberg J, PREDIMED-Plus study. CLINICAL Barón-López FJ, Colom A, Abete I, Ros E, López-Miranda J, Estruch R, NUTRITION. 38(3):1324-1331. I.F.: 5.496 Salas-Salvadó J . Cross-sectional Bueno-Cavanillas A, Arós F, Tur JA, associations of objectively-measured Tinahones F, Serra-Majem L, Martín V, 8. Konieczna J, Abete I, Galmés AM, Babio N, sleep characteristics with obesity and type Lapetra J, Vázquez C, Pintó X, Vidal J, Daimiel Colom A, Zulet MA, Estruch R, Vidal J, Toledo 2 diabetes in the PREDIMED-Plus trial. L, Delgado-Rodríguez M, Matía P, Ros E, E, Díaz-López A, Fiol M, Casas R, Vera J, SLEEP. 41(12). I.F.: 5.135 Fernández-Aranda F, Botella C, Portillo MP, Buil-Cosiales P, Martín V, Goday A, Lamuela-Raventós RM, Marcos A, Sáez G, Salas-Salvadó J, Martínez JA, Romaguera D, 13. Amor AJ, Cofán M, Mateo-Gallego R, Gómez-Gracia E, Ruiz-Canela M, Toledo E, PREDIMED-Plus Investigators. Body Cenarro A, Civeira F, Ortega E, Ros E, Alvarez-Alvarez I, Díez-Espino J, Sorlí JV, adiposity indicators and cardiometabolic Sala-Vila A. Dietary polyunsaturated fatty Basora J, Castañer O, Schröder H, risk: Cross-sectional analysis in acids mediate the inverse association of Navarrete-Muñoz EM, Zulet MA, García-Rios participants from the PREDIMED-Plus trial. stearoyl-CoA desaturase activity with the A, Salas-Salvadó J, PREDIMED-Plus CLINICAL NUTRITION. 38(4):1883-1891. risk of fatty liver in dyslipidaemic Investigators. Cohort Profile: Design and I.F.: 5.496 individuals. EUROPEAN JOURNAL OF methods of the PREDIMED-Plus NUTRITION. 58(4):1561-1568. I.F.: 4.423 randomized trial. INTERNATIONAL 9. Fontcuberta-PiSunyer M., Cervantes S., JOURNAL OF EPIDEMIOLOGY. Miquel E., Mora-Castilla S., Laurent L., Raya A., 14. Sánchez-Villegas A., Álvarez-Pérez J., 48(2):387-388o. I.F.: 8.360 Gomis R., Gasa R. Modulation of the Toledo E., Salas-Salvadó J., Ortega-Azorín C., endocrine transcriptional program by Zomeño M., Vioque J., Martínez J., Romaguera 5. Rosenstock J, Handelsman Y, Vidal J, Vidal targeting histone modifiers of the D., Pérez-López J., López-Miranda J., Estruch J, Ampudia Blasco FJ, Giorgino F, Liu M, H3K27me3 mark. BIOCHIMICA ET R., Bueno-Cavanillas A., Arós F., Tur J., Perfetti R, Meier JJ. Propensity- BIOPHYSICA ACTA - GENE REGULATORY Tinahones F., Lecea O., Martín V., score-matched comparative analyses of MECHANISMS. 1861(5):473-480. I.F.: 5.179 Ortega-Calvo M., Vázquez C., Pintó X., Vidal J., simultaneously administered fixed-ratio Daimiel L., Delgado-Rodríguez M., Matía P., insulin glargine 100 U and lixisenatide 10. Álvarez-Álvarez I, Martínez-González MÁ, Corella D., Díaz-López A., Babio N., Muñoz M., (iGlarLixi) vs sequential administration of Sánchez-Tainta A, Corella D, Díaz-López A, Fitó M., de la Hera M., Abete I., García-Rios A., insulin glargine and lixisenatide in Fitó M, Vioque J, Romaguera D, Martínez JA, Ros E., Ruíz-Canela M., Martínez-González M.,

210 DIABETES: METABOLIC AND MOLECULAR NETWORKS 3.14

Izquierdo M., Serra-Majem L. Seafood 18. Konugolu Venkata Sekar S., Farina A., 23. Beato-Víbora PI, Quirós-López C, consumption, omega-3 fatty acids intake, Dalla Mora A., Lindner C., Pagliazzi M., Mora M., Lázaro-Martín L, Martín-Frías M, and life-time prevalence of depression in Aranda G., Dehghani H., Durduran T., Taroni P., Barrio-Castellanos R, Gil-Poch E, Arroyo-Díez the PREDIMED-plus trial. NUTRIENTS. Pifferi A. Broadband (550-1350 nm) diffuse FJ, Giménez-Álvarez M. Impact of 10(12). I.F.: 4.196 optical characterization of thyroid Sensor-Augmented Pump Therapy with chromophores. SCIENTIFIC REPORTS. Predictive Low-Glucose Suspend 15. Cano-Ibáñez N, Bueno-Cavanillas A, 8(1):10015. I.F.: 4.122 Function on Glycemic Control and Patient Martínez-González MA, Corella D, Satisfaction in Adults and Children with Salas-Salvadó J, Zomeño MD, 19. Maldonado-Araque C; Valdés S; Type 1 Diabetes. DIABETES TECHNOLOGY García-de-la-Hera M, Romaguera D, Martínez Lago-Sampedro A; Lillo-Muñoz JA; AND THERAPEUTICS. 20(11):738-743. JA, Barón-López FJ, García-Ríos A, Estruch R, García-Fuentes E; Perez-Valero V; I.F.: 2.921 García-Molina L, Alonso Gómez Á, Tur JA, Gutiérrez-Repiso C; Goday A; Urrutia I; Peláez Tinahones F, Serra-Majem L, L; Calle-Pascual A; Castaño L; Castell C; 24. Bertinat, Romina; Westermeier, Francisco; Cubelos-Fernández N, Lapetra J, Vázquez C, Delgado E; Menéndez E; Franch-Nadal J; Silva, Pamela; Gatica, Rodrigo; Moitinho Pintó X, Vidal J, Daimiel L, Gaforio JJ, Matía P, Gaztambide S; Girbés J; Ortega E; Vendrell J; Oliveira, Joana; Nualart, Francisco; Gomis, Ros E, Diez-Espino J, Fernández-Carrión R, Chacón MR; Chaves FJ; Soriguer F. Iron Ramon; Yanez, Alejandro J. The Antidiabetic Basora J, Fitó M, Zazo JM, Colom A, Toledo E, deficiency is associated with Agent Sodium Tungstate Induces Díaz-López A, Muñoz MÁ, Ruiz-Canela M, Hypothyroxinemia and Abnormal Glycogen Accumulation in Gea A . Dietary Intake in Population with Hypotriiodothyroninemia in the Spanish Renal Proximal Tubules from Diabetic Metabolic Syndrome: Is the Prevalence of general adult population: [email protected] study. IRS2-Knockout Mice. JOURNAL OF Inadequate Intake Influenced by SCIENTIFIC REPORTS. 8(1):6571. I.F.: 4.122 DIABETES RESEARCH. 2018(5697970). Geographical Area? Cross-Sectional I.F.: 2.885 Analysis from PREDIMED-Plus Study. 20. Pané A, Ruiz S, Orois A, Martínez D, NUTRIENTS. 10(11). I.F.: 4.196 Squarcia M, Sastre L, Ruiz P, Caballería J, 25. Galilea-Zabalza I, Buil-Cosiales P, Hanzu FA, Halperin I. Primary adrenal Salas-Salvadó J, Toledo E, Ortega-Azorín C, 16. Haydar S., Paillot T., Fagot C., Cogne Y., insufficiency due to hereditary Díez-Espino J, Vázquez-Ruiz Z, Zomeño MD, Fountas A., Tutuncu Y., Vintila M., Tsatsoulis A., apolipoprotein AI amyloidosis: endocrine Vioque J, Martínez JA, Romaguera D, Chi P., Garandeau P., Chetea D., Badiu C., involvement beyond hypogonadism. Perez-Farinos N, López-Miranda J, Estruch R, Gheorghiu M., Ylli D., Lautier C., Jarec M., AMYLOID : THE INTERNATIONAL JOURNAL Bueno-Cavanillas A, Arós F, Tur JA, Tinahones Monnier L., Normand C., Šarac J., Barakat A., OF EXPERIMENTAL AND CLINICAL F, Serra-Majem L, Marcos-Delgado A, Missoni S., Pugeat M., Poucheret P., Hanzu F., INVESTIGATION : THE OFFICIAL JOURNAL Ortega-Calvo M, Vázquez C, Pintó X, Vidal J, Gomis R., Macias J., Litvinov S., Khusnutdinova OF THE INTERNATIONAL SOCIETY OF Daimiel L, Delgado-Rodríguez M, Matía P, E., Poiana C., Pasquali R., Lauro D., Sesti G., AMYLOIDOSIS. 25(2):75-78. I.F.: 4.048 Corella D, Diaz-López A, Babio N, Muñoz MA, Trischitta V., Abdelhak S., Zenati A., Ylli A., Fitó M, González-Palacios S, Abete I, Satman I., Kanninen T., Rinato Y., Grigorescu F. 21. Mena-Sánchez G, Babio N, García-Rios A, Ros E, Martínez-González MÁ, Branched-Chain Amino Acid Database Martínez-González MÁ, Corella D, Schröder H, PREDIMED-PLUS Study Investigators. Integrated in MEDIPAD Software as a Tool Vioque J, Romaguera D, Martínez JA, Mediterranean diet and quality of life: for Nutritional Investigation of Lopez-Miranda J, Estruch R, Wärnberg J, Baseline cross-sectional analysis of the Mediterranean Populations. NUTRIENTS. Bueno-Cavanillas A, Serra-Majem L, Tur JA, PREDIMED-PLUS trial. PLOS ONE. 10(10):1392. I.F.: 4.196 Arós F, Tinahones FJ, Sánchez VM, Lapetra J, 13(6):e0198974. I.F.: 2.766 Pintó X, Vidal J, Vázquez C, Ordovás JM, 17. Mallorquí-Bagué N., Lozano-Madrid M., Delgado-Rodriguez M, Matía-Martín P, Basora 26. Delgado-Oliver E, Vidal-Sicart S, Martínez Toledo E., Corella D., Salas-Salvadó J., J, Buil-Cosiales P, Fernandez-Carrion R, Fitó D, Squarcia M, Mora M, Hanzu FA, Halperin I, Cuenca-Royo A., Vioque J., Romaguera D., M, Salas-Salvadó J, PREDIMED-PLUS Fuster D, Fondevila C, Vidal-Perez Ó. Martínez J., Wärnberg J., López-Miranda J., investigators. Fermented dairy products, Applicability of sentinel lymph node biopsy Estruch R., Bueno-Cavanillas A., diet quality, and cardio–metabolic profile in papillary thyroid cancer. THE Alonso-Gómez Á., Tur J., Tinahones F., of a Mediterranean cohort at high QUARTERLY JOURNAL OF NUCLEAR Serra-Majem L., Martín V., Lapetra J., Vázquez cardiovascular risk. NUTRITION, MEDICINE AND MOLECULAR IMAGING : C., Pintó X., Vidal J., Daimiel L., Gaforio J., Matía METABOLISM AND CARDIOVASCULAR OFFICIAL PUBLICATION OF THE ITALIAN P., Ros E., Granero R., Buil-Cosiales P., DISEASES. 28(10):1002-1011. I.F.: 3.318 ASSOCIATION OF NUCLEAR MEDICINE Barragán R., Bulló M., Castañer O., (AIMN) [AND] THE INTERNATIONAL García-de-la-Hera M., Yáñez A., Abete I., 22. Aranda G., Fernandez-Ruiz R., Palomo M., ASSOCIATION OF RADIOPHARMACOLOGY García-Ríos A., Ruiz-Canela M., Díaz-López A., Romo M., Mora M., Halperin I., Casals G., (IAR), [AND] SECTION OF THE SOCIETY OF Jiménez-Murcia S., Martínez-González M., De Enseñat J., Vidal O., Diaz-Ricart M., Hanzu F. RADIOPHARMACEUTICAL CHEMISTRY la Torre R. Type 2 diabetes and cognitive Translational evidence of prothrombotic AND BIOLOGY. I.F.: 2.368 impairment in an older population with and inflammatory endothelial damage in overweight or obesity and metabolic Cushing syndrome after remission. 27. Biagi L, Bertachi A, Giménez M, Conget I, syndrome: baseline cross-sectional CLINICAL ENDOCRINOLOGY. 88(3):415-424. Bondia J, Martín-Fernández JA, Vehí J. analysis of the PREDIMED-plus study. I.F.: 3.077 Individual categorisation of glucose SCIENTIFIC REPORTS. 8(1):16128. I.F.: 4.122 profiles using compositional data analysis.

211 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

STATISTICAL METHODS IN MEDICAL 2. Valassi E, Feelders R, Maiter D, Chanson P, Gasa R. Direct reprogramming of human RESEARCH. 31:962280218808819. I.F.: 2.284 Yaneva M, Reincke M, Krsek M, Tóth M, Webb fibroblasts towards insulin-producing S, Santos A, Paiva I, Komerdus I, Droste M, cells. Tabarin A, Strasburger C, Franz H, Trainer P, Sponsored by: European Foundation for the Review / I.F.: 25.786 Newell-Price J, Wass J, Papakokkinou E, Study of Diabetes, EFSD/Lilly_2017 Ragnarsson O, Ambrogio A, Aranda G, Arosio Duration: 01/01/2018-31/12/2019 1. Pozo M, Claret M. Hypothalamic Control M, Balomenaki M, Beck-Peccoz P, of Systemic Glucose Homeostasis: The Berr-Kirmair C, Bolanowski M, Bollerslev J, Gomis R. Efectes beneficiosos de la quinoa Pancreas Connection. TRENDS IN Thierry B, Carvalho D, Cavagnini F, Christ E, (Chenopodium quinoa Willd) en la ENDOCRINOLOGY AND METABOLISM. Demtröder F, Denes J, Dimopoulou C, Dreval prevenció de la Diabetes Mellitus tipus 2. 29(8):581-594. I.F.: 10.769 A, Dusek T, Erdinc E, Evang J. Worse Sponsored by: Fundació Acadèmia de les Health-Related Quality of Life at long-term Ciències Mèdiques (ACD_GLloveras) 2. Graupera M., Claret M. Endothelial Cells: follow-up in patients with Cushing's Duration: 01/03/2017-28/02/2019 New Players in Obesity and Related disease than patients with cortisol Metabolic Disorders. TRENDS IN producing adenoma. Data from the Hanzu F. Cambios epigenéticos inducidos ENDOCRINOLOGY AND METABOLISM. ERCUSYN. CLINICAL ENDOCRINOLOGY. por el síndrome cushing en la plasticidad y 29(11):781-794. I.F.: 10.769 88(6):787-798. I.F.: 3.077 el kinoma del tejido adipso. Modelo animal y estudio en humanos. 3. Serra P, Santamaria P. Sponsored by: Instituto de Salud Carlos III Nanoparticle-based approaches to (ISCIII). PI15/00859 immune tolerance for the treatment of GRANTS FOR RESEARCH IN PROGRESS Duration: 01/01/2016-31/07/2019 autoimmune diseases. EUROPEAN JOURNAL OF IMMUNOLOGY. 48(5):751-756. Claret M. Investigando el papel de los Jiménez A. Inflamación hipotalámica en I.F.: 4.248 neuroesteroides derivados de las obesidad. Papel de la dieta y efectos de la neuronas POMC hipotalámicas como cirugía bariátrica. reguladores críticos del balance Sponsored by: Instituto de Salud Carlos III Consortium Publications / I.F.: 7.41 energético y el metabolismo. (ISCIII). PI17/00279 Sponsored by: Instituto de Salud Carlos III Duration: 01/01/2018-31/12/2020 1. Valassi E., Franz H., Brue T., Feelders R., (ISCIII). PI16/00963 Netea-Maier R., Tsagarakis S., Webb S., Duration: 01/01/2017-31/12/2019 Jiménez A. Malaltia d'Alzheimer preclínica, Yaneva M., Reincke M., Droste M., Komerdus I., diabetis mellitus tipus 2 i obesitat. Efectes Maiter D., Kastelan D., Chanson P., Pfeifer M., Claret M. Neuronas POMC: ¿en la interfaz de la cirurgia bariàtrica: un estudi Strasburger C., Tóth M., Chabre O., Krsek M., entre la detección de energía y el multimodal. Fajardo C., Bolanowski M., Santos A., Trainer comportamiento altruista? Sponsored by: Fundació La Marató TV3 P., Wass J., Tabarin A., Ambrogio A., Aranda G., Sponsored by: Ministerio de Economía y (201614.30) Arosio M., Balomenaki M., Beck-Peccoz P., Competitividad (MINECO). Duration: 10/03/2017-09/03/2020 Berr-Kirmair C., Bollerslev J., Carvalho D., BFU2015-72486-EXP Cavagnini F., Christ E., Denes J., Dimopoulou Duration: 01/05/2017-30/04/2020 Mora M, Gomis R. LUCA: Laser and C., Dreval A., Dusek T., Erdinc E., Valassi E., Ultrasound Co-Analyzer for thyroid Franz H., Brue T., Feelders R., Netea-Maier R., Claret M. MITOSENSING: Decoding nodules. Tsagarakis S., Webb S., Yaneva M., Reincke mitochondrial nutrient-sensing programs Sponsored by: European Commission. M., Droste M., Komerdus I., Maiter D., Kastelan in POMC neurons as key determinants of H2020_ICT_2015 (688303) D., Chanson P., Pfeifer M., Strasburger C., Tóth metabolic health. Duration: 01/02/2016-31/01/2020 M., Chabre O., Krsek M., Fajardo C., Sponsored by: European Commission. Bolanowski M., Santos A., Trainer P., Wass J., H2020_ERC_2016_CoG (725004) Ortega E. Cambios en la microcirculación Tabarin A., Ambrogio A., Aranda G., Arosio M., Duration: 01/04/2017-31/03/2022 retiniana y carotidea tras restauración de Balomenaki M., Beck-Peccoz P., Berr-Kirmair normoglicemia en pacientes con diabetes C., Bollerslev J., Carvalho D., Cavagnini F., Claret M. Mitochondrial fusion in tipo 2: angiografia retiniana mediante Christ E., Denes J., Dimopoulou C., Dreval A., endothelial cells: impact on systemic tomografía de coherencia óptica y Dusek T., Erdinc E., Valassi E., Franz H., Brue T., energy and glucose homeostasis. ultrasonido carotideo con contraste. Feelders R., Netea-Maier R., Tsagarakis S., Sponsored by: European Foundation for the Sponsored by: Instituto de Salud Carlos III Webb S., Yaneva M., Reincke M., Droste M., Study of Diabetes, EFSD/Lilly_2017 (ISCIII). PI17/01479 Komerdus I. Preoperative medical Duration: 15/02/2018-14/02/2020 Duration: 01/01/2018-31/12/2020 treatment in Cushing's syndrome: Frequency of use and its impact on Gasa R, Gomis R. Proliferación de la célula Santamaria P. Grup de Recerca en postoperative assessment: Data from β pancreática: impacto de nuevos autoimmunitat. ERCUSYN. EUROPEAN JOURNAL OF reguladores. Sponsored by: Generalitat de Catalunya. ENDOCRINOLOGY. 178(4):399-409. I.F.: Sponsored by: Instituto de Salud Carlos III AGAUR_SGR17_00338 4.333 (ISCIII). PI16/00774 Duration: 01/01/2017-31/12/2020 Duration: 01/01/2017-31/12/2019

212 DIABETES: METABOLIC AND MOLECULAR NETWORKS 3.14

Santamaria P. El papel de la autofagia Sponsored by: Instituto de Salud Carlos III celular en la tolerancia central y activación (ISCIII). PI17/00215 periférica de células TCD4+ Duration: 01/01/2018-31/12/2020 diabetogénicas. Sponsored by: Ministerio de Economía y Competitividad (MINECO). SAF2015-68187-R Duration: 01/01/2016-31/12/2019 DOCTORAL THESES

Santamaria P. Advancing human Conget I, Giménez M. Eficacia del uso de la antigen-specific T-regulatory cell tecnología en el tratamiento de la diabetes expanding nanomedicines for tipo I en nuestro entorno. De las Bombas autoimmune disease: Translational de insulina al páncreas artificial. studies in humanized mice. PhD student: Carmen Quirós López Sponsored by: Instituto de Salud Carlos III (ISCIII). PIE14/00027 Gasa R, Gomis R. Desenvolupament de Duration: 01/01/2015-30/06/2019 noves estratègies per generar cèl·lules productores d'insulina. Santamaria P. Red Temática de PhD student: Marta Fontcuberta Pi-Sunyer Investigación Cooperativa en Salud - Esclerosis múltiple. Gomis R, Gasa R. Regulation of pancreatic Sponsored by: Instituto de Salud Carlos III beta cell mass and function: the role of (ISCIII). RD16/0015/0020 glycogen metabolism and other intrinsic Duration: 01/01/2017-31/12/2021 factors. PhD student: Joan Ignasi Mir Coll Santamaria P. Advancing an antigen-specific nanomedicine for the Gomis R, Gasa R. Implicació de la treatment of central nervous system senyalització dependent de Gsa en autoimmunity. l'establiment de la massa cel·lular ß. Sponsored by: Ministerio de Economía y PhD student: Berta Serra Navarro Competitividad (MINECO). ERA-NET Neuron. Duration: 01/01/2015-31/122019 Gomis R. Improving islet-graft revascularization. PhD student: Hugo Jorge Alves Figuereido Serra P. Nanomedicines to expand type 1 diabetes specific T-regulatory-1 type cells: Hanzu F, Halperin I. Mecanismos mechanistic and translational studies. moleculares del riesgo metabólico y Sponsored by: Juvenile Diabetes Research cardiovascular en el Síndrome de Cushing Foundation. JDRF-CDA-2014-214-A-N antes y después de la curación: Enfoque Duration: 01/06/2014-31/05/2019 traslacional. PhD student: Gloria Beatriz Aranda Velazquez Vidal J. Diabetis: xarxes metabòliques i moleculars. Ortega E. Predicción de eventos Sponsored by: Generalitat de Catalunya. cardiovasculares: De las escalas de riesgo AGAUR_SGR17_01166 al uso de biomarcadores. Duration: 01/01/2017-31/12/2020 PhD student: Antonio Jesus Amor Fernandez

Vidal J. PREDIMED+DM Efecto de una dieta mediterránea hipocalórica y promoción de la actividad física en prevenciones de diabetes tipo 2 en personas con síndrome metabólico. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI14/00728 Duration: 01/01/2015-30/06/2018

Vidal J. PREDIMED+DM: Efecto de una pérdida de peso con dieta mediterránea hipocalórica y promoción de la actividad física en la prevención de diabetes tipo 2 en personas con síndrome metabólico.

213 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

Pathogenesis and 3.15 prevention of diabetes

COLLABORATORS Ana Isabel García-Díez (HCB) LOCATION CEK building, ﬂoor 5

STRATEGIC OBJECTIVES

1. Impact of lifestyle on diabetes: exercise and nutrition. KEYWORDS 2. Circulating microRNAs as potential 1. Islet amyloid polypeptide biomarkers and therapeutic targets in type TEAM LEADER 2 diabetes. (IAPP)/amylin Anna Novials (IDIBAPS) 3. New therapeutic targets for the treatment 2. Beta-cell dysfunction T. 93 227 54 00 (Ext.: 4153) of pancreatic islet dysfunction, type 2 3. Circulating microRNAs [email protected] 4. Endothelial dysfunction diabetes and obesity. 5. Exercise and nutrition 4. Mechanisms and treatment of endothelial dysfunction in type 2 diabetes. RESEARCHERS Antonio Ceriello (IDIBAPS) Marcelina Párrizas (CIBER) Joan Marc Servitja (IDIBAPS) MAIN LINES OF RESEARCH

Original publications 1. Impact of lifestyle on diabetes: metabolic from 2016 to 2018 POST-DOCTORAL RESEARCHERS Gema Alcarraz-Vizán (IDIBAPS) and molecular responses to exercise and YEAR I.F. TOTAL Q1 Q2 Laura Brugnara (CIBER) nutrition in diabetic patients and animal Valeria de Nigris (IDIBAPS) models. 2016 76.92 19 99 2. Role of circulating exosomal microRNAs in 2017 87.38 17 12 3 PRE-DOCTORAL RESEARCHERS the pathogenesis of type 2 diabetes and the 2018 62.28 15 85 Carlos Castaño (CIBER) control of lipid metabolism: impact of Sara de Pablo (IDIBAPS) exercise intervention. Daniela J. Díaz-Catalán (UB) 3. Circulating microRNAs as potential Serafín Murillo (CIBER) biomarkers of micro- and macrovascular Júlia Rodríguez-Comas (IDIBAPS) complications in diabetes. TEAM INVOLVED IN 4. Mechanisms of pancreatic islet dysfunction

CIBERDEM TECHNICIANS in type 2 diabetes mellitus: potential AGAUR_SGR17: 01390 Juan Moreno-Vedia (FCRB) protective effects of endoplasmic reticulum stress inhibitors and anti-inﬂammatory TEAM Anna Novials

214 PATHOGENESIS AND PREVENTION OF DIABETES 3.15

molecules against amyloid-induced Guillén C., Benito M. Pancreatic β cells AND BLOOD PRESSURE RESEARCH. beta-cell dysfunction. overexpressing hIAPP impaired 43(2):422-438. I.F.: 3.000 5. New therapeutic targets for the treatment mitophagy and unbalanced mitochondrial of type 2 diabetes and obesity: role of the dynamics. CELL DEATH DIS. 9(5):481. 11. Gentile S, Strollo F, Viazzi F, Russo G, protease Bace2 in the control of glucose I.F.: 5.638 Piscitelli P, Ceriello A, Giorda C, Guida P, homeostasis and body weight. Fioretto P, Pontremoli R, De Cosmo S, The 6. Modulation of signalling and transcriptional 5. La Sala L., Mrakic-Sposta S., Micheloni S., AMD-Annals Study Group. Five-Year networks in pancreatic islets in response to Prattichizzo F., Ceriello A. Glucose-sensing Predictors of Insulin Initiation in People metabolic stress and proinﬂammatory microRNA-21 disrupts ROS homeostasis with Type 2 Diabetes under Real-Life cytokines. and impairs antioxidant responses in Conditions. JOURNAL OF DIABETES 7. Impact of glucose oscillations on cellular glucose variability. RESEARCH. 2018:7153087. I.F.: 2.885 cardiovascular complications of diabetes: CARDIOVASCULAR DIABETOLOGY. mechanisms of endothelial dysfunction. 17(1):105. I.F.: 5.235 12. Russo GT; de Cosmo S; Viazzi F; Mirijello A; 8. Potential beneﬁcial effects of GLP-1 and Ceriello A; Guida P; Giorda C; Cucinotta D; DPP-4 inhibitors in endothelial cells 6. Viazzi F; Ceriello A; Fioretto P; Giorda C; Pontremoli R; Fioretto P; AMD-Annals Study exposed to hyperglycemic conditions. Guida P; Russo G; Greco E; de Cosmo S; Group. Diabetic kidney disease in the Pontremoli R; AMD-Annals Study Group. elderly: prevalence and clinical correlates. Changes in albuminuria and renal outcome BMC GERIATRICS. 18(1):38. I.F.: 2.866 in patients with type 2 diabetes and PUBLICATIONS hypertension: a real-life observational 13. Lamacchia O., Viazzi F., Fioretto P., Mirijello study. JOURNAL OF HYPERTENSION. A., Giorda C., Ceriello A., Russo G., Guida P., Originals / I.F.: 62.288 36(8):1719-1728. I.F.: 4.099 Pontremoli R., De Cosmo S. Normoalbuminuric kidney impairment in 1. Castaño C, Kalko S, Novials A, Párrizas M. 7. Davison, Gareth; Vinaixa, Maria; McGovern, patients with T1DM: Insights from annals Obesity-associated exosomal miRNAs Rose; Beltran, Antoni; Novials, Anna; Correig, initiative. DIABETOLOGY AND METABOLIC modulate glucose and lipid metabolism in Xavier; McClean, Conor. Metabolomic SYNDROME. 10(1):60. I.F.: 2.413 mice. PROCEEDINGS OF THE NATIONAL Response to Acute Hypoxic Exercise and ACADEMY OF SCIENCES OF THE UNITED Recovery in Adult Males. FRONTIERS IN 14. Mirijello A; Viazzi F; Fioretto P; Giorda C; STATES OF AMERICA. 115(48):12158-12163. PHYSIOLOGY. 9(1682):1682. I.F.: 3.394 Ceriello A; Russo GT; Guida P; Pontremoli R; I.F.: 9.504 de Cosmo S; AMD ANNALS Study Group. 8. Scavini M., Rossi M., Scardapane M., Association of kidney disease measures 2. Prattichizzo F., De Nigris V., Mancuso E., Nicolucci A., Manicardi V., Russo G., Di Bartolo with risk of renal function worsening in Spiga R., Giuliani A., Matacchione G., Lazzarini P., Giorda C., Musacchio N., Ceriello A., patients with type 1 diabetes. BMC R., Marcheselli F., Recchioni R., Testa R., La Genovese S., Molinari C., Dozio N. Portrait of NEPHROLOGY. 19(1):347. I.F.: 2.395 Sala L., Rippo M., Procopio A., Olivieri F., women with type 1 or type 2 diabetes of Ceriello A. Short-term sustained childbearing age attending diabetes clinics 15. Barberan-Garcia A., Gimeno-Santos E., hyperglycaemia fosters an archetypal in Italy: the AMD-Annals initiative. ACTA Blanco I., Cano I., Martínez-Pallí G., Burgos F., senescence-associated secretory DIABETOLOGICA. 55(2):193-199. I.F.: 3.126 Miralles F., Coca M., Murillo S., Sanz M., Steblin phenotype in endothelial cells and A., Ubré M., Benavent J., Vidal J., Sitges M., macrophages. REDOX BIOLOGY. 15:170-181. 9. Rossi M., Lucisano G., Ceriello A., Roca J. Protocol for regional I.F.: 7.126 Mazzucchelli C., Musacchio N., Ozzello A., implementation of collaborative Nicolucci A., Di Bartolo P., Annamaria N., Mario self-management services to promote 3. Mellado-Gil JM, Fuente-Martín E, Lorenzo V., Francesca S., Andrea D., Graziano S., physical activity. BMC HEALTH SERVICES PI, Cobo-Vuilleumier N, López-Noriega L, Giampaolo M., Gabriella G., Daniela A., Mario RESEARCH. 18(1):560. I.F.: 1.843 Martín-Montalvo A, Gómez IGH, L., Giovanni S., Mauro S., Francesco D., Ceballos-Chávez M, Gómez-Jaramillo L, Roberto A., Paolo D., Emilio R., Sergio L., Campos-Caro A, Romero-Zerbo SY, Giuseppe F., Carlo L., Laura T. Real-world use Review / I.F.: 63.903 Rodríguez-Comas J, Servitja JM, Servitja JM, of self-monitoring of blood glucose in Rojo-Martinez G, Rojo-Martinez G, Hmadcha people with type 2 diabetes: an urgent 1. Cosentino F, Ceriello A, Baeres FMM, A, Hmadcha A, Soria B, Soria B, Bugliani M, need for improvement. ACTA Fioretto P, Garber A, Stough WG, George JT, Marchetti P, Bérmudez-Silva FJ, DIABETOLOGICA. 55(10):1059-1066. Grant PJ, Khunti K, Langkilde AM, Plutzky J, Bérmudez-Silva FJ, Reyes JC, Aguilar- I.F.: 3.126 Rydén L, Scheen A, Standl E, Tuomilehto J, Diosdado M, Aguilar-Diosdado M, Gauthier Zannad F. Addressing cardiovascular risk BR. The type 2 diabetes-associated 10. Viazzi F; Greco E; Ceriello A; Fioretto P; in type 2 diabetes mellitus: a report from HMG20A gene is mandatory for islet beta Giorda C; Guida P; Russo G; de Cosmo S; the European Society of Cardiology cell functional maturity. CELL DEATH DIS. Pontremoli R; AMD-Annals Study Group. Cardiovascular Roundtable. EUROPEAN 9(3):279. I.F.: 5.638 Apparent Treatment Resistant HEART JOURNAL. I.F.: 23.425 Hypertension, Blood Pressure Control and 4. Hernández M., Aguilar A., Burillo J., Oca R., the Progression of Chronic Kidney Disease 2. Prattichizzo F., Giuliani A., Mensà E., Manca M., Novials A., Alcarraz-Vizan G., in Patients with Type 2 Diabetes. KIDNEY Sabbatinelli J., De Nigris V., Rippo M., La Sala

215 AREA 3 LIVER, DIGESTIVE SYSTEM AND METABOLISM

L., Procopio A., Olivieri F., Ceriello A. 10. Khunti K; Gavin JR; Boulton AJM; Novials A, Servitja JM. BACE2, una nueva Pleiotropic effects of metformin: Shaping Blickstead R; McGill M; Ceriello A; Raz I; diana terapéutica para el tratamiento de la the microbiome to manage type 2 diabetes Sadikot S; Wood DA; Cos X; Kalra S; Das AK; diabetes tipo 2 y la obesidad. and postpone ageing. AGEING RESEARCH Espinosa López C; Berlin Declaration Steering Sponsored by: Instituto de Salud Carlos III REVIEWS. 48:87-98. I.F.: 8.973 Group. The Berlin Declaration: A call to (ISCIII). PI17/00879 improve early actions related to type 2 Duration: 01/01/2018-31/12/2020 3. Prattichizzo F., De Nigris V., Spiga R., diabetes. Why is primary care important? Mancuso E., La Sala L., Antonicelli R., Testa R., PRIMARY CARE DIABETES. 12(5):383-392. Novials A. Els microRNAs exosomals Procopio A., Olivieri F., Ceriello A. I.F.: 1.702 induïts per l'exercici com a reguladors del Inflammageing and metaflammation: The metabolisme en humans i ratolins. yin and yang of type 2 diabetes. AGEING Sponsored by: Fundació Acadèmica de les RESEARCH REVIEWS. 41:1-17. I.F.: 8.973 Letters / I.F.: 5.235 Ciències Mèdiques (Beca Acadèmia 2018) Duration: 24/05/2018 4. Prattichizzo F, De Nigris V, Micheloni S, La 1. Schnell O, Standl E, Catrinoiu D, Genovese Sala L, Ceriello A. Increases in circulating S, Lalic N, Lalic K, Skrha J, Valensi P, Ceriello A. levels of ketone bodies and cardiovascular Report from the 3rd Cardiovascular protection with SGLT2 inhibitors: is Outcome Trial (CVOT) Summit of the low-grade inflammation the neglected Diabetes & Cardiovascular Disease component? DIABETES, OBESITY AND (D&CVD) EASD Study Group. METABOLISM. 20(11):2515-2522. I.F.: 5.980 CARDIOVASCULAR DIABETOLOGY. 17(1):30. I.F.: 5.235 5. Brunerova L., Rahelic D., Ceriello A., Broz J. Use of oral antidiabetic drugs in the treatment of maturity-onset diabetes of Clinical Guidelines / I.F.: 6.594 the young: A mini review. DIABETES/METABOLISM RESEARCH AND 1. Sanz M., Ceriello A., Buysschaert M., REVIEWS. 34(1):467. I.F.: 3.904 Chapple I., Demmer R., Graziani F., Herrera D., Jepsen S., Lione L., Madianos P., Mathur M., 6. La Sala L, Micheloni S, De Nigris V, Montanya E., Shapira L., Tonetti M., Vegh D. Prattichizzo F, Ceriello A,. Novel insights into Scientific evidence on the links between the regulation of miRNA transcriptional periodontal diseases and diabetes: control: implications for T2D and related Consensus report and guidelines of the complications. ACTA DIABETOLOGICA. joint workshop on periodontal diseases 55(10):989-998. I.F.: 3.126 and diabetes by the International Diabetes Federation and the European Federation 7. Viazzi F, Russo GT, Ceriello A, Fioretto P, of Periodontology. JOURNAL OF CLINICAL Giorda C, De Cosmo S, Pontremoli R. Natural PERIODONTOLOGY. 45(2):138-149. I.F.: 4.046 history and risk factors for diabetic kidney disease in patients with T2D: lessons from 2. Ceriello A., Gavin J., Boulton A., Blickstead the AMD-annals. JOURNAL OF R., McGill M., Raz I., Sadikot S., Wood D., Cos X., NEPHROLOGY. I.F.: 2.724 Khunti K., Kalra S., Das A., López C. Berlin Declaration Steering Group. A call to action 8. Khunti K., Ceriello A., Cos X., De Block C. to improve early actions related to type 2 Achievement of guideline targets for blood diabetes. How can specialist care help? pressure, lipid, and glycaemic control in DIABETES RESEARCH AND CLINICAL type 2 diabetes: A meta-analysis. PRACTICE. 139:392-399. I.F.: 2.548 DIABETES RESEARCH AND CLINICAL PRACTICE. 137:137-148. I.F.: 2.548

9. Bergman M, Manco M, Sesti G, Dankner R, GRANTS FOR RESEARCH IN PROGRESS Pareek M, Jagannathan R, Chetrit A, Abdul-Ghani M, Buysschaert M, Olsen MH, Ceriello A. Role of released and exosomial Nilsson PM, Medina JL, Roth J, Groop L, Del microRNAs, inﬂammatory and diabetes Prato S, Raz I, Ceriello A. Petition to replace associated (REx-MIDAs), in endothelial current OGTT criteria for diagnosing metabolic memory. prediabetes with the 1-hour post-load Sponsored by: Fundació La Marató de TV3. plasma glucose ≥ 155 mg/dl (8.6 mmol/l). 201606.10 DIABETES RESEARCH AND CLINICAL Duration: 10/03/2017-09/03/2020 PRACTICE. 146:18-33. I.F.: 2.548

216 PATHOGENESIS AND PREVENTION OF DIABETES 3.15

217 ANNUAL SCIENTIFIC REPORT 2018

AREA 4

CLINICAL AND EXPERIMENTAL NEUROSCIENCE 4

CLINICAL AND EXPERIMENTAL NEUROSCIENCE

4.1 Neuropharmacology and experimental neuropathology 220 Guadalupe Mengod

4.2 Brain ischemia: Clinical and experimental studies 225 Ángel Chamorro

4.3 Parkinson’s disease and other neurodegenerative movement disorders: clinical and experimental research 228 M. Josep Martí Domenech

4.4 Neurophysiology and functional studies of the nervous system 232 Alejandro Iranzo

4.5 Muscle research and mitochondrial function 236 Josep Maria Grau

4.6 Pathophysiology and treatment of neurodegenerative disorders 240 Jordi Alberch

4.7 Translational psychiatry and psychology 243 Eduard Vieta

4.8 Neuropsychology 257 Carme Junqué

4.9 Systems neuroscience 260 Maria Victoria Sánchez Vives

4.10 Clinical and experimental neuroimmunology 264 Josep Dalmau 4.11 Neurobiology Unit 270 Ramon Trullàs

4.12 Alzheimer’s disease and other cognitive disorders 272 Raquel Sánchez del Valle

219 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

Neuropharmacology and 4.1 experimental neuropathology

TECHNICIANS Felipe Jiménez (IIBB-CSIC) LOCATION Rocio Martin (CIBER) IIBB-CSIC labs Silvia Serrano (CIBER) UB School of Medicine Leticia Campa (IIBB-CSIC) Lluis Miquel (IIBB-CSIC) Ruth Montes (IIBB-CSIC) Verónica Paz (CIBER) Esther Ruiz (IDIBAPS) WEB www.iibb.csic.es Albert Parull (IIBB-CSIC) TEAM LEADER Rosario Ruiz (UB) www.ciberisciii.es Guadalupe Mengod (IIBB-CSIC) www.cibersam.es T. 93 363 83 23 ADMINISTRATIVE STAFF www.ciberesp.es [email protected] María Jaramillo (CIBER) www.ciberned.es

www.ub.edu/portal/web/dp- COLLABORATORS biomedicalsciences/neuroinﬂamacio. GROUP LEADERS Tony Valente (UB) -ip-josep-saura-marti Francesc Artigas (IIBB-CSIC) Jose Manuel Vidal (UB) T. 93 363 83 15 francesc.artigas @iibb.csic.es VISITING SCIENTISTS Sharon Manashirov Guadalupe Mengod (IIBB-CSIC) (Weizmann Institute of Scienceen, Israel) T. 93 363 83 23 KEYWORDS [email protected] 1. Neuropsychopharmacology 2. Brain aging and neurotoxicity Josep Saura (UB) STRATEGIC OBJECTIVES 3. Neurodegeneration T. 93 402 19 20 4. Neuroinﬂammation [email protected] Furthering of knowledge of the physiopathological mechanisms of Coral Sanfeliu (IIBB-CSIC) neurological and psychiatric diseases and T. 93 363 83 38 neurotoxic and aging processes of the central [email protected] nervous system, with a view to identifying new cellular and functional targets and proposing new treatments. Original publications

from 2016 to 2018 RESEARCHERS

YEAR I.F. TOTAL Q1 Q2 Roser Cortés (IIBB-CSIC) Mª Teresa Vilaró (IIBB-CSIC) MAIN LINES OF RESEARCH 2016 115.44 21 18 2 Analía Bortolozzi (IDIBAPS) 2017 110.30 24 19 4 Anna Castañé (IIBB-CSIC) - The Systems Neuropharmacology Group 2018 96.15 19 14 4 Maria Paz Celada (IDIBAPS) studies the brain circuits and neural Eduardo Rodríguez (IIBB-CSIC) elements involved in the physiopathology Cristina Suñol (IIBB-CSIC) and treatment of depression, schizophrenia Joan Serratosa (IIBB-CSIC) and Parkinson’s disease. Carme Solà (IIBB-CSIC)

TEAM INVOLVED IN - The Molecular Neuropharmacology group CIBERNED POST-DOCTORAL RESEARCHERS studies the involvement of the cAMP CIBERSAM Maurizio Riga (IDIBAPS) cascade in the polarization of microglia and CIBERESP Noemí Santana (CIBER) macrophage toward anti- or AGAUR_SGR17: 00106, 00717 Ruben Corpas (IIBB-CSIC) pro-inﬂammatory phenotypes both in cell culture with cell lines and primary cultures PRE-DOCTORAL RESEARCHERS and in the CNS of EAE (experimental Diana Alarcón (IDIBAPS) autoimmune encephalomyelitis) mice, a María Neus Fullana (IIBB-CSIC) multiple sclerosis animal model. Elena López (IIBB-CSIC) Rubén Pavía (IDIBAPS) - The aim of the Cellular Neurobiology group Mireia Tarrés (IIBB-CSIC) is the study of novel targets to modulate Elisa García (IIBB-CSIC) neuroinﬂammation. The group is focused Neus Rabaneda (IIBB-CSIC) on the role of transcription factors and neuronal-microglial communication

220 NEUROPHARMACOLOGY AND EXPERIMENTAL NEUROPATHOLOGY 4.1

molecules in microglial activation and in microglial-induced neurotoxicity.

- The Neurotoxicity and Neurodegeneration Mechanisms group carries out studies on nerve cell death and stress response, synaptic and cognitive functions, genomics and proteomics, for the determination of targets in toxicity and pathological aging. The goal is ﬁnding neuroprotective treatments.

RESEARCH GROUP SYSTEMS NEUROPHARMACOLOGY GROUP Francesc Artigas

GROUP LEADER Francesc Artigas (IIBB-CSIC)

The group research is focused on the characterization of the brain circuits and neural elements involved in the physiopathology and treatment of mental (major depression, schizophrenia) and neurodegenerative disorders (Parkinson’s disease). Using a variety of experimental models, we identify new therapeutic targets in order to improve treatments. Key ﬁndings are the characterization of the rodent infralimbic cortex as a key are to evoke depressive-like or antidepressant-like phenotypes based on modulating astrocyte-neuron interactions in glutamatergic synapses. . Moreover, therapeutic strategies based on RNAi have been developed for the treatment of major depression and Parkinson disease.

RESEARCH GROUP GROUP Guadalupe Mengod MOLECULAR NEUROPHARMACOLOGY We analyze the effect of phosphodiesterase of the expression of components of the PDE4, PDE7 inhibitors and other drugs, acting cholinergic system in the CNS of EAE mice in on different targets, on the course of EAE, a the acute and remitting phases of the disease. mouse model of multiple sclerosis and on the expression of inflammatory cytokines and PDEs and neuropathological changes in cellular populations of the CNS. GROUP LEADER Guadalupe Mengod (IIBB-CSIC) We study the role of components of the cAMP signaling cascade on in vitro cell We study cAMP in relation to the cellular and polarization toward pro-inflammatory (M1) molecular aspects of neurodegenerative or anti-inflammatory (M2) phenotype. diseases with an inflammatory component. We have performed a comparative study

221 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

RESEARCH GROUP CELLULAR NEUROBIOLOGY

GROUP LEADER Josep Saura (UB)

The aim of the Cellular Neurobiology group is the study of novel targets to modulate neuroinﬂammation. We are focused on the role of transcription factors of the C/EBP family and of neuronal-microglial communication molecules (CD200, CD200R, TREM2) in microglial activation and in microglial-induced neurotoxicity. We use primary cell cultures (murine mixed glial,

astroglial and microglial-enriched, neuronal, GROUP Josep Saura mixed neuron-glial; human monocyte-derived microglia-like cultures), cell lines, in vivo models of neuroinﬂammation and neurodegeneration, and human samples.

RESEARCH GROUP NEUROTOXICITY AND NEURODEGENERATION MECHANISMS

GROUP LEADER Coral Sanfeliu (IIBB-CSIC)

The group studies molecular targets in neurotoxicity and pathological brain aging by using in vivo and in vitro experimental models GROUP Coral Sanfeliu and human tissues. Mechanisms of neurotoxicity are focused in environmental contaminants as ubiquitous 2. exposures, whereas PUBLICATIONS Alarcon-Aris, Diana; Recasens, Ariadna; age-relatedneurodegeneration is centred in Galofre, Mireia; Carballo-Carbajal, Iria; Zacchi, Alzheimer's disease as the main cause of Originals / I.F.: 96.15 Nicolas; Ruiz-Bronchal, Esther; Pavia-Collado, dementia. Ruben; Chica, Rosario; Ferres-Coy, Albert; Neuroprotective mechanisms analysed 1. Corpas R., Griñán-Ferré C., Santos, Marina; Revilla, Raquel; Montefeltro, include those activated by lifestyles of physical Palomera-Ávalos V., Porquet D., García de Andres; Farinas, Isabel; Artigas, Francesc; Vila, Selective exercise and dietary components. This basic Frutos P., Franciscato Cozzolino S., Miguel; Bortolozzi, Analia. α-Synuclein Knockdown in Monoamine research will contribute to the design of new Rodríguez-Farré E., Pallàs M., Sanfeliu C., Neurons by Intranasal Oligonucleotide strategies and pharmacological treatments Cardoso B. Melatonin induces mechanisms Delivery: Potential Therapy for Parkinson's for increasing brain resilience against nerve of brain resilience against Disease cell injury and age-related neurodegeneration, neurodegeneration. JOURNAL OF PINEAL . MOLECULAR THERAPY. speciﬁcally Alzheimer's disease. RESEARCH. 65(4):e12515. I.F.: 11.613 26(2):550-567. I.F.: 7.008

222 NEUROPHARMACOLOGY AND EXPERIMENTAL NEUROPATHOLOGY 4.1

3. Torra, Albert; Parent, Annabelle; Cuadros, 2678089. I.F.: 4.936 transcriptomic profiling of primary murine Thais; Rodriguez-Galvan, Beatriz; microglia treated with LPS or LPS + IFNγ. Ruiz-Bronchal, Esther; Ballabio, Andrea; 9. Millares L, Barreiro E, Cortes R, SCIENTIFIC REPORTS. 8(1):16096. I.F.: 4.122 Bortolozzi, Analia; Vila, Miquel; Bove, Jordi. Martinez-Romero A, Balcells C, Cascante M, Overexpression of TFEB Drives a Enguita AB, Alvarez C, Rami-Porta R, Sánchez 16. Palomera-Ávalos V., Griñán-Ferré C., Pleiotropic Neurotrophic Effect and de Cos J, Seijo L, Monsó E, Grupo Izquierdo V., Camins A., Sanfeliu C., Canudas Prevents Parkinson's Disease-Related Colaborativo en Cáncer de Pulmón CIBERES- A., Pallàs M. Resveratrol modulates Neurodegeneration. MOLECULAR CIBERONC- SEPAR - Plataforma Biobanco response against acute inflammatory THERAPY. 26(6):1552-1567. I.F.: 7.008 Pulmonar. Tumor-associated metabolic stimuli in aged mouse brain. and inflammatory responses in early stage EXPERIMENTAL GERONTOLOGY. 102:3-11. 4. Navarro G, Borroto-Escuela D, Angelats E, non-small cell lung cancer: Local patterns I.F.: 3.224 Etayo Í, Reyes-Resina I, Pulido-Salgado M, and prognostic significance. LUNG Rodríguez-Pérez AI, Canela EI, Saura J, CANCER. 122:124-130. I.F.: 4.486 17. Olguin, Nair; Mueller, Marie-Lena; Lanciego JL, Labandeira-García JL, Saura CA, Rodriguez-Farre, Eduard; Sunol, Cristina. Fuxe K, Franco R. Receptor-heteromer 10. Griñán-Ferré C, Izquierdo V, Otero E, Neurotransmitter amines and antioxidant mediated regulation of endocannabinoid Puigoriol-Illamola D, Corpas R, Sanfeliu C, agents in neuronal protection against signaling in activated microglia. Role of Ortuño-Sahagún D, Pallàs M. Environmental methylmercury-induced cytotoxicity in CB1 and CB2 receptors and relevance for Enrichment Improves Cognitive Deficits, primary cultures of mice cortical neurons. Alzheimer's disease and AD Hallmarks and Epigenetic Alterations NEUROTOXICOLOGY. 69:278-287. levodopa-induced dyskinesia. BRAIN, Presented in 5xFAD Mouse Model. I.F.: 3.076 BEHAVIOR, AND IMMUNITY. 67:139-151. FRONTIERS IN CELLULAR NEUROSCIENCE. I.F.: 6.306 12:224. I.F.: 4.300 18. Lichtenstein MP, Carretero NM, Pérez E, Pulido-Salgado M, Moral-Vico J, Solà C, 5. Torres-Sanchez S, Perez-Caballero L, Mico 11. Riga M; Lladó-Pelfort L; Artigas F; Celada P. Casañ-Pastor N, Suñol C. Biosafety JA, Celada P, Berrocoso E. Effect of Deep The serotonin hallucinogen 5-MeO-DMT assessment of conducting nanostructured Brain Stimulation of the ventromedial alters cortico-thalamic activity in freely materials by using co-cultures of neurons prefrontal cortex on the noradrenergic moving mice: Regionally-selective and astrocytes. NEUROTOXICOLOGY. system in rats. BRAIN STIMULATION. involvement of 5-HT1A and 5-HT2A 68:115-125. I.F.: 3.076 11(1):222-230. I.F.: 6.120 receptors. NEUROPHARMACOLOGY. 142:219-230. I.F.: 4.249 19. Di Pinto G., Di Bari M., Martin-Alvarez R., 6. Perez-Villalba A., Sirerol-Piquer M., Sperduti S., Serrano-Acedo S., Gatta V., Tata Belenguer G., Soriano-Cantón R., 12. Mora, Santiago; Merchan, Ana; Vilchez, A., Mengod G. Comparative study of the Muñoz-Manchado A., Villadiego J., Olga; Aznar, Susana; Klein, Anders Bue; expression of cholinergic system Alarcón-Arís D., Soria F., Dehay B., Bezard E., Ultved, Lene; Campa, Leticia; Sunol, Cristina; components in the CNS of experimental Vila M., Bortolozzi A., Toledo-Aral J., Flores, Pilar; Moreno, Margarita. Reduced autoimmune encephalomyelitis mice: Pérez-Sánchez F., Fariñas I. Synaptic cortical serotonin 5-HT2A receptor Acute vs remitting phase. EUROPEAN regulator α-synuclein in dopaminergic binding and glutamate activity in high JOURNAL OF NEUROSCIENCE. fibers is essentially required for the compulsive drinker rats. 48(5):2165-2181. I.F.: 2.832 maintenance of subependymal neural NEUROPHARMACOLOGY. 143:10-19. stem cells. JOURNAL OF NEUROSCIENCE. I.F.: 4.249 38(4):814-825. I.F.: 5.971 Review / I.F.: 13.896 13. Amat-Foraster M, Jensen AA, Plath N, 7. Mir JF, Zagmutt S, Lichtenstein MP, Herrik KF, Celada P, Artigas F. Temporally 1. Artigas, Francesc; Bortolozzi, Analia; Celada, García-Villoria J, Weber M, Gracia A, Fabriàs dissociable effects of ketamine on Pau. Can we increase speed and efficacy of G, Casas J, López M, Casals N, Ribes A, Suñol neuronal discharge and gamma antidepressant treatments? Part I: General C, Herrero L, Serra D . Ghrelin Causes a oscillations in rat thalamo-cortical aspects and monoamine-based strategies. Decline in GABA Release by Reducing networks. NEUROPHARMACOLOGY. EUROPEAN Fatty Acid Oxidation in Cortex. 137:13-23. I.F.: 4.249 NEUROPSYCHOPHARMACOLOGY. MOLECULAR NEUROBIOLOGY. 28(4):445-456. I.F.: 4.129 55(9):7216-7228. I.F.: 5.076 14. Gasull-Camós J, Martínez-Torres S, Tarrés-Gatius M, Ozaita A, Artigas F, Castañé 2. Artigas, F.; Celada, P.; Bortolozzi, A. Can we 8. Arrifano, Gabriela P. F.; Lichtenstein, A. Serotonergic mechanisms involved in increase the speed and efficacy of Mathieu P.; Souza-Monteiro, Jose Rogerio; antidepressant-like responses evoked by antidepressant treatments? Part II. Farina, Marcelo; Rogez, Herve; Tavares GLT-1 blockade in rat infralimbic cortex. Glutamatergic and RNA interference Carvalho, Jose Carlos; Sunol, Cristina; NEUROPHARMACOLOGY. 139:41-51. strategies. EUROPEAN Crespo-Lopez, Maria Elena. Clarified Acai I.F.: 4.249 NEUROPSYCHOPHARMACOLOGY. (Euterpe oleracea) Juice as an 28(4):457-482. I.F.: 4.129 Anticonvulsant Agent: In Vitro Mechanistic 15. Pulido-Salgado, Marta; Vidal-Taboada, Study of GABAergic Targets. OXIDATIVE Jose M.; Garcia-Diaz Barriga, Gerardo; Sola, 3. Grinan-Ferre, Christian; Corpas, Ruben; MEDICINE AND CELLULAR LONGEVITY. Carme; Saura, Josep. RNA-Seq Puigoriol-Illamola, Dolors; Palomera-Avalos,

223 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

Veronica; Sanfeliu, Coral; Pallas, Merce. Sanfeliu C. Unveiling Soluble Epoxide Understanding Epigenetics in the Hydrolase as a new pharmacological Neurodegeneration of Alzheimer's target in Alzheimers disease: focus on Disease: SAMP8 Mouse Model. JOURNAL inﬂammation and proteolysis. OF ALZHEIMER'S DISEASE. 62(3):943-963. Sponsored by: Ministerio de Economía y I.F.: 3.476 Competitividad (MINECO). SAF-2016-77703-C2-2-R 4. Palacios JM, Mengod G . Receptor Duration: 30/12/2016-29/12/2019 visualization and the atomic bomb. A historical account of the development of Saura J. Nanoparticle delivery system for the chemical neuroanatomy of receptors neurodegenerative disorders. for neurotransmitters and drugs during the Sponsored by: Instituto de Salud Carlos III Cold War. JOURNAL OF CHEMICAL (ISCIII). AC14/00016 NEUROANATOMY. 88:76-112. I.F.: 2.162 Duration: 01/01/2015-30/06/2019

Saura J. C/EBPs microgliales como potencial diana terapéutica en la GRANTS FOR RESEARCH IN PROGRESS enfermedad de Parkinson. Sponsored by: Instituto de Salud Carlos III Artigas F. Alteraciones de la corteza (ISCIII). PI14/00302 infralímbica en depresión: mecanismo de Duration: 01/01/2015-30/06/2019 acción de nuevas estrategias antidepresivas. Solà C. El sistema CD200-CD200R1 como Sponsored by: Ministerio de Economía y diana terapéutica y biomarcador en Competitividad (MINECO). enfermedades neurológicas: la SAF2015-68346-P enfermedad de Parkinson. Duration: 01/01/2016-31/12/2019 Sponsored by: Instituto de Salud Carlos III (ISCIII). PI15/00033 Bortolozzi A. Nuevas estrategias Duration: 01/01/2016-30/09/2019 terapéuticas para el tratamiento de sinucleinopatías. Solà C. Búsqueda de nuevas indicaciones Sponsoredby: Ministerio de Economía y terapéuticas en el ámbito de Competitividad (MINECO). RTC-2014-2812-1 enfermedades neurodegenerativas y Duration: 04/02/2014-30/06/2018 mitocondriales para el compuesto PPAR gamma agonista MIN-102. Bortolozzi A. Sinucleinopatías y Sponsored by: Ministerio de Economía y oligonucleótidos inhibitorios: rol de alfa y Competitividad (MINECO). RTC-2017-5867-1 gama sinucleínas en la regulación de la Duration: 01/01/2018-31/12/2019 función cognitiva. Sponsored by: Ministerio de Economía y Competitividad (MINECO). SAF2016_75797_R DOCTORAL THESES Duration: 30/12/2016-29/12/2019 Artigas F (External supervisor). Modulating Celada MP. Modulación de circuitos NMDA receptors in the thalamo-cortical cortico-mesencefálicos y cortico-límbicos system. A novel approach to treat major por nuevas terapias antidepresivas. depression. Sponsored by: Instituto de Salud Carlos III PhD student: María Amat Foraster (ISCIII). PI16/00287 Duration: 01/01/2017-31/12/2019

Mengod G. ¿Están implicados los cambios fenotípicos de las microglía/macrófagos en los efectos beneﬁciosos de los inhibidores de PDEs del AMPc en la EAE crónica? Sponsored by: Instituto de Salud Carlos III (ISCIII). PI15/00148 Duration: 01/01/2016-30/06/2019

224 BRAIN ISCHEMIA: CLINICAL AND EXPERIMENTAL STUDIES 4.2

Brain ischemia: Clinical 4.2 and experimental studies

TECHNICIANS Francisca Ruiz (IDIBAPS) LOCATION ADMINISTRATIVE STAFF HCB building Martha Elena Vargas (HCB-FCRB) IIBB-CSIC labs NURSING STAFF Elisabet Gonzalez (HCB)

COLLABORATORS Angelica Maria Salas (FCRB) KEYWORDS Laura Llull (FCRB) TEAM LEADER Víctor Obach (FCRB) 1. Brain Ángel Chamorro (HCB) Arturo Renu (FCRB) 2. Stroke T. 93 227 54 00 (Ext.: 2118) 3. Cerebrovascular diseases [email protected] 4. Neuroinﬂammation 5. Oxidative stress STRATEGIC OBJECTIVES

RESEARCHERS Study of cerebrovascular pathology from the Sergio Amaro (HCB-IDIBAPS) clinical and basic perspective, with special Carles Justicia (IIBB-CSIC) emphasis on inﬂammation, immune response, Valerie Petegnief (IIBB-CSIC) and oxidative stress, as well as on the use of Anna Planas (IIBB-CSIC) neuroimaging techniques. Translational Original publications Xabier Urra (HCB-IDIBAPS) research integrating experimental models and from 2016 to 2018 Ramon Torné (HCB) clinical studies. The ultimate aim is to develop

YEAR I.F. TOTAL Q1 Q2 therapeutic strategies in application to stroke. POST-DOCTORAL RESEARCHERS 2016 97.32 12 11 1 Francesc Antoni Miró (FCRB) 2017 121.22 21 15 5

2018 165.34 20 17 2 PRE-DOCTORAL RESEARCHERS MAIN LINES OF RESEARCH Laura Díaz (IDIBAPS) Mattia Gallizioli (IIBB-CSIC) Inﬂammation and immunity in stroke Carlos Laredo (IDIBAPS) - Immunological mechanisms in the Amaia Ochoa (IIBB-CSIC) progression of stroke and infectious

TEAM INVOLVED IN Jordi Pedragosa (IIBB-CSIC) complications. RED INVICTUSPLUS Salvatore Rudilosso (FCRB) - Cerebral inﬁltration of myeloid cells and AGAUR_SGR17: 00645 Yashu Zhao (IDIBAPS-UB) lymphocytes after ischemic stroke: role in brain damage and repair. - Innate immunity in stroke: the lectin pathway of complement activation. TEAM Ángel Chamorro

225 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

- Inflammatory and immune responses as NEUROLOGY, THE. 17(1):47-53. I.F.: 27.144 Among Stroke Codes Activated Within 6 targets for stroke treatment. Hours From Symptom Onset. STROKE: A - Gut-brain interaction after stroke. 3. Ambrosioni J, Urra X, Hernández-Meneses JOURNAL OF CEREBRAL CIRCULATION. M, Almela M, Falces C, Tellez A, Quintana E, 49(9):2116-2121. I.F.: 6.239 Vascular damage Fuster D, Sandoval E, Vidal B, Tolosana JM, - Endothelial damage and blood-brain barrier Moreno A, Chamorro A, Miró JM, Hospital 9. Gelderblom M., Gallizioli M., Ludewig P., Thom disruption, after recanalization therapies. Clínic Infective Endocarditis Study Group . V., Arunachalam P., Rissiek B., Bernreuther C., - Hemorrhagic transformation after acute Mechanical thrombectomy for acute Glatzel M., Korn T., Arumugam T., Sedlacik J., ischemic stroke. ischemic stroke secondary to infective Gerloff C., Tolosa E., Planas A., Magnus T.IL-23 - Brain hemorrhage. endocarditis. CLINICAL INFECTIOUS (Interleukin-23)-producing conventional - Vascular dementia. DISEASES. 66(8):1286-1289. I.F.: 9.117 dendritic cells control the detrimental IL-17 (Interleukin-17) response in stroke. STROKE Brain protection and repair 4. Villa A., Klein B., Janssen B., Pedragosa J., A JOURNAL OF CEREBRAL CIRCULATION. - Antioxidant treatments in stroke (Uric acid). Pepe G., Zinnhardt B., Vugts D., Gelosa P., 49(1):155-164. I.F.: 6.239 - Functional recovery by rehabilitation Sironi L., Beaino W., Damont A., Dollé F., Jego therapies. B., Winkeler A., Ory D., Solin O., Vercouillie J., 10. Salas-Perdomo A, Miró-Mur F, Urra X, Funke U., Laner-Plamberger S., Blomster L., Justicia C, Gallizioli M, Zhao Y, Brait VH, Laredo C, Multimodal neuroimaging in Stroke Christophersen P., Vegeto E., Aigner L., Tudela R, Hidalgo A, Chamorro Á, Planas AM . T - Magnetic resonance imaging (MRI), Jacobs A., Planas A., Maggi A., Windhorst A. Cells Prevent Hemorrhagic Transformation CT/perfusion, optical imaging techniques. Identification of new molecular targets for in Ischemic Stroke by P-Selectin Binding. PET imaging of the microglial ARTERIOSCLEROSIS, THROMBOSIS, AND anti-inflammatory activation state. VASCULAR BIOLOGY. 38(8):1761-1771. I.F.: THERANOSTICS. 8(19):5400-5418. I.F.: 8.537 6.086 PUBLICATIONS 5. Jiménez-Xarrié E, Pérez B, Dantas AP, 11. Rudilosso S, Laredo C, Mancosu M, Originals / I.F.: 165.345 Puertas-Umbert L, Martí-Fabregas J, Chamorro Moya-Planas N, Zhao Y, Chirife O, Chamorro Á, Á, Planas AM, Vila E, Jiménez-Altayó F. Uric Acid Urra X . Cerebral perfusion and 1. Del Fresno C, Saz-Leal P, Enamorado M, Treatment After Stroke Prevents compensatory blood supply in patients with Wculek SK, Martínez-Cano S, Blanco- Long-Term Middle Cerebral Artery recent small subcortical infarcts. JOURNAL Menéndez N, Schulz O, Gallizioli M, Miró-Mur Remodelling and Attenuates Brain Damage OF CEREBRAL BLOOD FLOW AND F, Cano E, Planas A, Sancho D . DNGR-1 in in Spontaneously Hypertensive Rats. METABOLISM. 13:271678X18758548. I.F.: 6.045 dendritic cells limits tissue damage by TRANSLATIONAL STROKE RESEARCH. :1-16. dampening neutrophil recruitment. I.F.: 8.266 12. Pedragosa, Jordi; Salas-Perdomo, Angelica; SCIENCE. 362(6412):351-356. I.F.: 41.058 Gallizioli, Mattia; Cugota, Roger; Miro-Mur, 6. Miró-Mur F., Laredo C., Renú A., Rudilosso S., Francesc; Brianso, Ferran; Justicia, Carles; 2. Campbell, Bruce C. V.; van Zwam, Wim H.; Zhao Y., Amaro S., Llull L., Urra X., Planas A., Perez-Asensio, Fernando; Marquez-Kisinousky, Goyal, Mayank; Menon, Bijoy K.; Dippel, Chamorro Á. Adrenal hormones and Leonardo; Urra, Xabier; Gieryng, Anna; Diederik W. J.; Demchuk, Andrew M.; Bracard, circulating leukocyte subtypes in stroke Kaminska, Bozena; Chamorro, Angel; Planas, Serge; White, Philip; Davalos, Antoni; Majoie, patients treated with reperfusion therapy. Anna M. CNS-border associated Charles B. L. M.; van der Lugt, Aad; Ford, Gary BRAIN, BEHAVIOR, AND IMMUNITY. macrophages respond to acute ischemic A.; Perez de la Ossa, Natalia; Kelly, Michael; 70:346-353. I.F.: 6.306 stroke attracting granulocytes and Bourcier, Romain; Donnan, Geoffrey A.; Roos, promoting vascular leakage. ACTA Yvo B. W. E. M.; Bang, Oh Young; Nogueira, Raul 7. Kishore AK, Vail A, Jeans AR, Chamorro A, Di NEUROPATHOLOGICA G.; Devlin, Thomas G.; van den Berg, Lucie A.; Napoli M, Kalra L, Langhorne P, Roffe C, COMMUNICATIONS. 6(76):76. I.F.: 5.414 Clarencon, Frederic; Burns, Paul; Carpenter, Westendorp W, Nederkoorn PJ, Garau J, Van de Jeffrey; Berkhemer, Olvert A.; Yavagal, Dileep R.; Beek D, Montaner J, Woodhead M, Meisel A, 13. Thammisetty SS, Thammisetty SS, Pereira, Vitor Mendes; Ducrocq, Xavier; Dixit, Smith CJ, Pneumonia in Stroke Consensus Pedragosa J, Weng YC, Calon F, Calon F, Anand; Quesada, Helena; Epstein, Jonathan; (PISCES) Group. Microbiological Etiologies of Planas A, Kriz J, Kriz J. Age-related Davis, Stephen M.; Jansen, Olav; Rubiera, Marta; Pneumonia Complicating Stroke: A deregulation of TDP-43 after stroke Urra, Xabier; Micard, Emilien; Lingsma, Hester F.; Systematic Review. STROKE A JOURNAL OF enhances NF-κB-mediated inflammation Naggara, Olivier; Brown, Scott; Guillemin, Francis; CEREBRAL CIRCULATION. 49(7):1602-1609. and neuronal damage. JOURNAL OF Muir, Keith W.; van Oostenbrugge, Robert J.; I.F.: 6.239 NEUROINFLAMMATION. 15(1):312. I.F.: 5.193 Saver, Jeffrey L.; Jovin, Tudor G.; Hill, Michael D.; Mitchell, Peter J.;HERMES Collaborators. Effect 8. Requena, Manuel; Perez de la Ossa, Natalia; 14. García S, Torné R, Hoyos JA, of general anaesthesia on functional Abilleira, Sonia; Cardona, Pere; Urra, Xabier; Rodríguez-Hernández A, Amaro S, Llull L, outcome in patients with anterior Marti-Fabregas, Joan; Rodriguez-Campello, López-Rueda A, Enseñat J. Quantitative circulation ischaemic stroke having Anna; Boned, Sandra; Rubiera, Marta; versus qualitative blood amount endovascular thrombectomy versus Tomasello, Alejandro; Molina, Carlos A.; Ribo, assessment as a predictor for shunt- standard care: a meta-analysis of Marc;Catalan Stroke Code Reperfusion. dependent hydrocephalus following individual patient data. LANCET Predictors of Endovascular Treatment aneurysmal subarachnoid hemorrhage.

226 BRAIN ISCHEMIA: CLINICAL AND EXPERIMENTAL STUDIES 4.2

JOURNAL OF NEUROSURGERY. 21:1-8. I.F.: 4.319 Review / I.F.: 12.478 GRANTS FOR RESEARCH IN PROGRESS

15. Laredo C, Zhao Y, Rudilosso S, Renú A, 1. Planas, Anna M. Role of Immune Cells Amaro S, Justicia C. Blood brain barrier Pariente JC, Chamorro Á, Urra X . Prognostic Migrating to the Ischemic Brain. STROKE A disruption after subarachnoid hemorrhage: Significance of Infarct Size and Location: JOURNAL OF CEREBRAL CIRCULATION. clinical relevance, role of hyperglycemia and The Case of Insular Stroke. SCIENTIFIC 49(9):2261-2267. I.F.: 6.239 effect of potentiating endogenous antioxi- REPORTS. 8(1):9498. I.F.: 4.122 dant mechanisms. A translational study. 2. Bernhardt J, Zorowitz RD, Becker KJ, Keller E, Sponsored by: Fundació la Marató de TV3. 16. Romeo-Guitart D, Forés J, Saposnik G, Strbian D, Dichgans M, Dichgans M, 17/C/2017 Herrando-Grabulosa M, Valls R, Woo D, Reeves M, Thrift A, Kidwell CS, Olivot JM, Duration: 10/07/2018-09/07/2021 Leiva-Rodríguez T, Galea E, González-Pérez Goyal M, Pierot L, Bennett DA, Howard G, Ford F, Navarro X, Petegnief V, Bosch A, Coma M, GA, Goldstein LB, Planas AM, Yenari MA, Yenari Amaro S. Daño de la pared arterial en el Mas JM, Casas C. Neuroprotective Drug for MA, Greenberg SM, Pantoni L, Amin-Hanjani S, ictus isquémico agudo: detección con RM Nerve Trauma Revealed Using Artificial Tymianski M, Tymianski M, Tymianski M. avanzada, mecanismos subyacentes y Intelligence. SCIENTIFIC REPORTS. Advances in Stroke 2017. STROKE A valor pronóstico. 8(1):1879. I.F.: 4.122 JOURNAL OF CEREBRAL CIRCULATION. Sponsored by: Instituto de Salud Carlos III 49(5):e174-e199. I.F.: 6.239 (ISCIII). PI16/00711 17. Carrera D, Gorchs M, Querol M, Abilleira S, Duration: 01/01/2017-31/12/2019 Ribó M, Millán M, Ramos A, Cardona P, Urra X, Rodríguez-Campello A, Prats-Sánchez L, Letters / I.F.: 9.117 Chamorro A. The Chemical Optimization of Purroy F, Serena J, Cánovas D, Zaragoza- Cerebral Embolectomy (CHOICE) Trial. Brunet J, Krupinski JA, Ustrell X, Saura J, 1. Ambrosioni J, Urra X, Llopis J, Moreno A, Sponsored by: Fundació la Marató de TV3. García S, Mora MÀ, Jiménez X, Dávalos A, Chamorro A, Miró JM, Hospital Clinic Infective TV3_Ictus_17 Pérez de la Ossa N, Catalan Stroke Code and Endocarditis Investigators. Reply to author. Duration: 11/04/2018-10/0/2021 Reperfusion Consortium (Cat-SCR). CLINICAL INFECTIOUS DISEASES. Revalidation of the RACE scale after its 67(7):1146-1147. I.F.: 9.117 Chamorro A. Respuesta inmune y estrés regional implementation in Catalonia: a oxidativa en la hemorragia cerebral. triage tool for large vessel occlusion. Sponsored by: Instituto de Salud Carlos III JOURNAL OF NEUROINTERVENTIONAL Consortium Publications / I.F.: 54.288 (ISCIII). PI15/00430 SURGERY. 014519. I.F.: 3.526 Duration: 01/01/2016-18/03/2019 1. Bonati, Leo H.; Gregson, John; Dobson, 18. Aliena-Valero, Alicia; Lopez-Morales, Joanna; McCabe, Dominick J. H.; Nederkoorn, Chamorro A. Redes Temáticas de Mikahela A.; Burguete, Maria C.; Castello-Ruiz, Paul J.; van der Worp, H. Bart; de Borst, Gert J.; Investigación Cooperativa en Salud Maria; Jover-Mengual, Teresa; Hervas, David; Richards, Toby; Cleveland, Trevor; Mueller, (RETICS) del Instituto de Salud Carlos III. Torregrosa, German; Leira, Enrique C.; Mandy D.; Wolff, Thomas; Engelter, Stefan T.; Red de Enfermedades Vasculares Chamorro, Angel; Salom, Juan B. Emergent Lyrer, Philippe A.; Brown, Martin M.;Int Carotid Cerebrales: Red INVICTUSplus. Uric Acid Treatment is Synergistic with Stenting Study Investi. Restenosis and risk Sponsored by: Instituto de Salud Carlos III Mechanical Recanalization in Improving of stroke after stenting or endarterectomy (ISCIII). RD16/0019/0014 Stroke Outcomes in Male and Female Rats. for symptomatic carotid stenosis in the Duration: 01/01/2017-31/12/2021 NEUROSCIENCE. 388:263-273. I.F.: 3.382 International Carotid Stenting Study (ICSS): secondary analysis of a Chamorro A. CREST2. Carotid Revasculari- 19. Hong JM, Choi MH, Sohn SI, Hwang YH, Ahn randomised trial. LANCET NEUROLOGY, zation and Medical Management for SH, Lee YB, Shin DI, Chamorro Á, Choi DW, on THE. 17(7):587-596. I.F.: 27.144 Asymptomatic Carotid Stenosis Trial. the behalf of the SONIC investigators. Safety Sponsored by: National Institutes of Health and Optimal Neuroprotection of neu2000 in 2. Kasner, Scott E.; Swaminathan, Balakumar; (NIH). 5U01NS080168-05 acute Ischemic stroke with reCanalization: Lavados, Pablo; Sharma, Mukul; Muir, Keith; Duration: 01/03/2018-28/02/2021 study protocol for a randomized, Veltkamp, Roland; Ameriso, Sebastian F.; double-blinded, placebo-controlled, phase-II Endres, Matthias; Lutsep, Helmi; Messe, Planas AM. Grup d'Investigació trial. TRIALS. 19(1):375. I.F.: 2.067 Steven R.; Spence, J. David; Nedeltechev, Cerebrovascular (GICV). Krassen; Perera, Kanjana; Santo, Gustavo; Sponsored by: Generalitat de Catalunya. 20. Torné R., Reyes L., Rodríguez-Hernández A., Olavarria, Veronica; Lindgren, Arne; AGAUR_SGR17_00645 Urra X., Sanroman L., Enseñat J. Anatomical Shoamanesh, Ashkan; Berkowit, Scott D.; Duration: 01/01/2017-31/12/2020 Variations of Brain Venous Sinuses in Mundt, Nardi; Connolly, Stuart; Hart, Robert Patients with Arteriovenous Malformations: G.;NAVIGATE ESUS Investigators. Planas A, Urra X. Brain-gut cross-talk in Incidental Finding or Causative Factor? Rivaroxaban or aspirin for patent foramen stroke: targeting gut barrier dysfunction WORLD NEUROSURGERY. 113:E465-E470. ovale and embolic stroke of undetermined and immune responses to improve stroke I.F.: 1.924 source: a prespecified subgroup analysis outcome. from the NAVIGATE ESUS trial. LANCET Sponsored by: Fundació la Marató de TV3. NEUROLOGY, THE. 17(12):1053-1060. I.F.: 27.144 TV3_Ictus_17 Duration: 10/07/2018-09/07/2021

227 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

Parkinson disease and other neurodegenerative movement disorders: clinical and 4.3 experimental research

TEAM LEADER MAIN LINES OF RESEARCH M. Josep Martí Domenech (HCB) LOCATION T. 93 227 57 85 In 2018 we continued our research on HCB building [email protected] CELLEX building, ﬂoor 3 clinical and biological aspects of LRRK2-associated Parkinson‘s disease (LRRK2-PD)

EMERITUS which include results on microRNA Eduard Tolosa (UB) alterations in iPSC-derived dopaminergic neurons from LRRK2-PD and sporadic PD, RESEARCHERS characterization of mitochondrial function in KEYWORDS Yaroslau Compta (HCB) a cell model of LRRK2-PD, a study of 1. Parkinson disease Mario Antonio Ezquerra (IDIBAPS) candidate genetic modifiers of age at onset 2. Movement disorders Rubén Fernández (IDIBAPS) in LRRK2-PD. We have described the lack José Esteban Muñoz (HCB) of central and peripheral nervous system Francesc Valldeoriola (HCB) synuclein pathology in R1441G LRRK2-PD, unlike the case of G2019S LRRK2 PRE-DOCTORAL RESEARCHERS mutations and studies on the traits Alicia Garrido (FCRB) Cèlia Painous (FCRB) associated to healthy carriers of LRRK2 Original publications Alejandra Pérez (IDIBAPS) mutations. We are currently working from 2016 to 2018 Lluis Planellas (FCRB) towards deepening our knowledge of existing models of PD epigenetic alterations YEAR I.F. TOTAL Q1 Q2 Almudena Sánchez (HCB-FCRB) Cristina Simonet (FCRB) by using iPSC-DAn models and patient 2016 125.66 22 17 1 blood samples, work on miRNA/RNA 2017 172.56 29 21 3 TECHNICIANS prognostic and diagnostic biomarkers in 2018 137.65 26 18 5 Manel Fernández (IDIBAPS) blood, serum and cultured primary fibroblast of parkinsonisms (MSA, ADMINISTRATIVE STAFF idiopathic PD, LRRK2-PD, healthy controls) Laura Maragall (CIBER-FCRB) . We’ve described increased levels of differentt cytokines in multisystem atrophy TEAM INVOLVED IN NURSING STAFF Ana Cámara (HCB) (MSA) and observed differences in CIBERNED cerebellum connectivity in MSA compare to AGAUR_SGR17: 01502 parkinson patients. Experiments with the protein cyclic amplification method STRATEGIC OBJECTIVES RTQuIC for synuclein have been initiated in our lab using both CSF and brain tissue. 1. Development of research projects with We’ve also contributed to the International results aimed at impacting in a better DLB consortium and, in the field of diagnosis and treatment of Parkinson experimental therapeutics described the Disease (PD) and related effects of subthalamic and substantia nigra neurodegenerative movement disorders. pars reticulata deep brain stimulation upon the gait of patients with PD. 2. Identification of clinical, molecular and imaging biomarkers specific for the preclinical and prodromal phase of PD, as well as for the motor phase of disease. PUBLICATIONS 3. Recruitment of cohorts of PD patients and Originals / I.F.: 137.65 subjects at-risk of PD and establishment of biorepositories useful for state-of-the-art 1. Guerreiro R., Ross O., Kun-Rodrigues C., research in movement disorders. Hernandez D., Orme T., Eicher J., Shepherd C., Parkkinen L., Darwent L., Heckman M., Scholz 4. Identification of clinical, molecular and S., Troncoso J., Pletnikova O., Ansorge O., imaging biomarkers of atypical Clarimon J., Lleo A., Morenas-Rodriguez E., parkinsonism. Clark L., Honig L., Marder K., Lemstra A., Rogaeva E., St George-Hyslop P., Londos E., Zetterberg H., Barber I., Braae A., Brown K., Morgan K., Troakes C., Al-Sarraj S., Lashley T., Holton J., Compta Y., Van Deerlin V., Serrano

228 PARKINSON DISEASE AND OTHER NEURODEGENERATIVE MOVEMENT DISORDERS: CLINICAL AND EXPERIMENTAL RESEARCH 4.3

G., Beach T., Lesage S., Galasko D., Masliah E., Eye Movement Sleep Behavior Disorder. Monica; Vilas, Dolores; Santamaria, Joan; Guerreiro R., Ross O., Kun-Rodrigues C., SLEEP. 41(8). I.F.: 5.135 Gaig, Caries; Alvarez, Ramiro; Ariza, Aurelio; Hernandez D., Orme T., Eicher J., Shepherd C., Tolosa, Eduardo; Beyer, Katrin. Parkkinen L., Darwent L., Heckman M., Scholz 7. Kim H, Calatayud C, Guha S, Glucocerebrosidase gene variants are S., Troncoso J., Pletnikova O., Ansorge O., Fernández-Carasa I, Berkowitz L, accumulated in idiopathic REM sleep Clarimon J., Lleo A., Morenas-Rodriguez E., Carballo-Carbajal I, Ezquerra M, behavior disorder. PARKINSONISM AND Clark L., Honig L., Marder K., Lemstra A., Fernández-Santiago R, Kapahi P, Raya Á, RELATED DISORDERS. 50:94-98. I.F.: 4.721 Rogaeva E., St George-Hyslop P., Londos E., Miranda-Vizuete A, Lizcano JM, Vila M, Zetterberg H. Investigating the genetic Caldwell KA, Caldwell GA, Consiglio A, Dalfo E. 14. Borm CDJM, Krismer F, Wenning GK, architecture of dementia with Lewy The Small GTPase RAC1/CED-10 Is Seppi K, Poewe W, Pellecchia MT, Barone P, bodies: a two-stage genome-wide Essential in Maintaining Dopaminergic Johnsen EL, Østergaard K, Gurevich T, association study. LANCET NEUROLOGY, Neuron Function and Survival Against Djaldetti R, Sambati L, Cortelli P, Petrovi? I, THE. 17(1):64-74. I.F.: 27.144 α-Synuclein-Induced Toxicity. Kosti? VS, Brožová H, R?ži?ka E, Marti MJ, MOLECULAR NEUROBIOLOGY. Tolosa E, Canesi M, Post B, Nonnekes J, Bloem 2. Fernández-Santiago R, Garrido A, Infante J, 55(9):7533-7552. I.F.: 5.076 BR, European MSA Study Group (EMSA-SG). González-Aramburu I, Sierra M, Fernández M, Axial motor clues to identify atypical Valldeoriola F, Muñoz E, Compta Y, Martí MJ, 8. Fernandez Santiago, Ruben y Mario parkinsonism: A multicentre European Ríos J, Tolosa E, Ezquerra M, Barcelona Ezquerra. MTOR Pathway-Based cohort study. PARKINSONISM AND RELATED LRRK2 Study Group†. a-synuclein (SNCA) Discovery of Genetic Susceptibility to DISORDERS. 56:33-40. I.F.: 4.721 but not dynamin 3 (DNM3) influences L-DOPA-Induced Dyskinesia in age at onset of leucine-rich repeat kinase Parkinson’s Disease Patients. 15. González-Casacuberta I, Morén C, 2 (LRRK2) Parkinson's disease in Spain. MOLECULAR NEUROBIOLOGY. Juárez-Flores DL, Esteve-Codina A, Sierra C, MOVEMENT DISORDERS. 33(4):637-641. 56(3):2092-2100. I.F.: 5.076 Catalán-García M, Guitart-Mampel M, Tobías I.F.: 8.324 E, Milisenda JC, Pont-Sunyer C, Martí MJ, 9. Baggio HC, Abos A, Segura B, Campabadal Cardellach F, Tolosa E, Artuch R, Ezquerra M, 3. Mestre TA, Pont-Sunyer C, Kausar F, Visanji A, Garcia-Diaz A, Uribe C, Compta Y, Marti MJ, Fernández-Santiago R, Garrabou G. NP, Ghate T, Connolly BS, Gasca-Salas C, Valldeoriola F, Junque C . Statistical Transcriptional alterations in skin Kern DS, Jain J, Slow EJ, Faust-Socher A, inference in brain graphs using fibroblasts from Parkinson's disease Kasten M, Wadia PM, Zadikoff C, Kumar P, de threshold-free network-based statistics. patients with parkin mutations. Bie RM, Thomsen T, Lang AE, Schüle B, Klein HUMAN BRAIN MAPPING. 39(6):2289-2302. NEUROBIOLOGY OF AGING. 65:206-216. C, Tolosa E, Marras C . Clustering of motor I.F.: 4.927 I.F.: 4.454 and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease 10. Compta Y, Giraldo DM, Muñoz E, Antonelli 16. Tolosa E, Botta-Orfila T, Morató X, nonparkinsonian relatives: A multicenter F, Fernández M, Bravo P, Soto M, Cámara A, Calatayud C, Ferrer-Lorente R, Martí MJ, family study. MOVEMENT DISORDERS. Torres F, Martí MJ, Catalan MSA Registry Fernández M, Gaig C, Raya Á, Consiglio A, 33(6):960-965. I.F.: 8.324 (CMSAR). Cerebrospinal fluid levels of Ezquerra M, Fernández-Santiago R. coenzyme Q10 are reduced in multiple MicroRNA alterations in iPSC-derived 4. Recasens A, Carballo-Carbajal I, Parent A, system atrophy. PARKINSONISM AND dopaminergic neurons from Parkinson Bové J, Gelpi E, Tolosa E, Vila M. Lack of RELATED DISORDERS. 46:16-23. I.F.: 4.721 disease patients. NEUROBIOLOGY OF pathogenic potential of peripheral AGING. 69:283-291. I.F.: 4.454 α-synuclein aggregates from Parkinson's 11. Garcia-Diaz, A. I.; Segura, B.; Baggio, H. C.; disease patients. ACTA NEUROPATHOLO- Uribe, C.; Campabadal, A.; Abos, A.; Marti, M. J.; 17. Razquin C., Ortega-Cubero S., GICA COMMUNICATIONS. 6(1):8. I.F.: 5.414 Valldeoriola, F.; Compta, Y.; Bargallo, N.; Rojo-Bustamante E., Diez-Fairen M., Lorenzo Junque, C. Cortical thinning correlates of E., Alonso E., Ezquerra M., Ross O., Carcel M., 5. Stokholm MG, Iranzo A, Østergaard K, changes in visuospatial and Lorenzo-Betancor O., Soto A., Burgess J., Serradell M, Otto M, Bacher Svendsen K, visuoperceptual performance in Ertekin-Taner N., Dickson D., Pastor M., Tolosa Garrido A, Vilas D, Parbo P, Borghammer P, Parkinson's disease: A 4-year follow-up. E., Pastor P. Target-enriched sequencing of Santamaria J, Møller A, Gaig C, Brooks DJ, PARKINSONISM AND RELATED chromosome 17q21.31 in sporadic Tolosa E, Pavese N. Extrastriatal DISORDERS. 46:62-68. I.F.: 4.721 tauopathies reveals no candidate variants. monoaminergic dysfunction and NEUROBIOLOGY OF AGING. 66(177):e7-e10. enhanced microglial activation in 12. Uribe C., Segura B., Baggio H., Abos A., I.F.: 4.454 idiopathic rapid eye movement sleep Garcia-Diaz A., Campabadal A., Marti M., behaviour disorder. NEUROBIOLOGY OF Valldeoriola F., Compta Y., Tolosa E., Junque 18. Juárez-Flores DL, González-Casacuberta DISEASE. 115:9-16. I.F.: 5.227 C. Cortical atrophy patterns in early I, Ezquerra M, Bañó M, Carmona-Pontaque F, Parkinson's disease patients using Catalán-García M, Guitart-Mampel M, Rivero 6. Iranzo A, Borrego S, Vilaseca I, Martí C, hierarchical cluster analysis. JJ, Tobias E, Milisenda JC, Tolosa E, Marti MJ, Serradell M, Sánchez-Valle R, Kovacs GG, PARKINSONISM AND RELATED Fernández-Santiago R, Cardellach F, Morén Valldeoriola F, Gaig C, Santamaria J, Tolosa E, DISORDERS. 50:3-9. I.F.: 4.721 C, Garrabou G. Exhaustion of mitochondrial Gelpi E. Alpha-synuclein Aggregates in and autophagic reserve may contribute to Labial Salivary Glands of Idiopathic Rapid 13. Gamez-Valero, Ana; Iranzo, Alex; Serradell, the development of LRRK2 G2019S

229 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

-Parkinson's disease. JOURNAL OF Matellano F., Yáñez Baña R. Spanish expert Parkinson's disease: A pilot study. TRANSLATIONAL MEDICINE. 16(1):160-160. consensus on the use of saﬁnamide in PARKINSONISM & RELATED DISORDERS. I.F.: 4.197 Parkinson's disease. NEUROLOGIA. S1353-8020(18):30537-6. I.F.: 4.721 S0213-4853(18):30172-5. I.F.: 1.938 19. Uribe C., Segura B., Baggio H., Abos A., 4. Compta Y., Muñoz E., Martí M.. Ubiquinone, Garcia-Diaz A., Campabadal A., Marti M., 26. Valldeoriola F; Salvador A; ubiquinol, 4-hydroxybenzoic acid... What Valldeoriola F., Compta Y., Bargallo N., Junque Gómez-Arguelles J; Marey J; Moya M; Ayuga 'coenzyme Q10' should we care about in C. Gray/White matter contrast in Á; Ramirez F. The effects of transdermal multiple system atrophy? PARKINSONISM Parkinson's disease. FRONTIERS IN AGING rotigotine on non-motor symptoms of AND RELATED DISORDERS. 50:117-118. NEUROSCIENCE. 10(3):89. I.F.: 3.582 Parkinson's disease: a multicentre, I.F.: 4.721 observational, retrospective, 20. Uribe, Carme; Segura, Barbara; Baggio, post-marketing study. INTERNATIONAL 5. Rodríguez-Vázquez A, Vicente-Pascual M, Hugo C.; Campabadal, Anna; Abos, Alexandra; JOURNAL OF NEUROSCIENCE. Mayà-Casalprim G, Valldeoriola F. Compta, Yaroslau; Jose Marti, Maria; 128(4):369-375. I.F.: 1.848 Neuroimaging in hypoglycaemic Valldeoriola, Francesc; Bargallo, Nuria; encephalopathy diagnosis and prognosis: Junque, Carme. Differential Progression of A case report. NEUROLOGIA. Regional Hippocampal Atrophy in Aging Review / I.F.: 11.476 S0213-4853(17):30363-8. I.F.: 1.938 and Parkinson's Disease. FRONTIERS IN AGING NEUROSCIENCE. 10(10):325. 1. Fabbri M, Ferreira JJ, Lees A, Stocchi F, I.F.: 3.582 Poewe W, Tolosa E, Rascol O . Opicapone for Editorial / I.F.: 4.721 the treatment of Parkinson's disease: A 21. Fernández-Arcos A., Vilaseca I., Aldecoa I., review of a new licensed medicine. 1. Markopoulou K., Compta Y. Cerebrospinal Serradell M., Tolosa E., Santamaría J., Gelpi E., MOVEMENT DISORDERS. 33(10):1528-1539. ﬂuid levels of alpha-synuclein in Iranzo A. Alpha-synuclein aggregates in the I.F.: 8.324 PARKINSON'S disease: Another long and parotid gland of idiopathic REM sleep winding road. PARKINSONISM AND behavior disorder. SLEEP MEDICINE. 2. Lopez-Gonzalez Del Rey, Natalia; RELATED DISORDERS. 49:1-3. I.F.: 4.721 52:14-17. I.F.: 3.395 Quiroga-Varela, Ana; Garbayo, Elisa; Carballo-Carbajal, Iria; Fernandez-Santiago, 22. Müller T, Tolosa E, Badea L, Asgharnejad Ruben; Monje, Mariana H. G.; Trigo-Damas, Consortium Publications / I.F.: 74.851 M, Grieger F, Markowitz M, Nondonfaz X, Ines; Blanco-Prieto, Maria J.; Blesa, Javier. Bauer L, Timmermann L. An observational Advances in Parkinson’s disease: 200 1. Kia DA, Sabir MS, Ahmed S, Trinh J, study of rotigotine transdermal patch and years later. FRONTIERS IN Bandres-Ciga S; International Parkinson's other currently prescribed therapies in NEUROANATOMY. 12:113. I.F.: 3.152 Disease Genomics Consortium. LRP10 in patients with Parkinson's disease. alpha-synucleinopathies. LANCET JOURNAL OF NEURAL TRANSMISSION. NEUROLOGY, THE. 17(12):1032-1032. 125(6):953-963. I.F.: 2.779 Letters / I.F.: 24.711 I.F.: 27.144

23. Garcia-Diaz AI, Segura B, Baggio HC, 1. Vilas D, Gelpi E, Aldecoa I, Grau O, 2. Guerreiro R, Orme T, Neto JL, Bras J; Marti MJ, Valldeoriola F, Compta Y, Bargallo N, Rodriguez-Diehl R, Jaumà S, Martí MJ, Tolosa International DLB Genetics Consortium. Uribe C, Campabadal A, Abos A, Junque C . E. Lack of central and peripheral nervous LRP10 in α-synucleinopathies. LANCET Structural Brain Correlations of system synuclein pathology in R1441G NEUROLOGY, THE. 17(12):1033-1034. I.F.: 27.144 Visuospatial and Visuoperceptual Tests in LRRK2-associated Parkinson's disease. Parkinson's Disease. JOURNAL OF THE JOURNAL OF NEUROLOGY 3. Blauwendraat, Cornelis; Reed, Xylena; Kia, INTERNATIONAL NEUROPSYCHOLOGICAL NEUROSURGERY AND PSYCHIATRY. Demis A.; Gan-Or, Ziv; Lesage, Suzanne; SOCIETY : JINS. 24(1):33-44. I.F.: 2.777 318473(7):832-+. I.F.: 7.144 Pihistrom, Lasse; Guerreiro, Rita; Gibbs, J. Raphael; Sabir, Marya; Ahmed, Sarah; Ding, 24. Santos-García D, Catalán MJ, Puente V, 2. Borrego-Ecija, Sergi; Grau-Rivera, Oriol; Jinhui; Alcalay, Roy N.; Hassin-Baer, Sharon; Valldeoriola F, Regidor I, Mir P, Matías-Arbelo Colom-Cadena, Marti; Luis Molinuevo, Jose; Pittman, Alan M.; Brooks, Janet; Edsall, J, Parra JC, Grandas F. Continuous intestinal Tolosa, Eduard; Sanchez-Valle, Raquel; Gelpi, Connor; Hernandez, Dena G.; Chung, Sun Ju; infusion of levodopa-carbidopa in patients Ellen. Tauopathy with Hippocampal Goldwurm, Stefano; Toft, Mathias; Schulte, with advanced Parkinson's disease in 4-Repeat Tau Immunoreactive Spherical Claudia; Bras, Jose; Wood, Nicholas W.; Brice, Spain: Subanalysis by autonomous Inclusions in a Patient with PSP. BRAIN Alexis; Morris, Huw R.; Scholz, Sonja W.; Nalls, community. NEUROLOGIA. PATHOLOGY. 28(2):284-286. I.F.: 6.187 Mike A.; Singleton, Andrew B.; Cookson, Mark S0213-4853(17):30374-2. I.F.: 1.938 R.;COURAGE-PD Comprehensive Unbiased; 3. Valldeoriola F. Simultaneous French Parkinsons Dis Consortium; IPDGC. 25. Valldeoriola F., Grandas F., Arbelo J., low-frequency deep brain stimulation of Frequency of Loss of Function Variants in Blázquez Estrada M., Calopa Garriga M., the substantia nigra pars reticulata and LRRK2 in Parkinson Disease. JAMA Campos-Arillo V., Garcia Ruiz P., Gómez high-frequency stimulation of the NEUROLOGY. 75(11):1416-1422. I.F.: 11.460 Esteban J., Leiva Santana C., Martínez subthalamic nucleus to treat levodopa Castrillo J., Mir P., Salvador Aliaga A., Vivancos unresponsive freezing of gait in

230 PARKINSON DISEASE AND OTHER NEURODEGENERATIVE MOVEMENT DISORDERS: CLINICAL AND EXPERIMENTAL RESEARCH 4.3

4. Marek K, Chowdhury S, Siderowf A, Lasch Sponsored by: Instituto de Salud Carlos III Duration: 01/01/2018-31/12/2018 S, Coffey CS, Caspell-Garcia C, Simuni T, (ISCIII). PI14/00426 Jennings D, Tanner CM, Trojanowski JQ, Duration: 01/01/2015-31/12/2018 Martí MJ. Design of novel therapeutic Shaw LM, Seibyl J, Schuff N, Singleton A, agents against pathogenic α-synuclein Kieburtz K, Toga AW, Mollenhauer B, Galasko Fernández Santiago R. The beginnings of aggregation in Parkinson’s disease. D, Chahine LM, Weintraub D, Foroud T, Parkinson Disease: a study of early disease Sponsored by: Centre for Networked Tosun-Turgut D, Poston K, Arnedo V, Frasier mechanisms in a humanized in-vitro Biomedical Research on Bioengineering, M, Sherer T, Parkinson's Progression Markers model. Biomaterials and Nanomedicine Initiative. The Parkinson's progression Sponsored by: Ministerio de Economía y (CIBER-BBN) markers initiative (PPMI) - establishing a Competitividad (MINECO). Duration: 15/03/2017-30/10/2019 PD biomarker cohort. ANNALS OF SAF2015_73508_JIN CLINICAL AND TRANSLATIONAL Duration: 01/01/2017-31/12/2019 NEUROLOGY. 5(12):1460-1477. I.F.: 4.649 Fernández Santiago R. MicroRNAs AS 5. Blauwendraat C, Kia DA, Pihlstrøm L, biomarkers of the prodromal stage of Gan-Or Z, Lesage S, Gibbs JR, Ding J, Alcalay parkinson disease. Expansion of microrna RN, Hassin-Baer S, Pittman AM, Brooks J, ﬁndings to ashkenazi jew pd cohorts. Edsall C, Chung SJ, Goldwurm S, Toft M, Sponsored by: Michael J. Fox Foundation for Schulte C; International Parkinson's Disease Parkinson (MJFF). 11159.01 Genomics Consortium (IPDGC), Duration: 01/01/2017-31/12/2019 COURAGE-PD Consortium, Hernandez D, Singleton AB, Nalls MA, Brice A, Scholz SW, Martí MJ. Catalan Network of Multiple Wood NW. Insufficient evidence for System Atrophy: Biomarkers and pathogenicity of SNCA His50Gln (H50Q) Pathophysiology. in Parkinson's disease. NEUROBIOLOGY Sponsored by: Fundació Marató TV3. OF AGING. 64:159.e5-159.e8. I.F.: 4.454 Neuro_14 Duration: 03/06/2015-31/12/2018

Martí MJ. Parkinson and other GRANTS FOR RESEARCH IN PROGRESS Neurodegenerative Movement Disorders: Clinical and Experimental Research. Compta Y, Marti MJ. Ampliﬁcación de Sponsored by: Generalitat de Catalunya. autoagregación de alfa-sinucleina y 4R-tau AGAUR_SGR17_01502 en tejido cerebral y liquido cerebroespinal Duration: 01/01/2017-31/12/2020 mediante RTQuIC como biomarcador diferencial de parkinsonismos Martí MJ. Identiﬁcation of degenerativos. pathophysiological pathways and Sponsored by: Instituto de Salud Carlos III candidate biomarkers in the prediagnostic (ISCIII). PI17/00096 phase of Parkinson’s disease. Duration: 01/01/2018-31/12/2020 Sponsored by: Instituto de Salud Carlos III (ISCIII). CIBERNED Compta Y. FAIR-PARK-II: Conservative iron Period: 02/03/2016-01/03/2018 chelation as a disease-modifying strategy in Parkinsons disease: a multicentric Martí MJ. The Parkinson’s Progression parallel-group,placebo-controlled, Markers Initiative (PPMI). randomized clinical trial of deferiprone. Sponsored by: Michael J. Fox Foundation for Sponsored by: European commission. Parkinson (MJFF). 041396 H2020-PHC-2014-2s (633190) Duration: 06/11/2013-31/12/2023 Duration: 01/05/2015-30/04/2020 Martí MJ. LRRK2 peripheral blood Ezquerra M. MicroRNAs as biomarker of mononuclear cells and urine bisample conversion of REM behaviour disorder to collection. Parkinson's disease. Sponsored by: Michael J. Fox Foundation for Sponsored by: Fundación Tatiana Pérez de Parkinson (MJFF). 11849 Guzmán el Bueno. 16_PROY03 Duration: 08/03/2016-31/12/2018 Duration: 23/11/2016-22/11/2019 Martí MJ. FTF SPAIN 18: Fox Trial Finder Ezquerra M. Epigenetic analysis of Spain. iPSC-derived dopaminergic neurons and Sponsored by: Michael J. Fox Foundation for blood cells in Parkinson disease. Parkinson (MJFF). 11937.02

231 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

Neurophysiology and functional studies 4.4 of the nervous system

PRE-DOCTORAL RESEARCHERS Estefanía Conde (FCRB) LOCATION Lilia Correa (UB) HCB building Francisco Gil (HCB) UB Medical School Lenin Alejandro Reyes (UB) Alba Andrés-Bilbé (UB) Federico Miguez-Cabello (UB) Anna Pujol (IDIBAPS)

WEB Nuria Sánchez-Fernández (UB) www.ub.edu/neuroﬁsiologia Andreea Larisa Turcu (UB)

TEAM LEADER TECHNICIANS Alejandro Iranzo (HCB) Sara Abelló (UB) T. 93 227 54 13 [email protected] ADMINISTRATIVE STAFF Mònica Serradell (FCRB) KEYWORDS 1. Neurophysiology GROUP LEADER NURSING STAFF 2. Sleep Xavier Gasull (UB) Isabel Manzanares (HCB) 3. Neuropathic pain T. 93 402 45 19 4. Motor control and sensorimotor [email protected] COLLABORATORS integration Judith Navarro (HCB) 5. Epilepsy Ana Tercero (HCB) 6. Glutamate receptors EMERITUS Jordi Palés (UB) Josep Valls (HCB)

RESEARCHERS Maria del Mar Carreño (HCB) STRATEGIC OBJECTIVES Jordi Casanova (HCB) Original publications Antonio Jesús Donaire (HCB) Our goal is to expand on scientiﬁc knowledge from 2016 to 2018 Carles Gaig (HCB) of functional aspects of the nervous system, Joan Santamaria (HCB) with maximum integration of basic and clinical YEAR I.F. TOTAL Q1 Q2 Arcadi Gual (UB) aspects, fundamentally using

2016 129.87 28 15 8 David Soto (UB) neurophysiological techniques. Key words of our research include motor control, sensory 2017 123.29 20 15 2 POST-DOCTORAL RESEARCHERS perception, pain, sleep, epilepsy, neuronal 2018 125.84 24 17 7 Aida Castellanos (IDIBAPS) excitability, ion channels, dry eye and Núria Comes (UB) glaucoma. Esther Gratacós-Batlle (UB)

TEAM INVOLVED IN OFTARED CIBERNED TEAM Josep Valls Solé

232 NEUROPHYSIOLOGY AND FUNCTIONAL STUDIES OF THE NERVOUS SYSTEM 4.4

MAIN LINES OF RESEARCH root and trigeminal ganglia, and determining Pablo; Escriva, Hector; Roher, Nerea; Soto, which alterations occur during inflammatory David; Bayes, Alex. Metazoan evolution of Sleep and sleep disorders. and neuropathic pain states. We are especially glutamate receptors reveals unreported A clinical and electrophysiological interested on ocular pain after inflammation, phylogenetic groups and divergent assessment of normal sleep in humans and of injury or dry eye disease. On the other hand, in lineage-specific events. ELIFE. 7:e35774. sleep disorders including the anti-IgLON5 trabecular cells that regulate aqueous humor I.F.: 7.616 disease, REM sleep behavior disorder, flow in the eye and intraocular pressure, we parasomnias, narcolepsy, sleep apnea, are exploring the role of ion channels that 5. Ramos-Perdigués S., Baillés E., Mané A., insomnia, and restless legs syndrome. regulate contraction, shape and cell volume Carreño M., Donaire A., Rumià J., Bargalló N., and how this is related to the physiopathology Boget T., Setoain X., Valdés M., Pintor L. Neuropathic pain. of glaucoma. Another research area of the Psychiatric Symptoms in Refractory Electrophysiological evaluation of the group is glutamatergic signaling, studying the Epilepsy During the First Year After neuropathic pain using nociceptive evoked functional interaction between AMPARs, Surgery. NEUROTHERAPEUTICS. potentials and other tools including the startle auxiliary subunits and other interacting 15(4):1082-1092. I.F.: 5.719 reaction. Characterization of ion channels proteins, which determine this glutamate involved in neuronal excitability. Study of receptor function at the synapse. Also, the role 6. Castellanos A, Andres A, Bernal L, Callejo sensory transduction and the generation of of mutations in NMDA receptors that produce G, Comes N, Gual A, Giblin JP, Roza C, Gasull. inflammatory and neuropathic pain. neurological diseases is studied. Pyrethroids inhibit K2P channels and activate sensory neurons: basis of Motor control. insecticide-induced paraesthesias. PAIN. Assessment of the motor control in healthy 159(1):92-105. I.F.: 5.559 subjects and in patients with neurological PUBLICATIONS diseases using acoustic and somatosensorial 7. Stokholm MG, Iranzo A, Østergaard K, stimuli and prepulse. Originals / I.F.: 125.841 Serradell M, Otto M, Bacher Svendsen K, Garrido A, Vilas D, Parbo P, Borghammer P, Epilepsy. 1. Haselmann H, Mannara F, Werner C, Santamaria J, Møller A, Gaig C, Brooks DJ, Characterization of the epileptogenic activity Planagumà J, Miguez-Cabello F, Schmidl L, Tolosa E, Pavese N. Extrastriatal and the surgical and medical therapy of the Grünewald B, Petit-Pedrol M, Kirmse K, monoaminergic dysfunction and refractory epilepsy using functional MRI, Classen J, Demir F, Klöcker N, Soto D, Doose enhanced microglial activation in video-EEG and epidural assessment. S, Dalmau J, Hallermann S, Geis C. Human idiopathic rapid eye movement sleep Autoantibodies against the AMPA behaviour disorder. NEUROBIOLOGY OF Ocular pathophysiology. Receptor Subunit GluA2 Induce Receptor DISEASE. 115:9-16. I.F.: 5.227 Physiology of aqueous humour drainage and Reorganization and Memory Dysfunction. physiopathology of glaucoma. Ocular pathology NEURON. 100(1):91-105. I.F.: 14.319 8. Elorza-Vidal X, Sirisi S, Gaitán-Peñas H, in aging. Physiology of the ocular trabecular Pérez-Rius C, Alonso-Gardón M, meshwork. Physiopathology of dry eye. 2. Petit-Pedrol M., Sell J., Planagumà J., Armand-Ugón M, Lanciotti A, Brignone MS, Mannara F., Radosevic M., Haselmann H., Prat E, Nunes V, Ambrosini E, Gasull X, Glutamatergic neurotransmission. Ceanga M., Sabater L., Spatola M., Soto D., Estévez R . GlialCAM/MLC1 modulates Role of glutamate receptors and new Gasull X., Dalmau J., Geis C. LGI1 antibodies LRRC8/VRAC currents in an indirect accessory proteins. Role of mutations in these alter Kv1.1 and AMPA receptors changing manner: Implications for megalencephalic proteins producing neurological diseases. synaptic excitability, plasticity and leukoencephalopathy. NEUROBIOLOGY memory. BRAIN; A JOURNAL OF OF DISEASE. 119:88-99. I.F.: 5.227 NEUROLOGY. 141(11):3144-3159. I.F.: 10.848 9. Iranzo A, Borrego S, Vilaseca I, Martí C, RESEARCH GROUP 3. Perissinotti A., Niñerola-Baizán A., Rubí S., Serradell M, Sánchez-Valle R, Kovacs GG, NEUROPHYSIOLOGY Carreño M., Marti-Fuster B., Aparicio J., Valldeoriola F, Gaig C, Santamaria J, Tolosa E, Mayoral M., Donaire A., Sanchez-Izquierdo N., Gelpi E. Alpha-synuclein Aggregates in Bargalló N., Rumiá J., Boget T., Pons F., Labial Salivary Glands of Idiopathic Rapid Lomeña F., Ros D., Pavía J., Setoain X. Eye Movement Sleep Behavior Disorder. PISCOM: a new procedure for epilepsy SLEEP. 41(8). I.F.: 5.135 combining ictal SPECT and interictal PET. EUROPEAN JOURNAL OF NUCLEAR 10. Pizza F, Antelmi E, Vandi S, Meletti S, Erro MEDICINE AND MOLECULAR IMAGING. R, Baumann CR, Bhatia KP, Dauvilliers Y, GROUP LEADER 45(13):2358-2367. I.F.: 7.704 Edwards MJ, Iranzo A, Overeem S, Tinazzi M, Xavier Gasull (UB) Liguori R, Plazzi G . The Distinguishing Motor 4. Ramos-Vicente, David; Ji, Jie; Features of Cataplexy: A Study from Video Within the field of neurophysiology, the group Gratacos-Batlle, Esther; Gou, Gemma; Recorded Attacks. SLEEP. 41(5). I.F.: 5.135 is interested in establishing the role of different Reig-Viader, Rita; Luis, Javier; Burguera, ion channels implicated in shaping the Demian; Navas-Perez, Enrique; 11. Stefani A, Heidbreder A, Brandauer E, excitability of sensory neurons of the dorsal Garcia-Fernandez, Jordi; Fuentes-Prior, Guaita M, Neier LM, Mitterling T, Santamaria J,

233 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

Iranzo A, Videnovic A, Trenkwalder C, Sanchez-Fernandez, Nuria; Yefimenko, naming tasks. BRAIN AND LANGUAGE. Sixel-Döring F, Wenning GK, Chade A, Poewe Natalia; Miguez-Cabello, Federico; Fado, Rut; 180-182:24-30. I.F.: 2.851 W, Gershanik OS, Högl B . Screening for Casals, Nuria; Gasull, Xavier; Ambrosio, idiopathic REM sleep behavior disorder: Santiago; Soto, David. Mechanisms of 24. Rocamora R., Ley M., Molins A., Toledo M., usefulness of actigraphy. SLEEP. 41(6). CPT1C-Dependent AMPAR Trafficking Sansa G., Bertol V., Becerra J., Carreño M., I.F.: 5.135 Enhancement. FRONTIERS IN MOLECULAR Mauri J. Effect of lacosamide on depression NEUROSCIENCE. 11:275. I.F.: 3.902 and anxiety symptoms in patients with 12. Villanueva V, Montoya J, Castillo A, focal refractory epilepsy: A prospective Mauri-Llerda JÁ, Giner P, López-González FJ, 17. Cano-López I, Calvo A, Boget T, Carreño multicenter study. EPILEPSY AND Piera A, Villanueva-Hernández P, Bertol V, M, Donaire A, Setoain X, Pintor L, Rumià J, BEHAVIOR. 79:87-92. I.F.: 2.600 Garcia-Escrivá A, Garcia-Peñas JJ, González-Bono E, Junqué C, Bargalló N. Garamendi I, Esteve-Belloch P, Baiges- Typical asymmetry in the hemispheric Octavio JJ, Miró J, Falip M, Garcés M, Gómez activation during an fMRI verbal Review / I.F.: 22.592 A, Gil-López FJ, Carreño M, Rodriguez- comprehension paradigm is related to Uranga JJ, Campos D, Bonet M, Querol R, better performance in verbal and 1. Dauvilliers, Yves; Schenck, Carlos H.; Molins A, Tortosa D, Salas-Puig J . non-verbal tasks in patients with epilepsy. Postuma, Ronald B.; Iranzo, Alex; Luppi, Perampanel in routine clinical use in NEUROIMAGE: CLINICAL. 20:742-752. Pierre-Herve; Plazzi, Giuseppe; Montplaisir, idiopathic generalized epilepsy: The I.F.: 3.869 Jacques; Boeve, Bradley. REM sleep 12-month GENERAL study. EPILEPSIA. behaviour disorder. NATURE REVIEWS 59(9):1740-1752. I.F.: 5.067 18. Yagüe S., Veciana M., Casasnovas C., Ruiz DISEASE PRIMERS. 4(1):19. I.F.: 16.071 M., Pedro J., Valls-Solé J., Pujol A. Evaluation 13. Gamez-Valero, Ana; Iranzo, Alex; Serradell, of afferent pain pathways in 2. Gaig, Carles; Iranzo, Alex; Santamaria, Joan; Monica; Vilas, Dolores; Santamaria, Joan; adrenomyeloneuropathic patients. Graus, Francesc. The Sleep Disorder in Gaig, Caries; Alvarez, Ramiro; Ariza, Aurelio; CLINICAL NEUROPHYSIOLOGY. Anti-lgLON5 Disease. CURRENT Tolosa, Eduardo; Beyer, Katrin. 129(3):507-515. I.F.: 3.614 NEUROLOGY AND NEUROSCIENCE Glucocerebrosidase gene variants are REPORTS. 18(7):41. I.F.: 3.478 accumulated in idiopathic REM sleep 19. Tió E, Gaig C, Giner-Soriano M, Romero O, behavior disorder. PARKINSONISM AND Jurado MJ, Sansa G, Pujol M, Sans O, 3. Iranzo, Alex. The REM sleep circuit and RELATED DISORDERS. 50:94-98. I.F.: 4.721 Álvarez-Guerrico I, Caballol N, Jimenez M, how its impairment leads to REM sleep Becerra JL, Escartin A, Monasterio C, Molins behavior disorder. CELL AND TISSUE 14. Martin-Trias P., Lanteaume L., Solana E., A, Bove A, Viña J, Iranzo A, Cambrodi R, Calvo RESEARCH. 373(1):245-266. I.F.: 3.043 Cassé-Perrot C., Fernández-Cabello S., G, Morros R, Santamaria J. The prevalence Babiloni C., Marzano N., Junqué C., Rossini P., of narcolepsy in Catalunya (Spain). Micallef J., Truillet R., Charles E., Jouve E., JOURNAL OF SLEEP RESEARCH. Letters / I.F.: 3.395 Bordet R., Santamaria J., Jovicich J., Rossi S., 27(5):e12640. I.F.: 3.433 Pascual-Leone A., Blin O., Richardson J., 1. Iranzo A, Stefani A, Högl B, Santamaria J, Bartrés-Faz D. Adaptability and 20. Fernandez-Arcos, Ana; Vilaseca, Isabel; SINBAR. Kafkas’ insomnia and narrative reproducibility of a memory disruption Aldecoa, Iban; Serradell, Monica; Tolosa, works. SLEEP MEDICINE. 52:233-233. I.F.: rTMS protocol in the PharmaCog IMI Eduard; Santamaria, Joan; Gelpi, Ellen; Iranzo, 3.395 European project. SCIENTIFIC REPORTS. Alex. Alpha-synuclein aggregates in the 8(1):9371. I.F.: 4.122 parotid gland of idiopathic REM sleep behavior disorder. SLEEP MEDICINE. Editorial / I.F.: 1.015 15. Zhang Z, Mayer G, Dauvilliers Y, Plazzi G, 52:14-17. I.F.: 3.395 Pizza F, Fronczek R, Santamaria J, Partinen M, 1. Valls-Solé J. Challenges in the diagnosis Overeem S, Peraita-Adrados R, da Silva AM, 21. Iranzo A, Stefani A, Högl B, Santamaria J, and treatment of small fiber neuropathies. Sonka K, Rio-Villegas RD, Heinzer R, SINBAR. The insomnia of Franz Kafka. ARQUIVOS DE NEURO-PSIQUIATRIA. Wierzbicka A, Young P, Högl B, Bassetti CL, SLEEP MEDICINE. 50:24-28. I.F.: 3.395 76(3):129-130. I.F.: 1.015 Manconi M, Feketeova E, Mathis J, Paiva T, Canellas F, Lecendreux M, Baumann CR, 22. Gil-López FJ, Montoya J, Falip M, Aparicio Barateau L, Pesenti C, Antelmi E, Gaig C, J, López-González FJ, Toledano R, Gil-Nagel Iranzo A, Lillo-Triguero L, Medrano-Martínez A, Molins A, García I, Serrano P, Domenech G, GRANTS FOR RESEARCH IN PROGRESS P, Haba-Rubio J, Gorban C, Luca G, Lammers Torres F, Donaire A, Carreño M . GJ, Khatami R. Exploring the clinical Retrospective study of perampanel Carreño MM. Validación de la resonancia features of narcolepsy type 1 versus efficacy and tolerability in myoclonic funcional en reposo y tractografia para la narcolepsy type 2 from European seizures. ACTA NEUROLOGICA lateralización del lenguaje en pacientes Narcolepsy Network database with SCANDINAVICA. 138(2):122-129. I.F.: 3.126 epilépticos. machine learning. SCIENTIFIC REPORTS. Sponsored by: Instituto de Salud Carlos III 8(1):10628. I.F.: 4.122 23. Leote J, Castellote JM, Casanova-Molla J, (ISCIII). PI17/01211 Navarro-Otano J, Nunes RG, Ferreira HA, Duration: 01/01/2018-31/12/2020 16. Gratacos-Batlle, Esther; Olivella, Mireia; Valls-Sole J. Motor preparation in picture

234 NEUROPHYSIOLOGY AND FUNCTIONAL STUDIES OF THE NERVOUS SYSTEM 4.4

Carreño MM. Eﬁcacia y seguridad de la estimulación trigeminal externa como tratamiento de la epilepsia resistente a fármacos. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI13/00509 Duration: 01/01/2014-30/06/2018

Casanova-Molla J. Caracterización del daño axonal en la neuropatía por quimioterapia: perﬁl temporal de la degeneración y regeneración axonal y su repercusión en los diferentes sistemas funcionales. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI 16/00984 Duration: 01/01/2017-31/12/2019

Gasull X. Bases neuroﬁsiológicas del picor y dolor crónico: canales iónicos en neuronas sensoriales implicados en enfermedades inﬂamatorias y oculares. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI17/00296 Duration: 01/01/2018-31/12/2020

Gasull X. RETIC Oftared: Prevencion, deteccion precoz, tratamiento y rehabilitacion de las patologias oculares. Sponsored by: Instituto de Salud Carlos III. RD16/0008/0014 Duration: 01/01/2017-31/12/2021

Iranzo A. Detección in-vivo de alfa-sinucleina en biopsia de glándulas salivares menores en pacientes con trastorno de conducta del sueño REM, como modelo premotor de la enfermedad de Parkinson. Sponsored by: Instituto De Salud Carlos III (ISCIII). PI16/01050 Duration: 01/01/2017-31/12/2019

Soto D. Estudio funcional del proteoma de los receptores AMPA . Sponsored by: Ministerio de Economía y Competitividad (MINECO). BFU2017-83317-P Duration: 01/01/2018-31/12/2020

DOCTORAL THESES

Iranzo A. Caracterización clínica, polisomnograﬁca y evolutiva del trastorno de conducta de sueño Rem Idiopático. PhD student: Ana Fernandez Arcos

235 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

Muscle research 4.5 and mitochondrial function

TECHNICIANS Esther Tobias (UB) LOCATION

CELLEX building, ﬂoor 4B COLLABORATORS Faculty of Medicine and Xavier Bosch (HCB) Health Sciences University of Barcelona

STRATEGIC OBJECTIVES

1. Management of patients with rare KEYWORDS TEAM LEADER diseases (metabolic, mitochondrial and 1. Muscle Josep M. Grau Junyent (HCB) neuromuscular). 2. Mitochondria T. 93 227 55 39

3. Cardiomyopathy [email protected] 2. Mitochondrial, inﬂammatory, autoimmune 4. Chronic fatigue syndrome and toxic muscle disease. 5. Septic shock RESEARCHERS 3. Mitotoxicity. Francesc Cardellach (HCB) Pedro Castro (HCB) 4. Mitochondrial involvement in Joaquim Fernández (HCB) neurodegeneration and psychiatrics. Glòria Garrabou (CIBER) Josep M Nicolas (HCB) 5. Mitochondrial basis of obstetric Original publications outcome. from 2016 to 2018 POST-DOCTORAL RESEARCHERS

YEAR I.F. TOTAL Q1 Q2 Laura Garcia (HCB) 6. Cardiomyopathy in alcoholism and Mariona Guitart (IDIBAPS) hypertension. 2016 62.86 15 9 6 Anna Sandra Hernández (HCB) 2017 60.31 16 9 4 Constanza Isabel Moren (CIBER) 7. Chronic fatigue syndrome (CFS).

2018 98.63 129 3 PRE-DOCTORAL RESEARCHERS 8. Septic shock and organ failure. Cecilia Cuzco (HCB) Sara Fernandez (HCB) 9. Journalology. Ingrid Gonzalez (FCRB)

TEAM INVOLVED IN Diana Luz Juarez (UB) CIBERER Jose César Milisenda (HCB) CIBEROBN Pedro Juan Moreno (HCB) AGAUR_SGR17: 00893 Anna Peguero (HCB) TEAM Josep M. Grau Junyent

236 MUSCLE RESEARCH AND MITOCHONDRIAL FUNCTION 4.5

MAIN LINES OF RESEARCH PUBLICATIONS Prieto-González S., García-Martínez A., Hernández-Rodríguez J., Grau J., Cid M. 1. Diagnosis and management of patients Originals / I.F.: 98.626 Expression and function of IL12/23 related with rare diseases, inborn errors of cytokine subunits (p35, p40, and p19) in metabolism or neuromuscular disorders 1. Wittekamp BH, Plantinga NL, Cooper BS, giant-cell arteritis lesions: Contribution of (coordinating 42 groups). Research, Lopez-Contreras J, Coll P, Mancebo J, Wise p40 to Th1-and Th17-mediated training, register and biobanking. MP, Morgan MPG, Depuydt P, Boelens J, inflammatory pathways. FRONTIERS IN Dugernier T, Verbelen V, Jorens PG, IMMUNOLOGY. 9(809):809. I.F.: 5.511 2. Etiology, biomarkers and therapeutics in Verbrugghe W, Malhotra-Kumar S, Damas P, muscle pathology; special focus in inclusion Meex C, Leleu K, van den Abeele AM, Gomes 6. Pinal-Fernandez I, Pinal-Fernandez I, body myositis, myopathy secondary to Pimenta de Matos AF, Fernández Méndez S, Pinal-Fernandez I, Ferrer-Fabregas B, statins and mtDNA Vergara Gomez A, Tomic V, Sifrer F, Villarreal Trallero-Araguas E, Balada E, Martínez MA, mantainance-syndromes. Tello E, Ruiz Ramos J, Aragao I, Santos C, Milisenda JC, Aparicio-Español G, Sperning RHM, Coppadoro P, Nardi G, Labrador-Horrillo M, Garcia-Patos V, 3. Mitochondrial toxicity induced by drugs Brun-Buisson C, Bonten MJM. Garcia-Patos V, Grau-Junyent JM, (antiretrovirals, antibiotics, antipsychotics) Decontamination Strategies and Selva-O'Callaghan A, Selva-O'Callaghan A. or toxic agents (HIV, CO, tobacco). Bloodstream Infections With Tumour TIF1 mutations and loss of Antibiotic-Resistant Microorganisms in heterozygosity related to 4. Etiology, biomarkers and therapeutics in Ventilated Patients: A Randomized Clinical cancer-associated myositis. neurodegeneration and psychiatrics: Trial. JAMA-JOURNAL OF THE AMERICAN RHEUMATOLOGY. 57(2):388-396. I.F.: 5.245 Parkinson disease (familial Parkin and MEDICAL ASSOCIATION. LRRK2 or idiopathic forms), X-Fragile 320(20):2087-2098. I.F.: 47.661 7. Guitart-Mampel M, Gonzalez-Tendero A, syndrome, schizophrenia and autism. Niñerola S, Morén C, Catalán-Garcia M, 2. Brito-Zerón P, Kostov B, Moral-Moral P, González-Casacuberta I, Juárez-Flores DL, 5. Etiology, biomarkers and therapeutics in Martínez-Zapico A, Díaz-Pedroche C, Fraile G, Ugarteburu O, Matalonga L, Cascajo MV, Tort preeclampsia.and intrauterine growth Pérez-Guerrero P, Fonseca E, Robles A, F, Cortés A, Tobias E, Milisenda JC, Grau JM, restriction with associated cardiovascular Vaquero-Herrero MP, Calvo MA, Forner MJ, Crispi F, Gratacós E, Garrabou G, Cardellach fetal remodeling. Morcillo C, Larrañaga J, Rodriguez-Carballeira F. Cardiac and placental mitochondrial M, Ruiz-Muñoz M, Hurtado-García R, characterization in a rabbit model of 6. Pathological mechanisms of alcohol and Prieto-González S, Aguilar AA, intrauterine growth restriction. BBA hypertension at cardiocirculatory level: (i) Caminal-Montero L, Hernández-Jiménez P, BIOCHIMICA ET BIOPHYSICA ACTA. Prognosis of myocardiopathy and Fernández-Viagas CR, Castro P, Massó VM, 1862(5):1157-1167. I.F.: 5.108 management options; (ii) Muscle and Flores-Chavez A, Ramos-Casals M, myocardial apoptosis; (iii) Myocardial REGHEM-GEAS-SEMI Study Group. 8. González-Casacuberta I, Morén C, regeneration and fibrosis; (iv) and Myocyte Prognostic Factors of Death in 151 Adults Juárez-Flores DL, Esteve-Codina A, Sierra C, hyperthrophy (myostatin, IGF-1, Titin, With Hemophagocytic Syndrome: Catalán-García M, Guitart-Mampel M, Tobías FGF-21). Etiopathogenically Driven Analysis. MAYO E, Milisenda JC, Pont-Sunyer C, Martí MJ, CLIN PROC INNOV QUAL OUTCOMES. Cardellach F, Tolosa E, Artuch R, Ezquerra M, 7. Clinical and functional repercussions of 2(3):267-276. I.F.: 7.199 Fernández-Santiago R, Garrabou G. CFS. (i) Long-term multidisciplinar therapy, Transcriptional alterations in skin (ii) Role of co-morbidity, (iii) Influence of 3. Pozdniakova S, Guitart-Mampel M, fibroblasts from Parkinson's disease chemicals and environment. Garrabou G, Di Benedetto G, Ladilov Y, patients with parkin mutations. Regitz-Zagrosek V . 17β-estradiol reduces NEUROBIOLOGY OF AGING. 65:206-216. 8. Clinical and translational research on septic mitochondrial cAMP content and I.F.: 4.454 shock and multiorgan failure. Research on cytochrome oxidase activity in a antibiotic policies in critically-ill patients. phosphodiesterase 2-dependent manner. 9. Juárez-Flores DL, González-Casacuberta I, Critical care issues of special populations: BRITISH JOURNAL OF PHARMACOLOGY. Ezquerra M, Bañó M, Carmona-Pontaque F, elderly patients, hemato-oncological 175(20):3876-3890. I.F.: 6.810 Catalán-García M, Guitart-Mampel M, Rivero patients, patients with autoimmune JJ, Tobias E, Milisenda JC, Tolosa E, Marti MJ, diseases, patients with Human 4. Valenzuela-Alcaraz B, Cruz-Lemini M, Fernández-Santiago R, Cardellach F, Morén Immunodeficiency infection, patients with Rodríguez-López M, Goncé A, García-Otero C, Garrabou G. Exhaustion of mitochondrial imported tropical diseases and others. L, Ayuso H, Sitges M, Bijnens B, Balasch J, and autophagic reserve may contribute to Gratacós E, Crispi F. Fetal cardiac the development of LRRK2 G2019S 9. Journalology of biomedical journals: remodeling in twin pregnancies conceived -Parkinson's disease. JOURNAL OF research of editorial and ethical policies of by assisted reproductive technologies. TRANSLATIONAL MEDICINE. 16(1):160-160. biomedical journals. ULTRASOUND IN OBSTETRICS AND I.F.: 4.197 GYNECOLOGY. 51(1):94-100. I.F.: 5.654 10. Milisenda JC, Collado MV, 5. Espígol-Frigolé G., Planas-Rigol E., Lozano Pinal-Fernandez I, Hormaza Jaramillo A, E., Corbera-Bellalta M., Terrades-García N., Faruch Bilfeld M, Cano MD, García AI, Tomás

237 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

X, Grau JM. Correlation between Editorial / I.F.: 19.646 endocarditis due to Abiotrophia spp. and quantitative and semiquantitative Granulicatella spp.: Report of 76 cases magnetic resonance imaging and 1. Ugarte, Ainoa; Grau, Josep M.; Milisenda, (2000-2015). CLINICAL INFECTIOUS histopathology findings in Jose C. Amyloid polyneuropathy in 2 DISEASES. 66(1):104-111. I.F.: 9.117 dermatomyositis. CLINICAL AND patients after liver transplantation. EXPERIMENTAL RHEUMATOLOGY NEUROLOGY. 90(1):38-38. I.F.: 8.055 3. Figueroa-Bonaparte S., Llauger J., Segovia I.F.: 3.201 S., Belmonte I., Pedrosa I., Montiel E., 2. Vincent, Jean-Louis; Castro, Pedro; Hunt, Montesinos P., Sánchez-González J., 11. Mazarico E, Peguero A, Camprubí M, Beverley J.; Jorres, Achim; Praga, Manuel; Alonso-Jiménez A., Gallardo E., Illa I., Rovira C, Gomez Roig MD, Oros D, Rojas-Suarez, Jose; Watanabe, Eizo;. Barba-Romero M., Barcena J., Carbonell P., Ibáñez-Burillo P, Schoorlemmer J, Masoller N, Thrombocytopenia in the ICU: Carzorla M., Creus C., Coll-Cantí J., Díaz M., Tàssies MD, Figueras F. Study protocol for a disseminated intravascular coagulation Domínguez C., Fernández-Torrón R., randomised controlled trial: treatment of and thrombotic microangiopathies-what García-Antelo M., Grau J., De Munáin A., early intrauterine growth restriction with intensivists need to know. CRITICAL CARE. Martínez-García F., Morgado Y., Moreno A., low molecular weight heparin (TRACIP). 22(1):158. I.F.: 6.425 Morís G., Muñoz-Blanco M., Nascimento A., BMJ OPEN. 8(10):e020501-e020501. Parajua J., Robledo-Strauss A., Rojas-Marcos I.F.: 2.413 3. Fernández Solà J. Reversibility of Alcohol Í., Salazar J., Usón M., Díaz-Manera J. Dilated Cardiomyopathy. REVISTA Quantitative muscle MRI to follow up late 12. Carvalho E., Castro P., León E., Del Río A., ESPAÑOLA DE CARDIOLOGIA. onset Pompe patients: A prospective Crespo F., Trigo L., Fernández S., Trilla A., 71(8):603-605. I.F.: 5.166 study. SCIENTIFIC REPORTS. 8(1):10898. Varela P., Nicolás J. Multi-professional I.F.: 4.122 simulation and risk perception of health care workers caring for Ebola-infected Case Reports / I.F.: 6.25 4. Bowles H, Ambrosioni J, Mestres G, patients. NURSING IN CRITICAL CARE. Hernández-Meneses M, Sánchez N, Llopis J, 12396. I.F.: 1.173 1. Marco-Hernández J, Camprubí D, Aylagas Yugueros X, Almela M, Moreno A, Riambau V, C, Gupta H, Castro P. Failure of intravenous Fuster D, Miró JM, Hospital Clinic Endocarditis artesunate treatment for Plasmodium Study Group. Diagnostic yield of 18F-FDG Review / I.F.: 37.48 falciparum malaria in a splenectomized PET/CT in suspected diagnosis of traveller: A diagnostic challenge. TRAVEL vascular graft infection: A prospective 1. Selva-O'Callaghan, Albert; Pinal-Fernandez, MEDICINE AND INFECTIOUS DISEASE. cohort study. JOURNAL OF NUCLEAR Iago; Trallero-Araguas, Ernesto; Cesar S1477-8939(18):30300-4. I.F.: 4.450 CARDIOLOGY. 1-9. I.F.: 4.011 Milisenda, Jose; Maria Grau-Junyent, Josep; Mammen, Andrew L. Classification and 2. Rodriguez-Valero, N.; Castro, P.; Martinez, management of adult inflammatory G.; Hernandez, J. Marco; Fernandez, S.; myopathies. LANCET NEUROLOGY. Gascon, J.; Nicolas, J. M. Blackwater fever in GRANTS FOR RESEARCH IN PROGRESS 17(9):816-828. I.F.: 27.144 a non-immune patient with Plasmodium falciparum malaria after intravenous Cardellach F. Influencia de la dieta en la 2. Figueras F., Caradeux J., Crispi F., Eixarch artesunate. JOURNAL OF TRAVEL modulación mitocondrial y de E., Peguero A., Gratacos E. Diagnosis and MEDICINE. 25(1). I.F.: 1.800 cardiomiocinas del remodelado surveillance of late-onset fetal growth cardiovascular fetal asociado al restriction. AMERICAN JOURNAL OF crecimiento intrauterino restringido. OBSTETRICS AND GYNECOLOGY. Consortium Publications / I.F.: 26.367 Sponsored by: Instituto de Salud Carlos III 218(2):S790-S802. I.F.: 5.732 (ISCIII). PI15/00817 1. Ambrosioni J, Urra X, Hernández-Meneses Duration: 01/01/2016-31/12/2019 3. Selva-O’Callaghan A, Alvarado-Cardenas M, Almela M, Falces C, Tellez A, Quintana E, M, Pinal-Fernández I, Trallero-Araguás E, Fuster D, Sandoval E, Vidal B, Tolosana JM, Fernàndez-Solà J. Paper de les noves Milisenda J, Martínez M, Marín A, Moreno A, Chamorro A, Miró JM, Hospital cardiomiocines FGF21 i Metrnl en el dany Labrador-Horrillo M, Juárez C, Grau-Junyent Clínic Infective Endocarditis Study Group . cardíac induït per l'alcoholisme i la J. Statin-induced myalgia and myositis: an Mechanical thrombectomy for acute hipertensió arterial. update on pathogenesis and clinical ischemic stroke secondary to infective Sponsored by: Fundació la Marató de TV3. recommendations. EXPERT REVIEW OF endocarditis. CLINICAL INFECTIOUS TV3_Cor_15 CLINICAL IMMUNOLOGY. 14(3):215-224. DISEASES. 66(8):1286-1289. I.F.: 9.117 Duration: 29/06/2016-28/06/2019 I.F.: 3.436 2. Téllez A, Ambrosioni J, Llopis J, Pericàs JM, Morén C, Cardellach F. Elaboración de un 4. Fernández Solà J. Central sensitization Falces C, Almela M, Garcia de la Mària C, modelo in vitro de neuronas syndrome: towards the structuring of a Hernandez-Meneses M, Vidal B, Sandoval E, dopaminérgicas derivadas de pacientes multidisciplinary concept. MEDICINA Quintana E, Fuster D, Tolosana JM, Marco F, con enfermedad de Parkinson: plataforma CLINICA. 151(2):68-70. I.F.: 1.168 Moreno A, Miro JM, Hospital Clínic Infective para estudios moleculares y terapéuticos. Endocarditis Investigators . Epidemiology, Sponsored by: Fundación Privada Cellex. clinical features and outcome of infective Duration: 01/06/2017-31/12/2019

238 MUSCLE RESEARCH AND MITOCHONDRIAL FUNCTION 4.5

DOCTORAL THESES

Nicolas JM. Bayesian Statistical Modeling for Clinical Decision Making in Emergency Medicine. PhD student: Laila Rosalie Cochon Coen

Cardellach F, Garrabou G. Mitochondrial implication in intrauterine growth restriction and cardiovascular remodeling. PhD student: Mariona Guitart-Mampel

239 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

Pathophysiology and treatment of 4.6 neurodegenerative disorders

Nuria Suelves (UB)

LOCATION CELLEX building, ﬂoor 3B TECHNICIANS Mireia Galofre (IDIBAPS) UB School of Medicine Cristina Herranz (UB) Ana Maria López (CIBER) M. Teresa Muñoz (UB) Unai Perpiña (UB)

KEYWORDS 1. Huntington’s disease TEAM LEADER STRATEGIC OBJECTIVES 2. Motor and cognitive function Jordi Alberch (UB) 3. Psychiatric disturbances T. 93 403 52 85 1. Study of the cellular and molecular bases 4. Neuroprotection [email protected] involved in neuronal dysfunction and death 5. Trophic factors associated to motor, psychiatric and 6. Stem cells cognitive alterations in basal ganglia RESEARCHERS neurodegenerative disorders. Josep M Canals (UB) Silvia Ginés (UB) 2. Use of stem cell technology to differentiate Esther Pérez (UB) neurons for using in regenerative medicine for neurodegenerative disorders. POST-DOCTORAL RESEARCHERS Original publications Veronica Brito (UB) from 2016 to 2018 Albert Giralt (UB)

YEAR I.F. TOTAL Q1 Q2 Merce Massana (IDIBAPS) MAIN LINES OF RESEARCH Andres Miguez (IDIBAPS) 2016 73.96 15 11 4 Ana Saavedra (CIBER) 1. Group of neuroprotection and neuronal 2017 91.75 14 13 1 Philip Gordon Thomas Sanders (IDIBAPS) plasticity in Huntington’s disease. PI: 2018 59.43 139 3 Jordi Alberch: To study the mechanisms PRE-DOCTORAL RESEARCHERS that modulate cortico-striatal connectivity Andrea Comella (UB) for understanding the intracellular Jordi Creus (UB) mechanisms to develop molecules that Sara Fernandez (UB) modulate neuronal plasticity for the TEAM INVOLVED IN Gerardo Garcia (UB) treatment of Huntington’s disease. CIBERNED Marta Garcia (UB) HD-iPSCs Consortium Ened Rodriguez (UB) AGAUR_SGR17: 01408 Cristina Salado (UB) TEAM Jordi Alberch

240 PATHOPHYSIOLOGY AND TREATMENT OF NEURODE GENERATIVE DISORDERS 4.6

2. Group of kinases and phosphatases in V, Calvo L, Lisa S, Torres-Valle M, Palko ME, 10. Fernández-Flores F., García-Verdugo J., neuronal function and dysfunction. PI: Vicente-García C, Fernández-Fernández S, Martín-Ibáñez R., Herranz C., Fondevila D., Esther Pérez-Navarro: The group is Bolaños JP, Ginés S, Tessarollo L, Arévalo JC. Canals J., Arús C., Pumarola M. interested in studying the involvement of Regulation of BDNF release by Characterization of the canine rostral kinases and phosphatases in the control of ARMS/Kidins220 through modulation of ventricular-subventricular zone: motor and cognitive processes in Synaptotagmin-IV levels. JOURNAL OF Morphological, immunohistochemical, Huntington’s disease. NEUROSCIENCE. 38(23):5415-5428. I.F.: 5.971 ultrastructural, and neurosphere assay studies. JOURNAL OF COMPARATIVE 3. Group of neurodegeneration and 4. García-Forn M, Martínez-Torres S, NEUROLOGY. 526(4):721-741. I.F.: 3.400 cognitive dysfunction in Huntington’s García-Díaz Barriga G, Alberch J, Milà M, Disease. PI: Silvia Ginés: The research Azkona G, Pérez-Navarro E. 11. Cases S, Saavedra A, Tyebji S, Giralt A, group is interested in defining the molecular Pharmacogenetic modulation of STEP Alberch J, Pérez-Navarro E. Age-related mechanisms involved in depressive, improves motor and cognitive function in a changes in STriatal-Enriched protein cognitive and motor disorders in mouse model of Huntington's disease. tyrosine Phosphatase levels: Regulation Huntington’s disease. NEUROBIOLOGY OF DISEASE. 120:88-97. by BDNF. MOLECULAR AND CELLULAR I.F.: 5.227 NEUROSCIENCES. 86:41-49. I.F.: 3.312 4. Group of stem cells and regenerative medicine. PI: Josep M. Canals: To study the 5. Alvarez-Periel E., Puigdellívol M., Brito V., 12. Telezhkin V, Straccia M, Yarova P, Pardo mechanisms underlying the differentiation Plattner F., Bibb J., Alberch J., Ginés S. Cdk5 M, Yung S, Vinh NN, Hancock JM, Barriga GG, of stem cells into neurons, for exploring the Contributes to Huntington’s Disease Brown DA, Rosser AE, Brown JT, Canals JM, cellular mechanisms involved in Learning and Memory Deficits via Randall AD, Allen ND, Kemp PJ. Kv7 channels Huntington’s and Parkinson’s disease. Modulation of Brain Region-Specific are upregulated during striatal neuron Another line of research is the Substrates. MOLECULAR NEUROBIOLOGY. development and promote maturation of characterization of extrinsic factors and 55(8):6250-6268. I.F.: 5.076 human iPSC-derived neurons. PFLUGERS new transcription factors of human and ARCHIV EUROPEAN JOURNAL OF mouse brain development. 6. Creus-Muncunill J, Rué L, Alcalá-Vida R, PHYSIOLOGY. 470(9):1359-1376. I.F.: 2.765 Badillos-Rodríguez R, Romaní-Aumedes J, Marco S, Alberch J, Perez-Otaño I, 13. Illa M., Brito V., Pla L., Eixarch E., Malagelada C, Pérez-Navarro E. Increased Arbat-Plana A., Batallé D., Muñoz-Moreno E., PUBLICATIONS Levels of Rictor Prevent Mutant Crispi F., Udina E., Figueras F., Ginés S., Huntingtin-Induced Neuronal Gratacós E. Early Environmental Originals / I.F.:59.43 Degeneration. MOLECULAR Enrichment Enhances Abnormal Brain NEUROBIOLOGY. 55(10):7728-7742. I.F.: 5.076 Connectivity in a Rabbit Model of 1. Alarcon-Aris, Diana; Recasens, Ariadna; Intrauterine Growth Restriction. FETAL Galofre, Mireia; Carballo-Carbajal, Iria; Zacchi, 7. Cabezas-Llobet N., Vidal-Sancho L., DIAGNOSIS AND THERAPY. 44(3):184-193. Nicolas; Ruiz-Bronchal, Esther; Pavia-Collado, Masana M., Fournier A., Alberch J., Vaudry D., I.F.: 1.813 Ruben; Chica, Rosario; Ferres-Coy, Albert; Xifró X. Pituitary Adenylate Santos, Marina; Revilla, Raquel; Montefeltro, Cyclase-Activating Polypeptide (PACAP) Andres; Farinas, Isabel; Artigas, Francesc; Vila, Enhances Hippocampal Synaptic Review / I.F.: 4.598 Miguel; Bortolozzi, Analia. Selective Plasticity and Improves Memory α-Synuclein Knockdown in Monoamine Performance in Huntington’s Disease. 1. Saavedra A, García-Díaz Barriga G, Neurons by Intranasal Oligonucleotide MOLECULAR NEUROBIOLOGY. Pérez-Navarro E, Alberch J. Huntington's Delivery: Potential Therapy for Parkinson's 55(11):8263-8277. I.F.: 5.076 disease: novel therapeutic perspectives Disease. MOLECULAR THERAPY. hanging in the balance. EXPERT OPINION 26(2):550-567. I.F.: 7.008 8. Giralt A, de Pins B, Cifuentes-Díaz C, ON THERAPEUTIC TARGETS. López-Molina L, Farah AT, Tible M, 22(5):385-399. I.F.: 4.598 2. Moreno E, Chiarlone A, Medrano M, Deramecourt V, Arold ST, Ginés S, Hugon J, Puigdellívol M, Bibic L, Howell LA, Resel E, Girault JA. PTK2B/Pyk2 overexpression Puente N, Casarejos MJ, Perucho J, Botta J, improves a mouse model of Alzheimer's Suelves N, Ciruela F, Ginés S, Galve-Roperh I, disease. EXPERIMENTAL NEUROLOGY. GRANTS FOR RESEARCH IN PROGRESS Casadó V, Grandes P, Lutz B, Monory K, 307:62-73. I.F.: 4.483 Canela EI, Lluís C, McCormick PJ, Guzmán M. Alberch J. Enfermedades Singular Location and Signaling Profile of 9. Cabezas-Llobet N., Camprubí S., García B., neurodegenerativas “Modulación del Adenosine A2A-Cannabinoid CB1 Alberch J., Xifró X. Human alpha déficit de la plasticidad sináptica como Receptor Heteromers in the Dorsal 1-antitrypsin protects neurons and glial estrategia terapéutica en la enfermedad Striatum. cells against oxygen and glucose de Hunttington”. NEUROPSYCHOPHARMACOLOGY. deprivation through inhibition of Sponsored by: Fundació la Marató de TV3. 43(5):964-977. I.F.: 6.544 interleukins expression. BIOCHIMICA ET Duration: 04/03/2015-28/02/2018 BIOPHYSICA ACTA - GENERAL SUBJECTS. 3. López-Benito S, Sánchez-Sánchez J, Brito 1862(9):1852-1861. I.F.: 3.679

241 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

Alberch J. Enfermedades Canals JM. ASCTN-Training: Training on neurodegenerativas: enfermedad de Advanced Stem Cell Technologies in Huntington. Neurology. Sponsored by: Instituto de Salud Carlos III Sponsored by: European commission. H2020 (ISCIII). CIBERNED Duration: 01/10/2018-30/09/2022 Duration : 01/01/2006-31/12/2019 Gines S. Cdk5 como nueva diana Alberch J. Neuronal network dynamics terapéutica y biomarcador del trastorno modulation as therapeutic strategy to depresivo en la enfermedad de recover basal ganglia dysfunction in Huntington. movement disorders. Sponsored by: Ministerio de Economía y Sponsored by: Ministerio de Economía y Competitividad (MINECO). Competitividad (MINECO). Duration: 01/01/2016-31/12/2018. SAF2017-88076-R Duration : 01/01/2018-31/12/2020 Pérez-Navarro E. Alteraciones de la lámina nuclear y de la traducción proteica como Alberch J, Canals JM. European Training nuevos mecanismos patogénicos en la Network for Cell-Based Regenerative enfermedad de Huntington. Medicine (Training4CRM). Sponsored by: Ministerio de Economía y Sponsored by: European commission. H2020 Competitividad (MINECO). SAF2016-0873R Duration : 01/01/2016-31/12/2020 Duration: 31/12/2016-29/12/2019

Canals JM. Ajuts destinats a incentivar els plans d'actuació en transferència tecnològica dels desenvolupadors de DOCTORAL THESIS tecnologia catalans. Centre per a la producció i validació de teràpies Alberch J. Therapautic strategies based on avançades - ub (cat-ub). neuroprotective mechanisms of Sponsored by: Agència per a la Competitivitat neurotrophic factors in Huntington's de l'Empresa (ACCIÓ). TECDTP15-1-0022 Disease models. Duration: 01/01/2016-31/12/2017 PhD student: Alfonso Gerardo García Díaz-Barriga Canals JM. ADVANCECAT: acceleradora pel desenvolupament de teràpies Canals JM. Neuronal differentiation and avançades a Catalunya (ADVANCECAT: maturation of human pluripotent stem accelerating development for advanced cells for modeling Huntington’s disease. therapies in Catalonia). PhD student: Andrea Comella Bolla Sponsored by: Agència per a la Competitivitat de l'Empresa (ACCIÓ). COMRDI15-1-0013 Ginés S. Dual role of Cdk5 on cognitive Duration: 01/01/2016-31/12/2019 deﬁcits and striatal vulnerability in Huntington's disease. Canals JM. Red de Terapia Celular. PhD student: Elena Alvarez Periel Sponsored by: Instituto de Salud Carlos III (ISCIII). RD16/0011/0012 Ginés S. Evaluation of therapeutic targets Duration: 01/01/2017-31/12/2021 for the treatment of behavioral alterations and neuropathology in Huntington's Canals JM. Plan Nacional de biomedicina disease. Desarrollo, diferenciación y maduración PhD student: Núria Suelves Caballol neuronal en la enfermedad de Huntington. Sponsored by: Ministerio de Economía y Pérez E. Dual role of mTOR in Huntington's Competitividad (MINECO). disease: contribution to striatal neuronal SAF2015-66505-R survival and dysfunction. Duration: 01/01/2016-31/12/2019 PhD student: Jordi Creus Muncunill

Canals JM, Alberch J. European Training Network for Cell-based Regenerative Medicine. Sponsored by: European commission. H2020 Duration: 01/11/2016-31/10/2020

242 BIOLOGICAL BASES OF PSYCHIATRIC DISORDERS AND NUCLEAR PSYCHIATRY 4.7

Translational psychiatry 4.7 and psychology

RESEARCHERS Miquel Bioque (HCB-UB) LOCATION Rosa Catalán (HCB-UB) HCB building Luisa Garcia (HCB) Clemente García-Rizo (HCB-UB) Amalia Lafuente (UB) Sergi Mas (UB) Guillem Masana (HCB) KEYWORDS Eduard Parellada (HCB-UB) Schizophrenia 1. Rafael Penadés (HCB-UB) 2. Bipolar disorders TEAM LEADER Mercè Torra (HCB-UB) 3. Psychiatry Eduard Vieta (HCB) Manuel Valdés (HCB) 4. Addiction T. 93 227 54 00 (Ext.: 3130) Antonio Benabarre (HCB) 5. Child and adolescent psychiatry [email protected] José Manuel Goikolea (HCB) and psychology Iria Grande (HCB) 6. Depression Fernando Gutiérrez (HCB) Ana Isabel Martínez-Aran (HCB) Rocío Martín-Santos (HCB) GROUP LEADERS Miquel Bernardo (HCB) Luis Pintor (HCB-UB) T. 93 227 54 00 (Ext.: 3142) Joaquim Radua (IDIBAPS) Original publications [email protected] Carla Torrent (IDIBAPS) from 2016 to 2018 Susana Andrés (HCB) Inmaculada Baeza (HCB) Q1 Q2 Joseﬁna Castro (HCB) YEAR I.F. TOTAL T. 93 227 54 00 (Ext.: 2070) Luisa Lázaro (HCB) Astrid Morer (HCB) 2016 424.43 89 62 14 [email protected]

2017 301.37 84 51 28 Antoni Gual (HCB) POST-DOCTORAL RESEARCHERS 2018 381.07 90 57 20 T. 93 227 54 00 (Ext.: 3167) Bibiana Cabrera (CIBER) [email protected] Myriam Cavero (HCB) Gisela Mezquida (UB-FCRB) Gisela Sugranyes (HCB-IDIBAPS) Natalia Rodríguez (FCRB) TEAM INVOLVED IN Caterina del Mar Bonnín (FCRB) CIBERSAM T. 93 227 54 00 (Ext.: 4187) [email protected] Silvia Cañizares (HCB) Red de Trastornos Adictivos Miquel Àngel Fullana (HCB) (RTA-RETICS) Eduard Vieta (HCB) Ester Jiménez (IDIBAPS) AGAUR_SGR17: 01355, 00881, T. 93 227 54 00 (Ext.: 3130) Andrea Murru (HCB) 01460, 01562, 01798, 01365 [email protected] Isabella Pacchiarotti (HCB) María Reinares (CIBER)

AWARDS Premi Extraordinari de Doctorat en Medicina Institution: Universitat de Barcelona Awardee/s: Diego Hidalgo Mazzei Premi Extraordinari de Doctorat en Medicina Institution: : Universitat de Barcelona Awardee/s: Gisela Mezquida TEAM Eduard Vieta

243 244

GROUP Miquel Bernardo AREA 4 Mireia Graell(HCB) Elsa Caballeria(FCRB) Pol Bruguera(HCB) Chrysanthi Blithikioti(IDIBAPS) Eugènia Campeny(IDIBAPS) Mireia Masias(IDIBAPS) Adriana Fortea(HCB) Maria TeresaPlana(HCB-FCRB) Ana Pérez(FCRB) Iria Méndez(HCB) Daniel Ilzarbe(IDIBAPS) Blanca García(HCB) Patricia Camprodon(FCRB) Èlia Valls(CIBER) Eva Solé(HCB) José Sánchez-Moreno(CIBER) Estela Salagre(CIBER) Giovanni Oriolo(HCB) Laura Motejo(CIBER) Marina Garriga(IDIBAPS) Daniel Boloc(IDIBAPS) Silvia Amoretti(CIBER) PRE-DOCTORAL RESEARCHERS Miquel Monràs(HCB) Laia Miquel(HCB) Hugo López-Pelayo(IDIBAPS) Pablo Barrio(HCB) Mercè Balcells-Oliveró(HCB) Mireia Rosa(IDIBAPS) Soledad Romero(HCB) Olga Puig(HCB) Ana EncarnaciónOrtiz(HCB) Itziar Flamarique(HCB) Elena de(CIBER) Ana Blázquez(HCB) Marc Valentí(HCB) Imma Torres(CIBER) Anna Torres(HCB) Brissa Solé(IDIBAPS)

CLINICAL ANDEXPERIMENTAL NEUROSCIENCE of thedisease(genetics,neuromodulators, mechanisms involvedinthedevelopment neurobiological, anatomofunctional disorders fromthedifferentsperspectives: Our groupstudyseverepsychiatric STRATEGIC OBJECTIVES Soraya Sabater(HCB) Lluisa Ortega(HCB) Silvia Mondon(HCB) Cristal Martínez(HCB) Ana IsabelLópez(HCB) Cristina López(HCB) Anna Lligoña(HCB) Neus Freixa(HCB) Victor Navarro(HCB) María LuisaImaz(HCB) Joana Guarch(HCB) Patricia Gassó(UB) Emilio Fernández-Egea(CIBER) COLLABORATORS Lídia Teixidó(HCB) Ana Meseguer(CIBER) NURSING STAFF Nina Potapova(FCRB) Silvia Matrai(FCRB) Álvaro Castañón(FCRB) Fleur MarieBooth(FCRB) Francina Badia(FCRB) Rosa MariaPalaus(FCRB) Maria AliciaDurán(FCRB) TECHNICIANS Clara Oliveras(HCB) Laura Nuño(HCB) SCHIZOPHRENIA RESEARCH GROUP psychiatric instruments),perinatalandgender related disorders. adjustmentandvalidationofnew theirrelationshiptoenvironmental personalitydisorders(diagnosticsystems, Othermainresearchlinesfocuseson - aspectsinthemainneurologicaldiseases. focusesonpsychiatricandpsychological usedisorders.Theliaisonpsychiatry biomarkersofbrainimpairmentincannabis noveltherapeuticapproachesand usedisorders,aswellondeveloping detectionandbriefinteventionsinalcohol Theaddictiongroupfocusesonearly - thecourseofillness. associatedwithtreatmentresponseand neurobiologicalbasesandclinicalindicators Thedepressiongroupstudiesthe - childrenandadolescents. thedevelopmentofpsychoticdisordersin studyoftheneuralmechanismsunderlying neurodevelopmentaldisorders,andthe obsessive-compulsivedisorder, disorders,eating psychologyfocuseson:psychotic Thechildandadolescentpsychiatry - schizophrenia. episodes,resistantandcomorbid unitfocusesonﬁrstandsecondpsychotic TheSchizophreniaandrelateddisorders - detectionandpreventionofrecurrences. efficacyoftreatmentsfortheearly theneurobiologicalmechanismsand Thebipolardisordersgroupinvestigates - MAIN LINESOFRESEARCH therapeutical approaches. neuroimaging), aswellpsychologicaland hormone factors,molecularpsychiatryand episodes, childhood andadolescent-onset, The researchiscentered onthestudyofﬁrst care, researchand teaching. schizophrenia andrelateddisorders inclinical This interdisciplinarygroupfocuses on Miquel Bernardo GROUP LEADER (HCB) BIOLOGICAL BASES OF PSYCHIATRIC DISORDERS AND NUCLEAR PSYCHIATRY 4.7

resistant and comorbid schizophrenia. We have active collaboration (multicenter studies in translational and innovative investigation) with other IDIBAPS, CIBERSAM, and international research groups. We collaborate with a European network of research in schizophrenia and maintain close relationship to American research networks.

RESEARCH GROUP CHILD AND ADOLESCENT PSYCHIATRY AND PSYCHOLOGY GROUP Joseﬁna Castro-Fornieles GROUP LEADER Joseﬁna Castro-Fornieles (HCB) The group has established important This research group is integrated in the collaborations with other neuroscience Department of Child and Adolescent departments in the same center as well as Psychiatry of the Neuroscience Institute of the with other centers within the CIBERSAM. Hospital Clinic of Barcelona. At the international level the group The aim is to facilitate clinical research and to collaborates with the European College of collaborate with groups specialized in Neuopsychopharmacology, the University of genetics, neuroimaging and neurobiology. Pittsburgh (United States), and the Child and Adolescent Psychiatry Center of Yale.

RESEARCH GROUP ADDICTIONS GROUP

GROUP LEADER Antoni Gual (HCB)

Our group focuses mainly on alcohol use and cannabis use disorders (AUD and CUD respectively). More speciﬁcally, we work on early detection and brief interventions in AUD, as well as on novel therapeutic methods for treating cognitive impairments commonly found in alcoholic patients. In CUD, we aim to deﬁne the concept of “risky use” that might lead to physical, mental and social health problems, together with identifying

GROUP Antoni Gual biomarkers of chronic cannabis misuse for treatment monitorization and rehabilitation of cannabis dependent individuals.

245 246 detection andpreventionofrecurrences. psychological interventionsforthe early treatments andnoveltherapies, consequences, theefficacyofdrug course andneuropsychological neuroimaging) anditsrelapses,theclinical neuromodulators, hormonefactorsand the developmentofdisease(genetics, anatomofunctional mechanismsinvolvedin investigates theneurobiologicaland The bipolardisordersprogrammainly Eduard Vieta GROUP LEADER BIPOLAR DISORDERS RESEARCH GROUP functional outcomes. factors predictingtransitiontopsychosisand level, priorityisgiventotheidentiﬁcationof and cognitivephenotypes.Onatranslational between neuroimagingmeasuresandclinical ﬁndings, andtoexploretherelationship neurochemical underpinningsofthese We havenowsetouttoexplorethe to highercognitivefunctions. early stagesofpsychosisinbrainareasrelated structure inchildrenandadolescentsthe group-related changesinfunctionand brain functioninhealthyparticipants,and We havedescribedage-relatedchangesin development ofpsychoticdisordersinyouth. neural mechanismsunderlyingthe Dr. Sugranyes’groupaimstounderstandthe Gisela Sugranyes GROUP LEADER RISK ANDEARLYPSYCHOSIS MULTIMODAL NEUROIMAGINGINHIGH 50/50 PROGRAM AREA 4

CLINICAL ANDEXPERIMENTAL NEUROSCIENCE (HCB) (HCB-IDIBAPS)

GROUP Gisela Sugranyes Eva; Serlachius, Lazaro,Luisa;Ruck, Jangmo, Andreas; Feldman,Inna;Hesselmark, Lorena; Brander,Gustaf; Isomura,Kayoko; 3. 75(4):347-355. I.F.:16.642 With BipolarDisorder. Finnish NationwideCohortofPatients Prevention ofRehospitalizationin a Pharmacologic Treatmentsforthe Real-World Effectivenessof Hoti F,VattulainenP,VietaE,TiihonenJ. 2. PSYCHIATRY. Genome-Wide AssociationStudy. Lithium inBipolarAffectiveDisorder:A Inﬂammation GenesWithResponseto for SchizophreniaandHLAAntigen Frye MA. JR; EtainB;FalkaiP;ForstnerAJ;FrisénL; Dalkner N;DayerA;DelZompoM;DePaulo Chillotti C;CichonS;CruceanuCzerskiPM; Brichant-Petitjean C;CervantesP;ChenHC; Bengesser S;BiernackaJM;BirnerA; Bhattacharjee AK;BellivierF;BenabarreA; Ardau R;AriasB;AubryJM;BacklundL; Shekhtman T;AdliM;AkulaN;AkiyamaK; Degenhardt F;Tekola-AyeleHsuYH; KO; HouL;ClarkSR;PapiolS;HeilbronnerU; Genetics (ConLi+Gen);AmareAT;Schubert 1. Originals / PUBLICATIONS International ConsortiumonLithium Lähteenvuo M,TanskanenA,TaipaleH, Perez-Vigil, Ana;FernandezdelaCruz, Association ofPolygenicScore I.F.:381.07 75(1):65-74. I.F.:16.642 JAMA PSYCHIATRY.

JAMA KIK, CiulloV,Dallaspezia S,DenysD,Feusner A, BremS,Calvo CalvoR,ChengY,Cho MC, BenedettiF,Beucke JC,BollettiniI,Bose Ameis SH,AnticevicA,ArnoldPD,Batistuzzo 5. PSYCHIATRY. in themultinationalEU-GEIstudy. Treated incidenceofpsychoticdisorders Hubbard K.,BeardsS.,StiloTripoliG. Kirkbride J.,ReininghausU.,DiFortiM., Rutten B.,JonesP.,VanOsJ.,MorganC., Arrojo M.,Del-BenC.,MenezesP.,MurrayR., Bobes J.,BernardoM.,SanjuánSantos Berardi D.,TortelliA.,LlorcaP.,DeHaanL., Selten J.,TurnerC.,ArangoTarriconeI., Lasalvia A.,QuattroneD.,MulèSzöke L., LópezG.,JongsmaH.,Gayer-AndersonC., Solano J.,CarracedoA.,BernardoE.,Roldán S., StiloTripoliG.,ParelladaM.,CuadradoP., Reininghaus U.,DiFortiM.,HubbardK.,Beards Jones P.,VanOsJ.,MorganC.,Kirkbride Del-Ben C.,MenezesP.,MurrayR.,RuttenB., Bernardo M.,SanjuánJ.,SantosArrojo Tortelli A.,LlorcaP.,DeHaanL.,BobesJ., Turner C.,ArangoTarriconeI.,BerardiD., A., QuattroneD.,MulèSzökeSeltenJ., 4. JAMA PSYCHIATRY. Register-Based SiblingControlStudy. Educational AttainmentANationwide Disorder WithObjectiveIndicatorsof Association ofObsessive-Compulsive M.; Larsson,Henrik;Mataix-Cols,David. Christian; Kuja-Halkola,Ralf;D'Onofrio,Brian Boedhoe PSW,SchmaalL,AbeY,Alonso P, Jongsma H.,Gayer-AndersonC.,Lasalvia 75(1):36-46. I.F.:16.642 75(1):47-55. I.F.:16.642

JAMA

BIOLOGICAL BASES OF PSYCHIATRIC DISORDERS AND NUCLEAR PSYCHIATRY 4.7

JD, Fitzgerald KD, Fouche JP, Fridgeirsson Disorder Working Group. MOLECULAR Manuel J.;PEPs Group. Is cognitive EA, Gruner P, Hanna GL, Hibar DP, Hoexter PSYCHIATRY. 23(4):932-942. I.F.: 11.640 impairment associated with antipsychotic MQ, Hu H, Huyser C, Jahanshad N, James A, dose and anticholinergic equivalent loads Kathmann N, Kaufmann C, Koch K, Kwon JS, 7. Oriolo G, Egmond E, Mariño Z, Cavero M, in first-episode psychosis? Lazaro L, Lochner C, Marsh R, Navines R, Zamarrenho L, Solà R, Pujol J, PSYCHOLOGICAL MEDICINE. Martínez-Zalacaín I, Mataix-Cols D, Menchón Bargallo N, Forns X, Martin-Santos R . 48(13):2247-2256. I.F.: 5.475 JM, Minuzzi L, Morer A, Nakamae T, Nakao T, Systematic review with meta-analysis: Narayanaswamy JC, Nishida S, Nurmi E, neuroimaging in hepatitis C chronic 14. Fernandez-Egea E., Worbe Y., Bernardo O'Neill J, Piacentini J, Piras F, Reddy YCJ, infection. ALIMENTARY PHARMACOLOGY M., Robbins T. Distinct risk factors for Reess TJ, Sakai Y, Sato JR, Simpson HB, AND THERAPEUTICS. 47(9):1238-1252. obsessive and compulsive symptoms in Soreni N, Soriano-Mas C, Spalletta G, Stevens I.F.: 7.357 chronic schizophrenia. PSYCHOLOGICAL MC, Szeszko PR, Tolin DF, van Wingen GA, MEDICINE. 48(16):1-8. I.F.: 5.475 Venkatasubramanian G, Walitza S, Wang Z, 8. Núñez C, Stephan-Otto C, Usall J, Bioque M, Yun JY,, Thompson PM, Stein DJ, van den Lobo A, González-Pinto A, Pina-Camacho L, 15. Parker, Gordon; Tavella, Gabriela; Heuvel OA ENIGMA-OCD Working Group, Vieta E, Castro-Fornieles J, Rodriguez- Macqueen, Glenda; Berk, Michael; Grunze, ENIGMA OCD Working Group. Cortical Jimenez R, Butjosa A, Janssen J, Cabrera B, Heinz; Deckersbach, Thilo; Dunner, David L.; Abnormalities Associated With Pediatric Parellada M, Bernardo M, PEPs group . Sajatovic, Martha; Amsterdam, Jay D.; Ketter, and Adult Obsessive-Compulsive Neutrophil Count Is Associated With Terence A.; Yatham, Lakshmi N.; Kessing, Lars Disorder: Findings From the ENIGMA Reduced Gray Matter and Enlarged Vedel; Bassett, Darryl; Zimmerman, Mark; Obsessive-Compulsive Disorder Working Ventricles in First-Episode Psychosis. Fountoulakis, Kostas N.; Duffy, Anne; Alda, Group. AMERICAN JOURNAL OF SCHIZOPHRENIA BULLETIN. 45(4):846-858. Martin; Calkin, Cynthia; Sharma, Verinder; PSYCHIATRY. 175(5):453-462. I.F.: 13.396 I.F.: 6.944 Anand, Amit; Singh, Manpreet K.; Hajek, Tomas; Boyce, Philip; Frey, Benicio N.; Castle, 6. Hibar DP, Westlye LT, Doan NT, Jahanshad 9. Ramos-Perdigués S., Baillés E., Mané A., David J.; Young, Allan H.; Vieta, Eduard; N, Cheung JW, Ching CRK, Versace A, Carreño M., Donaire A., Rumià J., Bargalló N., Rybakowski, Janusz K.; Swartz, Holly A.; Bilderbeck AC, Uhlmann A, Mwangi B, Krämer Boget T., Setoain X., Valdés M., Pintor L. Schaffer, Ayal; Murray, Greg; Bayes, Adam; B, Overs B, Hartberg CB, Abé C, Dima D, Psychiatric Symptoms in Refractory Lam, Raymond W.; Bora, Emre; Post, Robert Grotegerd D, Sprooten E, Bøen E, Jimenez E, Epilepsy During the First Year After M.; Ostacher, Michael J.; Lafer, Beny; Cleare, Howells FM, Delvecchio G, Temmingh H, Surgery. NEUROTHERAPEUTICS. Anthony J.; Burdick, Katherine E.; O'Donovan, Starke J, Almeida JRC, Goikolea JM, Houenou 15(4):1082-1092. I.F.: 5.719 Claire; Ortiz, Abigail; Henry, Chantal; Kanba, J, Beard LM, Rauer L, Abramovic L, Bonnin M, Shigenobu; Rosenblat, Joshua D.; Parikh, Ponteduro MF, Keil M, Rive MM, Yao N, Yalin 10. Chye Y, Lorenzetti V, Suo C, Batalla A, Sagar V.; Bond, David J.; Grunebaum, Michael N, Najt P, Rosa PG, Redlich R, Trost S, Cousijn J, Goudriaan AE, Jenkinson M, F.; Frangou, Sophia; Goldberg, Joseph F.; Hagenaars S, Fears SC, Alonso-Lana S, van Martin-Santos R, Whittle S, Yücel M, Solowij N. Orum, Margo; Osser, David N.; Frye, Mark A.; Erp TGM, Nickson T, Chaim-Avancini TM, Alteration to hippocampal volume and McIntyre, Roger S.; Fagiolini, Andrea; Meier TB, Elvsåshagen T, Haukvik UK, Lee shape confined to cannabis dependence: Manicavasagar, Vijaya; Carlson, Gabrielle A.; WH, Schene AH, Lloyd AJ, Young AH, Nugent a multi-site study. ADDICTION BIOLOGY. Malhi, Gin S. Revising Diagnostic and A, Dale AM, Pfennig A, McIntosh AM, Lafer B, 12652. I.F.: 5.578 Statistical Manual of Mental Disorders, Baune BT, Ekman CJ, Zarate CA, Bearden CE, Fifth Edition, criteria for the bipolar Henry C, Simhandl C, McDonald C, Bourne C, 11. Castellanos A, Andres A, Bernal L, Callejo disorders: Phase I of the AREDOC project. Stein DJ, Wolf DH, Cannon DM, Glahn DC, G, Comes N, Gual A, Giblin JP, Roza C, Gasull AUSTRALIAN AND NEW ZEALAND Veltman DJ, Pomarol-Clotet E, Vieta E, X . Pyrethroids inhibit K2P channels and JOURNAL OF PSYCHIATRY. 52(12):1173-1182. Canales-Rodriguez EJ, Nery FG, Duran FLS, activate sensory neurons: basis of I.F.: 5.084 Busatto GF, Roberts G, Pearlson GD, insecticide-induced paraesthesias. PAIN. Goodwin GM, Kugel H, Whalley HC, Ruhe HG, 159(1):92-105. I.F.: 5.559 16. Amoretti S, Cabrera B, Torrent C, Soares JC, Fullerton JM, Rybakowski JK, Mezquida G, Lobo A, González-Pinto A, Savitz J, Chaim KT, Fatjó-Vilas M, 12. Boloc D, Rodríguez N, Gassó P, Abril JF, Parellada M, Corripio I, Vieta E, de la Serna E, Soeiro-de-Souza MG, Boks MP, Zanetti MV, Bernardo M, Lafuente A, Mas S. SiNoPsis: Butjosa A, Contreras F, Sarró S, Penadés R, Otaduy MCG, Schaufelberger MS, Alda M, Single Nucleotide Polymorphisms Sánchez-Torres AM, Cuesta M, Bernardo M, Ingvar M, Phillips ML, Kempton MJ, Bauer M, selection and promoter profiling. PEPsGroup. Cognitive reserve as an Landén M, Lawrence NS, van Haren NEM, BIOINFORMATICS. 34(2):303-305. I.F.: 5.481 outcome predictor: first-episode affective Horn NR, Freimer NB, Gruber O, Schofield PR, versus non-affective psychosis. ACTA Mitchell PB, Kahn RS, Lenroot R, 13. Ballesteros, Alejandro; Sanchez-Torres, PSYCHIATRICA SCANDINAVICA. Machado-Vieira R, Ophoff RA, Sarró S, Ana M.; Lopez-Ilundain, Jose M.; Cabrera, 138(5):441-455. I.F.: 4.984 Frangou S, Satterthwaite TD, Hajek T, Bibiana; Lobo, Antonio; Gonzalez-Pinto, Ana Dannlowski U, Malt UF, Arolt V, Gattaz WF, M.; Diaz-Caneja, Covadonga; Corripio, 17. Belbasis L., Köhler C., Stefanis N., Stubbs Drevets WC, Caseras X, Agartz I, Thompson Iluminada; Vieta, Eduard; de la Serna, Elena; B., van Os J., Vieta E., Seeman M., Arango C., PM, Andreassen OA . Cortical abnormalities Bobes, Julio; Usall, Judith; Contreras, Carvalho A., Evangelou E. Risk factors and in bipolar disorder: an MRI analysis of 6503 Fernando; Lorente-Omenaca, Ruth; peripheral biomarkers for schizophrenia individuals from the ENIGMA Bipolar Mezquida, Gisela; Bernardo, Miguel; Cuesta, spectrum disorders: An umbrella review of

247 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

meta-analyses. ACTA PSYCHIATRICA BIPOLAR DISORDERS. 20(3):184-194. Prevalence, psychopathological SCANDINAVICA. 137(2):88-97. I.F.: 4.984 I.F.: 4.490 correlates and associations with quality of life in a large sample. JOURNAL OF 18. Solé B, Bonnin CM, Jiménez E, Torrent C, 23. Hegerl U., Mergl R., Sander C., Dietzel J., PSYCHIATRIC RESEARCH. 96:145-152. Torres I, Varo C, Valls E, Montejo L, Bitter I., Demyttenaere K., Gusmão R., Arrillaga I.F.: 4.000 Gómez-Ocaña C, Tomioka Y, Vieta E, A., Zorrilla I., Alocén A., Sola V., Vieta E., Juckel Martinez-Aran A, Reinares M. Heterogeneity G., Zimmermann U., Bauer M., Sienaert P., 29. Barcones MF, MacDowell KS, of functional outcomes in patients with Quintão S., Edel M., Bolyos C., Ayuso-Mateos García-Bueno B, Bioque M, Gutiérrez-Galve L, bipolar disorder: a cluster-analytic J., López-García P., Kluge M. A multi-centre, González-Pinto A, Parellada MJ, Bobes J, approach. ACTA PSYCHIATRICA randomised, double-blind, Bernardo M, Lobo A, Leza JC. SCANDINAVICA. 137(6):516-527. I.F.: 4.984 placebo-controlled clinical trial of Cardiovascular risk in early psychosis. methylphenidate in the initial treatment of Relationship with inflammation and clinical 19. Sanchez-Moreno J, Bonnin CM, acute mania (MEMAP study). EUROPEAN features 6 months after diagnosis. González-Pinto A, Amann BL, Solé B, NEUROPSYCHOPHARMACOLOGY. INTERNATIONAL JOURNAL OF Balanzá-Martinez V, Arango C, Jiménez E, 28(1):185-194. I.F.: 4.129 NEUROPSYCHOPHARMACOLOGY. Tabarés-Seisdedos R, Garcia-Portilla MP, 21(5):410-422. I.F.: 3.981 Ibáñez A, Crespo JM, Ayuso-Mateos JL, 24. San L, Estrada G, Oudovenko N, Martinez-Aran A, Torrent C, Vieta E, Montañés F, Dobrovolskaya N, 30. Bioque M, García-Portilla MAP, CIBERSAM Functional Remediation Group. Bukhanovskaya O, Popov M, Vieta E . García-Rizo C, Cabrera B, Lobo A, Factors associated with poor functional PLACID study: A randomized trial González-Pinto A, Díaz-Caneja CM, Corripio I, outcome in bipolar disorder: comparing the efficacy and safety of Vieta E, Castro-Fornieles J, Bobes J, sociodemographic, clinical, and inhaled loxapine versus intramuscular Gutiérrez-Fraile M, Rodriguez-Jimenez R, neurocognitive variables. ACTA aripiprazole in acutely agitated patients Mezquida G, Llerena A, Saiz-Ruiz J, Bernardo PSYCHIATRICA SCANDINAVICA. with schizophrenia or bipolar disorder. M, PEPs GROUP. Evolution of metabolic 138(2):145-154. I.F.: 4.984 EUROPEAN risk factors over a two-year period in a NEUROPSYCHOPHARMACOLOGY. cohort of first episodes of psychosis. 20. Gasso, Patricia; Mas, Sergi; Bioque, 28(6):710-718. I.F.: 4.129 SCHIZOPHRENIA RESEARCH. 193:188-196. Miquel; Cabrera, Bibiana; Lobo, Antonio; I.F.: 3.958 Gonzalez-Pinto, Ana; Diaz-Caneja, 25. Jimenez, E.; Sole, B.; Arias, B.; Mitjans, M.; Covadonga M.; Corripio, Iluminada; Vieta, Varo, C.; Reinares, M.; Bonnin, C. M.; Salagre, 31. Sánchez-Gutiérrez T, García-Portilla MP, Eduard; Castro-Fornieles, Josefina; Sarro, E.; Ruiz, V.; Torres, I.; Tomioka, Y.; Saiz, P. A.; Parellada M, Bobes J, Calvo A, Moreno-Izco L, Salvador; Mane, Anna; Sanjuan, Julio; Llerena, Garcia-Portilla, M. P.; Buron, P.; Bobes, J.; González-Pinto A, Lobo A, de la Serna E, Adrian; Lafuente, Amalia; Saiz-Ruiz, Jeronimo; Martinez-Aran, A.; Torrent, C.; Vieta, E.; Cabrera B, Torrent C, Roldán L, Sanjuan J, Bernardo, Miguel; PEPs Group. Impact of Benabarre, A. Characterizing Ibáñez Á, Sánchez-Torres AM, Corripio I, NTRK2, DRD2 and ACE polymorphisms on decision-making and reward processing in Bernardo M, Cuesta MJ, PEPs group. prolactin levels in antipsychotic-treated bipolar disorder: A cluster analysis. Smoking does not impact social and patients with first-episode psychosis. EUROPEAN non-social cognition in patients with first JOURNAL OF PSYCHOPHARMACOLOGY. NEUROPSYCHOPHARMACOLOGY. episode psychosis. SCHIZOPHRENIA 32(6):702-710. I.F.: 4.738 28(7):863-874. I.F.: 4.129 RESEARCH. 199:64-74. I.F.: 3.958

21. Boloc D, Gortat A, Cheng-Zhang JQ, 26. Beraldi G., Prado K., Amann B., Radua J., 32. Noguera A., Castro-Fornieles J., Romero García-Cerro S, Rodríguez N, Parellada M, Friedman L., Elkis H. Meta-analyses of S., de la Serna E., Sugranyes G., Saiz-Ruiz J, Cuesta MJ, Gassó P, Lafuente A, cavum septum pellucidum in mood Sánchez-Gistau V., Moreno D., Díaz-Caneja C., Bernardo M, Mas S. Improving disorders in comparison with healthy Merchán-Naranjo J., Llorente C., Baeza I. pharmacogenetic prediction of controls or schizophrenia. EUROPEAN Attenuated psychotic symptoms in extrapyramidal symptoms induced by NEUROPSYCHOPHARMACOLOGY. children and adolescent offspring of antipsychotics. TRANSLATIONAL 28(12):1325-1338. I.F.: 4.129 patients with schizophrenia. PSYCHIATRY. 8(1):276. I.F.: 4.691 SCHIZOPHRENIA RESEARCH. 193:354-358. 27. González-Pinto A, López-Peña P, I.F.: 3.958 22. Miskowiak KW, Burdick KE, Bermúdez-Ampudia C, Vieta E, Martinez-Aran A, Bonnin CM, Bowie CR, Martinez-Cengotitabengoa M. Can lithium 33. Mezquida G., Savulich G., Garcia-Rizo C., Carvalho AF, Gallagher P, Lafer B, salts prevent depressive episodes in the Garcia-Portilla M., Toll A., Garcia-Alvarez L., López-Jaramillo C, Sumiyoshi T, McIntyre RS, real world? EUROPEAN Bobes J., Mané A., Bernardo M., Schaffer A, Porter RJ, Purdon S, Torres IJ, NEUROPSYCHOPHARMACOLOGY. Fernandez-Egea E. Inverse association Yatham LN, Young AH, Kessing LV, Vieta E. 28(12):1351-1359. I.F.: 4.129 between negative symptoms and body Assessing and addressing cognitive mass index in chronic schizophrenia. impairment in bipolar disorder: the 28. Nunes-Neto PR, Köhler CA, Schuch FB, SCHIZOPHRENIA RESEARCH. 192:69-74. I.F.: International Society for Bipolar Disorders Solmi M, Quevedo J, Maes M, Murru A, Vieta E, 3.958 Targeting Cognition Task Force McIntyre RS, McElroy SL, Gearhardt AN, recommendations for clinicians. Stubbs B, Carvalho AF . Food addiction: 34. Penadés R., López-Vílchez I., Catalán R.,

248 BIOLOGICAL BASES OF PSYCHIATRIC DISORDERS AND NUCLEAR PSYCHIATRY 4.7

Arias B., González-Rodríguez A., García-Rizo related to bipolarity and mixed features? 47. Hidalgo-Mazzei D, Reinares M, Mateu A, C., Masana G., Ruíz V., Mezquida G., Bernardo Results from the BRIDGE-II-Mix study. Nikolova VL, Bonnín CDM, Samalin L, M. BDNF as a marker of response to JOURNAL OF AFFECTIVE DISORDERS. García-Estela A, Pérez-Solá V, Young AH, cognitive remediation in patients with 229:164-170. I.F.: 3.786 Strejilevich S, Vieta E, Colom F . schizophrenia: A randomized and OpenSIMPLe: A real-world controlled trial. SCHIZOPHRENIA 41. Jiménez-López E., Sánchez-Morla E., implementation feasibility study of a RESEARCH. 197:458-464. I.F.: 3.958 Aparicio A., López-Villarreal A., smartphone-based psychoeducation Martínez-Vizcaíno V., Rodriguez-Jimenez R., programme for bipolar disorder. JOURNAL 35. Cano-López I, Calvo A, Boget T, Carreño Vieta E., Santos J. Psychosocial functioning OF AFFECTIVE DISORDERS. 241:436-445. M, Donaire A, Setoain X, Pintor L, Rumià J, in patients with psychotic and I.F.: 3.786 González-Bono E, Junqué C, Bargalló N. non-psychotic bipolar I disorder. A Typical asymmetry in the hemispheric comparative study with individuals with 48. Sánchez-Torres AM, Moreno-Izco L, activation during an fMRI verbal schizophrenia. JOURNAL OF AFFECTIVE Lorente-Omeñaca R, Cabrera B, Lobo A, comprehension paradigm is related to DISORDERS. 229:177-185. I.F.: 3.786 González-Pinto AM, Merchán-Naranjo J, better performance in verbal and Corripio I, Vieta E, de la Serna E, Butjosa A, non-verbal tasks in patients with epilepsy. 42. Torres I, Garriga M, Sole B, Bonnín CM, Contreras F, Sarró S, Mezquida G, Ribeiro M, NEUROIMAGE: CLINICAL. 20:742-752. I.F.: Corrales M, Jiménez E, Sole E, Bernardo M, Cuesta MJ, PEPs group. 3.869 Ramos-Quiroga JA, Vieta E, Goikolea JM, Individual trajectories of cognitive Martínez-Aran A. Functional impairment in performance in first episode psychosis: a 36. Tomioka Y., Jiménez E., Salagre E., Arias adult bipolar disorder with ADHD. 2-year follow-up study. EUROPEAN B., Mitjans M., Ruiz V., Sáiz P., García-Portilla M., JOURNAL OF AFFECTIVE DISORDERS. ARCHIVES OF PSYCHIATRY AND CLINICAL de la Fuente L., Gomes-da-Costa S., Bobes J., 227:117-125. I.F.: 3.786 NEUROSCIENCE. 268(7):1-13. I.F.: 3.617 Vieta E., Benabarre A., Grande I. Association between genetic variation in the 43. Vieta E., Sluth L., Olsen C. The effects of 49. Murru A, Pacchiarotti I, Verdolini N, myo-inositol monophosphatase 2 (IMPA2) vortioxetine on cognitive dysfunction in Reinares M, Torrent C, Geoffroy PA, Bellivier F, gene and age at onset of bipolar disorder. patients with inadequate response to Llorca PM, Vieta E, Samalin L. Modifiable and JOURNAL OF AFFECTIVE DISORDERS. current antidepressants in major non-modifiable factors associated with 232:229-236. I.F.: 3.786 depressive disorder: A short-term, functional impairment during the randomized, double-blind, exploratory inter-episodic periods of bipolar disorder. 37. Torrent C, Reinares M, Martinez-Arán A, study versus escitalopram. JOURNAL OF EUROPEAN ARCHIVES OF PSYCHIATRY Cabrera B, Amoretti S, Corripio I, Contreras F, AFFECTIVE DISORDERS. 227:803-809. AND CLINICAL NEUROSCIENCE. Sarró S, González-Pinto A, Lobo A, Cuesta I.F.: 3.786 268(8):749-755. I.F.: 3.617 MJ, Sánchez-Torres A, Bergé D, Castro-Fornieles J, Moreno C, Bernardo M, 44. Bonnín C., Yatham L., Michalak E., 50. Abdulkadir M, Londono D, Gordon D, Vieta E, PEPS group. Affective versus Martínez-Arán A., Dhanoa T., Torres I., Fernandez TV, Brown LW, Cheon KA, Coffey first-episode non-affective first-episode Santos-Pascual C., Valls E., Carvalho A., BJ, Elzerman L, Fremer C, Fründt O, psychoses: A longitudinal study. JOURNAL Sánchez-Moreno J., Valentí M., Grande I., Garcia-Delgar B, Gilbert DL, Grice DE, OF AFFECTIVE DISORDERS. 238:297-304. Hidalgo-Mazzei D., Vieta E., Reinares M. Hedderly T, Heyman I, Hong HJ, Huyser C, I.F.: 3.786 Psychometric properties of the well-being Ibanez-Gomez L, Jakubovski E, Kim YK, Kim index (WHO-5) spanish version in a sample YS, Koh YJ, Kook S, Kuperman S, Leventhal B, 38. Vidal-Rubio S., Balanzá-Martínez V., of euthymic patients with bipolar disorder. Ludolph AG, Madruga-Garrido M, Maras A, Cuenca M., Vila-Francés J., Vieta E., Romeu J. JOURNAL OF AFFECTIVE DISORDERS. Mir P, Morer A, Müller-Vahl K, Münchau A, Duration of euthymia and predominant 228:153-159. I.F.: 3.786 Murphy TL, Plessen KJ, Roessner V, Shin EY, polarity in bipolar disorder. JOURNAL OF Song DH, Song J, Tübing J, van den Ban E, AFFECTIVE DISORDERS. 241:356-359. 45. Zhang Y, Long X, Ma X, He Q, Luo X, Bian Visscher F, Wanderer S, Woods M, Zinner SH, I.F.: 3.786 Y, Xi Y, Sun X, Ng CH, Vieta E, Xiang YT . King RA, Tischfield JA, Heiman GA, Hoekstra Psychometric properties of the Chinese PJ, Dietrich A. Investigation of previously 39. Aedo A., Murru A., Sanchez R., Grande I., version of the Functioning Assessment implicated genetic variants in chronic tic Vieta E., Undurraga J. Clinical Short Test (FAST) in bipolar disorder. disorders: a transmission disequilibrium characterization of rapid cycling bipolar JOURNAL OF AFFECTIVE DISORDERS. test approach. EUROPEAN ARCHIVES OF disorder: Association with attention deficit 238:156-160. I.F.: 3.786 PSYCHIATRY AND CLINICAL hyperactivity disorder. JOURNAL OF NEUROSCIENCE. 268(3):301-316. I.F.: 3.617 AFFECTIVE DISORDERS. 240:187-192. 46. Bonnín CM, Martínez-Arán A, Reinares M, I.F.: 3.786 Valentí M, Solé B, Jiménez E, Montejo L, Vieta 51. Castro-Fornieles J, Bargalló N, Calvo A, E, Rosa AR . Thresholds for severity, Arango C, Baeza I, Gonzalez-Pinto A, 40. Mazzarini L, Kotzalidis GD, Piacentino D, remission and recovery using the Parellada M, Graell M, Moreno C, Otero S, Rizzato S, Angst J, Azorin JM, Bowden CL, functioning assessment short test (FAST) Janssen J, Rapado-Castro M, de la Serna E. Mosolov S, Young AH, Vieta E, Girardi P, in bipolar disorder. JOURNAL OF Gray matter changes and cognitive Perugi G, BRIDGE-II-Mix Study Group. Is AFFECTIVE DISORDERS. 240:57-62. predictors of 2-year follow-up recurrence in major depressive disorder I.F.: 3.786 abnormalities in early-onset first-episode

249 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

psychosis. EUROPEAN CHILD AND JOURNAL OF CHILD AND ADOLESCENT Mitchell, Philip B.; Vieta, Eduard; Frye, Mark A.; ADOLESCENT PSYCHIATRY. 27(1):113-126. PSYCHOPHARMACOLOGY. 28(4):252-257. Rybakowski, Janusz K.; Kuo, Po-Hsiu; Kato, I.F.: 3.553 I.F.: 2.901 Tadafumi; Grigoroiu-Serbanescu, Maria; Reif, Andreas; Del Zompo, Maria; Bellivier, Frank; 52. Díaz-Caneja CM, Morón-Nozaleda MG, 58. Baeza I, de la Serna E, Calvo-Escalona R, Schalling, Martin; Wray, Naomi R.; Kelsoe, John Vicente-Moreno RP, Rodríguez-Toscano E, Merchán-Naranjo J, Rodríguez-Latorre P, R.; Alda, Martin; McMahon, Francis J.; Schulze, Pina-Camacho L, de la Serna E, Sugranyes G, Martínez-Cantarero MC, Andrés P, Alda JA, Thomas G.; Rietschel, Marcella; Nothen, Baeza I, Romero S, Sánchez-Gistau V, Muñoz-Samons D, Ilzarbe D, Arango C, Markus M.; Cichon, Sven. Analysis of the Castro-Fornieles J, Moreno D. Temperament Castro-Fornieles J. One-Year Prospective Inﬂuence of microRNAs in Lithium in child and adolescent offspring of Study of Liver Function Tests in Children Response in Bipolar Disorder. FRONTIERS patients with schizophrenia and bipolar and Adolescents on Second-Generation IN PSYCHIATRY. 9(207):207. I.F.: 2.857 disorder. EUROPEAN CHILD AND Antipsychotics: Is There a Link with ADOLESCENT PSYCHIATRY. Metabolic Syndrome? JOURNAL OF CHILD 60. Miquel, Laia; Rehm, Juergen; Shield, Kevin 27(11):1459-1471. I.F.: 3.553 AND ADOLESCENT D.; Vela, Emili; Bustins, Montserrat; Segura, PSYCHOPHARMACOLOGY. 28(7):463-473. Lidia; Colom, Joan; Anderson, Peter; Gual, 53. Barrio P., Teixidor L., Ortega L., Lligoña A., I.F.: 2.901 Antoni. Alcohol, tobacco and health care Rico N., Bedini J., Vieta E., Gual A. Filling the costs: a population-wide cohort study gap between lab and clinical impact: An 59. Reinbold, Celine S.; Forstner, Andreas J.; (n=606 947 patients) of current drinkers open randomized diagnostic trial Hecker, Julian; Fullerton, Janice M.; Hoffmann, based on medical and administrative comparing urinary ethylglucuronide and Per; Hou, Liping; Heilbronner, Urs; Degenhardt, health records from Catalonia. EUROPEAN ethanol in alcohol dependent outpatients. Franziska; Adli, Mazda; Akiyama, Kazufumi; JOURNAL OF PUBLIC HEALTH. DRUG AND ALCOHOL DEPENDENCE. Akula, Nirmala; Ardau, Raffaella; Arias, 28(4):674-680. I.F.: 2.782 183:225-230. I.F.: 3.322 Barbara; Backlund, Lena; Benabarre, Antonio; Bengesser, Susanne; Bhattacharjee, Abesh K.; 61. García S, Alberich S, Martínez- 54. Garcia-Delgar B., Morer A., Varela E., Biernacka, Joanna M.; Birner, Armin; Cengotitabengoa M, Arango C, Romero S., García M., Coffey B., Lázaro L. Marie-Claire, Cynthia; Cervantes, Pablo; Chen, Castro-Fornieles J, Parellada M, Baeza I, Activation in children and adolescents Guo-Bo; Chen, Hsi-Chung; Chillotti, Caterina; Moreno C, Micó JA, Berrocoso E, Graell M, treated with selective serotonin reuptake Clark, Scott R.; Colom, Francesc; Cousins, Otero S, Simal T, González-Pinto A. The inhibitors. JOURNAL OF CLINICAL David A.; Cruceanu, Cristiana; Czerski, Piotr M.; complex association between the PSYCHOPHARMACOLOGY. 38(5):475-480. Dayer, Alexandre; Etain, Bruno; Falkai, Peter; antioxidant defense system and clinical I.F.: 3.134 Frisen, Louise; Gard, Sebastien; Garnham, status in early psychosis. PLOS ONE. Julie S.; Goes, Fernando S.; Grof, Paul; Gruber, 13(4):e0194685. I.F.: 2.766 55. Dolz M, Tor J, De la Serna E, Pardo M, Oliver; Hashimoto, Ryota; Hauser, Joanna; Muñoz-Samons D, Rodríguez-Pascual M, Puig Herms, Stefan; Jamain, Stephane; Jimenez, 62. Bramness J; Dom G; Gual A; Mann K; O, Sugranyes G, Usall J, Sánchez-Gistau V, Esther; Kahn, Jean-Pierre; Kassem, Layla; Wurst F. A Survey on the Medical Use of Baeza I. Characterization of children and Kittel-Schneider, Sarah; Kliwicki, Sebastian; Cannabis in Europe: A Position Paper. adolescents with psychosis risk Koenig, Barbara; Kusumi, Ichiro; Lackner, Nina; EUROPEAN ADDICTION RESEARCH. syndrome: The Children and Adolescents Laje, Gonzalo; Landen, Mikael; Lavebratt, 24(4):201-205. I.F.: 2.653 Psychosis Risk Syndrome (CAPRIS) study. Catharina; Leboyer, Marion; Leckband, Susan EARLY INTERVENTION IN PSYCHIATRY. G.; Lopez Jaramillo, Carlos A.; MacQueen, 63. Miquel L., Manthey J., Rehm J., Vela E., I.F.: 2.923 Glenda; Manchia, Mirko; Martinsson, Lina; Bustins M., Segura L., Vieta E., Colom J., Mattheisen, Manuel; McCarthy, Michael J.; Anderson P., Gual A. Risky Alcohol Use: The 56. Gasso, Patricia; Blazquez, Ana; Rodriguez, McElroy, Susan L.; Mitjans, Marina; Impact on Health Service Use. EUROPEAN Natalia; Boloc, Daniel; Torres, Teresa; Mas, Mondimore, Francis M.; Monteleone, Palmiero; ADDICTION RESEARCH. 24(5):234-244. I.F.: Sergi; Lafuente, Amalia; Lazaro, Luisa. Further Nievergelt, Caroline M.; Osby, Urban; Ozaki, 2.653 Support for the Involvement of Genetic Norio; Perlis, Roy H.; Pfennig, Andrea; Variants Related to the Serotonergic Reich-Erkelenz, Daniela; Rouleau, Guy A.; 64. Casajuana C., López-Pelayo H., Miquel L., Pathway in the Antidepressant Response Schoﬁeld, Peter R.; Schubert, K. Oliver; Balcells-Oliveró M., Colom J., Gual A. in Children and Adolescents After a Schweizer, Barbara W.; Seemueller, Florian; Quantitative Criteria to Screen for 12-Month Follow-Up: Impact of the HTR2A Severino, Giovanni; Shekhtman, Tatyana; Cannabis Use Disorder. EUROPEAN rs7997012 Polymorphism. JOURNAL OF Shilling, Paul D.; Shimoda, Kazutaka; Simhandl, ADDICTION RESEARCH. 24(3):109-117. CHILD AND ADOLESCENT Christian; Slaney, Claire M.; Smoller, Jordan W.; I.F.: 2.653 PSYCHOPHARMACOLOGY. 28(10):711-718. Squassina, Alessio; Stamm, Thomas J.; I.F.: 2.901 Stopkova, Pavla; Tighe, Sarah K.; Tortorella, 65. Bruguera P, Barrio P, Oliveras C, Braddick Alfonso; Turecki, Gustavo; Volkert, Julia; Witt, F, Gavotti C, Bruguera C, López-Pelayo H, 57. Fortea A, Ilzarbe D, Espinosa L, Stephanie H.; Wright, Adam J.; Young, L. Miquel L, Segura L, Colom J, Ortega L, Vieta E, Solerdelcoll M, de Castro C, Oriolo G, Trevor; Zandi, Peter P.; Potash, James B.; Gual A. Effectiveness of a specialized brief Sugranyes G, Baeza I. Long-Acting DePaulo, J. Raymond; Bauer, Michael; intervention for at-risk drinkers in an Injectable Atypical Antipsychotic Use in Reininghaus, Eva; Novak, Tomas; Aubry, Emergency Department. Short term Adolescents: An Observational Study. Jean-Michel; Maj, Mario; Baune, Bernhard T.; results of a randomized controlled trial.

250 BIOLOGICAL BASES OF PSYCHIATRIC DISORDERS AND NUCLEAR PSYCHIATRY 4.7

ACADEMIC EMERGENCY MEDICINE. psychotic symptoms: Validation of the in patients with alcohol use disorders and 25(5):517-525. I.F.: 2.612 Spanish version of the “Symptom Onset in neurocognitive disorders: A Pilot Study. Schizophrenia (SOS) inventory”. ADICCIONES. 30(2):93-100. I.F.: 2.021 66. Farré-Sender B, Farré-Sender B, Torres PSYCHIATRY RESEARCH. 261:68-72. A, Torres A, Torres A, Torres A, Gelabert E, I.F.: 2.223 81. Jürgen Rehm; Gerrit Gmel; Cristina Sierra Andrés S, Roca A, Lasheras G, Valdés M, Benito; Antoni Gual Solé. Reducción de la Valdés M, Garcia-Esteve L, Garcia-Esteve L, 74. Ballesteros-Urpí A, Pardo-Hernández H, mortalidad mediante una mejor detección Garcia-Esteve L. Mother-infant bonding in Ferrero-Gregori A, Torralbas-Ortega J, de la hipertensión y los problemas con el the postpartum period: assessment of the Puntí-Vidal J, Tàpies Olivet P, Izaguirre Eguren alcohol en atención primaria de salud en impact of pre-delivery factors in a clinical J, Vergés Balasch P, Lara Lloveras A, España. ADICCIONES. 30(1):9-18. I.F.: 2.021 sample. ARCHIVES OF WOMEN'S MENTAL Bertomeu S, Peramiquel M, Herreros V, Vidal HEALTH. 21(3):287-297. I.F.: 2.565 À, Font E, Romero S, Garcia M, Lázaro L, 82. López Pelayo H, Altamirano J, López E, Morer À. Validation of the Spanish and Barrio P, López A, Gual A, Lligoña A. Role of 67. Peri JM, Muñoz-Champel A, Torrubia R, Catalan versions of the Health of the Alcohol and Drug Detection by Regular Gutiérrez F. The General Criteria for Nation Outcome Scale for Children and Urine Sample Testing in pre-transplant Personality Disorders Assessed by Adolescents (HoNOSCA). PSYCHIATRY evaluation for Alcohol Liver Disease. Interview: Do They Still Have a Role to RESEARCH. 261:554-559. I.F.: 2.223 ADICCIONES. 0(0):1121. I.F.: 2.021 Play? JOURNAL OF PERSONALITY DISORDERS. 11:1-27. I.F.: 2.529 75. Nunes-Neto PR, Köhler CA, Schuch FB, 83. Mezquida, Gisela; Fernandez-Egea, Quevedo J, Solmi M, Murru A, Vieta E, Maes M, Emilio; Treen, Devi; Mane, Anna; Berge, Daniel; 68. Muñoz-Champel A, Gutiérrez F, Peri JM, Stubbs B, Carvalho AF. Psychometric Savulich, George; Garcia-Alvarez, Leticia; Torrubia R. Personality Disorders Are Not properties of the modified Yale Food Garcia-Portilla, Paz; Bobes, Julio; Bernardo, as We Thought: Hierarchical Factor Addiction Scale 2.0 in a large Brazilian Miguel; Garcia-Rizo, Clemente. Obstetric Structure at the Criterion Level. JOURNAL sample. REVISTA BRASILEIRA DE Phenotypes in the Heterogeneity of OF PERSONALITY ASSESSMENT. PSIQUIATRIA. 40(4):444-448. I.F.: 2.093 Schizophrenia. JOURNAL OF NERVOUS 100(1):16-29. I.F.: 2.339 AND MENTAL DISEASE. 206(11):882-886. 76. Sanvisens A, Zuluaga P, Rivas I, Rubio G, I.F.: 1.940 69. Albajes-Eizagirre A, Solanes A, Radua J. Gual A, Torrens M, Short A, Álvarez FJ, Tor J, Meta-analysis of non-statistically Farré M, Rodríguez de Fonseca F, Muga R . 84. Barrio P, Ortega L, Guardia J, Roncero C, significant unreported effects. Patients with alcohol use disorder: initial Yuguero L, Gual A. Who Receives STATISTICAL METHODS IN MEDICAL results from a prospective multicenter Nalmefene and How Does It Work in the RESEARCH. registry in the Spanish Network on Real World? A Single-Arm, Phase IV Study 962280218811349:962280218811349. Addiction Disorders. CohRTA Study. of Nalmefene in Alcohol Dependent I.F.: 2.284 ADICCIONES. 30(4):292-300. I.F.: 2.021 Outpatients: Baseline and 1-Month Results. CLINICAL DRUG INVESTIGATION. 70. Fernández-Candil J, Castelltort Mascó L, 77. Sanchez-Autet, Monica; Garriga, Marina; 38(2):147-155. I.F.: 1.918 Fàbregas Julià N, Urretavizcaya Sarachaga M, Javier Zamora, Francisco; Gonzalez, Idilio; Bernardo Arroyo M, Valero Castell R. Usall, Judith; Tolosa, Leticia; Benitez, 85. Rubio E, Martínez MJ, Gonzalo V, Anaesthesia in electroconvulsive therapy. Concepcion; Puertas, Raquel; Arranz, Belen. Barrachina J, Torner N, Martínez AI, Jané M, Special conditions. REVISTA DE Screening of alcohol use disorders in Vilella A, Del Rio A, Rodriguez-Valero N, Pinazo PSIQUIATRIA Y SALUD MENTAL. psychiatric outpatients: influence of MJ, Muñoz J, Soriano A, Trilla A, Vila J, Marcos S1888-9891(18):30061-2. I.F.: 2.233 gender, age, and psychiatric diagnosis. MÁ. Definitive diagnosis in suspected ADICCIONES. 30(4):251-263. I.F.: 2.021 Middle East Respiratory Syndrome 71. Bernardo M., de Dios C., Pérez V., Ignacio Coronavirus cases. JOURNAL OF TRAVEL E., Serrano M., Vieta E., Mira J., Guilabert M., 78. Barrio Giménez P, Ortega L, Guardia J, MEDICINE. 25(1). I.F.: 1.800 Roca M. Quality indicators in the treatment Roncero C, Yuguero L, Gual A. A comparison of patients with depression, bipolar between phase-III trials and a phase-IV 86. Berrocal-Izquierdo N, Bioque M, Bernardo disorder or schizophrenia. Consensus study of nalmefene in alcohol use disorder M. Relationship Between Antipsychotic study. REVISTA DE PSIQUIATRIA Y SALUD patients. Is there a difference? Medications and Cerebrovascular Disease MENTAL. 11(2):66-75. I.F.: 2.233 ADICCIONES. 0(0):1046. I.F.: 2.021 in Patients With Serious Mental Illness. JOURNAL OF PSYCHIATRIC PRACTICE. 72. Vieta E, Montes JM, Iborra P, Mozos A, 79. Gómez-Gil E, Simulionyte E, 24(2):72-78. I.F.: 1.722 Sáez C, Benabarre A. Management of Balcells-Oliveró M, Valdés M, Salamero M, asenapine treatment in clinical practice: Guillamón A, Esteva I . Patterns of alcohol, 87. Miquel L, López-Pelayo H, Nuño L, Arbesú Recommendations from a panel of tobacco, and illicit drug use among JÁ, Zarco J, Manthey J, Rehm J, Gual A. experts. REVISTA DE PSIQUIATRIA Y SALUD transsexuals. 0(0):945. I.F.: 2.021 Barriers to implement screening for MENTAL. S1888-9891(18):30042-9. I.F.: 2.233 alcohol consumption in Spanish 80. Frias-Torres, Cindy; Moreno-Espana, hypertensive patients. FAMILY PRACTICE. 73. Mezquida G., Cabrera B., Martínez-Arán A., Jose; Ortega, Lluisa; Barrio, Pablo; Gual, 35(3):295-301. I.F.: 1.675 Vieta E., Bernardo M. Detection of early Antoni; Teixidor, Lidia. Remediation therapy

251 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

88. Palacio-Vieira J., Segura L., Anderson P., Benyamina A, Caputo F, Dematteis M, Gual A, 12. Molero P, Ramos-Quiroga JA, Wolstenholme A., Drummond C., Bendtsen P., Lesch OM, Mann K, Maremmani I, Nutt D, Martin-Santos R, Calvo-Sánchez E, Wojnar M., Kaner E., Keurhorst M., van Paille F, Perney P, Rehm J, Reynaud M, Simon Gutiérrez-Rojas L, Meana JJ . Steenkiste B., K?oda K., Mierzecki A., N, Söderpalm B, Sommer WH, Walter H, Antidepressant Efficacy and Tolerability of Parkinson K., Newbury-Birch D., Spanagel R. Efficacy and safety of sodium Ketamine and Esketamine: A Critical Okulicz-Kozaryn K., Deluca P., Colom J., Gual oxybate in alcohol-dependent patients Review. CNS DRUGS. 32(5):411-420. A. Improving screening and brief with a very high drinking risk level. I.F.: 4.206 intervention activities in primary health ADDICTION BIOLOGY. 23(4):969-986. care: Secondary analysis of professional I.F.: 5.578 13. Arranz B, Garriga M, García-Rizo C, San L. accuracy based on the AUDIT-C. JOURNAL Clozapine use in patients with OF EVALUATION IN CLINICAL PRACTICE. 6. Morris G, Reiche EMV, Murru A, Carvalho schizophrenia and a comorbid substance 24(2):369-374. I.F.: 1.483 AF, Maes M, Berk M, Puri BK. Multiple use disorder: A systematic review. Immune-Inﬂammatory and Oxidative and EUROPEAN 89. Parellada E., Bioque M., Serrano M., Nitrosative Stress Pathways Explain the NEUROPSYCHOPHARMACOLOGY. Herrera B., García Dorado M. An Frequent Presence of Depression in 28(2):227-242. I.F.: 4.129 open-treatment six-week study of the Multiple Sclerosis. MOLECULAR clinical effectiveness of Paliperidone NEUROBIOLOGY. 55(8):6282-6306. 14. Donadon, Mariana Fortunata; Palmitate in schizophrenia: data from I.F.: 5.076 Martin-Santos, Rocio; Osorio, Flavia de Lima. acute units in Spain (SHADOW study). The Associations Between Oxytocin and INTERNATIONAL JOURNAL OF 7. Verdolini N, Hidalgo-Mazzei D, Murru A, Trauma in Humans: A Systematic Review. PSYCHIATRY IN CLINICAL PRACTICE. Pacchiarotti I, Samalin L, Young AH, Vieta E, FRONTIERS IN PHARMACOLOGY. 9:154. 22(3):191-199. I.F.: 1.337 Carvalho AF. Mixed states in bipolar and I.F.: 3.831 major depressive disorders: systematic 90. Garcia-Delgar B., de la Serna E., Lera S., review and quality appraisal of guidelines. 15. Menculini G., Verdolini N., Murru A., Varela E., Andrés-Perpiñá S., Lázaro L. ACTA PSYCHIATRICA SCANDINAVICA. Pacchiarotti I., Volpe U., Cervino A., Steardo L., Neuropsychological functioning in 138(3):196-222. I.F.: 4.984 Moretti P., Vieta E., Tortorella A. Depressive pediatric obsessive-compulsive disorder: mood and circadian rhythms disturbances One size does not ﬁt all. JOURNAL OF 8. Soria V, González-Rodríguez A, as outcomes of seasonal affective OBSESSIVE-COMPULSIVE AND RELATED Huerta-Ramos E, Usall J, Cobo J, Bioque M, disorder treatment: A systematic review. DISORDERS. 16:36-42. I.F.: 1.230 Barbero JD, García-Rizo C, Tost M, Monreal JOURNAL OF AFFECTIVE DISORDERS. JA,, Labad J PNECAT Group. Targeting 241:608-626. I.F.: 3.786 hypothalamic-pituitary-adrenal axis Review / I.F.: 150.923 hormones and sex steroids for improving 16. Chu CS, Stubbs B, Chen TY, Tang CH, Li cognition in major mood disorders and DJ, Yang WC, Wu CK, Carvalho AF, Vieta E, 1. Vieta E, Berk M, Schulze TG, Carvalho AF, schizophrenia: a systematic review and Miklowitz DJ, Tseng PT, Lin PY . The Suppes T, Calabrese JR, Gao K, Miskowiak narrative synthesis. effectiveness of adjunct KW, Grande I . Bipolar disorders. NATURE PSYCHONEUROENDOCRINOLOGY. 93:8-19. mindfulness-based intervention in REVIEWS DISEASE PRIMERS. 4:18008. I.F.: 4.731 treatment of bipolar disorder: A systematic I.F.: 16.071 review and meta-analysis. JOURNAL OF 9. Anderson P, Gual A, Rehm J. Reducing the AFFECTIVE DISORDERS. 225:234-245. 2. Seitz H., Bataller R., Cortez-Pinto H., Gao B., health risks derived from exposure to I.F.: 3.786 Gual A., Lackner C., Mathurin P., Mueller S., addictive substances. CURRENT OPINION Szabo G., Tsukamoto H. Alcoholic liver IN PSYCHIATRY. 31(4):333-341. I.F.: 4.266 17. Verdolini N., Pacchiarotti I., Köhler C., disease. NATURE REVIEWS DISEASE Reinares M., Samalin L., Colom F., Tortorella A., PRIMERS. 4(1):16. I.F.: 16.071 10. Segura, Lidia; Anderson, Peter; Gual, Stubbs B., Carvalho A., Vieta E., Murru A. Antoni. Optimizing the delivery of Violent criminal behavior in the context of 3. Bauer M, Andreassen OA, Geddes JR, interventions for harmful alcohol use in bipolar disorder: Systematic review and Vedel Kessing L, Lewitzka U, Schulze TG, primary healthcare: an update. CURRENT meta-analysis. JOURNAL OF AFFECTIVE Vieta E. Areas of uncertainties and unmet OPINION IN PSYCHIATRY. 31(4):324-332. DISORDERS. 239:161-170. I.F.: 3.786 needs in bipolar disorders: clinical and I.F.: 4.266 research perspectives. LANCET PSYCHIAT. 18. Grunze H, Vieta E, Goodwin GM, Bowden 5(11):930-939. I.F.: 15.233 11. Soo S., Zhang Z., Khong S., Low J., C, Licht RW, Azorin JM, Yatham L, Mosolov S, Vamadevan, Alhabsyi S., Chew Q., Sum M., Möller HJ, Kasper S, Members of the WFSBP 4. Vieta E, Salagre E, Grande I, Carvalho AF, Sengupta S., Vieta E., McIntyre R., Sim K. Task Force on Bipolar Affective Disorders Fernandes BS, Berk M, Birmaher B, Tohen M, Randomized controlled trials of Working on this topic. The World Federation Suppes T. Early Intervention in Bipolar psychoeducation modalities in the of Societies of Biological Psychiatry Disorder. AMERICAN JOURNAL OF management of bipolar disorder: A (WFSBP) Guidelines for the Biological PSYCHIATRY. 175(5):411-426. I.F.: 13.396 systematic review. JOURNAL OF CLINICAL Treatment of Bipolar Disorders: Acute and PSYCHIATRY. 79(3):3. I.F.: 4.247 long-term treatment of mixed states in 5. Van den Brink W, Addolorato G, Aubin HJ, bipolar disorder. WORLD JOURNAL OF

252 BIOLOGICAL BASES OF PSYCHIATRIC DISORDERS AND NUCLEAR PSYCHIATRY 4.7

BIOLOGICAL PSYCHIATRY. 19(1):2-58. I.F.: 3.713 26. Salagre E., Grande I., Solé B., 6. López-Pelayo H, Oliveras C, Segura L, Sanchez-Moreno J., Vieta E. Vortioxetine: A Colom J, Díaz E, Wallace P, Gual A. Quality of 19. Tor J., Dolz M., Sintes A., Muñoz D., Pardo new alternative for the treatment of major life role in risky alcohol use research: M., de la Serna E., Puig O., Sugranyes G., depressive disorder. REVISTA DE should it be a more relevant outcome in Baeza I. Clinical high risk for psychosis in PSIQUIATRIA Y SALUD MENTAL. 11(1):48-59. any study? ADICCIONES. 30(4):301-303. children and adolescents: a systematic I.F.: 2.233 I.F.: 2.021 review. EUROPEAN CHILD AND ADOLESCENT PSYCHIATRY. 27(6):683-700. 27. Murru, A; Carpiniello, B. Duration of 7. Oliveras C, Fortea A, Espinosa L, Barrio P, I.F.: 3.553 untreated illness as a key to early Lligoña A, Balcells-Olivero M. “Diazepam intervention in schizophrenia: A review. loading”: ¿Can a strategy for preventing 20. Vigo L., Ilzarbe D., Baeza I., Banerjea P., NEUROSCIENCE LETTERS. 669:59-67. alcohol withdrawal be used to treat Kyriakopoulos M. Shared psychotic I.F.: 2.159 benzodiazepine use disorder? disorder in children and young people: a ADICCIONES. 30(2):155-157. I.F.: 2.021 systematic review. EUROPEAN CHILD AND 28. Casajuana Köguel C, López-Pelayo H, ADOLESCENT PSYCHIATRY. Balcells-Olivero MM, Colom J, Gual A. 8. Barrio, Pablo; Ortega, Lluisa; Guardia, s00787-018-1236-7. I.F.: 3.553 Psychoactive constituents of cannabis Josep; Roncero, Carlos; Yuguero, Lara; Gual, and their clinical implications: a systematic Antoni. Reply to Braillon et al.: Nalmefene 21. Bioque M., Bernardo M. The current data review. ADICCIONES. 30(2):140-151. I.F.: 2.021 Phase IV Study: A Seeding Flying in the on the 3-month paliperidone palmitate Face of Evidence? CLINICAL DRUG formulation for the treatment of 29. Vieta E, Montes JM. A Review of INVESTIGATION. 38(4):387-388. I.F.: 1.918 schizophrenia. EXPERT OPINION ON Asenapine in the Treatment of Bipolar PHARMACOTHERAPY. 19(14):1623-1629. Disorder. CLINICAL DRUG INVESTIGATION. I.F.: 3.475 38(2):87-99. I.F.: 1.918 Editorial / I.F.: 19.546

22. Salagre, Estela; Dodd, Seetal; Aedo, 1. Freedman R., Brown A., Cannon T., Druss B., Alberto; Rosa, Adriane; Amoretti, Silvia; Pinzon, Letters / I.F.: 26.127 Earls F., Escobar J., Hurd Y., Lewis D., Justo; Reinares, Maria; Berk, Michael; Pereira López-Jaramillo C., Luby J., Mayberg H., Kapczinski, Flavio; Vieta, Eduard; Grande, Iria. 1. Alba Palé L., Cercós A., Samsó B., Moffitt T., Oquendo M., Perlis R., Pine D., Rush Toward Precision Psychiatry in Bipolar Sugranyes G. Childhood Visual A., Tamminga C., Tohen M., Vieta E., Wisner K., Disorder: Staging 2.0. FRONTIERS IN Hallucinations: A Case Report of Idiopathic Xin Y. Can a framework be established for PSYCHIATRY. 9(641):641. I.F.: 2.857 Occipital Epilepsy. JOURNAL OF THE the safe use of ketamine? AMERICAN AMERICAN ACADEMY OF CHILD AND JOURNAL OF PSYCHIATRY. 175(7):587-589. 23. Lopez-Fernandez, Ester; Sole, Brisa; ADOLESCENT PSYCHIATRY. 57(6):436-438. I.F.: 13.396 Jimenez, Esther; Salagre, Estela; Gimenez, I.F.: 6.250 Anna; Murru, Andrea; del Mar Bonnin, 2. Vieta E, Arango C, Rush AJ . The need for Caterina; Lorenz Amann, Benedikt; Grande, 2. Albajes-Eizagirre A., Radua J. What do paediatric registries to assess long-term Iria; Vieta, Eduard; Martinez-Aran, Anabel. results from coordinate-based brain effects of psychotropic medications: Cognitive Remediation Interventions in meta-analyses tell us? NEUROIMAGE. The case of bipolar disorder. EUROPEAN Schizoaffective Disorder: A Systematic 176:550-553. I.F.: 5.426 NEUROPSYCHOPHARMACOLOGY. Review. FRONTIERS IN PSYCHIATRY. 28(11):1181-1184. I.F.: 4.129 9(470):470. I.F.: 2.857 3. Savulich G, Mezquida G, Atkinson S, Bernardo M, Fernandez-Egea E. A Case 3. López-Pelayo H., De Montagut L., Kögel C., 24. Das T., Dey A., Sabesan P., Javadzadeh A., Study of Clozapine and Cognition: Friend Oliveró M. Posverdad del consumo de Théberge J., Radua J., Palaniyappan L. or Foe? JOURNAL OF CLINICAL cannabis: de regreso a la medicina basada Putative astroglial dysfunction in PSYCHOPHARMACOLOGY. 38(2):152-153. en la evidencia. ADICCIONES. schizophrenia: A meta-analysis of H-MRS I.F.: 3.134 30(4):237-242. I.F.: 2.021 studies of medial prefrontal myo-inositol. FRONTIERS IN PSYCHIATRY. 9(SEP):438. 4. Sánchez-González R, Rodríguez-Urrutia A, I.F.: 2.857 Monteagudo-Gimeno E, Vieta E, Pérez-Solá V, Case Reports / I.F.: 3.831 Herranz-Villanueva S, Pintor-Pérez L . Clinical 25. Emsley R, Parellada E, Bioque M, Herrera features of a sample of inpatients with 1. Luisa Imaz M., Oriolo G., Torra M., Soy D., B, Hernando T, García-Dorado M. Real-world adjustment disorder referred to a García-Esteve L., Martin-Santos R. Clozapine data on paliperidone palmitate for the consultation-liaison psychiatry service use during pregnancy and lactation: A treatment of schizophrenia and other over 10 years. GENERAL HOSPITAL case-series report. FRONTIERS IN psychotic disorders: a systematic review PSYCHIATRY. 55:98-99. I.F.: 2.989 PHARMACOLOGY. 9:264. I.F.: 3.831 of randomized and nonrandomized studies. INTERNATIONAL CLINICAL 5. Barrio P, Wurst FM, Gual A. New Alcohol PSYCHOPHARMACOLOGY. 33(1):15-33. Biomarkers. New challenges. ALCOHOL I.F.: 2.284 AND ALCOHOLISM. 53(6):762-763. I.F.: 2.368

253 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

Clinical Guidelines / I.F.: 37.39 Disorder and Schizophrenia Working Group of Variability and under-prescription. the Psychiatric Genomics Consortium. REVISTA DE PSIQUIATRIA Y SALUD 1. European Association for the Study of the Genomic Dissection of Bipolar Disorder MENTAL. S1888-9891(18):30015-6. I.F.: 2.233 Liver. Electronic address: and Schizophrenia, Including 28 [email protected], European Subphenotypes. CELL. 173(7):1705-1715.e16. Association for the Study of the Liver. EASL I.F.: 31.398 Clinical Practice Guidelines: Management GRANTS FOR RESEARCH IN PROGRESS of alcohol-related liver disease. JOURNAL 2. Kahn R, Winter van Rossum I, Leucht S, OF HEPATOLOGY, SUPPLEMENT. McGuire P, Lewis S, Leboyer M, Arango C, Baeza I. Estudio multicéntrico longitudinal 69(1):154-181. I.F.: 15.040 Dazzan P, Drake R, Heres S, Díaz-Caneja C, sobre marcadores neurobiológicos de Rujescu D, Weiser M, Galderisi S, Glenthøj B, estrés en niños y adolescentes con 2. Guidi J, Brakemeier EL, Bockting CLH, Eijkemans M, Fleischhacker W, Kapur S, síndrome de riesgo de psicosis y la Cosci F, Cuijpers P, Jarrett RB, Linden M, Sommer I, Kahn R, Somers M, Ywema P, transición a psicosis. Marks I, Peretti CS, Rafanelli C, Rief W, Kapur S, Meyer-Lindenberg A, Lewis S, Sponsored by: Instituto de Salud Carlos III Schneider S, Schnyder U, Sensky T, Tomba E, Fleischhacker W, Meijering A, Petter J, Van de (ISCIII). PI15/00444 Vazquez C, Vieta E, Zipfel S, Wright JH, Fava Brug R, Schotsman J, Zwerver J, Peuskens J, Duration: 01/01/2016-30/06/2020 GA. Methodological Recommendations for De Hert M, Thys E. Amisulpride and Trials of Psychological Interventions. olanzapine followed by open-label Benabarre A. Identificación de variables PSYCHOTHERAPY AND treatment with clozapine in first-episode biológicas asociadas a la conducta suicida PSYCHOSOMATICS. 87(5):276-284. schizophrenia and schizophreniform en el trastorno bipolar. I.F.: 13.122 disorder (OPTiMiSE): a three-phase Sponsored by: Instituto de Salud Carlos III switching study. LANCET PSYCHIATRY. (ISCIII). PI17/01122 3. Patel, Maxine X.; Sethi, Faisil N.; Barnes, 5(10):797-807. I.F.: 15.233 Duration: 01/01/2018-31/12/2020 Thomas R. E.; Dix, Roland; Dratcu, Luiz; Fox, Bernard; Garriga, Marina; Haste, Julie C.; Kahl, 3. Kong XZ, Mathias SR, Guadalupe T,, Glahn Bernardo M. Identificación y Kai G.; Lingford-Hughes, Anne; DC, Franke B, Crivello F, Tzourio-Mazoyer N, caracterización del valor predictivo de la McAllister-Williams, Hamish; O'Brien, Aileen; Fisher SE, Thompson PM, Francks C ENIGMA reserva cognitiva en el curso evolutivo y Parker, Caroline; Paterson, Brodie; Paton, Laterality Working Group. Mapping cortical respuesta en terapéutica en personas con Carol; Posporelis, Sotiris; Taylor, David M.; brain asymmetry in 17,141 healthy un primer episodio psicótico. Vieta, Eduard; Voellm, Birgit; Wilson-Jones, individuals worldwide via the ENIGMA Sponsoredby: Generalitat de Catalunya. Charlotte; Woods, Laura. Joint BAP NAPICU Consortium. PROCEEDINGS OF THE PERIS_Salut Mental (SLT006/17/00345) evidence-based consensus guidelines for NATIONAL ACADEMY OF SCIENCES OF Duration: 17/02/2018-31/12/2020 the clinical management of acute THE UNITED STATES OF AMERICA. disturbance: De-escalation and rapid 115(22):E5154-E5163. I.F.: 9.504 Bernardo M. Study of new noninvasive tranquillisation. JOURNAL OF strategies for the analysis of antipsychotic PSYCHOPHARMACOLOGY. 32(6):601-640. 4. Gil, Emilio; Garcia-Alonso, Fernando; drugs: achieving better clinical practices. I.F.: 4.738 Boldeanu, Anca; Teixeira, Thais Baleeiro; Sponsoredby: Fundacio Clinic per a la Tordera, Vicente; Palmer Viciedo, Ramon; Recerca Biomedica (FCRB). PonsBalmes16 4. Yatham LN, Kennedy SH, Parikh SV, Salgado, Purificacion; Domingo Ribas, Jordi; Duration: 02/05/2016-31/12/2018 Schaffer A, Bond DJ, Frey BN, Sharma V, Corripio Collado, Iluminada; Manuel Montes, Goldstein BI, Rej S, Beaulieu S, Alda M, Jose; Correas Lauffer, Javier; Ruiz Bernardo M. Estudio de aplicabilidad clínica MacQueen G, Milev RV, Ravindran A, Murugarrem, Salvador; Ovejero Garcia, de un modelo predictivo en recaídas en O'Donovan C, McIntosh D, Lam RW, Vazquez Santiago; Mora, Fernando; Lopez, Ataz; primeros episodios de esquizofrenia. G, Kapczinski F, McIntyre RS, Kozicky J, Fontalba Navas, Andres; Gonzalez Pinto, Ana Sponsoredby: Instituto de Salud Carlos III Kanba S, Lafer B, Suppes T, Calabrese JR, Ma; Martinez, Ricardo; Garcia Castrillo, Cesar; (ISCIII). PI14/00612 Vieta E, Malhi G, Post RM, Berk M . Canadian Toledo, Francisco; Vieta, Eduard; Gonzalez, Duration: 01/01/2015-30/06/2019 Network for Mood and Anxiety Emilio; Franco, Manuel; Virgil Drasovean, Treatments (CANMAT) and International Nicolae; Havard Dahl, Nils; Skagen, Bo; Zilles, Castro J. Grup de recerca en Psiquiatria i Society for Bipolar Disorders (ISBD) 2018 David; Zwanzger, Peter; Juckel, Georg; Kahl, Psicologia Infantil Clínic (GRUPPIC). guidelines for the management of patients Kai G.; Messer, Thomas; Kasper, Siegfried; Sponsored by: Generalitat de Catalunya. with bipolar disorder. BIPOLAR Loxapine Inhaled Home Use Study In. Safety AGAUR_SGR17_00881 DISORDERS. 20(2):97-170. I.F.: 4.490 and efficacy of self-administered inhaled Duration: 01/01/2017-31/12/2020 loxapine (ADASUVE) in agitated patients outside the hospital setting: protocol for a Castro J. Detecció del risc per Consortium Publications / I.F.: 60.781 phase IV, single-arm, open-label trial. BMJ esquizofrènia mitjançant PGRS en nens i OPEN. 8(10):e020242. I.F.: 2.413 adolescents fills de pacients amb 1. Bipolar Disorder and Schizophrenia esquizofrènia o trastorn bipolar. Working Group of the Psychiatric Genomics 5. Sanz-Fuentenebro FJ, Uriarte JJU, Bonet Sponsoredby: Generalitat de Catalunya. Consortium. Electronic address: Dalmau P, Molina Rodriguez V, Bernardo Arroyo PERIS_Salut Mental (SLT006/17/00346) [email protected], Bipolar M. Pattern of use of clozapine in Spain. Duration: 17/02/2018-31/12/2020

254 BIOLOGICAL BASES OF PSYCHIATRIC DISORDERS AND NUCLEAR PSYCHIATRY 4.7

Castro J. Estudio de seguimiento a 8 años Gual A. RTA - Red de Trastornos Adictivos Lázaro ML. Influencia de la genética y la de la primera evaluación de niños y 2017. epigenética en la eficacia del tratamiento adolescents hijos de pacientes con Sponsored by: Instituto de Salud Carlos III del trastorno obsesivo-Compulsivo con esquizofrenia o trastorno bipolar. (ISCIII). RD16/0017/0009 terapia cognitivo-conductual o Sponsored by: Instituto de Salud Carlos III Duration: 01/01/2017-31/12/2021 tratamiento farmacológico. (ISCIII). PI15/00467 Sponsored by: Instituto de Salud Carlos III Duration: 01/01/2016-30/06/2020 Gual A. La TRV como biomarcador de (ISCIII). PI16/01086 alteraciones cerebrales en el consumo Duration: 01/01/2017- 31/12/2019 Castro J. MATRICS: Multidisciplinary crónico de cánnabis (TRV-CAN). Approaches to Translational Research In Sponsored by: Instituto de Salud Carlos III Martínez-Arán A. Marcadors Conduct Syndromes. (ISCIII). PI17/00874 transdiagnòstics dels símptomes Sponsored by: European Commission Duration: 01/01/2018-31/12/2020 cognitius en els trastorns afectius. FP7_HEALTH_13 (603016-2) Sponsored by: Generalitat de Catalunya. Duration: 01/03/2014-28/03/2019 Gual A. SCALA: Scale-up of Prevention and PERIS_Salut Mental (SLT006/17/00177) Management of Alcohol Use Disorders and Duration: 17/02/2018-31/12/2020 Catalán R. Diferencias de género en la Comorbid Depression in Latin America. respuesta a antipsicóticos: analizando el Sponsored by: European commission. Martínez-Arán A. Eficacia de un módulo rol de la menopausia, los cambios H2020-SC1_17_1 e-neurocognitivo como coadyudante a la epigenéticos en los receptores de Duration: 01/12/2017-30/11/2021 rehabilitación funcional para pacientes estrógenos y los niveles de hormones con trastorno bipolar. sexuales. Gual A. FUTURIZE: A step ahead to tackle Sponsored by: Instituto de Salud Carlos III Sponsored by: Instituto de Salud Carlos III future trends in addictions. (ISCIII). PI15/00330 (ISCIII). PI16/01029 Sponsored by: European commission. Duration: 01/01/2016-30/06/2020 Duration: 01/01/2017-31/12/2019 JUST-2017-AG-DRU Duration: 01/10/2018-31/03/2020 Martin-Santos R. Estado de ánimo, Goikolea JM. Effectiveness of brief cognición, inflamación y daño cerebral en intervention on substance use in bipolar Gutiérrez F. Un modelo integrado para la pacientes con hepatitis C tratados con los disorders patients. patología de la personalidad: estructura "agentes antivirales directos" estudio de Sponsored by: Fundació Clínic per a la jerárquica, significación e impacto neuroimagen multimodal-Estudio Recerca Biomedica (FCRB). PonsBartran16 biográfico. PSICO-AAD. Duration: 02/05/2016-31/12/2018 Sponsored by: Instituto de Salud Carlos III Sponsored by: Instituto de Salud Carlos III (ISCIII). PI15/00536 (ISCIII). PI17/02297 García-Rizo C. Evolución metabólica e Duration: 01/01/2016-30/06/2020 Duration: 01/01/2018- 31/12/2020 immune del tratamiento con clozapina: implicaciones terapéuticas. Lafuente A. Mecanismos moleculares Martin-Santos R. Estudio de la actividad y Sponsored by: Instituto de Salud Carlos III implicados en la Farmacogenética del conectividad cerebral en el Trastorno de (ISCIII). PI14/00753 síndrome metabólico inducido por ansiedad social: búsqueda de nuevos Duration: 01/01/2015-30/06/2019 antipsicóticos. endofenotipos a través de la comparación Sponsored by: Instituto de Salud Carlos III con el S. Williams-Beuren”. Estudio Goikolea JM. Bases cerebrales de dos (ISCIII). PI16/01222 TASWI. intervenciones psicoterapéuticas eficaces Duration: 01/01/2017-31/12/2019 Sponsored by: Instituto de Salud Carlos III en el trastorno bipolar: la psicoeducación (ISCIII). PI14/01411 grupal y la rehabilitación funcional. Un Lázaro ML. Caracterització mitjançant Duration: 01/01/2015- 30/06/2019 estudio de neuroimagen multimodal. neuroimatge de predictors i mecanismes Sponsored by: Instituto de Salud Carlos III de resposta a la teràpia Morer A. European Multicentre Tics in (ISCIII). PI14/00723 cognitiu-conductual en el trastorn Children Studies. Duration: 01/01/2015-30/06/2019 obsessivocompulsiu. Sponsored by: European commission. Sponsored by: Generalitat de Catalunya. FP7-HEALTH-11 (278367) Grande I. Disbiosis en el trastorno bipolar: PERIS_Salut Mental (SLT006/17/00249) Duration: 01/12/2011-31/05/2018 MicrObiota Bipolar study (MOB study). Duration: 01/01/2017- 31/12/2019 Sponsored by: Instituto de Salud Carlos III Parellada E. Cellular, molecular, genetic and (ISCIII). PI16/00187 Lázaro ML. Microbiota i Factors cognitive-behavioural characterization of Duration: 01/01/2017-31/12/2019 (Epi)genètics en els trastorns del the antiapoptotic effect of clozapine and Neurodesenvolupament: TDAH i Autisme glutamate inhibitors in a postnatal Gual A. Definición del patrón de consumo al Llarg de la vida a Catalunya ketamine animal model of schizophrenia. de riesgo de cannabis: implicaciones para (MENTAL-Cat). Sponsored by: Fundacio Clinic per a la la detección y la intervención precoz. Sponsored by: Generalitat de Catalunya. Recerca Biomedica (FCRB). PonsBalmes18 Sponsored by: Ministerio de Sanidad, Politica PERIS_Salut Mental (SLT006/17/00287) Duration: 25/04/2018-31/12/2020 Social e Igualdad. MSSSI_PNSD17 Duration: 17/02/2018-31/12/2020 Duration: 01/01/2018-31/12/2020

255 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

Penades R. Rehabilitación cognitiva en la primeros episodios psicóticos en la DOCTORAL THESES esquizofrenia: variación genética en los infancia y adolescencia. genes BDNF (Val66Met) y COMT Seguimiento a 10 años. Morer A, Gassó P. Bases biológicas de (Val158Met) como posible modulador de la Sponsored by: Instituto de Salud Carlos III la fisiopatología y la farmacología del respuesta al tratamiento. (ISCIII). PI13/00614 trastorno obsesivo-compulsivo de inicio Sponsored by: Instituto de Salud Carlos III Duration: 01/01/2014-30/06/2018 en la infancia y la adolescencia. (ISCIII). PI17/00872 Influencia de la genética y la Duration: 01/01/2018-31/12/2020 Torrent C. Estudi sobre l'eficàcia d'un desregulación inmunológica. programa de potenciació de reserva PhD student: Natalia Rodríguez Ferret Penades R. Epigenetic regulation of bdnf cognitiva en població d'alt risc genètic a expression according to response to desenvolupar un trastorn bipolar. Vieta E, Pacchiarotti I. Self and cognitive remediation in schizophrenia. Sponsored by: Genderalitat de Catalunya. Hetero-Aggression: Clinical Implications Sponsored by: NARSAD 16_IIG _002 PERIS_Salut Mental (SLT006/17/00352) in Bipolar Disorder and Mixed States. Duration: 15/09/2016-14/09/2019 Duration: 17/02/2018-31/12/2020 PhD student: Norma Verdolini

Radua J. Predicción anatómico-clínica del Torrent C. Estudio sobre la eﬁcacia de la Bernardo M. Catalan R. Biomarcadors de riesgo de evolución desfavorable en el potenciación de la reserva cognitiva en resposta farmacològica en dones primer episodio psicótico: hacia la niños, adolescentes y adultos jóvenes de postmenopàusiques amb esquizofrènia. medicina personalizada en psiquiatría. alto riesgo genético para esquizofrenia o PhD student: Alexandre González Rodríguez Sponsored by: Instituto de Salud Carlos III trastorno bipolar. (ISCIII). CP14/00041 Sponsored by: Instituto de Salud Carlos III Gual A. La unitat estandarditzada de Duration: 01/01/2015-31/06/2019 (ISCIII). PI17/01066 cànnabis: un instrument per a la valoració Duration: 01/01/2018-31/12/2020 del consum de cànnabis i dels seus riscs. Romero S. Estudio multicéntrico del maltrato PhD student: Cristina Casajuana Kögel infantil en niños y adolescentes con Vieta E. INNOBRAIN: Noves tecnologies trastornos psiquiátricos: Modiﬁcaciones per a la innovació en rehabilitació i Gual A. Beure o viure: el dilema davant la epigenéticas y correlatos con marcadores estimulació cognitiva. malatia mèdica relacionada amb el periféricos de inmunidad innata. Sponsored by: Fundació Institut Guttmann. consum d'alcohol. Sponsored by: Instituto de Salud Carlos III COMRDI15-1-0017-07 PhD student: Hugo López Pelayo (ISCIII). PI15/00685 Duration: 02/01/2017-02/01/2020 Duration: 01/01/2016-30/06/2020 Gual A. Impacte del consum d'alcohol en Vieta E. Trastorn Bipolar. l'ús de recursos i costos sanitaris. Sugranyes G. Estudio del procesamiento Sponsored by: Generalitat de Catalunya. PhD student: Laia Miquel De Montagut perceptual temprano en adolescentes con AGAUR_SGR17_ 01365 esquizofrenia de debut reciente y Duration: 01/01/2017-31/12/2020 Pintor L, Baillès E. Evaluación de los pacientes con encefalitis anti-NMDAR síntomas psiquiátricos en pacientes con para evaluar la hipótesis glutamatérgica Vieta E. Caracterització dels pròdroms i epilepsia refractaria intervenidos de la esquizofrenia. detecció de factors predictors pronòstics quirúrgicamente a través de un estudio Sponsored by: Generalitat de Catalunya. en una mostra de pacients bipolars amb un prospectivo controlado durante 12 meses. PERIS_Salut Mental (SLT006/17/00362) primer episodi maniac. PhD student: Sònia Ramos Perdigués Duration: 17/02/2018-31/12/2020 Sponsored by: Genderalitat de Catalunya. PERIS_Salut Mental (SLT006/17/00357) Grande I, Trilla A. Evaluación de satisfacción Sugranyes G. Construction of a multimodal Duration: 17/02/2018-31/12/2020 de los pacientes que acuden a una Unidad model with diagnostic and prognostic de Trastornos Bipolares. potential in youth at high risk for psychosis: Vieta E. Implicación de variantes del gen PhD student: Juan Miguel Garrido Ocaña integration of genetic, environmental and DDR1 en la integridad de la mielina y en la neuroimaging factors. velocidad de procesamiento cognitivo en Valdés M, Garcia-Esteve LL. El vínculo Sponsored by: Fundacio Clinic per a la pacientes con trastorno bipolar en fase materno-infantil: Evaluación y detección Recerca Biomedica (FCRB). PonsBartran18 eutímica. de los factores de riesgo prenatales en Duration: 25/04/2018-31/12/2018 Sponsored by: Instituto de Salud Carlos III madres diagnosticadas de un trastorno (ISCIII). PI15/00283 mental. Sugranyes G. From the synapse to brain Duration: 01/01/2015-31/12/2019 PhD student: Borja Farré Sender structure and function: a comparative study between youth with early stage Vieta E. R-LiNK: Optimizing response to Li psychosis and patients with NMDA treatment through personalized Receptro Encephalitis. evaluation of individuals with bipolar I Sponsored by: NARSAD17_YIG _02B disorder: the R-LiNK initiative. Duration: 15/02/2018-14/02/2020 Sponsored by: European commission. H2020-SC1_17 (754907-1) Sugranyes G. Estudio longitudinal de Duration: 01/01/2018-31/12/2022

256 NEUROPSYCHOLOGY 4.8 4.8 Neuropsychology

STRATEGIC OBJECTIVES

LOCATION 1. To study the consequences of cerebral UB School of Medicine lesions and dysfunctions in behavior and cognition.

2. We are involved in the Barcelona Brain WEB Health Initiative project which is framed www.ub.edu/neuropsychology/ within the strategic research line towards a html/portada.html better understanding of the risk and TEAM LEADER protective factors, as well as the brain Carme Junqué (UB) mechanisms, related to preserved T. 93 403 92 98 cognitive function and mental health in late life. [email protected]

KEYWORDS 1. Magnetic resonance imaging MAIN LINES OF RESEARCH RESEARCHERS 2. Structural and functional connectivity Nuria Bargalló (HCB) 1. Neuropsychology and neuroimaging in 3. Aging and degenerative illness David Bartrés-Faz (UB) 4. Non-invasive brain stimulation Parkinson's disease: This line of research Teresa Boget (HCB) makes use of combined structural and 5. Brain plasticity functional magnetic resonance imaging to POST-DOCTORAL RESEARCHERS detect early alterations in brain connectivity Hugo Cesar Baggio (UB) and its evolution during the degenerative Gabriele Cattaneo (IDIBAPS) process. Dídac Macià (UB) Cristina Sanchez (UB) 2. Cerebral plasticity: In the ﬁeld we study Original publications Bàrbara Segura (UB) changes in brain structure and function from 2016 to 2018 Cristina Solé-Padulles (UB) induced by transcranial electric and

YEAR I.F. TOTAL Q1 Q2 magnetic stimulation through magnetic PRE-DOCTORAL RESEARCHERS resonance imaging. 2016 125.59 29 24 3 Kilian Abellaneda-Pérez (UB) Alexandra Abós (UB) 2017 94.34 22 14 6 3. Development of imaging techniques to Anna Campabadal (UB) study the brain areas implicated in 2018 106.19 22 18 4 Anna Inguanzo (UB) higher cognitive function impairment in Juan Pablo Martín (UB) epileptic patients, based on functional Carme Uribe (UB) magnetic resonance imaging. Lídia Vaqué-Alcázar (UB) TEAM Carme Junqué

257 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

4. Brain changes related to life style in 5. Rojas S, Brugulat-Serrat A, Bargalló N, 12. Palma-Gudiel H., Córdova-Palomera A., normal aging. The objective is to build a Minguillón C, Tucholka A, Falcon C, Carvalho Tornador C., Falcón C., Bargalló N., Deco G., prospective study cohort of >3.000 A, Morán S, Esteller M, Gramunt N, Fauria K, Fañanás L. Increased methylation at an volunteers aged 40 to 65 years to obtain Camí J, Molinuevo JL, Gispert JD . Higher unexplored glucocorticoid responsive information as regards lifestyles, and to prevalence of cerebral white matter element within exon 1Dof follow up a group of 1.500 yearly (including hyperintensities in homozygous APOE-ε4 NR3C1 gene is related to measures of MRI, EEG,...) and undertake a allele carriers aged 45-75: Results from the anxious-depressive disorders and non-pharmacological trial intervention to ALFA study. JOURNAL OF CEREBRAL decreased hippocampal connectivity. modify the brain health related habits. BLOOD FLOW AND METABOLISM. EUROPEAN 38(2):250-261. I.F.: 6.045 NEUROPSYCHOPHARMACOLOGY. 28(5):579-588. I.F.: 4.129 6. Ramos-Perdigués S., Baillés E., Mané A., PUBLICATIONS Carreño M., Donaire A., Rumià J., Bargalló N., 13. Martin-Trias P., Lanteaume L., Solana E., Boget T., Setoain X., Valdés M., Pintor L. Cassé-Perrot C., Fernández-Cabello S., Originals / I.F.: 106.191 Psychiatric Symptoms in Refractory Babiloni C., Marzano N., Junqué C., Rossini P., Epilepsy During the First Year After Micallef J., Truillet R., Charles E., Jouve E., 1. Hoogland J, van Wanrooij LL, Boel JA, Surgery. NEUROTHERAPEUTICS. Bordet R., Santamaria J., Jovicich J., Rossi S., Goldman JG, Stebbins GT, Dalrymple-Alford 15(4):1082-1092. I.F.: 5.719 Pascual-Leone A., Blin O., Richardson J., JC, Marras C, Adler CH, Junque C, Pedersen Bartrés-Faz D. Adaptability and KF, Mollenhauer B, Zabetian CP, Eslinger PJ, 7. Operto G, Cacciaglia R, Grau-Rivera O, reproducibility of a memory disruption Lewis SJG, Wu RM, Klein M, Rodriguez-Oroz Falcon C, Brugulat-Serrat A, Ródenas P, rTMS protocol in the PharmaCog IMI MC, Cammisuli DM, Barone P, Biundo R, de Ramos R, Morán S, Esteller M, Bargalló N, European project. SCIENTIFIC REPORTS. Bie RMA, Schmand BA, Tröster AI, Burn DJ, Molinuevo JL, Gispert JD, ALFA Study. White 8(1):9371. I.F.: 4.122 Litvan I, Filoteo JV, Geurtsen GJ, Weintraub D, matter microstructure is altered in IPMDS Study Group “Validation of Mild cognitively normal middle-aged APOE-ε4 14. Ottino-González J., Jurado M., Cognitive Impairment in Parkinson Disease”. homozygotes. ALZHEIMER'S RESEARCH García-García I., Segura B., Marqués-Iturria I., Detecting Mild Cognitive Deﬁcits in AND THERAPY. 10(1):48. I.F.: 5.015 Sender-Palacios M., Tor E., Prats-Soteras X., Parkinson's Disease: Comparison of Caldú X., Junqué C., Pasternak O., Garolera M. Neuropsychological Tests. MOVEMENT 8. Bartres-Faz, David; Cattaneo, Gabriele; Allostatic load and disordered white DISORDERS. 33(11):1750-1759. I.F.: 8.324 Solana, Javier; Tormos, Josep M.; matter microstructure in overweight Pascual-Leone, Alvaro. Meaning in life: adults. SCIENTIFIC REPORTS. 8(1):15898. I.F.: 2. Perissinotti A., Niñerola-Baizán A., Rubí S., resilience beyond reserve. ALZHEIMER'S 4.122 Carreño M., Marti-Fuster B., Aparicio J., RESEARCH AND THERAPY. 10(1):47. I.F.: 5.015 Mayoral M., Donaire A., Sanchez-Izquierdo N., 15. Thust SC, Heiland S, Falini A, Jäger HR, Bargalló N., Rumiá J., Boget T., Pons F., 9. Baggio HC, Abos A, Segura B, Campabadal Waldman AD, Sundgren PC, Godi C, Katsaros Lomeña F., Ros D., Pavía J., Setoain X. A, Garcia-Diaz A, Uribe C, Compta Y, Marti MJ, VK, Ramos A, Bargallo N, Vernooij MW, Yousry PISCOM: a new procedure for epilepsy Valldeoriola F, Junque C. Statistical T, Bendszus M, Smits M. Glioma imaging in combining ictal SPECT and interictal PET. inference in brain graphs using Europe: A survey of 220 centres and EUROPEAN JOURNAL OF NUCLEAR threshold-free network-based statistics. recommendations for best clinical MEDICINE AND MOLECULAR IMAGING. HUMAN BRAIN MAPPING. 39(6):2289-2302. practice. EUROPEAN RADIOLOGY. 45(13):2358-2367. I.F.: 7.704 I.F.: 4.927 28(8):3306-3317. I.F.: 4.027

3. Oriolo G, Egmond E, Mariño Z, Cavero M, 10. Garcia-Diaz, A. I.; Segura, B.; Baggio, H. C.; 16. Cano-López I, Calvo A, Boget T, Carreño Navines R, Zamarrenho L, Solà R, Pujol J, Uribe, C.; Campabadal, A.; Abos, A.; Marti, M. J.; M, Donaire A, Setoain X, Pintor L, Rumià J, Bargallo N, Forns X, Martin-Santos R . Valldeoriola, F.; Compta, Y.; Bargallo, N.; González-Bono E, Junqué C, Bargalló N. Systematic review with meta-analysis: Junque, C. Cortical thinning correlates of Typical asymmetry in the hemispheric neuroimaging in hepatitis C chronic changes in visuospatial and activation during an fMRI verbal infection. ALIMENTARY PHARMACOLOGY visuoperceptual performance in comprehension paradigm is related to AND THERAPEUTICS. 47(9):1238-1252. Parkinson's disease: A 4-year follow-up. better performance in verbal and I.F.: 7.357 PARKINSONISM AND RELATED non-verbal tasks in patients with epilepsy. DISORDERS. 46:62-68. I.F.: 4.721 NEUROIMAGE: CLINICAL. 20:742-752. 4. Perez-Laso, Carmen; Cerdan, Sebastian; I.F.: 3.869 Junque, Carme; Gomez, Angel; Ortega, 11. Uribe C., Segura B., Baggio H., Abos A., Esperanza; Mora, Mireia; Avendano, Carlos; Garcia-Diaz A., Campabadal A., Marti M., 17. Solana E., Martinez-Heras E., Gomez-Gil, Esther; Cruz Rodriguez del Cerro, Valldeoriola F., Compta Y., Tolosa E., Junque Martinez-Lapiscina E., Sepulveda M., Maria; Guillamon, Antonio. Effects of Adult C. Cortical atrophy patterns in early Sola-Valls N., Bargalló N., Berenguer J., Blanco Female Rat Androgenization on Brain Parkinson's disease patients using Y., Andorra M., Pulido-Valdeolivas I., Morphology and Metabolomic Proﬁle. hierarchical cluster analysis. Zubizarreta I., Saiz A., Llufriu S. Magnetic CEREBRAL CORTEX. 28(8):2846-2853. PARKINSONISM AND RELATED resonance markers of tissue damage I.F.: 6.308 DISORDERS. 50:3-9. I.F.: 4.721 related to connectivity disruption in

258 NEUROPSYCHOLOGY 4.8

multiple sclerosis. NEUROIMAGE: Clouston S, Estanga A, Ewers M, Franzmeier Bartres D. Barcelona Brain Health Initiative. CLINICAL. 20:161-168. I.F.: 3.869 N, Gold B, Habeck C, Jones R, Kempermann Sponsored by: Obra social La Caixa G, Kochhann R, Kremen W, Lim Y, (Fundació Abertis). 18. Uribe C., Segura B., Baggio H., Abos A., Martínez-Lage P, Morbelli S, Okonkwo O, Duration: 01/07/2016-01/07/2019 Garcia-Diaz A., Campabadal A., Marti M., Ossenkoppele R, Pettigrew C, Rosen A, Valldeoriola F., Compta Y., Bargallo N., Junque Scarmeas N. Whitepaper: Defining and Bartres D. Efectos del entrenamiento C. Gray/White matter contrast in investigating cognitive reserve, brain cognitivo combinado con estimulación Parkinson's disease. FRONTIERS IN AGING reserve, and brain maintenance. cerebral no-invasiva guiada por NEUROSCIENCE. 10(MAR):89. I.F.: 3.582 ALZHEIMER'S AND DEMENTIA. información funcional cerebral en el S1552-5260(18):33491-5. I.F.: 12.764 deterioro cognitivo leve. 19. Uribe, Carme; Segura, Barbara; Baggio, Sponsored by: Ministerio de Economía y Hugo C.; Campabadal, Anna; Abos, Alexandra; 2. Walhovd, Kristine B.; Fjell, Anders M.; Competitividad (MINECO). PSI2015-64227-R Compta, Yaroslau; Jose Marti, Maria; Westerhausen, Rene; Nyberg, Lars; Ebmeier, Duration: 01/01/2016-31/12/2018 Valldeoriola, Francesc; Bargallo, Nuria; Junque, Klaus P.; Lindenberger, Ulman; Bartres-Faz, Carme. Differential Progression of Regional David; Baare, William F. C.; Siebner, Hartwig R.; Bartres D. Healthy minds from 0-100 years: Hippocampal Atrophy in Aging and Henson, Richard; Drevon, Christian A.; Optimising the use of European brain Parkinson's Disease. FRONTIERS IN AGING Knudsen, Gun Peggy Stromstad; Ljosne, imaging cohorts (Lifebrain). NEUROSCIENCE. 10(OCT):325. I.F.: 3.582 Isabelle Budin; Penninx, Brenda W. J. H.; Sponsored by: European commission. Ghisletta, Paolo; Rogeberg, Ole; Tyler, Duration: 01/01/2017-31/12/2021 20. Castro-Fornieles J, Bargalló N, Calvo A, Lorraine; Bertram, Lars. Healthy minds Arango C, Baeza I, Gonzalez-Pinto A, 0-100 years: Optimising the use of Bartres D. Breaking new ground in lifespan Parellada M, Graell M, Moreno C, Otero S, European brain imaging cohorts cognitive neuroscience. Janssen J, Rapado-Castro M, de la Serna E. ("Lifebrain"). EUROPEAN PSYCHIATRY. Sponsored by: European commission. H2020 Gray matter changes and cognitive 50:47-56. I.F.: 4.129 Duration: 01/01/2017-31/12/2018 predictors of 2-year follow-up abnormalities in early-onset first-episode 3. Cattaneo G., Bartrés-Faz D., Morris T., Junqué C. Brain connectivity changes psychosis. EUROPEAN CHILD AND Sánchez J., Macià D., Tarrero C., Tormos J., during the degenerative process in ADOLESCENT PSYCHIATRY. 27(1):113-126. Pascual-Leone A. The Barcelona brain Parkinson's disease. I.F.: 3.553 health initiative: A cohort study to define Sponsored by: Fundació la Marató de TV3. and promote determinants of brain health. TV3_Neuro_14 21. Garcia-Diaz AI, Segura B, Baggio HC, Marti FRONTIERS IN AGING NEUROSCIENCE. Duration: 22/05/2015-31/12/2018 MJ, Valldeoriola F, Compta Y, Bargallo N, Uribe 10:321. I.F.: 3.582 C, Campabadal A, Abos A, Junque C . Junqué C. Fenotipos cognitivos en la Structural Brain Correlations of enfermedad de Parkinson mediante la Visuospatial and Visuoperceptual Tests in Consortium publication / I.F.: 79.260 identificación de patrones de Parkinson's Disease. JOURNAL OF THE neuroimagen multimodal. INTERNATIONAL NEUROPSYCHOLOGICAL 1. Estruch R, Ros E, Salas-Salvadó J, Covas Sponsored by: Ministerio de Economía y SOCIETY : JINS. 24(1):33-44. I.F.: 2.777 MI, Corella D, Arós F, Gómez-Gracia E, Competitividad (MINECO). PSI2017-86930-P Ruiz-Gutiérrez V, Fiol M, Lapetra J, Duration: 01/01/2018-31/12/2020 22. Wirsich J., Rey M., Guye M., Bénar C., Lamuela-Raventos RM, Serra-Majem L, Pintó Lanteaume L., Ridley B., Confort-Gouny S., X, Basora J, Muñoz MA, Sorlí JV, Martínez JA, Cassé-Perrot C., Soulier E., Viout P., Rouby F., Fitó M, Gea A, Hernán MA, Martínez-González Lefebvre M., Audebert C., Truillet R., Jouve E., MA, PREDIMED Study Investigators. Primary DOCTORAL THESES Payoux P., Bartrés-Faz D., Bordet R., Prevention of Cardiovascular Disease with Richardson J., Babiloni C., Rossini P., Micallef a Mediterranean Diet Supplemented with Junqué C, Segura B. Visuospatial and J., Blin O., Ranjeva J. Brain Networks are Extra-Virgin Olive Oil or Nuts. NEW visuoperceptual impairment and its Independently Modulated by Donepezil, ENGLAND JOURNAL OF MEDICINE. structural correlates as measures of Sleep, and Sleep Deprivation. BRAIN 378(25):e34. I.F.: 79.260 cognitive decline in Parkinson's disease. TOPOGRAPHY. 31(3):380-391. I.F.: 2.703 PhD student: Anna Isabel Garcia Diaz

Review / I.F.: 20.475 GRANTS FOR RESEARCH IN PROGRESS

1. Stern Y, Arenaza-Urquijo E, Bartrés-Faz D, Bargalló N. Validación de la Resonancia Belleville S, Cantilon M, Chetelat G, Ewers M, funcional de reposo y tractograﬁa para la Franzmeier N, Kempermann G, Kremen W, lateralización del lenguaje en pacientes Okonkwo O, Scarmeas N, Soldan A, epilépticos. Udeh-Momoh C, Valenzuela M, Vemuri P, Sponsored by: Instituto de Salud Carlos III Vuoksimaa E, Arenaza Urquiljo E, Bartrés-Faz (ISCIII). D, Belleville S, Cantillon M, Chetelat G, Duration 01-01-2018-31-12-2020.

259 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

Systems 4.9 neuroscience

Yerko Fuentealba (IDIBAPS) Lluís Hernández (IDIBAPS) LOCATION CEK building, ﬂoor -1 PRE-DOCTORAL RESEARCHERS Almudena Barbero (IDIBAPS) Alessandra Camassa (IDIBAPS) WEB Leonardo Dalla (IDIBAPS) www.sanchez-vives.org Melodia Torao (IDIBAPS) www.braincircuitsbehavior.org/ Joao Moura (IDIBAPS) David Sánchez-Bestué (IDIBAPS) Heike Stein (IDIBAPS) TEAM LEADER Ainhoa Hermoso (IDIBAPS) María Victoria Sánchez Vives Tíffany Oña (IDIBAPS) (ICREA-IDIBAPS) Genis Prat (IDIBAPS) T. 93 227 54 00 (Ext.: 4301) Simón Serka (IDIBAPS) [email protected] KEYWORDS 1. Cerebral cortex TECHNICIANS Tony Donegan (IDIBAPS) 2. Computational neuroscience GROUP LEADERS Alvaro Navarro-Guzman (IDIBAPS) 3. Oscillations Albert Compte (IDIBAPS) Carlos Prieto (IDIBAPS) 4. Virtual reality T. 93 227 54 00 (Ext.: 4151) Adrià Galan (IDIBAPS) 5. Body representation [email protected] Rafael Marín-Campos (IDIBAPS) 6. Working memory Rebecca Martinez (IDIBAPS) 7. Spatial memory Jaime de la Rocha (IDIBAPS) Alba Morató (IDIBAPS) 8. Decision-making T. 93 227 54 00 (Ext.: 4307) Laia Prades (IDIBAPS) [email protected] Albert Font (IDIBAPS) Anna Graell (IDIBAPS)

POST-DOCTORAL RESEARCHERS Lorena Jiménez (IDIBAPS) Miquel Bosch (IDIBAPS) Jordi Pastor (IDIBAPS) Miguel Dasilva (IDIBAPS) Balma Serrano (IDIBAPS) Original publications Vanessa Fernandez (IDIBAPS) from 2016 to 2018 Cristina Gonzalez (IDIBAPS) ADMINISTRATIVE STAFF Birgit Nierula (IDIBAPS) Lejla Bektic (IDIBAPS) YEAR I.F. TOTAL Q1 Q2 Beatriz Rebollo (IDIBAPS) Arnau Llobet (IDIBAPS) 2016 48.56 8 8- Belen Sancristobal (IDIBAPS) VISITING SCIENTISTS 2017 68.79 11 10 1 Daniel Linares (FCRB) Diego Lozano-Soldevilla (CIBER) Sara Caldas (IDIBAPS) 2018 53.31 11 10 1 Manuel Molano-Mazón (IDIBAPS) Daniel Duque (IDIBAPS)

TEAM INVOLVED IN AGAUR_SGR17: 01565, 01296

AWARDS FENS Kavli Network of Excellence scholar Awardee/s: Jame de la Rocha TEAM María Victoria Sánchez Vives

260 SYSTEMS NEUROSCIENCE 4.9

STRATEGIC OBJECTIVES (EVENT lab, www.event-lab.org). operate in the cerebral cortex during perceptual and cognitive processes. The growing knowledge of synaptic 2. Theoretical neurobiology of cortical We focus our efforts on cortical mechanisms physiology and brain circuits, together circuits. Headed by Dr. Compte: for working memory, and their failure in with the development of new instruments - Circuit mechanisms of spatial and feature anti-NMDAR encephalitis and schizophrenia with which to record, analyze and model the working memory. patients. activity of a large number of neurons has - Network basis of cognitive and perceptual Our methods include biologically plausible made it possible to address one of the great alterations in anti- NMDAr encephalitis computational modelling, together with pending challenges in neuroscience: patients. behavioral, electrophysiological and to understand the relationship between - Mechanisms of spatial working memory neuroimaging experiments in healthy the activity of the neuronal population deﬁcits in schizophrenia. human participants and in patients. and behavioral performance. By building computational models of The general objective of the Systems 3. Cortical circuit dynamics. Headed by cognitive function and testing model-derived Neuroscience group is to address this Dr. de la Rocha: hypotheses experimentally, we aim at challenge by combining experimental studies - Neural circuit dynamics during perceptual providing links between speciﬁc synaptic, in cerebral cortex networks with a combined decision making and Working Memory cellular and circuit mechanisms and cognitive experimental and theoretical approach. tasks. and perceptual functions and dysfunctions. - Network mechanisms underlying spontaneous activity and brain state changes. MAIN LINES OF RESEARCH - The role of hippocampal circuits during spatial RESEARCH GROUP long term memory acquisition and retrieval. CORTICAL CIRCUIT DYNAMICS 1. Cortical networks and EVENT Lab. Headed by Dr. Sánchez-Vives: We study different aspects of spontaneous and evoked cortical activity: the RESEARCH GROUP mechanisms that regulate it, the THEORETICAL NEUROBIOLOGY information it encodes, its spatiotemporal OF CORTICAL CIRCUITS properties and its consequences on the network. Moreover, we explore cortical GROUP LEADER activity in transgenic mouse models of Jaime de la Rocha (IDIBAPS) neurological disease in the search for the underlying altered mechanisms and their We study the neuronal circuit mechanisms possible reversion. In addition, we are underlying cognitive functions such as interested in the integration of cortical perception, decision making and memory. information that gives rise to body GROUP LEADER For this, (1) we train rodents to perform representation and in the combination of Albert Compte (IDIBAPS) perceptual discrimination and memory tasks, brain-computer interfaces and virtual (2) we quantitatively characterize the variables reality to understand these processes We investigate the circuit mechanisms that that determine their behavior and (3) identify the brain areas where these variables are represented and the detailed circuit dynamics underlying their processing. We investigate how expectation is formed from recent experiences and how it impacts the representation of sensory stimuli. We use pharmacology, population neural recordings, quantitative analysis and computational modeling to address these questions. We moreover apply these methods to understand neural disorders such as anti-NMDAR encephalitis. GROUP Albert Compte

261 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

asynchronous visuotactile stimulation. BODY IMAGE. 24:55-61. I.F.: 3.595

10. Rebollo B, Perez-Zabalza M, Ruiz-Mejias M, Perez-Mendez L, Sanchez-Vives MV. Beta and gamma oscillations in prefrontal cortex during NMDA hypofunction: an in vitro model of schizophrenia features. NEUROSCIENCE. 383:138-149. I.F.: 3.382

11. Morone G, Matamala-Gomez M, Sanchez-Vives MV, Paolucci S, Iosa M. Watch your step! Who can recover stair climbing independence after stroke? EUROPEAN JOURNAL OF PHYSICAL AND REHABILITATION MEDICINE. 54(6):811-818. I.F.: 2.208

Letters / I.F.: 9.251 GROUP Jaime de la Rocha 1. Prat-Ortega G., Rocha J. Selective integrated system for brain activity Attention: A Plausible Mechanism PUBLICATIONS recording and stimulation validated over Underlying Confirmation Bias. CURRENT cortical slow oscillations in vivo and in BIOLOGY. 28(19):R1151-R1154. I.F.: 9.251 Originals / I.F.: 53.305 vitro. SCIENTIFIC REPORTS. 8(1):16717. I.F.: 4.122 1. Hebert C, Masvidal-Codina E, Suarez-Perez A, Calia AB, Piret G, Garcia-Cortadella R, Illa X, 6. Mata, Agata; Gil, Vanessa; Perez-Clausell, Garcia ED, Sanchez JMD, Casals DV, Jeus; Dasilva, Miguel; Carmen Gonzalez- GRANTS FOR RESEARCH IN PROGRESS Prats-Alfonso E, Bousquet J, Godignon P, Calixto, Mari; Soriano, Eduardo; Manuel Yvert B, Villa R, Sanchez-Vives MV, Garcia-Verdugo, Jose; Sanchez-Vives, Maria Compte A. Dynamics in neuronal networks. Guimera-Brunet A , Garrido JA. Flexible New functions of Sponsored by: Generalitat de Catalunya. Graphene Solution‐Gated Field‐Effect V.; Antonio del Rio, Jose. Semaphorin 3E and its receptor PlexinD1 AGAUR_SGR17_01565 Transistors: Efficient Transducers for during developing and adult hippocampal Duration: 01/01/2017-31/12/2020 Micro‐Electrocorticography. ADVANCED formation. SCIENTIFIC REPORTS. 8(1):1381. FUNCTIONAL MATERIALS. 28(12):1703976. I.F.: 4.122 Compte A. Alteraciones cognitivas en I.F.: 13.325 pacientes adolescentes con encefalitis 7. Seinfeld S, Arroyo-Palacios J, anti-NMDAR: posible disfunción en la 2. D'Andola M, Rebollo B, Casali AG, Weinert Iruretagoyena G, Hortensius R, Zapata LE, percepción de la continuidad temporal y JF, Pigorini A, Villa R, Massimini M, Borland D, de Gelder B, Slater M, Sanchez- sus mecanismos. Sanchez-Vives MV. Bistability, Causality, Offenders become the victim in Sponsored by: Fundación Alicia Koplowitz. and Complexity in Cortical Networks: An In Vives MV. virtual reality: impact of changing 16_001 Vitro Perturbational Study. CEREBRAL perspective in domestic violence. Duration: 28/10/2016-31/12/2018 CORTEX. 28(7):2233-2242. I.F.: 6.308 SCIENTIFIC REPORTS. 8(1):2692-2692. I.F.: 4.122 Compte A. Prefrontal network mechanisms 3. Ramirez-Mahaluf, Juan P.; Perramon, Joan; of working memory dynamics: from Otal, Begonya; Villoslada, Pablo; Compte, 8. Suarez-Perez A, Gabriel G, Rebollo B, Illa X, dopamine neuromodulation to network Albert. Subgenual anterior cingulate cortex Guimerà-Brunet A, Hernández-Ferrer J, dysfunction in anti-NMDAR encephalitis. controls sadness-induced modulations of Sponsored by: Ministerio de Economía y cognitive and emotional network hubs. Martínez MT, Villa R, Sanchez-Vives MV. Quantification of Signal-to-Noise Ratio in Competitividad (MINECO). SCIENTIFIC REPORTS. 8(1):8566. I.F.: 4.122 Cerebral Cortex Recordings Using Flexible BFU2015_65318_R MEAs With Co-localized Platinum Black, Duration: 01/01/2016-31/12/2018 4. Linares D., Marin-Campos R., Dalmau J., Carbon Nanotubes, and Gold Electrodes. Compte A. Validation of motion perception FRONTIERS IN NEUROSCIENCE. 12:862 . De la Rocha J. La dinámica de los circuitos of briefly displayed images using a tablet. I.F.: 3.877 neuronales durante la toma de decisiones SCIENTIFIC REPORTS. 8(1):16056. I.F.: 4.122 perceptuales. 9. Perez-Marcos D., Martini M., Fuentes C., Sponsored by: Ministerio de Economía y 5. Pazzini L, Polese D, Weinert JF, Maiolo L, Bellido Rivas A., Haggard P., Sanchez-Vives M. Competitividad (MINECO). Maita F, Marrani M, Pecora A, Sanchez-Vives Selective distortion of body image by SAF2015_70324_R MV, Fortunato G. An ultra-compact Duration: 01/01/2016-31/12/2018

262 SYSTEMS NEUROSCIENCE 4.9

De la Rocha J. PRIORS: Neural circuit DOCTORAL THESES dynamics underlying expectation and their impact on the variability of perceptual Sánchez Vives MV. Interfacing the Cerebral choices. Cortex: Two-dimensional recording Sponsored by: European commission. techniques and electrical stimulation to CE_H2020_ERC_15_CoG (683209) explore and modulate spatio-temporal Duration: 01/09/2016-31/08/2021 network dynamics in the cortex. PhD student: Julia Franziska Weinert Sanchez-Vives MV. Neurovirtual. Sponsored by: Generalitat de Catalunya. AGAUR_SGR17_01296 Duration: 01/01/2017-31/12/2020

Sanchez-Vives MV. Traslacortex: Desde el estudio de la ﬁsiología cortical a la comprensión y tratamiento de las patologías que la afectan. Sponsored by: Ministerio de Economía y Competitividad (MINECO). BFU2017_85048_R Duration: 01/01/2015-31/12/2020

Sanchez-Vives MV. Dinámica de las oscilaciones lentas: experimentos, análisis, modelos e intervenciones terapéuticas (SloW-Dyn) Sponsored by: Ministerio de Economía y Competitividad (MINECO). PCIN-2015_162_C02_01 Duration: 01/12/2015-31/05/2019

Sanchez-Vives MV. HBP SGA2: Human Brain Project Speciﬁc Grant Agreement 2. Sponsored by: European commission. H2020_FLAG_HBP_17 (785907) Dutarion: 01/04/2018-31/03/2020

Sanchez-Vives MV. Graphene Core 2: Graphene Flagship Core Project 2. Sponsored by: European commission. H2020_FLAG_GRA_17 (785219) Duration: 01/04/2018-31/03/2020

Sanchez-Vives MV. SloW-Dyn: Slow Wave Dynamics: from experiments, analysis and models to rhythm restoration. Sponsored by: European commission. H2020_FLAG_ERA_2015 Duration: 01/12/2015-31/05/2019

Sanchez-Vives MV. Graphene-based disruptive technologies. Sponsored by: European commission. H2020-Adhoc-14-20 (696656) Dutarion: 01/04/2016-31/03/2018

Sanchez-Vives MV. Human Brain Project Speciﬁc Grant Agreement 1. Sponsored by: European commission. HBP_SCN15 (720270) Duration: 01/04/2016-31/03/2019

263 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

Clinical and experimental 4.10 neuroimmunology

Marta Muñoz (IDIBAPS) Nuria Sola-Valls (IDIBAPS) LOCATION Marianna Spatola (IDIBAPS) CELLEX building, ﬂoor 3A Magi Andorra (IDIBAPS) Irati Zubizarreta (IDIBAPS) Maria Sepulveda (FCRB)

WEB TECHNICIANS www.neuroimmunologybcn.org Esther Aguilar (IDIBAPS) Mercedes Alba (FCRB) Eva Maria Caballero (FCRB) TEAM LEADER Victor Lopez (CIBER) Josep Dalmau (ICREA-IDIBAPS) Rosa Rodriguez (IDIBAPS) T. 93 227 17 38 Salut Albà (IDIBAPS) [email protected] KEYWORDS Begoña Fernandez (IDIBAPS) 1. Autoantibodies Ana Isabel Guerrero (IDIBAPS) 2. Encephalitis Gemma Vila (IDIBAPS) TEAM LEADER 3. Multiple sclerosis Josep Dalmau (ICREA-IDIBAPS) 4. Paraneoplastic ADMINISTRATIVE STAFF T. 93 227 17 38 Gemma Castillo (FCRB) 5. Cancer [email protected] Laura Planas (IDIBAPS) Maria Rodés (IDIBAPS) GROUP LEADERS

Sara Llufriu (IDIBAPS) NURSING STAFF T. 93 227 54 14 Montserrat Artola (IDIBAPS) [email protected]

Original publications COLLABORATORS from 2016 to 2018 Pablo Villoslada (IDIBAPS) Domingo Escudero (HCB) T. 93 227 54 00 (Ext.: 4802) YEAR I.F. TOTAL Q1 Q2 Myrna Rosenfeld (IDIBAPS) [email protected] Bernardo Sanchez Dalmau (HCB) 2016 199.30 32 21 6

2017 127.24 23 18 2 EMERITUS 2018 208.50 31 27 1 Francesc Graus (HCB) STRATEGIC OBJECTIVES

RESEARCHERS The principal objective of the Thais Armangué (IDIBAPS) Neuroimmunology Group is the study of Pedro Luis Gambús (HCB) TEAM INVOLVED IN autoimmune (inflammatory) diseases of the Eugenia Maria Martinez-Hernandez REEM nervous system and the elucidation of the (HCB-IDIBAPS) underlying immunopathogenic mechanisms CIBERER Lidia Sabater (FCRB) AGAUR_SGR17: 00266 involved in the inflammatory response. Albert Saiz (HCB) Diseases under study include multiple MAGNIMS Elena Hernandez (HCB-IDIBAPS) sclerosis, neuromyelitis optica, autoimmune Yolanda Blanco (HCB) encephalitis and paraneoplastic neurological disorders. POST-DOCTORAL RESEARCHERS Helena Ariño (IDIBAPS) Pablo Jercog (IDIBAPS) AWARDS Francesco Mannara (IDIBAPS) MAIN LINES OF RESEARCH Sobek Award Marta Pedreño (FCRB) Institution: Stuttgart, Germany Maria del Mar Petit-Pedrol (IDIBAPS) 1. Identification of novel autoimmune Awardee/s: Josep Dalmau Jesus Planaguma (FCRB) diseases of the nervous system in adults Marija Radosevic (IDIBAPS) and children and the development of Zülch Prize for Irene Pulido (IDIBAPS) diagnostic tests for these disorders. Basic Neurological Research Eloy Martinez (IDIBAPS) Institution: Max Planck Society, Cologne Elisabeth Solana (FCRB) 2. Development of biomarkers and new Awardee/s: Josep Dalmau therapies for multiple sclerosis, PRE-DOCTORAL RESEARCHERS neuromyelitis optica and other Anna Garcia (IDIBAPS) demyelinating diseases. Estibaliz Maudes (IDIBAPS) Lucia Morales (IDIBAPS)

264 TEAM Sara Llufriu TEAM Josep Dalmau 3. uomuedsae ftenros system. autoimmunediseasesofthenervous 5. behavioralandin-silicomodels. advanced synapticfunctionandbrainnetworksusing neuroimaging, 4. disorders. encephalitisandparaneoplasticneurologic mechanismsthatresultinautoimmune Characterizationoftheimmunopathogenic h eeomn fmdl f The developmentofmodels To elucidatehowautoimmunityaffects electrophysiology, ehnsso ri lsiiyi demyelinating mechanismsofbrainplasticityin diseases. biomarkersoftreatmentresponseand substratesofclinicaldysfunction, resonanceimagingtechniquestoelucidate 7. demyelinating mechanismsleadingtobraindamagein diseases. brainimagingtodissecttheimmunological 6. Thedevelopmentofadvancedmagnetic The useofsystemsbiologyandfunctional CLINICAL ANDEXPERIMENTAL NEUROIMMUNOLOGY NEURONAL DISORDERS PATHOGENESIS OFAUTOIMMUNE RESEARCH GROUP (IMAGINEM) NEUROIMMUNOLOGICAL DISEASES ADVANCED IMAGINGIN 50/50 PROGRAM vitro, invivo,andin-silicomodeling. the targetproteinsandreceptors,byin antibodies modifythelevelsandfunctionof underlie thedisordersbyexamininghow We areinvestigatingthemechanismsthat plasticity. roles insynaptictransmission,signalingand and synapticreceptorsthatplayimportant with antibodiesthattargetneuronalproteins We haveshownthatthesediseasesassociate diagnostic testsandnewtreatments. target antigensanddevelopmentof immune-mechanisms, isolationofthe the descriptionofnovelsyn diseases triggeredbycancer.Studiesinclude diseases ofthesynapse Our researchfocusesonimmune-mediated Josep Dalmau GROUP LEADER We havedeveloped technicalimprovements cognitive rehabilitation. response ofdiseaseevolutionandafter mechanisms ofneuralreorganization asa Our groupisleadingstudiestounderstand the response toconventionalandnew therapies. physical andcognitivedisability of We aimtoidentifyimagingbiomarkers of magnetic resonancetechniques. diseases, throughtheuseofadvanced sclerosis andotherneuroimmunological of thebasisdiseaseevolutioninmultiple Our researchisfocusedontheunderstanding Sara Llufriu GROUP LEADER (IDIBAPS) (ICREA-IDIBAPS) and autoimmunebrain dromes and 4.10 265 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

with new sequences and novel image S, Dalmau J, Hallermann S, Geis C. Human Martínez-Sáez E, Rubio-Pérez C, Pineda E, processing to use in the translation of the Autoantibodies against the AMPA Cordero E, Cicuéndez M, Poca MA, research to the patient. We are part of the Receptor Subunit GluA2 Induce Receptor López-Bigas N, Ramon Y Cajal S, Vieito M, European network MAGNIMS (Magnetic Reorganization and Memory Dysfunction. Carles J, Tabernero J, Vivancos A, Gallego S, Resonance Imaging in Multiple Sclerosis). NEURON. 100(1):91-105. I.F.: 14.319 Graus F, Sahuquillo J, Seoane J . Molecular diagnosis of diffuse gliomas through 3. Montal V, Vilaplana E, Alcolea D, Pegueroles sequencing of cell-free circulating tumour J, Pasternak O, González-Ortiz S, Clarimón J, DNA from cerebrospinal fluid. CLINICAL RESEARCH GROUP Carmona-Iragui M, Illán-Gala I, CANCER RESEARCH. 24(12):2812-2819. PATHOGENESIS AND NEW Morenas-Rodríguez E, Ribosa-Nogué R, Sala I.F.: 10.199 TREATMENTS IN MULTIPLE I, Sánchez-Saudinós MB, García-Sebastian M, SCLEROSIS Villanúa J, Izagirre A, Estanga A, Ecay-Torres 9. Hara M, Martinez-Hernandez E, Ariño H, M, Iriondo A, Clerigue M, Tainta M, Pozueta A, Armangué T, Spatola M, Petit-Pedrol M, Saiz GROUP LEADER González A, Martínez-Heras E, Llufriu S, Blesa A, Rosenfeld MR, Graus F, Dalmau J. Clinical Pablo Villoslada (IDIBAPS) R, Sanchez-Juan P, Martínez-Lage P, Lleó A, and pathogenic significance of IgG, IgA, Fortea J. Cortical microstructural changes and IgM antibodies against the NMDA Our team is pioneering the application of along the Alzheimer's disease continuum. receptor. NEUROLOGY. 90(16):e1386-e1394. Systems Medicine to the study of Multiple ALZHEIMER'S AND DEMENTIA. I.F.: 8.055 Sclerosis (MS) and the development of new 14(3):340-351. I.F.: 12.764 tools for personalized medicine. We are 10. Spatola M, Sabater L, Planagumà J, developing new therapies such as the trophic 4. Andorra M, Nakamura K, Lampert EJ, Martínez-Hernandez E, Armangué T, Prüss H, factor like drug BN201 as neuroprotective Pulido-Valdeolivas I, Zubizarreta I, Llufriu S, Iizuka T, Caparó Oblitas RL, Antoine JC, Li R, therapy or antigen-specific tolerization for Martinez-Heras E, Sola-Valls N, Sepulveda M, Heaney N, Tubridy N, Munteis Olivas E, stopping the disease. We have developed Tercero-Uribe A, Blanco Y, Saiz A, Villoslada P, Rosenfeld MR, Graus F, Dalmau J. new diagnostic tools such as molecular Martinez-Lapiscina EH . Assessing Encephalitis with mGluR5 antibodies: imaging of the retina to monitor disease Biological and Methodological Aspects of Symptoms and antibody effects. progression. We have combined omics, imaging Brain Volume Loss in Multiple Sclerosis. NEUROLOGY. 90(22):e1964-e1972. I.F.: 8.055 and clinical information with machine learning JAMA NEUROLOGY. 75(10):1246-1255. I.F.: 11.460 tools in order to develop clinical decision support 11. Ladépêche L., Planagumà J., Thakur S., systems for personalized medicine. Lastly, the 5. Petit-Pedrol M., Sell J., Planagumà J., Suárez I., Hara M., Borbely J., Sandoval A., group has a commitment to innovation, both in Mannara F., Radosevic M., Haselmann H., Laparra-Cuervo L., Dalmau J., Lakadamyali M. terms of the generation of patents and as Ceanga M., Sabater L., Spatola M., Soto D., NMDA Receptor Autoantibodies in regards the creation of spin-off companies. Gasull X., Dalmau J., Geis C. LGI1 antibodies Autoimmune Encephalitis Cause a alter Kv1.1 and AMPA receptors changing Subunit-Specific Nanoscale synaptic excitability, plasticity and Redistribution of NMDA Receptors. CELL memory. BRAIN; A JOURNAL OF REPORTS. 23(13):3759-3768. I.F.: 8.032 PUBLICATIONS NEUROLOGY. 141(11):3144-3159. I.F.: 10.848 12. Sepúlveda M, Sola-Valls N, Escudero D, Originals / I.F.: 208.501 6. Matute-Blanch C, Villar LM, Rojc B, Barón M, Hernández-Echebarría L, Álvarez-Cermeño JC, Rejdak K, Evdoshenko Gómez B, Dalmau J, Saiz A, Graus F. Clinical 1. Armangue T, Spatola M, Vlagea A, Mattozzi E, Makshakov G, Nazarov V, Lapin S, Midaglia profile of patients with paraneoplastic S, Cárceles-Cordon M, Martinez-Heras E, L, Vidal-Jordana A, Drulovic J, García-Merino neuromyelitis optica spectrum disorder Llufriu S, Muchart J, Erro ME, Abraira L, Moris A, Sánchez-López AJ, Havrdova E, Saiz A, and aquaporin-4 antibodies. MULTIPLE G, Monros-Giménez L, Corral-Corral Í, Llufriu S, Alvarez-Lafuente R, Schroeder I, SCLEROSIS. 24(13):1753-1759. I.F.: 5.280 Montejo C, Toledo M, Bataller L, Secondi G, Zettl UK, Galimberti D, Ramió-Torrentà L, Ariño H, Martínez-Hernández E, Juan M, Robles R, Quintana E, Hegen H, 13. Sanchez-Dalmau B, Martinez-Lapiscina Marcos MA, Alsina L, Saiz A, Rosenfeld MR, Deisenhammer F, Río J, Tintoré M, Sánchez A, EH, Torres-Torres R, Ortiz-Perez S, Graus F, Dalmau J, Spanish Herpes Simplex Montalban X, Comabella M . Neurofilament Zubizarreta I, Pulido-Valdeolivas IV, Encephalitis Study Group. Frequency, light chain and oligoclonal bands are Alba-Arbalat S, Guerrero-Zamora A, Calbet D, symptoms, risk factors, and outcomes of prognostic biomarkers in radiologically Villoslada P. Early retinal atrophy predicts autoimmune encephalitis after herpes isolated syndrome. BRAIN; A JOURNAL OF long-term visual impairment after acute simplex encephalitis: a prospective NEUROLOGY. 141(4):1085-1093. I.F.: 10.848 optic neuritis. MULTIPLE SCLEROSIS. observational study and retrospective 24(9):1196-1204. I.F.: 5.280 analysis. LANCET NEUROLOGY, THE. 7. Patterson K., Dalmau J., Lancaster E. 17(9):760-772. I.F.: 27.144 Mechanisms of Caspr2 antibodies in 14. Gil-Varea E., Urcelay E., Vilariño-Güell C., autoimmune encephalitis and Costa C., Midaglia L., Matesanz F., 2. Haselmann H, Mannara F, Werner C, neuromyotonia. ANNALS OF NEUROLOGY. Rodríguez-Antigüedad A., Oksenberg J., Planagumà J, Miguez-Cabello F, Schmidl L, 83(1):40-51. I.F.: 10.250 Espino-Paisan L., Dessa Sadovnick A., Saiz A., Grünewald B, Petit-Pedrol M, Kirmse K, Villar L., García-Merino J., Ramió-Torrentà L., Classen J, Demir F, Klöcker N, Soto D, Doose 8. Martínez-Ricarte F, Mayor R, Triviño J., Quintana E., Robles R.,

266 CLINICAL AND EXPERIMENTAL NEUROIMMUNOLOGY 4.10

Sánchez-López A., Arroyo R., sadness-induced modulations of cognitive 27. González C, Jensen EW, Gambús PL, Alvarez-Cermeño J., Vidal-Jordana A., and emotional network hubs. SCIENTIFIC Vallverdú M. Poincaré plot analysis of Malhotra S., Fissolo N., Montalban X., REPORTS. 8(1):8566. I.F.: 4.122 cerebral blood flow signals: Feature Comabella M. Exome sequencing study in extraction and classification methods for patients with multiple sclerosis reveals 21. Martin-Trias P., Lanteaume L., Solana E., apnea detection. PLOS ONE. variants associated with disease course Cassé-Perrot C., Fernández-Cabello S., 13(12):e0208642. I.F.: 2.766 06 Biological Sciences 0604 Genetics 11 Babiloni C., Marzano N., Junqué C., Rossini P., Medical and Health Sciences 1109 Micallef J., Truillet R., Charles E., Jouve E., 28. Sanchez-Dalmau B, Martinez-Lapiscina Neurosciences. JOURNAL OF Bordet R., Santamaria J., Jovicich J., Rossi S., EH, Pulido-Valdeolivas I, Zubizarreta I, Llufriu S, NEUROINFLAMMATION. 15(1):265. I.F.: 5.193 Pascual-Leone A., Blin O., Richardson J., Blanco Y, Sola-Valls N, Sepulveda M, Guerrero Bartrés-Faz D. Adaptability and A, Alba S, Andorra M, Camos A, Sanchez-Vela 15. Sola-Valls N, Blanco Y, Sepúlveda M, reproducibility of a memory disruption L, Alfonso V, Saiz A, Villoslada P. Predictors of Llufriu S, Martínez-Lapiscina EH, Zubizarreta I, rTMS protocol in the PharmaCog IMI vision impairment in Multiple Sclerosis. Pulido-Valdeolivas I, Montejo C, Villoslada P, European project. SCIENTIFIC REPORTS. PLOS ONE. 13(4):e0195856. I.F.: 2.766 Saiz A. Combined walking outcome 8(1):9371. I.F.: 4.122 measures identify clinically meaningful 29. Sobhanian M., Agarwal R., Meltzer E., response to prolonged-release 22. Linares D., Marin-Campos R., Dalmau J., Kildebeck E., Frohman B., Frohman A., Galetta fampridine. THERAPEUTIC ADVANCES IN Compte A. Validation of motion perception S., Saidha S., White O., Villoslada P., Paul F., NEUROLOGICAL DISORDERS. of briefly displayed images using a tablet. Petzold A., Rennaker R., Martinez-Lapiscina E., 11:1756286418780007. I.F.: 4.750 SCIENTIFIC REPORTS. 8(1):16056. I.F.: 4.122 Balcer L., Kardon R., Frohman E., Frohman T. Identification and treatment of the visual 16. Siles A., Martínez-Hernández E., Araque J., 23. Rieger, Benedikt; Akcakaya, Mehmet; processing asymmetry in MS patients with Diaz-Manera J., Rojas-Garcia R., Gallardo E., Pariente, Jose C.; Llufriu, Sara; optic neuritis: The Pulfrich phenomenon. Illa I., Graus F., Querol L. Antibodies against Martinez-Heras, Eloy; Weingartner, Sebastian; JOURNAL OF THE NEUROLOGICAL cell adhesion molecules and neural Schad, Lothar R. Time efficient whole-brain SCIENCES. 387:60-69. I.F.: 2.448 structures in paraneoplastic neuropathies. coverage with MR Fingerprinting using ANNALS OF CLINICAL AND TRANSLATIONAL slice-interleaved echo-planar-imaging. 30. Muñoz JE, Gambús P, Jensen EW, NEUROLOGY. 5(5):559-569. I.F.: 4.649 SCIENTIFIC REPORTS. 8(1):6667. I.F.: 4.122 Vallverdú M. Time-frequency Features for Impedance Cardiography Signals During 17. Graus F, Escudero D, Oleaga L, Bruna J, 24. Solana E., Martinez-Heras E., Anesthesia Using Different Distribution Villarejo-Galende A, Ballabriga J, Barceló MI, Martinez-Lapiscina E., Sepulveda M., Kernels. METHODS OF INFORMATION IN Gilo F, Popkirov S, Stourac P, Dalmau J . Sola-Valls N., Bargalló N., Berenguer J., Blanco MEDICINE. 57(1):e1-e9. I.F.: 1.531 Syndrome and outcome of Y., Andorra M., Pulido-Valdeolivas I., antibody-negative limbic encephalitis. Zubizarreta I., Saiz A., Llufriu S. Magnetic 31. Mar Guasp; Josep Dalmau Obrador. EUROPEAN JOURNAL OF NEUROLOGY. resonance markers of tissue damage Encefalitis por anticuerpos contra el 25(8):1011-1016. I.F.: 4.621 related to connectivity disruption in receptor de NMDA. MEDICINA CLINICA. multiple sclerosis. NEUROIMAGE: 151(2):71-79. I.F.: 1.168 18. Cayuela N, Simó M, Majós C, Rifà-Ros X, CLINICAL. 20:161-168. I.F.: 3.869 Gállego Pérez-Larraya J, Ripollés P, Vidal N, Miró J, Gil F, Gil-Gil M, Plans G, Graus F, Bruna 25. Aguilera-Albesa S, Crespo-Eguílaz N, Del Review / I.F.: 117.501 J . Seizure-Susceptible brain regions in Pozo JL, Villoslada P, Sánchez-Carpintero R. glioblastoma: identification of patients at Anti-Basal Ganglia Antibodies and 1. Dalmau, Josep; Graus, Francesc. risk. EUROPEAN JOURNAL OF Streptococcal Infection in ADHD. Antibody-Mediated Encephalitis. NEW NEUROLOGY. 25(2):387-394. I.F.: 4.621 JOURNAL OF ATTENTION DISORDERS. ENGLAND JOURNAL OF MEDICINE. 22(9):864-871. I.F.: 3.668 378(9):840-851. I.F.: 79.260 19. Wong YYM, Hacohen Y, Hacohen Y, Armangue T, Armangue T, Wassmer E, 26. Maurel J, Sánchez-Cabús S, Laquente B, 2. Wells E., Hacohen Y., Waldman A., Tillema J., Verhelst H, Hemingway C, van Pelt ED, Gaba L, Visa L, Fabregat J, Povés I, Roselló S, Soldatos A., Ances B., Benseler S., Bielekova Catsman-Berrevoets CE, Hintzen RQ, Deiva Díaz-Beveridge R, Martín-Richard M, B., Dale R., Dalmau J., Gaillard W., Gorman M., K, Deiva K, Lim MJ, Lim MJ, Rostásy K, Rodriguez J, Sabater L, Conill C, Cambray M, Greenberg B., Hyslop A., Pardo C., Tasker R., Neuteboom RF. Paediatric ADEM followed Reig A, Ayuso JR, Valls C, Ferrández A, Bombí Yeh E., Bar-Or A., Pittock S., Vanderver A., by optic neuritis: disease course, JA, Ginés A, García-Albéniz X, Banwell B. Neuroimmune disorders of the treatment response and outcome. Fernández-Cruz L . Outcomes after central nervous system in children in the EUROPEAN JOURNAL OF NEUROLOGY. neoadjuvant treatment with gemcitabine molecular era. NATURE REVIEWS 25(5):782-786. I.F.: 4.621 and erlotinib followed by NEUROLOGY. 14(7):433-445. I.F.: 19.819 gemcitabine-erlotinib and radiotherapy for 20. Ramirez-Mahaluf, Juan P.; Perramon, resectable pancreatic cancer (GEMCAD 3. Florez-Grau, Georgina; Zubizarreta, Irati; Joan; Otal, Begonya; Villoslada, Pablo; 10-03 trial). CANCER CHEMOTHERAPY Cabezon, Raquel; Villoslada, Pablo; Compte, Albert. Subgenual anterior AND PHARMACOLOGY. 82(6):935-943. Benitez-Ribas, Daniel. Tolerogenic Dendritic cingulate cortex controls I.F.: 2.808 Cells as a Promising Antigen-Specific

267 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

Therapy in the Treatment of Multiple Médica Mutua Madrileña. AP162572016 (ISCIII). PI17/01228 Sclerosis and Neuromyelitis Optica From Duration: 18/07/2016-28/02/2020 Duration: 01/01/2018-31/12/2020 Preclinical to Clinical Trials. FRONTIERS IN IMMUNOLOGY. 9:1169. I.F.: 5.511 Blanco Y. Antigen-specific therapy in Martinez-Lapiscina E. MultipleMS: Multiple patients with NMO treated with tolerated manifestations of genetic and non-genetic 4. Jarius S, Paul F, Paul F, Aktas O, Asgari N, autologous dendritic cells (Phase 1b factors in Multiple Sclerosis disentangled Dale RC, de Seze J, Franciotta D, Fujihara K, clinical trial). wi a multi-omics approach to accelerate Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Sponsored by: The Guthy-Jackson Charitable personalised medicine. Palace J, Ruprecht K, Saiz A, Trebst C, Foundation. GJCF_NMO_18 Sponsored by: MERCK KGaA Account Weinshenker BG, Wildemann B. MOG Duration: 01/08/2018-31/12/2019 Payable. MerckSer_GMSI_16_01 encephalomyelitis: international Duration: 01/11/2016-31/10/2019 recommendations on diagnosis and Dalmau J. Clinical and Experimental antibody testing. JOURNAL OF Neuroimmunology Group. Martinez-Lapiscina E. MultipleMS: Multiple NEUROINFLAMMATION. 15(1):134. I.F.: 5.193 Sponsored by: Generalitat de Catalunya. manifestations of genetic and non-genetic AGAUR_SGR17_00266 factors in Multiple Sclerosis disentangled 5. Gaig, Carles; Iranzo, Alex; Santamaria, Joan; Duration: 01/01/2017-31/12/2020 wi a multi-omics approach to accelerate Graus, Francesc. The Sleep Disorder in personalised medicine. Anti-lgLON5 Disease. CURRENT Dalmau J. A Translational Model of Sponsored by: European Commission. NEUROLOGY AND NEUROSCIENCE Antibody-mediated Synaptic Disease: H2020-SC1_16 REPORTS. 18(7):41. I.F.: 3.478 Symptoms, Neuronal Circuits, and the Duration: 01/01/2017-31/12/2021 Mechanisms of Memory Loss and 6. Rosenfeld MR, Dalmau J. Paraneoplastic Recovery. Llufriu S. Rehabilitació cognitiva i plasticitat Neurologic Syndromes. NEUROLOGIC Sponsored by: Fundació Bancària La Caixa. cerebral a l'Esclerosi Múltiple: avaluació a CLINICS. 36(3):675-685. I.F.: 3.072 HR17_00149 través d'un assaig clínic aleatoritzat i Duration: 31/12/2018-30/12/2021 controlat. 7. Guasp M., Dalmau J. Encephalitis Sponsored by: Fundació Catalana de associated with antibodies against the Dalmau J. Encefalitis anti-NMDAR: Neurologia. Neurol_17 NMDA receptor. MEDICINA CLINICA. Subclases de anticuerpos, y estudio de los Duration: 05/05/2017-31/12/2018 151(2):71-79. I.F.: 1.168 efectos de la presencia crónica de anticuerpos en el cerebro de ratón adulto, Llufriu S. Rehabilitación cognitiva y desarrollo cerebral fetal y sinaptogénesis. plasticidad cerebral en la Esclerosis Editorial / I.F.: 6.523 Sponsored by: Instituto de Salud Carlos III Múltiple: evaluación a través de un ensayo (ISCIII). PI17/00234 clínico aleatorizado y controlado. 1. Gambus P, Shafer SL. Artificial Duration: 01/01/2018-31/12/2020 Sponsored by: Fundación Merck Salud. Intelligence for Everyone. 17-EM-010 ANESTHESIOLOGY. 128(3):431-433. Dalmau J. Inmune-mediated diseases of Duration: 01/06/2017-01/06/2020 I.F.: 6.523 the synapse: symptoms, brain networks, and the link to human memory. Llufriu S. Red Temática de Investigación Sponsored by: Instituto de Salud Carlos III Cooperativa en Salud - Esclerosis múltiple. Case Reports / I.F.: 2.655 (ISCIII). PIE16/00014 Sponsored by: Instituto de Salud Carlos III Duration: 01/01/2017-31/12/2019 (ISCIII). RD16/0015/0003 1. Tijero B., del Pino R., Pérez-Concha T., Acera Duration: 01/01/2017-31/12/2021 M., Gabilondo I., Berganzo K., Graus F., Gambús PL. PREDICTHEON: A project to Martinez-Alday J., Barcena J., develop predictive Monitoring Systems for Sabater L. Mecanismos patogénicos de los Gómez-Esteban J. Seronegative and clinical applications. anticuerpos IgG4 contra antígenos de seropositive autoimmune autonomic Sponsored by: Fundació Bancària La Caixa. superficie neuronal en encefalitis ganglionopathy (AAG): Same clinical CI16-00053 autoinmunes. picture, same response to Duration: 10/01/2017-30/04/2019 Sponsored by: Instituto de Salud Carlos III immunotherapy. JOURNAL OF (ISCIII). PI15/00377 NEUROIMMUNOLOGY. 319:68-70. I.F.: 2.655 Martinez-Lapiscina E. Molecular imaging of Duration: 01/01/2016-31/08/2019 the retina in patients with Multiple Sclerosis by Raman Spectroscopy. Saiz A. Diagnostic and prognostic Sponsored by: Fundació La Marató de TV3. biomarkers in pediatric multiple sclerosis GRANTS FOR RESEARCH IN PROGRESS Neuro_14 and related demyelinating disorders. Duration: 03/06/2015-09/01/2019 Sponsored by: Fundació la Marató de TV3. Armangué T. Autoinmunidad en encefalitis Neuro_14 herpética en la infancia: coreoatetosis Martinez-Lapiscina E. Vía visual aferente: Duration: 01/01/2017-31/12/2021 post-herpética, anticuerpos NMDAR e innovación para trastorno del Sueño REM interferon. y Parkinson. Saiz A, Llufriu S. Biomarcadores de Sponsored by: Fundación de Investigación Sponsored by: Instituto de Salud Carlos III resonancia magnética avanzada en

268 CLINICAL AND EXPERIMENTAL NEUROIMMUNOLOGY 4.10

esclerosis múltiple: asociación con el perﬁl clínico evolutivo y sustrato genético. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI15/00587 Duration: 01/01/2016-30/06/2020

Saiz A. REEM: Red española de esclerosis múltiple. Sponsored by: Instituto de Salud Carlos III (ISCIII). RD16/0015/0002 Duration: 01/01/2017-31/12/2021

Villoslada P. Estudio del daño axonal en esclerosis múltiple mediante esudios de neuroimagen de la vía óptica. Sponsored by: Instituto de Salud Carlos III (ISCIII). AC15/00052 Duration: 01/01/2016-30/06/2019

VillosladaP. Estudio del daño axonal en esclerosis múltiple mediante estudios de neuroimagen de la vía óptica. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI15/00061 Duration: 01/01/2016-31/12/2019

Villoslada P. Sys4MS: Personalizing health care in Multiple Sclerosis using systems medicine tolos. Sponsored by: European commission. ERACoSysMed_15 Duration: 01/05/2016-30/04/2019

DOCTORAL THESES

Martínez-Lapiscina EH, Villoslada P. Retinal imaging in preclinical models of neuroinﬂammatory disease. PhD student: Andrés Cruz Herranz

Dalmau J. Antigens and mechanisms of immune-mediated encephalitis. PhD student: María del Mar Petit Pedrol

Villoslada P, Adan A. Biomarcadores de calidad visual percibida en pacientes con neuritis óptica aguda y esclerosis multiple. PhD student: Bernardo Francisco Sánchez Dalmau

Dalmau J. Neuronal antibody-mediated encephalitis: Clinical characterization and pathological mechanisms. PhD student: Marianna Spatola

269 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

Neurobiology 4.11 Unit

STRATEGIC OBJECTIVES

LOCATION 1. To determine the role of mitochondrial IIBB-CSIC labs DNA, mitochondrial dynamics and UB Biomedical Sciences mitophagy on synapse elimination and neuronal death in models of neurodegenerative dementias and Parkinson’s disease. WEB http://www.idibaps.org/ 2. To gain knowledge on the mechanisms

research/903/neurobiology-unit TEAM LEADER regulating neuroinﬂammation in Ramon Trullàs (IIBB-CSIC) neurodegenerative disorders. T. 93 363 83 03 [email protected] 3. To characterize cell-free mitochondrial DNA as a biomarker for neurodegenerative diseases.

KEYWORDS RESEARCHERS 1. Neurodegeneration Anna Colell (IIBB-CSIC) 2. Alzheimer’s disease Petar Podlesniy (CIBER) MAIN LINES OF RESEARCH 3. Mitochondrial DNA Manuel José Rodríguez (UB) 4. Microglia The Neurobiology Unit group investigates the 5. Neuronal pentraxin PRE-DOCTORAL RESEARCHERS molecular mechanisms of neurodegeneration 6. Neuronal death Cristina de Dios (IIBB-CSIC) to identify new targets for therapeutic 7. Mitochondrial dynamics Margalida Puigròs (CIBER) intervention. Speciﬁc lines of research aim to: Vicente Roca (IIBB-CSIC) 1. Characterize cell-free mitochondrial DNA TECHNICIANS in cerebrospinal ﬂuid as a biomarker for the Carmen Andrade (UB) early detection of Alzheimer’s and Núria Serra (CIBER) Parkinson’s diseases. Original publications from 2016 to 2018 2. Investigate the function of Neuronal Pentraxin 1 in the neuronal death program, YEAR I.F. TOTAL Q1 Q2 with the hypothesis that inhibition of this 2016 39.09 5 41 protein may constitute a new treatment for chronic neurodegenerative disorders. 2017 7.37 2 1 1

2018 30.47 5 4 1

TEAM INVOLVED IN CIBERNED AGAUR_2017_SGR 177 TEAM Ramon Trullàs

270 NEUROBIOLOGY UNIT 4.11

3. Study the role of mitochondrial DNA and 5. Menal, Maria Jose; Jorba, Ignasi; Torres, mitochondrial dynamics in ﬁbroblasts from Marta; Montserrat, Josep M.; Gozal, David; patients with Parkinson’s disease and other Colell, Anna; Pinol-Ripoll, Gerard; Navajas, cellular models of neurodegeneration. Daniel; Almendros, Isaac; Farre, Ramon. Alzheimer's Disease Mutant Mice Exhibit 4. Study the mechanism by which KATP Reduced Brain Tissue Stiffness Compared channel participates in the control of to Wild-type Mice in both Normoxia and microglial activity in different neurological following Intermittent Hypoxia Mimicking disorders. Sleep Apnea. FRONTIERS IN NEUROLOGY. 9(JAN):1. I.F.: 3.508 5. Investigate the mechanisms whereby CX3CR1 regulates microglial activation in amyotrophic lateral sclerosis. GRANTS FOR RESEARCH IN PROGRESS 6. Study the mechanisms that alter the main proteolytic systems, including autophagy, Colell A. Cholesterol and Ab-induced involved in the maintenance of intracellular mitochondrial oxidative stress as a causal proteostasis. factors and therapeutic targets in Alzheimer’s Disease. 7. Study the role of mitochondrial function in Sponsored by: Fundació La Marató de TV3 neuroinﬂammation and amyloid Duration: 01/07/2015-31/12/2018 beta-induced cell death. Trullas R, Podlesniy P. Replication and transcription of mitochondrial DNA as a key mechanism of the pathological PUBLICATIONS sequence leading to neurodegeneration. Sponsored bt: Ministerio de Economía y Originals / I.F.: 30.475 Competitividad (MINECO). SAF2017-89791-R Duration: 01/01/2018- 31/12/2020 1. Barbero-Camps E, Roca-Agujetas V, Bartolessis I, de Dios C, Fernández-Checa JC, Marí M, Morales A, Hartmann T, Colell A. Cholesterol impairs autophagy-mediated clearance of amyloid beta while promoting its secretion. AUTOPHAGY. 14(7):1129-1154. I.F.: 11.100

2. Pulido Á., de Gregorio E., Chandra S., Colell A., Morales A., Kronenberg M., Marí M. Differential role of cathepsins S and B in hepatic APC-mediated NKT cell activation and cytokine secretion. FRONTIERS IN IMMUNOLOGY. 9(391):391. I.F.: 5.511

3. Leurs CE, Podlesniy P, Trullas R, Balk L, Steenwijk MD, Malekzadeh A, Piehl F, Uitdehaag BM, Killestein J, van Horssen J, Teunissen CE . Cerebrospinal ﬂuid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment. MULTIPLE SCLEROSIS. 24(4):472-480. I.F.: 5.280

4. Vidal-Taboada JM, Pugliese M, Salvadó M, Gámez J, Mahy N, Rodríguez MJ . KATPChannel Expression and Genetic Polymorphisms Associated with Progression and Survival in Amyotrophic Lateral Sclerosis. MOLECULAR NEUROBIOLOGY. 55(10):7962-7972. I.F.: 5.076

271 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

Alzheimer's disease and 4.12 other cognitive disorders

TEAM LEADER disease). Raquel Sánchez del Valle (HCB) - Study of genetic dementias in preclinical LOCATION T. 93 227 57 85 and early clinical phases. HCB building [email protected] - Biomarkers for sporadic early onset CELLEX building, ﬂoor 3B Alzheimer’s disease. - Biomarkers for non-Alzheimer dementias RESEARCHERS (prion diseases, frontotemporal dementia, Albert Lladó (HCB) primary progressive aphasia, Lewy body José Lluís Molinuevo (HCB) dem.). Lorena Rami (IDIBAPS) - Non-pharmacological interventions in KEYWORDS neurodegenerative cognitive disorders. 1. Alzheimer disease POST-DOCTORAL RESEARCHERS 2. Degenerative Anna Antonell (IDIBAPS) neurological deiseases Mircea Balasa (HCB) Beatriz Bosch (IDIBAPS) PUBLICATIONS

PRE-DOCTORAL RESEARCHERS Originals / I.F.: 237.83 Sergi Borrego (HCB) Nina Coll (IDIBAPS) 1. Atri A., Frölich L., Ballard C., Tariot P., Original publications Neus Falgas (FCRB) Molinuevo J., Boneva N., Windfeld K., Raket L., from 2016 to 2018 Jaume Olives (FCRB) Cummings J. Effect of idalopirdine as Oscar Ramos (IDIBAPS) adjunct to cholinesterase inhibitors on YEAR I.F. TOTAL Q1 Q2 Mariona Ruiz (FCRB) change in cognition in patients with 2016 144.23 24 17 5 Adria Tort (FCRB) Alzheimer disease three randomized

2017 140.93 25 17 8 clinical trials. JAMA- JOURNAL OF THE TECHNICIANS AMERICAN MEDICAL ASSOCIATION. 2018 237.83 27 23 4 Cristina Munoz (IDIBAPS) 319(2):130-142. I.F.: 47.661

NURSING STAFF 2. Pottier C, Zhou X, Perkerson RB, Baker M, Clara Coquard (FCRB) Jenkins GD, Serie DJ, Ghidoni R, Benussi L, Guadalupe Fernández Villullas (FCRB) Binetti G, López de Munain A, Zulaica M, TEAM INVOLVED IN Moreno F, Le Ber I, Pasquier F, Hannequin D, AGAUR_SGR17: 01507 COLLABORATORS Sánchez-Valle R, Antonell A, Lladó A, Parsons Magda Castellví (HCB) TM, Finch NA, Finger EC, Lippa CF, Huey ED, Neumann M, Heutink P, Synofzik M, Wilke C, Rissman RA, Slawek J, Sitek E, Johannsen P, Nielsen JE, Ren Y, van Blitterswijk M, STRATEGIC OBJECTIVES DeJesus-Hernandez M, Christopher E, Murray ME, Bieniek KF, Evers BM, Ferrari C, Rollinson S, - Investigation to improve diagnosis and Richardson A, Scarpini E, Fumagalli GG, treatment of neurodegenerative diseases. Padovani A, Hardy J, Momeni P, Ferrari R, - Investigations on clinical, molecular and Frangipane F, Maletta R, Anfossi M, Gallo M, imaging biomarkers that characterize the Petrucelli L, Suh E, Lopez OL, Wong TH, van preclinical phase of Alzheimer disease. Rooij JGJ, Seelaar H, Mead S, Caselli RJ, Reiman - Investigation of biological pathways EM, Noel Sabbagh M, Kjolby M, Nykjaer A, involved in the pathogenesis of Alzheimer’s Karydas AM, Boxer AL, Grinberg LT, Grafman J, disease and detection of new cognitive, Spina S, Oblak A, Mesulam MM, Weintraub S, biochemical and neuroimaging markers in Geula C, Hodges JR, Piguet O, Brooks WS, Irwin preclinical and prodromal patients. DJ, Trojanowski JQ, Lee EB, Josephs KA, Parisi JE, Ertekin-Taner N, Knopman DS, Nacmias B, Piaceri I, Bagnoli S, Sorbi S, Gearing M, Glass J, Beah TG, Black SE, Masellis M, Rogaeva E, MAIN LINES OF RESEARCH Vonsattel JP, Honig LS, Koﬂer J, Bruni AC, Snowden J, Mann D, Pickering-Brown S, The main research lines of the Alzheimer’s Diehl-Schmid J, Winkelmann J, Galimberti D, Disease and other Cognitive Disorders Unit Graff C, Öijerstedt L, Troakes C, Al-Sarraj S, (ADCDU) team are: Cruchaga C, Cairns NJ, Rohrer JD, Halliday GM, - Healthy aging-Alzheimer’s disease Kwok JB, van Swieten JC, White CL, Ghetti B, continuum (subjective cognitive decline, Murell JR, Mackenzie IRA, Hsiung GR, Borroni B, preclinical and prodromal Alzheimer’s Rossi G, Tagliavini F, Wszolek ZK, Petersen RC,

272 ALZHEIMER'S DISEASE AND OTHER COGNITIVE DISORDERS 4.12

Bigio EH, Grossman M, Van Deerlin VM, J., Aalten P., Aarsland D., Alcolea D., Almdahl I., 10. Iranzo A, Borrego S, Vilaseca I, Martí C, Seeley WW, Miller BL,Graff-Radford NR, Baldeiras I., van Buchem M., Cavedo E., Chen K., Serradell M, Sánchez-Valle R, Kovacs GG, Boeve BF, Dickson DW, Biernacka JM, Cohen A., Förster S., Fortea J., Frederiksen K., Valldeoriola F, Gaig C, Santamaria J, Tolosa E, Rademakers R. Potential genetic modifiers Freund-Levi Y., Gill K., Gkatzima O., Grimmer T., Gelpi E. Alpha-synuclein Aggregates in of disease risk and age at onset in patients Hampel H., Herukka S., Johannsen P., van Laere K., Labial Salivary Glands of Idiopathic Rapid with frontotemporal lobar degeneration Mattsson N., Groot C., Jansen W., Landau S., Eye Movement Sleep Behavior Disorder. and GRN mutations: a genome-wide Villemagne V., Engelborghs S., Mintun M., Lleo A., SLEEP. 41(8). I.F.: 5.135 association study. LANCET NEUROLOGY, Molinuevo J., Jagust W., Frisoni G., Ivanoiu A., THE. 17(6):548-558. I.F.: 27.144 Chételat G., Resende de Oliveira C., Rodrigue K., 11. Llorens F., Kruse N., Karch A., Schmitz M., Kornhuber J., Wallin A., Klimkowicz-Mrowiec A., Zafar S., Gotzmann N., Sun T., Köchy S., 3. Jansen; Willemijn J; Ossenkoppele; Rik; Kandimalla R., Popp J., Aalten P., Aarsland D., Knipper T., Cramm M., Golanska E., Sikorska Ossenkoppele; Rik; Tijms; Betty M; Fagan; Anne Alcolea D., Almdahl I., Baldeiras I., van Buchem M., B., Liberski P., Sánchez-Valle R., Fischer A., M; Hansson; Oskar; Klunk; William E; van der Flier; Cavedo E., Chen K., Cohen A., Förster S., Fortea J., Mollenhauer B., Zerr I. Validation of Wiesje M; van der Flier; Wiesje M; Villemagne; Frederiksen K., Freund-Levi Y., Gill K., Gkatzima O., α-Synuclein as a CSF Biomarker for Victor L; Frisoni; Giovanni B; Frisoni; Giovanni B; Grimmer T., Hampel H., Herukka S., Johannsen P., Sporadic Creutzfeldt-Jakob Disease. Fleisher; Adam S; Fleisher; Adam S; Lleó; Alberto; van Laere K., Mattsson N., Groot C., Jansen W., MOLECULAR NEUROBIOLOGY. Mintun; Mark A; Wallin; Anders; Engelborghs; Landau S., Villemagne V., Engelborghs S., Mintun 55(3):2249-2257. I.F.: 5.076 Sebastiaan; Na; Duk L; Chételat; Gäel; Molinuevo; M., Lleo A., Molinuevo J. Prevalence of the José Luis; Landau; Susan M; Mattsson; Niklas; apolipoprotein E ε4 allele in amyloid β 12. Operto G, Cacciaglia R, Grau-Rivera O, Kornhuber; Johannes; Sabri; Osama; Rowe; positive subjects across the spectrum of Falcon C, Brugulat-Serrat A, Ródenas P, Christopher C; Rowe; Christopher C; Parnetti; Alzheimer's disease. ALZHEIMER'S AND Ramos R, Morán S, Esteller M, Bargalló N, Lucilla; Popp; Julius; Fladby; Tormod; Jagust; DEMENTIA. 14(7):913-924. I.F.: 12.764 Molinuevo JL, Gispert JD, ALFA Study. White William J; Aalten; Pauline; Lee; Dong Young; matter microstructure is altered in Vandenberghe; Rik; Resende de Oliveira; 7. Vermunt L., Veal C., ter Meulen L., cognitively normal middle-aged APOE-ε4 Catarina; Kapaki; Elisabeth; Froelich. Chrysostomou C., van der Flier W., Frisoni G., homozygotes. ALZHEIMER'S RESEARCH Association of Cerebral Amyloid-β Guessous I., Kivipelto M., Marizzoni M., AND THERAPY. 10(1):48. I.F.: 5.015 Aggregation With Cognitive Functioning in Martinez-Lage P., Molinuevo J., Porteous D., Persons Without Dementia. JAMA Ritchie K., Scheltens P., Ousset P., Ritchie C., 13. Cummings J., Atri A., Ballard C., Boneva N., PSYCHIATRY. 75(1):84-95. I.F.: 16.642 Luscan G., Brookes A., Visser P. European Frölich L., Molinuevo J., Raket L., Tariot P. Prevention of Alzheimer's Dementia Insights into globalization: comparison of 4. Zerr I, Schmitz M, Karch A, Villar-Piqué A, Registry: Recruitment and prescreening patient characteristics and disease Kanata E, Golanska E, Díaz-Lucena D, approach for a longitudinal cohort and progression among geographic regions in Karsanidou A, Hermann P, Knipper T, Goebel prevention trials. ALZHEIMER'S AND a multinational Alzheimer's disease clinical S, Varges D, Sklaviadis T, Sikorska B, Liberski DEMENTIA. 14(6):837-842. I.F.: 12.764 program. ALZHEIMER'S RESEARCH AND PP, Santana I, Ferrer I, Zetterberg H, Blennow THERAPY. 10(1):116. I.F.: 5.015 K, Calero O, Calero M, Ladogana A, 8. Bergeron D; Gorno-Tempini ML; Rabinovici Sánchez-Valle R, Baldeiras I, Llorens F . GD; Santos-Santos MA; Seeley W; Miller BL; 14. Bos I, Vos S, Vandenberghe R, Scheltens Cerebrospinal fluid neurofilament light Pijnenburg Y; Keulen MA; Groot C; Van Berckel P, Engelborghs S, Frisoni G, Molinuevo JL, levels in neurodegenerative dementia: BNM; van der Flier WM; Scheltens P; Rohrer JD; Wallin A, Lleó A, Popp J, Martinez-Lage P, Evaluation of diagnostic accuracy in the Warren JD; Schott JM; Fox NC; Sanchez-Valle R; Baird A, Dobson R, Legido-Quigley C, differential diagnosis of prion diseases. Grau-Rivera O; Gelpi E; Seelaar H; Papma JM; Sleegers K, Van Broeckhoven C, Bertram L, ALZHEIMER'S AND DEMENTIA. van Swieten JC; Hodges JR; Leyton CE; Piguet Ten Kate M, Barkhof F, Zetterberg H, 14(6):751-763. I.F.: 12.764 O; Rogalsky EJ; Mesulam MM; Koric L; Nora K; Lovestone S, Streffer J, Visser PJ. The Pariente J; Dickerson B; Mackenzie IR; Hsiung EMIF-AD Multimodal Biomarker Discovery 5. Cacciaglia R, Molinuevo JL, Falcón C, GR; Belliard S; Irwin DJ; Wolk DA; Grossman M; study: design, methods and cohort Brugulat-Serrat A, Sánchez-Benavides G, Jones M; Harris J; Mann D. Prevalence of characteristics. ALZHEIMER'S RESEARCH Gramunt N, Esteller M, Morán S, Minguillón C, amyloid-β pathology in distinct variants of AND THERAPY. 10(1):64. I.F.: 5.015 Fauria K, Gispert JD, ALFA study. Effects of primary progressive aphasia. ANNALS OF APOE-?4 allele load on brain morphology NEUROLOGY. 84(5):729-740. I.F.: 10.250 15. Sánchez-Valle R, Heslegrave A, Foiani MS, in a cohort of middle-aged healthy Bosch B, Antonell A, Balasa M, Lladó A, individuals with enriched genetic risk for 9. Rojas S, Brugulat-Serrat A, Bargalló N, Zetterberg H, Fox NC . Serum neurofilament Alzheimer's disease. ALZHEIMER'S AND Minguillón C, Tucholka A, Falcon C, Carvalho light levels correlate with severity DEMENTIA. 14(7):902-912. I.F.: 12.764 A, Morán S, Esteller M, Gramunt N, Fauria K, measures and neurodegeneration Camí J, Molinuevo JL, Gispert JD . Higher markers in autosomal dominant 6. Mattsson N., Groot C., Jansen W., Landau prevalence of cerebral white matter Alzheimer's disease. ALZHEIMER'S S., Villemagne V., Engelborghs S., Mintun M., hyperintensities in homozygous APOE-ε4 RESEARCH AND THERAPY. 10(1):113. I.F.: 5.015 Lleo A., Molinuevo J., Jagust W., Frisoni G., allele carriers aged 45-75: Results from the Ivanoiu A., Chételat G., Resende de Oliveira C., ALFA study. JOURNAL OF CEREBRAL 16. Cacciaglia R., Molinuevo J., Rodrigue K., Kornhuber J., Wallin A., BLOOD FLOW AND METABOLISM. Sánchez-Benavides G., Falcón C., Gramunt N., Klimkowicz-Mrowiec A., Kandimalla R., Popp 38(2):250-261. I.F.: 6.045 Brugulat-Serrat A., Grau O., Gispert J., Camí J.,

273 AREA 4 CLINICAL AND EXPERIMENTAL NEUROSCIENCE

Fauria K., Suárez-Calvet M., Minguillón C., Miltenberger-Miltényi G., Hernández I., Boada FRONTIERS IN AGING NEUROSCIENCE. Salvadó G., Operto G., Crous-Bou M., Polo A., M., Ruiz A., Nacmias B., Sorbi S., Almeida M., 10(193):193. I.F.: 3.582 Mustata C., Tenas L., Marne P., Gotsens X., Santana I., Clarimón J., Lleó A., Frisoni G., Menchón T., Soteras A., Hernandez L., Sanchez-Valle R., Lladó A., Gómez-Tortosa E., 24. Ramos-Campoy O, Ávila-Polo R, Dominguez R., Prades S., Pascual M., Huesa Gelpi E., Van den Broeck M., Peeters K., Cras Grau-Rivera O, Antonell A, Clarimón J, G., Vilanova M., Segundo S., Huguet J. P., De Deyn P., Engelborghs S., Cruts M., Philtjens Rojas-García R, Charif S, Santiago-Valera V, Episodic memory and executive functions S. Rare nonsynonymous variants in SORT1 Hernandez I, Aguilar M, Almenar C, in cognitively healthy individuals display are associated with increased risk for Lopez-Villegas D, Bajo L, Pastor P, Van der distinct neuroanatomical correlates which frontotemporal dementia. NEUROBIOLOGY Zee J, Lladó A, Sanchez-Valle R, Gelpi E . are differentially modulated by aging. OF AGING. 66(181):e3-e10. I.F.: 4.454 Systematic Screening of Ubiquitin/p62 HUMAN BRAIN MAPPING. 39(11):4565-4579. Aggregates in Cerebellar Cortex Expands I.F.: 4.927 20. Baradaran-Heravi Y; Dillen L; Nguyen HP; the Neuropathological Phenotype of the Van Mossevelde S; Baets J; De Jonghe P; C9orf72 Expansion Mutation. JOURNAL 17. Meeter LHH; Gendron TF; Sias AC; Jiskoot Engelborghs S; de Deyn PP; Vandenbulcke M; OF NEUROPATHOLOGY AND LC; Russo SP; Donker Kaat L; Papma JM; Vandenberghe R; Van Damme P; Cras P; EXPERIMENTAL NEUROLOGY. Panman JL; van der Ende EL; Dopper EG; Salmon E; Synofzik M; Heutink P; Wilke C; 77(8):703-709. I.F.: 3.490 Franzen S; Graff C; Boxer AL; Rosen HJ; Simón-Sánchez J; Rojas-Garcia R; Turon-Sans Sanchez-Valle R; Galimberti D; Pijnenburg J; Lleo A; Illán-Gala I; Clarimon J; Borroni B; 25. Valech N., Tort-Merino A., Coll-Padrós N., YAL; Benussi L; Ghidoni R; Borroni B; Laforce Padovani A; Pastor P; Díez-Fairen M; Aguilar M; Olives J., León M., Rami L., Molinuevo J. R; del Campo M; Teunissen CE; van Minkelen Gelpi E; Sanchez-Valle R; Borrego-Écija S; Matej Executive and Language Subjective R; Rojas JC; Coppola G; Geschwind DH; R; Parobkova E; Nacmias B; Sorbi S; Bagnoli S; Cognitive Decline Complaints Discriminate Rademakers R; Karydas AM; Öijerstedt L; de Mendonça A; Ferreira C; Fraidakis MJ; Preclinical Alzheimer's Disease from Normal Scarpini E; Binetti G; Padovani A; Cash DM; Diehl-Schmid J; Alexopoulos P. No Aging. JOURNAL OF ALZHEIMER'S DISEASE. Dick KM; Bocchetta M; Miller BL; Rohrer JD; supportive evidence for TIA1 gene 61(2):689-703. I.F.: 3.476 Petrucelli L; van Swieten JC. Poly(GP), mutations in a European cohort of neurofilament and grey matter deficits in ALS-FTD spectrum patients. 26. Tucholka, Alan; Grau-Rivera, Oriol; Falcon, C9orf72 expansion carriers. ANNALS OF NEUROBIOLOGY OF AGING. 69(293):e9-e11. Carles; Rami, Lorena; Sanchez-Valle, Raquel; CLINICAL AND TRANSLATIONAL I.F.: 4.454 Llado, Albert; Domingo Gispert, Juan; Luis NEUROLOGY. 5(5):583-597. I.F.: 4.649 Molinuevo, Jose; Alzheimer's Dis 21. Lladó A., Tort-Merino A., Sánchez-Valle R., Neuroimaging Initia. Structural Connectivity 18. Verheijen J., van der Zee J., Gijselinck I., Falgàs N., Balasa M., Bosch B., Castellví M., Alterations Along the Alzheimer's Disease Van den Bossche T., Dillen L., Heeman B., Olives J., Antonell A., Hornberger M. The Continuum: Reproducibility Across Two Gómez-Tortosa E., Lladó A., Sanchez-Valle R., hippocampal longitudinal axis-relevance Independent Samples and Correlation Graff C., Pastor P., Pastor M., Benussi L., for underlying tau and TDP-43 pathology. with Cerebrospinal Fluid Amyloid-beta and Ghidoni R., Binetti G., Clarimon J., de Mendonça NEUROBIOLOGY OF AGING. 70:1-9. I.F.: 4.454 Tau. JOURNAL OF ALZHEIMER'S DISEASE. A., Gelpi E., Tsolaki M., Diehl-Schmid J., Nacmias 61(4):1575-1587. I.F.: 3.476 B., Almeida M., Borroni B., Matej R., Ruiz A., 22. Falcon C., Tucholka A., Monté-Rubio G., Engelborghs S., Vandenberghe R., De Deyn P., Cacciaglia R., Operto G., Rami L., Gispert J., 27. Casamitjana, Adria; Petrone, Paula; Cruts M., Van Broeckhoven C., Sleegers K., Molinuevo J. Longitudinal structural Tucholka, Alan; Falcon, Carles; Skouras, Goeman J., Nuytten D., Vandenbulcke M., cerebral changes related to core CSF Stavros; Luis Molinuevo, Jose; Vilaplana, Santens P., De Bleecker J., Sieben A., Dermaut B., biomarkers in preclinical Alzheimer's Veronica; Domingo Gispert, Juan; Alzheimers Versijpt J., Michotte A., Verheijen J., van der Zee disease: A study of two independent Dis Neuroimaging Initia. MRI-Based J., Gijselinck I., Van den Bossche T., Dillen L., datasets. NEUROIMAGE: CLINICAL. Screening of Preclinical Alzheimer's Heeman B., Gómez-Tortosa E., Lladó A., 19:190-201. I.F.: 3.869 Disease for Prevention Clinical Trials. Sanchez-Valle R., Graff C., Pastor P., Pastor M., JOURNAL OF ALZHEIMER'S DISEASE. Benussi L., Ghidoni R., Binetti G., Clarimon J., de 23. Bos, Isabelle; Vos, Stephanie J. B.; Jansen, 64(4):1099-1112. I.F.: 3.476 Mendonça A., Gelpi E., Tsolaki M., Diehl-Schmid Willemijn J.; Vandenberghe, Rik; Gabel, Silvy; J., Nacmias B., Almeida M., Borroni B., Matej R., Estanga, Ainara; Ecay-Torres, Mirian; Ruiz A., Engelborghs S., Vandenberghe R. Tomassen, Jori; den Braber, Anouk; Lleo, Review / I.F.: 35.829 Common and rare TBK1 variants in Alberto; Sala, Isabel; Wallin, Anders; Kettunen, early-onset Alzheimer disease in a Petronella; Molinuevo, Jose L.; Rami, Lorena; 1. Molinuevo JL, Ayton S, Batrla R, Bednar MM, European cohort. NEUROBIOLOGY OF Chetelat, Gael; de la Sayette, Vincent; Tsolaki, Bittner T, Cummings J, Fagan AM, Hampel H, AGING. 62(245):e1-e7. I.F.: 4.454 Magda; Freund-Levi, Yvonne; Johannsen, Mielke MM, Mikulskis A, O'Bryant S, Scheltens Peter; Novak, Gerald P.; Ramakers, Inez; P, Sevigny J, Shaw LM, Soares HD, Tong G, 19. Philtjens S., Van Mossevelde S., van der Verhey, Frans R.; Visser, Pieter Jelle; Trojanowski JQ, Zetterberg H, Blennow K. Zee J., Wauters E., Dillen L., Vandenbulcke M., Alzheimers Dis Neuroimaging Initia. Current state of Alzheimer's fluid Vandenberghe R., Ivanoiu A., Sieben A., Amyloid-beta, Tau, and Cognition in biomarkers. ACTA NEUROPATHOLOGICA. Willems C., Benussi L., Ghidoni R., Binetti G., Cognitively Normal Older Individuals: 136(6):821-853. I.F.: 15.876 Borroni B., Padovani A., Pastor P., Diez-Fairen Examining the Necessity to Adjust for M., Aguilar M., de Mendonça A., Biomarker Status in Normative Data. 2. Jack C., Bennett D., Blennow K., Carrillo M.,

274 ALZHEIMER'S DISEASE AND OTHER COGNITIVE DISORDERS 4.12

Dunn B., Haeberlein S., Holtzman D., Jagust W., Case Reports / I.F.: 4.649 y aumento de la actividad física sobre la Jessen F., Karlawish J., Liu E., Molinuevo J., congnición y la estructura y función Montine T., Phelps C., Rankin K., Rowe C., 1. Vicente-Pascual M., Rossi M., Gámez J., cerebrales determinados por resonancia Scheltens P., Siemers E., Snyder H., Sperling Lladó A., Valls J., Grau-Rivera O., Ávila Polo R., magnética funcional en individuos obesos R., Elliott C., Masliah E., Ryan L., Silverberg N. Llorens F., Zerr I., Ferrer I., Nos C., Parchi P., con síndrome metabólico. NIA-AA Research Framework: Toward a Sánchez-Valle R., Gelpí E. Variably Sponsoredby: Instituto de Salud Carlos III biological deﬁnition of Alzheimer's protease-sensitive prionopathy (ISCIII). PI14/00563 disease. ALZHEIMER'S AND DEMENTIA. presenting within ALS/FTD spectrum. Duration: 01/01/2015-30/06/2018 14(4):535-562. I.F.: 12.764 ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY. Sánchez-Valle R. Study of genetic 3. Lewczuk P; Riederer P; O'Bryant SE; 5(10):1297-1302. I.F.: 4.649 frontotemporal dementia in preclinical and Verbeek MM; Dubois B; Visser PJ; Jellinger early stages of the disease: cognitive KA; Engelborghs S; Ramírez Á; Parnetti L; performance, structural and functional Jack CR; Teunissen CE; Hampel H; Lleo A; GRANTS FOR RESEARCHIN PROGRESS neuroimaging and biochemical markers Jessen F; Glodzik L; de Leon MJ; Fagan AM; (GENFI2-Barcelona site). Molinuevo JL; Jansen WJ; Winblad B; Shaw LM; Antonell A. Comparative study between Sponsoredby: Fundació La Marató de TV3. Andreasson U; Otto M; Mollenhauer B; Wiltfang genetic Alzheimer’s disease and genetic Neuro_14 J; Turner MR. Cerebrospinal ﬂuid and blood Frontotemporal dementia using Duration: 12/05/2015-11/05/2020 biomarkers for neurodegenerative lymphoblastoid cell lines and brain tissue dementias: An update of the Consensus of from patients. Sanchez-Valle R. Estudio de biomarcadores the Task Force on Biological Markers in Sponsored by: Instituto de Salud Carlos III y desarrollo de nuevas estrategias Psychiatry of the World Federation of (ISCIII). PI17/00670 terapéuticas en una cohorte multicéntrica Societies of Biological Psychiatry. WORLD Duration:01/01/2018-31/12/2020 de Demencia Frontotemporal. JOURNAL OF BIOLOGICAL PSYCHIATRY. Sponsored by: Generalitat de Catalunya. 19(4):244-328. I.F.: 3.713 Balasa M. Primary-specialized Care PERIS (SLT002/16/00408) Partnership for an Earlier Diagnosis of Duration: 27/03/2017-31/12/2019 4. Luis Molinuevo, Jose; Minguillon, Carolina; Alzheimer´s Disease. Rami, Lorena; Domingo Gispert, Juan. The Sponsored by: Alzheimer’s Association & Sánchez-Valle R. Searching for therapeutic Rationale Behind the New Alzheimer's Global Brain Health Institute. interventions in frontotemporal dementia Disease Conceptualization: Lessons GBHI_ALZ-18-542110 with C9ORF72 repeat expansions in the Learned During the Last Decades. Duration:01/01/2018-31/07/2019 presymptomatic stage (PreFrontALS). JOURNAL OF ALZHEIMER'S DISEASE. Sponsoredby: Instituto de Salud Carlos III 62(3):1067-1077. I.F.: 3.476 Lladó A. Clinical phenotypes and new (ISCIII). AC14/00013 physiopathological, diagnostic and Duration: 01/01/2015-30/06/2019 prognostic biomarkers for early onset Letters / I.F.: 11.601 Alzheimer’s disease and behavioural Sánchez-Valle R. Genetic dementia variant of frontotemporal dementia. (autosomal dominant Alzheimer’s disease 1. Borrego-Ecija, Sergi; Grau-Rivera, Oriol; Sponsoredby: Instituto de Salud Carlos III and genetic prion disease) in preclinical Colom-Cadena, Marti; Luis Molinuevo, Jose; (ISCIII). PI14/00282 and early stages of the disease: cognitive Tolosa, Eduard; Sanchez-Valle, Raquel; Gelpi, Duration:01/01/2015-31/12/2018 performance, neuroimaging and Ellen. Tauopathy with Hippocampal biochemical markers. 4-Repeat Tau Immunoreactive Spherical Molinuevo JL. MEDIT-AGEING: Sponsoredby: Instituto de Salud Carlos III Inclusions in a Patient with PSP. BRAIN Investigating the impact of meditation (ISCIII). PI16/000235 PATHOLOGY. 28(2):284-286. I.F.: 6.187 training on mental health and wellbeing in Duration:01/01/2017-31/12/2019 the ageing population. 2. Fournier, Clemence; Anquetil, Vincent; Sponsored by: European commission. Sanchez-Valle R. AETIONOMY: Organising Camuzat, Agnes; Stirati-Buron, Sandrine; H2020_PHC_15 Knowledge about Neurodegenerative Sazdovitch, Veronique; Molina-Porcel, Laura; Duration: 01/01/2016-31/12/2020 Disease Mechanisms for the Improvement Turbant, Sabrina; Rinaldi, Daisy; of Drug Development and Therapy. Sanchez-Valle, Raquel; Barbier, Mathieu; Rami L. Subjective cognitive decline in Sponsored by: European commission. IMI_12 Latouche, Morwena; Stevanin, Giovanni; preclinical Alzheimer's Disease: European (115568) Seilhean, Danielle; Brice, Alexis; Duyckaerts, initiative on harmonization and on a Duration: 01/01/2014-12/02/2019 Charles; Le Ber, Isabelle; Neuro-CEB lifestyle-based prevention Neuropathology Network. Interrupted CAG strategy.(EURO-SCD) Sanchez-Valle R. ADPS: Alzheimer's expansions in ATXN2 gene expand the Sponsoredby: Instituto de Salud Carlos III Disease Prediction Service (ADPS): digital genetic spectrum of frontotemporal (ISCIII). AC14/00014 biomarker for Real-World Evidence (RWE) dementias. ACTA NEUROPATHOLOGICA Duration: 01/01/2015-30/06/2019 in AD. COMMUNICATIONS. 6(1):41. I.F.: 5.414 Sponsored by: European commission. Rami L. Efectos de la pérdida de peso EITHealth_2018 (18066) mediante dieta mediterránea hipocalórica Duration: 01/01/2018-12/02/2019

275 ANNUAL SCIENTIFIC REPORT 2018

AREA 5

ONCOLOGY AND HAEMATOLOGY 5

ONCOLOGY AND HAEMATOLOGY

5.1 Oncological molecular pathology 278 Elías Campo

5.2 Diagnosis and therapy in oncology 286 Francesca Pons

5.3 Molecular biology of reproduction and development 290 Rafael Oliva

5.4 Genetics 292 Montserrat Milà

5.5 Melanoma: imaging, genetics and immunology 295 Susana Puig

5.6 Hematopoietic progenitor cell transplantation 300 Álvaro Urbano-Ispizua

5.7 Hematological oncology 302 Francisco Cervantes

5.8 Physiopathology and molecular bases in hematology 293310 Dolors Colomer

5.9 Hemotherapy - hemostasis 314 Ginés Escolar

5.10 Molecular and translational oncology 318 Pere Gascón 5.11 Cell proliferation and signaling 321 Oriol Bachs

5.12 Cell compartments and signaling 323 Carles Enrich

5.13 Translational genomics and targeted therapeutics in solid tumors 326 Aleix Prat

277 AREA 5 ONCOLOGY AND HAEMATOLOGY

Oncological molecular 5.1 pathology

Alba Navarro (CIBER) Cecilia Rosales (IDIBAPS) LOCATION Laura Siles (FCRB) CEK building, ﬂoor 2

PRE-DOCTORAL RESEARCHERS Vicente Chapaprieta (UB) Martí Duran (IDIBAPS) Alvaro Eguileor (IDIBAPS) David Martín (IDIBAPS) KEYWORDS M Carmen Martínez (IDIBAPS) 1. Lymphoid neoplasms TEAM LEADER Ferran Nadeu (IDIBAPS) 2. Epigenome Elías Campo (HCB-UB) Chiara Ninfali (IDIBAPS) 3. Transcriptional regulation T. 93 227 54 50 Joan Enric Ramis (FCRB) 4. Molecular pathology [email protected] Lidia Sanchez (IDIBAPS)

5. Solid tumors Marta Sureda-Gómez (IDIBAPS) Roser Vilarrasa (IDIBAPS) GROUP LEADERS Elías Campo (HCB-UB) TECHNICIANS T. 93 227 54 50 Cristina Capdevila (IDIBAPS) [email protected] Noelia García (FCRB) Original publications Silvia Martín (CIBER) Miriam Cuatrecasas (HCB) Miriam Prieto (FCRB) from 2016 to 2018 T. 93 227 54 50 Marta Leonor Rodríguez (IDIBAPS) YEAR I.F. TOTAL Q1 Q2 [email protected] Nuria Russiñol (FCRB) Núria Proﬁtós (IDIBAPS) 2016 333.82 45 36 5 José Ignacio Martín-Subero (IDIBAPS) Nuria Verdaguer (UB) 2017 421.05 57 46 6 [email protected] 2018 489.84 39 34 5 ADMINISTRATIVE STAFF Antonio Postigo (ICREA - IDIBAPS) Mª Carmen Muro (FCRB) [email protected] Sílvia Ruiz (IDIBAPS)

COLLABORATORS TEAM INVOLVED IN RESEARCHERS Raquel Bermudo (IDIBAPS) AGAUR_SGR17: 01482, 00709, Iban Aldecoa (HCB) Anna Enjuanes (IDIBAPS) 01142, 00736, 01174, 01107 Llúcia Alós (HCB-UB) Magdalena Pinyol (IDIBAPS) CIBERONC Virginia Amador (IDIBAPS) ICGC Sílvia Beà (IDIBAPS) LLMPP Renée Beekman (IDIBAPS) European Mantle Cell Lymphoma Josep Antoni Bombi (HCB-UB) STRATEGIC OBJECTIVES network Pedro Luis Fernández (HCB-UB) Luis Hernández (IDIBAPS) Identification of genetic and molecular Pedro Jares (HCB-UB) mechanisms implicated in the development Carme Mallofré (HCB-UB) and progression of human neoplasms. Antonio Martínez (HCB-UB) Development of strategies to transfer to Alfons Nadal (HCB-UB) clinical practice the knowledge generated by José Francisco Ramírez (HCB-UB) basic research on human tumours. Teresa Ribalta (HCB-UB) Identification of parameters allowing the Itziar Salaverria (IDIBAPS) improved diagnosis and prognosis of Esther Sánchez (IDIBAPS) neoplastic disease, and the identification of Manel Solé (HCB-UB) possible therapeutic targets.

POST-DOCTORAL RESEARCHERS Patricia Balsas (FCRB) Guillem Clot (IDIBAPS) MAIN LINES OF RESEARCH Marlies Cortes (FCRB) Oriol de Barrios (IDIBAPS) Molecular Pathology of Lymphoid Santiago Demajo (IDIBAPS) Neoplasms Adriana García (HCB) Blanca Gonzalez (HCB) a) To understand the genetic and molecular Marta Teresa Kulis (IDIBAPS) mechanisms involved in the development Daniel Martínez (HCB) and progression of lymphoid neoplasms

278 ONCOLOGICAL MOLECULAR PATHOLOGY 5.1

and to identify parameters that may RESEARCH GROUP RESEARCH GROUP improve the diagnosis of these disease, MOLECULAR PATHOLOGY MOLECULAR PATHOLOGY stratify patients according to biological risk, OF LYMPHOID NEOPLASMS OF SOLID TUMORS and define possible therapeutic targets. GROUP LEADER b) To define the complete catalogue of Miriam Cuatrecasas (HCB) somatic genomic alterations in several lymphoid neoplasm and their clinical and Our study of solid neoplasms is mainly functional relevance. focused on breast, urological, digestive, skin, H&N and neurological cancers. We have Molecular Pathology of Solid neoplasms GROUP LEADER started massive genomic analysis of breast Elías Campo (HCB) carcinomas with NGS techniques with special a) To study the molecular mechanisms of interest in triple-negative tumours and we plan invasion and metastasis, transcriptional Lymphoid neoplasias are a very to correlate genomic abnormalities with expression profiles implicated in the heterogeneous group of tumors with clinicopathological parameters of the cases. development and progression of different remarkable variability in their biological This type of genomic studies is also being human tumours in relation to biological behaviour and clinical manifestations. applied to bladder cancer in addition to FISH aggressivity and therapeutic options. We Our group aims to understand the genetic, experiments in order to subclassify focus mainly on breast and prostate epigenetic, and molecular mechanisms transitional carcinomas in advanced stages. tumours as neoplasms under hormone underlying the biological diversity of these influence, and skin, digestive, urological and tumors and how they may influence the clinical airway neoplasms. evolution of the patients. b) Study of the possible criteria of treatment The use of new genomic technologies is RESEARCH GROUP response and prognosis in neurological providing new perspectives on the tumors we TRANSCRIPTIONAL REGULATION tumours. concentrate our research, particularly chronic OF GENE EXPRESSION lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma and diffuse large B-cell GROUP LEADER Transcriptional Regulation of Gene lymphoma. In addition to better understand Antonio Postigo (ICREA-IDIBAPS) Expression the pathogenesis of these tumors we are generating new approaches to translate this Our group investigates the regulation of gene a) Study the molecular mechanisms new information into the clinics. expression by the ZEB family of transcription regulating gene expression during normal factors (ZEB1 and ZEB2). We use cell lines, cell differentiation and in cancer. transgenic mice and human samples to study the role of ZEB factors in the regulation of cell b) Characterization of the transcription stemness and differentiation and tumor factors ZEB1 and ZEB2 as prognostic and progression using epithelial (colon, ovarian, predictive biomarkers in cancer (e.g., breast, lung), skeletal muscle and carcinomas, lymphomas) and other diseases (e.g. muscular dystrophies).

Biomedical Epigenomics a) To understand the epigenetic mechanisms involved both in normal differentiation and neoplastic cell transformation. In particular, focusing on B cells as cellular model, we aim at characterizing and understanding gene regulation alterations in the initiation and evolution of lymphoid malignancies. b) To identify novel biomarkers for a better classiﬁcation and estimation of prognosis in lymphoid neoplasms as well as to reveal novel molecular targets for therapeutic interventions. GROUP Elías Campo

279 AREA 5 ONCOLOGY AND HAEMATOLOGY

hematopoietic systems as models. The group has received funding from the Spanish and Catalan governments and the EU as well as from national and international private foundations (e.g., AECC, La Marató de TV3, Leukemia Research Foundation, Avon SAU, Cosmetics, ACMCB, FOT).

RESEARCH GROUP BIOMEDICAL EPIGENOMICS

GROUP LEADER

José Ignacio Martín-Subero (IDIBAPS) GROUP Antonio Postigo

The biomedical epigenomics group is PUBLICATIONS 2. Phelan JD, Young RM, Webster DE, focused on the application of whole-genome Roulland S, Wright GW, Kasbekar M, Shaffer technologies to characterize epigenomic Originals / I.F.: 489.835 AL, Ceribelli M, Wang JQ, Schmitz R, dynamics during cell differentiation and Nakagawa M, Bachy E, Huang DW, Ji Y, Chen neoplastic transformation, with particular 1. Schmitz R, Wright GW, Huang DW, Johnson L, Yang Y, Zhao H, Yu X, Xu W, Palisoc MM, emphasis on studying normal and neoplastic CA, Phelan JD, Wang JQ, Roulland S, Valadez RR, Davies-Hill T, Wilson WH, Chan B cells. A major goal of the group is to Kasbekar M, Young RM, Shaffer AL, Hodson WC, Jaffe ES, Gascoyne RD, Campo E, understand the molecular determinants of DJ, Xiao W, Yu X, Yang Y, Zhao H, Xu W, Liu X, Rosenwald A, Ott G, Delabie J, Rimsza LM, gene deregulation in lymphoid tumors through Zhou B, Du W, Chan WC, Jaffe ES, Gascoyne Rodriguez FJ, Estephan F, Holdhoff M, Kruhlak the integration of different layers of RD, Connors JM, Campo E, Lopez-Guillermo A, MJ, Hewitt SM, Thomas CJ, Pittaluga S, information, i.e., genetic alterations, DNA Rosenwald A, Ott G, Delabie J, Rimsza LM, Tay Oellerich T, Staudt LM. A multiprotein methylation, histone modifications, chromatin Kuang Wei K, Zelenetz AD, Leonard JP, Bartlett supercomplex controlling oncogenic accessibility and 3D chromatin structure. NL, Tran B, Shetty J, Zhao Y, Soppet DR, signalling in lymphoma. NATURE. The ultimate goal is to translate the generated Pittaluga S, Wilson WH, Staudt LM . Genetics 560(7718):387-391. I.F.: 41.577 epigenomic knowledge into a benefit for and Pathogenesis of Diffuse Large B-Cell patients, in terms of improved diagnosis, Lymphoma. NEW ENGLAND JOURNAL OF 3. Huet S, Tesson B, Jais JP, Feldman AL, estimation of prognosis and treatment. MEDICINE. 378(15):1396-1407. I.F.: 79.260 Magnano L, Thomas E, Traverse-Glehen A, Albaud B, Carrère M, Xerri L, Ansell SM, Baseggio L, Reyes C, Tarte K, Boyault S, Haioun C, Link BK, Feugier P, Lopez-Guillermo A, Tilly H, Brice P, Hayette S, Jardin F, Offner F, Sujobert P, Gentien D, Viari A, Campo E, Cerhan JR, Salles G . A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. LANCET ONCOLOGY. 19(4):549-561. I.F.: 36.421

4. Beekman R, Chapaprieta V, Russiñol N, Vilarrasa-Blasi R, Verdaguer-Dot N, Martens JHA, Duran-Ferrer M, Kulis M, Serra F, Javierre BM, Wingett SW, Clot G, Queirós AC, Castellano G, Blanc J, Gut M, Merkel A, Heath S, Vlasova A, Ullrich S, Palumbo E, Enjuanes A, Martín-García D, Beà S, Pinyol M, Aymerich M, Royo R, Puiggros M, Torrents D, Datta A, Lowy GROUP José Ignacio Martín-Subero

280 ONCOLOGICAL MOLECULAR PATHOLOGY 5.1

E, Kostadima M, Roller M, Clarke L, Flicek P, Summa S, Melle F, Motta G, De Iuliis V, Opinto Campo E, Cerutti A, Ponzoni M, Pattini L, Agirre X, Prosper F, Baumann T, Delgado J, G, Enjuanes A, Rega S, Gulino A, Agostinelli C, Caligaris-Cappio F, Ghia P, Brendolan A. A López-Guillermo A, Fraser P, Yaspo ML, Scattone A, Tommasi S, Mangia A, Mele F, retinoic acid-dependent stroma-leukemia Guigó R, Siebert R, Martí-Renom MA, Puente Simone G, Zito AF, Ingravallo G, Vitolo U, crosstalk promotes chronic lymphocytic XS, López-Otín C, Gut I, Stunnenberg HG, Chiappella A, Tarella C, Gianni AM, Rambaldi leukemia progression. NATURE Campo E, Martin-Subero JI. The reference A, Zinzani PL, Casadei B, Derenzini E, Loseto COMMUNICATIONS. 9(1):1787. I.F.: 12.353 epigenome and regulatory chromatin G, Pileri A, Tabanelli V, Fiori S, Rivas-Delgado landscape of chronic lymphocytic A, López-Guillermo A, Venesio T, Sapino A, 16. Ninfali C., Siles L., Darling D., Postigo A. leukemia. NATURE MEDICINE. Campo E, Tripodo C, Guarini A, Pileri SA . Regulation of muscle atrophy-related 24(6):868-880. I.F.: 32.621 Dissection of DLBCL Microenvironment genes by the opposing transcriptional Provides a Gene Expression-Based activities of ZEB1/CtBP and FOXO3. 5. Luna J, Boni J, Cuatrecasas M, Bofill-De Predictor of Survival Applicable to NUCLEIC ACIDS RESEARCH. Ros X, Núñez-Manchón E, Gironella M, Formalin-Fixed Paraffin-Embedded 46(20):10697-10708. I.F.: 11.561 Vaquero EC, Arbones ML, de la Luna S, Fillat Tissue. ANNALS OF ONCOLOGY. C. DYRK1A modulates c-MET in pancreatic 29(12):2363-2370. I.F.: 13.930 17. Gómez S, Garrido-Garcia A, Garcia- ductal adenocarcinoma to drive tumour Gerique L, Lemos I, Suñol M, de Torres C, Kulis growth. GUT. 316128(8):1465-1476. I.F.: 17.016 11. Paré L, Pascual T, Seguí E, Teixidó C, M, Pérez-Jaume S, Carcaboso ÁM, Luu B, Gonzalez-Cao M, Galván P, Rodríguez A, Kieran MW, Jabado N, Kozlenkov A, Dracheva 6. Clot G, Jares P, Giné E, Navarro A, Royo C, González B, Cuatrecasas M, Pineda E, Torné S, Ramaswamy V, Hovestadt V, Johann P, Pinyol M, Martín-Garcia D, Demajo S, Espinet A, Crespo G, Martin-Algarra S, Pérez-Ruiz E, Jones DTW, Pfister SM, Morales La Madrid A, B, Salar A, Ferrer A, Muntañola A, Aymerich M, Reig Ò, Viladot M, Font C, Adamo B, Vidal M, Cruz O, Taylor MD, Martin-Subero JI, Mora J, Rauert-Wunderlich H, Jaffe ES, Connors JM, Gaba L, Muñoz M, Victoria I, Ruiz G, Viñolas N, Lavarino C. A novel method for rapid Gascoyne RD, Delabie J, López-Guillermo A, Mellado B, Maurel J, Garcia-Corbacho J, molecular subgrouping of Ott G, Wright GW, Staudt LM, Rosenwald A, Molina-Vila MÁ, Juan M, Llovet JM, Reguart N, medulloblastoma. CLINICAL CANCER Scott DW, Rimsza LM, Beà S, Campo E . A Arance A, Prat A. Association between PD1 RESEARCH. 24(6):1355-1363. I.F.: 10.199 gene signature that distinguishes mRNA and response to anti-PD1 conventional and leukemic nonnodal monotherapy across multiple 18. Nadeu F, Clot G, Delgado J, Martín-García mantle cell lymphoma helps predict cancer-types. ANNALS OF ONCOLOGY. D, Baumann T, Salaverria I, Beà S, Pinyol M, outcome. BLOOD. 132(4):413-422. I.F.: 15.132 29(10):2121-2128. I.F.: 13.930 Jares P, Navarro A, Suárez-Cisneros H, Aymerich M, Rozman M, Villamor N, Colomer 7. Bretones G, Álvarez MG, Arango JR, 12. Albero R, Enjuanes A, Demajo S, D, González M, Alcoceba M, Terol MJ, Navarro Rodríguez D, Nadeu F, Prado MA, Valdés-Mas Castellano G, Pinyol M, García N, Capdevila C, B, Colado E, Payer ÁR, Puente XS, López-Otín R, Puente DA, Paulo JA, Delgado J, Villamor N, Clot G, Suárez-Cisneros H, Shimada M, C, López-Guillermo A, Enjuanes A, Campo E . López-Guillermo A, Finley DJ, Gygi SP, Karube K, López-Guerra M, Colomer D, Beà S, Clinical impact of the subclonal Campo E, Quesada V, López-Otín C . Altered Martin-Subero JI, Campo E, Jares P. Cyclin D1 architecture and mutational complexity in patterns of global protein synthesis and overexpression induces global chronic lymphocytic leukemia. LEUKEMIA. translational fidelity in RPS15-mutated transcriptional downregulation in 32(3):645-653. I.F.: 10.023 chronic lymphocytic leukemia. BLOOD. lymphoid neosplasms. JOURNAL OF 132(22):2375-2388. I.F.: 15.132 CLINICAL INVESTIGATION. 128(9):4132-4147. 19. Karube K, Enjuanes A, Dlouhy I, Jares P, I.F.: 13.251 Martin-Garcia D, Nadeu F, Ordóñez GR, 8. Schmidt J, Ramis-Zaldivar J, Bonzheim I, Rovira J, Clot G, Royo C, Navarro A, Steinhilber J, Müller I, Haake A, Yu S, Raffeld M, 13. Liu Y, Siles L, Lu X, Dean K, Cuatrecasas M, Gonzalez-Farre B, Vaghefi A, Castellano G, Fend F, Salaverria I, Siebert R, Jaffe E, Postigo A, Dean D. Mitotic polarization of Rubio-Perez C, Tamborero D, Briones J, Salar Quintanilla-Martinez L. CREBBP gene transcription factors during asymmetric A, Sancho JM, Mercadal S, Gonzalez-Barca E, mutations are frequently detected in in situ division establishes fate of forming cancer Escoda L, Miyoshi H, Ohshima K, Miyawaki K, follicular neoplasia. BLOOD. cells. NATURE COMMUNICATIONS. Kato K, Akashi K, Mozos A, Colomo L, 132(25):2687-2690. I.F.: 15.132 9(1):2424. I.F.: 12.353 Alcoceba M, Valera A, Carrió A, Costa D, Lopez-Bigas N, Schmitz R, Staudt LM, 9. Mottok A, Wright G, Rosenwald A, Ott G, 14. Liu, Bing; Sureda-Gomez, Marta; Zhen, Salaverria I, López-Guillermo A, Campo E . Ramsower C, Campo E, Braziel RM, Delabie J, Yang; Amador, Virginia; Reverter, David. A Integrating genomic alterations in diffuse Weisenburger DD, Song JY, Chan WC, Cook quaternary tetramer assembly inhibits the large B-cell lymphoma identifies new JR, Fu K, Greiner T, Smeland E, Holte H, deubiquitinating activity of USP25. relevant pathways and potential Savage KJ, Glinsmann-Gibson BJ, Gascoyne NATURE COMMUNICATIONS. 9(4973):4973. therapeutic targets. LEUKEMIA. RD, Staudt LM, Jaffe ES, Connors JM, Scott I.F.: 12.353 32(3):675-684. I.F.: 10.023 DW, Steidl C, Rimsza LM. Molecular classification of primary mediastinal large 15. Farinello D, Wozińska M, Lenti E, 20. Burns A, Alsolami R, Becq J, B-cell lymphoma using routinely available Genovese L, Bianchessi S, Migliori E, Stamatopoulos B, Timbs A, Bruce D, Robbe P, tissue specimens. BLOOD. Sacchetti N, di Lillo A, Bertilaccio MTS, de Lalla Vavoulis D, Clifford R, Cabes M, Dreau H, 132(22):2401-2405. I.F.: 15.132 C, Valsecchi R, Gleave SB, Lligé D, Scielzo C, Taylor J, Knight SJL, Mansson R, Bentley D, Mauri L, Ciampa MG, Scarfò L, Bernardi R, Beekman R, Martín-Subero JI, Campo E, 10. Ciavarella S, Vegliante MC, Fabbri M, De Lazarevic D, Gonzalez-Farre B, Bongiovanni L, Houlston RS, Ridout KE, Schuh A. Whole

281 AREA 5 ONCOLOGY AND HAEMATOLOGY

genome sequencing of chronic MODERN PATHOLOGY. 31(5):732-743. investigator's choice in relapsed or lymphocytic leukemia reveals distinct I.F.: 6.655 refractory mantle cell lymphoma. BRITISH differences in the mutational landscape JOURNAL OF HAEMATOLOGY. between IgHVmut and IgHVunmut 25. Miyaoka M, Kikuti YY, Carreras J, Ikoma H, 180(2):224-235. I.F.: 5.128 subgroups. LEUKEMIA. 32(2):332-342. Hiraiwa S, Ichiki A, Kojima M, Ando K, Yokose I.F.: 10.023 T, Sakai R, Hoshikawa M, Tomita N, Miura I, 30. Alonso V, Escudero P, Fernández-Martos Takata K, Yoshino T, Takizawa J, Bea S, C, Salud A, Méndez M, Gallego J, Rodriguez 21. Solans M, Castelló A, Benavente Y, Campo E, Nakamura N. Clinicopathological JR, Martín-Richard M, Fernández-Plana J, Marcos-Gragera R, Amiano P, and genomic analysis of double-hit Manzano H, Méndez JC, Zanui M, Falcó E, Gracia-Lavedan E, Costas L, Robles C, follicular lymphoma: comparison with Gil-Raga M, Rojo F, Cuatrecasas M, Feliu J, Gonzalez-Barca E, de la Banda E, Alonso E, high-grade B-cell lymphoma with MYC and García-Albéniz X, Maurel J. Coexpression of Aymerich M, Campo E, Dierssen-Sotos T, BCL2 and/or BCL6 rearrangements. p-IGF-1R and MMP-7 Modulates Fernández-Tardón G, Olmedo-Requena R, MODERN PATHOLOGY. 31(2):313-326. Panitumumab and Cetuximab Efficacy in Gimeno E, Castaño-Vinyals G, Aragonés N, I.F.: 6.655 RAS Wild-Type Metastatic Colorectal Kogevinas M, de Sanjose S, Pollán M, Cancer Patients. NEOPLASIA. Casabonne D. Adherence to the Western, 26. García-Barchino MJ, Sarasquete ME, 20(7):678-686. I.F.: 4.994 Prudent, and Mediterranean dietary Panizo C, Morscio J, Martinez A, Alcoceba M, patterns and chronic lymphocytic Fresquet V, Gonzalez-Farre B, Paiva B, Young 31. Franch-Expósito S, Esteban-Jurado C, leukemia in the MCC-Spain study. KH, Robles EF, Roa S, Celay J, Larrayoz M, Garre P, Quintanilla I, Duran-Sanchon S, HAEMATOLOGICA. 103(11):1881-1888. Rossi D, Gaidano G, Montes-Moreno S, Piris Díaz-Gay M, Bonjoch L, Cuatrecasas M, I.F.: 9.090 MA, Balanzategui A, Jimenez C, Rodriguez I, Samper E, Muñoz J, Ocaña T, Carballal S, Calasanz MJ, Larrayoz MJ, Segura V, López-Cerón M, Castells A, Vila-Casadesús 22. Companioni O, Bonet C, García N, Garcia-Muñoz R, Rabasa MP, Yi S, Li J, Zhang M, Derdak S, Laurie S, Beltran S, Carvajal J, Ramírez-Lázaro MJ, Lario S, Mendoza J, M, Xu-Monette ZY, Puig-Moron N, Orfao A, Bujanda L, Ruiz-Ponte C, Camps J, Gironella Adrados MM, Poves E, Espinosa L, Böttcher S, Hernandez-Rivas JM, Miguel JS, M, Lozano J, Balaguer F, Cubiella J, Caldés T, Pozo-Kreilinger JJ, Ortega L, Bujanda L, Prosper F, Tousseyn T, Sagaert X, Gonzalez Castellví-Bel S. Rare germline copy number Cosme A, Ferrández A, Muñoz G, M, Martinez-Climent JA. Richter variants in colorectal cancer Cuatrecasas M, Elizalde I, Andreu V, Paules transformation driven by Epstein-Barr predisposition characterized by exome MJ, Madrigal B, Barrio J, Berdasco M, Calvet X, virus reactivation during therapy-related sequencing analysis. JOURNAL OF Sanz-Anquela JM, Gisbert JP, González CA, immunosuppression in chronic GENETICS AND GENOMICS. 45(1):41-45. Sala N, Study Group. Genetic variation lymphocytic leukemia. JOURNAL OF I.F.: 4.066 analysis in a follow-up study of gastric PATHOLOGY. 245(1):61-73. I.F.: 6.253 cancer precursor lesions confirms the 32. Fraile J, Campos-Iglesias D, Rodríguez F, association of MUC2 variants with the 27. Wangsa D, Quintanilla I, Torabi K, Astudillo A, Vilarrasa-Blasi R, Verdaguer-Dot evolution of the lesions and identifies a Vila-Casadesús M, Ercilla A, Klus G, Yuce Z, N, Prado M, Paulo J, Gygi S, Martín-Subero J, significant association with NFKB1 and Galofré C, Cuatrecasas M, Lozano JJ, Agell N, Freije J, López-Otín C. Loss of the CD14. INTERNATIONAL JOURNAL OF Cimini D, Castells A, Ried T, Camps J . Deubiquitinase USP36 Destabilizes the CANCER. 143(11):2777-2786. I.F.: 7.360 Near-tetraploid cancer cells show RNA Helicase DHX33 and Causes chromosome instability triggered by Preimplantation Lethality in Mice. 23. Esteve-Arenys A, Valero J, replication stress and exhibit enhanced JOURNAL OF BIOLOGICAL CHEMISTRY. Chamorro-Jorganes A, Gonzalez D, invasiveness. FASEB JOURNAL. 293(6):2183-2194. I.F.: 4.011 Rodriguez V, Dlouhy I, Salaverria I, Campo E, 32(7):3502-3517. I.F.: 5.595 Colomer D, Martinez A, Rymkiewicz G, 33. Castella M, Boronat A, Martín-Ibáñez R, Pérez-Galán P, Lopez-Guillermo A, Roué G. 28. Ortiz-Maldonado V, Villamor N, Baumann Rodríguez V, Suñé G, Caballero M, Marzal B, The BET bromodomain inhibitor CPI203 T, Aymerich M, Magnano L, Mozas P, Pérez-Amill L, Martín-Antonio B, Castaño J, overcomes resistance to ABT-199 Rivas-Delgado A, Martínez-Trillos A, Giné E, Bueno C, Balagué O, González-Navarro EA, (venetoclax) by downregulation of Campo E, López-Guillermo A, Delgado J. Is Serra-Pages C, Engel P, Vilella R, BFL-1/A1 in in vitro and in vivo models of there a role for minimal residual disease Benitez-Ribas D, Ortiz-Maldonado V, Cid J, MYC+/BCL2+ double hit lymphoma. monitoring in the management of patients Tabera J, Canals JM, Lozano M, Baumann T, ONCOGENE. 37(14):1830-1844. I.F.: 6.854 with hairy-cell leukaemia? BRITISH Vilarrodona A, Trias E, Campo E, Menendez P, JOURNAL OF HAEMATOLOGY. Urbano-Ispizua Á, Yagüe J, Pérez-Galán P, 24. Rymkiewicz G, Grygalewicz B, 183(1):127-129. I.F.: 5.128 Rives S, Delgado J, Juan M. Development of Chechlinska M, Blachnio K, Bystydzienski Z, a Novel Anti-CD19 Chimeric Antigen Romejko-Jarosinska J, Woroniecka R, Zajdel 29. Arcaini L, Lamy T, Walewski J, Belada D, Receptor: A Paradigm for an Affordable M, Domanska-Czyz K, Martin-Garcia D, Mayer J, Radford J, Jurczak W, Morschhauser CAR T Cell Production at Academic Nadeu F, Swoboda P, Rygier J, F, Alexeeva J, Rule S, Cabeçadas J, Campo E, Institutions. MOL THER METHODS CLIN Pienkowska-Grela B, Siwicki JK, Prochorec- Pileri SA, Biyukov T, Patturajan M, Casadebaig DEV. 12:134-144. I.F.: 3.681 Sobieszek M, Salaverria I, Siebert R, Walewski Bravo ML, Trn?ný M, SPRINT Trial J. A comprehensive flow-cytometry-based Investigators. Prospective subgroup 34. De Lacy FB, van Laarhoven JJEM, Pena immunophenotypic characterization of analyses of the randomized MCL-002 R, Arroyave MC, Bravo R, Cuatrecasas M, Burkitt-like lymphoma with 11q aberration. (SPRINT) study: lenalidomide versus Lacy AM. Transanal total mesorectal

282 ONCOLOGICAL MOLECULAR PATHOLOGY 5.1

excision: pathological results of 186 Review / I.F.: 70.809 Clinical Guidelines / I.F.: 20.773 patients with mid and low rectal cancer. SURGICAL ENDOSCOPY AND OTHER 1. Oakes CC, Martin-Subero JI. Insight into 1. Rutter MD, Beintaris I, Valori R, Chiu HM, INTERVENTIONAL TECHNIQUES. origins, mechanisms & utility of DNA Corley DA, Cuatrecasas M, Dekker E, 32(5):2442-2447. I.F.: 3.117 methylation in B cell malignancies. BLOOD. Forsberg A, Gore-Booth J, Haug U, Kaminski 132(10):999-1006. I.F.: 15.132 MF, Matsuda T, Meijer GA, Morris E, Plumb 35. Benavente Y, Casabonne D, Costas L, AA, Rabeneck L, Robertson DJ, Schoen RE, Robles C, Alonso E, de la Banda E, 2. Puente XS, Jares P, Campo E . Chronic Singh H, Tinmouth J, Young GP, Sanduleanu Gonzalez-Barca E, Marcos-Gragera R, Llorca lymphocytic leukemia and mantle cell S. World Endoscopy Organization J, Tardón A, Monleon J, Aymerich M, Campo lymphoma: Crossroads of genetic and Consensus Statements on E, Gimeno-Vázquez E, Castaño-Vinyals G, microenvironment interactions. BLOOD. Post-Colonoscopy and Post-Imaging Aragonés N, Pollán M, Kogevinas M, de 131(21):2283-2296. I.F.: 15.132 Colorectal Cancer. Sanjosé S. Established and suggested GASTROENTEROLOGY. 155(3):909-925.e3. exposures on CLL/SLL etiology: Results 3. Ponzoni M, Campo E, Nakamura S . I.F.: 20.773 from the CLL-MCC-Spain study. CANCER Intravascular large b-cell lymphoma: a EPIDEMIOLOGY. 52:106-111. I.F.: 2.888 chameleon with multiple faces and many masks. BLOOD. 132(15):1561-1567. I.F.: 15.132 36. Guardiola M, Buitrago S, GRANTS FOR RESEARCH IN PROGRESS Fernández-Esparrach G, O'Callaghan JM, 4. Martin-Subero J., Oakes C. Charting the Romeu J, Cuatrecasas M, Córdova H, dynamic epigenome during B-cell Amador V. Descifrando las redes González Ballester MÁ, Camara O. Dielectric development. SEMINARS IN CANCER moleculares del microambiente protector properties of colon polyps, cancer and BIOLOGY. 51:139-148. I.F.: 10.198 y de las células madre en los linfomas de normal mucosa: ex vivo measurements células del manto agresivos para innovar from 0.5 to 20 GHz. MEDICAL PHYSICS. 5. Campo E, Cymbalista F, Ghia P, Jäger U, en estrategias terapéuticas. 45(8):3768-3782. I.F.: 2.884 Pospisilova S, Rosenquist R, Schuh A, Sponsored by: Ministerio de Economía y Stilgenbauer S. TP53 aberrations in chronic Competitividad (MINECO). 37. Del Rey J, Vidal F, Ramírez L, Borràs N, lymphocytic leukemia: an overview of the BFU2015-64879-R Corrales I, Garcia I, Martinez-Pasarell O, clinical implications of improved Duration: 01/01/2016-31/12/2018 Fernandez SF, Garcia-Cruz R, Pujol A, Plaja A, diagnostics. HAEMATOLOGICA. Salaverria I, Oliver-Bonet M, Benet J, Navarro 103(12):1956-1968. I.F.: 9.090 Amador V. Identifying immune system J. Novel Double Factor PGT strategy evasion mechanisms in aggressive Mantle analyzing blastocyst stage embryos in a 6. Liu Y, Siles L, Postigo A, Dean DC. Cell lymphoma (MCL). single NGS procedure. PLOS ONE. Epigenetically distinct sister chromatids Sponsored by: Asociación Española Contra el 13(10):e0205692. I.F.: 2.766 and asymmetric generation of tumor Cáncer. AECC_Investigador18 initiating cells. CELL CYCLE. Duration: 01/11/2018-31/12/2022 38. Martínez-Trillos A, Pinyol M, Delgado J, 17(18):2221-2229. I.F.: 3.304 Aymerich M, Rozman M, Baumann T, Beà S. Caracterización de la inestabilidad González-Díaz M, Hernández J, Alcoceba M, 7. Beekman R, Amador V, Campo E . SOX11, a genómica y las mutaciones somáticas en Muntañola A, Terol M, Navarro B, Giné E, Jares key oncogenic factor in mantle cell linfoma de células del manto y su impacto. P, Beà S, Navarro A, Colomer D, Nadeu F, lymphoma. CURRENT OPINION IN Sponsored by: Instituto de Salud Carlos III Colado E, Payer A, García-Cerecedo T, HEMATOLOGY. 25(4):299-306. I.F.: 2.821 (ISCIII). PI17/01061 Puente X, López-Otin C, Campo E, Duration: 01/01/2018-31/12/2020 López-Guillermo A, Villamor N. The mutational landscape of small lymphocytic Editorial / I.F.: 32.621 Beà S. Mutational landscape of follicular lymphoma compared to non-early stage lymphoma at late relapse, early failure and chronic lymphocytic leukemia. LEUKEMIA 1. Martin-Subero JI. Predicting leukemia histological transformation. AND LYMPHOMA. 59(10):2318-2326. I.F.: 2.644 relapse. NATURE MEDICINE. 24(4):385-387. Sponsored by: Asociación Española Contra el I.F.: 32.621 Cáncer. AECC_Proyectos18 39. Solé C, Martínez D, Giné E, Duration: 01/11/2018-31/10/2021 Gonzalez-Farre B, Pérez-Galán P, Roncador G, Campo E, Matutes E, López-Guillermo A, Case Reports / I.F.: 3.127 Campo E. Patologia Molecular Oncològica Roué G, Martínez A. Expression of a (Prèviament Oncomorfologia Funcional truncated B lymphocyte-induced 1. Cortés C., Bielsa S., Fernández J., Vilardell F., Humana i Experimental). maturation protein-1 isoform is associated Gonzalez-Farré B., Casanova J. Extensive Sponsored by: Generalitat de Catalunya. with an incomplete plasmacytic nasal plaque: An unusual presentation of AGAUR_SGR17_01142 differentiation program in chronic IgG4-related disease. ACTA Duration: 01/01/2017-31/12/2020 lymphocytic leukemia. LEUKEMIA AND DERMATO-VENEREOLOGICA. LYMPHOMA. 59(2):482-485. I.F.: 2.644 98(6):606-607. I.F.: 3.127 Campo E. La Medicina Personalitzada a Catalunya-Càncer (MedPerCan). Estudi pilot sobre l'impacte de l'anàlisi genòmica en la presa de decisions en oncologia.

283 AREA 5 ONCOLOGY AND HAEMATOLOGY

Sponsored by: Generalitat de Catalunya. Duration: 01/01/2018-31/12/2020 Sponsored by: Generalitat de Catalunya. PERIS_Programes16 (SLT002/16/00374) AGAUR_SGR17_01174 Duration: 27/03/2017-31/12/2019 Hernández L. Búsqueda de IncRNAs Duration: 01/01/2017-31/12/2020 relacionados con la polarización de Campo E. Impacto Clínico de la macrófagos pro-tumorogénicos Postigo A. ZEB proteins and tumor Heterogeneidad Genómica y Evolución (M2-TAM) en linfomas foliculares/ difusos progression. Role of ZEB1 and ZEB2 in Clonal en Neoplasias Linfoides B. de células grandes y evaluación de su valor oncogenic transformation Definición de Nuevos Modelos clínico. benign-malignant transition and cancer Diagnósticos y Pronósticos. Sponsored by: Instituto de Salud Carlos III cell proliferation and survival. Sponsored by: Ministerio de Economía y (ISCIII). PI15/00551 Sponsored by: Fundació La Marató de TV3. Competitividad (MINECO). Duration: 01/01/2016-31/12/2018 20133010 SAF2015-64885-R Duration: 15/04/2014-31/01/2018 Duration: 01/01/2016- 30/06/2019 Jares P. Nuevos mecanismos oncogénicos de ciclina D1 en linfoma de células del Postigo A. Papel de los factores ZEB en la Campo E. Genomic and epigenomic drivers manto (LCM): Implicación en la regulación especificación y activación of disease evolution in chronic transcripcional, la respuesta al daño en el hematopoyética y en la interacción célula lymphocytic leukemia. Targets for clinical ADN y el estrés eplicativo. maligna-microambiente en neoplasias intervention. Sponsored by: Instituto de Salud Carlos III hematológicas. Sponsored by: Fundació La Caixa. La (ISCIII). PI14/00355 Sponsored by: Ministerio de Economía y Caixa_HealthResearch17 (HR17-00221) Duration: 01/01/2015- 31/12/2018 Competitividad (MINECO). Duration: 31/12/2018-30/12/2021 SAF2014-52874-R Martín-Subero JI. Biomedical Epigenomics. Duration: 01/01/2015-30/11/2018 Campo E. Functional and Clinical Impact of Sponsored by: Generalitat de Catalunya. Genomics Analysis in CLL. AGAUR_SGR17_00736 Postigo A. ZEBTME: Metabolismo e Sponsored by: Instituto de Salud Carlos III Duration: 01/01/2017-31/12/2020 interacción tumor-microambiente: Papel (ISCIII). FIS_PMP15/00007 de los factores ZEB en la reprogramación Duration: 01/01/2016-31/12/2019 Martín-Subero JI. ChromMCL: Análisis a metabólica de las células tumorales y escala genómica de la estructura de la estromales y de su interacción mutua. Campo E. GENOMLYMPH: Impacto clínico cromatina en el linfoma de las células del Sponsored by: Ministerio de Economía y y biológico de las alteraciones genómicas manto: Impacto biológico y clínico. Competitividad (MINECO). en neoplasias linfoides. Sponsored by: Ministerio de Economía y SAF2017-84918-R Sponsored by: Ministerio de Economía y Competitividad (MINECO). SAF2017-86126-R Duration: 01/01/2018-31/12/2020 Competitividad (MINECO). Duration: 01/01/2018-31/12/2020 SAF2016-81860-REDT Postigo A. Validación del factor ZEB2 como Duration: 01/07/2017-30/06/2019 Martín-Subero JI. Characterization of biomarcador pronóstico predictivo y oncogenic (epi)genetically deregulated in potencial objetivo terapéutico en la Campo E. Genetic and cellular intratumor chronic lymphocytic leukemia. distrofia muscular de Duchenne. heterogeneity as predictor of chronic Sponsored by: Asociación Española Contra el Sponsored by: Asociación Duchenne Parent lymphocytic leukemia outcome and Cáncer. AECC_Contratos16 Project España treatment. Duration: 01/10/2016- Duration: 15/12/2018-14/12/2020 Sponsored by: Instituto de Salud Carlos III (ISCIII). FIS_AC15/00028 - Martín-Subero JI. Functional and clinical Salaverria I. Caracterización molecular, ERANET_TRANSC2_15 impact of enhancer DNA methylation in genética e inmunofenotípica de los (TRS-2015-00000160) mantle cell lymphoma. linfomas de centro germinal en pacientes Duration: 01/04/2016-31/03/2019 Sponsored by: Asociación Española Contra el pediátricos, adolescentes y jóvenes Cáncer. AECC_Accelerator Award17 adultos. Campo E. Molecular Diagnosis, Prognosis, Duration: 01/12/2018-30/11/2023 Sponsored by: Instituto de Salud Carlos III and Therapeutic Targets in Mantle Cell (ISCIII). PI15/00580 Lymphoma. Martinez A. SLPC asociados a Duration: 01/01/2016-31/12/2018 Sponsored by: National Institutes of Health, inmunodeficiencia: estudio de la NIH_PAR-16-457_01 transformación secretora y de la Salaverria I. Linfomas en niños y adultos Duration: 19/09/2018-31/08/2023 activación litica de los herpesvirus como jóvenes: Impacto de las alteraciones nuevas dianas terapéuticas. genéticas y moleculares en la clasificación Cuatrecasas M (and Camps J). Nuevas Sponsored by: Instituto de Salud Carlos III y estratificación de los pacientes. estrategias para la estratificación del (ISCIII). PI14/00333 Sponsored by: Asociación Española Contra el riesgo de recidiva en pacientes con cáncer Duration: 01/01/2015-30/06/2019 Cáncer. CICPF16025SALA de colon en estadio II: Integración de Duration: 01/12/2017-30/11/2020 perfiles genómicos y carga tumoral Postigo A. Group of Regulation in Cell ganglionar. Differentiation and Cancer. Prognostic and Sponsored by: Instituto de Salud Carlos III predictive biomarkers and therapeutic (ISCIII). PI17/01304 targets in cáncer.

284 ONCOLOGICAL MOLECULAR PATHOLOGY 5.1

DOCTORAL THESES

Amador V, Campo E. Deciphering the transcriptome and additional roles of Sox11 in mantle cell lymphoma. PhD student: Alvaro Eguileor Giné

Beà S. Caracterització genètica del Limfoma de Cèl.lules del Mantell i la Leucèmia Limfàtica Crònica mitjançant microarrays i tècniques de seqüenciació: noves eines pel diagnòstic i pronòstic. PhD student: David Martin García

285 286 AREA 5 5.2 2018 17 2017 70.70 2016 ERIF OA 1Q2 Q1 TOTAL I.F. YEAR from 2016 to 2018 Original publications 5. 4. 3. 2. 1. KEYWORDS HCB building LOCATION CIBER-BNN AGAUR_SGR17: 00682,01150 TEAM INVOLVEDIN

Radiotherapy Breastcancerdiagnosis Sentinellymphnode Positronemissiontomography Oncology molecularstudies 3.316 133.53

97 20 89.75 ONCOLOGY ANDHAEMATOLOGY 13 16 11 8 5 2

TEAM Francesca Pons Andres Perissinotti(HCB) Javier Pavía(HCB-UB) Pilar Paredes(HCB-UB) Mario Pagés(HCB-UB) Alfons Navarro(UB) Meritxell Molla(HCB) Lluís Donoso(HCB-UB) Francesc Casas(HCB) Sebastián Capurro(HCB) Francisco Campos(HCB) Xavier Bargalló(HCB-UB) COLLABORATORS Sergi Vidal-Sicart(HCB) Xavier Setoain(HCB-UB) Laura Oleaga(HCB-UB) María AfricaMuxí(HCB) Marià Monzó(UB) Fernando Gómez(HCB) David Fuster(HCB-UB) Carlos Conill(HCB-UB) Albert Biete(HCB-UB) RESEARCHERS [email protected] T. 932275773 Francesca Pons TEAM LEADER in oncology Diagnosis andtherapy (HCB)

1. MAIN LINESOFRESEARCH therapies inoncology. Development andapplicationofnew oncological patients. treatment responseassessmentin the diagnosis,prognosticevaluationand Development oftechniquesforimproving STRATEGIC OBJECTIVES Eugènia Verger(HCB) Izaskun Valduvieco(HCB) Marcelo Sánchez(HCB-UB) Angels Rovirosa(HCB-UB) Sonia Rodríguez(HCB) Teresa Pujol(HCB) 3. conventionalX-raysusedinradiotherapy. actionofsynchrotronradiationwith UAB,comparisonismadeofthebiological theneoplasticcell. 2. speciﬁc tissues,withaviewtoselectingmore treatments. microRNApatternsin pharmacogenomics. tumor cells: systemictreatmentinbreastcancer. topredictpathologicalresponseprimary

oeua tde nebyncad Molecular studiesinembryonicand Breast MRI. Effects ofsynchrotronradiationupon Tumouruptakeanddiffusion

plctost applications to Carried outjointlywith embryonic andtumor Cmaio f Comparisonof DIAGNOSIS AND THERAPY IN ONCOLOGY 5.2

4. Functional mRI techniques. Studies of 45(13):2358-2367. I.F.: 7.704 González-Bono E, Junqué C, Bargalló N. perfusion, diffusion and spectroscopy Typical asymmetry in the hemispheric applied to the staging and treatment 4. Boada A, Tejera-Vaquerizo A, Ribero S, activation during an fMRI verbal monitoring of brain and head and neck Puig S, Moreno-Ramírez D, comprehension paradigm is related to tumours. Descalzo-Gallego MA, Fierro MT, Quaglino better performance in verbal and P, Carrera C, Malvehy J, Vidal-Sicart S, non-verbal tasks in patients with 5. Scintigraphic detection of the Bennássar A, Rull R, Alos L, Requena C, epilepsy. NEUROIMAGE: CLINICAL. sentinel node and hybrid tracers in Bolumar I, Traves V, Pla Á, 20:742-752. I.F.: 3.869 radioguided surgery, applied in Fernández-Figueras MT, Ferrándiz C, different tumours to avoid unnecessary Pascual I, Manzano JL, Sánchez-Lucas M, 10. Gifre L, Humbert L, Muxi A, Del Rio L, lymphadenectomies. Radioguided Giménez-Xavier P, Ferrandiz L, Nagore E. Vidal J, Portell E, Monegal A, Guañabens N, surgery approaches with new tracers and Sentinel Lymph Node Biopsy vs Peris P. Analysis of the evolution of methodologies. Observation in Thick Melanoma: A cortical and trabecular bone Multicenter Propensity Score Matching compartments in the proximal femur 6. Positron Emission Tomography Study. INTERNATIONAL JOURNAL OF after spinal cord injury by 3D-DXA. (PET/CT) for the staging and control of CANCER. 142(3):641-648. I.F.: 7.360 OSTEOPOROSIS INTERNATIONAL. treatment response in different types of 29(1):201-209. I.F.: 3.857 tumors. 5. Perlaza P, Ortín J, Pagès M, Buxó E, Fernández-Esparrach G, Colletti PM, 11. Holub K, Biete A. New pre-treatment 7. Study of bacterial radiosensitivity in Rubello D, Mayoral M, Sánchez N, Ruiz C, eosinophil-related ratios as prognostic E. coli, S. epidermidis and S. aureus. Ginés A, Fuster D. Should 18F-FDG biomarkers for survival outcomes in PET/CT Be Routinely Performed in the endometrial cancer. BMC CANCER. Clinical Staging of Locally Advanced 18(1):1280. I.F.: 3.288 Gastric Adenocarcinoma? CLINICAL PUBLICATIONS NUCLEAR MEDICINE. 43(6):402-410. 12. Ambrosioni J, Martinez-Garcia C, Llopis I.F.: 6.309 J, Garcia-de-la-Maria C, Hernández- Originals / I.F.: 89.751 Meneses M, Tellez A, Falces C, Almela M, 6. Ramos-Perdigués S., Baillés E., Mané A., Vidal B, Sandoval E, Fuster D, Quintana E, 1. Ambrosioni J, Urra X, Carreño M., Donaire A., Rumià J., Bargalló N., Tolosana JM, Marco F, Moreno A, Miró JM, Hernández-Meneses M, Almela M, Falces C, Boget T., Setoain X., Valdés M., Pintor L. Hospital Clinic Infective Endocarditis Tellez A, Quintana E, Fuster D, Sandoval E, Psychiatric Symptoms in Refractory Investigators. HACEKinfective Vidal B, Tolosana JM, Moreno A, Chamorro Epilepsy During the First Year After endocarditis: epidemiology, clinical A, Miró JM, Hospital Clínic Infective Surgery. NEUROTHERAPEUTICS. features outcome: A case-control Endocarditis Study Group. Mechanical 15(4):1082-1092. I.F.: 5.719 study. INTERNATIONAL JOURNAL OF thrombectomy for acute ischemic INFECTIOUS DISEASES. 76:120-125. stroke secondary to infective 7. Graus F, Escudero D, Oleaga L, Bruna J, I.F.: 3.202 endocarditis. CLINICAL INFECTIOUS Villarejo-Galende A, Ballabriga J, Barceló MI, DISEASES. 66(8):1286-1289. I.F.: 9.117 Gilo F, Popkirov S, Stourac P, Dalmau J. 13. Santasusagna S., Moreno I., Navarro A., Syndrome and outcome of Castellano J., Martinez F., Hernández R., 2. Téllez A, Ambrosioni J, Llopis J, Pericàs antibody-negative limbic encephalitis. Muñoz C., Monzo M. Proteomic Analysis JM, Falces C, Almela M, Garcia de la Mària C, EUROPEAN JOURNAL OF NEUROLOGY. of Liquid Biopsy from Tumor-Draining Hernandez-Meneses M, Vidal B, Sandoval E, 25(8):1011-1016. I.F.: 4.621 Vein Indicates that High Expression of Quintana E, Fuster D, Tolosana JM, Marco F, Exosomal ECM1 Is Associated with Moreno A, Miro JM, Hospital Clínic Infective 8. García de la Mària C, Gasch O, Relapse in Stage I-III Colon Cancer. Endocarditis Investigators. Epidemiology, García-Gonzalez J, Soy D, Shaw E, TRANSLATIONAL ONCOLOGY. clinical features and outcome of Ambrosioni J, Almela M, Pericàs JM, Tellez 11(3):715-721. I.F.: 3.071 infective endocarditis due to A, Falces C, Hernandez-Meneses M, Abiotrophia spp. and Granulicatella Sandoval E, Quintana E, Vidal B, Tolosana 14. Capellades J., Puig J., Domenech S., Pujol spp.: Report of 76 cases (2000-2015). JM, Fuster D, Llopis J, Pujol M, Moreno A, T., Oleaga L., Camins A., Majós C., Diaz R., de CLINICAL INFECTIOUS DISEASES. Marco F, Miró JM . The Combination of Quintana C., Teixidor P., Conesa G., Plans G., 66(1):104-111. I.F.: 9.117 Daptomycin plus Fosfomycin has Gonzalez J., García-Balañà N., Velarde J., Synergistic, Potent and Rapid Balaña C. Is a pretreatment radiological 3. Perissinotti A., Niñerola-Baizán A., Rubí S., Bactericidal Activity against staging system feasible for suggesting Carreño M., Marti-Fuster B., Aparicio J., Methicillin-ResistantStaphylococcus the optimal extent of resection and Mayoral M., Donaire A., Sanchez-Izquierdo aureus(MRSA) in a Rabbit Model of predicting prognosis in glioblastoma? N., Bargalló N., Rumiá J., Boget T., Pons F., Experimental Endocarditis (EE). An observational study. JOURNAL OF Lomeña F., Ros D., Pavía J., Setoain X. ANTIMICROBIAL AGENTS AND NEURO-ONCOLOGY. 137(2):367-377. PISCOM: a new procedure for epilepsy CHEMOTHERAPY. 62(6):1-8. I.F.: 4.256 I.F.: 3.060 combining ictal SPECT and interictal PET. EUROPEAN JOURNAL OF NUCLEAR 9. Cano López I, Calvo A, Boget T, Carreño 15. Maurel J, Sánchez-Cabús S, Laquente B, MEDICINE AND MOLECULAR IMAGING. M, Donaire A, Setoain X, Pintor L, Rumià J, Gaba L, Visa L, Fabregat J, Povés I, Roselló

287 AREA 5 ONCOLOGY AND HAEMATOLOGY

S, Díaz-Beveridge R, Martín-Richard M, Review / I.F.: 4.808 Safety of Fosfomycin Plus Imipenem Rodriguez J, Sabater L, Conill C, Cambray M, vs. Vancomycin for Complicated Reig A, Ayuso JR, Valls C, Ferrández A, 1. Vidal-Sicart S, Valdés Olmos R, Nieweg Bacteremia and Endocarditis Due to Bombí JA, Ginés A, García-Albéniz X, O, Faccini R, Grootendorst M, Wester H, Methicillin- Resistant Staphylococcus Fernández- Cruz L. Outcomes after Navab N, Vojnovic B, van der Poel H, aureus: A Randomized Clinical Trial. neoadjuvant treatment with Martínez- Román S, Klode J, Wawroschek CLINICAL MICROBIOLOGY AND gemcitabine and erlotinib followed by F, van Leeuwen F. From interventionist INFECTION. 24(6):673-676. I.F.: 5.394 gemcitabine-erlotinib and radiotherapy imaging for resectable pancreatic cancer to intraoperative guidance: New 2. Moreno-Ramírez D., Vidal-Sicart S., Puig (GEMCAD 10-03 trial). CANCER perspectives by combining advanced S., Malvehy J. Should immediate CHEMOTHERAPY AND PHARMACOLOGY. tools and navigation with lymphadenectomy be discontinued in 82(6):935-943. I.F.: 2.808 radio-guided surgery. REVISTA patients with metastasis of a ESPANOLA DE MEDICINA NUCLEAR E melanoma in the sentinel lymph 16. Pericàs JM, Cervera C, Moreno A, IMAGEN MOLECULAR. 37(1):28-40. I.F.: node? Report of the results of the Garcia-de-la-Mària C, Almela M, Falces C, 1.202 Multicenter Selective Quintana E, Vidal B, Llopis J, Fuster D, Lymphadenectomy Trial-II. MEDICINA Mestres CA, Marco F, Miró JM, Hospital 2. Ruano Pérez R, Rebollo Aguirre AC, CLINICA. 150(8):323-326. I.F.: 1.168 Clinic Endocarditis Study Group. Outcome García-Talavera San Miguel P, Díaz of Enterococcus faecalis infective Expósito R, Vidal-Sicart S, Cordero García 3. Tapias A, Sánchez N, Torregrosa JV, endocarditis according to the length of JM, Carrera Salazar D, Rioja Martín ME, Fuster D, Perlaza P, Lomeña F. Triple antibiotic therapy: Preliminary data Grupo de Trabajo de Cirugía Radioguiada functioning renal allograft after from a cohort of 78 patients. PLOS ONE. de la SEMNIM. Review of the role of the repeated liver-kidney transplantation 13(2):e0192387. I.F.: 2.766 sentinel node biopsy in neoadjuvant due to liver failure. NEFROLOGíA. chemotherapy in women with breast 38(6):667-669. I.F.: 1.167 17. Campayo M, Navarro A, Benítez JC, cancer and negative or positive Santasusagna S, Ferrer C, Monzó M, Cirera axillary node at diagnosis. REVISTA L. miR-21, miR-99b and miR-375 ESPANOLA DE MEDICINA NUCLEAR E Case Reports / I.F.: 1.167 combination as predictive response IMAGEN MOLECULAR. 37(1):63-70. I.F.: signature for preoperative 1.202 1. Coloma A, Sánchez N, Fuster D, Ruiz C, chemoradiotherapy in rectal cancer. Xipell M, Orozco J, Tapias A, Torregrosa PLOS ONE. 13(11):e0206542. I.F.: 2.766 3. Vidal-Sicart S., Fuertes Cabero S., JV. Complex regional pain syndrome Danús Lainez M., Valdés Olmos R., associated with erythropoietin 18. Santasusagna S, Moreno I, Navarro A, Paredes Barranco P., Rayo Madrid J., Rioja therapy. NEFROLOGíA. 38(1):99-101. I.F.: Muñoz C, Martinez F, Hernández R, Martín M., Díaz Expósito R., Goñi Gironés 1.167 Castellano JJ, Monzo M. miR-328 E. Update on radioguided surgery: mediates a metabolic shift in colon from international consensus on cancer cells by targeting sentinel node in head and neck cancer SLC2A1/GLUT1. CLINICAL AND to the advances on gynaecological GRANTS FOR RESEARCH IN TRANSLATIONAL ONCOLOGY. tumors and localization of PROGRESS 20(9):1161-1167. I.F.: 2.392 non-palpable lesions. REVISTA ESPANOLA DE MEDICINA NUCLEAR E Oleaga A. Predictive geometrical model 19. Delgado-Oliver E, Vidal-Sicart S, IMAGEN MOLECULAR. 38(3):173-182. I.F.: for personalized ﬂow diverter sizing and Martínez D, Squarcia M, Mora M, Hanzu 1.202 interventional planning (PoroVIEW). FA, Halperin I, Fuster D, Fondevila C, Sponsored by: Ministerio de Economía y Vidal-Perez Ó. Applicability of sentinel 4. Vidal-Sicart S., Vera D., Valdés Olmos R. Competitividad (MINECO). lymph node biopsy in papillary thyroid Next generation of radiotracers for RTC-2016-5073-1. cancer. THE QUARTERLY JOURNAL OF sentinel lymph node biopsy: What is Duration: 01/11/2016-30/09/2019 NUCLEAR MEDICINE AND MOLECULAR still necessary to establish new IMAGING. imaging paradigms? REVISTA I.F.: 2.368 ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR. 37(6):373-379. I.F.: DOCTORAL THESES 20. Brito-Zerón P., Acar-Denizli N., 1.202 Sisó-Almirall A., Bosch X., Hernández F., Biete A. Tratamiento del carcinoma in Vilanova S., Villalta M., Kostov B., Paradela situ de la mama. Beneﬁcio de la M., Sanchez M., Ramírez J., Muxí A., Letters / I.F.: 7.729 administración de una dosis adicional Berruezo A., Galceran-Chaves C., Xaubet en el lecho de la tumorectomía a la A., Agustí C., Sellarés J., Ramos-Casals M. 1. Pericàs JM, Moreno A, Almela M, radioterapia complementaria de toda The Burden of Comorbidity and García-de-la-Mària C, Marco F, Muñoz P, la mama tras la cirugía conservadora. Complexity in Sarcoidosis: Impact of Peña C, de Alarcón A, Del Río A, Eworo A, Estudio retrospectivo. Associated Chronic Diseases. LUNG. Cruceta A, Paré JC, Mestres CA, Miró JM, PhD student: María José Cambra Serés 196(2):239-248. I.F.: 2.101 FOSIMI Investigators. Efficacy and

288 DIAGNOSIS AND THERAPY IN ONCOLOGY 5.2

Monzó M, Navarro A. Exosomes i microRNAS en biòpsia líquida com a biomarcadors pronòstics del càncer de colon. PhD student: Sandra Santasusagna Canal

289 AREA 5 ONCOLOGY AND HAEMATOLOGY

Molecular biology of 5.3 reproduction and development

COLLABORATORS Josep Lluís Ballescà (HCB) LOCATION Salvadora Cívico (HCB) UB School of Medicine Marta Guimerà (HCB)

STRATEGIC OBJECTIVES

KEYWORDS The mechanisms involved in cell differentiation

1. Germinal cell line TEAM LEADER during reproduction and development, with a 2. Male infertility Rafael Oliva (HCB-UB) particular focus on the germinal cell line and 3. Proteomics T. 93 402 18 77 / 93 227 55 10 the paternal contribution to the embryo, and 4. Epigenetics [email protected] / [email protected] the study of the endocrine disorders and cancer cell progression and regression are 5. Cancer the main objectives of our research group. 6. Endocrine system 7. iPSC RESEARCHERS Cristóbal Mezquita (UB) Jovita Mezquita (UB) Josep Oriola (HCB-UB) MAIN LINES OF RESEARCH

POST-DOCTORAL RESEARCHERS 1. Genomics, proteomics and epigenetics Judit Castillo (IDIBAPS) of the germinal cell line. Original publications Michael Edel (UB) Our interests include the study of the from 2016 to 2018 Meritxell Jodar (FCRB-UB) human sperm and seminal plasma Betlem Mezquita (UB) proteomes,small RNA content, and the YEAR I.F. TOTAL Q1 Q2 sperm cell epigenome to further 2 2016 10.95 3 1 PRE-DOCTORAL RESEARCHERS understand the function and mechanisms 2017 11.86 3 2 1 Ferran Barrachina (IDIBAPS) operating in the sperm cell, fertilization and early embryo development, and to enable 2018 13.60 4 2 1 Alberto de la Iglesia (IDIBAPS) Jose Manuel Mayorga (UB) translational research in male infertility. Montserrat Pau (UB) Ada Soler (UB) 2. Genetics of endocrine disorders. We are studying the genetic aspects of hereditary endocrine disorders (multiple TEAM INVOLVED IN ADMINISTRATIVE STAFF endocrine neoplasia, congenital adrenal AGAUR_SGR17: 01555 Nuria Roman (UB) hyperplasia and monogenic diabetes) for which we are a reference centre. Our interest also contribute to a better TEAM Rafael Oliva

290 MOLECULAR BIOLOGY OF REPRODUCTION AND DEVELOPMENT 5.3

understanding of the genotype-phenotype preimplantation embryo. HUMAN correlations in these syndromes. REPRODUCTION UPDATE. 24(5):535-555. I.F.: 11.852 3. Mechanisms involved in redifferentiation of cancer cells. 2. Soler-Ventura A, Castillo J, de la Iglesia A, Oncogenesis is essentially a cell Jodar M, Barrachina F, Ballesca JL, Oliva R. A dedifferentiation process. Molecules that Step-By-Step Protocol For Mammalian induce cell differentiation, such as retinoic Sperm Protamine Extraction And Analysis. acid, have been used for cancer therapy. PROTEIN AND PEPTIDE LETTERS. However, we have shown that retinoic acid 25(5):424-433. I.F.: 1.039 activates the pro-invasive pathway Src-Yap-Il6 in MDA-MB-231 triple negative 3. Gordon H, Mezquita-Pla J. Dixon's trace in breast cancer cells. At present we study the my personal career and the quantic jump mechanisms used by statins to block the experienced in regulatory information. pro-invasive action of retinoic acid. SYST BIOL REPROD MED. 64(6):448-468. I.F.: 1.582

PUBLICATIONS Editorial / I.F.: 1.582

Originals / I.F.: 13.6 1. Balhorn R., Davies P., Kleene K., Krawetz S., Mezquita-Pla J., Oliva R., States J., Tempest H. 1. Gutierrez-Nogués A; García-Herrero C; Special Issue in Honor of Gordon H. Dixon. Oriola J; Vincent O; Navas M. Functional SYSTEMS BIOLOGY IN REPRODUCTIVE characterization of MODY2 mutations in MEDICINE. 64(6):399-402. I.F.: 1.582 the nuclear export signal of glucokinase. BIOCHIMICA ET BIOPHYSICA ACTA - MOLECULAR BASIS OF DISEASE. Clinical Guidelines / I.F.: 1.168 1864(7):2385-2394. I.F.: 5.108 1. Alonso-Cerezo M., Calero Ruiz M., 2. Mezquita B, Mezquita P, Pau M, Gasa L, Chantada-Abal V., de la Fuente-Hernández L., Navarro L, Samitier M, Pons M, Mezquita C. García-Cobaleda I., García-Ochoa C., All-trans-retinoic acid activates the García-Sagredo J., Nuñez R., Oliva R., pro-invasive Src-YAP-Interleukin 6 axis in Orera-Clemente M., Pintado-Vera D., triple-negative MDA-MB-231 breast Sanchez-Ramon S. Recommendations cancer cells while cerivastatin reverses regarding the genetic and immunological this action. SCIENTIFIC REPORTS. 8(1):7047. study of reproductive dysfunction. I.F.: 4.122 MEDICINA CLINICA. 151(4):161.e1-161.e12. I.F.: 1.168 3. Torra-Massana M, Barragán M, Bellu E, Oliva R, Rodríguez A, Vassena R. Sperm telomere length in donor samples is not related to ICSI outcome. JOURNAL OF GRANTS FOR RESEARCHIN PROGRESS ASSISTED REPRODUCTION AND GENETICS. 35(4):649-657. I.F.: 2.788 Oliva R. Proteómica diferencial de espermatozoides e identificación de 4. Barrachina F, Anastasiadi D, Jodar M, biomarcadores diagnósticos y Castillo J, Estanyol JM, Piferrer F, Oliva R. pronósticos en reproducción asistida. Identification of a complex population of Sponsoredby: Instituto de Salud Carlos III chromatin-associated proteins in the (ISCIII). PI13/00699. European sea bass (Dicentrarchus labrax) Duration: 01/01/2014-30/06/2018 sperm. SYSTEMS BIOLOGY IN REPRODUCTIVE MEDICINE. 64(6):502-517. Oliva R. Análisis proteómico y I.F.: 1.582 transcriptómico del semen e identificación de biomarcadores capaces de evaluar la contribución paterna a la fertilización y la Review / I.F.: 14.473 embriogénesis. Sponsoredby: Instituto de Salud Carlos III 1. Castillo J, Jodar M, Oliva R. The (ISCIII). PI16/00346. contribution of human sperm proteins to Duration: 01/01/2017-31/12/2019 the development and epigenome of the

291 AREA 5 ONCOLOGY AND HAEMATOLOGY 5.4 Genetics

STRATEGIC OBJECTIVES

LOCATION To clinically, cytogenetic and molecular HCB building characterize rare genetic diseases. The main research lines are: i) study of molecular basis of intellectual disability using high throughput technologies; ii) identiﬁcation of a biological marker for FXTAS; iii) genotype–phenotype correlation of porphyrias; and iv) discovery of KEYWORDS new biomarkers that might help the diagnosis 1. Intellectual disability TEAM LEADER and prognosis of prostate cancer. 2. Next generation sequencing Montserrat Milà (HCB-UB) 3. Cryptic chromosomal imbalances T. 93 227 54 00 (Ext.: 2784) 4. FMR1 premutation associated [email protected]

pathologies MAIN LINES OF RESEARCH 5. Porphyria 6. Prostate cancer RESEARCHERS 1. Identification of genetic bases of ID. Anna Carrió (HCB) The application of high throughput Xavier Filella (HCB) sequencing to different groups of clinically Irene Madrigal (HCB) well characterized ID patients will allow us Ester Margarit (HCB) to identify new genes and to establish new Laia Rodríguez-Revenga (HCB) molecular causes of ID. Aurora Sanchez (HCB) Original publications Anna M Soler (HCB) 2. Fragile X syndrome: Study and better from 2016 to 2018 Jordi To (HCB) characterization of FMR1 premutation YEAR I.F. TOTAL Q1 Q2 associated pathologies. Identification of a POST-DOCTORAL RESEARCHERS susceptibility risk factor for FXTAS. 10 2016 78.25 21 3 Maria Isabel Álvarez (CIBER) 2017 53.59 14 6 7 3. Detection of cryptic chromosomal 2018 30.68 7 4 1 TECHNICIANS imbalances and identification of new Maria Dolores Jiménez (HCB) phenotypes based on cytogenetic – molecular techniques in a prenatal and COLLABORATORS postnatal diagnostic setting. Laura Foj (HCB) TEAM INVOLVED IN 4. Study of the genotype-phenotype CIBERER CB06/07/0020 correlation and expression mechanisms AGAUR_SGR17: 1134 of porphyria: TEAM Montserrat Milà

292 GENETICS 5.4

- Advance in the study of the alterations in García-Díaz Barriga G, Alberch J, Milà M, syndrome: an overview and update of the iron regulation and metabolism in skin and Azkona G, Pérez-Navarro E. FMR1 gene. CLINICAL GENETICS. erythropoietic porphyria. Pharmacogenetic modulation of STEP 93(2):197-205. improves motor and cognitive function in I.F.: 3.512 - Investigate the role of modifier genes that a mouse model of Huntington's disease. modulate the clinical expression of NEUROBIOLOGY OF DISEASE. 120:88-97. 3. Borrell A., Grande M., Pauta M., erythropoietic porphyria. I.F.: 5.227 Rodriguez-Revenga L., Figueras F. Chromosomal Microarray Analysis in - Study of new serum and urine biomarkers 4. Alvarez-Mora MI, Madrigal I, Martinez F, Fetuses with Growth Restriction and of acute porphyria severity of use in clinical Tejada MI, Izquierdo-Alvarez S, Normal Karyotype: A Systematic Review practice. Sanchez-Villar de Saz P, Caro-Llopis A, and Meta-Analysis. FETAL DIAGNOSIS Villate O, Rodríguez-Santiago B, Pérez AND THERAPY. 44(1):1-9. I.F.: 1.813 5. Prostate cancer: Jurado LA, Rodriguez-Revenga L, Milà M. Clinical implication of FMR1 intermediate - To study the value of miRNAs in urine for alleles in a Spanish population. CLINICAL Letters / I.F.: 2.014 the detection and prognosis of prostate GENETICS. 94(1):153-158. I.F.: 3.512 cancer. 1. Borrell A., Grande M., Meler E., Sabrià J., 5. Esteban I, Vilaró M, Adrover E, Angulo A, Mazarico E., Muñoz A., Rodriguez-Revenga - To isolate exosomes as a source of new Carrasco E, Gadea N, Sánchez A, Ocaña T, L., Badenas C., Figueras F. Genomic biomarkers of prostate cancer. Llort G, Jover R, Cubiella J, Servitja S, Microarray in Fetuses with Early Growth Herráiz M, Cid L, Martínez S, Restriction: A Multicenter Study. Oruezábal-Moreno MJ, Garau I, Khorrami S, OBSTETRICAL AND GYNECOLOGICAL Herreros-de-Tejada A, Morales R, Cano JM, SURVEY. 73(2):73-74. PUBLICATIONS Serrano R, López-Ceballos MH, I.F.: 2.014 González-Santiago S, Juan-Fita MJ, Originals / I.F.: 30.679 Alonso-Cerezo C, Casas A, Graña B, Teulé A, Alba E, Antón A, Guillén-Ponce C, Case Reports / I.F.: 13.551 1. Karube K, Enjuanes A, Dlouhy I, Jares P, Sánchez-Heras AB, Alés-Martínez JE, Martin-Garcia D, Nadeu F, Ordóñez GR, Brunet J, Balaguer F, Balmaña J. 1. Goncé A., Martínez M., Marbán-Castro E., Rovira J, Clot G, Royo C, Navarro A, Psychological impact of multi-gene Saco A., Soler A., Alvarez-Mora M., Peiro A., Gonzalez-Farre B, Vaghefi A, Castellano G, cancer panel testing in patients with a Gonzalo V., Hale G., Bhatnagar J., López M., Rubio-Perez C, Tamborero D, Briones J, clinical suspicion of hereditary cancer Zaki S., Ordi J., Bardají A. Spontaneous Salar A, Sancho JM, Mercadal S, across Spain. PSYCHO- ONCOLOGY. abortion associated with Zika virus Gonzalez-Barca E, Escoda L, Miyoshi H, 27(6):1530-1537. I.F.: 3.455 infection and persistent viremia. Ohshima K, Miyawaki K, Kato K, Akashi K, EMERGING INFECTIOUS DISEASES. Mozos A, Colomo L, Alcoceba M, Valera A, 6. Foj L, Filella X. Identification of Potential 24(5):933-935. I.F.: 7.422 Carrió A, Costa D, Lopez-Bigas N, Schmitz miRNAs Biomarkers for High-Grade R, Staudt LM, Salaverria I, López-Guillermo Prostate Cancer by Integrated 2. Podlipnik S., Guijarro F., Combalia A., A, Campo E. Integrating genomic Bioinformatics Analysis. PATHOLOGY To-Figueras J., Badenas C., Costa D., alterations in diffuse large B-cell ONCOLOGY RESEARCH. I.F.: 1.935 Rozman M., Jorge S., Aguilera P., Gaya A. lymphoma identifies new relevant Acquired erythropoietic uroporphyria pathways and potential therapeutic 7. Florez H., Mandelikova S., Filella X., secondary to myelodysplastic syndrome targets. LEUKEMIA. 32(3):675-684. I.F.: Monegal A., Guañabens N., Peris P. Clinical with chromosome 3 alterations: A case 10.023 significance of increased serum levels of report. BRITISH JOURNAL OF FGF-23 in fibrous dysplasia. MEDICINA DERMATOLOGY. 179(2):486-490. I.F.: 6.129 2. Kumar R., Gardner A., Homan C., Douglas CLINICA. 151(2):65-67. I.F.: 1.168 E., Mefford H., Wieczorek D., Lüdecke H., Stark Z., Sadedin S., Nowak C., Douglas J., Parsons G., Mark P., Loidi L., Herman G., Review / I.F.: 10.979 GRANTS FOR RESEARCH IN PROGRESS Mihalic Mosher T., Gillespie M., Brady L., Tarnopolsky M., Madrigal I., Eiris J., 1. Pauta M, Grande M, Rodriguez-Revenga Madrigal I. Identificación de genes Domènech Salgado L., Rabionet R., Strom L, Kolomietz E, Borrell A. Added value of modificadores de penetrancia en T., Ishihara N., Inagaki H., Kurahashi H., Chromosomal Microarray Analysis enfermedades raras hereditatias Dudding-Byth T., Palmer E., Field M., Gecz J. (CMA) over karyotyping in Early mediante secuenciación masiva. Severe neurocognitive and growth Pregnancy Loss - a Systematic Review Sponsored by: Instituto de Salud Carlos III disorders due to variation in THOC2, an and Meta-Analysis. ULTRASOUND IN (ISCIII). PI15/00483 essential component of nuclear mRNA OBSTETRICS AND GYNECOLOGY. Duration: 01/01/2016-31/12/2019 export machinery. HUMAN MUTATION. 51(4):453-462. I.F.: 5.654 39(8):1126-1138. I.F.: 5.359 Milà M. Estudio de la RAN translation en 2. Mila M, Alvarez-Mora MI, Madrigal I, FXTAS y C9ALS/FTD: correlación clínica y 3. García-Forn M, Martínez-Torres S, Rodriguez-Revenga L. Fragile X molecular.

293 AREA 5 ONCOLOGY AND HAEMATOLOGY

Sponsored by: Instituto de Salud Carlos III (ISCIII). PI17/01067 Duration: 01/01/2018-31/12/2020

Ribes A. Implementació de la medicina personalitzada basada en la Genòmica en Malalties Minoritàries Neurológiques no Diagnosticades. URDCat (Undiagnosed Rare Diseases Program of Catalonia). Sponsored by: Generalitat de Catalunya- PERIS_Programes16 (SLT002/16/00174) Duration: 27/03/2017-31/12/2019

Rodriguez-Revenga L. Estudio de las bases moleculares de los transtornos del neurodesarrollo. Sponsored by: Fundación Alicia Koplowitz. Duration: 01/11/2018-

294 MELANOMA: IMAGING, GENETICS AND IMMUNOLOGY 5.5

Melanoma: imaging, genetics 5.5 and immunology

TECHNICIANS Beatriz Alejo (FCRB) LOCATION Marc Combalia (FCRB) CEK building, ﬂoor 2 Alexandra Franco (FCRB) Judit Mateu (FCRB)

ADMINISTRATIVE STAFF Lilian Roca (FCRB)

KEYWORDS NURSING STAFF

1. Melanoma TEAM LEADER Mireia Dominguez (FCRB) 2. Genetics Susana Puig (HCB) Daniel Gabriel (FCRB) 3. Dermoscopy T. 93 227 54 00 (Ext.: 5692) Angels Herrero (FCRB) 4. Confocal microscopy [email protected] Pablo Iglesias (FCRB) 5. Susceptibility COLLABORATORS

RESEARCHERS Melinda González (FCRB) Celia Badenas (HCB) Ramon Pigem (IDIBAPS) Cristina Carrera (HCB) Carolina Sánchez (FCRB) Josep Malvehy (HCB) Agusti Toll (HCB) Original publications Joan Anton Puig (HCB) from 2016 to 2018 POST-DOCTORAL RESEARCHERS YEAR I.F. TOTAL Q1 Q2 Paula Aguilera (HCB) STRATEGIC OBJECTIVES Gemma Tell (CIBER) 2016 60.68 14 11 1 1. Development of non-invasive imaging, 2017 264.52 37 27 7 PRE-DOCTORAL RESEARCHERS biophotonics and physic techniques for the 2018 225.77 22 18 3 Alicia Ines Barreiro (IDIBAPS) diagnosis of melanoma and non- Neus Calbet (IDIBAPS) melanoma skin cancer. Natalia Espinosa (FCRB) Priscila Giavedoni (HCB) 2. Study of the genetic bases implicated in Javiera Perez (FCRB) susceptibility to melanoma, photocarcinogenesis and melanoma TEAM INVOLVED IN Sebastian Podlipnik (UB) AGAUR_SGR17: 01134 Miriam Potrony (IDIBAPS) prognosis. CIBERER: CB06/07/0020 (U726) Oriol Yélamos (IDIBAPS) 3. Development of treatment strategies in melanoma and skin cancer: speciﬁc TEAM Susana Puig

295 AREA 5 ONCOLOGY AND HAEMATOLOGY

molecular target / immunological therapies 2. Dreno B, Thompson JF, Smithers BM, of the ACMG Secondary Findings v2.0 list and photo-protection. Santinami M, Jouary T, Gutzmer R, Levchenko in a large cancer cohort and E, Rutkowski P, Grob JJ, Korovin S, Drucis K, ethnicity-matched controls. GENOME Grange F, Machet L, Hersey P, Krajsova I, MEDICINE. 10(1):99. I.F.: 8.898 Testori A, Conry R, Guillot B, Kruit WHJ, MAIN LINES OF RESEARCH Demidov L, Thompson JA, Bondarenko I, 5. Martinez-Garcia MA, Campos-Rodriguez F, Jaroszek J, Puig S, Cinat G, Hauschild A, Nagore E, Martorell A, Rodriguez-Peralto JL, 1. Dermoscopy, digital dermoscopy, Goeman JJ, van Houwelingen HC, Riveiro-Falkenbach E, Hernandez L, Bañuls J, Confocal microscopy & new photonic and Ulloa-Montoya F, Callegaro A, Dizier B, Arias E, Ortiz P, Cabriada V, Gardeazabal J, physic technologies. Description of new Spiessens B, Debois M, Brichard VG, Louahed Montserrat JM, Carrera C, Corral J, Masa JF, algorithms, study of the evolution of lesions, J, Therasse P, Debruyne C, Kirkwood JM. de Terreros JG, Abad J, Boada A, Mediano O, new classifications and the use of MAGE-A3 immunotherapeutic as adjuvant de Eusebio E, Chiner E, Landete P, Mayos M, telemedicine. therapy for patients with resected, Fortuño A, Barbé F, Sánchez de la Torre M, MAGE-A3-positive, stage III melanoma Sanchez de la Torre A, Cano I, Gonzalez C, 2. Giant congenital nevi, global research (DERMA): a double-blind, randomised, Pérez-Gil A, Gómez-García T, Cullen D, approach including clinical, genetics and placebo-controlled, phase 3 trial. LANCET Somoza M, Formigón M, Aizpuru F, Navarro C, psychological aspects. ONCOLOGY. 19(7):916-929. I.F.: 36.421 Selma-Ferrer MJ, Garcia-Ortega A, de Unamuno B, Almendros I, Farré R, Gozal D, 3. Genetic epidemiology in melanoma and 3. Walpole S, Pritchard AL, Cebulla CM, Spanish Sleep Network. Sleep-Disordered non melanoma skin cancer. Pilarski R, Stautberg M, Davidorf FH, de la Breathing is Independently Associated Fouchardière A, Cabaret O, Golmard L, with Increased Aggressiveness of 4. Study of the mechanisms involved in Stoppa-Lyonnet D, Garfield E, Njauw CN, Cutaneous Melanoma. A multicentre carcinogenesis and photocarcinogenesis Cheung M, Turunen JA, Repo P, Järvinen RS, observational study in 443 patients. in melanoma and non melanoma skin van Doorn R, Jager MJ, Luyten GPM, CHEST. 154(6):1348-1358. I.F.: 7.652 cancer. Marinkovic M, Chau C, Potrony M, Höiom V, Helgadottir H, Pastorino L, Bruno W, Andreotti 6. Boada A, Tejera-Vaquerizo A, Ribero S, 5. Development of new treatment strategies V, Dalmasso B, Ciccarese G, Queirolo P, Puig S, Moreno-Ramírez D, Descalzo-Gallego for melanoma and other skin tumours. Mastracci L, Wadt K, Kiilgaard JF, Speicher MA, Fierro MT, Quaglino P, Carrera C, Malvehy MR, van Poppelen N, Kilic E, Al-Jamal RT, J, Vidal-Sicart S, Bennássar A, Rull R, Alos L, 6. Evaluation of immune response in Dianzani I, Betti M, Bergmann C, Santagata S, Requena C, Bolumar I, Traves V, Pla Á, melanoma. Dahiya S, Taibjee S, Burke J, Poplawski N, Fernández-Figueras MT, Ferrándiz C, Pascual O'Shea SJ, Newton-Bishop J, Adlard J, Adams I, Manzano JL, Sánchez-Lucas M, Giménez- 7. Identification of genetic prognostic profiles DJ, Lane AM, Kim I, Klebe S, Racher H, Xavier P, Ferrandiz L, Nagore E. Sentinel in melanoma . Harbour JW, Nickerson ML, Murali R, Palmer Lymph Node Biopsy vs Observation in JM, Howlie M, Symmons J, Hamilton H, Thick Melanoma: A Multicenter Propensity 8. Analysis of the influence of the microbiota in Warrier S, Glasson W, Johansson P, Score Matching Study. INTERNATIONAL skin cancer. Robles-Espinoza CD, Ossio R, de Klein A, Puig JOURNAL OF CANCER. 142(3):641-648. I.F.: S, Ghiorzo P, Nielsen M, Kivelä TT, Tsao H, 7.360 9. Identification of biomarkers for melanoma : Testa JR, Gerami P, Stern MH, Paillerets BB, study of circulating free DNA (cfDNA) or Abdel-Rahman MH, Hayward NK. 7. Carrera C, Scope A, Dusza SW, Argenziano isolation of circulating melanoma cells Comprehensive Study of the Clinical G, Nazzaro G, Phan A, Tromme I, Rubegni P, (CMC) and single cell sequencing. Phenotype of Germline BAP1 Malvehy J, Puig S, Marghoob AA. Clinical and Variant-Carrying Families Worldwide. dermoscopic characterization of pediatric JOURNAL OF THE NATIONAL CANCER and childhood melanomas. Multicenter INSTITUTE. 110(12):1328-1341. I.F.: 11.238 study of 52 cases. JOURNAL OF THE PUBLICATIONS AMERICAN ACADEMY OF DERMATOLOGY. 4. Kim J., Luo W., Wang M., Wegman-Ostrosky 78(2):278-288. I.F.: 6.898 Originals / I.F.: 225.766 T., Frone M., Johnston J., Nickerson M., Rotunno M., Li S., Achatz M., Brodie S., Dean 8. Marchetti MA, Codella NCF, Dusza SW, 1. Eggermont AMM, Blank CU, Mandala M, M., De Andrade K., Fortes F., Gianferante M., Gutman DA, Helba B, Kalloo A, Mishra N, Long GV, Atkinson V, Dalle S, Haydon A, Khincha P., McMaster M., McReynolds L., Carrera C, Celebi ME, DeFazio JL, Jaimes N, Lichinitser M, Khattak A, Carlino MS, Sandhu Pemov A., Pinheiro M., Santiago K., Alter B., Marghoob AA, Quigley E, Scope A, Yélamos S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Caporaso N., Gadalla S., Goldin L., Greene M., O, Halpern AC, International Skin Imaging Schadendorf D, Koornstra R, Hernandez-Aya Loud J., Yang X., Freedman N., Gapstur S., Collaboration. Results of the 2016 L, Maio M, van den Eertwegh AJM, Grob JJ, Gaudet M., Calista D., Ghiorzo P., Fargnoli M., International Skin Imaging Collaboration Gutzmer R, Jamal R, Lorigan P, Ibrahim N, Nagore E., Peris K., Puig S., Landi M., Hicks B., International Symposium on Biomedical Marreaud S, van Akkooi ACJ, Suciu S, Robert Zhu B., Kim J., Luo W., Wang M., Imaging challenge: Comparison of the C. Adjuvant Pembrolizumab versus Wegman-Ostrosky T., Frone M., Johnston J., accuracy of computer algorithms to Placebo in Resected Stage III Melanoma. Nickerson M., Rotunno M., Li S., Achatz M. dermatologists for the diagnosis of NEW ENGLAND JOURNAL OF MEDICINE. Prevalence of pathogenic/likely melanoma from dermoscopic images. 378(19):1789-1801. I.F.: 79.260 pathogenic variants in the 24 cancer genes JOURNAL OF THE AMERICAN ACADEMY

296 MELANOMA: IMAGING, GENETICS AND IMMUNOLOGY 5.5

OF DERMATOLOGY. 78(2):270-277. common genetic variants and non-genetic HUMAN PATHOLOGY. 73:176-183. I.F.: 3.125 I.F.: 6.898 risk factors to predict risk of cutaneous melanoma. HUMAN MOLECULAR 20. Rey-Barroso L, Burgos-Fernández FJ, 9. Wolner ZJ, Bajaj S, Flores E, Carrera C, GENETICS. 27(23):4145-4156. I.F.: 4.902 Delpueyo X, Ares M, Royo S, Malvehy J, Puig Navarrete-Dechent C, Dusza SW, Rabinovitz S, Vilaseca M. Visible and Extended HS, Marchetti MA, Marghoob AA. Variation in 15. Cinotti E, Labeille B, Debarbieux S, Carrera Near-Infrared Multispectral Imaging for dermoscopic features of basal cell C, Lacarrubba F, Witkowski AM, Moscarella E, Skin Cancer Diagnosis. SENSORS. carcinoma as a function of anatomical Arzberger E, Kittler H, Bahadoran P, Gonzalez 18(5):1441. I.F.: 2.475 location and pigmentation status. BRITISH S, Guitera P, Agozzino M, Farnetani F, JOURNAL OF DERMATOLOGY. Hofmann-Wellenhof R, Ardigò M, Rubegni P, 21. Dubois A, Levecq O, Azimani H, Siret D, 178(2):e136-e137. I.F.: 6.129 Tognetti L, ?udzik J, Zalaudek I, Argenziano G, Barut A, Suppa M, Del Marmol V, Malvehy J, Longo C, Ribero S, Malvehy J, Pellacani G, Cinotti E, Rubegni P, Perrot JL. Line-field 10. Alonso N, Cañueto J, Ciria S, Bueno E, Cambazard F, Perrot JL. Dermoscopy confocal optical coherence tomography Palacios-Alvarez I, Alegre M, Badenas C, versus reflectance confocal microscopy for high-resolution noninvasive imaging of Barreiro A, Pena L, Maldonado C, for the diagnosis of lentigo maligna. skin tumors. JOURNAL OF BIOMEDICAL Nespeira-Jato MV, Peña-Penabad C, Azon A, JOURNAL OF THE EUROPEAN ACADEMY OPTICS. 23(10):1-9. I.F.: 2.367 Gavrilova M, Ferrer I, Sanmartin O, Robles L, OF DERMATOLOGY AND VENEREOLOGY. Hernandez-Martin A, Urioste M, Puig S, Puig L, 32(8):1284-1291. I.F.: 4.287 22. Caffery LJ, Clunie D, Curiel-Lewandrowski Gonzalez-Sarmiento R. Novel clinical and C, Malvehy J, Soyer HP, Halpern AC. molecular findings in Spanish patients with 16. Marchetti M., Marino M., Virmani P., Dusza Transforming Dermatologic Imaging for Nevoid Basal Cell Carcinoma Syndrome. S., Marghoob A., Nazzaro G., Lallas A., Landi C., the Digital Era: Metadata and Standards. BRITISH JOURNAL OF DERMATOLOGY. Cabo H., Quiñones R., Gomez E., Puig S., JOURNAL OF DIGITAL IMAGING. 178(1):198-206. I.F.: 6.129 Carrera C. Dermoscopic features and 31(4):568-577. I.F.: 1.536 patterns of poromas: A multicentre 11. Vallone MG, Tell-Marti G, Potrony M, observational case-control study Rebollo-Morell A, Badenas C, Puig-Butille JA, conducted by the International Review / I.F.: 2.392 Gimenez-Xavier P, Carrera C, Malvehy J, Puig Dermoscopy Society. JOURNAL OF THE S. Melanocortin 1 receptor (MC1R) EUROPEAN ACADEMY OF DERMATOLOGY 1. A. Boada García; Cristina Carrera; Sonia polymorphisms' influence on size and AND VENEREOLOGY. 32(8):1263-1271. Segura; Helena Collgros Totosaus; Paola dermoscopic features of nevi. PIGMENT I.F.: 4.287 Pasquali; D. Bodet; Susana Puig; Josep CELL AND MELANOMA RESEARCH. Malvehy. Cutaneous toxicities of new 31(1):39-50. I.F.: 6.115 17. Stratigos AJ, Fargnoli MC, De Nicolo A, treatments for melanoma. CLINICAL AND Peris K, Puig S, Soura E, Menin C, Calista D, TRANSLATIONAL ONCOLOGY. 12. Maiques O, Barceló C, Panosa A, Pijuan J, Ghiorzo P, Mandala M, Massi D, Rodolfo M, Del 20(11):1373-1384. I.F.: 2.392 Orgaz JL, Rodriguez-Hernandez I, Regno L, Stefanaki I, Gogas H, Bataille V, Matas-Nadal C, Tell G, Vilella R, Fabra A, Puig Tucker MA, Whiteman D, Nagore E, Landi MT. S, Sanz-Moreno V, Matias-Guiu X, Canti C, ΜelanoQ: A Consensus Questionnaire of Letters / I.F.: 77.927 Herreros J, Marti RM, Macià A. T-type Standardized Epidemiologic and Clinical calcium channels drive migration/invasion Variables for Melanoma Risk Assessment 1. Carrera, Cristina; Potrony, Miriam; Puig, in BRAFV600E melanoma cells through by the MelaNostrum Consortium. Susana. Sex as a predictor of response to Snail1. PIGMENT CELL AND MELANOMA JOURNAL OF THE EUROPEAN ACADEMY cancer immunotherapy. LANCET RESEARCH. 31(4):484-495. I.F.: 6.115 OF DERMATOLOGY AND VENEREOLOGY. ONCOLOGY. 19(8):E375-E375. I.F.: 36.421 32(12):2134-2141. I.F.: 4.287 13. Helgadottir H., Ghiorzo P., Van Doorn R., 2. Boada A, Tejera-Vaquerizo A, Ribero S, Puig S., Levin M., Kefford R., Lauss M., Queirolo 18. Potrony M, Puig-Butille JA, Farnham JM, Puig S, Nagore E, Moreno-Ramírez D, P., Pastorino L., Kapiteijn E., Potrony M., Giménez-Xavier P, Badenas C, Tell-Martí G, Descalzo-Gallego MA. Author's reply to: Carrera C., Olsson H., Höiom V., Jönsson G. Aguilera P, Carrera C, Malvehy J, Teerlink CC, Prognosis of sentinel lymph node biopsy in Efficacy of novel immunotherapy Puig S. Genome-wide linkage analysis in patients with thick melanoma by a regimens in patients with metastatic Spanish melanoma-prone families propensity score matching prospective melanoma with germline CDKN2A identifies a new familial melanoma study. INTERNATIONAL JOURNAL OF mutations. JOURNAL OF MEDICAL susceptibility locus at 11q. EUROPEAN CANCER. 142(7):1504-1504. I.F.: 7.360 GENETICS. I.F.: 5.751 JOURNAL OF HUMAN GENETICS. 26(8):1188-1193. I.F.: 3.636 3. Carrera C, Puig-Butille JA. Clinical, 14. Gu F, Chen TH, Pfeiffer RM, Fargnoli MC, Epidemiological, and Molecular Calista D, Ghiorzo P, Peris K, Puig S, Menin C, 19. Ch?opik A, Selim MA, Peng Y, Wu CL, Heterogeneity in Acral Melanoma. De Nicolo A, Rodolfo M, Pellegrini C, Pastorino Tell-Marti G, Paral KM, Shalin SC, Kraft S, Hsu JOURNAL OF INVESTIGATIVE L, Evangelou E, Zhang T, Hua X, DellaValle CT, CK, Shea CR, Puig S, Fernandez-Figueras MT, DERMATOLOGY. 138(2):254-255. I.F.: 6.448 Timothy Bishop D, MacGregor S, Iles MI, Law Biernat W, Ry? J, Marszalek A, Hoang MP. MH, Cust A, Brown KM, Stratigos AJ, Nagore Prognostic Role of Tumoral PDL1 4. Barragan-Estudillo Z., Jesus-Silva M., E, Chanock S, Shi J, Consortium MM, Expression and Peritumoral FoxP3+ Chavez-Bourgeois M., Brito J., Alos L., Puig S., Consortium M, Landi MT. Combining Lymphocytes in Vulvar Melanomas. Malvehy J. Image Gallery: Transition

297 AREA 5 ONCOLOGY AND HAEMATOLOGY

pattern in acral melanoma. BRITISH trichobacteriosis axilaris. JOURNAL OF Melanoma Meta-Analysis Consortium, JOURNAL OF DERMATOLOGY. THE EUROPEAN ACADEMY OF Goldstein AM, Trower AJ, Bishop DT, Iles MM, 178(3):e225-e225. I.F.: 6.129 DERMATOLOGY AND VENEREOLOGY. Duffy DL, MacGregor S, Amundadottir LT, 32(6):E208-E209. I.F.: 4.287 Law MH, Loftus SK, Pavan WJ, Brown KM 5. Villarreal-Martinez A, Bennàssar A, NISC Comparative Sequencing Program, Gonzalez S, Malvehy J, Puig S. Application of 3. Fernández-Sartorio C, Boada A, Melanoma Meta-Analysis Consortium. in vivo reflectance confocal microscopy Chavez-Bourgeois MM, Ruiz Ares GJ, Arance Cell-type-specific eQTL of primary (RCM) and ex vivo fluorescence confocal AM, Manzano JL, García-Herrera A, Carrera C. melanocytes facilitates identification of microscopy (FCM) in most common Aged-looking skin and encorafenib: an melanoma susceptibility genes. GENOME subtypes of Basal Cell Carcinoma and adverse event of BRAF inhibitors. RESEARCH. 28(11):1621-1635. I.F.: 10.101 correlation with histopathology. BRITISH MELANOMA RESEARCH. 28(2):160-162. JOURNAL OF DERMATOLOGY. I.F.: 3.135 3. Almendros, Isaac; Angel Martinez-Garcia, 178(5):1215-1217. I.F.: 6.129 Miguel; Campos-Rodriguez, Francisco; 4. Morgado-Carrasco D, Moreno-Rivera N, Riveiro-Falkenbach, Erica; Rodriguez-Peralto, 6. Malvehy J, Puig S. Response to 'Phase IV Fustà-Novell X, García-Herrera A, Carrera C, Jose L.; Nagore, Eduardo; Martorell- head-to-head randomized controlled trial Puig S. Histiocytoid Sweet's syndrome Calatayud, Antonio; Hernandez Blasco, Luis; comparing ingenol mebutate 0·015% gel during combined therapy with BRAF and Banuls Roca, Jose; Chiner Vives, Eusebi; with diclofenac sodium 3% gel for the MEK inhibitors for metastatic melanoma. Sanchez-de-la-Torre, Alicia; Abad-Capa, treatment of actinic keratosis on the face MELANOMA RESEARCH. 28(3):256-257. Jorge; Maria Montserrat, Josep; Perez-Gil, or scalp'. BRITISH JOURNAL OF I.F.: 3.135 Amalia; Cabriada-Nuno, Valentin; DERMATOLOGY. 178(3):812-813. I.F.: 6.129 Cano-Pumarega, Irene; Corral-Penafiel, 5. Alos L, Rodriguez-Carunchio L, Brugués A, Jaime; Diaz-Cambriles, Trinidad; Mediano, 7. Pellacani G, Gupta G, Micali G, Malvehy J, Fuster C, Pinyol M, Puig S. The Usefulness of Olga; Dalmau-Arias, Joan; Farre, Ramon; Stratigos AJ, Casari A, Chester J, Kaleci S, Molecular Tools for the Diagnosis of a Gozal, David; Spanish Sleep Network. Dirschka T. Actinic keratosis area severity Challenging Nevoid Melanoma. APPLIED Intermittent Hypoxia Is Associated With index (AKASI): Reproducibility study and IMMUNOHISTOCHEMISTRY AND High Hypoxia Inducible Factor-1 alpha but comparison with total lesion count. MOLECULAR MORPHOLOGY. I.F.: 2.042 Not High Vascular Endothelial Growth BRITISH JOURNAL OF DERMATOLOGY. Factor Cell Expression in Tumors of 179(3):763-764. I.F.: 6.129 Cutaneous Melanoma Patients. Clinical Guidelines / I.F.: 1.944 FRONTIERS IN NEUROLOGY. 9:272. 8. Borrell A., Grande M., Meler E., Sabrià J., I.F.: 3.508 Mazarico E., Muñoz A., Rodriguez-Revenga L., 1. Gutzmer R., Harrington K., Hoeller C., Lebbé Badenas C., Figueras F. Genomic Microarray C., Malvehy J., Öhrling K., Downey G., Dummer in Fetuses with Early Growth Restriction: A R. Practical clinical guide on the use of Multicenter Study. OBSTETRICAL AND talimogene laherparepvec monotherapy in GRANTS FOR RESEARCH IN PROGRESS GYNECOLOGICAL SURVEY. 73(2):73-74. patients with unresectable melanoma in I.F.: 2.014 Europe. EUROPEAN JOURNAL OF Malvehy J. Identificación de factores DERMATOLOGY. 28(6):736-749. I.F.: 1.944 genéticos en individuos con nevus 9. Moreno-Ramírez D., Vidal-Sicart S., Puig S., melanocíticos y su influencia en la Malvehy J. Should immediate determinacón de la mutación BRAF lymphadenectomy be discontinued in Consortium Publications / I.F.: 25.962 (V600E) en plasma. patients with metastasis of a melanoma in Sponsored by: Instituto de Salud Carlos III the sentinel lymph node? Report of the 1. Duffy DL, Zhu G, Li X, Sanna M, Iles MM, (ISCIII). PI15/00956 results of the Multicenter Selective Jacobs LC, Evans DM, Yazar S, Beesley J, Duration: 01/01/2016-31/12/2019. Lymphadenectomy Trial-II. MEDICINA Law MH, Kraft P, Visconti A, Taylor JC, Liu F, CLINICA. 150(8):323-326. I.F.: 1.168 Wright MJ, Henders AK, Bowdler L, Glass D, Malvehy J. El metabolismo de los Ikram MA, Uitterlinden AG, Madden PA, Heath esfingolípidos como diana terapéutica AC, Nelson EC, Green AC, Chanock S, Barrett para mejorar la inmunoterapia del Case Reports / I.F.: 18.728 JH, Brown MA, Hayward NK, MacGregor S, melanoma. Sturm RA, Hewitt AW,, Kayser M, Hunter DJ, Sponsored by: Instituto de Salud Carlos III 1. Podlipnik S., Guijarro F., Combalia A., Newton Bishop JA, Spector TD, Montgomery (ISCIII). FIS_AC16/00081 – To-Figueras J., Badenas C., Costa D., Rozman GW, Mackey DA, Smith GD, Nijsten TE, Bishop ERANET_TRANSC2_16 M., Jorge S., Aguilera P., Gaya A. Acquired DT, Bataille V, Falchi M, Han J, Martin NG Duration: 01/01/2017-31/12/2019. erythropoietic uroporphyria secondary to Melanoma GWAS Consortium. Novel myelodysplastic syndrome with pleiotropic risk loci for melanoma and Puig S. Grup d'estudi de Malalties Rares chromosome 3 alterations: A case report. nevus density implicate multiple biological d'Origen Genètic. BRITISH JOURNAL OF DERMATOLOGY. pathways. NATURE COMMUNICATIONS. Sponsored by: Generalitat de Catalunya. 179(2):486-490. I.F.: 6.129 9(1):4774. I.F.: 12.353 AGAUR_SGR17_01067 Duration: 01/01/2017-31/12/2020 2. Combalia A., Alejo B., Puig S. Reflectance 2. Zhang T, Choi J, Kovacs MA, Shi J, Xu M, confocal microscopy evaluation of NISC Comparative Sequencing Program,

298 MELANOMA: IMAGING, GENETICS AND IMMUNOLOGY 5.5

Puig S. Evaluación de las alteraciones inmunológicas subyacentes en el desarrollo, progresión y respuesta a las terapias inmunológicas en melanoma. Implicación de la microbiota en la inducción de tolerancia y efectos secundarios de las terapias inmunológicas. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI15/00716 Duration: 01/01/2016-31/12/2018

Puig S. Vías de diseminación metastásica en distintos subtipos del melanoma maligno: nuevos biomarcadores tumorales y dianas terapéuticas. Sponsored by: Asociación Española Contra el Cáncer. AECC_Grupo Estable15 (CB1515297850EN) Duration: 01/07/2015-30/06/2020

Puig S. Melanoma Survival Model of genetic variant involved in naevus count. Sponsored by: European Academy of Dermatology and Venereology. PPRC-2017-19 Duration: 01/01/2018-31/1272019

DOCTORAL THESES

Puig S, Puig JA. Rol del gen de pigmentació MC1R en la susceptibilitat a malalties neurodegeneratives. PhD student: Gemma Tell Martí

Puig S. Characterization of genetic factors associated with melanoma susceptibility and prognosis. PhD student: Miriam Potrony Mateu

299 AREA 5 ONCOLOGY AND HAEMATOLOGY

Hematopoietic progenitor 5.6 cell transplantation

MAIN LINES OF RESEARCH

LOCATION Clinical research lines CEK building, ﬂoor 2 1. Assessment of new hematopoietic precursor transplantation (HPT) indications.

2. Evaluation of new transplant modalities, KEYWORDS specially: 1. Allogeneic transplantation TEAM LEADER - Domiciliary autogenic HPT and allogenic 2. Immunotherapy Álvaro Urbano-Ispizua (HCB) HPT. 3. Veno-oclussive disease T. 93 227 57 76 - Haploidentical transplantation with 4. Graft versus host disease [email protected] unmanipulated bone marrow.

5. Infectious diseases 8. Chimeric antigen receptor 3. Studies addressing the prevention and RESEARCHERS treatment of the main complications of Francesc Fernández-Avilés (HCB) HPT. Pedro José Marín (HCB) - Prevention and treatment of Araceli Beatriz Martín-Antonio (FCRB) graft-versus-host disease with new agents Carmen Martínez (HCB) and participation in different multicenter Montserrat Rovira (HCB) studies. Original publications from 2016 to 2018 POST-DOCTORAL RESEARCHERS 4. CART and CARNK therapy in multiple Hugo Calderon (FCRB) myeloma. YEAR I.F. TOTAL Q1 Q2 Maria Castella (FCRB) 2016 41.58 6 4 2 Sònia Guedan (FCRB) 2017 68.07 16 6 8 Guillermo Suñé (FCRB) Basic and translational research lines

2018 48.32 8 9 2 PRE-DOCTORAL RESEARCHERS 1. Study of the post-HPT complications Lorena Pérez-Amil (FCRB) originating from endothelial dysfunction. María Suarez-Lledó (HCB-FCRB) Our project aims to characterize such dysfunction and the early diagnosis of ADMINISTRATIVE STAFF infections then to seek effective preventive LOCATION Mª José Sánchez-Melero (HCB) in HPT. RTICC_2012 Carme Torres (HCB) 2. Study of new techniques for the early diagnosis of infections in HPT.

STRATEGIC OBJECTIVES 3. Development of CARTs using autologous T cells and also from NK cells expanded We have started research lines in antitumor from umbilical cord blood. cell therapy (NK and CARTs), and cell immune modulation. Lastly, we plan to develop a line of research in the ﬁeld of the pharmacokinetics, PUBLICATIONS pharmacodynamics and pharmacogenomics of immune modulators, as well as in the Originals / I.F.: 48.322 development of in vitro predictive models of graft-versus-host disease. 1. Wing A, Fajardo CA, Posey AD, Shaw C, Da T, Young RM, Alemany R, June CH, Guedan S. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispeciﬁc T-cell Engager. CANCER IMMUNOL RES. 6(5):605-616. I.F.: 9.188

2. Schmid C., De Wreede L., Van Biezen A., Finke J., Ehninger G., Ganser A., Volin L., Niederwieser D., Beelen D., Alessandrino P., Kanz L., Schleuning M., Passweg J., Veelken

300 HEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION 5.6

H., Maertens J., Cornelissen J., Blaise D., F. Innovative strategies minimize Clinical Guidelines / I.F.: 1.707 Gramatzki M., Milpied N., Yakoub-Agha I., Mufti engraftment syndrome in multiple G., Rovira M., Arnold R., De Witte T., Robin M., myeloma patients with novel induction 1. Garcia-Vidal C, Alastruey-Izquierdo A, Kröger N. Outcome after relapse of therapy following autologous Aguilar-Guisado M, Carratalà J, Castro C, myelodysplastic syndrome and secondary hematopoietic stem cell transplantation. Fernández-Ruiz M, Aguado JM, Fernández acute myeloid leukemia following BONE MARROW TRANSPLANTATION. JM, Fortún J, Garnacho-Montero J, Gavaldà J, allogeneic stem cell transplantation: A 53(12):1541-1547. I.F.: 4.497 Gudiol C, Guinea J, Gómez-López A, Muñoz P, retrospective registry analysis on 698 Pemán J, Rovira M, Ruiz-Camps I, patients by the chronic malignancies 7. Suárez-Lledó M, Martínez-Cibrián N, Cuenca-Estrella M. Executive summary of working party of the european society of Gutiérrez-García G, Dimova-Svetoslavova V, clinical practice guideline for the blood and marrow transplantation. Marcos MA, Martín-Antonio B, management of invasive diseases caused HAEMATOLOGICA. 103(2):237-245. Martínez-Trillos A, Villamor N, Rosiñol L, by Aspergillus: 2018 Update by the I.F.: 9.090 Martínez C, Fernández-Avilés F, García-Vidal GEMICOMED-SEIMC/REIPI. C, Urbano-Ispizua Á, Rovira M. Deleterious ENFERMEDADES INFECCIOSAS Y 3. Smith SM, Godfrey J, Ahn KW, DiGilio A, Effect of Steroids on Cytomegalovirus MICROBIOLOGIA CLINICA. I.F.: 1.707 Ahmed S, Agrawal V, Bachanova V, Bacher U, Infection Rate after Allogeneic Stem Cell Bashey A, Bolaños-Meade J, Cairo M, Chen A, Transplantation Depends on Chhabra S, Copelan E, Dahi PB, Aljurf M, Pretransplant Cytomegalovirus Farooq U, Ganguly S, Hertzberg M, Holmberg Serostatus of Donors and Recipients. GRANTS FOR RESEARCH IN PROGRESS L, Inwards D, Kanate AS, Karmali R, Kenkre BIOLOGY OF BLOOD AND MARROW VP, Kharfan-Dabaja MA, Klein A, Lazarus HM, TRANSPLANTATION. 24(10):2088-2093. Martín B. Modiﬁcación de la comunicación Mei M, Mussetti A, Nishihori T, Ramakrishnan I.F.: 4.484 intercelular entre células inmunes y de Geethakumari P, Saad A, Savani BN, mieloma para mejorar la sensibilidad a Schouten HC, Shah N, Urbano-Ispizua A, Vij R, 8. Jorge A., Suárez-Lledó M., Pereira A., inmunoterapia y tratamientos Vose J, Sureda A, Hamadani M. Autologous Gutierrez G., Fernández-Avilés F., Rosiñol L., convencionales. transplantation versus allogeneic Llobet N., Solano T., Urbano-Ispízua Á., Rovira Sponsored by: Instituto de Salud Carlos III transplantation in patients with follicular M., Martínez C. Single Antigen-Mismatched (ISCIII). PI17/01043 lymphoma experiencing early treatment Unrelated Hematopoietic Stem Cell Duration: 01/01/2018-31/12/2020 failure. CANCER. 124(12):2541-2551. I.F.: 6.537 Transplantation Using High-Dose Post-Transplantation Cyclophosphamide 4. Lopez-Millan B, Diaz de la Guardia R, Is a Suitable Alternative for Patients Roca-Ho H, Anguita E, Islam ABMMK, Lacking HLA-Matched Donors. BIOLOGY Romero-Moya D, Prieto C, Gutierrez-Agüera OF BLOOD AND MARROW F, Bejarano-Garcia JA, Perez-Simon JA, TRANSPLANTATION. 24(6):1196-1202. Costales P, Rovira M, Marín P, Menendez S, I.F.: 4.484 Iglesias M, Fuster JL, Urbano-Ispizua A, Anjos-Afonso F, Bueno C, Menendez P. IMiDs mobilize acute myeloid leukemia blasts to Review / I.F.: 15.835 peripheral blood through downregulation of CXCR4 but fail to potentiate AraC/ 1. Snowden J., Panés J., Alexander T., Allez M., Idarubicin activity in preclinical models of Ardizzone S., Dierickx D., Finke J., Hasselblatt non del5q/5q- AML. ONCOIMMUNOLOGY. P., Hawkey C., Kazmi M., Lindsay J., Onida F., 7(9):e1477460. I.F.: 5.503 Salas A., Saccardi R., Vermeire S., Rovira M., Ricart E. Autologous haematopoietic stem 5. Lozano E, Díaz T, Mena MP, Suñe G, Calvo cell transplantation (AHSCT) in severe X, Calderón M, Pérez-Amill L, Rodríguez V, Crohn's disease: A review on behalf of Pérez-Galán P, Roué G, Cibeira MT, Rosiñol L, ECCO and EBMT. JOURNAL OF CROHN'S Isola I, Rodríguez-Lobato LG, Martin-Antonio AND COLITIS. 12(4):476-488. I.F.: 6.637 B, Bladé J, Fernández de Larrea C. Loss of the Immune Checkpoint CD85j/LILRB1 on 2. Guedan, Sonia; Alemany, Ramon. CAR-T Malignant Plasma Cells Contributes to Cells and Oncolytic Viruses: Joining Immune Escape in Multiple Myeloma. Forces to Overcome the Solid Tumor JOURNAL OF IMMUNOLOGY. Challenge. FRONTIERS IN IMMUNOLOGY. 200(8):2581-2591. I.F.: 4.539 9(2460):2460. I.F.: 5.511

6. Gutiérrez-García G., Rovira M., Magnano L., 3. Castella M., de Larrea C., Martín-Antonio B. Rosiñol L., Bataller A., Suárez-Lledó M., Cibeira Immunotherapy: A Novel Era of Promising M., de Larrea C., Garrote M., Jorge S., Moreno Treatments for Multiple Myeloma. A., Rodríguez-Lobato L., Carreras E., INTERNATIONAL JOURNAL OF Díaz-Ricart M., Palomo M., Martínez C., MOLECULAR SCIENCES. 19(11):3613. Urbano-Ispizua A., Bladé J., Fernández-Avilés I.F.: 3.687

301 AREA 5 ONCOLOGY AND HAEMATOLOGY

Hematological 5.7 oncology

ADMINISTRATIVE STAFF Laura Alcolea (HCB) LOCATION Vanessa Arellano (HCB-FCRB) HCB building

STRATEGIC OBJECTIVES

The main strategic objectives of our team KEYWORDS are clinical, applied and basic research in

1. Lymphoid neoplasms TEAM LEADER haematological oncology. 2. Genomic proﬁle Francisco Cervantes (HCB) The team is structured into three study groups 3. Multiple myeloma T. 93 227 54 28 of three major disease categories 4. Myeloproliferative neoplasms [email protected] 5. Acute myeloid leukemia

GROUP LEADERS MAIN LINES OF RESEARCH Joan Bladé (HCB) T. 93 227 54 75 1. Lymphoid neoplasms [email protected] - Mechanisms of progression . - Genomic proﬁle of diffuse large cell Original publications lymphoma. from 2016 to 2018 Francisco Cervantes (HCB) T. 93 227 54 28 - New prognostic models in T cell lymphomas . YEAR I.F. TOTAL Q1 Q2 [email protected] - Mechanisms of progression of chronic lymphoid leukemia (CLL). 2016 355.42 40 26 10 Carlos Fernández de Larrea (IDIBAPS-HCB) - Cellular microenvironment in CLL. 2017 511.46 57 40 13 T. 93 227 54 75 - Cellular proliferation in CLL. 2018 580.19 58 44 12 [email protected] - Project for the Chronic Lymphocytic Leukemia (CLL) Genome. Armando López-Guillermo (HCB) T. 93 227 54 75 2. Multiple myeloma and other [email protected] monoclonal gammopathies TEAM INVOLVED IN - Extramedullary involvement and plasma RTICC cell leukemia . AGAUR_SGR17: 01655, 00792 RESEARCHERS - Immune reconstitution and bone marrow Maria Teresa Cibeira (HCB) microenvironment in patients in response Julio Delgado (HCB) - Mechanisms of progression and control in Jordi Esteve (HCB) asymptomatic gammopathies. Eva Giné (HCB) - Impact of microRNA and other non-coding Emili Montserrat (HCB) RNA. Laura Rosiñol (HCB) - Cardiac involvement in AL amyloidosis. - Phase I, II and III clinical trials .

POST-DOCTORAL RESEARCHERS Alberto Álvarez-Larrán (HCB) 3. Myeloid neoplasms Tycho Stephan Baumann (HCB) - Chronic myeloid leukemia (CML): Marina Díaz (HCB) European Registry of CML. Tania Díaz (IDIBAPS) - Philadelphia-negative myeloproliferative Ester Lozano (IDIBAPS) neoplasms: Mechanisms of thrombosis; Laura Carola Magnano (HCB) mutational status and prognosis of Natalia Tovar (HCB) myeloﬁbrosis. - Acute myeloid leukemia (AML): Biological

PRE-DOCTORAL RESEARCHERS prognostic factors; expression of Juan Gonzalo Correa (HCB) non-coding RNA; treatment protocols for Daniel Esteban (FCRB) the CETLAM group; impact of molecular Anna Gaya (FCRB) markers in transplantation. Ignacio Isola (HCB) - Myelodysplastic syndromes (MDS): Raquel Jiménez (FCRB) cytogenetic and molecular abnormalities Valentín Ortiz (FCRB) and prognosis. Alfredo Rivas (HCB) - Phase I, II and III clinical trials for CML, Ana Triguero (FCRB) myeloﬁbrosis, AML, ALL and MDS.

302 HEMATOLOGICAL ONCOLOGY 5.7

RESEARCH GROUP MYELOMA AND OTHER MONOCLONAL GAMMAPATHIES

GROUP LEADER Joan Bladé (HCB)

Multiple myeloma and systemic AL amyloidosis. Minimal residual disease, extramedullary involvement in myeloma, cardiac involvement in amyloidosis, and multicentric clinical trials with novel drugs.

RESEARCH GROUP MYELOID NEOPLASMAS GROUP Francisco Cervantes

GROUP LEADER Francisco Cervantes (HCB)

Natural history and prognosis of chronic myeloid leukemia, myeloproliferative neoplasms, acute myeloid leukemia and myelodysplastic syndromes; prognostic importance of newer molecular markers in these diseases; clinical trials with new drugs.

50/50 PROGRAM MECHANISMS OF PROGRESSION IN MONOCLONAL GAMMOPATHIES GROUP Carlos Fernández de Larrea Rodríguez

GROUP LEADER Carlos Fernández de Larrea Rodríguez RESEARCH GROUP Study of progression mechanisms of the (HCB-IDIBAPS) LYMPHOID NEOPLASMS disease, genome of CLL and lymphoma, minimum residual disease and biological Mechanisms of progression and control in prognostic models. patients with multiple myeloma. Molecular and cellular features of patients with long-lasting stable monoclonal gammopathy of undetermined signiﬁcance and smoldering myeloma. Oligoclonal response and minimal residual disease in myeloma: impact of immune GROUP LEADER reconstitution and bone marrow microenviron- Armando López Guillermo (HCB) ment. Immunotherapy in monoclonal gammopathies. Clinical trials with novel molecules in Lymphomas, chronic lymphocytic leukemia myeloma and macroglobulinemia. and the other lymphoproliferative disorders:

303 AREA 5 ONCOLOGY AND HAEMATOLOGY

PUBLICATIONS Martin-Subero JI. The reference epigenome myelofibrosis previously treated with and regulatory chromatin landscape of ruxolitinib (SIMPLIFY 2): A randomised, Originals / I.F.: 580.188 chronic lymphocytic leukemia. NATURE open-label, phase 3 trial. THE LANCET MEDICINE. 24(6):868-880. I.F.: 32.621 HAEMATOLOGY. 5(2):E73-E81. I.F.: 10.698 1. Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar 5. Gay F., Jackson G., Rosiñol L., Holstein S., 10. Federico, Massimo; Caballero Barrigon, M, Young RM, Shaffer AL, Hodson DJ, Xiao W, Moreau P., Spada S., Davies F., Lahuerta J., Leleu Maria Dolores; Marcheselli, Luigi; Tarantino, Yu X, Yang Y, Zhao H, Xu W, Liu X, Zhou B, Du W, X., Bringhen S., Evangelista A., Hulin C., Panzani Vittoria; Manni, Martina; Sarkozy, Clementine; Chan WC, Jaffe ES, Gascoyne RD, Connors JM, U., Cairns D., Di Raimondo F., Macro M., Liberati Alonso-Alvarez, Sara; Wondergem, Marielle; Campo E, Lopez-Guillermo A, Rosenwald A, Ott A., Pawlyn C., Offidani M., Spencer A., Hájek R., Cartron, Guillaume; Lopez-Guillermo, Armando; G, Delabie J, Rimsza LM, Tay Kuang Wei K, Terpos E., Morgan G., Bladé J., Sonneveld P., Issa, Djamila; Morschhauser, Franck; Alcoceba, Zelenetz AD, Leonard JP, Bartlett NL, Tran B, San-Miguel J., McCarthy P., Ludwig H., Miguel; Kimby, Eva; Rusconi, Chiara; Chamuleau, Shetty J, Zhao Y, Soppet DR, Pittaluga S, Wilson Boccadoro M., Mateos M., Attal M. Martine; Holte, Harald; Lockmer, Sandra; WH, Staudt LM. Genetics and Pathogenesis Maintenance Treatment and Survival in Montoto, Silvia; da Silva, Maria Gomes; Aurer, of Diffuse Large B-Cell Lymphoma.NEW Patients with Myeloma: A Systematic Igor; Zucca, Emanuele; Paszkiewicz-Kozik, Ewa; ENGLAND JOURNAL OF MEDICINE. Review and Network Meta-Analysis. JAMA Minoia, Carla; Skrypets, Tetiana; Blaker, Yngvild 378(15):1396-1407. I.F.: 79.260 ONCOL. 4(10):1389-1397. I.F.: 20.871 Nuvin; Salles, Gilles; Coiffier, Bertrand; Aristotle Consortium. Rituximab and the risk of 2. Morschhauser, F.; Fowler, N. H.; Feugier, P.; 6. Clot G, Jares P, Giné E, Navarro A, Royo C, transformation of follicular lymphoma: a Bouabdallah, R.; Tilly, H.; Palomba, M. L.; Fruchart, Pinyol M, Martín-Garcia D, Demajo S, Espinet B, retrospective pooled analysis. THE C.; Libby, E. N.; Casasnovas, R-O.; Flinn, I. W.; Salar A, Ferrer A, Muntañola A, Aymerich M, LANCET HAEMATOLOGY. 5(8):E359-E367. Haioun, C.; Maisonneuve, H.; Ysebaert, L.; Bartlett, Rauert-Wunderlich H, Jaffe ES, Connors JM, I.F.: 10.698 N. L.; Bouabdallah, K.; Brice, P.; Ribrag, V.; Gascoyne RD, Delabie J, López-Guillermo A, Ott Daguindau, N.; Le Gouill, S.; Pica, G. M.; Martin G, Wright GW, Staudt LM, Rosenwald A, Scott 11. Nadeu F, Clot G, Delgado J, Martín-García D, Garcia-Sancho, A.; Lopez-Guillermo, A.; DW, Rimsza LM, Beà S, Campo E. A gene Baumann T, Salaverria I, Beà S, Pinyol M, Jares P, Larouche, J-F.; Ando, K.; Gomes da Silva, M.; signature that distinguishes conventional Navarro A, Suárez-Cisneros H, Aymerich M, Andre, M.; Zachee, P.; Sehn, L. H.; Tobinai, K.; and leukemic nonnodal mantle cell Rozman M, Villamor N, Colomer D, González M, Cartron, G.; Liu, D.; Wang, J.; Xerri, L.; Salles, G. lymphoma helps predict outcome. BLOOD. Alcoceba M, Terol MJ, Navarro B, Colado E, A.;RELEVANCE Trial Investigators. Rituximab 132(4):413-422. I.F.: 15.132 Payer ÁR, Puente XS, López-Otín C, plus Lenalidomide in Advanced Untreated López-Guillermo A, Enjuanes A, Campo E. Follicular Lymphoma. NEW ENGLAND 7. Bretones G, Álvarez MG, Arango JR, Clinical impact of the subclonal JOURNAL OF MEDICINE. 379(10):934-947. I.F.: Rodríguez D, Nadeu F, Prado MA, Valdés-Mas R, architecture and mutational complexity in 79.260 Puente DA, Paulo JA, Delgado J, Villamor N, chronic lymphocytic leukemia. LEUKEMIA. López-Guillermo A, Finley DJ, Gygi SP, Campo 32(3):645-653. I.F.: 10.023 3. Huet S, Tesson B, Jais JP, Feldman AL, E, Quesada V, López-Otín C. Altered patterns Magnano L, Thomas E, Traverse-Glehen A, of global protein synthesis and 12. Karube K, Enjuanes A, Dlouhy I, Jares P, Albaud B, Carrère M, Xerri L, Ansell SM, translational fidelity in RPS15-mutated Martin-Garcia D, Nadeu F, Ordóñez GR, Rovira J, Baseggio L, Reyes C, Tarte K, Boyault S, Haioun chronic lymphocytic leukemia. BLOOD. Clot G, Royo C, Navarro A, Gonzalez-Farre B, C, Link BK, Feugier P, Lopez-Guillermo A, Tilly H, 132(22):2375-2388. I.F.: 15.132 Vaghefi A, Castellano G, Rubio-Perez C, Brice P, Hayette S, Jardin F, Offner F, Sujobert P, Tamborero D, Briones J, Salar A, Sancho JM, Gentien D, Viari A, Campo E, Cerhan JR, Salles G. 8. Ciavarella S, Vegliante MC, Fabbri M, De Mercadal S, Gonzalez-Barca E, Escoda L, A gene-expression profiling score for Summa S, Melle F, Motta G, De Iuliis V, Opinto G, Miyoshi H, Ohshima K, Miyawaki K, Kato K, prediction of outcome in patients with Enjuanes A, Rega S, Gulino A, Agostinelli C, Akashi K, Mozos A, Colomo L, Alcoceba M, follicular lymphoma: a retrospective Scattone A, Tommasi S, Mangia A, Mele F, Valera A, Carrió A, Costa D, Lopez-Bigas N, training and validation analysis in three Simone G, Zito AF, Ingravallo G, Vitolo U, Schmitz R, Staudt LM, Salaverria I, López- international cohorts. LANCET Chiappella A, Tarella C, Gianni AM, Rambaldi A, Guillermo A, Campo E. Integrating genomic ONCOLOGY. 19(4):549-561. I.F.: 36.421 Zinzani PL, Casadei B, Derenzini E, Loseto G, alterations in diffuse large B-cell Pileri A, Tabanelli V, Fiori S, Rivas-Delgado A, lymphoma identifies new relevant 4. Beekman R, Chapaprieta V, Russiñol N, López-Guillermo A, Venesio T, Sapino A, Campo pathways and potential therapeutic Vilarrasa-Blasi R, Verdaguer-Dot N, Martens E, Tripodo C, Guarini A, Pileri SA. Dissection of targets. LEUKEMIA. 32(3):675-684. I.F.: 10.023 JHA, Duran-Ferrer M, Kulis M, Serra F, Javierre DLBCL Microenvironment Provides a BM, Wingett SW, Clot G, Queirós AC, Castellano Gene Expression-Based Predictor of 13. De Larrea C., Isola I., Pereira A., Cibeira M., G, Blanc J, Gut M, Merkel A, Heath S, Vlasova A, Survival Applicable to Formalin-Fixed Magnano L., Tovar N., Rodríguez-Lobato L., Ullrich S, Palumbo E, Enjuanes A, Martín-García Paraffin-Embedded Tissue.ANNALS OF Calvo X., Aróstegui J., Díaz T., Lozano E., Rozman D, Beà S, Pinyol M, Aymerich M, Royo R, ONCOLOGY. 29(12):2363-2370. I.F.: 13.930 M., Yagüe J., Bladé J., Rosiñol L.. Evolving Puiggros M, Torrents D, Datta A, Lowy E, M-protein pattern in patients with Kostadima M, Roller M, Clarke L, Flicek P, Agirre 9. Harrison C., Vannucchi A., Platzbecker U., smoldering multiple myeloma: impact on X, Prosper F, Baumann T, Delgado J, Cervantes F., Gupta V., Lavie D., Passamonti F., early progression. LEUKEMIA. López-Guillermo A, Fraser P, Yaspo ML, Guigó Winton E., Dong H., Kawashima J., Maltzman J., 32(6):1427-1434. I.F.: 10.023 R, Siebert R, Martí-Renom MA, Puente XS, Kiladjian J., Verstovsek S. Momelotinib versus López-Otín C, Gut I, Stunnenberg HG, Campo E, best available therapy in patients with 14. Hernández-Boluda J., Pereira A., Correa J.,

304 HEMATOLOGICAL ONCOLOGY 5.7

Alvarez-Larrán A., Ferrer-Marín F., Raya J., 103(9):e392-e394. I.F.: 9.090 24. Barraco D., Mora B., Guglielmelli P., Rumi E., Martínez-López J., Pérez-Encinas M., Estrada N., Maffioli M., Rambaldi A., Caramella M., Komrokji Velez P., Fox M., García-Gutiérrez V., Payer A., 19. Ruiz-Heredia Y, Sánchez-Vega B, Onecha E, R., Gotlib J., Kiladjian J., Cervantes F., Devos T., Kerguelen A., Cuevas B., Durán M., Ramírez M., Barrio S, Alonso R, Martínez-Ávila JC, Cuenca I, Palandri F., De Stefano V., Ruggeri M., Silver R., Gómez-Casares M., Mata-Vázquez M., Mora E., Agirre X, Braggio E, Hernández MT, Martínez R, Benevolo G., Albano F., Merli M., Pietra D., Barbui Martínez-Valverde C., Gómez M., Cervantes F. Rosiñol L, Gutierrez N, Martin-Ramos M, Ocio T., Rotunno G., Cazzola M., Giorgino T., Performance of the myelofibrosis EM, Echeveste MA, de Oteyza JP, Oriol A, Vannucchi A., Passamonti F. Gender effect on secondary to PV and ET-prognostic model Bargay J, Gironella M, Ayala R, Bladé J, Mateos phenotype and genotype in patients with (MYSEC-PM) in a series of 262 patients MV, Kortum KM, Stewart K, García-Sanz R, post-polycythemia vera and post-essential from the Spanish registry of myelofibrosis. Miguel JS, Lahuerta JJ, Martinez-Lopez J. thrombocythemia myelofibrosis: results LEUKEMIA. 32(2):553-555. I.F.: 10.023 Mutational screening of newly diagnosed from the MYSEC project. BLOOD CANCER multiple myeloma patients by deep JOURNAL. 8(10):89. I.F.: 8.125 15. Arana P, Paiva B, Cedena MT, Puig N, targeted sequencing. HAEMATOLOGICA. Cordon L, Vidriales MB, Gutierrez NC, Chiodi F, 103(11):e544-e548. I.F.: 9.090 25. De Stefano, Valerio; Carobbio, Alessandra; Burgos L, Anglada LL, Martinez-Lopez J, Di Lazzaro, Vincenzo; Guglielmelli, Paola; Iurlo, Hernandez MT, Teruel AI, Gironella M, 20. San-Miguel J., Gutierrez M., Špicka I., Mateos Alessandra; Finazzi, Maria Chiara; Rumi, Elisa; Echeveste MA, Rosiñol L, Martinez R, Oriol A, De M., Song K., Craig M., Bladé J., Hájek R., Chen C., Cervantes, Francisco; Elli, Elena Maria; Randi, la Rubia J, Orfao A, Blade J, Lahuerta JJ, Mateos Di Bacco A., Estevam J., Gupta N., Byrne C., Lu V., Maria Luigia; Griesshammer, Martin; Palandri, MV, San Miguel JF. Prognostic value of Van De Velde H., Lonial S. A phase I/II Francesca; Bonifacio, Massimiliano; antigen expression in multiple myeloma: a dose-escalation study investigating Hernandez-Boluda, Juan-Carlos; Cacciola, PETHEMA/GEM study on 1265 patients all-oral ixazomib-melphalanprednisone Rossella; Miroslava, Palova; Carli, Giuseppe; enrolled in four consecutive clinical trials. induction followed by single-agent Beggiato, Eloise; Ellis, Martin H.; Musolino, LEUKEMIA. 32(4):971-978. I.F.: 10.023 ixazomib maintenance in Caterina; Gaidano, Gianluca; Rapezzi, Davide; transplant-ineligible newly diagnosed Tieghi, Alessia; Lunghi, Francesca; Loscocco, 16. Rodríguez-Otero P., Mateos M., multiple myeloma. HAEMATOLOGICA. Giuseppe Gaetano; Cattaneo, Daniele; Martínez-López J., Martín-Calvo N., Hernández 103(9):1518-1526. I.F.: 9.090 Cortelezzi, Agostino; Betti, Silvia; Rossi, Elena; M., Ocio E., Rosiñol L., Martínez R., Teruel A., Finazzi, Guido; Censori, Bruno; Cazzola, Mario; Gutiérrez N., Bargay J., Bengoechea E., 21. Misiewicz-Krzeminska I, Corchete L, Rojas E, Bellini, Marta; Arellano-Rodrigo, Eduardo; González Y., de Oteyza J., Gironella M., Encinas Martínez-López J, García-Sanz R, Oriol A, Bladé Bertozzi, Irene; Sadjadian, Parvis; Vianelli, Nicola; C., Martín J., Cabrera C., Palomera L., de Arriba F., J, Lahuerta J, Miguel J, Mateos M, Gutiérrez N. A Scaffidi, Luigi; Gomez, Montse; Cacciola, Emma; Cedena M., Paiva B., Puig N., Oriol A., Bladé J., novel nano-immunoassay method for Vannucchi, Alessandro M.; Barbui, Tiziano. Lahuerta J., San Miguel J. Early quantification of proteins from Benefit-risk profile of cytoreductive drugs myeloma-related death in elderly patients: CD138-purified myeloma cells: Biological along with antiplatelet and antithrombotic development of a clinical prognostic score and clinical utility. HAEMATOLOGICA. therapy after transient ischemic attack or and evaluation of response sustainability 103(5):880-889. I.F.: 9.090 ischemic stroke in myeloproliferative role. LEUKEMIA. 32(11):1-8. I.F.: 10.023 neoplasms. BLOOD CANCER JOURNAL. 22. Mozas P, Rivas-Delgado A, Baumann T, 8(3):25. I.F.: 8.125 17. Poiré X, Labopin M, Polge E, Passweg J, Villamor N, Ortiz-Maldonado V, Aymerich M, Craddock C, Blaise D, Cornelissen JJ, Volin L, Costa D, Navarro A, Giné E, López-Guillermo A, 26. Esteve-Arenys A., Valero J., Russell NH, Socié G, Michallet M, Fegueux N, Montserrat E, Delgado J. Analysis of criteria Chamorro-Jorganes A., Gonzalez D., Rodriguez Chevallier P, Brecht A, Hunault-Berger M, Mohty for treatment initiation in patients with V., Dlouhy I., Salaverria I., Campo E., Colomer D., M, Esteve J, Nagler A. Allogeneic stem cell progressive chronic lymphocytic Martinez A., Rymkiewicz G., Pérez-Galán P., transplantation benefits for patients ≥ 60 leukemia. BLOOD CANCER JOURNAL. Lopez-Guillermo A., Roué G. The BET years with acute myeloid leukemia and 8(1):10. I.F.: 8.125 bromodomain inhibitor CPI203 FLT3-ITD; a study from the Acute overcomes resistance to ABT-199 Leukemia Working Party (ALWP) of the 23. Hernández-Boluda JC, Pereira A, (venetoclax) by downregulation of European Society of Blood and Marrow Pastor-Galán I, Alvarez-Larrán A, Savchuk A, BFL-1/A1 in in vitro and in vivo models of Transplantation (EBMT). Puerta JM, Sánchez-Pina JM, Collado R, MYC+/BCL2+ double hit lymphoma. HAEMATOLOGICA. 103(2):256-265. I.F.: 9.090 Díaz-González A, Angona A, Sagüés M, ONCOGENE. 37(14):1830-1844. I.F.: 6.854 García-Gutiérrez V, Boqué C, Osorio S, Vallansot 18. Mora B, Giorgino T, Guglielmelli P, Rumi E, R, Palomera L, Mendizábal A, Casado LF, 27. Ciurea SO, Labopin M, Socie G, Volin L, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Pérez-Encinas M, Pérez-López R, Ferrer-Marín Passweg J, Chevallier P, Beelen D, Milpied N, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, F, Sánchez-Guijo F, García C, Heras NL, Blaise D, Cornelissen JJ, Fegueux N, Polge E, Palandri F, De Stefano V, Ruggeri M, Silver RT, López-Lorenzo JL, Cervantes F, Steegmann JL, Kongtim P, Rondon G, Esteve J, Mohty M, Savani Benevolo G, Albano F, Cavalloni C, Barraco D, Grupo Español de Leucemia Mieloide Crónica BN, Champlin RE, Nagler A. Relapse and Merli M, Pietra D, Casalone R, Barbui T, Rotunno (GELMC). Feasibility of treatment survival after transplantation for complex G, Cazzola M, Vannucchi AM, Passamonti F. discontinuation in chronic myeloid karyotype acute myeloid leukemia: A Value of cytogenetic abnormalities in leukemia in clinical practice: results from a report from the Acute Leukemia Working post-polycythemia vera and post-essential nationwide series of 236 patients. BLOOD Party of the European Society for Blood thrombocythemia myelofibrosis: a study CANCER JOURNAL. 8(10):91. I.F.: 8.125 and Marrow Transplantation and the of the MYSEC project. HAEMATOLOGICA. University of Texas MD Anderson Cancer

305 AREA 5 ONCOLOGY AND HAEMATOLOGY

Center. CANCER. 124(10):2134-2141. I.F.: 6.537 33.-de la Guardia R., Correa J., López-Millán B., 38. Jiménez-Ubieto A., Grande C., Caballero D., Juan M., Bueno C., Cervantes F., Menéndez P. Yáñez L., Hernández-Garcia M., Novelli S., Arranz 28. Espígol-Frigolé G., Planas-Rigol E., Lozano Detection of inflammatory monocytes but R., Ferreiro J., Bobillo S., Mercadal S., Galeo A., E., Corbera-Bellalta M., Terrades-García N., not mesenchymal stem/stromal cells in Jiménez J., Moraleda J., Vallejo C., Albo C., Pérez Prieto-González S., García-Martínez A., peripheral blood of patients with E., Marrero C., Magnano L., Palomera L., Jarque I., Hernández-Rodríguez J., Grau J., Cid M. myelofibrosis. BRITISH JOURNAL OF Martínez-Sánchez P., Martín A., Coria E., Expression and function of IL12/23 related HAEMATOLOGY. 181(1):133-137. I.F.: 5.128 López-Guillermo A., Salar A., Lahuerta J. cytokine subunits (p35, p40, and p19) in Secondary malignancies and survival giant-cell arteritis lesions: Contribution of 34. Montalban, Carlos; Diaz-Lopez, Antonio; outcomes after autologous stem cell p40 to Th1-and Th17-mediated Martin, Alejandro; Baile, Monica; Sanchez, Jose transplantation for follicular lymphoma in inflammatory pathways. FRONTIERS IN M.; Sancho, Juan M.; Garcia, Olga; Novelli, the pre-rituximab and rituximab eras: a IMMUNOLOGY. 9(809):809. I.F.: 5.511 Silvana; Monter-Rovira, Anna; Salar, Antonio; long-term follow-up analysis from the Bastos, Mariana; Gutierrez, Antonio; Bento, Spanish GELTAMO registry. BONE 29. Lazarevic VL, Labopin M, Depei W, Leyre; Corboda, Raul; Arquero, Teresa; MARROW TRANSPLANTATION. Yakoub-Agha I, Huynh A, Ljungman P, Schaap N, Gonzalez de Villambrosia, Sonia; Barranco, 53(6):780-783. I.F.: 4.497 Cornelissen JJ, Maillard N, Pioltelli P, Gedde-Dahl Gilberto; De Ona, Raquel; Lopez Guillermo, T, Lenhoff S, Houhou M, Esteve J, Mohty M, Armando; Rodriguez Salazar, Maria J.; 39. Suárez-Lledó M, Martínez-Cibrián N, Nagler A. Relatively favorable outcome Dominguez, Juan F.; Fernandez, Ruben; Gutiérrez-García G, Dimova-Svetoslavova V, after allogeneic stem cell transplantation Queizan, Jose A.; Rodriguez, Jose; Abraira, Marcos MA, Martín-Antonio B, Martínez-Trillos for BCR-ABL1-positive AML: A survey from Victor; Garcia, Juan F.;GELTAMO-IPI Project A, Villamor N, Rosiñol L, Martínez C, the acute leukemia working party of the Investigators. Differential prognostic impact Fernández-Avilés F, García-Vidal C, European Society for blood and marrow of GELTAMO-IPI in cell of origin subtypes Urbano-Ispizua Á, Rovira M . Deleterious transplantation (EBMT). AMERICAN of Diffuse Large B Cell Lymphoma as Effect of Steroids on Cytomegalovirus JOURNAL OF HEMATOLOGY. 93(1):31-39. defined by the Hans algorithm. BRITISH Infection Rate after Allogeneic Stem Cell I.F.: 5.303 JOURNAL OF HAEMATOLOGY. Transplantation Depends on 182(4):534-541. I.F.: 5.128 Pretransplant Cytomegalovirus 30. Lorentino F., Labopin M., Bernardi M., Ciceri Serostatus of Donors and Recipients. F., Socié G., Cornelissen J., Esteve J., Ruggeri A., 35. Lozano E, Díaz T, Mena MP, Suñe G, Calvo BIOLOGY OF BLOOD AND MARROW Volin L., Yacoub-Agha I., Craddock C., Passweg X, Calderón M, Pérez-Amill L, Rodríguez V, TRANSPLANTATION. 24(10):2088-2093. J., Blaise D., Gedde-Dahl T., Poiani M., Fegueux Pérez-Galán P, Roué G, Cibeira MT, Rosiñol L, I.F.: 4.484 N., Mohty M., Nagler A. Comparable Isola I, Rodríguez-Lobato LG, Martin-Antonio B, outcomes of haploidentical, 10/10 and Bladé J, Fernández de Larrea C. Loss of the 40. Jorge A., Suárez-Lledó M., Pereira A., 9/10 unrelated donor transplantation in Immune Checkpoint CD85j/LILRB1 on Gutierrez G., Fernández-Avilés F., Rosiñol L., adverse karyotype AML in first complete Malignant Plasma Cells Contributes to Llobet N., Solano T., Urbano-Ispízua Á., Rovira M., remission. AMERICAN JOURNAL OF Immune Escape in Multiple Myeloma. Martínez C. Single Antigen-Mismatched HEMATOLOGY. 93(10):1236-1244. I.F.: 5.303 JOURNAL OF IMMUNOLOGY. Unrelated Hematopoietic Stem Cell 200(8):2581-2591. I.F.: 4.539 Transplantation Using High-Dose 31. Ortiz-Maldonado V, Villamor N, Baumann T, Post-Transplantation Cyclophosphamide Aymerich M, Magnano L, Mozas P, 36. Gutiérrez-García G., Rovira M., Magnano L., Is a Suitable Alternative for Patients Rivas-Delgado A, Martínez-Trillos A, Giné E, Rosiñol L., Bataller A., Suárez-Lledó M., Cibeira Lacking HLA-Matched Donors. BIOLOGY Campo E, López-Guillermo A, Delgado J . Is M., de Larrea C., Garrote M., Jorge S., Moreno A., OF BLOOD AND MARROW there a role for minimal residual disease Rodríguez-Lobato L., Carreras E., Díaz-Ricart M., TRANSPLANTATION. 24(6):1196-1202. monitoring in the management of patients Palomo M., Martínez C., Urbano-Ispizua A., Bladé I.F.: 4.484 with hairy-cell leukaemia? BRITISH J., Fernández-Avilés F. Innovative strategies JOURNAL OF HAEMATOLOGY. minimize engraftment syndrome in 41. Bermejo M, Ambrosioni J, Bautista G, 183(1):127-129. I.F.: 5.128 multiple myeloma patients with novel Climent N, Mateos E, Rovira C, Rodríguez-Mora induction therapy following autologous S, López-Huertas MR, García-Gutiérrez V, 32. Hernández-Boluda JC, Correa JG, hematopoietic stem cell transplantation. Steegmann JL, Duarte R, Cervantes F, Plana M, Alvarez-Larrán A, Ferrer-Marín F, Raya JM, BONE MARROW TRANSPLANTATION. Miró JM, Alcamí J, Coiras M. Evaluation of Martínez-López J, Velez P, Pérez-Encinas M, 53(12):1541-1547. I.F.: 4.497 resistance to HIV-1 infection ex vivo of Estrada N, García-Gutiérrez V, Fox ML, Luño E, PBMCs isolated from patients with chronic Kerguelen A, Cuevas B, Durán MA, Ramírez MJ, 37. Halaburda K, Labopin M, Houhou M, myeloid leukemia treated with different Gómez-Casares M, Mata-Vázquez MI, Niederwieser D, Finke J, Volin L, Maertens J, tyrosine kinase inhibitors. BIOCHEMICAL Regadera A, Pereira A, Cervantes F, Grupo Cornelissen JJ, Milpied N, Stuhler G, Kröger N, PHARMACOLOGY. 156:248-264. I.F.: 4.235 Español de Enfermedades Mieloproliferativas Esteve J, Mohty M, Nagler A. AlloHSCT for Filadelfia Negativas (GEMFIN). Clinical inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a 42. Tovar N, Rodríguez-Lobato LG, Cibeira MT, characteristics, prognosis and treatment report from the acute leukemia working Magnano L, Isola I, Rosiñol L, Bladé J, Fernández of myelofibrosis patients with severe party of the European society for blood de Larrea C. Bone marrow plasma cell thrombocytopenia. BRITISH JOURNAL OF and marrow transplantation. BONE infiltration in light chain amyloidosis: HAEMATOLOGY. 181(3):386-417. I.F.: 5.128 MARROW TRANSPLANTATION. impact on organ involvement and 53(6):683-691. I.F.: 4.497 outcome. AMYLOID : THE INTERNATIONAL

306 HEMATOLOGICAL ONCOLOGY 5.7

JOURNAL OF EXPERIMENTAL AND Mensa J, Esteve J, Soriano A . Risk factors for LYMPHOMA. 59(10):2394-2404. I.F.: 2.644 CLINICAL INVESTIGATION. 25(2):79-85. mortality in patients with acute leukemia I.F.: 4.048 and bloodstream infections in the era of 53. Guillem V, Calabuig M, Brunet S, Esteve J, multiresistance. PLOS ONE. 13(6):e0199531. Escoda L, Gallardo D, Ribera JM, Queipo de 43. Jiménez-Ubieto A, Grande C, Caballero D, I.F.: 2.766 Llano MP, Arnan M, Pedro C, Amigo ML, Yáñez L, Novelli S, Hernández-Garcia MT, Martí-Tutusaus JM, García-Guiñón A, Bargay J, Manzanares M, Arranz R, Ferreiro JJ, Bobillo S, 48. Banús-Mulet A., Etxabe A., Cornet-Masana Sampol A, Salamero O, Font L, Talarn C, Hoyos Mercadal S, Galeo A, Jiménez JL, Moraleda JM, J., Torrente M., Lara-Castillo M., Palomo L., M, Díaz-Beyá M, Garrido A, Navarro B, Vallejo C, Albo C, Pérez E, Marrero C, Magnano Nomdedeu M., Díaz-Beyá M., Solé F., Nomdedeu Nomdédeu J, Sierra J, Tormo M. Bone marrow L, Palomera L, Jarque I, Martínez-Sánchez P, B., Esteve J., Risueño R. Serotonin receptor VEGFC expression is associated with Martín A, Coria E, López-Guillermo A, Salar A, type 1B constitutes a therapeutic target for multilineage dysplasia and several Lahuerta JJ, GELTAMO (Grupo Español de MDS and CMML. PLOS ONE. 8(1):13883. prognostic markers in adult acute myeloid Linfomas y Trasplantes de Médula Ósea) I.F.: 2.766 leukemia, but not with survival. LEUKEMIA Cooperative Study Group. Autologous stem AND LYMPHOMA. 59(10):1-11. I.F.: 2.644 cell transplantation may be curative for 49. Lopez-Anglada L; Cueto-Felgueroso C; patients with follicular lymphoma with Rosinol L; Oriol A; Teruel AI; Lopez De La Guia A; 54. González-Gascón Y Marín I, early therapy failure who reach complete Bengoechea E; Palomera L; de Arriba F; Hernández-Sanchez M, Rodríguez-Vicente AE, response after rescue treatment. Hernandez JM; Granell M; Penalver FJ; Puiggros A, Collado R, Luño E, González T, HEMATOLOGICAL ONCOLOGY. Garcia-Sanz R; Besalduch J; González Y; Ruiz-Xivillé N, Ortega M, Gimeno E, Muñoz C, 36(5):765-772. I.F.: 3.193 Martinez RB; Hernández MT; Gutierrez NC; Infante MS, Delgado J, Vargas MT, González M, Puerta P; Valeri A; Paiva B; Blade J; Mateos MV; Bosch F, Espinet B, Hernández-Rivas JM, Grupo 44. Alvarez-Larran A., Martínez D., Arenillas L., San Miguel J; Lahuerta JJ; Martinez-Lopez J; Español de Leucemia Linfática Crónica Rubio A., Arellano-Rodrigo E., Boluda J., Papaleo GEM (Grupo Español de MM)/PETHEMA (GELLC) and Grupo Cooperativo Español de N., Caballero G., Martínez C., Ferrer-Marín F., (Programa para el Estudio de la Terapéutica en Citogenética Hematológica (GCECGH). Mata M., Pérez-Encinas M., Durán M., Alonso J., Hemopatías Malignas) Cooperative Study Characterizing patients with multiple Carreño-Tarragona G., Noya S., Magro E., Pérez Group. Prognostic utility of serum free light chromosomal aberrations detected by R., López-Guerra M., Pastor-Galán I., Cervantes chain ratios and heavy-light chain ratios in FISH in chronic lymphocytic leukemia. F., Besses C., Colomo L., Rozman M. Essential multiple myeloma in three LEUKEMIA AND LYMPHOMA. 59(3):633-642. thrombocythaemia with mutation in MPL: PETHEMA/GEM phase III clinical trials. I.F.: 2.644 Clinicopathological correlation and PLOS ONE. 13(9):e0203392. I.F.: 2.766 comparison with JAK 2V617F-mutated 55. Fernández-Galán E., Massana N., and CALR- mutated genotypes. JOURNAL 50. Martínez-Trillos A., Pinyol M., Delgado J., Parra-Robert M., Hidalgo S., Casals G., Esteve J., OF CLINICAL PATHOLOGY - CLINICAL Aymerich M., Rozman M., Baumann T., Jiménez W. Validation of a routine gas MOLECULAR PATHOLOGY. 71(11):975-980. González-Díaz M., Hernández J., Alcoceba M., chromatography mass spectrometry I.F.: 2.894 Muntañola A., Terol M., Navarro B., Giné E., Jares method for 2-hydroxyglutarate P., Beà S., Navarro A., Colomer D., Nadeu F., quantification in human serum as a 45. Hernández-Boluda J., Pereira A., Correa J., Colado E., Payer A., García-Cerecedo T., Puente screening tool for detection of idh Alvarez-Larrán A., Ferrer-Marín F., Raya J., X., López-Otin C., Campo E., López-Guillermo A., mutations. JOURNAL OF Martínez-López J., Velez P., Pérez-Encinas M., Villamor N. The mutational landscape of CHROMATOGRAPHY B: ANALYTICAL Estrada N., García-Gutiérrez V., Fox M., Payer A., small lymphocytic lymphoma compared to TECHNOLOGIES IN THE BIOMEDICAL AND Kerguelen A., Cuevas B., Durán M., Ramírez M., non-early stage chronic lymphocytic LIFE SCIENCES. 1083:28-34. I.F.: 2.441 Gómez-Casares M., Mata-Vázquez M., Mora E., leukemia. LEUKEMIA AND LYMPHOMA. Gómez M., Cervantes F. Prognostic risk 59(10):2318-2326. I.F.: 2.644 56. Blade J, Calleja MÁ, Lahuerta JJ, Poveda JL, models for transplant decision-making in de Paz HD, Lizán L. Defining a set of myelofibrosis. ANNALS OF HEMATOLOGY. 51. Solé C, Martínez D, Giné E, Gonzalez-Farre standardised outcome measures for 97(5):813-820. I.F.: 2.845 B, Pérez-Galán P, Roncador G, Campo E, newly diagnosed patients with multiple Matutes E, López-Guillermo A, Roué G, Martínez myeloma using the Delphi consensus 46. Bobillo S., Abrisqueta P., Sánchez-González A. Expression of a truncated B method: the IMPORTA project. BMJ OPEN. B., Giné E., Romero S., Alcoceba M., lymphocyte-induced maturation protein-1 8(2):e018850. I.F.: 2.413 González-Barca E., González de Villambrosía S., isoform is associated with an incomplete Sancho J., Gómez P., Bento L., Montoro J., plasmacytic differentiation program in 57. Mora, Barbara; Giorgino, Toni; Guglielmelli, Montes S., López A., Bosch F. Posttransplant chronic lymphocytic leukemia. LEUKEMIA Paola; Rumi, Elisa; Maffioli, Margherita; Rambaldi, monomorphic Burkitt’s lymphoma: clinical AND LYMPHOMA. 59(2):482-485. I.F.: 2.644 Alessandro; Caramella, Marianna; Komrokji, characteristics and outcome of a Rami; Gotlib, Jason; Kiladjian, Jean Jacques; multicenter series. ANNALS OF 52. Torrebadell M; Díaz-Beyá M; Kalko SG; Cervantes, Francisco; Devos, Timothy; Palandri, HEMATOLOGY. 97(12):2417-2424. I.F.: 2.845 Pratcorona M; Nomdedéu J; Navarro A; Gel B; Francesca; de Stefano, Valerio; Ruggeri, Marco; Brunet S; Sierra J; Camos M; Esteve J. A 4-gene Silver, Richard T.; Benevolo, Giulia; Albano, 47. Garcia-Vidal C, Cardozo-Espinola C, expression prognostic signature might Francesco; Cavalloni, Chiara; Barraco, Daniela; Puerta-Alcalde P, Marco F, Tellez A, Agüero D, guide post-remission therapy in patients Pietra, Daniela; Barbui, Tiziano; Rotunno, Giada; Romero-Santana F, Díaz-Beyá M, Giné E, with intermediate-risk cytogenetic acute Vannucchi, Alessandro Maria; Passamonti, Morata L, Rodríguez-Núñez O, Martinez JA, myeloid leukemia. LEUKEMIA AND Francesco. Phenotype variability of patients

307 AREA 5 ONCOLOGY AND HAEMATOLOGY

with post polycythemia vera and post assessment in solitary plasmacytoma: GRANTS FOR RESEARCH IN PROGRESS essential thrombocythemia myelofibrosis updated recommendations from a is associated with the time to progression European Expert Panel. JOURNAL OF Delgado J. Estudio piloto de la infusión de from polycythemia vera and essential HEMATOLOGY AND ONCOLOGY. 11(1):10-10. linfocitos T autólogos modificados thrombocythemia. LEUKEMIA RESEARCH. I.F.: 7.333 genéticamente para expresar anti-CD19 69:100-102. I.F.: 2.319 en pacientes con leucemia o linfoma 5. Giebel S., Marks D., Boissel N., Baron F., CD19+ resistente o refractario a 58. Wong S., Hegenbart U., Palladini G., Shah G., Chiaretti S., Ciceri F., Cornelissen J., Doubek M., tratamiento. Landau H., Warner M., Toskic D., Jaccard A., Esteve J., Fielding A., Foa R., Gorin N., Gökbuget Sponsored by: Instituto de Salud Carlos III (ISCIII) Hansen T., Bladé J., Cibeira M., Kastritis E., N., Hallböök H., Hoelzer D., Paravichnikova E., ICI 14/00122 Dispenzieri A., Wechalekar A., Varga C., Ribera J., Savani B., Rijneveld A., Schmid C., Duration: 01/01/2015-31/12/2018 Schönland S., Comenzo R. Outcome of Wartiovaara-Kautto U., Mohty M., Nagler A., Patients With Newly Diagnosed Systemic Dombret H. Hematopoietic stem cell Delgado J. Rol de los nuevos fármacos en la Light-Chain Amyloidosis Associated With transplantation for adults with Philadelphia optimización del efecto antitumoral del Deletion of 17p. CLINICAL LYMPHOMA, chromosome-negative acute tratamiento mediante linfocitos T con MYELOMA AND LEUKEMIA. 18(11):e493-e499. lymphoblastic leukemia in first remission: receptores antigénicos quiméricos anti I.F.: 2.308 a position statement of the European CD19 (CART19) en leucemia linfática Working Group for Adult Acute crónica. Lymphoblastic Leukemia (EWALL) and the Sponsored by: Fundación Española de Review / I.F.: 61.923 Acute Leukemia Working Party of the Hematología y Hemoterapia (FEHH). European Society for Blood and Marrow BECAS17_02 1. Bladé J., Rosiñol L., Teresa Cibeira M., De Transplantation (EBMT). BONE MARROW Duration: 01/03/2018-31/12/2018 Larrea C. Treatment of relapsed myeloma in TRANSPLANTATION. I.F.: 4.497 a patient with renal insufficiency.JOURNAL Esteve J. Estudio post-autorización OF CLINICAL ONCOLOGY. 36(20):2012-2016. 6. Castella M., de Larrea C., Martín-Antonio B. prospectivo de terapia adaptada al riesgo I.F.: 26.360 Immunotherapy: A Novel Era of Promising en la leucemia mieloide aguda y síndromes Treatments for Multiple Myeloma. mielodisplásicos de alto riesgo: 2. Barbui T., Tefferi A., Vannucchi A., Passamonti INTERNATIONAL JOURNAL OF importancia del perfil genómico y de la F., Silver R., Hoffman R., Verstovsek S., Mesa R., MOLECULAR SCIENCES. 19(11):3613. I.F.: 3.687 enfermedad residual mínima en la Kiladjian J., Hehlmann R., Reiter A., Cervantes F., asignación del tratamiento. Harrison C., Mc Mullin M., Hasselbalch H., Sponsored by: Generalitat de Catalunya. PERIS Koschmieder S., Marchetti M., Bacigalupo A., Letters / I.F.: 27.799 (SLT002/16/00433) Finazzi G., Kroeger N., Griesshammer M., Duration: 27/03/2017-31/12/2019 Birgegard G., Barosi G. Philadelphia 1. Bladé J, Cibeira MT. M-protein-related chromosome-negative classical disorders: MGCS. BLOOD. 132(14):1464-1465. Esteve J. Caracterización genética de la myeloproliferative neoplasms: revised I.F.: 15.132 leucemia mieloblástica aguda de riesgo management recommendations from citogenético intermedio y genotipo European LeukemiaNet. LEUKEMIA. 2. Fernández de Larrea C., Isola I., Pereira A., NPM1/CEBPA/FLT3-ITD triple negativo; 32(5):1057-1069. Cibeira M., Bladé J., Rosiñol L.. The pattern of análisis mutacional, expresión de I.F.: 10.023 the M-protein in smoldering myeloma over IncRNAs. the time: an evolving risk factor. LEUKEMIA. Sponsored by: Instituto de Salud Carlos III (ISCIII). 3. Ludwig H, Delforge M, Facon T, Einsele H, Gay 32(9):2082-2083. I.F.: 10.023 PI16/01027 F, Moreau P, Avet-Loiseau H, Boccadoro M, Duration: 01/01/2017-31/12/2019 Hajek R, Mohty M, Cavo M, Dimopoulos M, 3. Muchtar E., Bladé J., Gertz M. Testicular San-Miguel J, Terpos E, Zweegman S, Garderet plasmacytoma: unique location or Fernández de Larrea C. Mecanismos de L, Mateos M, Cook G, Leleu X, Goldschmidt H, circumstantial presentation? LEUKEMIA control inmunológico involucrados en la Jackson G, Kaiser M, Weisel K, Van De Donk N, AND LYMPHOMA. 59(8):1769-1771. I.F.: 2.644 progresión tras tratamiento en el mieloma Waage A, Beksac M, Mellqvist U, Engelhardt M, multiple. Caers J, Driessen C, Bladé J, Sonneveld P. Sponsored by: Instituto de Salud Carlos III (ISCIII). Prevention and management of adverse Case Reports / I.F.: 6.129 PI16/00423 events of novel agents in multiple Duration: 01/01/2017-31/12/2019 myeloma: A consensus of the European 1. Podlipnik S., Guijarro F., Combalia A., Myeloma Network. LEUKEMIA. To-Figueras J., Badenas C., Costa D., Rozman Fernández de Larrea C. Reposicionamiento 32(7):1542-1560. I.F.: 10.023 M., Jorge S., Aguilera P., Gaya A. Acquired de la Doxiciclina en el tratamiento de la erythropoietic uroporphyria secondary to amiloidosis AL cardiaca. 4. Caers J, Paiva B, Zamagni E, Leleu X, Bladé J, myelodysplastic syndrome with Sponsored by: Instituto de Salud Carlos III (ISCIII). Kristinsson SY, Touzeau C, Abildgaard N, Terpos chromosome 3 alterations: A case report. AC16/00058 E, Heusschen R, Ocio E, Delforge M, Sezer O, BRITISH JOURNAL OF DERMATOLOGY. Duration: 01/01/2017-31/12/2019 Beksac M, Ludwig H, Merlini G, Moreau P, 179(2):486-490. I.F.: 6.129 Zweegman S, Engelhardt M, Rosiñol L. Fernández de Larrea C. ReDox: Repurposing Diagnosis, treatment, and response doxycycline in the treatment of cardiac AL

308 HEMATOLOGICAL ONCOLOGY 5.7

amyloidosis. Sponsored by: European Commission. E-RARE_JTC_2016 Duration: 01/05/2017-30/04/2020

López A. Estudio longitudinal del perﬁl mutacional del linfoma difuso de células grandes mediante técnicas de biopsia líquida. Signiﬁcado biológico e impacto clínico. Sponsored by: Instituto de Salud Carlos III (ISCIII) PI16/00420 Duration: 01/01/2017-31/12/2019

López A. Sequential assessment of the mutational landscape of follicular lymphoma in different clinical situations, including late relapse, early failure and histological transformation. Sponsored by: GILEAD SCIENCES. GLD17/00197 Duration: 11/12/2017-31/12/2018

DOCTORAL THESES

Esteve J, Camós M. Análisis del valor pronóstico del perﬁl de expresión génica en la leucemia mieloblástica aguda de riesgo citogenético intermedio según la opción terapéutica post-remisión. PhD student: Montserrat Torrebadell Burriel

Fernández De Larrea C, Bladé J. Factores pronóstico en pacientes con amiloidosis sistémica por cadenas ligeras. PhD student: Luis Gerardo Rodríguez Lobato

López Guillermo A. Estudio de factores clínico-biológicos relacionados con el microambiente, la transformación histológica y la respuesta al tratamiento en pacientes con linfoma folicular. PhD student: Laura Magnano Mayer

Nomdedeu B. Valoració pronòstica de les síndromes mielodisplàstiques i de la leucèmia mielomonocítica crònica. PhD student: Xavier Calvo González

309 AREA 5 ONCOLOGY AND HAEMATOLOGY

Physiopathology and molecular bases 5.8 in hematology

TECHNICIANS Sandra Cabezas (FCRB) LOCATION Ariadna Giró (CIBER) CEK building, ﬂoor 2 Laura Jiménez (FCRB)

ADMINISTRATIVE STAFF Patricia Carvajal (IDIBAPS)

COLLABORATORS KEYWORDS Mònica López (HCB-FCRB)

1. Lymphoid malignancies TEAM LEADER 2. Targeted therapies Dolors Colomer (HCB) VISITING SCIENTISTS 3. Clinico-biological studies T. 93 227 54 00 (Ext.: 2269) Morihiro Hihashi (IDIBAPS) 4. Rare anemias [email protected]

RESEARCHERS STRATEGIC OBJECTIVES Marta Aymerich (HCB) Mª Teresa Estrach (HCB) - Identiﬁcation of potential points of intervention and development of new Original publications Patricia Pérez-Galan (IDIBAPS) therapeutic strategies and combination from 2016 to 2018 María Rozman (HCB) Neus Villamor (HCB) approaches in lymphoid malignancies. YEAR I.F. TOTAL Q1 Q2 - To improve the diagnosis of lymphoid 2016 102.06 15 13 2 POST-DOCTORAL RESEARCHERS Fabian Arenas (CIBER) malignancies using histopathological, 17 2017 148.12 25 5 Juan García (IDIBAPS) immunophenotypic and molecular biology 2018 192.06 27 17 7 Laia Rosich (IDIBAPS) technologies. Neus Serrat (IDIBAPS) Rupal Tripathi (IDIBAPS)

PRE-DOCTORAL RESEARCHERS MAIN LINES OF RESEARCH TEAM INVOLVED IN Neus Gimenez (IDIBAPS) RTICC Martina Guerrero (IDIBAPS) 1. New targeted therapiesagainst recurrent AGAUR_SGR17: 01009 Irene López (IDIBAPS) alterations in lymphoid malignancies. CIBERONC Clara Recasens (IDIBAPS) 2. Characterization of molecular pathways activated by microenvironment in lymphoid malignancies. TEAM Dolors Colomer

310 PHYSIOPATHOLOGY AND MOLECULAR BASES IN HEMATOLOGY 5.8

3. New targeted therapies against R, Puente DA, Paulo JA, Delgado J, Villamor N, leukemia. BLOOD CANCER JOURNAL. oncogenes, microenvironment and López-Guillermo A, Finley DJ, Gygi SP, 8(1):10. I.F.: 8.125 epigenetic regulators in lymphoid Campo E, Quesada V, López-Otín C. Altered malignancies. patterns of global protein synthesis and 9. Cabello I., Alia P., Pintó X., Muniesa C., translational ﬁdelity in RPS15-mutated Fernandez-De-Misa R., Peñate Y., Morillo M., 4. Cytological, immunophenotypic and chronic lymphocytic leukemia. BLOOD. Perez-Farriols A., Estrach T., Izu R., Gallardo F., molecular study of malignant 132(22):2375-2388. I.F.: 15.132 Román C., Cervigón I., Ortiz-Brugues A., hematological diseases. Development of Ortiz-Romero P., Servitje O. Association of new technologies for the diagnosis and 4. Albero R, Enjuanes A, Demajo S, Castellano APOA5 and APOC3 Genetic analysis of minimal residual disease (MRD). G, Pinyol M, García N, Capdevila C, Clot G, Polymorphisms with Severity of Suárez-Cisneros H, Shimada M, Karube K, Hypertriglyceridemia in Patients with 5. Promotion of cooperative strategies in the López-Guerra M, Colomer D, Beà S, Cutaneous T-Cell Lymphoma Treated with molecular diagnostic setting of leukemias Martin-Subero JI, Campo E, Jares P. Bexarotene. JAMA DERMATOLOGY. and lymphomas. Design and Cyclin D1 overexpression induces global 154(12):1424-1431. I.F.: 8.107 implementation of internal and external transcriptional downregulation in quality control programs. lymphoid neosplasms. JOURNAL OF 10. Heine S, Kleih M, Giménez N, Böpple K, Ott CLINICAL INVESTIGATION. G, Colomer D, Aulitzky WE, van der Kuip H, 7. Cutaneous T and B cell lymphomas. 128(9):4132-4147. I.F.: 13.251 Silkenstedt E. Cyclin D1-CDK4 activity Clinical, histopathological and drives sensitivity to bortezomib in mantle immunophenotypic study. Prognostic 5. Nadeu F, Clot G, Delgado J, Martín-García cell lymphoma by blocking factors and epidemiology. D, Baumann T, Salaverria I, Beà S, Pinyol M, autophagy-mediated proteolysis of NOXA. Jares P, Navarro A, Suárez-Cisneros H, JOURNAL OF HEMATOLOGY & Aymerich M, Rozman M, Villamor N, Colomer ONCOLOGY. 11(1):112. I.F.: 7.333 D, González M, Alcoceba M, Terol MJ, Navarro PUBLICATIONS B, Colado E, Payer ÁR, Puente XS, López-Otín 11. López-Lerma I, Peñate Y, Gallardo F, Martí C, López-Guillermo A, Enjuanes A, Campo E. RM, Mitxelena J, Bielsa I, Velasco-Tamariz V, Originals / I.F.: 192.058 Clinical impact of the subclonal Yanguas-Bayona JI, Sánchez-Sambucety P, architecture and mutational complexity in García-Patos V, Ortiz-Romero PL, Pujol RM, 1. Beekman R, Chapaprieta V, Russiñol N, chronic lymphocytic leukemia. LEUKEMIA. Estrach T. Subcutaneous panniculitis-like Vilarrasa-Blasi R, Verdaguer-Dot N, Martens 32(3):645-653. I.F.: 10.023 T-cell lymphoma: Clinical features, JHA, Duran-Ferrer M, Kulis M, Serra F, Javierre therapeutic approach, and outcome in a BM, Wingett SW, Clot G, Queirós AC, 6. De Larrea C., Isola I., Pereira A., Cibeira M., case series of 16 patients. JOURNAL OF Castellano G, Blanc J, Gut M, Merkel A, Heath Magnano L., Tovar N., Rodríguez-Lobato L., THE AMERICAN ACADEMY OF S, Vlasova A, Ullrich S, Palumbo E, Enjuanes A, Calvo X., Aróstegui J., Díaz T., Lozano E., DERMATOLOGY. 79(5):892-898. I.F.: 6.898 Martín-García D, Beà S, Pinyol M, Aymerich M, Rozman M., Yagüe J., Bladé J., Rosiñol L. Royo R, Puiggros M, Torrents D, Datta A, Lowy Evolving M-protein pattern in patients with 12. Esteve-Arenys A., Valero J., E, Kostadima M, Roller M, Clarke L, Flicek P, smoldering multiple myeloma: impact on Chamorro-Jorganes A., Gonzalez D., Agirre X, Prosper F, Baumann T, Delgado J, early progression. LEUKEMIA. Rodriguez V., Dlouhy I., Salaverria I., Campo E., López-Guillermo A, Fraser P, Yaspo ML, 32(6):1427-1434. I.F.: 10.023 Colomer D., Martinez A., Rymkiewicz G., Guigó R, Siebert R, Martí-Renom MA, Puente Pérez-Galán P., Lopez-Guillermo A., Roué G. XS, López-Otín C, Gut I, Stunnenberg HG, 7. Solans M, Castelló A, Benavente Y, The BET bromodomain inhibitor CPI203 Campo E, Martin-Subero JI. The reference Marcos-Gragera R, Amiano P, overcomes resistance to ABT-199 epigenome and regulatory chromatin Gracia-Lavedan E, Costas L, Robles C, (venetoclax) by downregulation of landscape of chronic lymphocytic Gonzalez-Barca E, de la Banda E, Alonso E, BFL-1/A1 in in vitro and in vivo models of leukemia. NATURE MEDICINE. Aymerich M, Campo E, Dierssen-Sotos T, MYC+/BCL2+ double hit lymphoma. 24(6):868-880. I.F.: 32.621 Fernández-Tardón G, Olmedo-Requena R, ONCOGENE. 37(14):1830-1844. I.F.: 6.854 Gimeno E, Castaño-Vinyals G, Aragonés N, 2. Clot G, Jares P, Giné E, Navarro A, Royo C, Kogevinas M, de Sanjose S, Pollán M, 13. Maroñas-Jiménez L, Estrach T, Gallardo F, Pinyol M, Martín-Garcia D, Demajo S, Espinet Casabonne D. Adherence to the Western, Pérez A, Andrés Borja H, Servitje O, Pérez B, Salar A, Ferrer A, Muntañola A, Aymerich M, Prudent, and Mediterranean dietary Gala S, Linares Barrio M, Jiménez Gallo D, Rauert-Wunderlich H, Jaffe ES, Connors JM, patterns and chronic lymphocytic Sanz-Bueno J, Lora D, Monsálvez V, Gascoyne RD, Delabie J, López-Guillermo A, leukemia in the MCC-Spain study. Ortiz-Romero PL. Aprepitant improves Ott G, Wright GW, Staudt LM, Rosenwald A, HAEMATOLOGICA. 103(11):1881-1888. I.F.: refractory pruritus in primary cutaneous Scott DW, Rimsza LM, Beà S, Campo E . 9.090 T-cell lymphomas: experience of the A gene signature that distinguishes Spanish Working Group on Cutaneous conventional and leukemic nonnodal 8. Mozas P, Rivas-Delgado A, Baumann T, Lymphomas. BRITISH JOURNAL OF mantle cell lymphoma helps predict Villamor N, Ortiz-Maldonado V, Aymerich M, DERMATOLOGY. 178(4):e273-e274. I.F.: 6.129 outcome. BLOOD. 132(4):413-422. I.F.: 15.132 Costa D, Navarro A, Giné E, López-Guillermo A, Montserrat E, Delgado J. Analysis of 14. Rossi C., Gravelle P., Decaup E., 3. Bretones G, Álvarez MG, Arango JR, criteria for treatment initiation in patients Bordenave J., Poupot M., Tosolini M., Franchini Rodríguez D, Nadeu F, Prado MA, Valdés-Mas with progressive chronic lymphocytic D., Laurent C., Morin R., Lagarde J., Ysebaert L.,

311 AREA 5 ONCOLOGY AND HAEMATOLOGY

Ligat L., Jean C., Savina A., Klein C., Céspedes Papaleo N., Caballero G., Martínez C., Martínez A. Expression of a truncated B A., Perez-Galan P., Fournié J., Bezombes C. Ferrer-Marín F., Mata M., Pérez-Encinas M., lymphocyte-induced maturation protein-1 Boosting γδ T cell-mediated Durán M., Alonso J., Carreño-Tarragona G., isoform is associated with an incomplete antibody-dependent cellular cytotoxicity Noya S., Magro E., Pérez R., López-Guerra M., plasmacytic differentiation program in by PD-1 blockade in follicular lymphoma. Pastor-Galán I., Cervantes F., Besses C., chronic lymphocytic leukemia. LEUKEMIA ONCOIMMUNOLOGY. 8(3):1554175. I.F.: 5.503 Colomo L., Rozman M. Essential AND LYMPHOMA. 59(2):482-485. I.F.: 2.644 thrombocythaemia with mutation in MPL: 15. Ortiz-Maldonado V, Villamor N, Baumann Clinicopathological correlation and 24. Rozas-Muñoz, Eduardo; Gallardo, T, Aymerich M, Magnano L, Mozas P, comparison with JAK 2V617F-mutated Fernando; Maria Pujol, Ramon; Perez-Ferriols, Rivas-Delgado A, Martínez-Trillos A, Giné E, and CALR- mutated genotypes. JOURNAL Amparo; Servitje, Octavio; Estrach, Teresa; Campo E, López-Guillermo A, Delgado J . Is OF CLINICAL PATHOLOGY - CLINICAL Bastida, Jesus; Roman, Concha; Palacio-Aller, there a role for minimal residual disease MOLECULAR PATHOLOGY. 71(11):975-980. Lucia; Gil, Inmaculada; Maria Marti, Rosa; monitoring in the management of patients I.F.: 2.894 Vidal-Sarro, David; Pilar Garcia-Muret, Maria. with hairy-cell leukaemia? BRITISH Extranodal natural killer/T-cell lymphoma, JOURNAL OF HAEMATOLOGY. 20. Benavente Y., Casabonne D., Costas L., nasal type: a Spanish multicentric 183(1):127-129. I.F.: 5.128 Robles C., Alonso E., de la Banda E., retrospective survey. EUROPEAN Gonzalez-Barca E., Marcos-Gragera R., JOURNAL OF DERMATOLOGY. 28(1):64-70. 16. Lozano E, Díaz T, Mena MP, Suñe G, Calvo Llorca J., Tardón A., Monleon J., Aymerich M., I.F.: 1.944 X, Calderón M, Pérez-Amill L, Rodríguez V, Campo E., Gimeno-Vázquez E., Pérez-Galán P, Roué G, Cibeira MT, Rosiñol L, Castaño-Vinyals G., Aragonés N., Pollán M., 25. Riquelme-Mc Loughlin C, Estrach T, Isola I, Rodríguez-Lobato LG, Martin-Antonio Kogevinas M., de Sanjosé S. Established and Morgado-Carrasco D, Fustà-Novell X, B, Bladé J, Fernández de Larrea C . Loss of suggested exposures on CLL/SLL Riera-Monroig J, Iranzo P. Rituximab for the the Immune Checkpoint CD85j/LILRB1 on etiology: Results from the CLL-MCC-Spain treatment of autoimmune subepidermal Malignant Plasma Cells Contributes to study. CANCER EPIDEMIOLOGY. 52:106-111. blistering diseases. DERMATOLOGIC Immune Escape in Multiple Myeloma. I.F.: 2.888 THERAPY. 31(5):e12687. I.F.: 1.563 JOURNAL OF IMMUNOLOGY. 200(8):2581-2591. I.F.: 4.539 21. Rawstron A, Kreuzer K, Soosapilla A, 26. Fernández-de-Misa R, Spacek M, Stehlikova O, Gambell P, Hernández-Machín B, Servitje O, 17. Suárez-Lledó M, Martínez-Cibrián N, McIver-Brown N, Villamor N, Psarra K, Arroz Valentí-Medina F, Maroñas-Jiménez L, Gutiérrez-García G, Dimova-Svetoslavova V, M, Milani R, de la Serna J, Cedena M, Jaksic O, Ortiz-Romero PL, Sánchez Schmidt J, Pujol Marcos MA, Martín-Antonio B, Nomdedeu J, Moreno C, Rigolin G, Cuneo A, RM, Gallardo F, Pau-Charles I, García Muret Martínez-Trillos A, Villamor N, Rosiñol L, Johansen P, Johnsen H, Rosenquist R, MP, Pérez Gala S, Román C, Cañueto J, Martínez C, Fernández-Avilés F, García-Vidal Niemann C, Kern W, Westerman D, Trneny M, Blanch Rius L, Izu R, Ortiz-Brugués A, Martí C, Urbano-Ispizua Á, Rovira M. Deleterious Mulligan S, Doubek M, Pospisilova S, Hillmen RM, Blanes M, Morillo M, Sánchez P, Peñate Y, Effect of Steroids on Cytomegalovirus P, Oscier D, Hallek M, Ghia P, Montserrat E. Bastida J, Pérez Gil A, Lopez-Lerma I, Muniesa Infection Rate after Allogeneic Stem Cell Reproducible diagnosis of chronic C, Estrach T. First-line treatment in Transplantation Depends on lymphocytic leukemia by ﬂow cytometry: lymphomatoid papulosis: a retrospective Pretransplant Cytomegalovirus An European Research Initiative on CLL multicentre study. CLINICAL AND Serostatus of Donors and Recipients. (ERIC) & European Society for EXPERIMENTAL DERMATOLOGY. BIOLOGY OF BLOOD AND MARROW Clinical Cell Analysis (ESCCA) 43(2):137-143. I.F.: 1.484 TRANSPLANTATION. 24(10):2088-2093. Harmonisation project. CYTOMETRY PART I.F.: 4.484 B - CLINICAL CYTOMETRY. 94(B):121-128. 27. Varo R, Sitoe A, Cossa A, Ordi J, Rozman I.F.: 2.757 M, Bassat Q. Leukoerythroblastosis in a 18. Castella M, Boronat A, Martín-Ibáñez R, Young Child with Severe Malaria and Rodríguez V, Suñé G, Caballero M, Marzal B, 22. Martínez-Trillos A., Pinyol M., Delgado J., Superimposed Gram Negative Infection. Pérez-Amill L, Martín-Antonio B, Castaño J, Aymerich M., Rozman M., Baumann T., JOURNAL OF TROPICAL PEDIATRICS. Bueno C, Balagué O, González-Navarro EA, González-Díaz M., Hernández J., Alcoceba M., 64(6):553-556. I.F.: 1.187 Serra-Pages C, Engel P, Vilella R, Muntañola A., Terol M., Navarro B., Giné E., Benitez-Ribas D, Ortiz-Maldonado V, Cid J, Jares P., Beà S., Navarro A., Colomer D., Nadeu Tabera J, Canals JM, Lozano M, Baumann T, F., Colado E., Payer A., García-Cerecedo T., Case Reports / I.F.: 12.859 Vilarrodona A, Trias E, Campo E, Menendez P, Puente X., López-Otin C., Campo E., Urbano-Ispizua Á, Yagüe J, Pérez-Galán P, López-Guillermo A., Villamor N. The 1. Podlipnik S., Guijarro F., Combalia A., Rives S, Delgado J, Juan M. Development of mutational landscape of small lymphocytic To-Figueras J., Badenas C., Costa D., Rozman a Novel Anti-CD19 Chimeric Antigen lymphoma compared to non-early stage M., Jorge S., Aguilera P., Gaya A. Acquired Receptor: A Paradigm for an Affordable chronic lymphocytic leukemia. LEUKEMIA erythropoietic uroporphyria secondary to CAR T Cell Production at Academic AND LYMPHOMA. 59(10):2318-2326. myelodysplastic syndrome with Institutions. MOL THER METHODS CLIN I.F.: 2.644 chromosome 3 alterations: A case report. DEV. 12:134-144. I.F.: 3.681 BRITISH JOURNAL OF DERMATOLOGY. 23. Solé C, Martínez D, Giné E, Gonzalez- 179(2):486-490. I.F.: 6.129 19. Alvarez-Larran A., Martínez D., Arenillas L., Farre B, Pérez-Galán P, Roncador G, Campo Rubio A., Arellano-Rodrigo E., Boluda J., E, Matutes E, López-Guillermo A, Roué G, 2. Guijarro F., Rozman M., Matutes E.

312 PHYSIOPATHOLOGY AND MOLECULAR BASES IN HEMATOLOGY 5.8

Multinucleated giant myeloma cells after in chronic inflammatory diseases and failure of daratumumab therapy. BRITISH lymphoproliferative disorders as a target JOURNAL OF HAEMATOLOGY. for new therapeutic intervention. 181(4):432-432. I.F.: 5.128 Sponsored by: Ministerio de Economía y Competitividad (MINECO). 3. Fernández-Sartorio C, Combalia A, SAF2014-88275-R Ferrando J, Alsina M, Iranzo P, Estrach T, Duration: 01/01/2015-30/06/2018 Hernández-Ruiz E, Mascaró JM. Pancreatic panniculitis: A case series from a tertiary university hospital in Spain. AUSTRALASIAN JOURNAL OF DOCTORAL THESES DERMATOLOGY. 59(4):e269-e272. I.F.: 1.602 Colomer D. Novel therapeutic strategies for chronic lymphocytic leukemia. PhD student: María Eriong Lee Vergés. GRANTS FOR RESEARCH IN PROGRESS Pérez P, Roué G. Preclinical evaluation of Colomer D. Identificació de noves the antitumor activity of a new CXCR4 estratègies terapéutiques en la leucèmia inhibitor: a novel therapeutic approach in limfàtica crònica (LLC). diffuse large B-cell lymphoma. Sponsored by: Universitat de Barcelona. PhD student: Clara Recasens Zorzo 2015-DI-075 Duration: 01/04/2016-31/03/2019 Villamor N. Influencia de las mutaciones genéticas en las características clínicas, Colomer D. Dianes terapèutiques i noves biológicas y evolutivas de los pacientes tècniques diagnostiques en neoplàsies con leucemia linfática crónica y linfoma limfoides. linfocítico. Sponsored by: Generalitat de Catalunya. PhD student: Sofia Alejandra Martínez Trillos AGAUR_SGR17_01009 Duration: 01/01/2017-31/12/2019

Colomer D. Estrategias terapéuticas dirigidas contra la heterogeneidad molecular y la resistencia en leucemia linfática crónica y linfoma de células del manto. Sponsored by: Ministerio de Economía y Competitividad (MINECO). SAF2015-67633-R Duration: 01/01/2016-31/07/2019

Pérez-Galán P. IMLINFO: Red transfonteriza de immunoterapias personalizadas para linfomas no hodgkin. Sponsoredby: European Commission. Interreg-16_POCTE (EFA281/16) Duration: 01/01/2018-31/12/2020

Pérez-Galán P. Multi-cellular interactions in the progression of chronic inﬂammatory diseases and lymphoproliferative disorders: 3D models to investigate targeted immune therapies -3DIMMUNETARGET . Sponsored by: Ministerio de Economía y Competitividad (MINECO). SAF2017-88275-R Duration 01/01/2018-31/12/2020

Pérez-Galán P . Crosstalk between lymphocytes and their microenvironment

313 AREA 5 ONCOLOGY AND HAEMATOLOGY 5.9 Hemotherapy - hemostasis

STRATEGIC OBJECTIVES

LOCATION 1. Mechanisms regulating blood cell function HCB building and their interactions with the vascular wall.

2. Characterization of bleeding and thrombotic phenotypes and genotypes. Evaluation of pharmacological/transfusional therapies. KEYWORDS 1. Platelets TEAM LEADER 3. Analysis of the efficacy and safety of new 2. Coagulation Ginés Escolar (HCB) strategies for sparing blood component 3. Thrombosis T. 93 227 54 00 (Ext.: 2034) transfusions. 4. Transfusion [email protected] 5. Aphaeresis 4. Laboratory and animal models of hemostasis. RESEARCHERS Joan Cid (HCB) Maribel Diaz (HCB) MAIN LINES OF RESEARCH Pablo García (CSIC) Original publications Miguel Lozano (HCB) 1. Study of the molecular mechanisms from 2016 to 2018 Anna M Merino (HCB) involved in the development of bleeding Juan Monteagudo (HCB) and thrombotic disorders. YEAR I.F. TOTAL Q1 Q2 Arturo Pereira (HCB)

2016 116.91 25 14 5 Juan Carlos Reverter (HCB) 2. Characterization of endothelial dysfunction Cristina Chantal Sanz (HCB) in association with stem cell transplantation 2017 103.98 23 14 5 Mª Dolors Tassies (HCB) and development of early complications. 2018 120.51 24 12 6 Search for biomarkers of graft-versus-host POST-DOCTORAL RESEARCHERS disease (GVHD). Irene Lopez (IDIBAPS) 3. Diagnosis and treatment of thrombotic PRE-DOCTORAL RESEARCHERS microangiopathies. TEAM INVOLVED IN Didac Jerez (FCRB) AGAUR_SGR14 Ana Belén Moreno (HCB) 4. Evaluation of the physiological and AGAUR_SGR17: 00675 Sergi Torramade (IDIBAPS) pathological implications of circulating and/or platelet associated procoagulant TECHNICIANS microparticles in atherothrombosis. Patricia Molina (HCB) Marcos Pino (HCB) TEAM Ginés Escolar

314 HEMOTHERAPY – HEMOSTASIS 5.9

5. New strategies for the treatment of Evolving M-protein pattern in patients with Moreno A., Rodríguez-Lobato L., Carreras E., combined humoral immunity in therapeutic smoldering multiple myeloma: impact on Díaz-Ricart M., Palomo M., Martínez C., apheresis. early progression. LEUKEMIA. Urbano-Ispizua A., Bladé J., Fernández-Avilés 32(6):1427-1434. I.F.: 10.023 F. Innovative strategies minimize 6. Evaluation of the participation of engraftment syndrome in multiple serotoninergic and purinergic mechanisms 5. Hernández-Boluda JC, Pereira A, myeloma patients with novel induction in platelet function. Study of the Pastor-Galán I, Alvarez-Larrán A, Savchuk A, therapy following autologous antithrombotic potential of Puerta JM, Sánchez-Pina JM, Collado R, hematopoietic stem cell transplantation. pharmacological inhibitors. Díaz-González A, Angona A, Sagüés M, BONE MARROW TRANSPLANTATION. García-Gutiérrez V, Boqué C, Osorio S, 53(12):1541-1547. I.F.: 4.497 7. Role of the phenotype/genotype of Vallansot R, Palomera L, Mendizábal A, fibrinolysis and its repercussions upon Casado LF, Pérez-Encinas M, Pérez-López R, 11. Jorge A., Suárez-Lledó M., Pereira A., global or specific functional tests in Ferrer-Marín F, Sánchez-Guijo F, García C, Gutierrez G., Fernández-Avilés F., Rosiñol L., hemorrhagic and thrombotic pathology. Heras NL, López-Lorenzo JL, Cervantes F, Llobet N., Solano T., Urbano-Ispízua Á., Rovira Steegmann JL, Grupo Español de Leucemia M., Martínez C. Single Antigen-Mismatched 8. Implications of the GAS6 vitamin Mieloide Crónica (GELMC). Feasibility of Unrelated Hematopoietic Stem Cell K-dependent protein in hemostasis and the treatment discontinuation in chronic Transplantation Using High-Dose vascular wall, in knockout mice. myeloid leukemia in clinical practice: Post-Transplantation Cyclophosphamide results from a nationwide series of 236 Is a Suitable Alternative for Patients 9. Evaluation of antidotes to reverse the patients. BLOOD CANCER JOURNAL. Lacking HLA-Matched Donors. anticoagulant action of the new oral 8(10):91. I.F.: 8.125 BIOLOGY OF BLOOD AND MARROW antithrombotic agents. TRANSPLANTATION. 24(6):1196-1202. 6. Vera M, Torramade-Moix S, I.F.: 4.484 Martin-Rodriguez S, Cases A, Cruzado JM, Rivera J, Escolar G, Palomo M, Diaz-Ricart M. 12. Serafín V., Torrente-Rodríguez R., PUBLICATIONS Antioxidant and Anti-Inflammatory González-Cortés A., García de Frutos P., Strategies Based on the Potentiation of Sabaté M., Campuzano S., Yáñez-Sedeño P., Originals / I.F.: 120.505 Glutathione Peroxidase Activity Prevent Pingarrón J. An electrochemical Endothelial Dysfunction in Chronic Kidney immunosensor for brain natriuretic 1. Blasi A, Calvo A, Prado V, Reverter E, Disease. CELLULAR PHYSIOLOGY AND peptide prepared with screen-printed Reverter JC, Hernández-Tejero M, Aziz F, BIOCHEMISTRY. 51(3):1287-1300. I.F.: 5.500 carbon electrodes nanostructured with Amoros A, Cardenas A, Fernández J. gold nanoparticles grafted through aryl Coagulation failure in patients with 7. Hernández-Boluda JC, Correa JG, diazonium salt chemistry. TALANTA. Acute-on-Chronic Liver Failure (ACLF) and Alvarez-Larrán A, Ferrer-Marín F, Raya JM, 179:131-138. I.F.: 4.244 decompensated cirrhosis: beyond INR. Martínez-López J, Velez P, Pérez-Encinas M, HEPATOLOGY. 68(6):2325-2337. I.F.: 14.079 Estrada N, García-Gutiérrez V, Fox ML, Luño 13. García D., Aguilera A., Antolín F., Arroyo J., E, Kerguelen A, Cuevas B, Durán MA, Ramírez Lozano M., Sanroma P., Romón I. Home 2. Hurtado B; Trakala M; Ximénez-Embún P; El MJ, Gómez-Casares M, Mata-Vázquez MI, transfusion: three decades of practice at a Bakkali A; Partida D; Sanz-Castillo B; Regadera A, Pereira A, Cervantes F, Grupo tertiary care hospital. TRANSFUSION. Álvarez-Fernández M; Maroto M; Español de Enfermedades Mieloproliferativas 58(10):2309-2319. I.F.: 3.423 Sánchez-Martínez R; Martinez L; Muñoz J; Filadelfia Negativas (GEMFIN). Clinical Garcia de Frutos P; Malumbres M. characteristics, prognosis and treatment 14. Pagano MB, Dunbar NM, Tinmouth A, Thrombocytopenia-associated mutations of myelofibrosis patients with severe Apelseth TO, Lozano M, Cohn CS, Stanworth in Ser/Thr kinase MASTL deregulate actin thrombocytopenia. BRITISH JOURNAL OF SJ, Biomedical Excellence for Safer cytoskeletal dynamics in platelets. HAEMATOLOGY. 181(3):386-417. I.F.: 5.128 Transfusion (BEST) Collaborative. JOURNAL OF CLINICAL INVESTIGATION. A methodological review of the quality of 128(12):5351-5367. I.F.: 13.251 8. Cid J, Guijarro F, Carbassé G, Lozano M. reporting of surveys in transfusion 24-h continuous infusion of platelets for medicine. TRANSFUSION. 58(11):2720-2727. 3. Corpas R., Griñán-Ferré C., patients with platelet transfusion I.F.: 3.423 Palomera-Ávalos V., Porquet D., García de refractoriness. BRITISH JOURNAL OF Frutos P., Franciscato Cozzolino S., HAEMATOLOGY. 181(3):386-389. I.F.: 5.128 15. Mirabet S., García-Osuna A., Garcia De Rodríguez-Farré E., Pallàs M., Sanfeliu C., Frutos P., Ferrero-Gregori A., Brossa V., Lopez Cardoso B. Melatonin induces mechanisms 9. Salvador J., Tassies D., Reverter J., Marco L., Leta R., Garcia-Picart J., Padro J., of brain resilience against M. Enzyme-linked immunosorbent assays Sánchez-Quesada J., Cinca J., neurodegeneration. JOURNAL OF PINEAL for therapeutic drug monitoring coumarin Ordonez-Llanos J., Roig E. High-Sensitivity RESEARCH. 65(4):e12515. I.F.: 11.613 oral anticoagulants in plasma. ANALYTICA Troponin T and Soluble Form of AXL as CHIMICA ACTA. 1028:59-65. I.F.: 5.123 Long-Term Prognostic Biomarkers after 4. De Larrea C., Isola I., Pereira A., Cibeira M., Heart Transplantation. DISEASE MARKERS. Magnano L., Tovar N., Rodríguez-Lobato L., 10. Gutiérrez-García G., Rovira M., Magnano 2018(6243529). I.F.: 2.949 Calvo X., Aróstegui J., Díaz T., Lozano E., L., Rosiñol L., Bataller A., Suárez-Lledó M., Rozman M., Yagüe J., Bladé J., Rosiñol L. Cibeira M., de Larrea C., Garrote M., Jorge S., 16. Hernández-Boluda J., Pereira A., Correa J.,

315 AREA 5 ONCOLOGY AND HAEMATOLOGY

Alvarez-Larrán A., Ferrer-Marín F., Raya J., VOX SANGUINIS. 113(5):492-498. I.F.: 2.107 HEMATOLOGY. 40 (1):46-53. I.F.: 1.919 Martínez-López J., Velez P., Pérez-Encinas M., Estrada N., García-Gutiérrez V., Fox M., Payer 22. Molina A., Guiñon L., Perez A., Segurana A., 4. Garraud O, Brand A, Henschler R, Vuk T, A., Kerguelen A., Cuevas B., Durán M., Ramírez Bedini J., Reverter J., Merino A. State of the Haddad A, Lozano M, Ertuğrul Örüç N, Politis M., Gómez-Casares M., Mata-Vázquez M., art vs biological variability: Comparison on C, de Angelis V, Laspina S, Tissot JD, Mora E., Gómez M., Cervantes F. Prognostic hematology parameters using Spanish 'European and Mediterranean Initiative in risk models for transplant decision-making EQAS data. INTERNATIONAL JOURNAL OF Transfusion Medicine' (EMITm) group. in myelofibrosis. ANNALS OF LABORATORY HEMATOLOGY. Medical student education in transfusion HEMATOLOGY. 97(5):813-820. I.F.: 2.845 40(3):284-291. I.F.: 1.919 medicine: Proposal from the European and Mediterranean initiative in transfusion 17. Plasín-Rodríguez M., Rodríguez-Pintó I., 23. Blasi A, Hernandez V, Fernandez J, medicine. TRANSFUSION AND APHERESIS Patricio P., Monteagudo J., Cervera R., Colmenero J, Beltran J, Garcia-Valdecasas SCIENCE. 57(5):593-597. I.F.: 1.755 Reverter J., Espinosa G., Tàssies D. The H1 JC, Reverter JC. Venous Thrombotic haplotype of the endothelial protein C Events After Liver Transplantation. 5. Díaz-Ricart M., Isola I., Escolar G. receptor protects against arterial CLINICAL AND APPLIED Emicizumab for routine prophylaxis to thrombosis in patients with THROMBOSIS/HEMOSTASIS. 24(2):317-322. prevent bleeding episodes in patients with antiphospholipid syndrome. THROMBOSIS I.F.: 1.852 hemophilia A. DRUGS OF TODAY. RESEARCH. 169:128-134. I.F.: 2.779 54(10):591-600. I.F.: 1.325 24. Olson J., Jennings I., Meijer P., Bon C., 18. Piñeiro G., De Sousa-Amorim E., Solé M., Bonar R., Favaloro E., Higgins R., Keeney M., Ríos J., Lozano M., Cofán F., Ventura-Aguiar P., Mammen J., Marlar R., Meley R., Nair S., Letters / I.F.: 14.922 Cucchiari D., Revuelta I., Cid J., Palou E., Nichols W., Raby A., Reverter J., Srivastava A., Campistol J., Oppenheimer F., Rovira J., Walker I. Lack of grading agreement among 1. Fernández de Larrea C., Isola I., Pereira A., Diekmann F. Rituximab, plasma exchange international hemostasis external quality Cibeira M., Bladé J., Rosiñol L.. The pattern of and immunoglobulins: An ineffective assessment programs. BLOOD the M-protein in smoldering myeloma over treatment for chronic active COAGULATION AND FIBRINOLYSIS. the time: an evolving risk factor. LEUKEMIA. antibody-mediated rejection. BMC 29(1):111-119. I.F.: 1.119 32(9):2082-2083. I.F.: 10.023 NEPHROLOGY. 19(1):261. I.F.: 2.395 2. Zafar, M. U.; Badimon, J. J.; Escolar, G. 19. Cid J, Carbassé G, Cid-Caballero M, Review / I.F.: 11.803 Incomplete reversibility of platelet López-Púa Y, Alba C, Perea D, Lozano M. inhibition following prolonged exposure to The Barcelona Hospital Clínic therapeutic 1. Gonzalez-Vicent, Marta; Sanz, Jaime; Luis ticagrelor: comment. JOURNAL OF apheresis database. JOURNAL OF Fuster, Jose; Cid, Joan; Diaz de Heredia, THROMBOSIS AND HAEMOSTASIS. CLINICAL APHERESIS. 33(3):259-264. Cristina; Morillo, Daniel; Maria Fernandez, 16(3):605-606. I.F.: 4.899 I.F.: 2.392 Jose; Pascual, Antonia; Badell, Isabel; Serrano, David; Fox, Laura; de la Serna, Javier; Benito, 20. Yazer MH, Spinella PC, Allard S, Roxby D, Ana; Miguel Couselo, Jose; Molina, Blanca; So-Osman C, Lozano M, Gunn K, Shih AW, Angel Diaz, Miguel; Angel Sanz, Miguel. GRANTS FOR RESEARCH IN PROGRESS Stensballe J, Johansson PI, Bagge Hansen M, Autoimmune hemolytic anemia (AIHA) Maegele M, Doughty H, Crombie N, Jenkins following allogeneic hematopoietic stem Diaz-Ricart M. Caracterización genética e DH, McGinity A, Schaefer RM, Martinaud C, cell transplantation (HSCT): A identificación de nuevos genes diana en el Shinar E, Strugo R, Chen J, Russcher H. Vox retrospective analysis and a proposal of diagnóstico de las anemias congénitas no Sanguinis International Forum on the use treatment on behalf of the Grupo filiadas. of prehospital blood products and Español De Trasplante de Medula Osea Sponsored by: Instituto de Salud Carlos III pharmaceuticals in the treatment of en Niños (GETMON) and the Grupo (ISCIII). PI14/00772 patients with traumatic haemorrhage. VOX Español de Trasplante Hematopoyetico Duration: 01/01/2015-30/09/2018 SANGUINIS. 113(7):701-706. I.F.: 2.107 (GETH). TRANSFUSION MEDICINE REVIEWS. 32(3):179-185. I.F.: 4.111 Escolar G. HEMOTROM. 21. De Vooght KMK, Lozano M, Bueno JL, Sponsored by: Generalitat de Catalunya. Alarcón A, Romera I, Suzuki K, Zhiburt E, 2. Blasi A, Reverter JC. Time to change the AGAUR_SGR17_00675 Holbro A, Infanti L, Buser A, Hustinx H, Deneys classical vision of coagulation in liver Duration: 01/01/2017-31/12/2020 V, Frélik A, Thiry C, Murphy M, Staves J, disease: from the balance disequilibrium Selleng K, Greinacher A, Kutner JM, Bonet to the systems biology network Escolar G. Microchip-based point of care Bub C, Castilho L, Kaufman R, Colling ME, modelling. MINERVA ANESTESIOLOGICA. devices for a global evaluation of Perseghin P, Incontri A, Dassi M, Brilhante D, 84(7):848-857. I.F.: 2.693 hemostasis under flow conditions: Macêdo A, Cserti-Gazdewich C, Pendergrast application to the screening of bleeding, JM, Hawes J, Lundgren MN, Storry JR, Jain A, 3. Rodellar J, Alférez S, Acevedo A, Molina thrombosis and monitoring of Marwaha N, Sharma RR. Vox Sanguinis A, Merino A. Image processing and antithrombotic therapies. International Forum on typing and machine learning in the morphological Sponsored by: Instituto de Salud Carlos III matching strategies in patients on analysis of blood cells. INTERNATIONAL (ISCIII). DTS16/00133 anti-CD38 monoclonal therapy: summary. JOURNAL OF LABORATORY Duration: 01/01/2017-31/10/2019

316 HEMOTHERAPY – HEMOSTASIS 5.9

Escolar G. Targeting endothelial dysfunction in highly prevalent diseases: characterization and validating of prognostic biomarkers and identiﬁcation of potential therapeutic strategies. Sponsored by: Instituto de Salud Carlos III (ISCIII). PIE15/00027 Duration: 01/01/2016-31/12.2018

DOCTORAL THESES

Diaz-Ricart MI, Palomo M. Endothelial dysfunction ocurring in acute graft-versus-host disease. Potential preventive and therapeutic agents. PhD student: Enrique Mir Fuertes

317 AREA 5 ONCOLOGY AND HAEMATOLOGY

Molecular and 5.10 translational oncology

COLLABORATORS Neus Carbó (UB) LOCATION Maria Angeles Sierra (FCRB) CELLEX building, ﬂoor 1A

STRATEGIC OBJECTIVES

The overall objective of our team is to KEYWORDS understand how the microenvironment, in

1. Inﬂammation and neuropeptides TEAM LEADER particular the nervous system, interacts with 2. Tumor microenvironment Pere Gascón (HCB) and inﬂuences tumour cells metabolism, 3. Cell dormancy T. 93 227 54 02 proliferation or survival and how these 4. Chemotherapy resistance [email protected] mechanisms contribute to breast cancer 5. Tumor heterogeneity progression and therapy resistance. 6. Epigenetic plasticity We want to identify new biomarkers and RESEARCHERS therapeutic targets that could be transferred Francisco Javier Avilés (HCB) to the clinical practice. Isabel Vilaseca (HCB)

POST-DOCTORAL RESEARCHERS MAIN LINES OF RESEARCH Original publications Paloma Bragado (IDIBAPS) Patricia Fernández (FCRB) from 2016 to 2018 Gemma Fuster (FCRB) 1. Stress and microenvironment YEAR I.F. TOTAL Q1 Q2 Mario Mancino (FCRB) inﬂuences in breast cancer.

2016 69.47 14 1- PRE-DOCTORAL RESEARCHERS - Study the role of neuropeptides and 2017 23.62 6 2 1 Núria Moragas (IDIBAPS) neurotransmitters in the control of breast 2018 41.16 8 6 1 Aleix Noguera (UB) cancer progression. Leire Recalde (UB) - Evaluate the potential of different

TECHNICIANS components of the microenvironment such Miriam Badia (FCRB) as ﬁbroblasts or bone marrow TEAM INVOLVED IN Patricia Jauregui (FCRB) mesenchymal stem cells on the generation AGAUR_SGR17: 01305, 01581 Anna Lopez (FCRB) of breast cancer heterogeneity.

ADMINISTRATIVE STAFF - Analyse the role of several stress factors, Darya Kulyk (FCRB) such as cathecolamines, glucocorticoids, hormones and neural related system TEAM Pere Gascón

318 MOLECULAR AND TRANSLATIONAL ONCOLOGY 5.10

factors in the transition of carcinoma ductal A., Enreig E., Carbó N., Almendro V., Gascón P., of efficacy, safety, economic, and in situ to invasive. Bragado P., Fuster G. Glucocorticoids health-related quality-of-life outcomes promote transition of ductal carcinoma in of short- and long-acting 2. Microenvironmental mechanisms of situ to invasive ductal carcinoma by erythropoiesis-stimulating agents in the tumour dormancy and metastasis. inducing myoepithelial cell apoptosis. treatment of chemotherapy-induced BREAST CANCER RESEARCH. 20(1):65. anemia and chronic kidney disease - Determine the role of the TAC1 gene in the I.F.: 6.142 anemia. CRITICAL REVIEWS IN metastatic process in breast cancer. ONCOLOGY/HEMATOLOGY. 129:79-90. 4. Harbeck N., Gascón P., Krendyukov A., I.F.: 4.495 - Study the role of the microenvironment on Hoebel N., Gattu S., Blackwell K. Safety disseminated tumour cells dormancy, Profile of Biosimilar Filgrastim 3. Aapro M., Krendyukov A., Schiestl M., survival and progression to metastasis. (Zarzio/Zarxio): A Combined Analysis Gascón P. Epoetin Biosimilars in the of Phase III Studies. ONCOLOGIST. Treatment of Chemotherapy-Induced - Metastasis pathogenesis. 23(4):403-409. I.F.: 5.306 Anemia: 10 Years’ Experience Gained. BIODRUGS. 32(2):129-135. I.F.: 3.825 3. Tumor resistance mechanisms: 5. Gascon, Pere; Arranz, Reyes; Bargay, Joan; Ramos, Fernando. Fatigue- and 4. Cornes, Paul; Gascon, Pere; Chan, - Characterization of the mechanisms of health-related quality-of-life in anemic Stephen; Hameed, Khalid; Mitchell, epigenetic adaptation and cellular plasticity patients with lymphoma or multiple Catherine R.; Field, Polly; Latymer, Mark; during the adquisition of chemoresistance. myeloma. SUPPORTIVE CARE IN Arantes, Luiz H., Jr. Systematic Review CANCER. 26(4):1253-1264. I.F.: 2.676 and Meta-analysis of Short- versus - Study the mechanisms of tumour Long-Acting Granulocyte progression in breast cancer HER2+ 6. Gascon, Pere; Krendyukov, Andriy; Colony-Stimulating Factors for induced by the acquisition of resistance to Hoebel, Nadja; Aapro, Matti. Reduction of Chemotherapy-Induced Trastuzumab and Lapatinib. Role of MONITOR-GCSF DLBCL subanalysis: Febrile Neutropenia. ADVANCES IN fibroblasts on antiHER therapies Treatment THERAPY. 35(11):1816-1829. I.F.: 3.085 resistance . patterns/outcomes with biosimilar filgrastim for chemotherapy- induced/febrile neutropenia Clinical Guidelines / I.F.: 16.322 prophylaxis. EUROPEAN JOURNAL OF PUBLICATIONS HAEMATOLOGY. 100(3):241-246. I.F.: 2.595 1. Aapro M; Beguin Y; Bokemeyer C; Dicato M; Gascon P; Glaspy J; Hofmann A; Link H; Originals / I.F.: 41.157 7. Valls-Mateus M., Nogués-Sabaté A., Littlewood T; Ludwig H; Österborg A; Blanch J., Bernal-Sprekelsen M., Pronzato P; Santini V; Schrijvers D; Stauder 1. Blackwell, K.; Gascon, P.; Krendyukov, A.; Avilés-Jurado F., Vilaseca I. Narrow band R; Jordan K; Herrstedt J; ESMO Guidelines Gattu, S.; Li, Y.; Harbeck, N. Safety and imaging for head and neck malignancies: Committee. Management of anaemia and efficacy of alternating treatment with Lessons learned from mistakes. HEAD iron deficiency in patients with cancer: EP2006, a filgrastim biosimilar, and AND NECK. 40(6):1164-1173. I.F.: 2.471 ESMO Clinical Practice Guidelines. reference filgrastim: a phase III, ANNALS OF ONCOLOGY. randomised, double-blind clinical study in 8. Nogués-Sabaté A., Aviles-Jurado F., 29(Supplement_4):iv96-iv110. I.F.: 13.930 the prevention of severe neutropenia in Ruiz-Sevilla L., Lehrer E., Santamaría-Gadea patients with breast cancer receiving A., Valls-Mateus M., Vilaseca I. Intra and 2. Lopez Lopez, R.; Camps Herrero, C.; myelosuppressive chemotherapy. interobserver agreement of narrow band Khosravi-Shahi, P.; Guillem Porta, V.; Carrato ANNALS OF ONCOLOGY. 29(1):244-249. imaging for the detection of head and Mena, A.; Garcia-Foncillas, J.; Cruz I.F.: 13.930 neck tumors. EUROPEAN ARCHIVES OF Hernandez, J. J.; Gascon Vilaplana, P.; Anton OTO-RHINO-LARYNGOLOGY. Torres, A.; Diaz-Rubio, E.; Feyjoo Saus, M.; 2. Fernández-Nogueira P., Noguera-Castells 275(9):2349-2354. I.F.: 1.546 Aranda Aguilar, E. Oncologist's A., Fuster G., Recalde-Percaz L., Moragas N., knowledge and implementation of López-Plana A., Enreig E., Jauregui P., Carbó guidelines for breakthrough cancer pain N., Almendro V., Gascón P., Bragado P., Review / I.F.: 17.643 in Spain: CONOCE study. CLINICAL AND Mancino M. Histamine receptor 1 inhibition TRANSLATIONAL ONCOLOGY. enhances antitumor therapeutic 1. Aapro, Matti; Krendyukov, Andriy; Hoebel, 20(5):613-618. I.F.: 2.392 responses through extracellular Nadja; Seidl, Andreas; Gascon, Pere. signal-regulated kinase (ERK) activation Development and 10-year history of a in breast cancer. CANCER LETTERS. biosimilar: the example of Binocrit (R). 424:70-83. I.F.: 6.491 RAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, THE. 10:1-8. I.F.: 6.238 3. Zubeldia-Plazaola A., Recalde-Percaz L., Moragas N., Alcaraz M., Chen X., Mancino M., 2. Arantes L., Crawford J., Gascon P., Fernández-Nogueira P., Prats de Puig M., Latymer M., Launay-Vacher V., Rolland C., Guzman F., Noguera-Castells A., López-Plana Scotte F., Wish J. A quick scoping review

319 AREA 5 ONCOLOGY AND HAEMATOLOGY

GRANTS FOR RESEARCH IN PROGRESS

Avilés FJ. Head Neck Clínic. Sponsored by: Generalitat de Catalunya. AGAUR_SGR17_01581 Duration: 01/01/2017-31/12/2020

Bragado P. El reloj de la metástasis: Regulación circadiana de las células tumorales diseminadas. Sponsored by: Fundación BBVA. BBM-TRA-0041 Duration: 15/09/2018-14/09/2019

Gascón P. Role of neuropeptides and neurotransmitters in the regulation of tumorigenesis, disseminated tumour cells biology and metastasis in breast cancer. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI15/00661 Duration: 01/01/2016-15/03/2019

320 CELL PROLIFERATION AND SIGNALING 5.11

Cell proliferation 5.11 and signaling

STRATEGIC OBJECTIVES

LOCATION The aim of the group is to study the UB School of Medicine mechanisms involved in cell cycle regulation and in the cellular responses to different types of stresses. We also aim to analyse the alterations of these mechanisms in different types of cancers as for instance colorectal cancer and leukemias. The knowledge of KEYWORDS these mechanisms will allow improving 1. Cell cycle TEAM LEADER cancer therapy. 2. Signalling Oriol Bachs (UB) 3. Oncogenesis T. 93 403 52 86 [email protected] MAIN LINES OF RESEARCH

RESEARCHERS Involvement of p27 (Kip1) in cancer Rosa Aligué (UB) progression: p27 (Kip1), a classical inhibitor Original publications María Jesús Pujol (UB) of cyclin dependent kinases, is also a from 2016 to 2018 transcriptional regulator. We are analysing the POST-DOCTORAL RESEARCHERS mechanisms by which p27 regulates YEAR I.F. TOTAL Q1 Q2 Edurne Gallastegui (UB) transcription and which are the transcriptional 2016 16.18 2 2- Judit Macias (UB) programs regulated by this protein. p27 is Ramon Marqués (UB) decreased in many different types of human 2017 25.66 4 4 - Serena Orlando (UB) tumours and this reduction is associated with 2018 8.16 2 2 - Laura Sin (UB) a worse outcome. Thus, the identiﬁcation of Tula Yanze (UB) the transcriptional programs regulated by p27 helps to understand how p27 participates in PRE-DOCTORAL RESEARCHERS the progression of malignancy. Carla Domuro (UB) TEAM INVOLVED IN Rodrigo Duran (UB) Protein kinases in cancer: Our research ProteoRed Julia Llanes (UB) focuses on identifying the molecular CIBERONC Edgar Martin (UB) mechanism by which the CaMK family Jonatan Martinez (UB) regulate cell cycle control and stress response. We are actually focused in VISITING SCIENTISTS dissecting the role of the CaMKK2 in cancer Toni Hurtado (University of Oslo) development and metabolic stress. TEAM Oriol Bachs

321 AREA 5 ONCOLOGY AND HAEMATOLOGY

Preliminary results have indicated that, DOCTORAL THESES CaMKK2 has a role in glucosae uptake and nutrient homeostasis. The identiﬁcation of Aligué RM. Caracterización de una nueva Ckk2 substrates through the analysis of ﬁtasa y su expresión en Pichia pastoris. phospho-peptides indicates that there is a PhD student: Ramon Marquès Mascarell crosstalk between Ckk2 and TOR pathway. Bachs O. Papel del p21 en la regulación de la vía de Wnt y su implicación en la neurogénesis. PUBLICATIONS PhD student: Laura Sin Díaz

Originals / I.F.: 8.163

1. Sanchez-Marinas M, Gimenez-Zaragoza D, Martin-Ramos E, Llanes J, Cansado J, Pujol MJ, Bachs O, Aligue R. Cmk2 kinase is essential for survival in arsenite by modulating translation together with RACK1 orthologue Cpc2 in Schizosaccharomyces pombe. FREE RADICAL BIOLOGY AND MEDICINE. 129:116-126. I.F.: 6.020

2. Hamdi M., Pérez J., Létourneau-Montminy M., Franco-Rosselló R., Aligue R., Solà-Oriol D. The effects ofmicrobial phytases and dietary calcium and phosphorus levels on the productive performance and bone mineralization of broilers. ANIMAL FEED SCIENCE AND TECHNOLOGY. 243:41-51. I.F.: 2.143

GRANTS FOR RESEARCH IN PROGRESS

Aligué R. Role of Calmodulin dependent kinases in glucose uptake and nutrient homeostasis: connexion with the mTOR pathway. Sponsored by: Ministerio de Economía y competitividad (MINECO). BFU2015-65311-R Duration: 01/01/2016-31/12/2018

Bachs O. CiberONC (Cancer network). Sponsored by Instituto de Salud Carlos III (ISCIII). CB16/12/00244 Duration: 01/01/2017-31/12/2021

Bachs O. Carlos III Networked Proteomics Plattform (ProteoRed). Sponsored by: Instituto de Salud Carlos III (ISCIII). PT13/0001/0036 Duration: 01/01/2017-31/12/2021

Bachs O. Role of the transcriptional programs regulated by p27Kip1 in cancer. Sponsored by: Ministerio de Economía y competitividad (MINECO). SAF2015-64344-R Duration: 01/01/2016-31/12/2018

322 CELL COMPARTMENTS AND SIGNALING 5.12

Cell compartments 5.12 and signaling

STRATEGIC OBJECTIVES

LOCATION Our objective is to understand how the signals CELLEX building, ﬂoor 1B originated in the cell surface are transduced to UB School of Medicine trigger reactions that lead metabolic changes, proliferation, or survival and how these mechanisms are affected during disease. We are currently studying the endocytic

WEB compartment, lipid droplets and the www.celltrafficbcn.cat endoplasmic reticulum, and the signalling TEAM LEADER pathways that regulate the cell cycle and Carles Enrich (UB) apoptosis. T. (34) 93 402 19 08 [email protected]

KEYWORDS MAIN LINES OF RESEARCH 1. Cell biology GROUP LEADERS 2. Endocytosis and exocytosis Neus Agell (UB) Endocytosis and intracellular trafficking of proteins and cholesterol: 3. Lipids transport and storage T. (34) 93 402 19 07 [email protected] Our objective is the study of the mechanisms 4. Signal transduction that regulate the endocytosis and exocytosis 5. Cell cycle Carles Enrich (UB) of proteins and cholesterol and the signalling T.(34) 93 402 19 08 pathways associated with these processes. [email protected] We focus on determining the role of annexin A6 in signalling, membrane trafficking and liver Albert Pol (ICREA-IDIBAPS) regeneration. T. (34) 93 227 54 00 (Ext. 3337) Original publications [email protected] Lipid trafficking and disease: from 2016 to 2018 Our objective is to characterize the intracellular transport and storage of lipids and YEAR I.F. TOTAL Q1 Q2 RESEARCHERS the implication of these mechanisms in 2016 41.75 7 7 - Montserrat Jaumot (UB) disease progression (lipotoxicity). We are 2017 29.53 7 5 2 Francesc Tebar (IDIBAPS-UB) Interested in lipid droplet biogenesis/metabolism and the intracellular 2018 12.32 3 3 - POST-DOCTORAL RESEARCHERS trafficking of cholesterol mediated by Marta Bosch (UB) caveolins, Albert Gubern (IDIBAPS) Carles Rentero (UB) Signal transduction and cell cycle: Teresa Royo (UB) Our objective is to analyse the signal transduction mechanisms that regulate cell PRE-DOCTORAL RESEARCHERS cycle progression and their alterations in Baraa Abusaker (UB) oncogenesis. Speciﬁcally we are studying the Patricia Blanco (UB) function and regulation of the Ras and Rho Debora Cabot (UB) family of GTPases and the signal transduction Albert Chavero (UB) pathways regulating replication stress in Sonia Feu (UB) normal and tumour cells. Elsa Meneses (UB) Frederic Morales (IDIBAPS) Fernando Unzueta (UB)

TECHNICIANS Sonia Brun (UB) Josep Maria Estanyol (UB) Alba Fajardo (IDIBAPS)

323 AREA 5 ONCOLOGY AND HAEMATOLOGY

RESEARCH GROUP SIGNAL TRANSDUCTION AND CELL CYCLE

GROUP LEADER Neus Agell (UB)

Our group is interested in studying signal transduction pathways activated upon proliferative signals or upon replication stress and their alteration in tumorigenesis. Speciﬁcally we analyse the regulation of GTPases proteins of the Rho and Ras family signalling from different plasma membrane and endocytic platforms, and implications of this signalling compartmentalization in various cellular processes such as proliferation, cell GROUP Neus Agell migration and mobility, and also in oncogenesis. We are also analysing signalling from arrested replication forks that lead to cell cycle arrest and senescence.

RESEARCH GROUP ENDOCYTOSIS AND INTRACELLULAR TRAFFICKING OF PROTEINS AND CHOLESTEROL

GROUP LEADER Carles Enrich (UB)

Our group is interested on the molecular

mechanisms of membrane traffic in GROUP Carles Enrich mammalian cells. This basic research is important for understanding a number of diseases including cancer, diabetes, and heart disease or liver disorders. We study the regulation of a variety of aspects of protein and cholesterol trafficking and signal transduction in the endocytic compartment; a sorting and processing station for proteins internalized by cells as well as of the secretory pathway. We are focus in the study of Annexin A6. Annexins are an evolutionarily conserved multigene family with roles in vesicle trafficking, phospholipid metabolism, actin dynamics, apoptosis and cell transformation.

324 CELL COMPARTMENTS AND SIGNALING 5.12

RESEARCH GROUP LIPID TRAFFICKING AND DISEASE

GROUP LEADER Albert Pol (ICREA-IDIBAPS)

Lipid droplets are organelles that collect, store and supply lipids in all eukaryotic cells. These organelles are also cellular hallmarks of prevalent diseases ranging from obesity to cancer. The cell biology of lipid droplets and its role in pathogenesis are still unclear. Our group is interested in the mechanisms of lipid droplet biogenesis and consumption. Cholesterol accumulation promotes mitochondrial dysfunction and oxidative damage underlying in the pathogenesis of GROUP Albert Pol steatohepatitis, neurodegeneration and Review / I.F.: 3.687 Sponsored by: Fundació la Marató de TV3. atherosclerosis. In this context, we are TV3_Diabet_16 especially interested in how caveolin-1 1. Rentero C., Blanco-Muñoz P., Duration: 24/02/2017-23/02/2020 regulates cholesterol trafficking and storage. Meneses-Salas E., Grewal T., Enrich C. Annexins-coordinators of cholesterol Pol A. Nuevas funciones de ACSL3, CAV1 y homeostasis in endocytic pathways. colesterol en el retículo endoplásmico: INTERNATIONAL JOURNAL OF sensores homeostáticos que determinan PUBLICATIONS MOLECULAR SCIENCES. 19(5):1444. la supervivencia o la muerte de las células. I.F.: 3.687 Sponsored by: Ministerio de Economía y Originals / I.F.: 12.316 Competitividad (MINECO). BFU2015-66401-R 1. Wangsa D, Quintanilla I, Torabi K, Duration: 01/01/2016-30/06/2019 Vila-Casadesús M, Ercilla A, Klus G, Yuce Z, GRANTS FOR RESEARCH IN PROGRESS Galofré C, Cuatrecasas M, Lozano JJ, Agell N, Pol A. Discovering the Partners of PCSK9 Cimini D, Castells A, Ried T, Camps J. Agell N. La fosforilacion de KRAS, su in Hepatic Endosomes: The Where, How, Near-tetraploid cancer cells show interaccion con calmodulina, y la and Why of PCSK9 in Atherosclerosis. chromosome instability triggered by respuesta al estrés replicativo, en la Sponsored by: AMGEN. PCSK9_18 replication stress and exhibit enhanced progresion del cancer colorectal y en el Duration: 01/09/2018-31/08/2020 invasiveness. FASEB JOURNAL. diseño de nuevas terapias. 32(7):3502-3517. I.F.: 5.595 Sponsored by: Ministerio de Economía y Competitividad (MINECO). 2. Garrido E, Lázaro J, Jaumot M, Agell N, SAF2016-76239-R Rubio-Martinez J. Modeling and subtleties Duration: 30/12/2016-29/12/2019 of K-Ras and Calmodulin interaction. PLOS COMPUTATIONAL BIOLOGY. Enrich C, Tebar F. Contribución del 14(10):e1006552. I.F.: 3.955 compartimiento endocítico a la migración celular: regulación por colesterol, annexin 3. Cairns R, Fischer AW, Blanco-Munoz P, A6 y Rac1. Alvarez-Guaita A, Meneses-Salas E, Egert A, Sponsored by: Ministerio de Economía y Buechler C, Hoy AJ, Heeren J, Enrich C, Competitividad (MINECO). BFU2015-66785-P Rentero C, Grewal T. Altered hepatic Duration: 01/01/2016-31/12/2019 glucose homeostasis in AnxA6-KO mice fed a high-fat diet. PLOS ONE. Pol A. Lipid Droplet Overloading Promotes 13(8):e0201310. I.F.: 2.766 Pathogenesis and Progression of Type 2 Diabetes: Identifying New Therapeutic Targets and Applying Upgraded Therapies.

325 AREA 5 ONCOLOGY AND HAEMATOLOGY

Translational genomics and targeted therapeutics 5.13 in solid tumors

Leire Pedrosa (FCRB) Estela Pineda (HCB) LOCATION Oscar Reig (FCRB) CEK building, ﬂoor 2 Margarita Viladot (HCB)

TECHNICIANS Mari Carmen Diaz (FCRB) WEB Patricia Galván (FCRB) www.clinicbarcelona.org/en/ Natalia Jiménez (FCRB) idibaps/research-areas Sandra López (FCRB) TEAM LEADER Aleix Prat (HCB) ADMINISTRATIVE STAFF T. 93 227 54 00 (Ext.: 2203) Eva Paradell (FCRB) [email protected]

COLLABORATORS Carme Font (HCB) RESEARCHERS Susana Garcia (FCRB) Ana Arance (HCB) Montserrat Muñoz (HCB) Nuria de la Iglesia (IDIBAPS) Núria Viñolas (HCB) Juan Jose Grau (HCB) KEYWORDS Joan Maurel (HCB) 1. Breast cancer Begoña Mellado (HCB) 2. Lung cancer Noemí Reguart (HCB-IDIBAPS) STRATEGIC OBJECTIVES 3. Melanoma Maria Jesús Vidal (HCB) 4. Urologic cancer Use genomic or molecular data to guide 5. Solid tumors POST-DOCTORAL RESEARCHERS clinical trial design and biomarker 6. Targeted therapies Barbara Adamo (HCB) development and study molecular 7. Immunotherapy Fara Brasó (IDIBAPS) mechanisms of drug sensitivity in order 8. Biomarkers Juan Miguel Cejalvo (IDIBAPS) to identify optimal treatment regimens for 9. Genomics Mercedes Marin (FCRB) patients with solid tumors. Laia Paré (CIBER) 10. Solid tumors Cristina Teixidó (IDIBAPS) 11. Immunotherapy

PRE-DOCTORAL RESEARCHERS Javier Garcia (FCRB) Gaia Griguolo (IDIBAPS) Tomas Pascual (FCRB)

Original publications from 2016 to 2018

YEAR I.F. TOTAL Q1 Q2

2016 124.54 16 15 1

2017 311.46 31 27 1

2018 254.96 26 18 5

TEAM INVOLVED IN AGAUR_SGR17: 01554 TEAM Aleix Prat

326 TRANSLATIONAL GENOMICS AND TARGETED THERAPEUTICS IN SOLID TUMORS 5.13

MAIN LINES OF RESEARCH Central nervous system tumors Sanchez-Cespedes M, Girard N, Brevet M, - Study of the molecular mechanisms of Giroux-Leprieur E, Dumenil C, Pradotto M, Breast cancer treatment resistance in glioblastoma Bironzo P, Capelletto E, Novello S, Cortot A, - To evaluate the impact of the identification Copin MC, Karachaliou N, Gonzalez-Cao M, of the intrinsic molecular subtypes of breast - Characterization of the biology behind the Peralta S, Montuenga LM, Gil-Bazo I, Baraibar cancer in the clinical setting. intrinsic molecular subtypes of I, Lozano MD, Varela M, Ruffinelli JC, Palmero glioblastoma. R, Nadal E, Moran T, Perez L, Ramos I, Xiao Q, - To study the mechanisms of drug Fernandez AF, Fraga MF, Gut M, Gut I, Teixidó resistance and tumor progression in Urologic cancer C, Vilariño N, Prat A, Reguart N, Benito A, Luminal A and B breast cancer. - To study the molecular mechanisms of Garrido P, Barragan I, Emile JF, Rosell R, resistance to taxanes and novel Brambilla E, Esteller M. Epigenetic - To identify genomic biomarkers predictive hormone-therapies in preclinical models, prediction of response to anti-PD-1 of response to anti-HER2 drugs in HER2 circulating tumor cells and patients with treatment in non-small-cell lung cancer: a -positive and mechanisms of castration resistant prostate cancer. multicentre, retrospective analysis. THE resistancebreast cancer. LANCET. RESPIRATORY MEDICINE. - To investigate the role of the androgen 6(10):771-781. I.F.: 21.466 receptor variants in epithelial to Colorectal cancer mesenchymal transition and progression 4. Gawrzak S, Rinaldi L, Gregorio S, Arenas E, - To evaluate intrinsic and acquired and therapy resistance in castration Salvador F, Urosevic J, Figueras-Puig C, Rojo mechanisms of resistance to resistant prostate cancer. F, Del Barco Barrantes I, Cejalvo J, Palafox M, chemotherapy and targeted agents in Guiu M, Berenguer-Llergo A, Symeonidi A, metastatic colorectal cancer, in the three - To investigate mechanisms of resistance Bellmunt A, Kalafatovic D, Arnal-Estapé A, genotypes (KRAS/NRAS mutant, BRAF to anti-angiogenic therapy and Fernández E, Müllauer B, Groeneveld R, mutant and triple-WT). identification of new therapeutic targets in Slobodnyuk K, Stephan-Otto Attolini C, Saura renal cell carcinoma. C, Arribas J, Cortes J, Rovira A, Muñoz M, - To characterize epithelial and Lluch A, Serra V, Albanell J, Prat A, Nebreda A, mesenchymal phenotypes in resectable Benitah S, Gomis R. MSK1 regulates luminal and metastatic pancreatic carcinoma and cell differentiation and metastatic it’s correlation with drug resistance. PUBLICATIONS dormancy in ER+ breast cancer. NATURE CELL BIOLOGY. 20(2):211-221. I.F.: 19.064 Melanoma Originals / I.F.: 254.959 - To evaluate the impact of the immune 5. Mouliere F, Chandrananda D, Piskorz AM, system in the response to immune 1. Dummer R, Ascierto P, Gogas H, Arance A, Moore EK, Morris J, Ahlborn LB, Mair R, checkpoint inhibitors and BRAF inhibitors. Mandala M, Liszkay G, Garbe C, Schadendorf Goranova T, Marass F, Heider K, Wan JCM, D, Krajsova I, Gutzmer R, Chiarion Sileni V, Supernat A, Hudecova I, Gounaris I, Ros S, - To study the mechanisms of drug Dutriaux C, de Groot J, Yamazaki N, Loquai C, Jimenez-Linan M, Garcia-Corbacho J, Patel K, resistance and tumor progression. Moutouh-de Parseval L, Pickard M, Sandor V, Østrup O, Murphy S, Eldridge MD, Gale D, Robert C, Flaherty K. Overall survival in Stewart GD, Burge J, Cooper WN, van der - To identify genomic biomarkers predictive patients with BRAF-mutant melanoma Heijden MS, Massie CE, Watts C, Corrie P, of response to anti-PD1 and anti-CTLA4 receiving encorafenib plus binimetinib Pacey S, Brindle KM, Baird RD, Mau-Sørensen drugs. versus vemurafenib or encorafenib M, Parkinson CA, Smith CG, Brenton JD, (COLUMBUS): a multicentre, open-label, Rosenfeld N. Enhanced detection of Lung cancer randomised, phase 3 trial. LANCET circulating tumor DNA by fragment size - Validate novel molecular technologies to ONCOLOGY. 19(10):1315-1327. I.F.: 36.421 analysis. SCIENCE TRANSLATIONAL streamline the screening of targetable MEDICINE. 10(466). I.F.: 16.710 biomarkers in non-small cell lung cancer 2. Dummer R, Ascierto P, Gogas H, Arance A, (NSCLC). Mandala M, Liszkay G, Garbe C, Schadendorf 6. Paré L, Pascual T, Seguí E, Teixidó C, D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Gonzalez-Cao M, Galván P, Rodríguez A, - Identification of novel fusion gene variants Dutriaux C, de Groot J, Yamazaki N, Loquai C, González B, Cuatrecasas M, Pineda E, Torné in NSCLC: phenotypic characterization of Moutouh-de Parseval L, Pickard M, Sandor V, A, Crespo G, Martin-Algarra S, Pérez-Ruiz E, targeted population and prospective Robert C, Flaherty K. Encorafenib plus Reig Ò, Viladot M, Font C, Adamo B, Vidal M, clinical validation of their predictive value to binimetinib versus vemurafenib or Gaba L, Muñoz M, Victoria I, Ruiz G, Viñolas N, targeted treatments. encorafenib in patients with BRAF-mutant Mellado B, Maurel J, Garcia-Corbacho J, melanoma (COLUMBUS): a multicentre, Molina-Vila MÁ, Juan M, Llovet JM, Reguart N, - Characterize the “stroma-tumor cell” open-label, randomised phase 3 trial. Arance A, Prat A. Association between PD1 crosstalk in NSCLC and the role of tumor LANCET ONCOLOGY. 19(5):603-615. mRNA and response to anti-PD1 fibroblasts in the tumorigenesis of both I.F.: 36.421 monotherapy across multiple major NSCLC subtypes: adenocarcinoma cancer-types. ANNALS OF ONCOLOGY. (ADC) and squamous cell carcinoma 3. Duruisseaux M, Martínez-Cardús A, 29(10):2121-2128. I.F.: 13.930 (SQC). This project is being done in Calleja-Cervantes ME, Moran S, Castro de collaboration with Dr. Alcaraz at the UB, Moura M, Davalos V, Piñeyro D, Hospital Clinic.

327 AREA 5 ONCOLOGY AND HAEMATOLOGY

7. Nuciforo P, Pascual T, Cortés J, cancers from targeted therapy. 17. Teixidó C, Giménez-Capitán A, Molina-Vila Llombart-Cussac A, Fasani R, Paré L, Oliveira PROCEEDINGS OF THE NATIONAL MÁ, Peg V, Karachaliou N, Rodríguez-Capote M, Galvan P, Martínez N, Bermejo B, Vidal M, ACADEMY OF SCIENCES OF THE UNITED A, Castellví J, Rosell R. RNA Analysis as a Pernas S, López R, Muñoz M, Garau I, Manso STATES OF AMERICA. 115(11):E2594-E2603. Tool to Determine Clinically Relevant Gene L, Alarcón J, Martínez E, Rodrik-Outmezguine I.F.: 9.504 Fusions and Splice Variants. ARCHIVES OF V, Brase JC, Villagrasa P, Prat A, Holgado E. PATHOLOGY AND LABORATORY A predictive model of pathological 12. Valpione S, Carlino M, Mangana J, MEDICINE. 142(4):474-479. I.F.: 3.658 response based on tumor cellularity and Mooradian M, McArthur G, Schadendorf D, tumor-infiltrating lymphocytes (CelTIL) in Hauschild A, Menzies A, Arance A, Ascierto P, 18. García del Muro X, Maurel J, Martínez HER2-positive breast cancer treated with Di Giacomo A, de Rosa F, Larkin J, Park J, Trufero J, Lavernia J, López Pousa A, de las chemo-free dual HER2 blockade. ANNALS Goldinger S, Sullivan R, Xu W, Livingstone E, Peñas R, Cubedo R, Berros J, Casado Herráez OF ONCOLOGY. 29(1):170-177. I.F.: 13.930 Weichenthal M, Rai R, Gaba L, Long G, Lorigan A, de Juan A, Martín Broto J. Phase II trial of P. Rechallenge with BRAF-directed ifosfamide in combination with the VEGFR 8. Puig I, Tenbaum SP, Chicote I, Arqués O, treatment in metastatic melanoma: A inhibitor sorafenib in advanced soft tissue Martínez-Quintanilla J, Cuesta-Borrás E, multi-institutional retrospective study. sarcoma: a Spanish group for research on Ramírez L, Gonzalo P, Soto A, Aguilar S, EUROPEAN JOURNAL OF CANCER. sarcomas (GEIS) study. INVESTIGATIONAL Eguizabal C, Caratù G, Prat A, Argilés G, 91:116-124. I.F.: 7.191 NEW DRUGS. 36(3):468-475. I.F.: 3.502 Landolfi S, Casanovas O, Serra V, Villanueva A, Arroyo AG, Terracciano L, Nuciforo P, 13. Hamid O, Robert C, Ribas A, Hodi F, 19. Laurberg T, Tramm T, Nielsen T, Alsner J, Seoane J, Recio JA, Vivancos A, Dienstmann Walpole E, Daud A, Arance A, Brown E, Hoeller Nord S, Myhre S, Sørlie T, Leung S, Fan C, R, Tabernero J, Palmer HG. TET2 controls C, Mortier L, Schachter J, Long J, Ebbinghaus Perou C, Gelmon K, Overgaard J, Voduc D, chemoresistant slow-cycling cancer cell S, Ibrahim N, Butler M. Antitumour activity of Prat A, Cheang M. Intrinsic subtypes and survival and tumor recurrence. JOURNAL pembrolizumab in advanced mucosal benefit from postmastectomy OF CLINICAL INVESTIGATION. melanoma: a post-hoc analysis of radiotherapy in node-positive 128(9):3887-3905. I.F.: 13.251 KEYNOTE-001, 002, 006. BRITISH premenopausal breast cancer patients JOURNAL OF CANCER. 119(6):670-674. who received adjuvant chemotherapy 9. Martínez-Ricarte F, Mayor R, I.F.: 5.922 -results from two independent Martínez-Sáez E, Rubio-Pérez C, Pineda E, randomized trials. ACTA ONCOLOGICA. Cordero E, Cicuéndez M, Poca MA, 14. Alonso V, Escudero P, Fernández-Martos 57(1):38-43. I.F.: 3.473 López-Bigas N, Ramon Y Cajal S, Vieito M, C, Salud A, Méndez M, Gallego J, Rodriguez Carles J, Tabernero J, Vivancos A, Gallego S, JR, Martín-Richard M, Fernández-Plana J, 20. Maurel J, Sánchez-Cabús S, Laquente B, Graus F, Sahuquillo J, Seoane J. Molecular Manzano H, Méndez JC, Zanui M, Falcó E, Gaba L, Visa L, Fabregat J, Povés I, Roselló S, diagnosis of diffuse gliomas through Gil-Raga M, Rojo F, Cuatrecasas M, Feliu J, Díaz-Beveridge R, Martín-Richard M, sequencing of cell-free circulating tumour García-Albéniz X, Maurel J. Coexpression of Rodriguez J, Sabater L, Conill C, Cambray M, DNA from cerebrospinal fluid. CLINICAL p-IGF-1R and MMP-7 Modulates Reig A, Ayuso JR, Valls C, Ferrández A, Bombí CANCER RESEARCH. 24(12):2812-2819. Panitumumab and Cetuximab Efficacy in JA, Ginés A, García-Albéniz X, I.F.: 10.199 RAS Wild-Type Metastatic Colorectal Fernández-Cruz L. Outcomes after Cancer Patients. NEOPLASIA. neoadjuvant treatment with gemcitabine 10. Sharma P, Lopez-Tarruella S, 20(7):678-686. I.F.: 4.994 and erlotinib followed by García-Saenz J, Khan Q, Gomez H, Prat A, gemcitabine-erlotinib and radiotherapy for Moreno F, Jerez-Gilarranz Y, Barnadas A, 15. Mohr P, Ascierto P, Arance A, McArthur G, resectable pancreatic cancer (GEMCAD Picornell A, del Monte-Millan M, Hernaez A, Kaskel P, Shinde R, Stevinson K. 10-03 trial). CANCER CHEMOTHERAPY Gonzalez-Rivera M, Massarrah T, Real-world treatment patterns and AND PHARMACOLOGY. 82(6):935-943. Pelaez-Lorenzo B, Palomero M, del Val R, outcomes among metastatic cutaneous I.F.: 2.808 Cortes J, Fuentes-Rivera H, Morales D, melanoma patients treated with Marquez-Rodas I, Perou C, Lehn C, Wang Y, ipilimumab. JOURNAL OF THE EUROPEAN 21. Tuca, Albert; Gomez-Martinez, Monica; Klemp J, Mammen J, Wagner J, Amin A, O'Dea ACADEMY OF DERMATOLOGY AND Prat, Aleix. Predictive model of complexity A, Heldstab J, Jensen R, Kimler B, Godwin A, VENEREOLOGY. 32(6):962-971. I.F.: 4.287 in early palliative care: a cohort of Martín M. Pathological Response and advanced cancer patients (PALCOM Survival in Triple-Negative Breast Cancer 16. Ruiz-Patiño A, Castro CD, Ricaurte LM, study). SUPPORTIVE CARE IN CANCER. Following Neoadjuvant Carboplatin plus Cardona AF, Rojas L, Zatarain-Barrón ZL, 26(1):241-249. I.F.: 2.676 Docetaxel. CLINICAL CANCER RESEARCH. Wills B, Reguart N, Carranza H, Vargas C, 24(23):5820-5829. I.F.: 10.199 Otero J, Corrales L, Martín C, Archila P, 22. Barril S, Alonso A, Rodríguez-Portal JA, Rodriguez J, Avila J, Bravo M, Pino LE, Rosell Viladot M, Giner J, Aparicio F, Romero-Ortiz A, 11. Floros K, Lochmann T, Hu B, Monterrubio R, Arrieta O, Latin-American Consortium for Acosta O, Castillo D. Palliative Care in C, Hughes M, Wells J, Morales C, Ghotra M, the Investigation of Lung Cancer (CLICaP). Diffuse Interstitial Lund Disease: Results of Costa C, Souers A, Boikos S, Leverson J, Tan EGFR Amplification and Sensitizing a Spanish Survey. ARCHIVOS DE M, Serra V, Koblinski J, Arribas J, Prat A, Paré L, Mutations Correlate with Survival in Lung BRONCONEUMOLOGIA. 54(3):123-127. Miller T, Dozmorov M, Harada H, Windle B, Adenocarcinoma Patients Treated with I.F.: 2.633 Scaltriti M, Faber A. Coamplification of Erlotinib (MutP-CLICaP). TARGETED miR-4728 protects HER2-amplified breast ONCOLOGY. 13(5):621-629. I.F.: 3.907 23. Carles J, Castellano D, Méndez-Vidal M,

328 TRANSLATIONAL GENOMICS AND TARGETED THERAPEUTICS IN SOLID TUMORS 5.13

Mellado B, Saez M, González del Alba A, A, Brasó-Maristany F, Gomis RR, Perou CM, Clinical Guidelines / I.F.: 21.106 Perez-Gracia J, Jimenez J, Suárez C, Muñoz M, Prat A. Clinical implications of the Sepúlveda J, Manneh R, Porras I, López C, non-luminal intrinsic subtypes in hormone 1. Cardoso F, Senkus E, Costa A, Morales-Barrera R, Arranz J. Circulating receptor-positive breast cancer. CANCER Papadopoulos E, Aapro M, André F, Harbeck Tumor Cells as a Biomarker of Survival and TREATMENT REVIEWS. 67:63-70. I.F.: 8.122 N, Aguilar Lopez B, Barrios CH, Bergh J, Response to Radium-223 Therapy: Biganzoli L, Boers-Doets CB, Cardoso MJ, Experience in a Cohort of Patients With 4. Teixidó C, Vilariño N, Reyes R, Reguart N. Carey LA, Cortés J, Curigliano G, Diéras V, El Metastatic Castration-Resistant Prostate PD-L1 expression testing in non-small cell Saghir NS, Eniu A, Fallowﬁeld L, Francis PA, Cancer. CLINICAL GENITOURINARY lung cancer. THERAPEUTIC ADVANCES IN Gelmon K, Johnston SRD, Kaufman B, CANCER. 16(6):e1133-e1139. I.F.: 2.539 MEDICAL ONCOLOGY. 10:1-17. I.F.: 6.238 Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch- 24. Balaña C, Estival A, Teruel I, Hardy-Werbin 5. Remon J, Mezquita L, Corral J, Vilariño N, Shimon S, Penault-Llorca F, Prat A, Rugo HS, M, Sepulveda J, Pineda E, Martinez-García M, Reguart N. Immune-related adverse events Sledge GW, Spence D, Thomssen C, Vorobiof Gallego O, Luque R, Gil-Gil M, Mesia C, Del with immune checkpoint inhibitors in DA, Xu B, Norton L, Winer EP. 4th ESO-ESMO Barco S, Herrero A, Berrocal A, Perez-Segura thoracic malignancies: Focusing on International Consensus Guidelines for P, De Las Penas R, Marruecos J, Fuentes R, non-small cell lung cancer patients. Advanced Breast Cancer (ABC 4). ANNALS Reynes G, Velarde JM, Cardona A, Verger E, JOURNAL OF THORACIC DISEASE. 10(suppl OF ONCOLOGY. 29(8):1634-1657. I.F.: 13.930 Panciroli C, Villà S. Delay in starting 13):S1516-S1533. I.F.: 1.804 radiotherapy due to neoadjuvant therapy 2. Balañá C, Alonso M, Hernandez A, does not worsen survival in unresected Perez-Segura P, Pineda E, Ramos A, Sanchez glioblastoma patients. CLINICAL AND Letters / I.F.: 5.088 A, Teixidor P, Verger E, Benavides M. SEOM TRANSLATIONAL ONCOLOGY. clinical guidelines for anaplastic gliomas 20(12):1529-1537. I.F.: 2.392 1. Balaña C, Estival A, Pineda E. Bevacizumab (2017). CLINICAL AND TRANSLATIONAL rechallenge in glioblastoma patients with ONCOLOGY. 20(1):16-21. I.F.: 2.392 25. Carles J, Méndez MJ, Pinto Á, Sáez MI, initial response to bevacizumab who later Arranz JA, Maroto P, López-Criado P, Mellado progress off therapy.JOURNAL OF 3. Berrocal A, Arance A, Castellon V, de la B, Donas JG, Hernando S, León L, Del Alba NEURO-ONCOLOGY. 139(3):779-780. Cruz L, Espinosa E, Cao M, Larriba J, AG, Laínez N, Esteban E, Reynés G, I.F.: 3.060 Márquez-Rodas I, Soria A, Algarra S. SEOM Pérez-Gracia JL, Germà JR, López-Brea M, clinical guideline for the management of Pérez-Valderrama B, Moretones C, 2. Rody A, Ettl J, Marmé F, Prat A. Molecular malignant melanoma (2017). CLINICAL Castellano D. Radium-223 international Tumor Boards. BREAST CARE. 13(2):141-143. AND TRANSLATIONAL ONCOLOGY. early access program: results from the I.F.: 2.028 20(1):69-74. I.F.: 2.392 Spanish subset. FUTURE ONCOLOGY. 14(1):41-50. I.F.: 2.369 4. Cassinello J, Arranz J, Piulats J, Sánchez A, Case Reports / I.F.: 10.302 Pérez-Valderrama B, Mellado B, Climent M, 26. Buxó E, Sosa A, Reig O, Victoria I, Olmos D, Carles J, Lázaro M. SEOM clinical Caballero M, Grau JJ, Garcia-Morillo M. 1. Xipell M, Victoria I, Hoffmann V, Villarreal J, guidelines for the treatment of metastatic Intravenous 5-Fluorouracil in Patients With García-Herrera A, Reig O, Rodas L, Blasco M, prostate cancer (2017). CLINICAL AND Advanced Squamous Cell Carcinoma: A Poch E, Mellado B, Quintana L. Acute TRANSLATIONAL ONCOLOGY. 20(1):57-68. Retrospective Study. ANNALS OF tubulointerstitial nephritis associated with I.F.: 2.392 OTOLOGY, RHINOLOGY AND atezolizumab, an anti-programmed LARYNGOLOGY. 127(7):456-462. I.F.: 1.513 death-ligand 1 (pd-l1) antibody therapy. ONCOIMMUNOLOGY. 7(7):e1445952. I.F.: 5.503 GRANTS FOR RESEARCH IN PROGRESS Review / I.F.: 32.408 2. Fernández-Sartorio C, Boada A, Maurel J. Estudio observacional para 1. Remon J, Hendriks L, Cabrera C, Reguart N, Chavez-Bourgeois MM, Ruiz Ares GJ, Arance evaluar la estrategia de uso de las terapias Besse B. Immunotherapy for AM, Manzano JL, García-Herrera A, Carrera C. dirigidas, en cáncer de colon metastásico. oncogenic-driven advanced non-small cell Aged-looking skin and encorafenib: an Sponsored by: Instituto de Salud Carlos III lung cancers: Is the time ripe for a change? adverse event of BRAF inhibitors. (ISCIII). PI13/01728 CANCER TREATMENT REVIEWS. 71:47-58. MELANOMA RESEARCH. 28(2):160-162. Duration: 01/01/2014-30/06/2019 I.F.: 8.122 I.F.: 3.135 Mellado B. Caracterización molecular del 2. Remon J, Vilariño N, Reguart N. Immune 3. Cortes-Mateus, Karen S.; Holub, Katarzyna; cáncer de próstata en función de la checkpoint inhibitors in non-small cell lung Racca, Fabricio; Jose Grau, Juan; Capdevila, expresión de TMPRSS2-ERG: cancer (NSCLC): Approaches on special Jaume. Concurrent palliative external implicaciones terapéuticas. subgroups and unresolved burning radiotherapy with sorafenib or doxorubicin Sponsored by: Instituto Carlos III (ISCIII). questions. CANCER TREATMENT for bulky differentiated thyroid carcinoma: PI15/00676 REVIEWS. 64:21-29. I.F.: 8.122 A case report. ONCOLOGY LETTERS. Duration: 01/01/2016-21/05/2019 16(3):4085-4089. I.F.: 1.664 3. Cejalvo JM, Pascual T, Fernández-Martínez

329 AREA 5 ONCOLOGY AND HAEMATOLOGY

Pineda E. Study of the molecular Prat A. Financial Support for the Breast mechanisms involved in primary Cancer Intergroup Correlative Science (glioblastoma) and secondary Studies. (metastasis) brain tumors to identify novel Sponsored by: Regents of the University of therapeutic targets and anti-cancer Michigan. BCRF_2015 agents, biomarkers to select treatments Duration: 01/10/2014-30/09/2019 and novel non-invasive methods for molecular diagnos. Reguart N. Validación de un ensayo Sponsored by: Fundación Científica multiplex personalizado para la detección Asociación Española Contra el Cancer de oncogenes y firmas inmunes en Cáncer (AECC). GCTRA16015SEDA de Pulmón (CP): estudio observacional, Duration: 15/11/2017-14/11/2022 prospectivo y multicéntrico. Sponsored by: Instituto de Salud Carlos III Prat A. Translational Genomics and (ISCIII). PI16/00890 Targeted Therapeutics in Solid Tumors. Duration: 01/01/2017-31/12/2019 Sponsored by: Generalitat de Catalunya. AGAUR_SGR17_01554 Duration: 01/01/2017-31/12/2020 DOCTORAL THESIS Prat A. Identificación y validación de una firma genómica predictiva de beneficio a Prat A. Caracterización de la expresión de fármacos anti-PD1 en múltiples tumores ácido ribonucleico mensajero en distintos sólidos. subtipos histológicos de carcinoma Sponsored by: Fundación Sociedad Española basocelular. de Oncología Médica (SEOM_16) PhD student: Patricia Bassas Freixas Duration: 01/11/2016-31/10/2019

Prat A. Identiﬁcació d'alteracions moleculars accionables durant la progressió metastàsica del càncer de mama luminal. Sponsored by: Fundación Sociedad Española de Oncología Médica (SEOM_14). PROYECTOS16_01 Duration: 01/11/2016-31/10/2019

Prat A. Estudio prospectivo exploratorio para la determinación de DNA circulante tumoral (ctDNA) en muestras sanguíneas de pacientes tratadas por cáncer de mama en seguimiento y sin evidencia de recidiva: ESTUDIO B-CRONOS. Sponsored by: Fundación de Investigación Médica Mútua Madrileña (FundMM). AP168952018 Duration: 06/07/2018-05/07/2021

Prat A. Estudio del fenotipo HER2-enriquecido en cáncer de mama HER2-negativo. Sponsored by: Fundación Astrazeneca. JOVINV17_003 Duration: 12/12/2017-31/12/2018

Prat A. Doble bloque HER2 sin quimioterapia en cáncer de mama precoz HER2+. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI16/00904 Duration: 01/01/2017-31/12/2019

330 TRANSLATIONAL GENOMICS AND TARGETED THERAPEUTICS IN SOLID TUMORS 5.13

331 ANNUAL SCIENTIFIC REPORT 2018

TRANSVERSAL AREA

TRANSVERSAL RESEARCH GROUPS T

TRANSVERSAL RESEARCH GROUPS

T.1 Primary healthcare transversal research group 334 Antoni Sisó

T.2 Research in nursing 337 Adelaida Zabalegui

T.3 Clinical pharmacology 339 Gonzalo Calvo

333 TRANSVERSAL AREA TRANSVERSAL RESEARCH GROUPS

Primary healthcare T.1 transversal research group

Marina Rovira (HCB) Antoni Salvà (CAPSBE) LOCATION Núria Sánchez (CAPSBE) EAP Les Corts Mireia Sans (CAPSBE) EAP Comte Borrell Elisenda Sant (CAPSBE) EAP Casanova Ethel Sequeira (CAPSBE) Josep Miquel Sotoca (HCB) Josep Maria Vilaseca (CAPSBE)

WEB PRE-DOCTORAL RESEARCHERS www.clinicbarcelona.org/en/ TEAM LEADER Maria Antonieta Also (CAPSBE) idibaps/research-areas Antoni Sisó Almirall (EAP Les Corts) Laia Cayuelas (CAPSBE) T. 93 227 99 24 Laia Gené (CAPSBE) [email protected] Alba Herrero (CAPSBE) Enma Marianela Morales (AP-Consorci Hospital Terrassa) RESEARCHERS Sonia Moreno (PAMEM) Mª Carmen Alvira (CAPSBE) Aina Perelló (UB) August Anguita (CAPSBE) KEYWORDS Jaume Benavent (CAPSBE) TECHNICIANS 1. Primary healthcare Lluisa Benito (CAPSBE) Belchin Kostov (IDIBAPS) 2. Chronic diseases Esther Blat (CAPSBE) Cardiovascular diseases 3. Marta Catalán (CAPSBE) COLLABORATORS & cardiovascular risk factors Cristina Colungo (CAPSBE) Pilar Brito (HCB) 4. Health technology assessment Noemí García (CAPSBE) Diana Alicia Diaz (IDIBAPS) 5. Autoimmune & rheumatic diseases Imma Garrell (CAPSBE) Imma Grau (HCB) Joan Gené (CAPSBE) Manel Ramos-Casals (HCB) Núria Gimferrer (CAPSBE) Lluís González (CAPSBE) Susana González (CAPSBE) Carmen Herranz (CAPSBE) STRATEGIC OBJECTIVES Original publications Zoe Herreras (CAPSBE) from 2016 to 2018 Mireia López (CAPSBE) Primary care is the point of patient entry Angela Martínez (CAPSBE) to the healthcare system. YEAR I.F. TOTAL Q1 Q2 Ignacio Menacho (CAPSBE) In the research context, the multidisciplinary and 2016 56.83 18 7 4 Pilar Navarrete (CAPSBE) transverse nature of the activities of the primary Marta Navarro (CAPSBE) care professional favours a biological, 2017 42.58 16 5 6 Jacinto Ortiz (CAPSBE) psychological and social approach to the 2018 19.18 8 1 4 Anna Pereira (CAPSBE) patients and their illnesses, in both the consulting Montserrat Pinyol (CAPSBE) office and in the home. Silvia Roura (CAPSBE) TEAM Antoni Sisó Almirall

334 PRIMARY HEALTHCARE TRANSVERSAL RESEARCH GROUP T.1

MAIN LINES OF RESEARCH 2. Flores-Chávez A, Kostov B, Solans R, Fraile 8. Blánquez Moreno C., Colungo Francia C., G, Maure B, Feijoo-Massó C, Rascón FJ, Alvira Balada M., Kostov B., González-de Paz Main outcomes: Pérez-Alvarez R, Zamora-Pasadas M, L., Sisó-Almirall A. Effectiveness of an - Conduction of population-based studies García-Pérez A, Lopez-Dupla M, educational program for respiratory (both descriptive and evaluating Duarte-Millán MÁ, Ripoll M, Fonseca-Aizpuru rehabilitation of Chronic Obstructive interventions and follow-up), in an E, Guisado-Vasco P, Pinilla B, de-la-Red G, Pulmonary Disease patients in Primary accessible and well defined population of Chamorro AJ, Morcillo C, Fanlo P, Care in improving the quality of life, subjects, taking advantage of the Soto-Cárdenas MJ, Retamozo S, symptoms, and clinical risk. ATENCION computer-based filing of clinical data. Ramos-Casals M, Brito-Zerón P, GEAS-SS PRIMARIA. 50(9):539-546. I.F.: 1.148 - Conduction of research into healthcare SEMI Registry. Severe, life-threatening results or outcomes. phenotype of primary Sjögren's syndrome: - Description of the natural history of the clinical characterisation and outcomes in Editorial / I.F.: 3.464 patient and disease from a biological, 1580 patients (GEAS-SS Registry). psychological and social perspective. CLINICAL AND EXPERIMENTAL 1. Vilaseca JM, Sans M. Alma Ata 40th - Conduction of studies of risk factors and RHEUMATOLOGY. 36 Suppl 112(3):121-129. anniversary: Milestones of primary health preventive medicine. I.F.: 3.201 care. MEDICINA CLINICA. 151(11):441-443. - Analysis of the morbidity and mortality of I.F.: 1.168 the most prevalent disorders. 3. Gené Huguet L., Navarro González M., - Development of collaborative studies with Kostov B., Ortega Carmona M., Colungo 2. Gené Badia J, Gallo de Puelles P, de the administration and research entities or Francia C., Carpallo Nieto M., Hervás Docón A., Lecuona I. Big data y seguridad de la groups allowing the implementation of Vilarrasa Sauquet R., García Prado R., información. ATENCION PRIMARIA. transversal research. Sisó-Almirall A. Pre Frail 80: Multifactorial 50(1):3-5. I.F.: 1.148 Intervention to Prevent Progression of The main lines of research include: Pre-Frailty to Frailty in The Elderly. THE 3. Badia JG, Zurro AM. Julian Tudor Hart - Healthcare continuity and management of JOURNAL OF NUTRITION, HEALTH & AGING. (1927-2018): indisputable world leader in chronic diseases. 22(10):1266-1274. I.F.: 2.868 primary care. ATENCION PRIMARIA. - Use of healthcare services. 50(7):385-386. I.F.: 1.148 - The fragility – geriatrics – dependency – 4. Peralta-Gallego L, Gené-Badia J, Gallo P. home care axis. Effects of undocumented immigrants - Use of medicines. exclusion from health care coverage in Consortium Publications / I.F.: 6.462 - Primary care and autoimmunity. Spain. HEALTH POLICY. 122(11):1155-1160. - Atherogenesis, risk factors and I.F.: 2.293 1. Bruyndonckx R, Hens N, Verheij TJ, Aerts M, cardiovascular diseases. Ieven M, Butler CC, Little P, Goossens H, - Chronic pain. 5. Brito-Zerón P., Acar-Denizli N., Sisó-Almirall Coenen S, GRACE project group. - Mental health, smoking and other addictions. A., Bosch X., Hernández F., Vilanova S., Villalta Development of a prediction tool for - Respiratory diseases. M., Kostov B., Paradela M., Sanchez M., patients presenting with acute cough in - Digestive and liver diseases. Ramírez J., Muxí A., Berruezo A., primary care: a prognostic study spanning - HIV infection-AIDS and other infectious Galceran-Chaves C., Xaubet A., Agustí C., six European countries. BRITISH JOURNAL diseases. Sellarés J., Ramos-Casals M. The Burden of OF GENERAL PRACTICE. - 2.0. Health. Comorbidity and Complexity in 68(670):e342-e350. I.F.: 3.261 Sarcoidosis: Impact of Associated Chronic Diseases. LUNG. 196(2):239-248. I.F.: 2.101 2. Brito-Zerón P, Acar-Denizli N, Ng WF, Zeher M, Rasmussen A, Mandl T, Seror R, Li X, Baldini PUBLICATIONS 6. Barberan-Garcia A., Gimeno-Santos E., C, Gottenberg JE, Danda D, Quartuccio L, Blanco I., Cano I., Martínez-Pallí G., Burgos F., Priori R, Hernandez-Molina G, Armagan B, Originals / I.F.: 19.176 Miralles F., Coca M., Murillo S., Sanz M., Steblin Kruize AA, Kwok SK, Kvarnström M, A., Ubré M., Benavent J., Vidal J., Sitges M., Praprotnik S, Sène D, Bartoloni E, Solans R, 1. Martinez-Perez A; Roure Díez S; Roca J. Protocol for regional Rischmueller M, Suzuki Y, Isenberg DA, Valim Belhasen-Garcia M; Torrús-Tendero D; implementation of collaborative V, Wiland P, Nordmark G, Fraile G, Bootsma H, Perez-Arellano JL; Cabezas T; Soler C; self-management services to promote Nakamura T, Giacomelli R, Devauchelle Díaz-Menéndez M; Navarro M; Treviño B; physical activity. BMC HEALTH SERVICES -Pensec V, Knopf A, Bombardieri M, Trevisani Salvador-Vélez F; Soil-Transmitted RESEARCH. 18(1):560. I.F.: 1.843 VF, Hammenfors D, Pasoto SG, Retamozo S, Helminths’ Study Group of the Spanish Gheita TA, Atzeni F, Morel J, Vollenveider C, Society of Tropical Medicine and 7. Farré M, Kostov B, Haro JM, Cabrera E, Horvath IF, Sivils KL, Olsson P, De Vita S, International Health (SEMTSI). Risco E, Alvira M, Miguel S, Zabalegui A. Costs Sánchez-Guerrero J, Kilic L, Wahren- Management of severe strongyloidiasis and Burden Associated with Loss of Labor Herlenius M, Mariette X, Ramos-Casals M, attended at reference centers in Spain. Productivity in Informal Caregivers of Sjögren Big Data Consortium. How PLOS NEGLECTED TROPICAL DISEASES. People with Dementia: Results from Spain. immunological profile drives clinical 12(2):e0006272-e0006272. I.F.: 4.367 JOURNAL OF OCCUPATIONAL AND phenotype of primary Sjögren's syndrome ENVIRONMENTAL MEDICINE. 60(5):449-456. at diagnosis: analysis of 10,500 patients I.F.: 1.355 (Sjögren Big Data Project). CLINICAL AND

335 TRANSVERSAL AREA TRANSVERSAL RESEARCH GROUPS

EXPERIMENTAL RHEUMATOLOGY. 36(3):102-112. I.F.: 3.201

GRANTS FOR RESEARCH IN PROGRESS

Herranz C. Avaluació d’una Intervenció Comunitària per disminuir la percepció de soledat en les persones majors. Sponsored by: Consorci d’Atenció Primària de Salut Barcelona Esquerra (CAPSBE) Duration: 01/06/2017-01/06/2018

Sequeira E. CRIB-MI: cribado en pacientes inmigrantes mediante Herramienta informática adaptada a la historia Clínica en Atención Primaria. Sponsored by: Generalitat de Catalunya (PERIS). Duration: 01/01/2017-31/12/2019

Sisó A. Validez de un método de monitorización de la Presión Arterial de 1 hora frente a los métodos habituales: estudio de evaluación de tecnología diagnóstica . Sponsored by: Instituto de Salud Carlos III (ISCIII). Duration: 01/01/2017-31/12/2019

DOCTORAL THESES

Sisó A, Ramos M. Dolor crónico generalizado y Fibromialgia: estudio de pruebas objetivas, comorbilidad, complejidad y gasto sanitario. PhD student: Enma Marianela Morales Espinoza

336 RESEARCH IN NURSING T.2

Research T.2 in nursing

TEAM LEADER focus groups, clinical assessments and Adelaida Zabalegui (HCB) analysis of new interventions in different LOCATION T. 93 227 54 00 (Ext.: 3055) nursing settings (homecare, institutional long HCB building [email protected] term and hospital.

Innovation: POST-DOCTORAL RESEARCHERS As an instrument to improve the efficiency and Ester Risco (HCB) quality of care processes involving cardiac and respiratory diseases, as well as other KEYWORDS PRE-DOCTORAL RESEARCHERS areas of clinical practice. Implementation of 1. Older people Cindy Esther Frías (HCB) Dedicated Educational Units. 2. Chronic-care / Long-term care Marta García (HCB) 3. Dementia Sara Pedragosa (HCB) Professional Competencies: 4. Best practice Sonia Sevilla (HCB) To determine how hospital nurse staffing, skill 5. Advance nursing practice mix, educational composition, and quality of NURSING STAFF the nurse work environment impact on Ana Alonso (HCB) different hospital outcomes such as mortality, Sheila Baena (HCB) failure to rescue, quality of care, and patient Lourdes Corominas (HCB) satisfaction. These ﬁndings will allow Marta Farré (HCB) researchers to reﬁne existing nurse workforce. Marta García (HCB) Original publications Miguel Ángel Giménez (HCB) Advanced Practice: from 2016 to 2018 Dolors Robles (HCB) To describe and analyse including the YEAR I.F. TOTAL Q1 Q2 Victoria Ruiz (HCB) development of a new instrument to measure M. Carmen Sánchez (HCB) the different dimentions at APNs, the advance 2016 16.96 9 1 3 practice role and competences in nursing. 2017 20.94 6 4 2 COLLABORATORS

2018 24.51 12 27 Montserrat Amigó (HCB)

PUBLICATIONS

STRATEGIC OBJECTIVES Originals / I.F.: 24.511 TEAM INVOLVED IN AGAUR_SGR17: 01114 Research in nursing is essential for 1. Costa, Nadege; Wuebker, Ansgar; De responding to the healing demands of the Mauleon, Adelaide; Zwakhalen, Sandra M. G.; current healthcare system. Its complexity in Challis, David; Leino-Kilpi, Helena; Hallberg, the hospital setting is derived from the Ingalill R.; Stephan, Astrid; Zabalegui, Adelaida; associated increase in patient severity upon Saks, Kai; Molinier, Laurent; Wimo, Anders; admission, the reduction in hospital stay, the Vellas, Bruno; Sauerland, Dirk; Binot, Ingrid; incorporation of new technologies, the aging Soto, Maria E. RightTimePlaceCare of the population, patient requests for Consortium. Costs of Care of Agitation information, social change, and the global Associated With Dementia in 8 European crisis. Countries: Results From the RightTimePlaceCare Study. JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION. 19(1):95.e1-95.e10. I.F.: 5.325 MAIN LINES OF RESEARCH 2. Renom-Guiteras, Anna; Thurmann, Petra A.; Empowerment: Miralles, Ramon; Klaassen-Mielke, Renate; The main target is to increase the patient Thiem, Ulrich; Stephan, Astrid; Bleijlevens, empowerment and develop assessment tools Michel H. C.; Jolley, David; Leino-Kilpi, Helena; for educational interventions to improve their Hallberg, Ingalill Rahm; Saks, Kai; Soto-Martin, bio-physiological, functional and social Maria; Zabalegui, Adelaida; Meyer, Gabriele; wellbeing. RightTimePlaceCare Consortium. Potentially inappropriate medication among people Chronic & aging care: with dementia in eight European countries. Dementia care: The main target is to improve AGE AND AGEING. 47(1):68-74. I.F.: 4.013 health service for people with dementia through careful development of best practice 3. Römhild J; Fleischer S; Meyer G; Stephan A; strategies using various data collection Zwakhalen S; Leino-Kilpi H; Zabalegui A; Saks methods including extensive literature review, K; Soto-Martin M; Sutcliffe C; Rahm Hallberg I;

337 TRANSVERSAL AREA TRANSVERSAL RESEARCH GROUPS

Berg A; RightTimePlaceCare Consortium. JOURNAL OF OLDER PEOPLE NURSING. Inter-rater agreement of the Quality of 13(3):e12193. I.F.: 1.333 Life-Alzheimer's Disease (QoL-AD) self-rating and proxy rating scale: 10. Sevilla Guerra, Sonia; Miranda Salmeron, secondary analysis of Josep; Zabalegui, Adelaida. Proﬁle of RightTimePlaceCare data. HEALTH AND advanced nursing practice in Spain: A QUALITY OF LIFE OUTCOMES. 16(1):131-131. cross-sectional study. NURSING AND I.F.: 2.278 HEALTH SCIENCES. 20(1):99-106. I.F.: 1.237

4. Martina Pellice Arino, Olga Rodriguez, 11. Cano-Plans S, Lacueva-Pérez L, Cabrera Isabel Fortes, Silvia Valls, Miguel Ángel E, Zabalegui A. Knowledge expectations of Giménez Lejara, Juan Ambrosioni, Jose orthopaedic patients. INTERNATIONAL Antonio Martinez, Alejandro Soriano, Elisa De JOURNAL OF NURSING PRACTICE. Lazzari, Ana Del Rio. Reduction of Catheter 24(3):e12639. I.F.: 1.142 Related Bloodstream Infections (CRBI) Rates After Implementation of 2% 12. Sevilla Guerra, Sonia; Risco Vilarasau, Gluconate- Chlorhexidine-Impregnated Ester; Galisteo Gimenez, Maria; Zabalegui, Wipes (CHG Wipes) Daily Bathing in a Adelaida. Spanish version of the modiﬁed Cardiovascular Surgical Intensive Care Advanced Practice Role Delineation tool, Unit (CSICU). AMERICAN JOURNAL OF adaptation and psychometric properties. INFECTION CONTROL. 46(6):45. I.F.: 1.929 INTERNATIONAL JOURNAL OF NURSING PRACTICE. 24(3):e12635. I.F.: 1.142 5. Lethin C., Leino-Kilpi H., Bleijlevens M., Stephan A., Martin M., Nilsson K., Nilsson C., Zabalegui A., Karlsson S. Predicting caregiver burden in informal caregivers GRANTS FOR RESEARCH IN PROGRESS caring for persons with dementia living at home – A follow-up cohort study. Zabalegui A. Avaluació d’una intervenció DEMENTIA. :1471301218782502. I.F.: 1.671 innovadora informativa, formativa i de suport social (INFOSA-DEM) als cuidadors 6. Risco E., Cabrera E., Alvira M., Farré M., informals de persones amb demència al Miguel S., Zabalegui A. Risk factors related domicili. to the admission of people with dementia Sponsored: Fundació La Marató de TV3 into a long-term care institution in Spain: an (20144410) explorative study. AGEING AND SOCIETY. Duration: 12/05/2015-11/05/2018 38(1):192-211. I.F.: 1.620 Zabalegui A. Cuidado de personas mayores 7. Charalambous A, Papastavrou E, con alteración cognitiva o demencia Valkeapää K, Zabalegui A, Ingadóttir B, hospitalizadas en unidades de Lemonidou C, Fatkulina N, Jouko K, traumatologia. Leino-Kilpi H. Content of Orthopedic Patient Sponsored by: Instituto de Salud Carlos III Education Provided by Nurses in Seven (ISCIII). PI17/01049 European Countries. CLINICAL NURSING Duration: 01/01/2018-31/12/2020 RESEARCH. 27(7):770-789. I.F.: 1.466

8. Farré M, Kostov B, Haro JM, Cabrera E, Risco E, Alvira M, Miguel S, Zabalegui A. Costs DOCTORAL THESES and Burden Associated with Loss of Labor Productivity in Informal Caregivers of Zabalegui A. The implementation of People with Dementia: Results from Spain. advanced practice nursing in catalonia. JOURNAL OF OCCUPATIONAL AND PhD student: Sonia Sevilla Guerra ENVIRONMENTAL MEDICINE. 60(5):449-456. I.F.: 1.355 Zabalegui A. L’evolució de la professió infermera a l’Hospital Clínic de Barcelona. 9. Copanitsanou P., Sourtzi P., Cano S., Una Investigació Històrica (1906-2018). Cabrera E., Charalambous A., Katajisto J., PhD student: Montse Venturas Nieto Leino-Kilpi H., Papastavrou E., Valkeapää K., Zabalegui A., Lemonidou C. Empowering education of arthroplasty patients' signiﬁcant others in three Southern European countries. INTERNATIONAL

338 CLINICAL PHARMACOLOGY T.3

Clinical T.3 pharmacology

TEAM LEADER - Statistical support of clinical research: Gonzalo Calvo Rojas (HCB) Statistics and data management are basic LOCATION T. 93 227 93 28 aspects of clinical research. We provide Rosselló 138 [email protected] these tools to the investigators of our (rooms 12, 20, 21, 25) institution.

Mallorca 183 RESEARCHERS (rooms 3, 10, 78, 86, 89, 90, 91) - Pharmacovigilance and Joan Albert Arnaiz (HCB) pharmacoepidemiology: We also provide support to observational COLLABORATORS studies with the aim to improve the safety Ferran Torres (HCB) of drug use in our institution. Joaquín Sáez-Peñataro (HCB) KEYWORDS Andrea Scalise (HCB) - Pharmacogenetics and 1. Clinical trials, design Juan José Aragonés (FCRB) pharmacogenomics: and methodology Alexandre Bernalte (FCRB) These are important tools to improve the 2. Ethics in clinical research Georgina Casanovas (FCRB) efficient use of drugs in the context of the 3. Drug regulation Ana Cruceta (FCRB) personalized medicine. 4. Pharmacoepidemiology Gemma Domenech (IDIBAPS) 5. Pharmacovigilance Juan Ferrero (FCRB) David García (FCRB) Judit Pich (FCRB) PUBLICATIONS Jose Ríos (IDIBAPS) Sandra Serrano (IDIBAPS) Originals / I.F.: 14.624 Sara Varea (FCRB) Original publications from 2016 to 2018 1. Leal L., Guardo A., Morón-López S., Salgado M., Mothe B., Heirman C., Pannus P., Vanham YEAR I.F. TOTAL Q1 Q2 G., van den Ham H., Gruters R., Andeweg A., STRATEGIC OBJECTIVES 2016 35.37 5 4 1 Van Meirvenne S., Pich J., Arnaiz J., Gatell J., Brander C., Thielemans K., Martínez-Picado 2017 21.75 6 5 1 1. We provide support of all technical and J., Plana M., García F. Phase I clinical trial 2018 14.62 4 13 administrative aspects related to of an intranodally administered randomized clinical trials carried out in the mRNA-based therapeutic vaccine Institution. against HIV-1 infection. AIDS. 32(17):2533-2545. I.F.: 4.914 2. We provide support for the conduction of TEAM INVOLVED IN academic-driven clinical trials. 2. Tió E, Gaig C, Giner-Soriano M, Romero O, SCReN Jurado MJ, Sansa G, Pujol M, Sans O, ECRIN 3. We also offer support activities in Álvarez-Guerrico I, Caballol N, Jimenez M, AGAUR_SGR14 pharmacovigilance and Becerra JL, Escartin A, Monasterio C, Molins pharmacoepidemiology. A, Bove A, Viña J, Iranzo A, Cambrodi R, Calvo G, Morros R, Santamaria J. The prevalence 4. Collaboration with the Pharmacology Unit of narcolepsy in Catalunya (Spain). of the UB in pharmacogenetic studies. JOURNAL OF SLEEP RESEARCH. 27(5):e12640. I.F.: 3.433

3. Gómez-Outes A., Terleira-Fernández A., MAIN LINES OF RESEARCH Lecumberri R., Suárez-Gea M., Calvo-Rojas G., Vargas-Castrillón E. Causes of Death in - Ethics in clinical research: Patients with Venous Thromboembolism Ethics methodological aspects of clinical Anticoagulated with Direct Oral research currently are of increasing Anticoagulants: A Systematic Review importance; based on the main ethical and Meta-Analysis. SEMINARS IN principals; respect for persons, THROMBOSIS AND HEMOSTASIS. beneﬁcence, non-maleﬁcence and justice. 44(4):377-387. I.F.: 3.345

- Clinical trials, design and methodology: 4. Pett SL, Amin J, Horban A, Andrade- Our aim is to give support to the Villanueva J, Losso M, Porteiro N, Madero JS, investigators of our institution in designing Belloso W, Tu E, Silk D, Kelleher A, Harrigan R, and performing academic clinical trials. Clark A, Sugiura W, Wolff M, Gill J, Gatell J, Clarke A, Ruxrungtham K, Prazuck T, Kaiser R, Woolley I, Alberto Arnaiz J, Cooper D,

339 TRANSVERSAL AREA TRANSVERSAL RESEARCH GROUPS

Rockstroh JK, Mallon P, Emery S, MARCH Calvo G. ORTHOpedic randomized clinical study group. Week 96 results of the trial with expanded bone marrow MSC and randomized, multicentre Maraviroc Switch bioceramics versus autograpt in long bone (MARCH) study. HIV MEDICINE. 19(1):65-71. nonUNIONs (ORTHOUNION). I.F.: 2.932 Sponsored by: European Clinical Research Infrastructure Network (ECRIN-ERIC). H2020-SC1 (733288) Duration: 01/01/2017-31/12/2021 GRANTS FOR RESEARCH IN PROGRESS

Arnaiz JA. Mecanismos moleculares implicados en la Farmacogenética del síndrome metabólico inducido por antipsicóticos. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI16/01222 Duration: 01/01/2017-31/12/2019

Arnaiz JA. Evaluating a combination of immune-based therapies to achieve a functional cure of HIV infection (HIVACAR). Sponsored by: European Clinical Research Infrastructure Network (ECRIN-ERIC). H2020-SC1 (GA n.731626) Duration: 01/01/2017-31/12/2021

Arnaiz JA. Simvastatin and Rifaximin as new therapy for patients with decompensated cirrhosis (LIVERHOPE). Sponsored by: European Clinical Research Infrastructure Network (ECRIN-ERIC). H2020-SC1 (GA n.731875) Duration: 01/01/2017-31/12/2021

Calvo G. Coste-efectividad y coste utilidad de una estrategia de transfusión de hematíes “liberal” vs. otra “restrictiva” en pacientes con infarto agudo de miocardio y anemia. Estudio REALITY. Sponsored by: Instituto de Salud Carlos III (ISCIII). PI15/00915 Duration: 01/01/2016-31/12/2018

Calvo G. Plataforma de unidades de investigación clínica y ensayos clínicos. Sponsored by: Instituto de Salud Carlos III (ISCIII). PT13/0002/0009 Duration: 01/01/2014-31/12/2018

Calvo G. Plataforma de unidades de investigación clínica y ensayos clínicos. Spanish Clinical Research Network (SCReN). Sponsored by: Instituto de Salud Carlos III (ISCIII). PT17/0017/0031 Duration: 01/01/2018-31/12/2020

340 CLINICAL PHARMACOLOGY T.3

341

342 TEAM AND GROUP LEADERS INDEX

Team and group leaders index

A G Alfredo Adán ...... 90 Juan Carlos García-Pagán ...... 177 Albert Parés ...... 186 Neus Agell ...... 324 Pere Gascón ...... 318 Carmen Peralta ...... 193 Alvar Agustí ...... 145 Xavier Gasull ...... 233 Albert Pol ...... 325 Jordi Alberch ...... 240 Pere Ginés ...... 166 Francesca Pons ...... 286 Antonio Alcaraz ...... 148 Ramon Gomis ...... 208 Antonio Postigo ...... 279 Francesc Artigas ...... 221 Jordi Gracia-Sancho ...... 179 Aleix Prat ...... 326 Eduard Gratacós ...... 156 Susana Puig ...... 295 B Josep Maria Grau ...... 236 Oriol Bachs ...... 321 Antoni Gual ...... 245 R Joan Albert Barberà ...... 133 Núria Guañabens ...... 186 Ignacio Revuelta ...... 115 Miquel Bernardo ...... 244 Eduard Guasch ...... 106 Antonia Ribes ...... 203 Joan Bladé ...... Isabel Blanco ...... 134 H S Josep Brugada ...... 104 Felicia A. Hanzu ...... 209 Manel Sabaté ...... 96 Jordi Bruix ...... 172 Raquel Sánchez del Valle ...... 272 I Maria Victoria Sánchez-Vives ...... 260 C Alejandro Iranzo ...... 232 Pau Sancho-Bru ...... 168 Gonzalo Calvo ...... 339 Coral Sanfeliu ...... 222 Elías Campo ...... 278 J Raimon Sanmartí ...... 58 Antoni Castells ...... 197 Wladimiro Jiménez ...... 168 Pere Santamaria ...... 209 Sergi Castellví-Bel ...... 198 Carme Junqué ...... 257 Josep Saura ...... 222 Joseﬁna Castro-Fornieles ...... 245 Antoni Sisó ...... 334 L Francisco Cervantes ...... 302 Marta Sitges ...... 107 Ricard Cervera ...... 60 Josep Maria Llovet ...... 173 Alex Soriano ...... 68 Ángel Chamorro ...... 225 Sara Llufriu ...... 265 Gisela Sugranyes ...... 246 Maria Cinta Cid ...... 61 Armando López-Guillermo ...... 303 Marc Claret ...... 208 Francisco Lozano ...... 76 T Joan Clària ...... 167 Antoni Torres ...... 127 Daniel Closa ...... 88 M Ramon Trullàs ...... 270 Dolors Colomer ...... 310 Josep Mallolas ...... 67 U Albert Compte ...... 261 Maria Josep Martí ...... 228 Miriam Cuatrecasas ...... 279 Jose Ignacio Martín-Subero ...... 280 Álvaro Urbano-Ispizua ...... 300 María Ángeles Martínez-Zamora ...... 154 D Guadalupe Mengod ...... 220 V Josep Dalmau ...... 264 Montserrat Milà ...... 292 Josep Vidal ...... 207 Jaime de la Rocha ...... 261 Josep Maria Miró ...... 66 Eduard Vieta ...... 243 Fritz Diekmann ...... 114 Oscar Miró ...... 82 Pablo Villoslada ...... 266 Lluis Mont ...... 106 E Josep Maria Montserrat ...... 128 Y Gustavo Egea ...... 105 Albert Morales ...... 173 Jordi Yagüe ...... 79 Carles Enrich ...... 323 Asunción Moreno ...... 68 Z Ginés Escolar ...... 314 Joaquim Mullol ...... 138 Ramon Estruch ...... 118 Adelaida Zabalegui ...... 337 N F Miquel Navasa ...... 192 Ramon Farré ...... 124 Anna Novials ...... 214 Carlos Fernández de Larrea ...... 303 José Carlos Fernández-Checa ...... 189 O Mercedes Fernández-Lobato ...... 178 Rafael Oliva ...... 290 Jorge Ferrer ...... 205 Cristina Fillat ...... 198 P Xavier Forns ...... 162 Julià Panés ...... 182

343 Rosselló, 149-153 08036 Barcelona www.idibaps.org [email protected] www.facebook.com/idibaps @idibaps

The mission of IDIBAPS is to combine high-quality clinical research with high-level basic research in order to achieve a more effective transfer of scientiﬁc results in the prevention and treatment of the most common health issues in our country.